primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Renal disorder,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Haemoglobin increased,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Atrial fibrillation,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Renal injury,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Pulmonary congestion,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Hypotension,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Hypovolaemia,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Presyncope,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Dehydration,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Skin disorder,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Acute kidney injury,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Bradycardia,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Heart rate irregular,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Haematocrit increased,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Left atrial dilatation,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Dizziness,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Arrhythmia,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Oedema peripheral,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Syncope,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
1608836711,16088367,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q1,Mucosal dryness,,2022,Q1,11,F,20180101.0,20220304.0,20190319,20220317,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220317,,MD,PT,PT,2022,Q1,Elderly
162271323,16227132,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Left atrial dilatation,,2022,Q1,3,F,20180101.0,20220304.0,20190423,20220316,EXP,,PT-AUROBINDO-AUR-APL-2019-021632,AUROBINDO,,71.0,YR,,M,Y,,,20220316,,MD,PT,PT,2022,Q1,Elderly
162271323,16227132,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Haemoglobin increased,,2022,Q1,3,F,20180101.0,20220304.0,20190423,20220316,EXP,,PT-AUROBINDO-AUR-APL-2019-021632,AUROBINDO,,71.0,YR,,M,Y,,,20220316,,MD,PT,PT,2022,Q1,Elderly
162271323,16227132,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Hypovolaemia,,2022,Q1,3,F,20180101.0,20220304.0,20190423,20220316,EXP,,PT-AUROBINDO-AUR-APL-2019-021632,AUROBINDO,,71.0,YR,,M,Y,,,20220316,,MD,PT,PT,2022,Q1,Elderly
162271323,16227132,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Mucosal dryness,,2022,Q1,3,F,20180101.0,20220304.0,20190423,20220316,EXP,,PT-AUROBINDO-AUR-APL-2019-021632,AUROBINDO,,71.0,YR,,M,Y,,,20220316,,MD,PT,PT,2022,Q1,Elderly
162271323,16227132,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Hypotension,,2022,Q1,3,F,20180101.0,20220304.0,20190423,20220316,EXP,,PT-AUROBINDO-AUR-APL-2019-021632,AUROBINDO,,71.0,YR,,M,Y,,,20220316,,MD,PT,PT,2022,Q1,Elderly
162271323,16227132,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Dehydration,,2022,Q1,3,F,20180101.0,20220304.0,20190423,20220316,EXP,,PT-AUROBINDO-AUR-APL-2019-021632,AUROBINDO,,71.0,YR,,M,Y,,,20220316,,MD,PT,PT,2022,Q1,Elderly
162271323,16227132,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Haematocrit increased,,2022,Q1,3,F,20180101.0,20220304.0,20190423,20220316,EXP,,PT-AUROBINDO-AUR-APL-2019-021632,AUROBINDO,,71.0,YR,,M,Y,,,20220316,,MD,PT,PT,2022,Q1,Elderly
162271323,16227132,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Presyncope,,2022,Q1,3,F,20180101.0,20220304.0,20190423,20220316,EXP,,PT-AUROBINDO-AUR-APL-2019-021632,AUROBINDO,,71.0,YR,,M,Y,,,20220316,,MD,PT,PT,2022,Q1,Elderly
162271323,16227132,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Syncope,,2022,Q1,3,F,20180101.0,20220304.0,20190423,20220316,EXP,,PT-AUROBINDO-AUR-APL-2019-021632,AUROBINDO,,71.0,YR,,M,Y,,,20220316,,MD,PT,PT,2022,Q1,Elderly
162271323,16227132,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Arrhythmia,,2022,Q1,3,F,20180101.0,20220304.0,20190423,20220316,EXP,,PT-AUROBINDO-AUR-APL-2019-021632,AUROBINDO,,71.0,YR,,M,Y,,,20220316,,MD,PT,PT,2022,Q1,Elderly
162271323,16227132,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Dizziness,,2022,Q1,3,F,20180101.0,20220304.0,20190423,20220316,EXP,,PT-AUROBINDO-AUR-APL-2019-021632,AUROBINDO,,71.0,YR,,M,Y,,,20220316,,MD,PT,PT,2022,Q1,Elderly
162271323,16227132,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Atrial fibrillation,,2022,Q1,3,F,20180101.0,20220304.0,20190423,20220316,EXP,,PT-AUROBINDO-AUR-APL-2019-021632,AUROBINDO,,71.0,YR,,M,Y,,,20220316,,MD,PT,PT,2022,Q1,Elderly
162271323,16227132,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Skin disorder,,2022,Q1,3,F,20180101.0,20220304.0,20190423,20220316,EXP,,PT-AUROBINDO-AUR-APL-2019-021632,AUROBINDO,,71.0,YR,,M,Y,,,20220316,,MD,PT,PT,2022,Q1,Elderly
162271323,16227132,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Acute kidney injury,,2022,Q1,3,F,20180101.0,20220304.0,20190423,20220316,EXP,,PT-AUROBINDO-AUR-APL-2019-021632,AUROBINDO,,71.0,YR,,M,Y,,,20220316,,MD,PT,PT,2022,Q1,Elderly
162271323,16227132,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Bradycardia,,2022,Q1,3,F,20180101.0,20220304.0,20190423,20220316,EXP,,PT-AUROBINDO-AUR-APL-2019-021632,AUROBINDO,,71.0,YR,,M,Y,,,20220316,,MD,PT,PT,2022,Q1,Elderly
167881622,16788162,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q1,Hyperkalaemia,,2022,Q1,2,F,20190721.0,20220208.0,20190909,20220222,EXP,,ES-AUROBINDO-AUR-APL-2019-058503,AUROBINDO,,68.0,YR,,F,Y,,,20220222,,MD,ES,ES,2022,Q1,Elderly
167881622,16788162,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q1,Chronic kidney disease,,2022,Q1,2,F,20190721.0,20220208.0,20190909,20220222,EXP,,ES-AUROBINDO-AUR-APL-2019-058503,AUROBINDO,,68.0,YR,,F,Y,,,20220222,,MD,ES,ES,2022,Q1,Elderly
171461652,17146165,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q1,Cytomegalovirus oesophagitis,,2022,Q1,2,F,,20220118.0,20191212,20220202,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2019R1-230088,RANBAXY,"Yamamoto S, Iwamuro M, Miyake M, Nishimura N, Mizuno M, Okada H. Severe bleeding due to cytomegalovirus esophagitis in a patient with diabetes after interbody fusion surgery. Intern Med. 2019;58(20):2949-2955",49.0,YR,,M,Y,,,20220202,,HP,JP,JP,2022,Q1,Adult
171461652,17146165,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q1,Haematemesis,,2022,Q1,2,F,,20220118.0,20191212,20220202,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2019R1-230088,RANBAXY,"Yamamoto S, Iwamuro M, Miyake M, Nishimura N, Mizuno M, Okada H. Severe bleeding due to cytomegalovirus esophagitis in a patient with diabetes after interbody fusion surgery. Intern Med. 2019;58(20):2949-2955",49.0,YR,,M,Y,,,20220202,,HP,JP,JP,2022,Q1,Adult
171461652,17146165,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q1,Haemodynamic instability,,2022,Q1,2,F,,20220118.0,20191212,20220202,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2019R1-230088,RANBAXY,"Yamamoto S, Iwamuro M, Miyake M, Nishimura N, Mizuno M, Okada H. Severe bleeding due to cytomegalovirus esophagitis in a patient with diabetes after interbody fusion surgery. Intern Med. 2019;58(20):2949-2955",49.0,YR,,M,Y,,,20220202,,HP,JP,JP,2022,Q1,Adult
173243842,17324384,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,,,,,2022,Q1,Acquired haemophilia,,2022,Q1,2,F,20190901.0,20200121.0,20200127,20220201,EXP,,CH-TEVA-2020-CH-1175006,TEVA,,68.0,YR,E,M,Y,,,20220201,,MD,CH,CH,2022,Q1,Elderly
184552649,18455264,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q1,Expired product administered,,2022,Q1,9,F,20200423.0,20220209.0,20201102,20220215,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20220215,,CN,CO,CO,2022,Q1,Elderly
184552649,18455264,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q1,Body height increased,,2022,Q1,9,F,20200423.0,20220209.0,20201102,20220215,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20220215,,CN,CO,CO,2022,Q1,Elderly
184552649,18455264,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q1,Weight decreased,,2022,Q1,9,F,20200423.0,20220209.0,20201102,20220215,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20220215,,CN,CO,CO,2022,Q1,Elderly
184552649,18455264,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q1,Weight increased,,2022,Q1,9,F,20200423.0,20220209.0,20201102,20220215,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20220215,,CN,CO,CO,2022,Q1,Elderly
184552649,18455264,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q1,Chronic obstructive pulmonary disease,,2022,Q1,9,F,20200423.0,20220209.0,20201102,20220215,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20220215,,CN,CO,CO,2022,Q1,Elderly
184552649,18455264,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q1,Hypothyroidism,,2022,Q1,9,F,20200423.0,20220209.0,20201102,20220215,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20220215,,CN,CO,CO,2022,Q1,Elderly
184552649,18455264,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q1,Type 2 diabetes mellitus,,2022,Q1,9,F,20200423.0,20220209.0,20201102,20220215,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20220215,,CN,CO,CO,2022,Q1,Elderly
193546173,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q1,Hepatic steatosis,,2022,Q1,3,F,20180918.0,20220315.0,20210602,20220318,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
193546173,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q1,Renal cyst,,2022,Q1,3,F,20180918.0,20220315.0,20210602,20220318,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
193546173,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q1,Hepatic cyst,,2022,Q1,3,F,20180918.0,20220315.0,20210602,20220318,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
193546173,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q1,Scan abnormal,,2022,Q1,3,F,20180918.0,20220315.0,20210602,20220318,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
193546173,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q1,Diverticulum intestinal,,2022,Q1,3,F,20180918.0,20220315.0,20210602,20220318,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
193546173,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q1,Splenomegaly,,2022,Q1,3,F,20180918.0,20220315.0,20210602,20220318,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
193546173,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q1,Platelet count decreased,,2022,Q1,3,F,20180918.0,20220315.0,20210602,20220318,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
193546173,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q1,Cholelithiasis,,2022,Q1,3,F,20180918.0,20220315.0,20210602,20220318,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
193546173,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q1,Neutropenia,,2022,Q1,3,F,20180918.0,20220315.0,20210602,20220318,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
193546173,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q1,Pneumonia pneumococcal,,2022,Q1,3,F,20180918.0,20220315.0,20210602,20220318,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
193546173,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q1,Bladder diverticulum,,2022,Q1,3,F,20180918.0,20220315.0,20210602,20220318,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
194474162,19447416,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, bid",,,U,U,,,,5.0,MG,,BID,2022,Q1,Abdominal discomfort,,2022,Q1,2,F,20210101.0,20210610.0,20210622,20220111,EXP,,AU-NOVOPROD-783744,NOVO NORDISK,,46.0,YR,,M,Y,113.2,KG,20220111,,MD,AU,AU,2022,Q1,Adult
194474162,19447416,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, bid",,,U,U,,,,5.0,MG,,BID,2022,Q1,Vomiting,,2022,Q1,2,F,20210101.0,20210610.0,20210622,20220111,EXP,,AU-NOVOPROD-783744,NOVO NORDISK,,46.0,YR,,M,Y,113.2,KG,20220111,,MD,AU,AU,2022,Q1,Adult
194474162,19447416,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, bid",,,U,U,,,,5.0,MG,,BID,2022,Q1,Somnolence,,2022,Q1,2,F,20210101.0,20210610.0,20210622,20220111,EXP,,AU-NOVOPROD-783744,NOVO NORDISK,,46.0,YR,,M,Y,113.2,KG,20220111,,MD,AU,AU,2022,Q1,Adult
194474162,19447416,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, bid",,,U,U,,,,5.0,MG,,BID,2022,Q1,Fatigue,,2022,Q1,2,F,20210101.0,20210610.0,20210622,20220111,EXP,,AU-NOVOPROD-783744,NOVO NORDISK,,46.0,YR,,M,Y,113.2,KG,20220111,,MD,AU,AU,2022,Q1,Adult
194474162,19447416,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, bid",,,U,U,,,,5.0,MG,,BID,2022,Q1,Constipation,,2022,Q1,2,F,20210101.0,20210610.0,20210622,20220111,EXP,,AU-NOVOPROD-783744,NOVO NORDISK,,46.0,YR,,M,Y,113.2,KG,20220111,,MD,AU,AU,2022,Q1,Adult
194474162,19447416,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, bid",,,U,U,,,,5.0,MG,,BID,2022,Q1,Acute kidney injury,,2022,Q1,2,F,20210101.0,20210610.0,20210622,20220111,EXP,,AU-NOVOPROD-783744,NOVO NORDISK,,46.0,YR,,M,Y,113.2,KG,20220111,,MD,AU,AU,2022,Q1,Adult
195111574,19511157,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram (1-0-0-0),,,U,,,,,10.0,MG,Tablet,,2022,Q1,Bradycardia,,2022,Q1,4,F,20210412.0,20220120.0,20210709,20220203,EXP,,DE-AUROBINDO-AUR-APL-2021-028055,AUROBINDO,,95.0,YR,,M,Y,,,20220204,,MD,DE,DE,2022,Q1,Elderly
195111574,19511157,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram (1-0-0-0),,,U,,,,,10.0,MG,Tablet,,2022,Q1,Wrong product administered,,2022,Q1,4,F,20210412.0,20220120.0,20210709,20220203,EXP,,DE-AUROBINDO-AUR-APL-2021-028055,AUROBINDO,,95.0,YR,,M,Y,,,20220204,,MD,DE,DE,2022,Q1,Elderly
195111574,19511157,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram (1-0-0-0),,,U,,,,,10.0,MG,Tablet,,2022,Q1,Hypotension,,2022,Q1,4,F,20210412.0,20220120.0,20210709,20220203,EXP,,DE-AUROBINDO-AUR-APL-2021-028055,AUROBINDO,,95.0,YR,,M,Y,,,20220204,,MD,DE,DE,2022,Q1,Elderly
195111574,19511157,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, Once a Day (10 mg, 1-0-0-0, tablets)",,,U,,,,,,,Tablet,QD,2022,Q1,Bradycardia,,2022,Q1,4,F,20210412.0,20220120.0,20210709,20220203,EXP,,DE-AUROBINDO-AUR-APL-2021-028055,AUROBINDO,,95.0,YR,,M,Y,,,20220204,,MD,DE,DE,2022,Q1,Elderly
195111574,19511157,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, Once a Day (10 mg, 1-0-0-0, tablets)",,,U,,,,,,,Tablet,QD,2022,Q1,Wrong product administered,,2022,Q1,4,F,20210412.0,20220120.0,20210709,20220203,EXP,,DE-AUROBINDO-AUR-APL-2021-028055,AUROBINDO,,95.0,YR,,M,Y,,,20220204,,MD,DE,DE,2022,Q1,Elderly
195111574,19511157,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, Once a Day (10 mg, 1-0-0-0, tablets)",,,U,,,,,,,Tablet,QD,2022,Q1,Hypotension,,2022,Q1,4,F,20210412.0,20220120.0,20210709,20220203,EXP,,DE-AUROBINDO-AUR-APL-2021-028055,AUROBINDO,,95.0,YR,,M,Y,,,20220204,,MD,DE,DE,2022,Q1,Elderly
195382462,19538246,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,,,Tablet,QD,2022,Q1,Wrong product administered,,2022,Q1,2,F,20210412.0,20220124.0,20210714,20220131,EXP,,DE-drreddys-SPO/GER/21/0137549,DR REDDYS,,95.0,YR,E,M,Y,,,20220131,,MD,DE,DE,2022,Q1,Elderly
195382462,19538246,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,,,Tablet,QD,2022,Q1,Hypotension,,2022,Q1,2,F,20210412.0,20220124.0,20210714,20220131,EXP,,DE-drreddys-SPO/GER/21/0137549,DR REDDYS,,95.0,YR,E,M,Y,,,20220131,,MD,DE,DE,2022,Q1,Elderly
195382462,19538246,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,,,Tablet,QD,2022,Q1,Bradycardia,,2022,Q1,2,F,20210412.0,20220124.0,20210714,20220131,EXP,,DE-drreddys-SPO/GER/21/0137549,DR REDDYS,,95.0,YR,E,M,Y,,,20220131,,MD,DE,DE,2022,Q1,Elderly
195748174,19574817,6,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"AP, qd",,,U,,,,,,,Tablet,QD,2022,Q1,Adrenal insufficiency,,2022,Q1,4,F,20210606.0,20220311.0,20210719,20220318,EXP,,JP-009507513-2107JPN001290J,MERCK,,67.0,YR,,M,Y,47.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
195748174,19574817,6,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"AP, qd",,,U,,,,,,,Tablet,QD,2022,Q1,Drug eruption,,2022,Q1,4,F,20210606.0,20220311.0,20210719,20220318,EXP,,JP-009507513-2107JPN001290J,MERCK,,67.0,YR,,M,Y,47.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
195748174,19574817,6,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"AP, qd",,,U,,,,,,,Tablet,QD,2022,Q1,Interstitial lung disease,,2022,Q1,4,F,20210606.0,20220311.0,20210719,20220318,EXP,,JP-009507513-2107JPN001290J,MERCK,,67.0,YR,,M,Y,47.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
195748174,19574817,7,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q1,Adrenal insufficiency,,2022,Q1,4,F,20210606.0,20220311.0,20210719,20220318,EXP,,JP-009507513-2107JPN001290J,MERCK,,67.0,YR,,M,Y,47.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
195748174,19574817,7,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q1,Drug eruption,,2022,Q1,4,F,20210606.0,20220311.0,20210719,20220318,EXP,,JP-009507513-2107JPN001290J,MERCK,,67.0,YR,,M,Y,47.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
195748174,19574817,7,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2022,Q1,Interstitial lung disease,,2022,Q1,4,F,20210606.0,20220311.0,20210719,20220318,EXP,,JP-009507513-2107JPN001290J,MERCK,,67.0,YR,,M,Y,47.0,KG,20220318,,MD,JP,JP,2022,Q1,Elderly
196103592,19610359,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qAM",,,,,,,,25.0,MG,Tablet,,2022,Q1,Dizziness,,2022,Q1,2,F,20170414.0,20220105.0,20210726,20220112,EXP,,US-AMERICAN REGENT INC-2021001964,AMERICAN REGENT,,43.0,YR,,F,Y,106.12,KG,20220112,,MD,US,US,2022,Q1,Adult
196103592,19610359,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qAM",,,,,,,,25.0,MG,Tablet,,2022,Q1,Palpitations,,2022,Q1,2,F,20170414.0,20220105.0,20210726,20220112,EXP,,US-AMERICAN REGENT INC-2021001964,AMERICAN REGENT,,43.0,YR,,F,Y,106.12,KG,20220112,,MD,US,US,2022,Q1,Adult
196103592,19610359,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qAM",,,,,,,,25.0,MG,Tablet,,2022,Q1,Rash,,2022,Q1,2,F,20170414.0,20220105.0,20210726,20220112,EXP,,US-AMERICAN REGENT INC-2021001964,AMERICAN REGENT,,43.0,YR,,F,Y,106.12,KG,20220112,,MD,US,US,2022,Q1,Adult
196103592,19610359,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qAM",,,,,,,,25.0,MG,Tablet,,2022,Q1,Syncope,,2022,Q1,2,F,20170414.0,20220105.0,20210726,20220112,EXP,,US-AMERICAN REGENT INC-2021001964,AMERICAN REGENT,,43.0,YR,,F,Y,106.12,KG,20220112,,MD,US,US,2022,Q1,Adult
196103592,19610359,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qAM",,,,,,,,25.0,MG,Tablet,,2022,Q1,Incorrect product administration duration,,2022,Q1,2,F,20170414.0,20220105.0,20210726,20220112,EXP,,US-AMERICAN REGENT INC-2021001964,AMERICAN REGENT,,43.0,YR,,F,Y,106.12,KG,20220112,,MD,US,US,2022,Q1,Adult
196103592,19610359,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qAM",,,,,,,,25.0,MG,Tablet,,2022,Q1,Nausea,,2022,Q1,2,F,20170414.0,20220105.0,20210726,20220112,EXP,,US-AMERICAN REGENT INC-2021001964,AMERICAN REGENT,,43.0,YR,,F,Y,106.12,KG,20220112,,MD,US,US,2022,Q1,Adult
196103592,19610359,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qAM",,,,,,,,25.0,MG,Tablet,,2022,Q1,Blood glucose increased,,2022,Q1,2,F,20170414.0,20220105.0,20210726,20220112,EXP,,US-AMERICAN REGENT INC-2021001964,AMERICAN REGENT,,43.0,YR,,F,Y,106.12,KG,20220112,,MD,US,US,2022,Q1,Adult
196116695,19611669,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2022,Q1,Hepatic cirrhosis,,2022,Q1,5,F,20210124.0,20220329.0,20210726,20220330,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220330,,MD,CN,CN,2022,Q1,Elderly
196116695,19611669,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2022,Q1,Hepatic cirrhosis,,2022,Q1,5,F,20210124.0,20220329.0,20210726,20220330,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220330,,MD,CN,CN,2022,Q1,Elderly
196116695,19611669,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2022,Q1,Hepatitis,,2022,Q1,5,F,20210124.0,20220329.0,20210726,20220330,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220330,,MD,CN,CN,2022,Q1,Elderly
196116695,19611669,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2022,Q1,Hepatic cirrhosis,,2022,Q1,5,F,20210124.0,20220329.0,20210726,20220330,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220330,,MD,CN,CN,2022,Q1,Elderly
196116695,19611669,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2022,Q1,Hepatic cirrhosis,,2022,Q1,5,F,20210124.0,20220329.0,20210726,20220330,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220330,,MD,CN,CN,2022,Q1,Elderly
196116695,19611669,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2022,Q1,Hepatic cirrhosis,,2022,Q1,5,F,20210124.0,20220329.0,20210726,20220330,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220330,,MD,CN,CN,2022,Q1,Elderly
196116695,19611669,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2022,Q1,Liver injury,,2022,Q1,5,F,20210124.0,20220329.0,20210726,20220330,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220330,,MD,CN,CN,2022,Q1,Elderly
196793052,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Fatigue,,2022,Q1,2,F,20140601.0,20220118.0,20210809,20220128,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20220128,,LW,US,US,2022,Q1,Adult
196793052,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Renal impairment,,2022,Q1,2,F,20140601.0,20220118.0,20210809,20220128,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20220128,,LW,US,US,2022,Q1,Adult
196793052,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Acute kidney injury,,2022,Q1,2,F,20140601.0,20220118.0,20210809,20220128,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20220128,,LW,US,US,2022,Q1,Adult
196793052,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Asthenia,,2022,Q1,2,F,20140601.0,20220118.0,20210809,20220128,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20220128,,LW,US,US,2022,Q1,Adult
196793052,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Blood test abnormal,,2022,Q1,2,F,20140601.0,20220118.0,20210809,20220128,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20220128,,LW,US,US,2022,Q1,Adult
196793052,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Anxiety,,2022,Q1,2,F,20140601.0,20220118.0,20210809,20220128,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20220128,,LW,US,US,2022,Q1,Adult
196793052,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Anhedonia,,2022,Q1,2,F,20140601.0,20220118.0,20210809,20220128,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20220128,,LW,US,US,2022,Q1,Adult
196793052,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Emotional distress,,2022,Q1,2,F,20140601.0,20220118.0,20210809,20220128,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20220128,,LW,US,US,2022,Q1,Adult
196793052,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Blood creatinine increased,,2022,Q1,2,F,20140601.0,20220118.0,20210809,20220128,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20220128,,LW,US,US,2022,Q1,Adult
196793052,19679305,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Pain,,2022,Q1,2,F,20140601.0,20220118.0,20210809,20220128,PER,,US-GILEAD-2021-0542480,GILEAD,,41.0,YR,A,F,Y,147.39,KG,20220128,,LW,US,US,2022,Q1,Adult
1973930612,19739306,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Colitis,,2022,Q1,12,F,20210811.0,20220113.0,20210824,20220118,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-083340,BRISTOL MYERS SQUIBB,,73.0,YR,,F,Y,69.0,KG,20220118,,HP,ES,ES,2022,Q1,Elderly
1973930612,19739306,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Sepsis,,2022,Q1,12,F,20210811.0,20220113.0,20210824,20220118,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-083340,BRISTOL MYERS SQUIBB,,73.0,YR,,F,Y,69.0,KG,20220118,,HP,ES,ES,2022,Q1,Elderly
197898062,19789806,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Infection,,2022,Q1,2,F,20210813.0,20220209.0,20210904,20220216,EXP,,CA-DECIPHERA PHARMACEUTICALS LLC-2021CA000733,DECIPHERA PHARMACEUTICALS,,68.0,YR,,F,Y,,,20220217,,PH,CA,CA,2022,Q1,Elderly
199519823,19951982,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram 1-0-0-0, Tablet",,,,,,,,10.0,MG,Tablet,QD,2022,Q1,Wrong product administered,,2022,Q1,3,F,20210412.0,20220225.0,20211013,20220301,EXP,,DE-MYLANLABS-2021M1071393,MYLAN,,95.0,YR,,M,Y,,,20220301,,MD,DE,DE,2022,Q1,Elderly
199519823,19951982,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram 1-0-0-0, Tablet",,,,,,,,10.0,MG,Tablet,QD,2022,Q1,Hypotension,,2022,Q1,3,F,20210412.0,20220225.0,20211013,20220301,EXP,,DE-MYLANLABS-2021M1071393,MYLAN,,95.0,YR,,M,Y,,,20220301,,MD,DE,DE,2022,Q1,Elderly
199519823,19951982,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram 1-0-0-0, Tablet",,,,,,,,10.0,MG,Tablet,QD,2022,Q1,Intentional product misuse,,2022,Q1,3,F,20210412.0,20220225.0,20211013,20220301,EXP,,DE-MYLANLABS-2021M1071393,MYLAN,,95.0,YR,,M,Y,,,20220301,,MD,DE,DE,2022,Q1,Elderly
199519823,19951982,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram 1-0-0-0, Tablet",,,,,,,,10.0,MG,Tablet,QD,2022,Q1,Bradycardia,,2022,Q1,3,F,20210412.0,20220225.0,20211013,20220301,EXP,,DE-MYLANLABS-2021M1071393,MYLAN,,95.0,YR,,M,Y,,,20220301,,MD,DE,DE,2022,Q1,Elderly
199519823,19951982,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD (10 mg, 1-0-0-0, tablets)",,,,,,,,,,Tablet,,2022,Q1,Wrong product administered,,2022,Q1,3,F,20210412.0,20220225.0,20211013,20220301,EXP,,DE-MYLANLABS-2021M1071393,MYLAN,,95.0,YR,,M,Y,,,20220301,,MD,DE,DE,2022,Q1,Elderly
199519823,19951982,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD (10 mg, 1-0-0-0, tablets)",,,,,,,,,,Tablet,,2022,Q1,Hypotension,,2022,Q1,3,F,20210412.0,20220225.0,20211013,20220301,EXP,,DE-MYLANLABS-2021M1071393,MYLAN,,95.0,YR,,M,Y,,,20220301,,MD,DE,DE,2022,Q1,Elderly
199519823,19951982,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD (10 mg, 1-0-0-0, tablets)",,,,,,,,,,Tablet,,2022,Q1,Intentional product misuse,,2022,Q1,3,F,20210412.0,20220225.0,20211013,20220301,EXP,,DE-MYLANLABS-2021M1071393,MYLAN,,95.0,YR,,M,Y,,,20220301,,MD,DE,DE,2022,Q1,Elderly
199519823,19951982,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD (10 mg, 1-0-0-0, tablets)",,,,,,,,,,Tablet,,2022,Q1,Bradycardia,,2022,Q1,3,F,20210412.0,20220225.0,20211013,20220301,EXP,,DE-MYLANLABS-2021M1071393,MYLAN,,95.0,YR,,M,Y,,,20220301,,MD,DE,DE,2022,Q1,Elderly
200313154,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2022,Q1,Shock,,2022,Q1,4,F,,20220105.0,20211103,20220107,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220107,,MD,PT,PT,2022,Q1,Elderly
200313154,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2022,Q1,Bronchospasm,,2022,Q1,4,F,,20220105.0,20211103,20220107,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220107,,MD,PT,PT,2022,Q1,Elderly
200313154,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2022,Q1,Tachycardia,,2022,Q1,4,F,,20220105.0,20211103,20220107,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220107,,MD,PT,PT,2022,Q1,Elderly
200313154,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2022,Q1,Tachypnoea,,2022,Q1,4,F,,20220105.0,20211103,20220107,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220107,,MD,PT,PT,2022,Q1,Elderly
200313154,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2022,Q1,Asthenia,,2022,Q1,4,F,,20220105.0,20211103,20220107,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220107,,MD,PT,PT,2022,Q1,Elderly
200313154,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2022,Q1,Aortic thrombosis,,2022,Q1,4,F,,20220105.0,20211103,20220107,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220107,,MD,PT,PT,2022,Q1,Elderly
200313154,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2022,Q1,Acidosis,,2022,Q1,4,F,,20220105.0,20211103,20220107,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220107,,MD,PT,PT,2022,Q1,Elderly
200313154,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2022,Q1,Hyperhidrosis,,2022,Q1,4,F,,20220105.0,20211103,20220107,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220107,,MD,PT,PT,2022,Q1,Elderly
200313154,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2022,Q1,Venous pressure jugular,,2022,Q1,4,F,,20220105.0,20211103,20220107,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220107,,MD,PT,PT,2022,Q1,Elderly
200313154,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,4,F,,20220105.0,20211103,20220107,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220107,,MD,PT,PT,2022,Q1,Elderly
200313154,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2022,Q1,Oliguria,,2022,Q1,4,F,,20220105.0,20211103,20220107,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220107,,MD,PT,PT,2022,Q1,Elderly
200313154,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2022,Q1,Multiple organ dysfunction syndrome,,2022,Q1,4,F,,20220105.0,20211103,20220107,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220107,,MD,PT,PT,2022,Q1,Elderly
200313154,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2022,Q1,Orthopnoea,,2022,Q1,4,F,,20220105.0,20211103,20220107,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220107,,MD,PT,PT,2022,Q1,Elderly
200313154,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2022,Q1,Metabolic acidosis,,2022,Q1,4,F,,20220105.0,20211103,20220107,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220107,,MD,PT,PT,2022,Q1,Elderly
200313154,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2022,Q1,Acute kidney injury,,2022,Q1,4,F,,20220105.0,20211103,20220107,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220107,,MD,PT,PT,2022,Q1,Elderly
200475743,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,D,,,,,10.0,MG,,,2022,Q1,Orthopnoea,,2022,Q1,3,F,,20211229.0,20211109,20220108,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;567-567",73.0,YR,,M,Y,,,20220109,,MD,PT,PT,2022,Q1,Elderly
200475743,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,D,,,,,10.0,MG,,,2022,Q1,Tachycardia,,2022,Q1,3,F,,20211229.0,20211109,20220108,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;567-567",73.0,YR,,M,Y,,,20220109,,MD,PT,PT,2022,Q1,Elderly
200475743,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,D,,,,,10.0,MG,,,2022,Q1,Multiple organ dysfunction syndrome,,2022,Q1,3,F,,20211229.0,20211109,20220108,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;567-567",73.0,YR,,M,Y,,,20220109,,MD,PT,PT,2022,Q1,Elderly
200475743,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,D,,,,,10.0,MG,,,2022,Q1,Bronchospasm,,2022,Q1,3,F,,20211229.0,20211109,20220108,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;567-567",73.0,YR,,M,Y,,,20220109,,MD,PT,PT,2022,Q1,Elderly
200475743,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,D,,,,,10.0,MG,,,2022,Q1,Acidosis,,2022,Q1,3,F,,20211229.0,20211109,20220108,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;567-567",73.0,YR,,M,Y,,,20220109,,MD,PT,PT,2022,Q1,Elderly
200475743,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,D,,,,,10.0,MG,,,2022,Q1,Acute kidney injury,,2022,Q1,3,F,,20211229.0,20211109,20220108,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;567-567",73.0,YR,,M,Y,,,20220109,,MD,PT,PT,2022,Q1,Elderly
200475743,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,D,,,,,10.0,MG,,,2022,Q1,Venous pressure jugular,,2022,Q1,3,F,,20211229.0,20211109,20220108,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;567-567",73.0,YR,,M,Y,,,20220109,,MD,PT,PT,2022,Q1,Elderly
200475743,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,D,,,,,10.0,MG,,,2022,Q1,Oliguria,,2022,Q1,3,F,,20211229.0,20211109,20220108,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;567-567",73.0,YR,,M,Y,,,20220109,,MD,PT,PT,2022,Q1,Elderly
200475743,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,D,,,,,10.0,MG,,,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,3,F,,20211229.0,20211109,20220108,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;567-567",73.0,YR,,M,Y,,,20220109,,MD,PT,PT,2022,Q1,Elderly
200475743,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,D,,,,,10.0,MG,,,2022,Q1,Metabolic acidosis,,2022,Q1,3,F,,20211229.0,20211109,20220108,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;567-567",73.0,YR,,M,Y,,,20220109,,MD,PT,PT,2022,Q1,Elderly
200475743,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,D,,,,,10.0,MG,,,2022,Q1,Aortic thrombosis,,2022,Q1,3,F,,20211229.0,20211109,20220108,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;567-567",73.0,YR,,M,Y,,,20220109,,MD,PT,PT,2022,Q1,Elderly
200475743,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,D,,,,,10.0,MG,,,2022,Q1,Tachypnoea,,2022,Q1,3,F,,20211229.0,20211109,20220108,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;567-567",73.0,YR,,M,Y,,,20220109,,MD,PT,PT,2022,Q1,Elderly
200475743,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,D,,,,,10.0,MG,,,2022,Q1,Asthenia,,2022,Q1,3,F,,20211229.0,20211109,20220108,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;567-567",73.0,YR,,M,Y,,,20220109,,MD,PT,PT,2022,Q1,Elderly
200475743,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,D,,,,,10.0,MG,,,2022,Q1,Shock,,2022,Q1,3,F,,20211229.0,20211109,20220108,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;567-567",73.0,YR,,M,Y,,,20220109,,MD,PT,PT,2022,Q1,Elderly
200475743,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,D,,,,,10.0,MG,,,2022,Q1,Hyperhidrosis,,2022,Q1,3,F,,20211229.0,20211109,20220108,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;567-567",73.0,YR,,M,Y,,,20220109,,MD,PT,PT,2022,Q1,Elderly
200889582,20088958,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Overdose,,2022,Q1,2,F,20211012.0,20220113.0,20211119,20220131,PER,,US-DECIPHERA PHARMACEUTICALS LLC-2021US000959,DECIPHERA PHARMACEUTICALS,,82.0,YR,,M,Y,,,20220131,,CN,US,US,2022,Q1,Elderly
200889582,20088958,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,2,F,20211012.0,20220113.0,20211119,20220131,PER,,US-DECIPHERA PHARMACEUTICALS LLC-2021US000959,DECIPHERA PHARMACEUTICALS,,82.0,YR,,M,Y,,,20220131,,CN,US,US,2022,Q1,Elderly
200957173,20095717,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q1,Condition aggravated,,2022,Q1,3,F,20200309.0,20220310.0,20211122,20220318,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20220318,,MD,CA,CA,2022,Q1,Adult
200957173,20095717,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q1,C-reactive protein increased,,2022,Q1,3,F,20200309.0,20220310.0,20211122,20220318,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20220318,,MD,CA,CA,2022,Q1,Adult
200957173,20095717,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q1,Weight decreased,,2022,Q1,3,F,20200309.0,20220310.0,20211122,20220318,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20220318,,MD,CA,CA,2022,Q1,Adult
200957173,20095717,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q1,Psoriasis,,2022,Q1,3,F,20200309.0,20220310.0,20211122,20220318,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20220318,,MD,CA,CA,2022,Q1,Adult
200957173,20095717,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q1,Hepatotoxicity,,2022,Q1,3,F,20200309.0,20220310.0,20211122,20220318,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20220318,,MD,CA,CA,2022,Q1,Adult
200957173,20095717,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q1,Drug ineffective,,2022,Q1,3,F,20200309.0,20220310.0,20211122,20220318,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20220318,,MD,CA,CA,2022,Q1,Adult
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,General physical health deterioration,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Diarrhoea,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Bone lesion,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Osteolysis,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Arthralgia,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Metastases to bone,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Tissue infiltration,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Vomiting,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Thrombocytopenia,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Hormone receptor positive HER2 negative breast cancer,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,PIK3CA-activated mutation,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Nausea,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Fatigue,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Carcinoembryonic antigen increased,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Metastases to liver,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Pathological fracture,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Product dose omission issue,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Bone erosion,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,Tablet,QD,2022,Q1,Anaemia,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,General physical health deterioration,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Diarrhoea,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Bone lesion,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Osteolysis,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Arthralgia,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Metastases to bone,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Tissue infiltration,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Vomiting,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Thrombocytopenia,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Hormone receptor positive HER2 negative breast cancer,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,PIK3CA-activated mutation,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Nausea,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Fatigue,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Carcinoembryonic antigen increased,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Metastases to liver,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Pathological fracture,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Product dose omission issue,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Bone erosion,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
200975504,20097550,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"5 mg, QD",,,D,,,,,5.0,MG,Tablet,QD,2022,Q1,Anaemia,,2022,Q1,4,F,20190101.0,20211231.0,20211122,20220206,EXP,,NVSC2021BR263570,NOVARTIS,,69.0,YR,,F,Y,60.0,KG,20220204,,MD,BR,BR,2022,Q1,Elderly
201116883,20111688,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2022,Q1,Peritonsillar abscess,,2022,Q1,3,F,20210604.0,20220105.0,20211125,20220106,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140330",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,73.0,KG,20220107,,MD,JP,JP,2022,Q1,Adult
201116883,20111688,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2022,Q1,Diabetes mellitus inadequate control,,2022,Q1,3,F,20210604.0,20220105.0,20211125,20220106,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140330",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,73.0,KG,20220107,,MD,JP,JP,2022,Q1,Adult
201116883,20111688,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2022,Q1,Ketosis,,2022,Q1,3,F,20210604.0,20220105.0,20211125,20220106,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140330",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,73.0,KG,20220107,,MD,JP,JP,2022,Q1,Adult
201116883,20111688,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2022,Q1,Diabetic ketoacidosis,,2022,Q1,3,F,20210604.0,20220105.0,20211125,20220106,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140330",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,73.0,KG,20220107,,MD,JP,JP,2022,Q1,Adult
201116883,20111688,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2022,Q1,Sepsis,,2022,Q1,3,F,20210604.0,20220105.0,20211125,20220106,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140330",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,73.0,KG,20220107,,MD,JP,JP,2022,Q1,Adult
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Fatigue,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Pathological fracture,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Diarrhoea,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Bone erosion,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Vomiting,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Nausea,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Bone lesion,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Hypermetabolism,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Carcinoembryonic antigen increased,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Fatigue,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Metastases to liver,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Bone pain,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Arthralgia,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Thrombocytopenia,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Metastases to bone,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Anaemia,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Metastases to spinal cord,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Bone lesion,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Peripheral nerve lesion,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201125833,20112583,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (one tablet 25mg/5mg)",,,D,,,,,,,Tablet,QD,2022,Q1,Osteolysis,,2022,Q1,3,F,20190101.0,20211231.0,20211125,20220111,EXP,,NVSC2021BR268807,NOVARTIS,,71.0,YR,,F,Y,60.0,KG,20220111,,MD,BR,BR,2022,Q1,Elderly
201162333,20116233,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2022,Q1,Haematuria,,2022,Q1,3,F,20210716.0,20220228.0,20211126,20220307,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220307,,MD,GB,GB,2022,Q1,Elderly
201162333,20116233,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2022,Q1,Diarrhoea,,2022,Q1,3,F,20210716.0,20220228.0,20211126,20220307,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220307,,MD,GB,GB,2022,Q1,Elderly
201162333,20116233,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2022,Q1,Glycosuria,,2022,Q1,3,F,20210716.0,20220228.0,20211126,20220307,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220307,,MD,GB,GB,2022,Q1,Elderly
201162333,20116233,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2022,Q1,Hypothyroidism,,2022,Q1,3,F,20210716.0,20220228.0,20211126,20220307,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220307,,MD,GB,GB,2022,Q1,Elderly
201162333,20116233,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2022,Q1,Hyperthyroidism,,2022,Q1,3,F,20210716.0,20220228.0,20211126,20220307,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220307,,MD,GB,GB,2022,Q1,Elderly
201162333,20116233,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Haematuria,,2022,Q1,3,F,20210716.0,20220228.0,20211126,20220307,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220307,,MD,GB,GB,2022,Q1,Elderly
201162333,20116233,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,3,F,20210716.0,20220228.0,20211126,20220307,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220307,,MD,GB,GB,2022,Q1,Elderly
201162333,20116233,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Glycosuria,,2022,Q1,3,F,20210716.0,20220228.0,20211126,20220307,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220307,,MD,GB,GB,2022,Q1,Elderly
201162333,20116233,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Hypothyroidism,,2022,Q1,3,F,20210716.0,20220228.0,20211126,20220307,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220307,,MD,GB,GB,2022,Q1,Elderly
201162333,20116233,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Hyperthyroidism,,2022,Q1,3,F,20210716.0,20220228.0,20211126,20220307,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220307,,MD,GB,GB,2022,Q1,Elderly
201774643,20177464,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 Tablet,,,,,,,,,,Tablets,QD,2022,Q1,Hepatitis B,,2022,Q1,3,F,20211124.0,20220112.0,20211213,20220120,EXP,,US-CELGENEUS-USA-20211201459,CELGENE,,74.0,YR,,M,Y,88.984,KG,20220120,,MD,US,US,2022,Q1,Elderly
201817853,20181785,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,,,,10.0,MG,,QD,2022,Q1,Cardiac failure,,2022,Q1,3,F,20210301.0,20220206.0,20211214,20220215,EXP,,PL-TEVA-2021-PL-1988144,TEVA,,71.0,YR,E,M,Y,,,20220215,,MD,PL,PL,2022,Q1,Elderly
201817853,20181785,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,,,,10.0,MG,,QD,2022,Q1,Acute kidney injury,,2022,Q1,3,F,20210301.0,20220206.0,20211214,20220215,EXP,,PL-TEVA-2021-PL-1988144,TEVA,,71.0,YR,E,M,Y,,,20220215,,MD,PL,PL,2022,Q1,Elderly
201817853,20181785,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,,,,10.0,MG,,QD,2022,Q1,Glomerular filtration rate abnormal,,2022,Q1,3,F,20210301.0,20220206.0,20211214,20220215,EXP,,PL-TEVA-2021-PL-1988144,TEVA,,71.0,YR,E,M,Y,,,20220215,,MD,PL,PL,2022,Q1,Elderly
201817853,20181785,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,,,,10.0,MG,,QD,2022,Q1,Congestive cardiomyopathy,,2022,Q1,3,F,20210301.0,20220206.0,20211214,20220215,EXP,,PL-TEVA-2021-PL-1988144,TEVA,,71.0,YR,E,M,Y,,,20220215,,MD,PL,PL,2022,Q1,Elderly
201817853,20181785,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,,,,10.0,MG,,QD,2022,Q1,Lung disorder,,2022,Q1,3,F,20210301.0,20220206.0,20211214,20220215,EXP,,PL-TEVA-2021-PL-1988144,TEVA,,71.0,YR,E,M,Y,,,20220215,,MD,PL,PL,2022,Q1,Elderly
201817853,20181785,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,,,,10.0,MG,,QD,2022,Q1,N-terminal prohormone brain natriuretic peptide increased,,2022,Q1,3,F,20210301.0,20220206.0,20211214,20220215,EXP,,PL-TEVA-2021-PL-1988144,TEVA,,71.0,YR,E,M,Y,,,20220215,,MD,PL,PL,2022,Q1,Elderly
201817853,20181785,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,,,,10.0,MG,,QD,2022,Q1,Wrong technique in product usage process,,2022,Q1,3,F,20210301.0,20220206.0,20211214,20220215,EXP,,PL-TEVA-2021-PL-1988144,TEVA,,71.0,YR,E,M,Y,,,20220215,,MD,PL,PL,2022,Q1,Elderly
201922352,20192235,21,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q1,Glomerular filtration rate abnormal,,2022,Q1,2,F,20210301.0,20220125.0,20211216,20220208,EXP,,PL-AUROBINDO-AUR-APL-2021-051139,AUROBINDO,,71.0,YR,,M,Y,,,20220208,,MD,PL,PL,2022,Q1,Elderly
201922352,20192235,21,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q1,Acute kidney injury,,2022,Q1,2,F,20210301.0,20220125.0,20211216,20220208,EXP,,PL-AUROBINDO-AUR-APL-2021-051139,AUROBINDO,,71.0,YR,,M,Y,,,20220208,,MD,PL,PL,2022,Q1,Elderly
201922352,20192235,21,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q1,Congestive cardiomyopathy,,2022,Q1,2,F,20210301.0,20220125.0,20211216,20220208,EXP,,PL-AUROBINDO-AUR-APL-2021-051139,AUROBINDO,,71.0,YR,,M,Y,,,20220208,,MD,PL,PL,2022,Q1,Elderly
201922352,20192235,21,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q1,Cardiac failure,,2022,Q1,2,F,20210301.0,20220125.0,20211216,20220208,EXP,,PL-AUROBINDO-AUR-APL-2021-051139,AUROBINDO,,71.0,YR,,M,Y,,,20220208,,MD,PL,PL,2022,Q1,Elderly
201922352,20192235,21,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q1,Lung disorder,,2022,Q1,2,F,20210301.0,20220125.0,20211216,20220208,EXP,,PL-AUROBINDO-AUR-APL-2021-051139,AUROBINDO,,71.0,YR,,M,Y,,,20220208,,MD,PL,PL,2022,Q1,Elderly
201922352,20192235,21,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q1,Wrong technique in product usage process,,2022,Q1,2,F,20210301.0,20220125.0,20211216,20220208,EXP,,PL-AUROBINDO-AUR-APL-2021-051139,AUROBINDO,,71.0,YR,,M,Y,,,20220208,,MD,PL,PL,2022,Q1,Elderly
201922352,20192235,21,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q1,N-terminal prohormone brain natriuretic peptide increased,,2022,Q1,2,F,20210301.0,20220125.0,20211216,20220208,EXP,,PL-AUROBINDO-AUR-APL-2021-051139,AUROBINDO,,71.0,YR,,M,Y,,,20220208,,MD,PL,PL,2022,Q1,Elderly
201950475,20195047,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1000/12,5 milligram, bid",,,,,UNKNOWNS,,,,,Unknown,,2022,Q1,Intestinal obstruction,,2022,Q1,5,F,20211117.0,20220314.0,20211216,20220322,EXP,,ES-Fresenius Kabi-FK202113930,FRESENIUS KABI,,56.0,YR,,M,Y,,,20220322,,HP,NL,,2022,Q1,Adult
201950475,20195047,17,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1000/12,5 milligram, bid",,,,,UNKNOWNS,,,,,Unknown,,2022,Q1,Neutropenia,,2022,Q1,5,F,20211117.0,20220314.0,20211216,20220322,EXP,,ES-Fresenius Kabi-FK202113930,FRESENIUS KABI,,56.0,YR,,M,Y,,,20220322,,HP,NL,,2022,Q1,Adult
201958792,20195879,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, unknown",,,,,,,,10.0,MG,,,2022,Q1,Toxicity to various agents,,2022,Q1,2,F,20210410.0,20220329.0,20211216,20220331,EXP,GB-MHRA-EYC 00268653,GB-ELI_LILLY_AND_COMPANY-GB202112006154,ELI LILLY AND CO,,49.0,YR,,M,Y,176.0,KG,20220331,,CN,GB,GB,2022,Q1,Adult
201958792,20195879,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, unknown",,,,,,,,10.0,MG,,,2022,Q1,Cardiomegaly,,2022,Q1,2,F,20210410.0,20220329.0,20211216,20220331,EXP,GB-MHRA-EYC 00268653,GB-ELI_LILLY_AND_COMPANY-GB202112006154,ELI LILLY AND CO,,49.0,YR,,M,Y,176.0,KG,20220331,,CN,GB,GB,2022,Q1,Adult
201958792,20195879,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, unknown",,,,,,,,10.0,MG,,,2022,Q1,Malaise,,2022,Q1,2,F,20210410.0,20220329.0,20211216,20220331,EXP,GB-MHRA-EYC 00268653,GB-ELI_LILLY_AND_COMPANY-GB202112006154,ELI LILLY AND CO,,49.0,YR,,M,Y,176.0,KG,20220331,,CN,GB,GB,2022,Q1,Adult
202094102,20209410,42,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,D,,,,,,,,,2022,Q1,Drug interaction,,2022,Q1,2,F,20211101.0,20220126.0,20211220,20220202,EXP,CH-SM-2021-29093,CH-JNJFOC-20211239184,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20220202,,MD,CH,CH,2022,Q1,Adult
202094102,20209410,42,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,D,,,,,,,,,2022,Q1,Confusional state,,2022,Q1,2,F,20211101.0,20220126.0,20211220,20220202,EXP,CH-SM-2021-29093,CH-JNJFOC-20211239184,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20220202,,MD,CH,CH,2022,Q1,Adult
202094102,20209410,42,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,D,,,,,,,,,2022,Q1,Respiratory failure,,2022,Q1,2,F,20211101.0,20220126.0,20211220,20220202,EXP,CH-SM-2021-29093,CH-JNJFOC-20211239184,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20220202,,MD,CH,CH,2022,Q1,Adult
202094102,20209410,42,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,D,,,,,,,,,2022,Q1,Depressed level of consciousness,,2022,Q1,2,F,20211101.0,20220126.0,20211220,20220202,EXP,CH-SM-2021-29093,CH-JNJFOC-20211239184,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20220202,,MD,CH,CH,2022,Q1,Adult
202094102,20209410,42,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,D,,,,,,,,,2022,Q1,Trismus,,2022,Q1,2,F,20211101.0,20220126.0,20211220,20220202,EXP,CH-SM-2021-29093,CH-JNJFOC-20211239184,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20220202,,MD,CH,CH,2022,Q1,Adult
202171612,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2022,Q1,Blood urea increased,,2022,Q1,2,F,20170520.0,20211221.0,20211222,20220104,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20220104,,MD,JP,JP,2022,Q1,Elderly
202171612,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2022,Q1,Drug interaction,,2022,Q1,2,F,20170520.0,20211221.0,20211222,20220104,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20220104,,MD,JP,JP,2022,Q1,Elderly
202171612,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2022,Q1,Diabetes mellitus,,2022,Q1,2,F,20170520.0,20211221.0,20211222,20220104,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20220104,,MD,JP,JP,2022,Q1,Elderly
202171612,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2022,Q1,Orthostatic hypotension,,2022,Q1,2,F,20170520.0,20211221.0,20211222,20220104,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20220104,,MD,JP,JP,2022,Q1,Elderly
202171612,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2022,Q1,Off label use,,2022,Q1,2,F,20170520.0,20211221.0,20211222,20220104,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20220104,,MD,JP,JP,2022,Q1,Elderly
202171612,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2022,Q1,Weight decreased,,2022,Q1,2,F,20170520.0,20211221.0,20211222,20220104,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20220104,,MD,JP,JP,2022,Q1,Elderly
202171612,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2022,Q1,Hyperglycaemia,,2022,Q1,2,F,20170520.0,20211221.0,20211222,20220104,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20220104,,MD,JP,JP,2022,Q1,Elderly
202171612,20217161,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,Y,,,,,10.0,MG,,QD,2022,Q1,Hypercatabolism,,2022,Q1,2,F,20170520.0,20211221.0,20211222,20220104,EXP,,JP-PFIZER INC-202101756465,PFIZER,"Nawata, T.. Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.. Rheumatology Advances in Practice. 2021;5(3):1-3",71.0,YR,,F,Y,61.5,KG,20220104,,MD,JP,JP,2022,Q1,Elderly
202187433,20218743,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2022,Q1,Multiple organ dysfunction syndrome,,2022,Q1,3,F,20211011.0,20220112.0,20211222,20220114,EXP,,ES-CELGENEUS-ESP-20211205864,CELGENE,,75.0,YR,,F,Y,62.5,KG,20220114,,HP,ES,ES,2022,Q1,Elderly
202187433,20218743,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Multiple organ dysfunction syndrome,,2022,Q1,3,F,20211011.0,20220112.0,20211222,20220114,EXP,,ES-CELGENEUS-ESP-20211205864,CELGENE,,75.0,YR,,F,Y,62.5,KG,20220114,,HP,ES,ES,2022,Q1,Elderly
202195122,20219512,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,N,,,,,,Tablet,,2022,Q1,Anaemia,,2022,Q1,2,F,,20220117.0,20211222,20220121,EXP,,DE-ANIPHARMA-2021-DE-000278,ANI,,79.0,YR,,M,Y,90.0,KG,20220121,,PH,DE,DE,2022,Q1,Elderly
202195122,20219512,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,N,,,,,,Tablet,,2022,Q1,Frequent bowel movements,,2022,Q1,2,F,,20220117.0,20211222,20220121,EXP,,DE-ANIPHARMA-2021-DE-000278,ANI,,79.0,YR,,M,Y,90.0,KG,20220121,,PH,DE,DE,2022,Q1,Elderly
202195122,20219512,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,N,,,,,,Tablet,,2022,Q1,Upper gastrointestinal haemorrhage,,2022,Q1,2,F,,20220117.0,20211222,20220121,EXP,,DE-ANIPHARMA-2021-DE-000278,ANI,,79.0,YR,,M,Y,90.0,KG,20220121,,PH,DE,DE,2022,Q1,Elderly
202195122,20219512,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,N,,,,,,Tablet,,2022,Q1,Faeces discoloured,,2022,Q1,2,F,,20220117.0,20211222,20220121,EXP,,DE-ANIPHARMA-2021-DE-000278,ANI,,79.0,YR,,M,Y,90.0,KG,20220121,,PH,DE,DE,2022,Q1,Elderly
202235822,20223582,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,UNK,,,10.0,MG,,,2022,Q1,Hypertension,,2022,Q1,2,F,20211204.0,20220317.0,20211223,20220322,EXP,,NVSC2021PT294361,NOVARTIS,,63.0,YR,,M,Y,92.0,KG,20220322,,PH,PT,PT,2022,Q1,Adult
202235822,20223582,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,UNK,,,10.0,MG,,,2022,Q1,Inappropriate schedule of product administration,,2022,Q1,2,F,20211204.0,20220317.0,20211223,20220322,EXP,,NVSC2021PT294361,NOVARTIS,,63.0,YR,,M,Y,92.0,KG,20220322,,PH,PT,PT,2022,Q1,Adult
202251002,20225100,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q1,Peripheral arterial occlusive disease,,2022,Q1,2,F,20210601.0,20220119.0,20211223,20220124,EXP,,NVSJ2021JP021084,NOVARTIS,,65.0,YR,,M,Y,,,20220124,,MD,JP,JP,2022,Q1,Elderly
202251002,20225100,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q1,Cerebral infarction,,2022,Q1,2,F,20210601.0,20220119.0,20211223,20220124,EXP,,NVSJ2021JP021084,NOVARTIS,,65.0,YR,,M,Y,,,20220124,,MD,JP,JP,2022,Q1,Elderly
202251002,20225100,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q1,Dysarthria,,2022,Q1,2,F,20210601.0,20220119.0,20211223,20220124,EXP,,NVSJ2021JP021084,NOVARTIS,,65.0,YR,,M,Y,,,20220124,,MD,JP,JP,2022,Q1,Elderly
202251002,20225100,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q1,Coronary artery occlusion,,2022,Q1,2,F,20210601.0,20220119.0,20211223,20220124,EXP,,NVSJ2021JP021084,NOVARTIS,,65.0,YR,,M,Y,,,20220124,,MD,JP,JP,2022,Q1,Elderly
202251002,20225100,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q1,Carotid artery stenosis,,2022,Q1,2,F,20210601.0,20220119.0,20211223,20220124,EXP,,NVSJ2021JP021084,NOVARTIS,,65.0,YR,,M,Y,,,20220124,,MD,JP,JP,2022,Q1,Elderly
202251002,20225100,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q1,Hypoaesthesia,,2022,Q1,2,F,20210601.0,20220119.0,20211223,20220124,EXP,,NVSJ2021JP021084,NOVARTIS,,65.0,YR,,M,Y,,,20220124,,MD,JP,JP,2022,Q1,Elderly
202251002,20225100,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,U,,,,,25.0,MG,,,2022,Q1,Peripheral arterial occlusive disease,,2022,Q1,2,F,20210601.0,20220119.0,20211223,20220124,EXP,,NVSJ2021JP021084,NOVARTIS,,65.0,YR,,M,Y,,,20220124,,MD,JP,JP,2022,Q1,Elderly
202251002,20225100,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,U,,,,,25.0,MG,,,2022,Q1,Cerebral infarction,,2022,Q1,2,F,20210601.0,20220119.0,20211223,20220124,EXP,,NVSJ2021JP021084,NOVARTIS,,65.0,YR,,M,Y,,,20220124,,MD,JP,JP,2022,Q1,Elderly
202251002,20225100,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,U,,,,,25.0,MG,,,2022,Q1,Dysarthria,,2022,Q1,2,F,20210601.0,20220119.0,20211223,20220124,EXP,,NVSJ2021JP021084,NOVARTIS,,65.0,YR,,M,Y,,,20220124,,MD,JP,JP,2022,Q1,Elderly
202251002,20225100,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,U,,,,,25.0,MG,,,2022,Q1,Coronary artery occlusion,,2022,Q1,2,F,20210601.0,20220119.0,20211223,20220124,EXP,,NVSJ2021JP021084,NOVARTIS,,65.0,YR,,M,Y,,,20220124,,MD,JP,JP,2022,Q1,Elderly
202251002,20225100,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,U,,,,,25.0,MG,,,2022,Q1,Carotid artery stenosis,,2022,Q1,2,F,20210601.0,20220119.0,20211223,20220124,EXP,,NVSJ2021JP021084,NOVARTIS,,65.0,YR,,M,Y,,,20220124,,MD,JP,JP,2022,Q1,Elderly
202251002,20225100,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,U,,,,,25.0,MG,,,2022,Q1,Hypoaesthesia,,2022,Q1,2,F,20210601.0,20220119.0,20211223,20220124,EXP,,NVSJ2021JP021084,NOVARTIS,,65.0,YR,,M,Y,,,20220124,,MD,JP,JP,2022,Q1,Elderly
202274642,20227464,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q1,Productive cough,,2022,Q1,2,F,20211209.0,20211216.0,20211224,20220114,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2021-117353",REGENERON,,61.0,YR,,M,Y,,,20220114,,HP,US,US,2022,Q1,Adult
202274642,20227464,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q1,Blood creatinine increased,,2022,Q1,2,F,20211209.0,20211216.0,20211224,20220114,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2021-117353",REGENERON,,61.0,YR,,M,Y,,,20220114,,HP,US,US,2022,Q1,Adult
202274642,20227464,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q1,Haemoglobin decreased,,2022,Q1,2,F,20211209.0,20211216.0,20211224,20220114,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2021-117353",REGENERON,,61.0,YR,,M,Y,,,20220114,,HP,US,US,2022,Q1,Adult
202274642,20227464,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q1,Incorrect dose administered,,2022,Q1,2,F,20211209.0,20211216.0,20211224,20220114,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2021-117353",REGENERON,,61.0,YR,,M,Y,,,20220114,,HP,US,US,2022,Q1,Adult
202274642,20227464,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q1,Prothrombin time prolonged,,2022,Q1,2,F,20211209.0,20211216.0,20211224,20220114,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2021-117353",REGENERON,,61.0,YR,,M,Y,,,20220114,,HP,US,US,2022,Q1,Adult
202274642,20227464,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q1,Pyrexia,,2022,Q1,2,F,20211209.0,20211216.0,20211224,20220114,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2021-117353",REGENERON,,61.0,YR,,M,Y,,,20220114,,HP,US,US,2022,Q1,Adult
202341012,20234101,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg QD,,,U,N,,,,,,Tablet,,2022,Q1,Muscular weakness,,2022,Q1,2,F,,20220110.0,20211227,20220112,EXP,,DE-ANIPHARMA-2021-DE-000285,ANI,,79.0,YR,,M,Y,,,20220112,,PH,DE,DE,2022,Q1,Elderly
202341012,20234101,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg QD,,,U,N,,,,,,Tablet,,2022,Q1,Haematochezia,,2022,Q1,2,F,,20220110.0,20211227,20220112,EXP,,DE-ANIPHARMA-2021-DE-000285,ANI,,79.0,YR,,M,Y,,,20220112,,PH,DE,DE,2022,Q1,Elderly
202341012,20234101,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg QD,,,U,N,,,,,,Tablet,,2022,Q1,Anaemia,,2022,Q1,2,F,,20220110.0,20211227,20220112,EXP,,DE-ANIPHARMA-2021-DE-000285,ANI,,79.0,YR,,M,Y,,,20220112,,PH,DE,DE,2022,Q1,Elderly
202341012,20234101,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg QD,,,U,N,,,,,,Tablet,,2022,Q1,Product monitoring error,,2022,Q1,2,F,,20220110.0,20211227,20220112,EXP,,DE-ANIPHARMA-2021-DE-000285,ANI,,79.0,YR,,M,Y,,,20220112,,PH,DE,DE,2022,Q1,Elderly
202341012,20234101,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg QD,,,U,N,,,,,,Tablet,,2022,Q1,General physical health deterioration,,2022,Q1,2,F,,20220110.0,20211227,20220112,EXP,,DE-ANIPHARMA-2021-DE-000285,ANI,,79.0,YR,,M,Y,,,20220112,,PH,DE,DE,2022,Q1,Elderly
202363932,20236393,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850 mg.,,,U,,Unknown,,206111.0,,,,Q12H,2022,Q1,Diabetic ketoacidosis,,2022,Q1,2,F,,20211226.0,20211228,20220113,EXP,,"VN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145481",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,70.0,KG,20220113,,MD,VN,VN,2022,Q1,Adult
202403803,20240380,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q1,Haematochezia,,2022,Q1,3,F,,20220114.0,20211228,20220125,EXP,,DE-PFIZER INC-202101852624,PFIZER,,79.0,YR,,M,Y,,,20220125,,PH,DE,DE,2022,Q1,Elderly
202403803,20240380,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q1,Product monitoring error,,2022,Q1,3,F,,20220114.0,20211228,20220125,EXP,,DE-PFIZER INC-202101852624,PFIZER,,79.0,YR,,M,Y,,,20220125,,PH,DE,DE,2022,Q1,Elderly
202403803,20240380,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q1,General physical health deterioration,,2022,Q1,3,F,,20220114.0,20211228,20220125,EXP,,DE-PFIZER INC-202101852624,PFIZER,,79.0,YR,,M,Y,,,20220125,,PH,DE,DE,2022,Q1,Elderly
202403803,20240380,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q1,Anaemia,,2022,Q1,3,F,,20220114.0,20211228,20220125,EXP,,DE-PFIZER INC-202101852624,PFIZER,,79.0,YR,,M,Y,,,20220125,,PH,DE,DE,2022,Q1,Elderly
202403803,20240380,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q1,Muscular weakness,,2022,Q1,3,F,,20220114.0,20211228,20220125,EXP,,DE-PFIZER INC-202101852624,PFIZER,,79.0,YR,,M,Y,,,20220125,,PH,DE,DE,2022,Q1,Elderly
202551432,20255143,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10Milligram,,,Y,,,,,10.0,MG,,,2022,Q1,Nausea,,2022,Q1,2,F,20210527.0,20220228.0,20211230,20220314,EXP,,DE-TEVA-2021-DE-1992398,TEVA,,58.0,YR,A,F,Y,90.0,KG,20220314,,MD,DE,DE,2022,Q1,Adult
202551432,20255143,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10Milligram,,,Y,,,,,10.0,MG,,,2022,Q1,Lactic acidosis,,2022,Q1,2,F,20210527.0,20220228.0,20211230,20220314,EXP,,DE-TEVA-2021-DE-1992398,TEVA,,58.0,YR,A,F,Y,90.0,KG,20220314,,MD,DE,DE,2022,Q1,Adult
202551432,20255143,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10Milligram,,,Y,,,,,10.0,MG,,,2022,Q1,Hyperglycaemia,,2022,Q1,2,F,20210527.0,20220228.0,20211230,20220314,EXP,,DE-TEVA-2021-DE-1992398,TEVA,,58.0,YR,A,F,Y,90.0,KG,20220314,,MD,DE,DE,2022,Q1,Adult
202551432,20255143,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10Milligram,,,Y,,,,,10.0,MG,,,2022,Q1,Renal impairment,,2022,Q1,2,F,20210527.0,20220228.0,20211230,20220314,EXP,,DE-TEVA-2021-DE-1992398,TEVA,,58.0,YR,A,F,Y,90.0,KG,20220314,,MD,DE,DE,2022,Q1,Adult
202551432,20255143,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10Milligram,,,Y,,,,,10.0,MG,,,2022,Q1,Pain in extremity,,2022,Q1,2,F,20210527.0,20220228.0,20211230,20220314,EXP,,DE-TEVA-2021-DE-1992398,TEVA,,58.0,YR,A,F,Y,90.0,KG,20220314,,MD,DE,DE,2022,Q1,Adult
202551432,20255143,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10Milligram,,,Y,,,,,10.0,MG,,,2022,Q1,Vomiting,,2022,Q1,2,F,20210527.0,20220228.0,20211230,20220314,EXP,,DE-TEVA-2021-DE-1992398,TEVA,,58.0,YR,A,F,Y,90.0,KG,20220314,,MD,DE,DE,2022,Q1,Adult
202551432,20255143,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10Milligram,,,Y,,,,,10.0,MG,,,2022,Q1,Ketoacidosis,,2022,Q1,2,F,20210527.0,20220228.0,20211230,20220314,EXP,,DE-TEVA-2021-DE-1992398,TEVA,,58.0,YR,A,F,Y,90.0,KG,20220314,,MD,DE,DE,2022,Q1,Adult
202782322,20278232,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Inappropriate schedule of product administration,,2022,Q1,2,F,20211205.0,20220201.0,20220103,20220211,PER,JP-ONO-2021JP033072,JP-AMGEN-JPNSP2021206909,AMGEN,,52.0,YR,A,M,Y,,,20220211,,MD,JP,JP,2022,Q1,Adult
202782322,20278232,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Atrial tachycardia,,2022,Q1,2,F,20211205.0,20220201.0,20220103,20220211,PER,JP-ONO-2021JP033072,JP-AMGEN-JPNSP2021206909,AMGEN,,52.0,YR,A,M,Y,,,20220211,,MD,JP,JP,2022,Q1,Adult
202795002,20279500,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Wrong technique in product usage process,,2022,Q1,2,F,20210301.0,20220228.0,20220103,20220307,EXP,,PL-MYLANLABS-2021M1096293,MYLAN,,71.0,YR,,M,Y,,,20220307,,MD,PL,PL,2022,Q1,Elderly
202795002,20279500,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Acute kidney injury,,2022,Q1,2,F,20210301.0,20220228.0,20220103,20220307,EXP,,PL-MYLANLABS-2021M1096293,MYLAN,,71.0,YR,,M,Y,,,20220307,,MD,PL,PL,2022,Q1,Elderly
202795002,20279500,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,N-terminal prohormone brain natriuretic peptide increased,,2022,Q1,2,F,20210301.0,20220228.0,20220103,20220307,EXP,,PL-MYLANLABS-2021M1096293,MYLAN,,71.0,YR,,M,Y,,,20220307,,MD,PL,PL,2022,Q1,Elderly
202795002,20279500,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Glomerular filtration rate abnormal,,2022,Q1,2,F,20210301.0,20220228.0,20220103,20220307,EXP,,PL-MYLANLABS-2021M1096293,MYLAN,,71.0,YR,,M,Y,,,20220307,,MD,PL,PL,2022,Q1,Elderly
202795002,20279500,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Lung disorder,,2022,Q1,2,F,20210301.0,20220228.0,20220103,20220307,EXP,,PL-MYLANLABS-2021M1096293,MYLAN,,71.0,YR,,M,Y,,,20220307,,MD,PL,PL,2022,Q1,Elderly
202795002,20279500,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Cardiac failure,,2022,Q1,2,F,20210301.0,20220228.0,20220103,20220307,EXP,,PL-MYLANLABS-2021M1096293,MYLAN,,71.0,YR,,M,Y,,,20220307,,MD,PL,PL,2022,Q1,Elderly
202795002,20279500,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Congestive cardiomyopathy,,2022,Q1,2,F,20210301.0,20220228.0,20220103,20220307,EXP,,PL-MYLANLABS-2021M1096293,MYLAN,,71.0,YR,,M,Y,,,20220307,,MD,PL,PL,2022,Q1,Elderly
202795961,20279596,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,Tablet,,2022,Q1,Upper gastrointestinal haemorrhage,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096453,MYLAN,,79.0,YR,,M,Y,90.0,KG,20220103,,PH,DE,DE,2022,Q1,Elderly
202795961,20279596,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,Tablet,,2022,Q1,Anaemia,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096453,MYLAN,,79.0,YR,,M,Y,90.0,KG,20220103,,PH,DE,DE,2022,Q1,Elderly
202795961,20279596,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,Tablet,,2022,Q1,Faeces discoloured,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096453,MYLAN,,79.0,YR,,M,Y,90.0,KG,20220103,,PH,DE,DE,2022,Q1,Elderly
202795961,20279596,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,Tablet,,2022,Q1,Frequent bowel movements,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096453,MYLAN,,79.0,YR,,M,Y,90.0,KG,20220103,,PH,DE,DE,2022,Q1,Elderly
202795961,20279596,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,Tablet,,2022,Q1,Product prescribing error,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096453,MYLAN,,79.0,YR,,M,Y,90.0,KG,20220103,,PH,DE,DE,2022,Q1,Elderly
202804221,20280422,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 10 mg, 1.5-0-0-0, Tabletten",,,,,,,,10.0,MG,Tablet,,2022,Q1,Atrial fibrillation,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096911,MYLAN,,77.0,YR,,M,Y,75.0,KG,20220103,,PH,DE,DE,2022,Q1,Elderly
202804221,20280422,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 10 mg, 1.5-0-0-0, Tabletten",,,,,,,,10.0,MG,Tablet,,2022,Q1,Dysuria,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096911,MYLAN,,77.0,YR,,M,Y,75.0,KG,20220103,,PH,DE,DE,2022,Q1,Elderly
202804221,20280422,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 10 mg, 1.5-0-0-0, Tabletten",,,,,,,,10.0,MG,Tablet,,2022,Q1,Dyspnoea,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096911,MYLAN,,77.0,YR,,M,Y,75.0,KG,20220103,,PH,DE,DE,2022,Q1,Elderly
202820981,20282098,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Tabletten",,,,,,,,,,,,2022,Q1,Pallor,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096523,MYLAN,,69.0,YR,,F,Y,,,20220103,,PH,DE,DE,2022,Q1,Elderly
202820981,20282098,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Tabletten",,,,,,,,,,,,2022,Q1,Haematemesis,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096523,MYLAN,,69.0,YR,,F,Y,,,20220103,,PH,DE,DE,2022,Q1,Elderly
202820981,20282098,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Tabletten",,,,,,,,,,,,2022,Q1,Product prescribing error,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096523,MYLAN,,69.0,YR,,F,Y,,,20220103,,PH,DE,DE,2022,Q1,Elderly
202820981,20282098,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Tabletten",,,,,,,,,,,,2022,Q1,Abdominal pain,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096523,MYLAN,,69.0,YR,,F,Y,,,20220103,,PH,DE,DE,2022,Q1,Elderly
202820981,20282098,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Tabletten",,,,,,,,,,,,2022,Q1,Dyspnoea,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096523,MYLAN,,69.0,YR,,F,Y,,,20220103,,PH,DE,DE,2022,Q1,Elderly
202820981,20282098,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Tabletten",,,,,,,,,,,,2022,Q1,Cold sweat,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096523,MYLAN,,69.0,YR,,F,Y,,,20220103,,PH,DE,DE,2022,Q1,Elderly
202885111,20288511,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2022,Q1,Abdominal pain upper,,2022,Q1,1,I,20211201.0,20211231.0,20220104,20220104,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-146416",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220104,,CN,MX,MX,2022,Q1,Adult
202885111,20288511,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2022,Q1,Thirst decreased,,2022,Q1,1,I,20211201.0,20211231.0,20220104,20220104,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-146416",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220104,,CN,MX,MX,2022,Q1,Adult
202885111,20288511,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2022,Q1,Food aversion,,2022,Q1,1,I,20211201.0,20211231.0,20220104,20220104,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-146416",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220104,,CN,MX,MX,2022,Q1,Adult
202885111,20288511,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2022,Q1,Kidney infection,,2022,Q1,1,I,20211201.0,20211231.0,20220104,20220104,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-146416",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220104,,CN,MX,MX,2022,Q1,Adult
202885111,20288511,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2022,Q1,Vomiting,,2022,Q1,1,I,20211201.0,20211231.0,20220104,20220104,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-146416",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220104,,CN,MX,MX,2022,Q1,Adult
202885111,20288511,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2022,Q1,Decreased appetite,,2022,Q1,1,I,20211201.0,20211231.0,20220104,20220104,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-146416",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220104,,CN,MX,MX,2022,Q1,Adult
202885111,20288511,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2022,Q1,Chills,,2022,Q1,1,I,20211201.0,20211231.0,20220104,20220104,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-146416",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220104,,CN,MX,MX,2022,Q1,Adult
202897311,20289731,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 milligram,,,,,,,,10.0,MG,,,2022,Q1,Vomiting,,2022,Q1,1,I,20210527.0,20211230.0,20220104,20220104,EXP,,DE-MYLANLABS-2021M1097824,MYLAN,,58.0,YR,,F,Y,90.0,KG,20220104,,MD,DE,DE,2022,Q1,Adult
202897311,20289731,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 milligram,,,,,,,,10.0,MG,,,2022,Q1,Lactic acidosis,,2022,Q1,1,I,20210527.0,20211230.0,20220104,20220104,EXP,,DE-MYLANLABS-2021M1097824,MYLAN,,58.0,YR,,F,Y,90.0,KG,20220104,,MD,DE,DE,2022,Q1,Adult
202897311,20289731,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 milligram,,,,,,,,10.0,MG,,,2022,Q1,Renal injury,,2022,Q1,1,I,20210527.0,20211230.0,20220104,20220104,EXP,,DE-MYLANLABS-2021M1097824,MYLAN,,58.0,YR,,F,Y,90.0,KG,20220104,,MD,DE,DE,2022,Q1,Adult
202897311,20289731,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 milligram,,,,,,,,10.0,MG,,,2022,Q1,Ketoacidosis,,2022,Q1,1,I,20210527.0,20211230.0,20220104,20220104,EXP,,DE-MYLANLABS-2021M1097824,MYLAN,,58.0,YR,,F,Y,90.0,KG,20220104,,MD,DE,DE,2022,Q1,Adult
202897311,20289731,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 milligram,,,,,,,,10.0,MG,,,2022,Q1,Nausea,,2022,Q1,1,I,20210527.0,20211230.0,20220104,20220104,EXP,,DE-MYLANLABS-2021M1097824,MYLAN,,58.0,YR,,F,Y,90.0,KG,20220104,,MD,DE,DE,2022,Q1,Adult
202897311,20289731,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 milligram,,,,,,,,10.0,MG,,,2022,Q1,Hypoglycaemia,,2022,Q1,1,I,20210527.0,20211230.0,20220104,20220104,EXP,,DE-MYLANLABS-2021M1097824,MYLAN,,58.0,YR,,F,Y,90.0,KG,20220104,,MD,DE,DE,2022,Q1,Adult
202897311,20289731,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 milligram,,,,,,,,10.0,MG,,,2022,Q1,Pain in extremity,,2022,Q1,1,I,20210527.0,20211230.0,20220104,20220104,EXP,,DE-MYLANLABS-2021M1097824,MYLAN,,58.0,YR,,F,Y,90.0,KG,20220104,,MD,DE,DE,2022,Q1,Adult
202900031,20290003,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 dosage form, qd",,,,,,,,,,,QD,2022,Q1,Blister,,2022,Q1,1,I,20211218.0,20211228.0,20220104,20220104,EXP,GB-MHRA-TPP31317404C3204233YC1640249125102,GB-MYLANLABS-2021M1097402,MYLAN,,49.0,YR,,M,Y,98.0,KG,20220104,,MD,GB,GB,2022,Q1,Adult
202900031,20290003,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 dosage form, qd",,,,,,,,,,,QD,2022,Q1,Penile rash,,2022,Q1,1,I,20211218.0,20211228.0,20220104,20220104,EXP,GB-MHRA-TPP31317404C3204233YC1640249125102,GB-MYLANLABS-2021M1097402,MYLAN,,49.0,YR,,M,Y,98.0,KG,20220104,,MD,GB,GB,2022,Q1,Adult
202902452,20290245,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD(0.5x1)",,,U,,,,,10.0,MG,,QD,2022,Q1,Heart rate increased,,2022,Q1,2,F,,20211224.0,20220104,20220106,EXP,,NVSC2021TH297081,NOVARTIS,,62.0,YR,,M,Y,,,20220106,,MD,TH,TH,2022,Q1,Adult
202902452,20290245,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD(0.5x1)",,,U,,,,,10.0,MG,,QD,2022,Q1,Hypotension,,2022,Q1,2,F,,20211224.0,20220104,20220106,EXP,,NVSC2021TH297081,NOVARTIS,,62.0,YR,,M,Y,,,20220106,,MD,TH,TH,2022,Q1,Adult
202902452,20290245,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD(0.5x1)",,,U,,,,,10.0,MG,,QD,2022,Q1,Cardiac failure chronic,,2022,Q1,2,F,,20211224.0,20220104,20220106,EXP,,NVSC2021TH297081,NOVARTIS,,62.0,YR,,M,Y,,,20220106,,MD,TH,TH,2022,Q1,Adult
202902452,20290245,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD(0.5x1)",,,U,,,,,10.0,MG,,QD,2022,Q1,Coronary artery stenosis,,2022,Q1,2,F,,20211224.0,20220104,20220106,EXP,,NVSC2021TH297081,NOVARTIS,,62.0,YR,,M,Y,,,20220106,,MD,TH,TH,2022,Q1,Adult
202902452,20290245,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD(0.5x1)",,,U,,,,,10.0,MG,,QD,2022,Q1,Wrong technique in product usage process,,2022,Q1,2,F,,20211224.0,20220104,20220106,EXP,,NVSC2021TH297081,NOVARTIS,,62.0,YR,,M,Y,,,20220106,,MD,TH,TH,2022,Q1,Adult
202902452,20290245,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD(0.5x1)",,,U,,,,,10.0,MG,,QD,2022,Q1,Glomerular filtration rate decreased,,2022,Q1,2,F,,20211224.0,20220104,20220106,EXP,,NVSC2021TH297081,NOVARTIS,,62.0,YR,,M,Y,,,20220106,,MD,TH,TH,2022,Q1,Adult
202912761,20291276,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Negative thoughts,,2022,Q1,1,I,20211004.0,,20220103,20220103,DIR,597504,,FDA-CTU,,39.0,YR,,F,N,103.0,KG,20220103,N,PH,US,,2022,Q1,Adult
202912761,20291276,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Anxiety,,2022,Q1,1,I,20211004.0,,20220103,20220103,DIR,597504,,FDA-CTU,,39.0,YR,,F,N,103.0,KG,20220103,N,PH,US,,2022,Q1,Adult
202912761,20291276,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Depression,,2022,Q1,1,I,20211004.0,,20220103,20220103,DIR,597504,,FDA-CTU,,39.0,YR,,F,N,103.0,KG,20220103,N,PH,US,,2022,Q1,Adult
202913932,20291393,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5mg/ 1000mg, 1 DF dosage form",,,Y,U,unknown,,206111.0,,,Film-coated tablet,Q12H,2022,Q1,Acute kidney injury,,2022,Q1,2,F,,20220120.0,20220104,20220127,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-143227",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20220127,,PH,MY,MY,2022,Q1,Elderly
202913932,20291393,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5mg/ 1000mg, 1 DF dosage form",,,Y,U,unknown,,206111.0,,,Film-coated tablet,Q12H,2022,Q1,Dehydration,,2022,Q1,2,F,,20220120.0,20220104,20220127,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-143227",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20220127,,PH,MY,MY,2022,Q1,Elderly
202919211,20291921,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,U,,,,10.0,MG,,QD,2022,Q1,General physical health deterioration,,2022,Q1,1,I,,20211230.0,20220104,20220104,EXP,,DE-MYLANLABS-2021M1097720,MYLAN,,79.0,YR,,M,Y,,,20220104,,PH,DE,DE,2022,Q1,Elderly
202919211,20291921,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,U,,,,10.0,MG,,QD,2022,Q1,Product monitoring error,,2022,Q1,1,I,,20211230.0,20220104,20220104,EXP,,DE-MYLANLABS-2021M1097720,MYLAN,,79.0,YR,,M,Y,,,20220104,,PH,DE,DE,2022,Q1,Elderly
202919211,20291921,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,U,,,,10.0,MG,,QD,2022,Q1,Anaemia,,2022,Q1,1,I,,20211230.0,20220104,20220104,EXP,,DE-MYLANLABS-2021M1097720,MYLAN,,79.0,YR,,M,Y,,,20220104,,PH,DE,DE,2022,Q1,Elderly
202919211,20291921,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,U,,,,10.0,MG,,QD,2022,Q1,Haematochezia,,2022,Q1,1,I,,20211230.0,20220104,20220104,EXP,,DE-MYLANLABS-2021M1097720,MYLAN,,79.0,YR,,M,Y,,,20220104,,PH,DE,DE,2022,Q1,Elderly
202919211,20291921,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,U,,,,10.0,MG,,QD,2022,Q1,Muscular weakness,,2022,Q1,1,I,,20211230.0,20220104,20220104,EXP,,DE-MYLANLABS-2021M1097720,MYLAN,,79.0,YR,,M,Y,,,20220104,,PH,DE,DE,2022,Q1,Elderly
202923882,20292388,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 0-2-0-0, Tabletten",,,,,,,,,,Tablet,,2022,Q1,Product prescribing error,,2022,Q1,2,F,,20211230.0,20220104,20220110,EXP,,DE-MYLANLABS-2021M1098083,MYLAN,,68.0,YR,,F,Y,103.3,KG,20220110,,PH,DE,DE,2022,Q1,Elderly
202923882,20292388,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 0-2-0-0, Tabletten",,,,,,,,,,Tablet,,2022,Q1,Dyspnoea,,2022,Q1,2,F,,20211230.0,20220104,20220110,EXP,,DE-MYLANLABS-2021M1098083,MYLAN,,68.0,YR,,F,Y,103.3,KG,20220110,,PH,DE,DE,2022,Q1,Elderly
202970111,20297011,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,Tablet,QD,2022,Q1,Penile rash,,2022,Q1,1,I,20211218.0,20211228.0,20220105,20220105,EXP,GB-MHRA-TPP31317404C3204233YC1640249125102,GB-TEVA-2021-GB-1995293,TEVA,,49.0,YR,A,M,Y,98.0,KG,20220105,,MD,GB,GB,2022,Q1,Adult
202970111,20297011,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,Tablet,QD,2022,Q1,Blister,,2022,Q1,1,I,20211218.0,20211228.0,20220105,20220105,EXP,GB-MHRA-TPP31317404C3204233YC1640249125102,GB-TEVA-2021-GB-1995293,TEVA,,49.0,YR,A,M,Y,98.0,KG,20220105,,MD,GB,GB,2022,Q1,Adult
202972431,20297243,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1.5-0-0-0, tablets, unk",,,U,,,,,,,Tablet,,2022,Q1,Dysuria,,2022,Q1,1,I,,20211221.0,20220105,20220105,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322814,RANBAXY,,77.0,YR,,M,Y,75.0,KG,20220105,,PH,DE,DE,2022,Q1,Elderly
202972431,20297243,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1.5-0-0-0, tablets, unk",,,U,,,,,,,Tablet,,2022,Q1,Atrial fibrillation,,2022,Q1,1,I,,20211221.0,20220105,20220105,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322814,RANBAXY,,77.0,YR,,M,Y,75.0,KG,20220105,,PH,DE,DE,2022,Q1,Elderly
202972431,20297243,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1.5-0-0-0, tablets, unk",,,U,,,,,,,Tablet,,2022,Q1,Dyspnoea,,2022,Q1,1,I,,20211221.0,20220105,20220105,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322814,RANBAXY,,77.0,YR,,M,Y,75.0,KG,20220105,,PH,DE,DE,2022,Q1,Elderly
202983824,20298382,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg x 4 x 1 Days,,,,,,,,10.0,MG,Unknown,QID,2022,Q1,Neurotoxicity,,2022,Q1,4,F,20211225.0,20220217.0,20220105,20220223,EXP,,AT-CELGENEUS-AUT-20211208544,CELGENE,,71.0,YR,,M,Y,88.0,KG,20220223,,MD,AT,AT,2022,Q1,Elderly
202985451,20298545,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Urinary tract infection,,2022,Q1,1,I,20210928.0,,20220104,20220104,DIR,FDA-CDER-CTU-2022-841,,FDA-CTU,,67.0,YR,,M,N,,,20211220,N,PH,US,,2022,Q1,Elderly
203020911,20302091,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablets ()",,,U,,,,,,,Tablet,,2022,Q1,Pruritus,,2022,Q1,1,I,,20211223.0,20220105,20220105,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322719,RANBAXY,,78.0,YR,,F,Y,90.0,KG,20220106,,PH,DE,DE,2022,Q1,Elderly
203020911,20302091,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablets ()",,,U,,,,,,,Tablet,,2022,Q1,Liver function test abnormal,,2022,Q1,1,I,,20211223.0,20220105,20220105,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322719,RANBAXY,,78.0,YR,,F,Y,90.0,KG,20220106,,PH,DE,DE,2022,Q1,Elderly
203021271,20302127,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg/day,,,U,,,,,25.0,MG,,,2022,Q1,Drug ineffective,,2022,Q1,1,I,,20211227.0,20220105,20220105,EXP,,KR-ALS-000477,ALIGNSCIENCE PHARMA,"Ku E.J., Oh T.K., Lee D., Jeon H.J. Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: a 3-year prospective observational study. Diabetes Res Clin Pract. 2021;182:109123. doi:10.1016/j.diabres.2021.109123",72.0,YR,E,M,Y,,,20220106,,HP,KR,KR,2022,Q1,Elderly
203021271,20302127,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg/day,,,U,,,,,25.0,MG,,,2022,Q1,Glycosylated haemoglobin increased,,2022,Q1,1,I,,20211227.0,20220105,20220105,EXP,,KR-ALS-000477,ALIGNSCIENCE PHARMA,"Ku E.J., Oh T.K., Lee D., Jeon H.J. Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: a 3-year prospective observational study. Diabetes Res Clin Pract. 2021;182:109123. doi:10.1016/j.diabres.2021.109123",72.0,YR,E,M,Y,,,20220106,,HP,KR,KR,2022,Q1,Elderly
203025581,20302558,4,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Off label use,,2022,Q1,1,I,,20211221.0,20220106,20220106,PER,,LB-LUPIN PHARMACEUTICALS INC.-2021-26271,LUPIN,"Naous E, Nassani B-M, Yaghi C, Nasr F, Medlej R. Hemophagocytic lymphohistiocytosis, a new cause of death during ^post-acute COVID-19 syndrome? A case report.. Journal of hematopathology. 2021;14 (3):229-233",69.0,YR,,F,Y,,,20220106,,HP,LB,LB,2022,Q1,Elderly
203039045,20303904,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Drug Dose First Administered is 10 TABLET ;Ongoing: Yes,,,,,,,,,,Tablet,QD,2022,Q1,Uveitis,,2022,Q1,5,F,20211225.0,20220317.0,20220106,20220325,EXP,,US-ROCHE-2992171,ROCHE,,58.0,YR,,M,Y,94.0,KG,20220325,,MD,US,,2022,Q1,Adult
203069561,20306956,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablet",,,U,,,,,,,Tablet,,2022,Q1,Product monitoring error,,2022,Q1,1,I,,20211223.0,20220107,20220107,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322998,RANBAXY,,79.0,YR,,M,Y,,,20220107,,PH,DE,DE,2022,Q1,Elderly
203069561,20306956,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablet",,,U,,,,,,,Tablet,,2022,Q1,Muscular weakness,,2022,Q1,1,I,,20211223.0,20220107,20220107,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322998,RANBAXY,,79.0,YR,,M,Y,,,20220107,,PH,DE,DE,2022,Q1,Elderly
203069561,20306956,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablet",,,U,,,,,,,Tablet,,2022,Q1,General physical health deterioration,,2022,Q1,1,I,,20211223.0,20220107,20220107,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322998,RANBAXY,,79.0,YR,,M,Y,,,20220107,,PH,DE,DE,2022,Q1,Elderly
203069561,20306956,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablet",,,U,,,,,,,Tablet,,2022,Q1,Haematochezia,,2022,Q1,1,I,,20211223.0,20220107,20220107,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322998,RANBAXY,,79.0,YR,,M,Y,,,20220107,,PH,DE,DE,2022,Q1,Elderly
203069561,20306956,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablet",,,U,,,,,,,Tablet,,2022,Q1,Anaemia,,2022,Q1,1,I,,20211223.0,20220107,20220107,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322998,RANBAXY,,79.0,YR,,M,Y,,,20220107,,PH,DE,DE,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Blood pressure decreased,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Malaise,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Blood pressure fluctuation,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Fatigue,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Blood pressure systolic increased,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Small intestinal obstruction,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Cardiac failure congestive,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Limb injury,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Blood pressure diastolic increased,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Vital functions abnormal,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Joint injury,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Influenza,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Blood pressure increased,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Dyspnoea,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Palpitations,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Oedema peripheral,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Heart rate decreased,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Orthopnoea,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Dizziness,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Pneumonia,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Cough,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Rales,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Bronchitis,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Inappropriate schedule of product administration,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Fall,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Atrial fibrillation,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Pericardial effusion,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Heart rate increased,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203091601,20309160,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Pulmonary oedema,,2022,Q1,1,I,,20211224.0,20220107,20220107,EXP,CA-HC-000494735,CA-ALVOGEN-2022-ALVOGEN-118104,ALVOGEN,,66.0,YR,,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203106402,20310640,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,2,F,20211221.0,20220307.0,20220107,20220308,EXP,,US-BAYER-2022A002300,BAYER,,65.0,YR,E,M,Y,,,20220308,,HP,US,US,2022,Q1,Elderly
203106402,20310640,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Haemorrhoids,,2022,Q1,2,F,20211221.0,20220307.0,20220107,20220308,EXP,,US-BAYER-2022A002300,BAYER,,65.0,YR,E,M,Y,,,20220308,,HP,US,US,2022,Q1,Elderly
203106402,20310640,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Haemorrhoidal haemorrhage,,2022,Q1,2,F,20211221.0,20220307.0,20220107,20220308,EXP,,US-BAYER-2022A002300,BAYER,,65.0,YR,E,M,Y,,,20220308,,HP,US,US,2022,Q1,Elderly
203106402,20310640,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Peripheral swelling,,2022,Q1,2,F,20211221.0,20220307.0,20220107,20220308,EXP,,US-BAYER-2022A002300,BAYER,,65.0,YR,E,M,Y,,,20220308,,HP,US,US,2022,Q1,Elderly
203111253,20311125,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, unknown",,,,,,,,,,,,2022,Q1,Vomiting,,2022,Q1,3,F,20211201.0,20220103.0,20220107,20220118,EXP,,MX-ELI_LILLY_AND_COMPANY-MX202201000133,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20220118,,CN,MX,MX,2022,Q1,Adult
203111253,20311125,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, unknown",,,,,,,,,,,,2022,Q1,Decreased appetite,,2022,Q1,3,F,20211201.0,20220103.0,20220107,20220118,EXP,,MX-ELI_LILLY_AND_COMPANY-MX202201000133,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20220118,,CN,MX,MX,2022,Q1,Adult
203111253,20311125,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, unknown",,,,,,,,,,,,2022,Q1,Kidney infection,,2022,Q1,3,F,20211201.0,20220103.0,20220107,20220118,EXP,,MX-ELI_LILLY_AND_COMPANY-MX202201000133,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20220118,,CN,MX,MX,2022,Q1,Adult
203111253,20311125,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, unknown",,,,,,,,,,,,2022,Q1,Thirst decreased,,2022,Q1,3,F,20211201.0,20220103.0,20220107,20220118,EXP,,MX-ELI_LILLY_AND_COMPANY-MX202201000133,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20220118,,CN,MX,MX,2022,Q1,Adult
203111253,20311125,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, unknown",,,,,,,,,,,,2022,Q1,Nausea,,2022,Q1,3,F,20211201.0,20220103.0,20220107,20220118,EXP,,MX-ELI_LILLY_AND_COMPANY-MX202201000133,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20220118,,CN,MX,MX,2022,Q1,Adult
203111253,20311125,2,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, unknown",,,,,,,,,,,,2022,Q1,Abdominal pain upper,,2022,Q1,3,F,20211201.0,20220103.0,20220107,20220118,EXP,,MX-ELI_LILLY_AND_COMPANY-MX202201000133,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20220118,,CN,MX,MX,2022,Q1,Adult
203148921,20314892,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, 1x/day",,,,,,,,,,,QD,2022,Q1,Penile blister,,2022,Q1,1,I,20211218.0,20211228.0,20220110,20220110,EXP,GB-MHRA-TPP31317404C3204233YC1640249125102,GB-PFIZER INC-202101870464,PFIZER,,49.0,YR,,M,Y,98.0,KG,20220110,,MD,GB,GB,2022,Q1,Adult
203148921,20314892,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, 1x/day",,,,,,,,,,,QD,2022,Q1,Penile rash,,2022,Q1,1,I,20211218.0,20211228.0,20220110,20220110,EXP,GB-MHRA-TPP31317404C3204233YC1640249125102,GB-PFIZER INC-202101870464,PFIZER,,49.0,YR,,M,Y,98.0,KG,20220110,,MD,GB,GB,2022,Q1,Adult
203160212,20316021,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 - 1000 mg, bid",,,,,UNKNOWN,,,,,"Tablet, coated",,2022,Q1,Constipation,,2022,Q1,2,F,20211121.0,20220112.0,20220110,20220124,EXP,,CO-NOVOPROD-870068,NOVO NORDISK,,73.0,YR,,M,Y,,,20220124,,CN,CO,CO,2022,Q1,Elderly
203160212,20316021,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 - 1000 mg, bid",,,,,UNKNOWN,,,,,"Tablet, coated",,2022,Q1,Decreased appetite,,2022,Q1,2,F,20211121.0,20220112.0,20220110,20220124,EXP,,CO-NOVOPROD-870068,NOVO NORDISK,,73.0,YR,,M,Y,,,20220124,,CN,CO,CO,2022,Q1,Elderly
203160212,20316021,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 - 1000 mg, bid",,,,,UNKNOWN,,,,,"Tablet, coated",,2022,Q1,Vomiting,,2022,Q1,2,F,20211121.0,20220112.0,20220110,20220124,EXP,,CO-NOVOPROD-870068,NOVO NORDISK,,73.0,YR,,M,Y,,,20220124,,CN,CO,CO,2022,Q1,Elderly
203160212,20316021,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 - 1000 mg, bid",,,,,UNKNOWN,,,,,"Tablet, coated",,2022,Q1,Diarrhoea,,2022,Q1,2,F,20211121.0,20220112.0,20220110,20220124,EXP,,CO-NOVOPROD-870068,NOVO NORDISK,,73.0,YR,,M,Y,,,20220124,,CN,CO,CO,2022,Q1,Elderly
203161451,20316145,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,Y,,,,,25.0,MG,,,2022,Q1,Constipation,,2022,Q1,1,I,20200305.0,20220102.0,20220110,20220110,EXP,,GB-AUROBINDO-AUR-APL-2022-000822,AUROBINDO,,56.0,YR,,M,Y,,,20220110,,PH,GB,GB,2022,Q1,Adult
203161451,20316145,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,Y,,,,,25.0,MG,,,2022,Q1,Abdominal pain,,2022,Q1,1,I,20200305.0,20220102.0,20220110,20220110,EXP,,GB-AUROBINDO-AUR-APL-2022-000822,AUROBINDO,,56.0,YR,,M,Y,,,20220110,,PH,GB,GB,2022,Q1,Adult
203161451,20316145,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,Y,,,,,25.0,MG,,,2022,Q1,Urinary retention,,2022,Q1,1,I,20200305.0,20220102.0,20220110,20220110,EXP,,GB-AUROBINDO-AUR-APL-2022-000822,AUROBINDO,,56.0,YR,,M,Y,,,20220110,,PH,GB,GB,2022,Q1,Adult
203161451,20316145,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,Y,,,,,25.0,MG,,,2022,Q1,Urinary tract infection,,2022,Q1,1,I,20200305.0,20220102.0,20220110,20220110,EXP,,GB-AUROBINDO-AUR-APL-2022-000822,AUROBINDO,,56.0,YR,,M,Y,,,20220110,,PH,GB,GB,2022,Q1,Adult
203161451,20316145,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,Y,,,,,25.0,MG,,,2022,Q1,Acute kidney injury,,2022,Q1,1,I,20200305.0,20220102.0,20220110,20220110,EXP,,GB-AUROBINDO-AUR-APL-2022-000822,AUROBINDO,,56.0,YR,,M,Y,,,20220110,,PH,GB,GB,2022,Q1,Adult
203161451,20316145,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,Y,,,,,25.0,MG,,,2022,Q1,Faecaloma,,2022,Q1,1,I,20200305.0,20220102.0,20220110,20220110,EXP,,GB-AUROBINDO-AUR-APL-2022-000822,AUROBINDO,,56.0,YR,,M,Y,,,20220110,,PH,GB,GB,2022,Q1,Adult
203161451,20316145,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,Y,,,,,25.0,MG,,,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20200305.0,20220102.0,20220110,20220110,EXP,,GB-AUROBINDO-AUR-APL-2022-000822,AUROBINDO,,56.0,YR,,M,Y,,,20220110,,PH,GB,GB,2022,Q1,Adult
203171681,20317168,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd (10 milligram, 1-0-0-0, Tabletten)",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q1,Somnolence,,2022,Q1,1,I,,20211230.0,20220110,20220110,EXP,,DE-MYLANLABS-2021M1097939,MYLAN,,71.0,YR,,M,Y,,,20220110,,PH,DE,DE,2022,Q1,Elderly
203171681,20317168,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd (10 milligram, 1-0-0-0, Tabletten)",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q1,Thirst,,2022,Q1,1,I,,20211230.0,20220110,20220110,EXP,,DE-MYLANLABS-2021M1097939,MYLAN,,71.0,YR,,M,Y,,,20220110,,PH,DE,DE,2022,Q1,Elderly
203171681,20317168,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd (10 milligram, 1-0-0-0, Tabletten)",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q1,Hyperglycaemia,,2022,Q1,1,I,,20211230.0,20220110,20220110,EXP,,DE-MYLANLABS-2021M1097939,MYLAN,,71.0,YR,,M,Y,,,20220110,,PH,DE,DE,2022,Q1,Elderly
203171681,20317168,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd (10 milligram, 1-0-0-0, Tabletten)",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q1,Polyuria,,2022,Q1,1,I,,20211230.0,20220110,20220110,EXP,,DE-MYLANLABS-2021M1097939,MYLAN,,71.0,YR,,M,Y,,,20220110,,PH,DE,DE,2022,Q1,Elderly
203171681,20317168,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd (10 milligram, 1-0-0-0, Tabletten)",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q1,Headache,,2022,Q1,1,I,,20211230.0,20220110,20220110,EXP,,DE-MYLANLABS-2021M1097939,MYLAN,,71.0,YR,,M,Y,,,20220110,,PH,DE,DE,2022,Q1,Elderly
203171681,20317168,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd (10 milligram, 1-0-0-0, Tabletten)",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q1,Product monitoring error,,2022,Q1,1,I,,20211230.0,20220110,20220110,EXP,,DE-MYLANLABS-2021M1097939,MYLAN,,71.0,YR,,M,Y,,,20220110,,PH,DE,DE,2022,Q1,Elderly
203171681,20317168,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd (10 milligram, 1-0-0-0, Tabletten)",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q1,Nausea,,2022,Q1,1,I,,20211230.0,20220110,20220110,EXP,,DE-MYLANLABS-2021M1097939,MYLAN,,71.0,YR,,M,Y,,,20220110,,PH,DE,DE,2022,Q1,Elderly
203195121,20319512,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,,2022,Q1,Acute kidney injury,,2022,Q1,1,I,,20220102.0,20220110,20220110,EXP,,"GB-Canton Laboratories, LLC-2123785",CANTON LABORATORIES,,56.0,YR,,M,Y,,,20220110,,HP,GB,GB,2022,Q1,Adult
203195121,20319512,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,,2022,Q1,Urinary retention,,2022,Q1,1,I,,20220102.0,20220110,20220110,EXP,,"GB-Canton Laboratories, LLC-2123785",CANTON LABORATORIES,,56.0,YR,,M,Y,,,20220110,,HP,GB,GB,2022,Q1,Adult
203195121,20319512,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,,2022,Q1,Constipation,,2022,Q1,1,I,,20220102.0,20220110,20220110,EXP,,"GB-Canton Laboratories, LLC-2123785",CANTON LABORATORIES,,56.0,YR,,M,Y,,,20220110,,HP,GB,GB,2022,Q1,Adult
203195121,20319512,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,,2022,Q1,Urinary tract infection,,2022,Q1,1,I,,20220102.0,20220110,20220110,EXP,,"GB-Canton Laboratories, LLC-2123785",CANTON LABORATORIES,,56.0,YR,,M,Y,,,20220110,,HP,GB,GB,2022,Q1,Adult
203195121,20319512,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,,2022,Q1,Abdominal pain,,2022,Q1,1,I,,20220102.0,20220110,20220110,EXP,,"GB-Canton Laboratories, LLC-2123785",CANTON LABORATORIES,,56.0,YR,,M,Y,,,20220110,,HP,GB,GB,2022,Q1,Adult
203195121,20319512,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,,2022,Q1,Faecaloma,,2022,Q1,1,I,,20220102.0,20220110,20220110,EXP,,"GB-Canton Laboratories, LLC-2123785",CANTON LABORATORIES,,56.0,YR,,M,Y,,,20220110,,HP,GB,GB,2022,Q1,Adult
203195121,20319512,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,,20220102.0,20220110,20220110,EXP,,"GB-Canton Laboratories, LLC-2123785",CANTON LABORATORIES,,56.0,YR,,M,Y,,,20220110,,HP,GB,GB,2022,Q1,Adult
203197951,20319795,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Erythema,,2022,Q1,1,I,,20220107.0,20220111,20220111,EXP,GB-MHRA-EYC 00270678,GB-ORGANON-O2201GBR000647,ORGANON,,51.0,YR,,F,Y,87.0,KG,20220111,,CN,GB,GB,2022,Q1,Adult
203197951,20319795,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Chemical burn of skin,,2022,Q1,1,I,,20220107.0,20220111,20220111,EXP,GB-MHRA-EYC 00270678,GB-ORGANON-O2201GBR000647,ORGANON,,51.0,YR,,F,Y,87.0,KG,20220111,,CN,GB,GB,2022,Q1,Adult
203197951,20319795,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Blister,,2022,Q1,1,I,,20220107.0,20220111,20220111,EXP,GB-MHRA-EYC 00270678,GB-ORGANON-O2201GBR000647,ORGANON,,51.0,YR,,F,Y,87.0,KG,20220111,,CN,GB,GB,2022,Q1,Adult
203208921,20320892,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,,2022,Q1,Urinary tract infection,,2022,Q1,1,I,20200305.0,20220102.0,20220111,20220111,EXP,GB-MHRA-ADR 26417461,GB-Accord-249877,ACCORD,,56.0,YR,,M,Y,,,20220111,,PH,GB,GB,2022,Q1,Adult
203208921,20320892,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,,2022,Q1,Urinary retention,,2022,Q1,1,I,20200305.0,20220102.0,20220111,20220111,EXP,GB-MHRA-ADR 26417461,GB-Accord-249877,ACCORD,,56.0,YR,,M,Y,,,20220111,,PH,GB,GB,2022,Q1,Adult
203208921,20320892,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,,2022,Q1,Faecaloma,,2022,Q1,1,I,20200305.0,20220102.0,20220111,20220111,EXP,GB-MHRA-ADR 26417461,GB-Accord-249877,ACCORD,,56.0,YR,,M,Y,,,20220111,,PH,GB,GB,2022,Q1,Adult
203208921,20320892,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,,2022,Q1,Acute kidney injury,,2022,Q1,1,I,20200305.0,20220102.0,20220111,20220111,EXP,GB-MHRA-ADR 26417461,GB-Accord-249877,ACCORD,,56.0,YR,,M,Y,,,20220111,,PH,GB,GB,2022,Q1,Adult
203208921,20320892,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,,2022,Q1,Abdominal pain,,2022,Q1,1,I,20200305.0,20220102.0,20220111,20220111,EXP,GB-MHRA-ADR 26417461,GB-Accord-249877,ACCORD,,56.0,YR,,M,Y,,,20220111,,PH,GB,GB,2022,Q1,Adult
203208921,20320892,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,,2022,Q1,Constipation,,2022,Q1,1,I,20200305.0,20220102.0,20220111,20220111,EXP,GB-MHRA-ADR 26417461,GB-Accord-249877,ACCORD,,56.0,YR,,M,Y,,,20220111,,PH,GB,GB,2022,Q1,Adult
203208921,20320892,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20200305.0,20220102.0,20220111,20220111,EXP,GB-MHRA-ADR 26417461,GB-Accord-249877,ACCORD,,56.0,YR,,M,Y,,,20220111,,PH,GB,GB,2022,Q1,Adult
203214601,20321460,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Drug intolerance,,2022,Q1,1,I,,,20220107,20220107,DIR,FDA-CDER-CTU-2022-2128,,FDA-CTU,,52.0,YR,,M,N,106.0,KG,20220107,N,MD,US,,2022,Q1,Adult
203214601,20321460,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Therapeutic response changed,,2022,Q1,1,I,,,20220107,20220107,DIR,FDA-CDER-CTU-2022-2128,,FDA-CTU,,52.0,YR,,M,N,106.0,KG,20220107,N,MD,US,,2022,Q1,Adult
203214601,20321460,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Product substitution issue,,2022,Q1,1,I,,,20220107,20220107,DIR,FDA-CDER-CTU-2022-2128,,FDA-CTU,,52.0,YR,,M,N,106.0,KG,20220107,N,MD,US,,2022,Q1,Adult
203234761,20323476,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q1,Rash,,2022,Q1,1,I,20210827.0,,20220111,20220111,DIR,FDA-CDER-CTU-2022-2670,,FDA-CTU,,71.0,YR,,M,N,68.49,KG,20211021,N,PH,US,,2022,Q1,Elderly
203272581,20327258,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q1,Hydronephrosis,,2022,Q1,1,I,20211122.0,,20220112,20220112,DIR,FDA-CDER-CTU-2022-2886,,FDA-CTU,,73.0,YR,,M,N,62.0,KG,20220107,N,PH,US,,2022,Q1,Elderly
203272581,20327258,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q1,Klebsiella test positive,,2022,Q1,1,I,20211122.0,,20220112,20220112,DIR,FDA-CDER-CTU-2022-2886,,FDA-CTU,,73.0,YR,,M,N,62.0,KG,20220107,N,PH,US,,2022,Q1,Elderly
203272581,20327258,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q1,Prostatomegaly,,2022,Q1,1,I,20211122.0,,20220112,20220112,DIR,FDA-CDER-CTU-2022-2886,,FDA-CTU,,73.0,YR,,M,N,62.0,KG,20220107,N,PH,US,,2022,Q1,Elderly
203272581,20327258,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20211122.0,,20220112,20220112,DIR,FDA-CDER-CTU-2022-2886,,FDA-CTU,,73.0,YR,,M,N,62.0,KG,20220107,N,PH,US,,2022,Q1,Elderly
203272581,20327258,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q1,Emphysematous cystitis,,2022,Q1,1,I,20211122.0,,20220112,20220112,DIR,FDA-CDER-CTU-2022-2886,,FDA-CTU,,73.0,YR,,M,N,62.0,KG,20220107,N,PH,US,,2022,Q1,Elderly
203272581,20327258,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q1,Flatulence,,2022,Q1,1,I,20211122.0,,20220112,20220112,DIR,FDA-CDER-CTU-2022-2886,,FDA-CTU,,73.0,YR,,M,N,62.0,KG,20220107,N,PH,US,,2022,Q1,Elderly
203272581,20327258,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q1,Anion gap increased,,2022,Q1,1,I,20211122.0,,20220112,20220112,DIR,FDA-CDER-CTU-2022-2886,,FDA-CTU,,73.0,YR,,M,N,62.0,KG,20220107,N,PH,US,,2022,Q1,Elderly
203272581,20327258,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q1,Urinary tract infection,,2022,Q1,1,I,20211122.0,,20220112,20220112,DIR,FDA-CDER-CTU-2022-2886,,FDA-CTU,,73.0,YR,,M,N,62.0,KG,20220107,N,PH,US,,2022,Q1,Elderly
203273271,20327327,3,C,empagliflozin 25mg,,2,,,,,,,,,,25.0,MG,TAB,,2022,Q1,Memory impairment,,2022,Q1,1,I,20211001.0,20211219.0,20220112,20220112,PER,,US-SCIEGENP-2021SCSPO01052,SCIEGEN,,63.0,YR,A,,Y,181.0,KG,20220112,,CN,US,US,2022,Q1,Adult
203289601,20328960,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,Unknown,,2022,Q1,Ageusia,,2022,Q1,1,I,,20220110.0,20220112,20220112,PER,,US-CELGENEUS-USA-20220102323,CELGENE,,89.0,YR,,M,Y,69.008,KG,20220112,,CN,US,US,2022,Q1,Elderly
203304221,20330422,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 day,,,U,,,,,,,,,2022,Q1,Pneumonia aspiration,,2022,Q1,1,I,,20220103.0,20220113,20220113,EXP,CA-MHPD-E2B_03532949,CA-Accord-249906,ACCORD,,75.0,YR,,M,Y,,,20220113,,CN,CA,CA,2022,Q1,Elderly
203304221,20330422,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 day,,,U,,,,,,,,,2022,Q1,Wheezing,,2022,Q1,1,I,,20220103.0,20220113,20220113,EXP,CA-MHPD-E2B_03532949,CA-Accord-249906,ACCORD,,75.0,YR,,M,Y,,,20220113,,CN,CA,CA,2022,Q1,Elderly
203304221,20330422,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 day,,,U,,,,,,,,,2022,Q1,Atelectasis,,2022,Q1,1,I,,20220103.0,20220113,20220113,EXP,CA-MHPD-E2B_03532949,CA-Accord-249906,ACCORD,,75.0,YR,,M,Y,,,20220113,,CN,CA,CA,2022,Q1,Elderly
203304221,20330422,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 day,,,U,,,,,,,,,2022,Q1,Osteonecrosis,,2022,Q1,1,I,,20220103.0,20220113,20220113,EXP,CA-MHPD-E2B_03532949,CA-Accord-249906,ACCORD,,75.0,YR,,M,Y,,,20220113,,CN,CA,CA,2022,Q1,Elderly
203304221,20330422,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 day,,,U,,,,,,,,,2022,Q1,Cough,,2022,Q1,1,I,,20220103.0,20220113,20220113,EXP,CA-MHPD-E2B_03532949,CA-Accord-249906,ACCORD,,75.0,YR,,M,Y,,,20220113,,CN,CA,CA,2022,Q1,Elderly
203304221,20330422,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 day,,,U,,,,,,,,,2022,Q1,Lower respiratory tract infection,,2022,Q1,1,I,,20220103.0,20220113,20220113,EXP,CA-MHPD-E2B_03532949,CA-Accord-249906,ACCORD,,75.0,YR,,M,Y,,,20220113,,CN,CA,CA,2022,Q1,Elderly
203304221,20330422,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 day,,,U,,,,,,,,,2022,Q1,Asthma,,2022,Q1,1,I,,20220103.0,20220113,20220113,EXP,CA-MHPD-E2B_03532949,CA-Accord-249906,ACCORD,,75.0,YR,,M,Y,,,20220113,,CN,CA,CA,2022,Q1,Elderly
203313941,20331394,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q1,Faecaloma,,2022,Q1,1,I,20200305.0,20220102.0,20220113,20220113,EXP,GB-MHRA-EYC 00270312,GB-MYLANLABS-2022M1000752,MYLAN,,56.0,YR,,M,Y,,,20220113,,PH,GB,GB,2022,Q1,Adult
203313941,20331394,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q1,Malaise,,2022,Q1,1,I,20200305.0,20220102.0,20220113,20220113,EXP,GB-MHRA-EYC 00270312,GB-MYLANLABS-2022M1000752,MYLAN,,56.0,YR,,M,Y,,,20220113,,PH,GB,GB,2022,Q1,Adult
203313941,20331394,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q1,Acute kidney injury,,2022,Q1,1,I,20200305.0,20220102.0,20220113,20220113,EXP,GB-MHRA-EYC 00270312,GB-MYLANLABS-2022M1000752,MYLAN,,56.0,YR,,M,Y,,,20220113,,PH,GB,GB,2022,Q1,Adult
203313941,20331394,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q1,Urinary tract infection,,2022,Q1,1,I,20200305.0,20220102.0,20220113,20220113,EXP,GB-MHRA-EYC 00270312,GB-MYLANLABS-2022M1000752,MYLAN,,56.0,YR,,M,Y,,,20220113,,PH,GB,GB,2022,Q1,Adult
203313941,20331394,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q1,Constipation,,2022,Q1,1,I,20200305.0,20220102.0,20220113,20220113,EXP,GB-MHRA-EYC 00270312,GB-MYLANLABS-2022M1000752,MYLAN,,56.0,YR,,M,Y,,,20220113,,PH,GB,GB,2022,Q1,Adult
203313941,20331394,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q1,Abdominal pain,,2022,Q1,1,I,20200305.0,20220102.0,20220113,20220113,EXP,GB-MHRA-EYC 00270312,GB-MYLANLABS-2022M1000752,MYLAN,,56.0,YR,,M,Y,,,20220113,,PH,GB,GB,2022,Q1,Adult
203313941,20331394,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20200305.0,20220102.0,20220113,20220113,EXP,GB-MHRA-EYC 00270312,GB-MYLANLABS-2022M1000752,MYLAN,,56.0,YR,,M,Y,,,20220113,,PH,GB,GB,2022,Q1,Adult
203313941,20331394,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q1,Urinary retention,,2022,Q1,1,I,20200305.0,20220102.0,20220113,20220113,EXP,GB-MHRA-EYC 00270312,GB-MYLANLABS-2022M1000752,MYLAN,,56.0,YR,,M,Y,,,20220113,,PH,GB,GB,2022,Q1,Adult
2033327512,20333275,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2022,Q1,Alanine aminotransferase increased,,2022,Q1,12,F,20220105.0,20220321.0,20220113,20220329,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20220329,,MD,BR,,2022,Q1,Adult
2033327512,20333275,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2022,Q1,Aspartate aminotransferase increased,,2022,Q1,12,F,20220105.0,20220321.0,20220113,20220329,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20220329,,MD,BR,,2022,Q1,Adult
2033327512,20333275,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2022,Q1,Anaemia,,2022,Q1,12,F,20220105.0,20220321.0,20220113,20220329,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20220329,,MD,BR,,2022,Q1,Adult
2033327512,20333275,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2022,Q1,Adrenal insufficiency,,2022,Q1,12,F,20220105.0,20220321.0,20220113,20220329,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20220329,,MD,BR,,2022,Q1,Adult
203341251,20334125,4,C,empagliflozin 10,,2,,,,,,,,,,,,,,2022,Q1,Chest pain,,2022,Q1,1,I,20220108.0,,20220112,20220112,DIR,598833,,FDA-CTU,,66.0,YR,,M,N,80.0,KG,20220112,N,PH,US,,2022,Q1,Elderly
203341251,20334125,4,C,empagliflozin 10,,2,,,,,,,,,,,,,,2022,Q1,Oropharyngeal pain,,2022,Q1,1,I,20220108.0,,20220112,20220112,DIR,598833,,FDA-CTU,,66.0,YR,,M,N,80.0,KG,20220112,N,PH,US,,2022,Q1,Elderly
203341251,20334125,4,C,empagliflozin 10,,2,,,,,,,,,,,,,,2022,Q1,Swollen tongue,,2022,Q1,1,I,20220108.0,,20220112,20220112,DIR,598833,,FDA-CTU,,66.0,YR,,M,N,80.0,KG,20220112,N,PH,US,,2022,Q1,Elderly
203341251,20334125,4,C,empagliflozin 10,,2,,,,,,,,,,,,,,2022,Q1,Blood pressure increased,,2022,Q1,1,I,20220108.0,,20220112,20220112,DIR,598833,,FDA-CTU,,66.0,YR,,M,N,80.0,KG,20220112,N,PH,US,,2022,Q1,Elderly
203369385,20336938,20,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q1,Neutropenia,,2022,Q1,5,F,20211117.0,20220302.0,20220114,20220324,EXP,,ES-JAZZ-2021-ES-023900,JAZZ,,56.0,YR,,M,Y,,,20220324,,MD,ES,ES,2022,Q1,Adult
203369385,20336938,20,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q1,Intestinal obstruction,,2022,Q1,5,F,20211117.0,20220302.0,20220114,20220324,EXP,,ES-JAZZ-2021-ES-023900,JAZZ,,56.0,YR,,M,Y,,,20220324,,MD,ES,ES,2022,Q1,Adult
203390891,20339089,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,20220102.0,20220113.0,20220117,20220117,EXP,GB-MHRA-EYC 00271127,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-107584",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,91.2,KG,20220117,,PH,GB,GB,2022,Q1,Adult
203393461,20339346,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Erythema,,2022,Q1,1,I,,20220107.0,20220117,20220117,EXP,GB-MHRA-EYC 00270678,GB-TEVA-2022-GB-1998214,TEVA,,51.0,YR,A,F,Y,87.0,KG,20220117,,CN,GB,GB,2022,Q1,Adult
203393461,20339346,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Blister,,2022,Q1,1,I,,20220107.0,20220117,20220117,EXP,GB-MHRA-EYC 00270678,GB-TEVA-2022-GB-1998214,TEVA,,51.0,YR,A,F,Y,87.0,KG,20220117,,CN,GB,GB,2022,Q1,Adult
203393461,20339346,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Chemical burn of skin,,2022,Q1,1,I,,20220107.0,20220117,20220117,EXP,GB-MHRA-EYC 00270678,GB-TEVA-2022-GB-1998214,TEVA,,51.0,YR,A,F,Y,87.0,KG,20220117,,CN,GB,GB,2022,Q1,Adult
203429091,20342909,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,N,,,,,,,,2022,Q1,Atrioventricular block complete,,2022,Q1,1,I,,20220113.0,20220117,20220117,EXP,,GR-ANIPHARMA-2022-GR-000001,ANI,"Kyziridis T, Nimatoudis I..Complete atrioventricular block due to lithium intoxication. Case report and brief  literature review. .Archives of Hellenic Medicine.2021;38(5):660-663.",64.0,YR,,M,Y,,,20220117,,HP,GR,GR,2022,Q1,Adult
203429091,20342909,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,N,,,,,,,,2022,Q1,Renal impairment,,2022,Q1,1,I,,20220113.0,20220117,20220117,EXP,,GR-ANIPHARMA-2022-GR-000001,ANI,"Kyziridis T, Nimatoudis I..Complete atrioventricular block due to lithium intoxication. Case report and brief  literature review. .Archives of Hellenic Medicine.2021;38(5):660-663.",64.0,YR,,M,Y,,,20220117,,HP,GR,GR,2022,Q1,Adult
203429091,20342909,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,N,,,,,,,,2022,Q1,Toxicity to various agents,,2022,Q1,1,I,,20220113.0,20220117,20220117,EXP,,GR-ANIPHARMA-2022-GR-000001,ANI,"Kyziridis T, Nimatoudis I..Complete atrioventricular block due to lithium intoxication. Case report and brief  literature review. .Archives of Hellenic Medicine.2021;38(5):660-663.",64.0,YR,,M,Y,,,20220117,,HP,GR,GR,2022,Q1,Adult
203431162,20343116,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Dosage of 12.5/1000mg,,,Y,U,Unknown,,208658.0,,,,QD,2022,Q1,Diabetic ketoacidosis,,2022,Q1,2,F,,20220118.0,20220117,20220119,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-107832",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,,,20220119,,MD,IL,IL,2022,Q1,Adult
203431162,20343116,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Dosage of 12.5/1000mg,,,Y,U,Unknown,,208658.0,,,,QD,2022,Q1,Viral infection,,2022,Q1,2,F,,20220118.0,20220117,20220119,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-107832",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,,,20220119,,MD,IL,IL,2022,Q1,Adult
203433362,20343336,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,,2022,Q1,Cardiac failure,,2022,Q1,2,F,,20220208.0,20220117,20220222,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-323727,RANBAXY,,71.0,YR,,M,Y,,,20220222,,MD,PL,PL,2022,Q1,Elderly
203433362,20343336,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,,2022,Q1,N-terminal prohormone brain natriuretic peptide increased,,2022,Q1,2,F,,20220208.0,20220117,20220222,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-323727,RANBAXY,,71.0,YR,,M,Y,,,20220222,,MD,PL,PL,2022,Q1,Elderly
203433362,20343336,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,,2022,Q1,Glomerular filtration rate abnormal,,2022,Q1,2,F,,20220208.0,20220117,20220222,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-323727,RANBAXY,,71.0,YR,,M,Y,,,20220222,,MD,PL,PL,2022,Q1,Elderly
203433362,20343336,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,,2022,Q1,Acute kidney injury,,2022,Q1,2,F,,20220208.0,20220117,20220222,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-323727,RANBAXY,,71.0,YR,,M,Y,,,20220222,,MD,PL,PL,2022,Q1,Elderly
203433362,20343336,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,,2022,Q1,Wrong technique in product usage process,,2022,Q1,2,F,,20220208.0,20220117,20220222,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-323727,RANBAXY,,71.0,YR,,M,Y,,,20220222,,MD,PL,PL,2022,Q1,Elderly
203433362,20343336,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,,2022,Q1,Congestive cardiomyopathy,,2022,Q1,2,F,,20220208.0,20220117,20220222,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-323727,RANBAXY,,71.0,YR,,M,Y,,,20220222,,MD,PL,PL,2022,Q1,Elderly
203433362,20343336,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,,2022,Q1,Lung disorder,,2022,Q1,2,F,,20220208.0,20220117,20220222,EXP,,PL-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-323727,RANBAXY,,71.0,YR,,M,Y,,,20220222,,MD,PL,PL,2022,Q1,Elderly
203463021,20346302,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,20210101.0,20220111.0,20220118,20220118,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-107071",BOEHRINGER INGELHEIM,,37.0,YR,A,M,Y,,,20220118,,HP,MY,MY,2022,Q1,Adult
203463021,20346302,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,General physical health deterioration,,2022,Q1,1,I,20210101.0,20220111.0,20220118,20220118,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-107071",BOEHRINGER INGELHEIM,,37.0,YR,A,M,Y,,,20220118,,HP,MY,MY,2022,Q1,Adult
203463021,20346302,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20210101.0,20220111.0,20220118,20220118,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-107071",BOEHRINGER INGELHEIM,,37.0,YR,A,M,Y,,,20220118,,HP,MY,MY,2022,Q1,Adult
203463021,20346302,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Tachypnoea,,2022,Q1,1,I,20210101.0,20220111.0,20220118,20220118,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-107071",BOEHRINGER INGELHEIM,,37.0,YR,A,M,Y,,,20220118,,HP,MY,MY,2022,Q1,Adult
203463021,20346302,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Confusional state,,2022,Q1,1,I,20210101.0,20220111.0,20220118,20220118,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-107071",BOEHRINGER INGELHEIM,,37.0,YR,A,M,Y,,,20220118,,HP,MY,MY,2022,Q1,Adult
203472172,20347217,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q1,Asthmatic crisis,,2022,Q1,2,F,20220106.0,20220120.0,20220118,20220127,EXP,,CO-GLAXOSMITHKLINE-CO2022AMR007108,GLAXOSMITHKLINE,,62.0,YR,,F,Y,,,20220127,,PH,CO,CO,2022,Q1,Adult
203473171,20347317,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20211004.0,,20220118,20220118,DIR,FDA-CDER-CTU-2022-4502,,FDA-CTU,,55.0,YR,,M,N,126.0,KG,20211220,N,PH,US,,2022,Q1,Adult
203482051,20348205,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2022,Q1,Arterial stenosis,,2022,Q1,1,I,,20220117.0,20220119,20220119,EXP,,JP-VKT Pharma Private Limited-2124068,VKT PHARMA PRIVATE LIMITED,"Yokose (M), Tomoe (T), Yamaguchi (T), Yasu (T) An autopsy case of pulmonary arterial hypertension in an elderly patient with multimorbidity: a case report",72.0,YR,,F,Y,,,20220119,,MD,JP,JP,2022,Q1,Elderly
203482051,20348205,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2022,Q1,Condition aggravated,,2022,Q1,1,I,,20220117.0,20220119,20220119,EXP,,JP-VKT Pharma Private Limited-2124068,VKT PHARMA PRIVATE LIMITED,"Yokose (M), Tomoe (T), Yamaguchi (T), Yasu (T) An autopsy case of pulmonary arterial hypertension in an elderly patient with multimorbidity: a case report",72.0,YR,,F,Y,,,20220119,,MD,JP,JP,2022,Q1,Elderly
203482051,20348205,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2022,Q1,Drug ineffective,,2022,Q1,1,I,,20220117.0,20220119,20220119,EXP,,JP-VKT Pharma Private Limited-2124068,VKT PHARMA PRIVATE LIMITED,"Yokose (M), Tomoe (T), Yamaguchi (T), Yasu (T) An autopsy case of pulmonary arterial hypertension in an elderly patient with multimorbidity: a case report",72.0,YR,,F,Y,,,20220119,,MD,JP,JP,2022,Q1,Elderly
203482051,20348205,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2022,Q1,Pulmonary arterial hypertension,,2022,Q1,1,I,,20220117.0,20220119,20220119,EXP,,JP-VKT Pharma Private Limited-2124068,VKT PHARMA PRIVATE LIMITED,"Yokose (M), Tomoe (T), Yamaguchi (T), Yasu (T) An autopsy case of pulmonary arterial hypertension in an elderly patient with multimorbidity: a case report",72.0,YR,,F,Y,,,20220119,,MD,JP,JP,2022,Q1,Elderly
203487911,20348791,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20211118.0,20220116.0,20220119,20220119,EXP,GB-MHRA-ADR 26472528,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-107847",BOEHRINGER INGELHEIM,,83.0,YR,E,F,Y,73.0,KG,20220119,,HP,GB,GB,2022,Q1,Elderly
203540141,20354014,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,COVID-19,,2022,Q1,1,I,20211224.0,20220113.0,20220120,20220120,EXP,,DE-ROCHE-2994105,ROCHE,,63.0,YR,,M,Y,,,20220120,,MD,DE,,2022,Q1,Adult
203577001,20357700,10,C,empagliflozin (Jardiance) 25 mg tablet,,2,,,,,,,,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,20220111.0,,20220120,20220120,DIR,599985,,FDA-CTU,,55.0,YR,,F,N,,,20220120,Y,,US,,2022,Q1,Adult
203577001,20357700,10,C,empagliflozin (Jardiance) 25 mg tablet,,2,,,,,,,,,,,,,,2022,Q1,Impaired work ability,,2022,Q1,1,I,20220111.0,,20220120,20220120,DIR,599985,,FDA-CTU,,55.0,YR,,F,N,,,20220120,Y,,US,,2022,Q1,Adult
203577001,20357700,10,C,empagliflozin (Jardiance) 25 mg tablet,,2,,,,,,,,,,,,,,2022,Q1,Nausea,,2022,Q1,1,I,20220111.0,,20220120,20220120,DIR,599985,,FDA-CTU,,55.0,YR,,F,N,,,20220120,Y,,US,,2022,Q1,Adult
203577001,20357700,10,C,empagliflozin (Jardiance) 25 mg tablet,,2,,,,,,,,,,,,,,2022,Q1,Vomiting,,2022,Q1,1,I,20220111.0,,20220120,20220120,DIR,599985,,FDA-CTU,,55.0,YR,,F,N,,,20220120,Y,,US,,2022,Q1,Adult
203577001,20357700,10,C,empagliflozin (Jardiance) 25 mg tablet,,2,,,,,,,,,,,,,,2022,Q1,Abdominal discomfort,,2022,Q1,1,I,20220111.0,,20220120,20220120,DIR,599985,,FDA-CTU,,55.0,YR,,F,N,,,20220120,Y,,US,,2022,Q1,Adult
203577001,20357700,10,C,empagliflozin (Jardiance) 25 mg tablet,,2,,,,,,,,,,,,,,2022,Q1,Loss of personal independence in daily activities,,2022,Q1,1,I,20220111.0,,20220120,20220120,DIR,599985,,FDA-CTU,,55.0,YR,,F,N,,,20220120,Y,,US,,2022,Q1,Adult
203642691,20364269,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,20211213.0,,20220121,20220121,DIR,FDA-CDER-CTU-2022-5614,,FDA-CTU,,59.0,YR,,M,N,95.71,KG,20220115,N,PH,US,,2022,Q1,Adult
203642691,20364269,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Renal impairment,,2022,Q1,1,I,20211213.0,,20220121,20220121,DIR,FDA-CDER-CTU-2022-5614,,FDA-CTU,,59.0,YR,,M,N,95.71,KG,20220115,N,PH,US,,2022,Q1,Adult
203643181,20364318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q1,Rash,,2022,Q1,1,I,20201217.0,,20220121,20220121,DIR,FDA-CDER-CTU-2022-5681,,FDA-CTU,,67.0,YR,,M,N,88.0,KG,20201230,N,PH,US,,2022,Q1,Elderly
203643181,20364318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q1,Necrosis,,2022,Q1,1,I,20201217.0,,20220121,20220121,DIR,FDA-CDER-CTU-2022-5681,,FDA-CTU,,67.0,YR,,M,N,88.0,KG,20201230,N,PH,US,,2022,Q1,Elderly
203643181,20364318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q1,Infection,,2022,Q1,1,I,20201217.0,,20220121,20220121,DIR,FDA-CDER-CTU-2022-5681,,FDA-CTU,,67.0,YR,,M,N,88.0,KG,20201230,N,PH,US,,2022,Q1,Elderly
203643201,20364320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2022,Q1,Urinary tract infection,,2022,Q1,1,I,20200128.0,,20220121,20220121,DIR,FDA-CDER-CTU-2022-5685,,FDA-CTU,,71.0,YR,,M,N,,,20200211,N,PH,US,,2022,Q1,Elderly
203671812,20367181,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2022,Q1,Intraductal papillary mucinous neoplasm,,2022,Q1,2,F,,20220201.0,20220123,20220208,EXP,,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-108040",BOEHRINGER INGELHEIM,,71.0,YR,E,F,Y,,,20220208,,MD,IT,IT,2022,Q1,Elderly
203709741,20370974,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20220112.0,20220123.0,20220124,20220124,EXP,GB-MHRA-EYC 00271871,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-109156",BOEHRINGER INGELHEIM,,77.0,YR,E,M,Y,95.0,KG,20220124,,HP,GB,GB,2022,Q1,Elderly
203712691,20371269,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25mg,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,20211211.0,20220123.0,20220124,20220124,EXP,GB-MHRA-EYC 00271874,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-109152",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,83.0,KG,20220124,,HP,GB,GB,2022,Q1,Adult
203737962,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,,,2022,Q1,Hyperthyroidism,,2022,Q1,2,F,,20220223.0,20220125,20220303,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220303,,MD,CA,CA,2022,Q1,Elderly
203737962,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,,,2022,Q1,Hypotension,,2022,Q1,2,F,,20220223.0,20220125,20220303,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220303,,MD,CA,CA,2022,Q1,Elderly
203737962,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,,,2022,Q1,Troponin increased,,2022,Q1,2,F,,20220223.0,20220125,20220303,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220303,,MD,CA,CA,2022,Q1,Elderly
203737962,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,,,2022,Q1,Adrenal insufficiency,,2022,Q1,2,F,,20220223.0,20220125,20220303,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220303,,MD,CA,CA,2022,Q1,Elderly
203770725,20377072,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg x 4 x 1 Days,,,,,,,,10.0,MG,Unknown,QID,2022,Q1,Neutropenic sepsis,,2022,Q1,5,F,20220120.0,20220307.0,20220125,20220312,EXP,,AT-CELGENEUS-AUT-20220106085,CELGENE,,71.0,YR,,M,Y,88.0,KG,20220312,,MD,AT,AT,2022,Q1,Elderly
203774131,20377413,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,20220109.0,20220125.0,20220126,20220126,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-150050",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,,,20220126,,HP,SG,SG,2022,Q1,Adult
203799561,20379956,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q1,Prostate cancer,,2022,Q1,1,I,20120101.0,20220117.0,20220126,20220126,EXP,,"BG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-108101",BOEHRINGER INGELHEIM,"Tchernev G, Oliveira N, Kandathil L, Dimchova N, Patterson J, Terziev I. et al. Telmisartan (and/or nitrosamine) induced prostate carcinoma and atypical fibroxanthoma: first report in world literature. ?. Medical Review. 2022; 58: 65-67.",68.0,YR,E,M,Y,,,20220126,,MD,BG,BG,2022,Q1,Elderly
203803781,20380378,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q1,Thrombocytopenia,,2022,Q1,1,I,,20220120.0,20220127,20220127,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-011281,BRISTOL MYERS SQUIBB,,87.0,YR,,M,Y,61.0,KG,20220127,,CN,IN,IN,2022,Q1,Elderly
203803781,20380378,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q1,Dengue fever,,2022,Q1,1,I,,20220120.0,20220127,20220127,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-011281,BRISTOL MYERS SQUIBB,,87.0,YR,,M,Y,61.0,KG,20220127,,CN,IN,IN,2022,Q1,Elderly
203821442,20382144,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Fatigue,,2022,Q1,2,F,20210930.0,20220203.0,20220127,20220210,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20220210,,CN,CA,CA,2022,Q1,Adult
203821442,20382144,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Blood pressure increased,,2022,Q1,2,F,20210930.0,20220203.0,20220127,20220210,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20220210,,CN,CA,CA,2022,Q1,Adult
203821442,20382144,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Product dose omission issue,,2022,Q1,2,F,20210930.0,20220203.0,20220127,20220210,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20220210,,CN,CA,CA,2022,Q1,Adult
203823101,20382310,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,D16518,20240331.0,,12.5,MG,,QD,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,20211125.0,,20220127,20220127,DIR,FDA-CDER-CTU-2022-7408,,FDA-CTU,,75.0,YR,,M,N,73.0,KG,20220124,N,PH,US,,2022,Q1,Elderly
203887022,20388702,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Rectal haemorrhage,,2022,Q1,2,F,,20220128.0,20220128,20220203,EXP,,CA-JNJFOC-20220118848,JOHNSON AND JOHNSON,,49.0,YR,A,M,Y,118.0,KG,20220204,,HP,CA,CA,2022,Q1,Adult
203887022,20388702,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Drug ineffective,,2022,Q1,2,F,,20220128.0,20220128,20220203,EXP,,CA-JNJFOC-20220118848,JOHNSON AND JOHNSON,,49.0,YR,A,M,Y,118.0,KG,20220204,,HP,CA,CA,2022,Q1,Adult
203887022,20388702,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Condition aggravated,,2022,Q1,2,F,,20220128.0,20220128,20220203,EXP,,CA-JNJFOC-20220118848,JOHNSON AND JOHNSON,,49.0,YR,A,M,Y,118.0,KG,20220204,,HP,CA,CA,2022,Q1,Adult
203887022,20388702,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Drug level below therapeutic,,2022,Q1,2,F,,20220128.0,20220128,20220203,EXP,,CA-JNJFOC-20220118848,JOHNSON AND JOHNSON,,49.0,YR,A,M,Y,118.0,KG,20220204,,HP,CA,CA,2022,Q1,Adult
203887022,20388702,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Arthralgia,,2022,Q1,2,F,,20220128.0,20220128,20220203,EXP,,CA-JNJFOC-20220118848,JOHNSON AND JOHNSON,,49.0,YR,A,M,Y,118.0,KG,20220204,,HP,CA,CA,2022,Q1,Adult
203887022,20388702,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Drug specific antibody present,,2022,Q1,2,F,,20220128.0,20220128,20220203,EXP,,CA-JNJFOC-20220118848,JOHNSON AND JOHNSON,,49.0,YR,A,M,Y,118.0,KG,20220204,,HP,CA,CA,2022,Q1,Adult
203905841,20390584,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,,Unknown,,,,,,,2022,Q1,Completed suicide,,2022,Q1,1,I,20200101.0,20211213.0,20220128,20220128,EXP,,US-Intellipharmaceutics Corp.-2124390,INTELLIPHARMACEUTICS,"Journal: Clinical Toxicology?Author: Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Bronstein AC, Rivers LJ et al?Title: 2020 Annual Report of the American Association of Poison Control Centers^ National Poison Data System (NPDS): 38th Annual?Report?Volume: 59(12) Year: 2021 Pages: 1282-501",15.0,YR,,M,Y,,,20220128,,MD,US,US,2022,Q1,Youth
203941361,20394136,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, 12.5/1000 (1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q1,Atrial flutter,,2022,Q1,1,I,20211213.0,20220121.0,20220129,20220129,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,84.0,KG,20220129,,HP,TH,TH,2022,Q1,Adult
203941361,20394136,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, 12.5/1000 (1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q1,Glomerular filtration rate decreased,,2022,Q1,1,I,20211213.0,20220121.0,20220129,20220129,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,84.0,KG,20220129,,HP,TH,TH,2022,Q1,Adult
203941361,20394136,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, 12.5/1000 (1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q1,Blood glucose increased,,2022,Q1,1,I,20211213.0,20220121.0,20220129,20220129,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,84.0,KG,20220129,,HP,TH,TH,2022,Q1,Adult
203941361,20394136,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, 12.5/1000 (1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q1,International normalised ratio decreased,,2022,Q1,1,I,20211213.0,20220121.0,20220129,20220129,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,84.0,KG,20220129,,HP,TH,TH,2022,Q1,Adult
203941361,20394136,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, 12.5/1000 (1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q1,Atrial fibrillation,,2022,Q1,1,I,20211213.0,20220121.0,20220129,20220129,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,84.0,KG,20220129,,HP,TH,TH,2022,Q1,Adult
203941361,20394136,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, 12.5/1000 (1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q1,Prothrombin time abnormal,,2022,Q1,1,I,20211213.0,20220121.0,20220129,20220129,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,84.0,KG,20220129,,HP,TH,TH,2022,Q1,Adult
203941361,20394136,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, 12.5/1000 (1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q1,Arteriosclerosis,,2022,Q1,1,I,20211213.0,20220121.0,20220129,20220129,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,84.0,KG,20220129,,HP,TH,TH,2022,Q1,Adult
203943411,20394341,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0,  Tablet",,,U,,,,,,,Tablet,,2022,Q1,Liver function test abnormal,,2022,Q1,1,I,,20220118.0,20220129,20220129,EXP,DE-BFARM-21011745,DE-Accord-251575,ACCORD,,78.0,YR,E,F,Y,90.0,KG,20220129,,PH,DE,DE,2022,Q1,Elderly
203943411,20394341,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0,  Tablet",,,U,,,,,,,Tablet,,2022,Q1,Pruritus,,2022,Q1,1,I,,20220118.0,20220129,20220129,EXP,DE-BFARM-21011745,DE-Accord-251575,ACCORD,,78.0,YR,E,F,Y,90.0,KG,20220129,,PH,DE,DE,2022,Q1,Elderly
203949811,20394981,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Food allergy,,2022,Q1,1,I,20211001.0,20220119.0,20220130,20220130,EXP,,US-AMNEAL PHARMACEUTICALS-2022-AMRX-00126,AMNEAL,,75.0,YR,,M,Y,92.0,KG,20220130,,CN,US,US,2022,Q1,Elderly
204042511,20404251,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, strength 10 mg",,,,,,,,,,,,2022,Q1,Dry mouth,,2022,Q1,1,I,,20220118.0,20220131,20220131,EXP,DE-BFARM-21011682,DE-Accord-251556,ACCORD,,79.0,YR,E,F,Y,49.0,KG,20220131,,MD,DE,DE,2022,Q1,Elderly
204042511,20404251,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, strength 10 mg",,,,,,,,,,,,2022,Q1,Decreased appetite,,2022,Q1,1,I,,20220118.0,20220131,20220131,EXP,DE-BFARM-21011682,DE-Accord-251556,ACCORD,,79.0,YR,E,F,Y,49.0,KG,20220131,,MD,DE,DE,2022,Q1,Elderly
204042511,20404251,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, strength 10 mg",,,,,,,,,,,,2022,Q1,Weight decreased,,2022,Q1,1,I,,20220118.0,20220131,20220131,EXP,DE-BFARM-21011682,DE-Accord-251556,ACCORD,,79.0,YR,E,F,Y,49.0,KG,20220131,,MD,DE,DE,2022,Q1,Elderly
204042511,20404251,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, strength 10 mg",,,,,,,,,,,,2022,Q1,Constipation,,2022,Q1,1,I,,20220118.0,20220131,20220131,EXP,DE-BFARM-21011682,DE-Accord-251556,ACCORD,,79.0,YR,E,F,Y,49.0,KG,20220131,,MD,DE,DE,2022,Q1,Elderly
204042511,20404251,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, strength 10 mg",,,,,,,,,,,,2022,Q1,Abdominal pain lower,,2022,Q1,1,I,,20220118.0,20220131,20220131,EXP,DE-BFARM-21011682,DE-Accord-251556,ACCORD,,79.0,YR,E,F,Y,49.0,KG,20220131,,MD,DE,DE,2022,Q1,Elderly
204042511,20404251,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, strength 10 mg",,,,,,,,,,,,2022,Q1,Haematochezia,,2022,Q1,1,I,,20220118.0,20220131,20220131,EXP,DE-BFARM-21011682,DE-Accord-251556,ACCORD,,79.0,YR,E,F,Y,49.0,KG,20220131,,MD,DE,DE,2022,Q1,Elderly
204042511,20404251,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, strength 10 mg",,,,,,,,,,,,2022,Q1,Abdominal pain upper,,2022,Q1,1,I,,20220118.0,20220131,20220131,EXP,DE-BFARM-21011682,DE-Accord-251556,ACCORD,,79.0,YR,E,F,Y,49.0,KG,20220131,,MD,DE,DE,2022,Q1,Elderly
204042511,20404251,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, strength 10 mg",,,,,,,,,,,,2022,Q1,Vomiting,,2022,Q1,1,I,,20220118.0,20220131,20220131,EXP,DE-BFARM-21011682,DE-Accord-251556,ACCORD,,79.0,YR,E,F,Y,49.0,KG,20220131,,MD,DE,DE,2022,Q1,Elderly
204089981,20408998,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10,,,Y,U,Unknown,,204629.0,,,,,2022,Q1,Nausea,,2022,Q1,1,I,,20220127.0,20220201,20220201,EXP,GB-MHRA-EYC 00272131,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-150789",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,81.0,KG,20220201,,HP,GB,GB,2022,Q1,Elderly
204089981,20408998,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10,,,Y,U,Unknown,,204629.0,,,,,2022,Q1,Medication error,,2022,Q1,1,I,,20220127.0,20220201,20220201,EXP,GB-MHRA-EYC 00272131,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-150789",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,81.0,KG,20220201,,HP,GB,GB,2022,Q1,Elderly
204089981,20408998,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10,,,Y,U,Unknown,,204629.0,,,,,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,,20220127.0,20220201,20220201,EXP,GB-MHRA-EYC 00272131,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-150789",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,81.0,KG,20220201,,HP,GB,GB,2022,Q1,Elderly
204089981,20408998,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10,,,Y,U,Unknown,,204629.0,,,,,2022,Q1,Product administration error,,2022,Q1,1,I,,20220127.0,20220201,20220201,EXP,GB-MHRA-EYC 00272131,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-150789",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,81.0,KG,20220201,,HP,GB,GB,2022,Q1,Elderly
204099202,20409920,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,N,Asked But Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Coma,,2022,Q1,2,F,20211201.0,20220204.0,20220201,20220211,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-151299",BOEHRINGER INGELHEIM,,56.0,YR,A,M,Y,85.0,KG,20220211,,MD,AT,AT,2022,Q1,Adult
204099202,20409920,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,N,Asked But Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Pyrexia,,2022,Q1,2,F,20211201.0,20220204.0,20220201,20220211,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-151299",BOEHRINGER INGELHEIM,,56.0,YR,A,M,Y,85.0,KG,20220211,,MD,AT,AT,2022,Q1,Adult
204099202,20409920,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,N,Asked But Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Surgery,,2022,Q1,2,F,20211201.0,20220204.0,20220201,20220211,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-151299",BOEHRINGER INGELHEIM,,56.0,YR,A,M,Y,85.0,KG,20220211,,MD,AT,AT,2022,Q1,Adult
204099202,20409920,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,N,Asked But Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Ketoacidosis,,2022,Q1,2,F,20211201.0,20220204.0,20220201,20220211,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-151299",BOEHRINGER INGELHEIM,,56.0,YR,A,M,Y,85.0,KG,20220211,,MD,AT,AT,2022,Q1,Adult
204110721,20411072,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q1,Fournier's gangrene,,2022,Q1,1,I,20210901.0,,20220131,20220131,DIR,FDA-CDER-CTU-2022-8753,,FDA-CTU,,71.0,YR,,M,N,,,20211006,N,PH,US,,2022,Q1,Elderly
204110721,20411072,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q1,Vomiting,,2022,Q1,1,I,20210901.0,,20220131,20220131,DIR,FDA-CDER-CTU-2022-8753,,FDA-CTU,,71.0,YR,,M,N,,,20211006,N,PH,US,,2022,Q1,Elderly
204110721,20411072,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q1,Nausea,,2022,Q1,1,I,20210901.0,,20220131,20220131,DIR,FDA-CDER-CTU-2022-8753,,FDA-CTU,,71.0,YR,,M,N,,,20211006,N,PH,US,,2022,Q1,Elderly
204110721,20411072,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q1,Chills,,2022,Q1,1,I,20210901.0,,20220131,20220131,DIR,FDA-CDER-CTU-2022-8753,,FDA-CTU,,71.0,YR,,M,N,,,20211006,N,PH,US,,2022,Q1,Elderly
204110761,20411076,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q1,Pancreatitis,,2022,Q1,1,I,20210914.0,,20220131,20220131,DIR,FDA-CDER-CTU-2022-8757,,FDA-CTU,,72.0,YR,,M,N,,,20210915,N,PH,US,,2022,Q1,Elderly
204111291,20411129,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Acute kidney injury,,2022,Q1,1,I,20211118.0,,20220201,20220201,DIR,FDA-CDER-CTU-2022-8871,,FDA-CTU,,53.0,YR,,M,N,,,20220118,N,PH,US,,2022,Q1,Adult
204114651,20411465,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20220124.0,,20220201,20220201,DIR,601743,,FDA-CTU,,64.0,YR,,F,N,64.0,KG,20220201,N,PH,US,,2022,Q1,Adult
204114651,20411465,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q1,Haemodialysis,,2022,Q1,1,I,20220124.0,,20220201,20220201,DIR,601743,,FDA-CTU,,64.0,YR,,F,N,64.0,KG,20220201,N,PH,US,,2022,Q1,Adult
204114651,20411465,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q1,Hypothermia,,2022,Q1,1,I,20220124.0,,20220201,20220201,DIR,601743,,FDA-CTU,,64.0,YR,,F,N,64.0,KG,20220201,N,PH,US,,2022,Q1,Adult
204114651,20411465,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q1,Encephalopathy,,2022,Q1,1,I,20220124.0,,20220201,20220201,DIR,601743,,FDA-CTU,,64.0,YR,,F,N,64.0,KG,20220201,N,PH,US,,2022,Q1,Adult
204114651,20411465,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q1,Unresponsive to stimuli,,2022,Q1,1,I,20220124.0,,20220201,20220201,DIR,601743,,FDA-CTU,,64.0,YR,,F,N,64.0,KG,20220201,N,PH,US,,2022,Q1,Adult
204114651,20411465,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q1,Acute kidney injury,,2022,Q1,1,I,20220124.0,,20220201,20220201,DIR,601743,,FDA-CTU,,64.0,YR,,F,N,64.0,KG,20220201,N,PH,US,,2022,Q1,Adult
204114651,20411465,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q1,COVID-19,,2022,Q1,1,I,20220124.0,,20220201,20220201,DIR,601743,,FDA-CTU,,64.0,YR,,F,N,64.0,KG,20220201,N,PH,US,,2022,Q1,Adult
204115841,20411584,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2022,Q1,Dyspnoea,,2022,Q1,1,I,20210901.0,20220125.0,20220201,20220201,EXP,,NVSC2022PL018218,NOVARTIS,,39.0,YR,,M,Y,,,20220201,,MD,PL,PL,2022,Q1,Adult
204115841,20411584,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2022,Q1,Heart rate increased,,2022,Q1,1,I,20210901.0,20220125.0,20220201,20220201,EXP,,NVSC2022PL018218,NOVARTIS,,39.0,YR,,M,Y,,,20220201,,MD,PL,PL,2022,Q1,Adult
204115841,20411584,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2022,Q1,Dizziness postural,,2022,Q1,1,I,20210901.0,20220125.0,20220201,20220201,EXP,,NVSC2022PL018218,NOVARTIS,,39.0,YR,,M,Y,,,20220201,,MD,PL,PL,2022,Q1,Adult
204115841,20411584,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2022,Q1,Cardiac ventricular thrombosis,,2022,Q1,1,I,20210901.0,20220125.0,20220201,20220201,EXP,,NVSC2022PL018218,NOVARTIS,,39.0,YR,,M,Y,,,20220201,,MD,PL,PL,2022,Q1,Adult
204115841,20411584,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2022,Q1,Non-compaction cardiomyopathy,,2022,Q1,1,I,20210901.0,20220125.0,20220201,20220201,EXP,,NVSC2022PL018218,NOVARTIS,,39.0,YR,,M,Y,,,20220201,,MD,PL,PL,2022,Q1,Adult
204115841,20411584,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2022,Q1,Left ventricular enlargement,,2022,Q1,1,I,20210901.0,20220125.0,20220201,20220201,EXP,,NVSC2022PL018218,NOVARTIS,,39.0,YR,,M,Y,,,20220201,,MD,PL,PL,2022,Q1,Adult
204115841,20411584,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2022,Q1,Left atrial enlargement,,2022,Q1,1,I,20210901.0,20220125.0,20220201,20220201,EXP,,NVSC2022PL018218,NOVARTIS,,39.0,YR,,M,Y,,,20220201,,MD,PL,PL,2022,Q1,Adult
204115841,20411584,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2022,Q1,Hypotension,,2022,Q1,1,I,20210901.0,20220125.0,20220201,20220201,EXP,,NVSC2022PL018218,NOVARTIS,,39.0,YR,,M,Y,,,20220201,,MD,PL,PL,2022,Q1,Adult
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Vomiting,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Dyspepsia,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Decreased appetite,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Abdominal distension,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Carbohydrate antigen 19-9 increased,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Abdominal pain,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Gastric polyps,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Hiccups,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Abdominal pain upper,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Malaise,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Diarrhoea,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Nausea,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Product dispensing issue,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Weight decreased,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Musculoskeletal pain,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Chest pain,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Intentional product use issue,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Eructation,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Back pain,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204142211,20414221,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Gastrooesophageal reflux disease,,2022,Q1,1,I,20210114.0,20220121.0,20220202,20220202,EXP,,GB-NOVOPROD-865330,NOVO NORDISK,,66.0,YR,,F,Y,88.0,KG,20220202,,HP,GB,GB,2022,Q1,Elderly
204148794,20414879,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Jardiance Duo 12.5/1gm,,,Y,U,Unknown,,206111.0,,,,,2022,Q1,Asthenia,,2022,Q1,4,F,20220110.0,20220216.0,20220202,20220223,EXP,,"PH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-151073",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,100.0,KG,20220223,,MD,PH,PH,2022,Q1,Adult
204148794,20414879,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Jardiance Duo 12.5/1gm,,,Y,U,Unknown,,206111.0,,,,,2022,Q1,Nausea,,2022,Q1,4,F,20220110.0,20220216.0,20220202,20220223,EXP,,"PH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-151073",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,100.0,KG,20220223,,MD,PH,PH,2022,Q1,Adult
204148794,20414879,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Jardiance Duo 12.5/1gm,,,Y,U,Unknown,,206111.0,,,,,2022,Q1,COVID-19,,2022,Q1,4,F,20220110.0,20220216.0,20220202,20220223,EXP,,"PH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-151073",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,100.0,KG,20220223,,MD,PH,PH,2022,Q1,Adult
204148794,20414879,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Jardiance Duo 12.5/1gm,,,Y,U,Unknown,,206111.0,,,,,2022,Q1,Electrolyte imbalance,,2022,Q1,4,F,20220110.0,20220216.0,20220202,20220223,EXP,,"PH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-151073",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,100.0,KG,20220223,,MD,PH,PH,2022,Q1,Adult
204158101,20415810,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,D,D,,,,12.5,MG,,QD,2022,Q1,Chills,,2022,Q1,1,I,20190708.0,,20220201,20220201,DIR,FDA-CDER-CTU-2022-9118,,FDA-CTU,,75.0,YR,,M,N,194.0,KG,20190813,N,PH,US,,2022,Q1,Elderly
204158101,20415810,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,D,D,,,,12.5,MG,,QD,2022,Q1,Dizziness,,2022,Q1,1,I,20190708.0,,20220201,20220201,DIR,FDA-CDER-CTU-2022-9118,,FDA-CTU,,75.0,YR,,M,N,194.0,KG,20190813,N,PH,US,,2022,Q1,Elderly
204158101,20415810,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,D,D,,,,12.5,MG,,QD,2022,Q1,Urosepsis,,2022,Q1,1,I,20190708.0,,20220201,20220201,DIR,FDA-CDER-CTU-2022-9118,,FDA-CTU,,75.0,YR,,M,N,194.0,KG,20190813,N,PH,US,,2022,Q1,Elderly
204158101,20415810,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,D,D,,,,12.5,MG,,QD,2022,Q1,Asthenia,,2022,Q1,1,I,20190708.0,,20220201,20220201,DIR,FDA-CDER-CTU-2022-9118,,FDA-CTU,,75.0,YR,,M,N,194.0,KG,20190813,N,PH,US,,2022,Q1,Elderly
204163811,20416381,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q1,Pemphigoid,,2022,Q1,1,I,,20220126.0,20220202,20220202,EXP,,"KR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-150486",BOEHRINGER INGELHEIM,"Park K, Lee S, Lee K, Ishii N, Hashimoto T, Kim J. et al. Rare case of bullous pemphigoid occurring on atrophic centers of disseminated superficial porokeratosis lesions. Journal of Dermatology. 2021; 48(11): 530-531.",69.0,YR,E,M,Y,,,20220202,,HP,KR,KR,2022,Q1,Elderly
204181121,20418112,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram per day,,,U,,,,,,,,,2022,Q1,Glomerular filtration rate abnormal,,2022,Q1,1,I,,20220125.0,20220202,20220202,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-011999,BRISTOL MYERS SQUIBB,,71.0,YR,,M,Y,,,20220202,,MD,PL,PL,2022,Q1,Elderly
204181121,20418112,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram per day,,,U,,,,,,,,,2022,Q1,Cardiac failure,,2022,Q1,1,I,,20220125.0,20220202,20220202,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-011999,BRISTOL MYERS SQUIBB,,71.0,YR,,M,Y,,,20220202,,MD,PL,PL,2022,Q1,Elderly
204181121,20418112,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram per day,,,U,,,,,,,,,2022,Q1,Lung disorder,,2022,Q1,1,I,,20220125.0,20220202,20220202,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-011999,BRISTOL MYERS SQUIBB,,71.0,YR,,M,Y,,,20220202,,MD,PL,PL,2022,Q1,Elderly
204181121,20418112,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram per day,,,U,,,,,,,,,2022,Q1,N-terminal prohormone brain natriuretic peptide increased,,2022,Q1,1,I,,20220125.0,20220202,20220202,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-011999,BRISTOL MYERS SQUIBB,,71.0,YR,,M,Y,,,20220202,,MD,PL,PL,2022,Q1,Elderly
204181121,20418112,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram per day,,,U,,,,,,,,,2022,Q1,Congestive cardiomyopathy,,2022,Q1,1,I,,20220125.0,20220202,20220202,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-011999,BRISTOL MYERS SQUIBB,,71.0,YR,,M,Y,,,20220202,,MD,PL,PL,2022,Q1,Elderly
204181121,20418112,16,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram per day,,,U,,,,,,,,,2022,Q1,Acute kidney injury,,2022,Q1,1,I,,20220125.0,20220202,20220202,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-011999,BRISTOL MYERS SQUIBB,,71.0,YR,,M,Y,,,20220202,,MD,PL,PL,2022,Q1,Elderly
204217651,20421765,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER FREQUENCY : AM;?,,,Y,D,,,,12.5,MG,,999,2022,Q1,Urinary tract infection,,2022,Q1,1,I,20211103.0,,20220203,20220203,DIR,FDA-CDER-CTU-2022-9651,,FDA-CTU,,77.0,YR,,M,N,,,20220118,N,PH,US,,2022,Q1,Elderly
204217751,20421775,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2022,Q1,Rash,,2022,Q1,1,I,20211110.0,,20220203,20220203,DIR,FDA-CDER-CTU-2022-9654,,FDA-CTU,,69.0,YR,,M,N,153.0,LBS,20220118,N,PH,US,,2022,Q1,Elderly
204224035,20422403,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2022,Q1,Cardiac arrest,,2022,Q1,5,F,20220122.0,20220223.0,20220203,20220301,EXP,,CN-DSJP-DSE-2022-102968,DAIICHI,,69.0,YR,,M,Y,74.0,KG,20220301,,MD,CN,CN,2022,Q1,Elderly
204224035,20422403,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,,,,,,10.0,MG,,QD,2022,Q1,Gastrointestinal haemorrhage,,2022,Q1,5,F,20220122.0,20220223.0,20220203,20220301,EXP,,CN-DSJP-DSE-2022-102968,DAIICHI,,69.0,YR,,M,Y,74.0,KG,20220301,,MD,CN,CN,2022,Q1,Elderly
204277431,20427743,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,,,Tablet,,2022,Q1,Basal ganglia haemorrhage,,2022,Q1,1,I,20220120.0,20220124.0,20220204,20220204,EXP,,CN-ROCHE-3015536,ROCHE,,75.0,YR,,F,Y,77.5,KG,20220204,,MD,CN,CN,2022,Q1,Elderly
204277431,20427743,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,,,Tablet,,2022,Q1,Atrial flutter,,2022,Q1,1,I,20220120.0,20220124.0,20220204,20220204,EXP,,CN-ROCHE-3015536,ROCHE,,75.0,YR,,F,Y,77.5,KG,20220204,,MD,CN,CN,2022,Q1,Elderly
204312412,20431241,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2022,Q1,Illness,,2022,Q1,2,F,,20220314.0,20220204,20220323,EXP,,GB-JNJFOC-20220147362,JOHNSON AND JOHNSON,,6.0,DEC,A,M,Y,,,20220323,,CN,GB,GB,2022,Q1,Child
204312412,20431241,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2022,Q1,Adverse drug reaction,,2022,Q1,2,F,,20220314.0,20220204,20220323,EXP,,GB-JNJFOC-20220147362,JOHNSON AND JOHNSON,,6.0,DEC,A,M,Y,,,20220323,,CN,GB,GB,2022,Q1,Child
204312412,20431241,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2022,Q1,Chest crushing,,2022,Q1,2,F,,20220314.0,20220204,20220323,EXP,,GB-JNJFOC-20220147362,JOHNSON AND JOHNSON,,6.0,DEC,A,M,Y,,,20220323,,CN,GB,GB,2022,Q1,Child
204312412,20431241,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,QD,2022,Q1,Pain in extremity,,2022,Q1,2,F,,20220314.0,20220204,20220323,EXP,,GB-JNJFOC-20220147362,JOHNSON AND JOHNSON,,6.0,DEC,A,M,Y,,,20220323,,CN,GB,GB,2022,Q1,Child
204314901,20431490,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Dyspnoea,,2022,Q1,1,I,20220108.0,20220131.0,20220204,20220204,EXP,,US-ABBVIE-22K-163-4264742-00,ABBVIE,,66.0,YR,,M,Y,80.0,KG,20220204,,PH,US,US,2022,Q1,Elderly
204314901,20431490,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Oropharyngeal pain,,2022,Q1,1,I,20220108.0,20220131.0,20220204,20220204,EXP,,US-ABBVIE-22K-163-4264742-00,ABBVIE,,66.0,YR,,M,Y,80.0,KG,20220204,,PH,US,US,2022,Q1,Elderly
204314901,20431490,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Chest pain,,2022,Q1,1,I,20220108.0,20220131.0,20220204,20220204,EXP,,US-ABBVIE-22K-163-4264742-00,ABBVIE,,66.0,YR,,M,Y,80.0,KG,20220204,,PH,US,US,2022,Q1,Elderly
204314901,20431490,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Blood pressure increased,,2022,Q1,1,I,20220108.0,20220131.0,20220204,20220204,EXP,,US-ABBVIE-22K-163-4264742-00,ABBVIE,,66.0,YR,,M,Y,80.0,KG,20220204,,PH,US,US,2022,Q1,Elderly
204314901,20431490,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Swollen tongue,,2022,Q1,1,I,20220108.0,20220131.0,20220204,20220204,EXP,,US-ABBVIE-22K-163-4264742-00,ABBVIE,,66.0,YR,,M,Y,80.0,KG,20220204,,PH,US,US,2022,Q1,Elderly
204386361,20438636,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,10.0,MG,,QD,2022,Q1,Drug hypersensitivity,,2022,Q1,1,I,20220116.0,,20220204,20220204,DIR,602304,,FDA-CTU,,61.0,YR,,M,N,,,20220204,N,PH,US,,2022,Q1,Adult
204386361,20438636,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,10.0,MG,,QD,2022,Q1,Fournier's gangrene,,2022,Q1,1,I,20220116.0,,20220204,20220204,DIR,602304,,FDA-CTU,,61.0,YR,,M,N,,,20220204,N,PH,US,,2022,Q1,Adult
204386361,20438636,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,10.0,MG,,QD,2022,Q1,Diabetes mellitus inadequate control,,2022,Q1,1,I,20220116.0,,20220204,20220204,DIR,602304,,FDA-CTU,,61.0,YR,,M,N,,,20220204,N,PH,US,,2022,Q1,Adult
204397461,20439746,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,,,2022,Q1,Toxicity to various agents,,2022,Q1,1,I,,20220204.0,20220207,20220207,EXP,,US-AstraZeneca-2022A060686,ASTRAZENECA,,15.0,YR,,M,Y,,,20220207,,MD,US,,2022,Q1,Youth
204397461,20439746,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,,,,,,,,,2022,Q1,Completed suicide,,2022,Q1,1,I,,20220204.0,20220207,20220207,EXP,,US-AstraZeneca-2022A060686,ASTRAZENECA,,15.0,YR,,M,Y,,,20220207,,MD,US,,2022,Q1,Youth
204401281,20440128,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,,,,,,,Unknown,,2022,Q1,Toxicity to various agents,,2022,Q1,1,I,,20220131.0,20220207,20220207,EXP,,US-JNJFOC-20220208498,JOHNSON AND JOHNSON,,15.0,YR,T,M,Y,,,20220207,,MD,US,US,2022,Q1,Youth
204403591,20440359,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,D16514,20240331.0,,25.0,MG,,QD,2022,Q1,Fournier's gangrene,,2022,Q1,1,I,20220124.0,,20220207,20220207,DIR,FDA-CDER-CTU-2022-10603,,FDA-CTU,,55.0,YR,,M,N,120.0,KG,20220127,N,PH,US,,2022,Q1,Adult
204404411,20440441,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q1,Rash,,2022,Q1,1,I,20211130.0,,20220207,20220207,DIR,FDA-CDER-CTU-2022-10616,,FDA-CTU,,84.0,YR,,M,N,80.0,KG,20220118,N,HP,US,,2022,Q1,Elderly
204404431,20440443,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q1,Rash,,2022,Q1,1,I,20211130.0,,20220207,20220207,DIR,FDA-CDER-CTU-2022-10614,,FDA-CTU,,67.0,YR,,M,N,90.0,KG,20220118,N,PH,US,,2022,Q1,Elderly
204404601,20440460,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,d10952,20240101.0,,25.0,MG,,QD,2022,Q1,Orthostatic hypotension,,2022,Q1,1,I,20211113.0,,20220207,20220207,DIR,FDA-CDER-CTU-2022-10625,,FDA-CTU,,56.0,YR,,M,N,43.09,KG,20220118,N,PH,US,,2022,Q1,Adult
204404601,20440460,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,d10952,20240101.0,,25.0,MG,,QD,2022,Q1,Syncope,,2022,Q1,1,I,20211113.0,,20220207,20220207,DIR,FDA-CDER-CTU-2022-10625,,FDA-CTU,,56.0,YR,,M,N,43.09,KG,20220118,N,PH,US,,2022,Q1,Adult
204404611,20440461,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,D16517,20240301.0,,,,Tablet,QD,2022,Q1,Flatulence,,2022,Q1,1,I,20211110.0,,20220207,20220207,DIR,FDA-CDER-CTU-2022-10632,,FDA-CTU,,68.0,YR,,M,N,97.07,KG,20220118,N,PH,US,,2022,Q1,Elderly
204404611,20440461,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,D16517,20240301.0,,,,Tablet,QD,2022,Q1,Diarrhoea,,2022,Q1,1,I,20211110.0,,20220207,20220207,DIR,FDA-CDER-CTU-2022-10632,,FDA-CTU,,68.0,YR,,M,N,97.07,KG,20220118,N,PH,US,,2022,Q1,Elderly
204449742,20444974,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Febrile neutropenia,,2022,Q1,2,F,,20220208.0,20220208,20220210,EXP,,TR-GILEAD-2022-0568783,GILEAD,,59.0,YR,A,M,Y,,,20220210,,MD,TR,TR,2022,Q1,Adult
204469091,20446909,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q1,Chills,,2022,Q1,1,I,20210101.0,20220208.0,20220208,20220208,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-152616",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,,,20220209,,HP,SG,SG,2022,Q1,Adult
204514861,20451486,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily for diabetes,,,,,,,,,,,QD,2022,Q1,Urticaria,,2022,Q1,1,I,20220203.0,20220207.0,20220209,20220209,EXP,,GB-SYNTHON BV-IN51PV22_62749,SYNTHON,,63.0,YR,,M,Y,93.0,KG,20220209,,MD,GB,GB,2022,Q1,Adult
204514861,20451486,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily for diabetes,,,,,,,,,,,QD,2022,Q1,Throat tightness,,2022,Q1,1,I,20220203.0,20220207.0,20220209,20220209,EXP,,GB-SYNTHON BV-IN51PV22_62749,SYNTHON,,63.0,YR,,M,Y,93.0,KG,20220209,,MD,GB,GB,2022,Q1,Adult
204516861,20451686,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,N,,Unknown,,206111.0,,,,,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,,20220209.0,20220209,20220209,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-152953",BOEHRINGER INGELHEIM,,4.0,DEC,A,M,Y,,,20220209,,MD,IL,IL,2022,Q1,Child
204516861,20451686,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,N,,Unknown,,206111.0,,,,,2022,Q1,COVID-19,,2022,Q1,1,I,,20220209.0,20220209,20220209,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-152953",BOEHRINGER INGELHEIM,,4.0,DEC,A,M,Y,,,20220209,,MD,IL,IL,2022,Q1,Child
204516861,20451686,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,N,,Unknown,,206111.0,,,,,2022,Q1,Renal impairment,,2022,Q1,1,I,,20220209.0,20220209,20220209,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-152953",BOEHRINGER INGELHEIM,,4.0,DEC,A,M,Y,,,20220209,,MD,IL,IL,2022,Q1,Child
204516861,20451686,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,N,,Unknown,,206111.0,,,,,2022,Q1,Circulatory collapse,,2022,Q1,1,I,,20220209.0,20220209,20220209,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-152953",BOEHRINGER INGELHEIM,,4.0,DEC,A,M,Y,,,20220209,,MD,IL,IL,2022,Q1,Child
204516861,20451686,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,N,,Unknown,,206111.0,,,,,2022,Q1,Medical induction of coma,,2022,Q1,1,I,,20220209.0,20220209,20220209,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-152953",BOEHRINGER INGELHEIM,,4.0,DEC,A,M,Y,,,20220209,,MD,IL,IL,2022,Q1,Child
204561741,20456174,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,D,D,,,,12.5,MG,,QD,2022,Q1,Metabolic acidosis,,2022,Q1,1,I,20210619.0,,20220210,20220210,DIR,FDA-CDER-CTU-2022-11844,,FDA-CTU,,64.0,YR,,M,N,83.0,KG,20210922,N,PH,US,,2022,Q1,Adult
204570201,20457020,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,Unknown,,,,,,,2022,Q1,Fatigue,,2022,Q1,1,I,20210606.0,20210611.0,20220210,20220210,PER,,US-PERRIGO-21US008063,PERRIGO,,74.0,YR,,M,Y,113.38,KG,20220210,,CN,US,US,2022,Q1,Elderly
204570201,20457020,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,Unknown,,,,,,,2022,Q1,Drug effective for unapproved indication,,2022,Q1,1,I,20210606.0,20210611.0,20220210,20220210,PER,,US-PERRIGO-21US008063,PERRIGO,,74.0,YR,,M,Y,113.38,KG,20220210,,CN,US,US,2022,Q1,Elderly
204570201,20457020,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,Unknown,,,,,,,2022,Q1,Somnolence,,2022,Q1,1,I,20210606.0,20210611.0,20220210,20220210,PER,,US-PERRIGO-21US008063,PERRIGO,,74.0,YR,,M,Y,113.38,KG,20220210,,CN,US,US,2022,Q1,Elderly
204571871,20457187,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,JARDIANCE DUO 5 MG/850 MG X 24 tabs,,,U,,Unknown,,208658.0,,,Tablet,,2022,Q1,Micturition urgency,,2022,Q1,1,I,,20220209.0,20220210,20220210,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153107",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,,,20220210,,CN,IL,IL,2022,Q1,Elderly
204571871,20457187,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,JARDIANCE DUO 5 MG/850 MG X 24 tabs,,,U,,Unknown,,208658.0,,,Tablet,,2022,Q1,Haematuria,,2022,Q1,1,I,,20220209.0,20220210,20220210,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153107",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,,,20220210,,CN,IL,IL,2022,Q1,Elderly
204571871,20457187,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,JARDIANCE DUO 5 MG/850 MG X 24 tabs,,,U,,Unknown,,208658.0,,,Tablet,,2022,Q1,Dysuria,,2022,Q1,1,I,,20220209.0,20220210,20220210,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153107",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,,,20220210,,CN,IL,IL,2022,Q1,Elderly
204571871,20457187,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,JARDIANCE DUO 5 MG/850 MG X 24 tabs,,,U,,Unknown,,208658.0,,,Tablet,,2022,Q1,Pollakiuria,,2022,Q1,1,I,,20220209.0,20220210,20220210,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153107",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,,,20220210,,CN,IL,IL,2022,Q1,Elderly
204571871,20457187,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,JARDIANCE DUO 5 MG/850 MG X 24 tabs,,,U,,Unknown,,208658.0,,,Tablet,,2022,Q1,Candida infection,,2022,Q1,1,I,,20220209.0,20220210,20220210,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153107",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,,,20220210,,CN,IL,IL,2022,Q1,Elderly
204595471,20459547,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5/500,,,Y,U,Unknown,,206111.0,,,,,2022,Q1,Ketosis,,2022,Q1,1,I,,20220210.0,20220211,20220211,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153173",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,,,20220211,,MD,IN,IN,2022,Q1,Adult
204617841,20461784,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,,,,,2022,Q1,COVID-19 pneumonia,,2022,Q1,1,I,,20220209.0,20220211,20220211,EXP,,"BE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153185",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20220211,,HP,BE,BE,2022,Q1,Adult
204617841,20461784,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,,,,,2022,Q1,Acute respiratory distress syndrome,,2022,Q1,1,I,,20220209.0,20220211,20220211,EXP,,"BE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153185",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20220211,,HP,BE,BE,2022,Q1,Adult
204617841,20461784,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,,,,,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,,20220209.0,20220211,20220211,EXP,,"BE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153185",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20220211,,HP,BE,BE,2022,Q1,Adult
204617841,20461784,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,,,,,2022,Q1,Pneumonia bacterial,,2022,Q1,1,I,,20220209.0,20220211,20220211,EXP,,"BE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153185",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20220211,,HP,BE,BE,2022,Q1,Adult
204617841,20461784,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,,,,,2022,Q1,Off label use,,2022,Q1,1,I,,20220209.0,20220211,20220211,EXP,,"BE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153185",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20220211,,HP,BE,BE,2022,Q1,Adult
204617841,20461784,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,,,,,2022,Q1,Pulmonary embolism,,2022,Q1,1,I,,20220209.0,20220211,20220211,EXP,,"BE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153185",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20220211,,HP,BE,BE,2022,Q1,Adult
204632171,20463217,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,,QD,2022,Q1,Urticaria,,2022,Q1,1,I,20220203.0,20220206.0,20220211,20220211,EXP,GB-MHRA-TPP14613171C1159253YC1643888089809,GB-TEVA-2022-GB-2006593,TEVA,,63.0,YR,A,M,Y,93.0,KG,20220211,,MD,GB,GB,2022,Q1,Adult
204632171,20463217,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,,QD,2022,Q1,Throat tightness,,2022,Q1,1,I,20220203.0,20220206.0,20220211,20220211,EXP,GB-MHRA-TPP14613171C1159253YC1643888089809,GB-TEVA-2022-GB-2006593,TEVA,,63.0,YR,A,M,Y,93.0,KG,20220211,,MD,GB,GB,2022,Q1,Adult
204670611,20467061,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,Y,,,,,10.0,MG,,,2022,Q1,Hypotension,,2022,Q1,1,I,20210901.0,20220202.0,20220214,20220214,EXP,,PL-AUROBINDO-AUR-APL-2022-003979,AUROBINDO,,39.0,YR,,M,Y,,,20220214,,MD,PL,PL,2022,Q1,Adult
204670611,20467061,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,Y,,,,,10.0,MG,,,2022,Q1,Dyspnoea,,2022,Q1,1,I,20210901.0,20220202.0,20220214,20220214,EXP,,PL-AUROBINDO-AUR-APL-2022-003979,AUROBINDO,,39.0,YR,,M,Y,,,20220214,,MD,PL,PL,2022,Q1,Adult
204670611,20467061,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,Y,,,,,10.0,MG,,,2022,Q1,Dizziness postural,,2022,Q1,1,I,20210901.0,20220202.0,20220214,20220214,EXP,,PL-AUROBINDO-AUR-APL-2022-003979,AUROBINDO,,39.0,YR,,M,Y,,,20220214,,MD,PL,PL,2022,Q1,Adult
204670611,20467061,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,Y,,,,,10.0,MG,,,2022,Q1,Left ventricular enlargement,,2022,Q1,1,I,20210901.0,20220202.0,20220214,20220214,EXP,,PL-AUROBINDO-AUR-APL-2022-003979,AUROBINDO,,39.0,YR,,M,Y,,,20220214,,MD,PL,PL,2022,Q1,Adult
204670611,20467061,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,Y,,,,,10.0,MG,,,2022,Q1,Non-compaction cardiomyopathy,,2022,Q1,1,I,20210901.0,20220202.0,20220214,20220214,EXP,,PL-AUROBINDO-AUR-APL-2022-003979,AUROBINDO,,39.0,YR,,M,Y,,,20220214,,MD,PL,PL,2022,Q1,Adult
204670611,20467061,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,Y,,,,,10.0,MG,,,2022,Q1,Heart rate increased,,2022,Q1,1,I,20210901.0,20220202.0,20220214,20220214,EXP,,PL-AUROBINDO-AUR-APL-2022-003979,AUROBINDO,,39.0,YR,,M,Y,,,20220214,,MD,PL,PL,2022,Q1,Adult
204670611,20467061,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,Y,,,,,10.0,MG,,,2022,Q1,Cardiac ventricular thrombosis,,2022,Q1,1,I,20210901.0,20220202.0,20220214,20220214,EXP,,PL-AUROBINDO-AUR-APL-2022-003979,AUROBINDO,,39.0,YR,,M,Y,,,20220214,,MD,PL,PL,2022,Q1,Adult
204670611,20467061,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,Y,,,,,10.0,MG,,,2022,Q1,Left atrial enlargement,,2022,Q1,1,I,20210901.0,20220202.0,20220214,20220214,EXP,,PL-AUROBINDO-AUR-APL-2022-003979,AUROBINDO,,39.0,YR,,M,Y,,,20220214,,MD,PL,PL,2022,Q1,Adult
204680081,20468008,6,C,Jardiance [Empagliflozin],,2,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q1,Arthritis,,2022,Q1,1,I,20210204.0,20220111.0,20220214,20220214,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20220214,,CN,DE,DE,2022,Q1,Adult
204680081,20468008,6,C,Jardiance [Empagliflozin],,2,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q1,Feeling cold,,2022,Q1,1,I,20210204.0,20220111.0,20220214,20220214,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20220214,,CN,DE,DE,2022,Q1,Adult
204680081,20468008,6,C,Jardiance [Empagliflozin],,2,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q1,Eye pain,,2022,Q1,1,I,20210204.0,20220111.0,20220214,20220214,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20220214,,CN,DE,DE,2022,Q1,Adult
204680081,20468008,6,C,Jardiance [Empagliflozin],,2,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q1,Pain in extremity,,2022,Q1,1,I,20210204.0,20220111.0,20220214,20220214,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20220214,,CN,DE,DE,2022,Q1,Adult
204680081,20468008,6,C,Jardiance [Empagliflozin],,2,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q1,Off label use,,2022,Q1,1,I,20210204.0,20220111.0,20220214,20220214,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20220214,,CN,DE,DE,2022,Q1,Adult
204680081,20468008,6,C,Jardiance [Empagliflozin],,2,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q1,Vulvovaginal mycotic infection,,2022,Q1,1,I,20210204.0,20220111.0,20220214,20220214,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20220214,,CN,DE,DE,2022,Q1,Adult
204680081,20468008,6,C,Jardiance [Empagliflozin],,2,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q1,Toothache,,2022,Q1,1,I,20210204.0,20220111.0,20220214,20220214,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20220214,,CN,DE,DE,2022,Q1,Adult
204680081,20468008,6,C,Jardiance [Empagliflozin],,2,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q1,Fatigue,,2022,Q1,1,I,20210204.0,20220111.0,20220214,20220214,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20220214,,CN,DE,DE,2022,Q1,Adult
204680081,20468008,6,C,Jardiance [Empagliflozin],,2,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q1,Fatigue,,2022,Q1,1,I,20210204.0,20220111.0,20220214,20220214,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20220214,,CN,DE,DE,2022,Q1,Adult
204680081,20468008,6,C,Jardiance [Empagliflozin],,2,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q1,Nausea,,2022,Q1,1,I,20210204.0,20220111.0,20220214,20220214,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20220214,,CN,DE,DE,2022,Q1,Adult
204680081,20468008,6,C,Jardiance [Empagliflozin],,2,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q1,Hypertension,,2022,Q1,1,I,20210204.0,20220111.0,20220214,20220214,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20220214,,CN,DE,DE,2022,Q1,Adult
204680081,20468008,6,C,Jardiance [Empagliflozin],,2,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q1,Muscle spasms,,2022,Q1,1,I,20210204.0,20220111.0,20220214,20220214,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20220214,,CN,DE,DE,2022,Q1,Adult
204680081,20468008,6,C,Jardiance [Empagliflozin],,2,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q1,Noninfective gingivitis,,2022,Q1,1,I,20210204.0,20220111.0,20220214,20220214,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-06524,ALKEM,,42.0,YR,,F,Y,,,20220214,,CN,DE,DE,2022,Q1,Adult
204682261,20468226,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5mg/850mg,,,,,Unknown,,206111.0,,,Tablet,Q12H,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,,20220210.0,20220214,20220214,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153582",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,,,20220214,,CN,IL,IL,2022,Q1,Elderly
204682261,20468226,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5mg/850mg,,,,,Unknown,,206111.0,,,Tablet,Q12H,2022,Q1,Pneumonia,,2022,Q1,1,I,,20220210.0,20220214,20220214,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153582",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,,,20220214,,CN,IL,IL,2022,Q1,Elderly
204693631,20469363,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q1,Ketoacidosis,,2022,Q1,1,I,20220206.0,20220214.0,20220214,20220214,EXP,NL-LRB-00790736,"NL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153653",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,73.0,KG,20220214,,MD,NL,NL,2022,Q1,Adult
204711111,20471111,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20220131.0,20220211.0,20220214,20220214,EXP,GB-MHRA-ADR 26580844,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153702",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,64.0,KG,20220214,,HP,GB,GB,2022,Q1,Elderly
204746221,20474622,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg,,,Y,U,Unknown,,206111.0,,,Tablet,,2022,Q1,Acute myocardial infarction,,2022,Q1,1,I,20200301.0,20220208.0,20220215,20220215,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-152591",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,99.0,KG,20220215,,MD,CZ,CZ,2022,Q1,Elderly
204746221,20474622,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg,,,Y,U,Unknown,,206111.0,,,Tablet,,2022,Q1,COVID-19 pneumonia,,2022,Q1,1,I,20200301.0,20220208.0,20220215,20220215,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-152591",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,99.0,KG,20220215,,MD,CZ,CZ,2022,Q1,Elderly
204766011,20476601,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"Unknown, Unknown",,,D,,Unknown,,,,,,,2022,Q1,Exposure to toxic agent,,2022,Q1,1,I,20200101.0,20220203.0,20220215,20220215,EXP,,US-PERRIGO-22US002475,PERRIGO,,15.0,YR,,M,Y,,,20220215,,MD,US,US,2022,Q1,Youth
204782701,20478270,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q1,Fournier's gangrene,,2022,Q1,1,I,,20220215.0,20220216,20220216,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154051",BOEHRINGER INGELHEIM,"Sevilla S, McCaleb J, Alkasir A, Currie D. THE DEVELOPMENT OF FOURNIER?S GANGRENE IN A PATIENT WITH A HISTORY OF SCROTAL ABSCESS AND UNDERLYING TYPE 2 DIABETES TREATED WITH A SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR. Journal of Investigative Medicine. 2022; 70: 298-",72.0,YR,E,M,Y,,,20220216,,HP,US,US,2022,Q1,Elderly
204784161,20478416,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;  to help control diab...,,,,,,,,,,Tablet,QD,2022,Q1,Pruritus,,2022,Q1,1,I,20220203.0,20220206.0,20220216,20220216,EXP,GB-MHRA-TPP11948919C5625868YC1643882925063,GB-TEVA-2022-GB-2006548,TEVA,,73.0,YR,E,F,Y,74.0,KG,20220216,,HP,GB,GB,2022,Q1,Elderly
204784161,20478416,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;  to help control diab...,,,,,,,,,,Tablet,QD,2022,Q1,Lip swelling,,2022,Q1,1,I,20220203.0,20220206.0,20220216,20220216,EXP,GB-MHRA-TPP11948919C5625868YC1643882925063,GB-TEVA-2022-GB-2006548,TEVA,,73.0,YR,E,F,Y,74.0,KG,20220216,,HP,GB,GB,2022,Q1,Elderly
204813601,20481360,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q1,Erythema nodosum,,2022,Q1,1,I,20220112.0,20220215.0,20220216,20220216,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154126",BOEHRINGER INGELHEIM,,91.0,YR,E,F,Y,,,20220216,,HP,SG,SG,2022,Q1,Elderly
204813601,20481360,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q1,Rash erythematous,,2022,Q1,1,I,20220112.0,20220215.0,20220216,20220216,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154126",BOEHRINGER INGELHEIM,,91.0,YR,E,F,Y,,,20220216,,HP,SG,SG,2022,Q1,Elderly
204815451,20481545,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, AM",,,,,,,,10.0,MG,Tablet,QD,2022,Q1,Dizziness,,2022,Q1,1,I,,20220117.0,20220216,20220216,EXP,,PT-MYLANLABS-2022M1005422,MYLAN,"Seoane M, Breda I, Fernandes MD,Varela P et.al. Bullous Pemphigoid -A diagnosis to consider. AIMGF Magazine. 2021;11 (3):51-56",69.0,YR,,M,Y,,,20220216,,MD,PT,PT,2022,Q1,Elderly
204815451,20481545,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, AM",,,,,,,,10.0,MG,Tablet,QD,2022,Q1,Pemphigoid,,2022,Q1,1,I,,20220117.0,20220216,20220216,EXP,,PT-MYLANLABS-2022M1005422,MYLAN,"Seoane M, Breda I, Fernandes MD,Varela P et.al. Bullous Pemphigoid -A diagnosis to consider. AIMGF Magazine. 2021;11 (3):51-56",69.0,YR,,M,Y,,,20220216,,MD,PT,PT,2022,Q1,Elderly
204890971,20489097,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Pyelonephritis,,2022,Q1,1,I,20211219.0,,20220217,20220217,DIR,FDA-CDER-CTU-2022-13575,,FDA-CTU,,61.0,YR,,F,N,,,20220211,N,PH,US,,2022,Q1,Adult
204890971,20489097,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Urinary tract infection,,2022,Q1,1,I,20211219.0,,20220217,20220217,DIR,FDA-CDER-CTU-2022-13575,,FDA-CTU,,61.0,YR,,F,N,,,20220211,N,PH,US,,2022,Q1,Adult
204895271,20489527,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2022,Q1,Left ventricular enlargement,,2022,Q1,1,I,20210901.0,20220207.0,20220218,20220218,EXP,,PL-PFIZER INC-202200238655,PFIZER,,39.0,YR,,M,Y,,,20220218,,MD,PL,PL,2022,Q1,Adult
204895271,20489527,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2022,Q1,Dizziness postural,,2022,Q1,1,I,20210901.0,20220207.0,20220218,20220218,EXP,,PL-PFIZER INC-202200238655,PFIZER,,39.0,YR,,M,Y,,,20220218,,MD,PL,PL,2022,Q1,Adult
204895271,20489527,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2022,Q1,Dyspnoea,,2022,Q1,1,I,20210901.0,20220207.0,20220218,20220218,EXP,,PL-PFIZER INC-202200238655,PFIZER,,39.0,YR,,M,Y,,,20220218,,MD,PL,PL,2022,Q1,Adult
204895271,20489527,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2022,Q1,Non-compaction cardiomyopathy,,2022,Q1,1,I,20210901.0,20220207.0,20220218,20220218,EXP,,PL-PFIZER INC-202200238655,PFIZER,,39.0,YR,,M,Y,,,20220218,,MD,PL,PL,2022,Q1,Adult
204895271,20489527,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2022,Q1,Hypotension,,2022,Q1,1,I,20210901.0,20220207.0,20220218,20220218,EXP,,PL-PFIZER INC-202200238655,PFIZER,,39.0,YR,,M,Y,,,20220218,,MD,PL,PL,2022,Q1,Adult
204895271,20489527,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2022,Q1,Left atrial enlargement,,2022,Q1,1,I,20210901.0,20220207.0,20220218,20220218,EXP,,PL-PFIZER INC-202200238655,PFIZER,,39.0,YR,,M,Y,,,20220218,,MD,PL,PL,2022,Q1,Adult
204895271,20489527,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2022,Q1,Heart rate increased,,2022,Q1,1,I,20210901.0,20220207.0,20220218,20220218,EXP,,PL-PFIZER INC-202200238655,PFIZER,,39.0,YR,,M,Y,,,20220218,,MD,PL,PL,2022,Q1,Adult
204895271,20489527,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2022,Q1,Cardiac ventricular thrombosis,,2022,Q1,1,I,20210901.0,20220207.0,20220218,20220218,EXP,,PL-PFIZER INC-202200238655,PFIZER,,39.0,YR,,M,Y,,,20220218,,MD,PL,PL,2022,Q1,Adult
204897371,20489737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q1,Encephalopathy,,2022,Q1,1,I,,20220211.0,20220218,20220218,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153518",BOEHRINGER INGELHEIM,"Mackintosh C, Tewari A, Siegel J, Wang D, Freeman W. Postoperative Euglycemic Diabetic Ketoacidosis and Encephalopathy Related to SGLT-2 Inhibitors: A Case Report and Discussion of Diabetes Treatment and ?Sweet Pee Encephalopathy? in Perioperative Hospital Management. The Neurohospitalist. 2020; 10 (1): 51-54.",68.0,YR,E,F,Y,,,20220218,,MD,US,US,2022,Q1,Elderly
204897371,20489737,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,,20220211.0,20220218,20220218,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153518",BOEHRINGER INGELHEIM,"Mackintosh C, Tewari A, Siegel J, Wang D, Freeman W. Postoperative Euglycemic Diabetic Ketoacidosis and Encephalopathy Related to SGLT-2 Inhibitors: A Case Report and Discussion of Diabetes Treatment and ?Sweet Pee Encephalopathy? in Perioperative Hospital Management. The Neurohospitalist. 2020; 10 (1): 51-54.",68.0,YR,E,F,Y,,,20220218,,MD,US,US,2022,Q1,Elderly
204903611,20490361,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,,20220215.0,20220218,20220218,EXP,,US-EMD Serono-9300612,EMD SERONO INC,"Sathyanarayanan S, Hamid K, Taggart K, Gibbons K, Jamous F. When the machine fails: A different approach to euglycemic diabetic ketoacidosis treatment. Critical Care Medicine. 2022 JAN 01;50(1 SUPPL):214.",44.0,YR,A,F,Y,,,20220218,,HP,US,,2022,Q1,Adult
204963291,20496329,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2022,Q1,Cardiac failure,,2022,Q1,1,I,,20220214.0,20220221,20220221,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154163",BOEHRINGER INGELHEIM,,7.0,DEC,E,M,Y,,,20220221,,PH,JP,JP,2022,Q1,Child
204970251,20497025,45,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Congestive cardiomyopathy,,2022,Q1,1,I,20210301.0,20220209.0,20220221,20220221,EXP,,PL-US-Provell Pharmaceuticals LLC-E2B_90086866,PROVELL PHARMACEUTICALS,,71.0,YR,E,M,Y,,,20220219,,MD,PL,PL,2022,Q1,Elderly
204970251,20497025,45,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Acute kidney injury,,2022,Q1,1,I,20210301.0,20220209.0,20220221,20220221,EXP,,PL-US-Provell Pharmaceuticals LLC-E2B_90086866,PROVELL PHARMACEUTICALS,,71.0,YR,E,M,Y,,,20220219,,MD,PL,PL,2022,Q1,Elderly
204970251,20497025,45,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Glomerular filtration rate abnormal,,2022,Q1,1,I,20210301.0,20220209.0,20220221,20220221,EXP,,PL-US-Provell Pharmaceuticals LLC-E2B_90086866,PROVELL PHARMACEUTICALS,,71.0,YR,E,M,Y,,,20220219,,MD,PL,PL,2022,Q1,Elderly
204970251,20497025,45,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Wrong technique in product usage process,,2022,Q1,1,I,20210301.0,20220209.0,20220221,20220221,EXP,,PL-US-Provell Pharmaceuticals LLC-E2B_90086866,PROVELL PHARMACEUTICALS,,71.0,YR,E,M,Y,,,20220219,,MD,PL,PL,2022,Q1,Elderly
204970251,20497025,45,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,N-terminal prohormone brain natriuretic peptide increased,,2022,Q1,1,I,20210301.0,20220209.0,20220221,20220221,EXP,,PL-US-Provell Pharmaceuticals LLC-E2B_90086866,PROVELL PHARMACEUTICALS,,71.0,YR,E,M,Y,,,20220219,,MD,PL,PL,2022,Q1,Elderly
204970251,20497025,45,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Cardiac failure,,2022,Q1,1,I,20210301.0,20220209.0,20220221,20220221,EXP,,PL-US-Provell Pharmaceuticals LLC-E2B_90086866,PROVELL PHARMACEUTICALS,,71.0,YR,E,M,Y,,,20220219,,MD,PL,PL,2022,Q1,Elderly
204970251,20497025,45,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Lung disorder,,2022,Q1,1,I,20210301.0,20220209.0,20220221,20220221,EXP,,PL-US-Provell Pharmaceuticals LLC-E2B_90086866,PROVELL PHARMACEUTICALS,,71.0,YR,E,M,Y,,,20220219,,MD,PL,PL,2022,Q1,Elderly
205012621,20501262,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,,,,,2022,Q1,Oedema peripheral,,2022,Q1,1,I,,20220215.0,20220222,20220222,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153945",BOEHRINGER INGELHEIM,"Amole M, Leey-Casella J. Stopping Empagliflozin Unmasks Heart Failure. Federal Practitioner : for the Health Care Professionals of the VA, DoD, and PHS. 2021; 38: 44-45.",58.0,YR,A,M,Y,,,20220222,,MD,US,US,2022,Q1,Adult
205012621,20501262,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,,,,,2022,Q1,Rales,,2022,Q1,1,I,,20220215.0,20220222,20220222,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153945",BOEHRINGER INGELHEIM,"Amole M, Leey-Casella J. Stopping Empagliflozin Unmasks Heart Failure. Federal Practitioner : for the Health Care Professionals of the VA, DoD, and PHS. 2021; 38: 44-45.",58.0,YR,A,M,Y,,,20220222,,MD,US,US,2022,Q1,Adult
205012621,20501262,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,,,,,2022,Q1,Ejection fraction decreased,,2022,Q1,1,I,,20220215.0,20220222,20220222,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-153945",BOEHRINGER INGELHEIM,"Amole M, Leey-Casella J. Stopping Empagliflozin Unmasks Heart Failure. Federal Practitioner : for the Health Care Professionals of the VA, DoD, and PHS. 2021; 38: 44-45.",58.0,YR,A,M,Y,,,20220222,,MD,US,US,2022,Q1,Adult
205019861,20501986,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg10.0mg UNKNOWN,,,U,,,,,10.0,MG,,,2022,Q1,Cardiac ventricular thrombosis,,2022,Q1,1,I,20210901.0,20220209.0,20220222,20220222,EXP,PL-002147023-NVSC2022PL018218,PL-TOPROL-2022000062,TOPROL ACQUISITION,,39.0,YR,A,M,Y,,,20220222,,HP,PL,PL,2022,Q1,Adult
205019861,20501986,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg10.0mg UNKNOWN,,,U,,,,,10.0,MG,,,2022,Q1,Left ventricular enlargement,,2022,Q1,1,I,20210901.0,20220209.0,20220222,20220222,EXP,PL-002147023-NVSC2022PL018218,PL-TOPROL-2022000062,TOPROL ACQUISITION,,39.0,YR,A,M,Y,,,20220222,,HP,PL,PL,2022,Q1,Adult
205019861,20501986,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg10.0mg UNKNOWN,,,U,,,,,10.0,MG,,,2022,Q1,Hypotension,,2022,Q1,1,I,20210901.0,20220209.0,20220222,20220222,EXP,PL-002147023-NVSC2022PL018218,PL-TOPROL-2022000062,TOPROL ACQUISITION,,39.0,YR,A,M,Y,,,20220222,,HP,PL,PL,2022,Q1,Adult
205019861,20501986,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg10.0mg UNKNOWN,,,U,,,,,10.0,MG,,,2022,Q1,Dyspnoea,,2022,Q1,1,I,20210901.0,20220209.0,20220222,20220222,EXP,PL-002147023-NVSC2022PL018218,PL-TOPROL-2022000062,TOPROL ACQUISITION,,39.0,YR,A,M,Y,,,20220222,,HP,PL,PL,2022,Q1,Adult
205019861,20501986,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg10.0mg UNKNOWN,,,U,,,,,10.0,MG,,,2022,Q1,Left atrial enlargement,,2022,Q1,1,I,20210901.0,20220209.0,20220222,20220222,EXP,PL-002147023-NVSC2022PL018218,PL-TOPROL-2022000062,TOPROL ACQUISITION,,39.0,YR,A,M,Y,,,20220222,,HP,PL,PL,2022,Q1,Adult
205019861,20501986,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg10.0mg UNKNOWN,,,U,,,,,10.0,MG,,,2022,Q1,Heart rate increased,,2022,Q1,1,I,20210901.0,20220209.0,20220222,20220222,EXP,PL-002147023-NVSC2022PL018218,PL-TOPROL-2022000062,TOPROL ACQUISITION,,39.0,YR,A,M,Y,,,20220222,,HP,PL,PL,2022,Q1,Adult
205019861,20501986,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg10.0mg UNKNOWN,,,U,,,,,10.0,MG,,,2022,Q1,Non-compaction cardiomyopathy,,2022,Q1,1,I,20210901.0,20220209.0,20220222,20220222,EXP,PL-002147023-NVSC2022PL018218,PL-TOPROL-2022000062,TOPROL ACQUISITION,,39.0,YR,A,M,Y,,,20220222,,HP,PL,PL,2022,Q1,Adult
205019861,20501986,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg10.0mg UNKNOWN,,,U,,,,,10.0,MG,,,2022,Q1,Dizziness postural,,2022,Q1,1,I,20210901.0,20220209.0,20220222,20220222,EXP,PL-002147023-NVSC2022PL018218,PL-TOPROL-2022000062,TOPROL ACQUISITION,,39.0,YR,A,M,Y,,,20220222,,HP,PL,PL,2022,Q1,Adult
205050872,20505087,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q1,Cardiac failure,,2022,Q1,2,F,20220119.0,20220304.0,20220223,20220312,PER,,DE-AMGEN-DEUNI2022030097,AMGEN,,63.0,YR,A,M,Y,105.0,KG,20220312,,HP,DE,DE,2022,Q1,Adult
205050872,20505087,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q1,Overdose,,2022,Q1,2,F,20220119.0,20220304.0,20220223,20220312,PER,,DE-AMGEN-DEUNI2022030097,AMGEN,,63.0,YR,A,M,Y,105.0,KG,20220312,,HP,DE,DE,2022,Q1,Adult
205056843,20505684,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U,Unknown,,204629.0,10.0,MG,,,2022,Q1,Diabetic ketoacidosis,,2022,Q1,3,F,20211209.0,20220302.0,20220223,20220310,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-155225",BOEHRINGER INGELHEIM,,65.0,YR,E,F,Y,80.0,KG,20220310,,MD,NZ,NZ,2022,Q1,Elderly
205056843,20505684,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U,Unknown,,204629.0,10.0,MG,,,2022,Q1,Cholecystitis,,2022,Q1,3,F,20211209.0,20220302.0,20220223,20220310,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-155225",BOEHRINGER INGELHEIM,,65.0,YR,E,F,Y,80.0,KG,20220310,,MD,NZ,NZ,2022,Q1,Elderly
205066051,20506605,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,,20220217.0,20220223,20220223,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154470",BOEHRINGER INGELHEIM,"Berman J, Alban L, Mistry N. Euglycemic DKA in a pregnant patient: an uncommon presentation of a common ICU admission. Critical care medicine. 2022; 50: 414-",39.0,YR,A,F,Y,,,20220223,,HP,US,US,2022,Q1,Adult
205066051,20506605,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q1,Pre-eclampsia,,2022,Q1,1,I,,20220217.0,20220223,20220223,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154470",BOEHRINGER INGELHEIM,"Berman J, Alban L, Mistry N. Euglycemic DKA in a pregnant patient: an uncommon presentation of a common ICU admission. Critical care medicine. 2022; 50: 414-",39.0,YR,A,F,Y,,,20220223,,HP,US,US,2022,Q1,Adult
205066051,20506605,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q1,Maternal exposure during pregnancy,,2022,Q1,1,I,,20220217.0,20220223,20220223,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-154470",BOEHRINGER INGELHEIM,"Berman J, Alban L, Mistry N. Euglycemic DKA in a pregnant patient: an uncommon presentation of a common ICU admission. Critical care medicine. 2022; 50: 414-",39.0,YR,A,F,Y,,,20220223,,HP,US,US,2022,Q1,Adult
205085301,20508530,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"2.5 mg, qd",,,,,,,,,,,QD,2022,Q1,Off label use,,2022,Q1,1,I,,20220215.0,20220223,20220223,PER,,BR-LUPIN PHARMACEUTICALS INC.-2022-02354,LUPIN,"Dos Santos SS, Ramaldes LA, Gabbay MAL, Moises RCS, Dib SA. Use of a sodium-glucose cotransporter 2 inhibitor, empagliflozin, in a patient with rabson-mendenhall syndrome. Harmone research in pediatric. 2021;94:313-316",2.0,YR,,M,Y,,,20220223,,HP,BR,BR,2022,Q1,Child
205085301,20508530,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"2.5 mg, qd",,,,,,,,,,,QD,2022,Q1,Condition aggravated,,2022,Q1,1,I,,20220215.0,20220223,20220223,PER,,BR-LUPIN PHARMACEUTICALS INC.-2022-02354,LUPIN,"Dos Santos SS, Ramaldes LA, Gabbay MAL, Moises RCS, Dib SA. Use of a sodium-glucose cotransporter 2 inhibitor, empagliflozin, in a patient with rabson-mendenhall syndrome. Harmone research in pediatric. 2021;94:313-316",2.0,YR,,M,Y,,,20220223,,HP,BR,BR,2022,Q1,Child
205085301,20508530,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"2.5 mg, qd",,,,,,,,,,,QD,2022,Q1,Drug ineffective,,2022,Q1,1,I,,20220215.0,20220223,20220223,PER,,BR-LUPIN PHARMACEUTICALS INC.-2022-02354,LUPIN,"Dos Santos SS, Ramaldes LA, Gabbay MAL, Moises RCS, Dib SA. Use of a sodium-glucose cotransporter 2 inhibitor, empagliflozin, in a patient with rabson-mendenhall syndrome. Harmone research in pediatric. 2021;94:313-316",2.0,YR,,M,Y,,,20220223,,HP,BR,BR,2022,Q1,Child
205085301,20508530,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, qd",,,,,,,,,,,QD,2022,Q1,Off label use,,2022,Q1,1,I,,20220215.0,20220223,20220223,PER,,BR-LUPIN PHARMACEUTICALS INC.-2022-02354,LUPIN,"Dos Santos SS, Ramaldes LA, Gabbay MAL, Moises RCS, Dib SA. Use of a sodium-glucose cotransporter 2 inhibitor, empagliflozin, in a patient with rabson-mendenhall syndrome. Harmone research in pediatric. 2021;94:313-316",2.0,YR,,M,Y,,,20220223,,HP,BR,BR,2022,Q1,Child
205085301,20508530,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, qd",,,,,,,,,,,QD,2022,Q1,Condition aggravated,,2022,Q1,1,I,,20220215.0,20220223,20220223,PER,,BR-LUPIN PHARMACEUTICALS INC.-2022-02354,LUPIN,"Dos Santos SS, Ramaldes LA, Gabbay MAL, Moises RCS, Dib SA. Use of a sodium-glucose cotransporter 2 inhibitor, empagliflozin, in a patient with rabson-mendenhall syndrome. Harmone research in pediatric. 2021;94:313-316",2.0,YR,,M,Y,,,20220223,,HP,BR,BR,2022,Q1,Child
205085301,20508530,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 mg, qd",,,,,,,,,,,QD,2022,Q1,Drug ineffective,,2022,Q1,1,I,,20220215.0,20220223,20220223,PER,,BR-LUPIN PHARMACEUTICALS INC.-2022-02354,LUPIN,"Dos Santos SS, Ramaldes LA, Gabbay MAL, Moises RCS, Dib SA. Use of a sodium-glucose cotransporter 2 inhibitor, empagliflozin, in a patient with rabson-mendenhall syndrome. Harmone research in pediatric. 2021;94:313-316",2.0,YR,,M,Y,,,20220223,,HP,BR,BR,2022,Q1,Child
205122053,20512205,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2022,Q1,Infection,,2022,Q1,3,F,20220209.0,20220321.0,20220224,20220328,EXP,,BR-Eisai Medical Research-EC-2022-109187,EISAI,,65.0,YR,E,F,Y,61.5,KG,20220328,,MD,BR,,2022,Q1,Elderly
205128851,20512885,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,100.0,MG,Y,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q1,Pemphigus,,2022,Q1,1,I,20211204.0,20220223.0,20220224,20220224,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-155731",BOEHRINGER INGELHEIM,,96.0,YR,E,F,Y,,,20220224,,PH,GB,GB,2022,Q1,Elderly
205128851,20512885,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,100.0,MG,Y,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q1,Malaise,,2022,Q1,1,I,20211204.0,20220223.0,20220224,20220224,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-155731",BOEHRINGER INGELHEIM,,96.0,YR,E,F,Y,,,20220224,,PH,GB,GB,2022,Q1,Elderly
205136921,20513692,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,Unknown,,,,,,,2022,Q1,Maternal exposure during pregnancy,,2022,Q1,1,I,,20220216.0,20220224,20220224,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02413,LUPIN,"Berman J, Alban L, Mistry N. Euglycemic DKA in a pregnant patient: An uncommon presentation of a common ICU admission. Critical Care Medicine. 2022;50 (1):414",39.0,YR,,F,Y,,,20220224,,HP,US,US,2022,Q1,Adult
205142941,20514294,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, AM",,,U,,,,,10.0,MG,Tablet,QD,2022,Q1,Pemphigoid,,2022,Q1,1,I,,20220221.0,20220224,20220224,EXP,,NVSC2022PT042615,NOVARTIS,"Seoane M, Breda I, Fernandes MD, Varela P et.al.. Bullous Pemphigoid- A diagnosis to consider. AIMGF MAGAZINE. 2021;11(3):51-6",69.0,YR,,M,Y,,,20220224,,HP,PT,PT,2022,Q1,Elderly
205142941,20514294,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, AM",,,U,,,,,10.0,MG,Tablet,QD,2022,Q1,Dizziness,,2022,Q1,1,I,,20220221.0,20220224,20220224,EXP,,NVSC2022PT042615,NOVARTIS,"Seoane M, Breda I, Fernandes MD, Varela P et.al.. Bullous Pemphigoid- A diagnosis to consider. AIMGF MAGAZINE. 2021;11(3):51-6",69.0,YR,,M,Y,,,20220224,,HP,PT,PT,2022,Q1,Elderly
205152661,20515266,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg: 1 comprimido ao pequeno-almoco,,,,,,,,,,,,2022,Q1,Metabolic acidosis,,2022,Q1,1,I,20220124.0,20220215.0,20220224,20220224,EXP,PT-INFARMED-T202201-1936,PT-Vifor (International) Inc.-VIT-2022-01041,VIFOR,,67.0,YR,,M,Y,61.0,KG,20220224,,PH,PT,PT,2022,Q1,Elderly
205154211,20515421,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1/2 tablet (12.5 mg) qd",,,,,,,,25.0,MG,,QD,2022,Q1,Arthralgia,,2022,Q1,1,I,,20210722.0,20220224,20220224,PER,,US-LANTHEUS-LMI-2021-00851,LANTHEUS MEDICAL IMAGING,,58.0,YR,,M,Y,,,20220211,,CN,US,US,2022,Q1,Adult
205154211,20515421,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1/2 tablet (12.5 mg) qd",,,,,,,,25.0,MG,,QD,2022,Q1,Back pain,,2022,Q1,1,I,,20210722.0,20220224,20220224,PER,,US-LANTHEUS-LMI-2021-00851,LANTHEUS MEDICAL IMAGING,,58.0,YR,,M,Y,,,20220211,,CN,US,US,2022,Q1,Adult
205154211,20515421,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1/2 tablet (12.5 mg) qd",,,,,,,,25.0,MG,,QD,2022,Q1,Pain in extremity,,2022,Q1,1,I,,20210722.0,20220224,20220224,PER,,US-LANTHEUS-LMI-2021-00851,LANTHEUS MEDICAL IMAGING,,58.0,YR,,M,Y,,,20220211,,CN,US,US,2022,Q1,Adult
205154211,20515421,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1/2 tablet (12.5 mg) qd",,,,,,,,25.0,MG,,QD,2022,Q1,Respiratory rate increased,,2022,Q1,1,I,,20210722.0,20220224,20220224,PER,,US-LANTHEUS-LMI-2021-00851,LANTHEUS MEDICAL IMAGING,,58.0,YR,,M,Y,,,20220211,,CN,US,US,2022,Q1,Adult
205179121,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,20201201.0,20220215.0,20220225,20220225,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220225,,CN,US,,2022,Q1,Elderly
205179121,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Cardiac disorder,,2022,Q1,1,I,20201201.0,20220215.0,20220225,20220225,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220225,,CN,US,,2022,Q1,Elderly
205179121,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Paranasal sinus hyposecretion,,2022,Q1,1,I,20201201.0,20220215.0,20220225,20220225,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220225,,CN,US,,2022,Q1,Elderly
205179121,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Sleep apnoea syndrome,,2022,Q1,1,I,20201201.0,20220215.0,20220225,20220225,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220225,,CN,US,,2022,Q1,Elderly
205179121,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Sinus congestion,,2022,Q1,1,I,20201201.0,20220215.0,20220225,20220225,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220225,,CN,US,,2022,Q1,Elderly
205179121,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Respiratory rate decreased,,2022,Q1,1,I,20201201.0,20220215.0,20220225,20220225,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220225,,CN,US,,2022,Q1,Elderly
205179121,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Diabetes mellitus,,2022,Q1,1,I,20201201.0,20220215.0,20220225,20220225,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220225,,CN,US,,2022,Q1,Elderly
205179121,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Dizziness,,2022,Q1,1,I,20201201.0,20220215.0,20220225,20220225,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220225,,CN,US,,2022,Q1,Elderly
205191181,20519118,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Perineal abscess,,2022,Q1,1,I,20220221.0,,20220225,20220225,DIR,605113,,FDA-CTU,,68.0,YR,,M,N,124.0,KG,20220225,N,PH,US,,2022,Q1,Elderly
205191181,20519118,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Fluctuance,,2022,Q1,1,I,20220221.0,,20220225,20220225,DIR,605113,,FDA-CTU,,68.0,YR,,M,N,124.0,KG,20220225,N,PH,US,,2022,Q1,Elderly
205191181,20519118,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Tenderness,,2022,Q1,1,I,20220221.0,,20220225,20220225,DIR,605113,,FDA-CTU,,68.0,YR,,M,N,124.0,KG,20220225,N,PH,US,,2022,Q1,Elderly
205191181,20519118,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Fournier's gangrene,,2022,Q1,1,I,20220221.0,,20220225,20220225,DIR,605113,,FDA-CTU,,68.0,YR,,M,N,124.0,KG,20220225,N,PH,US,,2022,Q1,Elderly
205239732,20523973,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,AM,,,,,,,,10.0,MG,Tablet,QD,2022,Q1,Pemphigoid,,2022,Q1,2,F,,20220309.0,20220228,20220315,EXP,,PT-BAUSCH-BL-2022-005078,BAUSCH AND LOMB,"Seoane M, Breda I, Fernandes M, Varela P. Bullous Pemphigoid -A diagnosis to consider Penfigoide Bolhoso- Um Diagnostico A Considerar. AIMGF magazine. 2021;11 (3):51-56.",69.0,YR,,M,Y,,,20220315,,HP,PT,PT,2022,Q1,Elderly
205239732,20523973,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,AM,,,,,,,,10.0,MG,Tablet,QD,2022,Q1,Dizziness,,2022,Q1,2,F,,20220309.0,20220228,20220315,EXP,,PT-BAUSCH-BL-2022-005078,BAUSCH AND LOMB,"Seoane M, Breda I, Fernandes M, Varela P. Bullous Pemphigoid -A diagnosis to consider Penfigoide Bolhoso- Um Diagnostico A Considerar. AIMGF magazine. 2021;11 (3):51-56.",69.0,YR,,M,Y,,,20220315,,HP,PT,PT,2022,Q1,Elderly
205344131,20534413,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day (AM)",,,,,,,,10.0,MG,Tablet,QD,2022,Q1,Pemphigoid,,2022,Q1,1,I,,20220218.0,20220302,20220302,EXP,,PT-AUROBINDO-AUR-APL-2022-005915,AUROBINDO,"Seoane M, Breda I, Fernandes MD,Varela P et.al.. Bullous Pemphigoid -A diagnosis to consider.. AIMGF Magazine.. 2021;11 (3):51-56",69.0,YR,,M,Y,,,20220302,,MD,PT,PT,2022,Q1,Elderly
205344131,20534413,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day (AM)",,,,,,,,10.0,MG,Tablet,QD,2022,Q1,Dizziness,,2022,Q1,1,I,,20220218.0,20220302,20220302,EXP,,PT-AUROBINDO-AUR-APL-2022-005915,AUROBINDO,"Seoane M, Breda I, Fernandes MD,Varela P et.al.. Bullous Pemphigoid -A diagnosis to consider.. AIMGF Magazine.. 2021;11 (3):51-56",69.0,YR,,M,Y,,,20220302,,MD,PT,PT,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Tachycardia,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Apnoea,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Dyspnoea,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Condition aggravated,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Pupils unequal,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Tachypnoea,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Electrolyte imbalance,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Hypotonia,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Oedema peripheral,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Renal impairment,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Systemic infection,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Loss of consciousness,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Hypotension,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Bradypnoea,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,General physical health deterioration,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Anuria,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Skin pressure mark,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Disorientation,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Nuchal rigidity,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Hyperglycaemia,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Skin irritation,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Dehydration,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Cyanosis,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Decubitus ulcer,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205381551,20538155,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,,,,,,,,,2022,Q1,Electrocardiogram abnormal,,2022,Q1,1,I,,20210902.0,20220302,20220302,EXP,,DE-JNJFOC-20210908112,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20220302,,PH,DE,DE,2022,Q1,Elderly
205409271,20540927,21,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"metformin 500 mg, empagliflozin 5 mg",,,,,,,,,,,,2022,Q1,Pancytopenia,,2022,Q1,1,I,20210908.0,20211014.0,20220302,20220302,EXP,CH-SM-2021-24150,CH-JNJFOC-20211025869,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20220302,,PH,CH,CH,2022,Q1,Elderly
205468041,20546804,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Diabetes mellitus,,2022,Q1,1,I,20180926.0,20220114.0,20220303,20220303,EXP,,CA-GILEAD-2022-0570604,GILEAD,,66.0,YR,E,F,Y,,,20220303,,MD,CA,CA,2022,Q1,Elderly
205468041,20546804,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Transplant rejection,,2022,Q1,1,I,20180926.0,20220114.0,20220303,20220303,EXP,,CA-GILEAD-2022-0570604,GILEAD,,66.0,YR,E,F,Y,,,20220303,,MD,CA,CA,2022,Q1,Elderly
205512311,20551231,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,,20220225.0,20220304,20220304,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-156141",BOEHRINGER INGELHEIM,"Perez-Cruz N, Ramos-Marquez R, Del Olmo F. EUGLYCEMIC DIABETIC KETOACIDOSIS IN A PATIENT WITH COVID-19 CASE REPORT. Journal of Investigative Medicine. 2022; 70: 519-",61.0,YR,A,M,Y,,,20220304,,HP,US,US,2022,Q1,Adult
205512681,20551268,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,strength 5mg/1000mg,,,U,,Asked But Unknown,,206111.0,,,,,2022,Q1,Fall,,2022,Q1,1,I,,20220303.0,20220304,20220304,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157430",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220304,,MD,AU,AU,2022,Q1,Elderly
205512681,20551268,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,strength 5mg/1000mg,,,U,,Asked But Unknown,,206111.0,,,,,2022,Q1,Pollakiuria,,2022,Q1,1,I,,20220303.0,20220304,20220304,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157430",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220304,,MD,AU,AU,2022,Q1,Elderly
205512681,20551268,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,strength 5mg/1000mg,,,U,,Asked But Unknown,,206111.0,,,,,2022,Q1,Urinary incontinence,,2022,Q1,1,I,,20220303.0,20220304,20220304,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157430",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220304,,MD,AU,AU,2022,Q1,Elderly
205512681,20551268,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,strength 5mg/1000mg,,,U,,Asked But Unknown,,206111.0,,,,,2022,Q1,Hip fracture,,2022,Q1,1,I,,20220303.0,20220304,20220304,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157430",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220304,,MD,AU,AU,2022,Q1,Elderly
205531121,20553112,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q1,Weight decreased,,2022,Q1,1,I,20220113.0,,20220304,20220304,DIR,FDA-CDER-CTU-2022-17705,,FDA-CTU,,77.0,YR,,M,N,73.0,KG,20220301,N,PH,US,,2022,Q1,Elderly
205531121,20553112,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,20220113.0,,20220304,20220304,DIR,FDA-CDER-CTU-2022-17705,,FDA-CTU,,77.0,YR,,M,N,73.0,KG,20220301,N,PH,US,,2022,Q1,Elderly
205531121,20553112,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q1,Ketonuria,,2022,Q1,1,I,20220113.0,,20220304,20220304,DIR,FDA-CDER-CTU-2022-17705,,FDA-CTU,,77.0,YR,,M,N,73.0,KG,20220301,N,PH,US,,2022,Q1,Elderly
205531121,20553112,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q1,Acetonaemia,,2022,Q1,1,I,20220113.0,,20220304,20220304,DIR,FDA-CDER-CTU-2022-17705,,FDA-CTU,,77.0,YR,,M,N,73.0,KG,20220301,N,PH,US,,2022,Q1,Elderly
205548361,20554836,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q1,Haemorrhage subcutaneous,,2022,Q1,1,I,20220219.0,20220302.0,20220304,20220304,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157189",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20220304,,MD,JP,JP,2022,Q1,Elderly
205548361,20554836,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q1,Cerebral haemorrhage,,2022,Q1,1,I,20220219.0,20220302.0,20220304,20220304,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157189",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20220304,,MD,JP,JP,2022,Q1,Elderly
205548361,20554836,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q1,Fall,,2022,Q1,1,I,20220219.0,20220302.0,20220304,20220304,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157189",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20220304,,MD,JP,JP,2022,Q1,Elderly
205572681,20557268,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Decreased appetite,,2022,Q1,1,I,20211202.0,20220225.0,20220307,20220307,EXP,,CO-NOVOPROD-877999,NOVO NORDISK,,73.0,YR,,M,Y,100.0,KG,20220307,,CN,CO,CO,2022,Q1,Elderly
205572681,20557268,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Discouragement,,2022,Q1,1,I,20211202.0,20220225.0,20220307,20220307,EXP,,CO-NOVOPROD-877999,NOVO NORDISK,,73.0,YR,,M,Y,100.0,KG,20220307,,CN,CO,CO,2022,Q1,Elderly
205572681,20557268,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Headache,,2022,Q1,1,I,20211202.0,20220225.0,20220307,20220307,EXP,,CO-NOVOPROD-877999,NOVO NORDISK,,73.0,YR,,M,Y,100.0,KG,20220307,,CN,CO,CO,2022,Q1,Elderly
205572681,20557268,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Dysgeusia,,2022,Q1,1,I,20211202.0,20220225.0,20220307,20220307,EXP,,CO-NOVOPROD-877999,NOVO NORDISK,,73.0,YR,,M,Y,100.0,KG,20220307,,CN,CO,CO,2022,Q1,Elderly
205572681,20557268,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Abdominal pain,,2022,Q1,1,I,20211202.0,20220225.0,20220307,20220307,EXP,,CO-NOVOPROD-877999,NOVO NORDISK,,73.0,YR,,M,Y,100.0,KG,20220307,,CN,CO,CO,2022,Q1,Elderly
205572681,20557268,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Orchitis,,2022,Q1,1,I,20211202.0,20220225.0,20220307,20220307,EXP,,CO-NOVOPROD-877999,NOVO NORDISK,,73.0,YR,,M,Y,100.0,KG,20220307,,CN,CO,CO,2022,Q1,Elderly
205572681,20557268,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Abdominal pain,,2022,Q1,1,I,20211202.0,20220225.0,20220307,20220307,EXP,,CO-NOVOPROD-877999,NOVO NORDISK,,73.0,YR,,M,Y,100.0,KG,20220307,,CN,CO,CO,2022,Q1,Elderly
205572681,20557268,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Asthenia,,2022,Q1,1,I,20211202.0,20220225.0,20220307,20220307,EXP,,CO-NOVOPROD-877999,NOVO NORDISK,,73.0,YR,,M,Y,100.0,KG,20220307,,CN,CO,CO,2022,Q1,Elderly
205572681,20557268,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Urinary tract infection,,2022,Q1,1,I,20211202.0,20220225.0,20220307,20220307,EXP,,CO-NOVOPROD-877999,NOVO NORDISK,,73.0,YR,,M,Y,100.0,KG,20220307,,CN,CO,CO,2022,Q1,Elderly
205572681,20557268,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Dental caries,,2022,Q1,1,I,20211202.0,20220225.0,20220307,20220307,EXP,,CO-NOVOPROD-877999,NOVO NORDISK,,73.0,YR,,M,Y,100.0,KG,20220307,,CN,CO,CO,2022,Q1,Elderly
205572681,20557268,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Hypotension,,2022,Q1,1,I,20211202.0,20220225.0,20220307,20220307,EXP,,CO-NOVOPROD-877999,NOVO NORDISK,,73.0,YR,,M,Y,100.0,KG,20220307,,CN,CO,CO,2022,Q1,Elderly
205572681,20557268,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Influenza,,2022,Q1,1,I,20211202.0,20220225.0,20220307,20220307,EXP,,CO-NOVOPROD-877999,NOVO NORDISK,,73.0,YR,,M,Y,100.0,KG,20220307,,CN,CO,CO,2022,Q1,Elderly
205572681,20557268,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Immune system disorder,,2022,Q1,1,I,20211202.0,20220225.0,20220307,20220307,EXP,,CO-NOVOPROD-877999,NOVO NORDISK,,73.0,YR,,M,Y,100.0,KG,20220307,,CN,CO,CO,2022,Q1,Elderly
205572681,20557268,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Weight decreased,,2022,Q1,1,I,20211202.0,20220225.0,20220307,20220307,EXP,,CO-NOVOPROD-877999,NOVO NORDISK,,73.0,YR,,M,Y,100.0,KG,20220307,,CN,CO,CO,2022,Q1,Elderly
205572681,20557268,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q1,Constipation,,2022,Q1,1,I,20211202.0,20220225.0,20220307,20220307,EXP,,CO-NOVOPROD-877999,NOVO NORDISK,,73.0,YR,,M,Y,100.0,KG,20220307,,CN,CO,CO,2022,Q1,Elderly
205622142,20562214,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,25.0,MG,Powder for infusion,QD,2022,Q1,Malaise,,2022,Q1,2,F,,20220325.0,20220307,20220329,EXP,GB-MHRA-TPP22985747C7305299YC1646319093393,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157839",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,114.0,KG,20220329,,HP,GB,GB,2022,Q1,Elderly
205622142,20562214,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,25.0,MG,Powder for infusion,QD,2022,Q1,Ketonuria,,2022,Q1,2,F,,20220325.0,20220307,20220329,EXP,GB-MHRA-TPP22985747C7305299YC1646319093393,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157839",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,114.0,KG,20220329,,HP,GB,GB,2022,Q1,Elderly
205622142,20562214,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,25.0,MG,Powder for infusion,QD,2022,Q1,Nausea,,2022,Q1,2,F,,20220325.0,20220307,20220329,EXP,GB-MHRA-TPP22985747C7305299YC1646319093393,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157839",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,114.0,KG,20220329,,HP,GB,GB,2022,Q1,Elderly
205622142,20562214,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,,,204629.0,,,,,2022,Q1,Malaise,,2022,Q1,2,F,,20220325.0,20220307,20220329,EXP,GB-MHRA-TPP22985747C7305299YC1646319093393,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157839",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,114.0,KG,20220329,,HP,GB,GB,2022,Q1,Elderly
205622142,20562214,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,,,204629.0,,,,,2022,Q1,Ketonuria,,2022,Q1,2,F,,20220325.0,20220307,20220329,EXP,GB-MHRA-TPP22985747C7305299YC1646319093393,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157839",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,114.0,KG,20220329,,HP,GB,GB,2022,Q1,Elderly
205622142,20562214,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,,,204629.0,,,,,2022,Q1,Nausea,,2022,Q1,2,F,,20220325.0,20220307,20220329,EXP,GB-MHRA-TPP22985747C7305299YC1646319093393,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157839",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,114.0,KG,20220329,,HP,GB,GB,2022,Q1,Elderly
205626831,20562683,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,Unknown,,208658.0,,,,,2022,Q1,Confusional state,,2022,Q1,1,I,,20220307.0,20220307,20220307,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157735",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220307,,MD,AU,AU,2022,Q1,Elderly
205626831,20562683,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,Unknown,,208658.0,,,,,2022,Q1,Pneumonia,,2022,Q1,1,I,,20220307.0,20220307,20220307,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157735",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220307,,MD,AU,AU,2022,Q1,Elderly
205626831,20562683,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,Unknown,,208658.0,,,,,2022,Q1,Blood ketone body increased,,2022,Q1,1,I,,20220307.0,20220307,20220307,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157735",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220307,,MD,AU,AU,2022,Q1,Elderly
205626831,20562683,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,Unknown,,208658.0,,,,,2022,Q1,Blood pH decreased,,2022,Q1,1,I,,20220307.0,20220307,20220307,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157735",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220307,,MD,AU,AU,2022,Q1,Elderly
205639801,20563980,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,,20220301.0,20220308,20220308,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-156855",BOEHRINGER INGELHEIM,"Mora B, Benjanuwattra J, Abdelnabi M, Elgwairi E, Eshak N, Elmassry M. et al. Euglycemic diabetic ketoacidosis after the first dose of Empagliflozin in acutely-ill patient. Journal of investigative medicine. 2022; 70: 516-",32.0,YR,A,F,Y,,,20220308,,HP,US,US,2022,Q1,Young Adult
205653762,20565376,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q1,Hypoxia,,2022,Q1,2,F,20220201.0,20220317.0,20220308,20220318,EXP,,NZ-MYLANLABS-2022M1017552,MYLAN,,51.0,YR,,M,Y,116.0,KG,20220318,,PH,NZ,NZ,2022,Q1,Adult
205653762,20565376,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q1,Chronic obstructive pulmonary disease,,2022,Q1,2,F,20220201.0,20220317.0,20220308,20220318,EXP,,NZ-MYLANLABS-2022M1017552,MYLAN,,51.0,YR,,M,Y,116.0,KG,20220318,,PH,NZ,NZ,2022,Q1,Adult
205672381,20567238,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK Unknown, Unknown",,,D,,,,,,,,,2022,Q1,Completed suicide,,2022,Q1,1,I,20200101.0,20220222.0,20220308,20220308,EXP,,US-ENDO PHARMACEUTICALS INC-2022-001505,ENDO,,15.0,YR,,M,Y,,,20220308,,PH,US,US,2022,Q1,Youth
205707861,20570786,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q1,Skin burning sensation,,2022,Q1,1,I,20220215.0,20220305.0,20220309,20220309,EXP,GB-MHRA-TPP28724860C5838851YC1646139403706,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157837",BOEHRINGER INGELHEIM,,46.0,YR,A,M,Y,90.0,KG,20220309,,MD,GB,GB,2022,Q1,Adult
205707861,20570786,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q1,Abdominal pain,,2022,Q1,1,I,20220215.0,20220305.0,20220309,20220309,EXP,GB-MHRA-TPP28724860C5838851YC1646139403706,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157837",BOEHRINGER INGELHEIM,,46.0,YR,A,M,Y,90.0,KG,20220309,,MD,GB,GB,2022,Q1,Adult
205749811,20574981,5,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,,,,,,,,2022,Q1,Completed suicide,,2022,Q1,1,I,,20220304.0,20220310,20220310,EXP,,US-ALVOGEN-2022-ALVOGEN-118486,ALVOGEN,"Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Bronstein AC, Rivers LJ, Pham NPT, Weber J. 2020 Annual Report of the American Association of Poison Control Centers^ National Poison Data System (NPDS): 38th Annual Report. Clin Toxicol (Phila). 2021 Dec;59(12):1282-1501. doi: 10.1080/15563650.2021.1989785.",15.0,YR,,M,Y,,,20220310,,MD,US,US,2022,Q1,Youth
205750061,20575006,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,,,Unknown,,212614.0,,,,,2022,Q1,Self-medication,,2022,Q1,1,I,20220301.0,20220308.0,20220310,20220310,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-158497",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,,,20220310,,CN,US,US,2022,Q1,Adult
205776651,20577665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2022,Q1,Somnolence,,2022,Q1,1,I,20220302.0,,20220310,20220310,DIR,FDA-CDER-CTU-2022-19407,,FDA-CTU,,72.0,YR,,M,N,105.23,KG,20220304,N,PH,US,,2022,Q1,Elderly
205776651,20577665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2022,Q1,Sedation,,2022,Q1,1,I,20220302.0,,20220310,20220310,DIR,FDA-CDER-CTU-2022-19407,,FDA-CTU,,72.0,YR,,M,N,105.23,KG,20220304,N,PH,US,,2022,Q1,Elderly
205783651,20578365,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,,QD,2022,Q1,Cardiogenic shock,,2022,Q1,1,I,20220224.0,20220301.0,20220310,20220310,EXP,,NVSC2022MY055140,NOVARTIS,,56.0,YR,,M,Y,,,20220310,,MD,MY,MY,2022,Q1,Adult
205783651,20578365,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,D,,,,,25.0,MG,,QD,2022,Q1,Acute myocardial infarction,,2022,Q1,1,I,20220224.0,20220301.0,20220310,20220310,EXP,,NVSC2022MY055140,NOVARTIS,,56.0,YR,,M,Y,,,20220310,,MD,MY,MY,2022,Q1,Adult
205790891,20579089,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q1,Fungal cystitis,,2022,Q1,1,I,20201001.0,,20220310,20220310,DIR,FDA-CDER-CTU-2022-19590,,FDA-CTU,,65.0,YR,,M,N,80.0,KG,20201218,N,PH,US,,2022,Q1,Elderly
205790891,20579089,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q1,Renal impairment,,2022,Q1,1,I,20201001.0,,20220310,20220310,DIR,FDA-CDER-CTU-2022-19590,,FDA-CTU,,65.0,YR,,M,N,80.0,KG,20201218,N,PH,US,,2022,Q1,Elderly
205790891,20579089,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q1,Urinary retention,,2022,Q1,1,I,20201001.0,,20220310,20220310,DIR,FDA-CDER-CTU-2022-19590,,FDA-CTU,,65.0,YR,,M,N,80.0,KG,20201218,N,PH,US,,2022,Q1,Elderly
205791191,20579119,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q1,Urinary tract infection,,2022,Q1,1,I,20200811.0,,20220310,20220310,DIR,FDA-CDER-CTU-2022-19605,,FDA-CTU,,75.0,YR,,M,N,,,20201018,N,PH,US,,2022,Q1,Elderly
205799331,20579933,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg every morning,,,Y,N,,,,,,,,2022,Q1,Drug level decreased,,2022,Q1,1,I,,20220310.0,20220310,20220310,EXP,,AU-ANIPHARMA-2022-AU-000055,ANI,Armstrong GP.Empagliflozin-mediated lithium excretion: A case study and clinical applications..American Journal of Case Reports.2020;21.,29.0,YR,,M,Y,,,20220310,,HP,AU,AU,2022,Q1,Young Adult
205799331,20579933,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg every morning,,,Y,N,,,,,,,,2022,Q1,Drug interaction,,2022,Q1,1,I,,20220310.0,20220310,20220310,EXP,,AU-ANIPHARMA-2022-AU-000055,ANI,Armstrong GP.Empagliflozin-mediated lithium excretion: A case study and clinical applications..American Journal of Case Reports.2020;21.,29.0,YR,,M,Y,,,20220310,,HP,AU,AU,2022,Q1,Young Adult
205814291,20581429,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q1,Hepatotoxicity,,2022,Q1,1,I,,20220307.0,20220311,20220311,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20220311,,HP,CA,CA,2022,Q1,Adult
205814291,20581429,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q1,Drug ineffective,,2022,Q1,1,I,,20220307.0,20220311,20220311,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20220311,,HP,CA,CA,2022,Q1,Adult
205814291,20581429,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q1,Weight decreased,,2022,Q1,1,I,,20220307.0,20220311,20220311,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20220311,,HP,CA,CA,2022,Q1,Adult
205814291,20581429,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q1,Psoriasis,,2022,Q1,1,I,,20220307.0,20220311,20220311,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20220311,,HP,CA,CA,2022,Q1,Adult
205814291,20581429,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q1,C-reactive protein increased,,2022,Q1,1,I,,20220307.0,20220311,20220311,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20220311,,HP,CA,CA,2022,Q1,Adult
205818241,20581824,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,unknown,,204629.0,,,Tablet,QD,2022,Q1,Dry mouth,,2022,Q1,1,I,20220304.0,20220306.0,20220311,20220311,EXP,GB-MHRA-TPP717068C8209282YC1646395981802,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157820",BOEHRINGER INGELHEIM,,75.0,YR,E,M,Y,80.0,KG,20220311,,MD,GB,GB,2022,Q1,Elderly
205818241,20581824,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,unknown,,204629.0,,,Tablet,,2022,Q1,Dry mouth,,2022,Q1,1,I,20220304.0,20220306.0,20220311,20220311,EXP,GB-MHRA-TPP717068C8209282YC1646395981802,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157820",BOEHRINGER INGELHEIM,,75.0,YR,E,M,Y,80.0,KG,20220311,,MD,GB,GB,2022,Q1,Elderly
205818452,20581845,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q1,Dizziness,,2022,Q1,2,F,20211228.0,20220317.0,20220311,20220328,EXP,,"CO-REGENERON PHARMACEUTICALS, INC.-2022-015775",REGENERON,,66.0,YR,,M,Y,,,20220328,,CN,CO,CO,2022,Q1,Elderly
205818452,20581845,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q1,Chills,,2022,Q1,2,F,20211228.0,20220317.0,20220311,20220328,EXP,,"CO-REGENERON PHARMACEUTICALS, INC.-2022-015775",REGENERON,,66.0,YR,,M,Y,,,20220328,,CN,CO,CO,2022,Q1,Elderly
205818452,20581845,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q1,Syncope,,2022,Q1,2,F,20211228.0,20220317.0,20220311,20220328,EXP,,"CO-REGENERON PHARMACEUTICALS, INC.-2022-015775",REGENERON,,66.0,YR,,M,Y,,,20220328,,CN,CO,CO,2022,Q1,Elderly
205818452,20581845,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q1,Urinary tract infection,,2022,Q1,2,F,20211228.0,20220317.0,20220311,20220328,EXP,,"CO-REGENERON PHARMACEUTICALS, INC.-2022-015775",REGENERON,,66.0,YR,,M,Y,,,20220328,,CN,CO,CO,2022,Q1,Elderly
205818452,20581845,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q1,Myocardial infarction,,2022,Q1,2,F,20211228.0,20220317.0,20220311,20220328,EXP,,"CO-REGENERON PHARMACEUTICALS, INC.-2022-015775",REGENERON,,66.0,YR,,M,Y,,,20220328,,CN,CO,CO,2022,Q1,Elderly
205818452,20581845,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q1,Pyrexia,,2022,Q1,2,F,20211228.0,20220317.0,20220311,20220328,EXP,,"CO-REGENERON PHARMACEUTICALS, INC.-2022-015775",REGENERON,,66.0,YR,,M,Y,,,20220328,,CN,CO,CO,2022,Q1,Elderly
205818452,20581845,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q1,Peripheral coldness,,2022,Q1,2,F,20211228.0,20220317.0,20220311,20220328,EXP,,"CO-REGENERON PHARMACEUTICALS, INC.-2022-015775",REGENERON,,66.0,YR,,M,Y,,,20220328,,CN,CO,CO,2022,Q1,Elderly
205818452,20581845,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q1,Blood pressure decreased,,2022,Q1,2,F,20211228.0,20220317.0,20220311,20220328,EXP,,"CO-REGENERON PHARMACEUTICALS, INC.-2022-015775",REGENERON,,66.0,YR,,M,Y,,,20220328,,CN,CO,CO,2022,Q1,Elderly
205825551,20582555,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Glycosylated haemoglobin increased,,2022,Q1,1,I,20210101.0,20220308.0,20220311,20220311,EXP,,SK-SA-2022SA066564,SANOFI AVENTIS,,63.0,YR,A,F,Y,89.0,KG,20220311,,MD,SK,SK,2022,Q1,Adult
205825551,20582555,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Hypoglycaemia,,2022,Q1,1,I,20210101.0,20220308.0,20220311,20220311,EXP,,SK-SA-2022SA066564,SANOFI AVENTIS,,63.0,YR,A,F,Y,89.0,KG,20220311,,MD,SK,SK,2022,Q1,Adult
205825551,20582555,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Hospitalisation,,2022,Q1,1,I,20210101.0,20220308.0,20220311,20220311,EXP,,SK-SA-2022SA066564,SANOFI AVENTIS,,63.0,YR,A,F,Y,89.0,KG,20220311,,MD,SK,SK,2022,Q1,Adult
205825551,20582555,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q1,Weight increased,,2022,Q1,1,I,20210101.0,20220308.0,20220311,20220311,EXP,,SK-SA-2022SA066564,SANOFI AVENTIS,,63.0,YR,A,F,Y,89.0,KG,20220311,,MD,SK,SK,2022,Q1,Adult
205842821,20584282,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/1000 mg. Medication started 3-4 months ago.,,,U,,Unknown,,208658.0,,,,Q8H,2022,Q1,Overdose,,2022,Q1,1,I,,20220310.0,20220311,20220311,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-158632",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20220311,,MD,IL,IL,2022,Q1,Elderly
205842821,20584282,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/1000 mg. Medication started 3-4 months ago.,,,U,,Unknown,,208658.0,,,,Q8H,2022,Q1,Transitional cell carcinoma,,2022,Q1,1,I,,20220310.0,20220311,20220311,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-158632",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20220311,,MD,IL,IL,2022,Q1,Elderly
205842821,20584282,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/1000 mg. Medication started 3-4 months ago.,,,U,,Unknown,,208658.0,,,,Q8H,2022,Q1,Haemorrhage urinary tract,,2022,Q1,1,I,,20220310.0,20220311,20220311,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-158632",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20220311,,MD,IL,IL,2022,Q1,Elderly
205842821,20584282,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/1000 mg. Medication started 3-4 months ago.,,,U,,Unknown,,208658.0,,,,Q8H,2022,Q1,Urine odour abnormal,,2022,Q1,1,I,,20220310.0,20220311,20220311,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-158632",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20220311,,MD,IL,IL,2022,Q1,Elderly
205842821,20584282,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/1000 mg. Medication started 3-4 months ago.,,,U,,Unknown,,208658.0,,,,Q8H,2022,Q1,Burning sensation,,2022,Q1,1,I,,20220310.0,20220311,20220311,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-158632",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20220311,,MD,IL,IL,2022,Q1,Elderly
205845322,20584532,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q1,Thrombocytopenia,,2022,Q1,2,F,,20220309.0,20220311,20220316,EXP,,PT-009507513-2203PRT002934,MERCK,,57.0,YR,,F,Y,,,20220316,,MD,PT,PT,2022,Q1,Adult
205876061,20587606,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Weight decreased,,2022,Q1,1,I,,20220309.0,20220314,20220314,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20220314,,HP,CA,CA,2022,Q1,Adult
205876061,20587606,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,C-reactive protein increased,,2022,Q1,1,I,,20220309.0,20220314,20220314,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20220314,,HP,CA,CA,2022,Q1,Adult
205876061,20587606,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Hepatotoxicity,,2022,Q1,1,I,,20220309.0,20220314,20220314,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20220314,,HP,CA,CA,2022,Q1,Adult
205876061,20587606,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Psoriasis,,2022,Q1,1,I,,20220309.0,20220314,20220314,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20220314,,HP,CA,CA,2022,Q1,Adult
205876061,20587606,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q1,Drug ineffective,,2022,Q1,1,I,,20220309.0,20220314,20220314,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20220314,,HP,CA,CA,2022,Q1,Adult
205891661,20589166,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,Y,U,,,,10.0,MG,,,2022,Q1,Left atrial enlargement,,2022,Q1,1,I,20210901.0,20220307.0,20220314,20220314,EXP,,PL-MYLANLABS-2022M1018339,MYLAN,,39.0,YR,,M,Y,,,20220314,,MD,PL,PL,2022,Q1,Adult
205891661,20589166,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,Y,U,,,,10.0,MG,,,2022,Q1,Cardiac ventricular thrombosis,,2022,Q1,1,I,20210901.0,20220307.0,20220314,20220314,EXP,,PL-MYLANLABS-2022M1018339,MYLAN,,39.0,YR,,M,Y,,,20220314,,MD,PL,PL,2022,Q1,Adult
205891661,20589166,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,Y,U,,,,10.0,MG,,,2022,Q1,Dyspnoea exertional,,2022,Q1,1,I,20210901.0,20220307.0,20220314,20220314,EXP,,PL-MYLANLABS-2022M1018339,MYLAN,,39.0,YR,,M,Y,,,20220314,,MD,PL,PL,2022,Q1,Adult
205891661,20589166,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,Y,U,,,,10.0,MG,,,2022,Q1,Heart rate increased,,2022,Q1,1,I,20210901.0,20220307.0,20220314,20220314,EXP,,PL-MYLANLABS-2022M1018339,MYLAN,,39.0,YR,,M,Y,,,20220314,,MD,PL,PL,2022,Q1,Adult
205891661,20589166,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,Y,U,,,,10.0,MG,,,2022,Q1,Dizziness postural,,2022,Q1,1,I,20210901.0,20220307.0,20220314,20220314,EXP,,PL-MYLANLABS-2022M1018339,MYLAN,,39.0,YR,,M,Y,,,20220314,,MD,PL,PL,2022,Q1,Adult
205891661,20589166,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,Y,U,,,,10.0,MG,,,2022,Q1,Non-compaction cardiomyopathy,,2022,Q1,1,I,20210901.0,20220307.0,20220314,20220314,EXP,,PL-MYLANLABS-2022M1018339,MYLAN,,39.0,YR,,M,Y,,,20220314,,MD,PL,PL,2022,Q1,Adult
205891661,20589166,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,Y,U,,,,10.0,MG,,,2022,Q1,Left ventricular enlargement,,2022,Q1,1,I,20210901.0,20220307.0,20220314,20220314,EXP,,PL-MYLANLABS-2022M1018339,MYLAN,,39.0,YR,,M,Y,,,20220314,,MD,PL,PL,2022,Q1,Adult
205891661,20589166,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,Y,U,,,,10.0,MG,,,2022,Q1,Hypotension,,2022,Q1,1,I,20210901.0,20220307.0,20220314,20220314,EXP,,PL-MYLANLABS-2022M1018339,MYLAN,,39.0,YR,,M,Y,,,20220314,,MD,PL,PL,2022,Q1,Adult
205891712,20589171,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q1,Pancreatitis acute,,2022,Q1,2,F,20220223.0,20220311.0,20220314,20220317,EXP,NL-LRB-00796310,"NL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-158525",BOEHRINGER INGELHEIM,,72.0,YR,E,M,Y,90.0,KG,20220318,,MD,NL,NL,2022,Q1,Elderly
205899261,20589926,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,,2022,Q1,Glomerular filtration rate abnormal,,2022,Q1,1,I,,20220302.0,20220314,20220314,EXP,PL-EMA-DD-20220203-pawar_p-144421,PL-Accord-256837,ACCORD,,71.0,YR,,M,Y,,,20220314,,MD,PL,PL,2022,Q1,Elderly
205899261,20589926,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,,2022,Q1,Acute kidney injury,,2022,Q1,1,I,,20220302.0,20220314,20220314,EXP,PL-EMA-DD-20220203-pawar_p-144421,PL-Accord-256837,ACCORD,,71.0,YR,,M,Y,,,20220314,,MD,PL,PL,2022,Q1,Elderly
205899261,20589926,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,,2022,Q1,Congestive cardiomyopathy,,2022,Q1,1,I,,20220302.0,20220314,20220314,EXP,PL-EMA-DD-20220203-pawar_p-144421,PL-Accord-256837,ACCORD,,71.0,YR,,M,Y,,,20220314,,MD,PL,PL,2022,Q1,Elderly
205899261,20589926,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,,2022,Q1,Wrong technique in product usage process,,2022,Q1,1,I,,20220302.0,20220314,20220314,EXP,PL-EMA-DD-20220203-pawar_p-144421,PL-Accord-256837,ACCORD,,71.0,YR,,M,Y,,,20220314,,MD,PL,PL,2022,Q1,Elderly
205899261,20589926,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,,2022,Q1,N-terminal prohormone brain natriuretic peptide increased,,2022,Q1,1,I,,20220302.0,20220314,20220314,EXP,PL-EMA-DD-20220203-pawar_p-144421,PL-Accord-256837,ACCORD,,71.0,YR,,M,Y,,,20220314,,MD,PL,PL,2022,Q1,Elderly
205899261,20589926,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,,2022,Q1,Lung disorder,,2022,Q1,1,I,,20220302.0,20220314,20220314,EXP,PL-EMA-DD-20220203-pawar_p-144421,PL-Accord-256837,ACCORD,,71.0,YR,,M,Y,,,20220314,,MD,PL,PL,2022,Q1,Elderly
205899261,20589926,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,,2022,Q1,Cardiac failure,,2022,Q1,1,I,,20220302.0,20220314,20220314,EXP,PL-EMA-DD-20220203-pawar_p-144421,PL-Accord-256837,ACCORD,,71.0,YR,,M,Y,,,20220314,,MD,PL,PL,2022,Q1,Elderly
205912991,20591299,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Product prescribing error,,2022,Q1,1,I,20220214.0,20220314.0,20220314,20220314,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-159075",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,75.0,KG,20220314,,MD,DE,DE,2022,Q1,Elderly
205912991,20591299,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,20220214.0,20220314.0,20220314,20220314,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-159075",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,75.0,KG,20220314,,MD,DE,DE,2022,Q1,Elderly
205912991,20591299,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Failure to suspend medication,,2022,Q1,1,I,20220214.0,20220314.0,20220314,20220314,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-159075",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,75.0,KG,20220314,,MD,DE,DE,2022,Q1,Elderly
205945771,20594577,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Fall,,2022,Q1,1,I,,20220309.0,20220315,20220315,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-158377",BOEHRINGER INGELHEIM,"Sharkey S, Jay D, Henry T. Acute inferior myocardial infarction or not?. JAMA internal medicine. 2022; 182;2: 224-225.",6.0,DEC,A,,Y,,,20220315,,MD,US,US,2022,Q1,Child
205945771,20594577,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Confusional state,,2022,Q1,1,I,,20220309.0,20220315,20220315,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-158377",BOEHRINGER INGELHEIM,"Sharkey S, Jay D, Henry T. Acute inferior myocardial infarction or not?. JAMA internal medicine. 2022; 182;2: 224-225.",6.0,DEC,A,,Y,,,20220315,,MD,US,US,2022,Q1,Child
205945771,20594577,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,,20220309.0,20220315,20220315,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-158377",BOEHRINGER INGELHEIM,"Sharkey S, Jay D, Henry T. Acute inferior myocardial infarction or not?. JAMA internal medicine. 2022; 182;2: 224-225.",6.0,DEC,A,,Y,,,20220315,,MD,US,US,2022,Q1,Child
205962001,20596200,3,C,EMPAGLIFLOZIN-LINAGLIPTIN,,2,Oral,25-5mg Take by mouth twice daily,,,,,,,,,,Tablet,Q12H,2022,Q1,Weight decreased,,2022,Q1,1,I,,20220310.0,20220315,20220315,EXP,,US-BAUSCH-BL-2021-028450,BAUSCH AND LOMB,,76.0,YR,,M,Y,,,20220315,,MD,US,US,2022,Q1,Elderly
205962001,20596200,3,C,EMPAGLIFLOZIN-LINAGLIPTIN,,2,Oral,25-5mg Take by mouth twice daily,,,,,,,,,,Tablet,Q12H,2022,Q1,Inability to afford medication,,2022,Q1,1,I,,20220310.0,20220315,20220315,EXP,,US-BAUSCH-BL-2021-028450,BAUSCH AND LOMB,,76.0,YR,,M,Y,,,20220315,,MD,US,US,2022,Q1,Elderly
205973742,20597374,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,U,Unknown,,204629.0,25.0,MG,Powder for infusion,QD,2022,Q1,Diabetic ketoacidosis,,2022,Q1,2,F,20220305.0,20220316.0,20220315,20220318,EXP,GB-MHRA-MED-202203101412383150-URW17,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-159078",BOEHRINGER INGELHEIM,,44.0,YR,A,M,Y,,,20220318,,PH,GB,GB,2022,Q1,Adult
205998301,20599830,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Thrombocytopenia,,2022,Q1,1,I,,20220307.0,20220316,20220316,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-330072,RANBAXY,"Temmoku J, Asano T, Saito K, Matsumoto H, Fujita Y, Furuya-Yashiro M, et al. Effect of a multitarget therapy with prednisolone, mycophenolate mofetil, and tacrolimus in a patient with type B insulin resistance syndrome complicated by lupus nephritis. Mod Rheumatol Case Rep. 2022;6(1):41-46",59.0,YR,,M,Y,68.1,KG,20220316,,HP,JP,JP,2022,Q1,Adult
205998301,20599830,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Hyperglycaemia,,2022,Q1,1,I,,20220307.0,20220316,20220316,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-330072,RANBAXY,"Temmoku J, Asano T, Saito K, Matsumoto H, Fujita Y, Furuya-Yashiro M, et al. Effect of a multitarget therapy with prednisolone, mycophenolate mofetil, and tacrolimus in a patient with type B insulin resistance syndrome complicated by lupus nephritis. Mod Rheumatol Case Rep. 2022;6(1):41-46",59.0,YR,,M,Y,68.1,KG,20220316,,HP,JP,JP,2022,Q1,Adult
205998301,20599830,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Therapeutic product effect incomplete,,2022,Q1,1,I,,20220307.0,20220316,20220316,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-330072,RANBAXY,"Temmoku J, Asano T, Saito K, Matsumoto H, Fujita Y, Furuya-Yashiro M, et al. Effect of a multitarget therapy with prednisolone, mycophenolate mofetil, and tacrolimus in a patient with type B insulin resistance syndrome complicated by lupus nephritis. Mod Rheumatol Case Rep. 2022;6(1):41-46",59.0,YR,,M,Y,68.1,KG,20220316,,HP,JP,JP,2022,Q1,Adult
205998301,20599830,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Proteinuria,,2022,Q1,1,I,,20220307.0,20220316,20220316,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-330072,RANBAXY,"Temmoku J, Asano T, Saito K, Matsumoto H, Fujita Y, Furuya-Yashiro M, et al. Effect of a multitarget therapy with prednisolone, mycophenolate mofetil, and tacrolimus in a patient with type B insulin resistance syndrome complicated by lupus nephritis. Mod Rheumatol Case Rep. 2022;6(1):41-46",59.0,YR,,M,Y,68.1,KG,20220316,,HP,JP,JP,2022,Q1,Adult
206036241,20603624,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, OTHER (OM)",,,U,,,,,10.0,MG,,,2022,Q1,Transferrin saturation decreased,,2022,Q1,1,I,20210101.0,20220308.0,20220316,20220316,EXP,,NVSC2022SG056013,NOVARTIS,,63.0,YR,,M,Y,,,20220316,,MD,SG,SG,2022,Q1,Adult
206036241,20603624,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, OTHER (OM)",,,U,,,,,10.0,MG,,,2022,Q1,Mitral valve incompetence,,2022,Q1,1,I,20210101.0,20220308.0,20220316,20220316,EXP,,NVSC2022SG056013,NOVARTIS,,63.0,YR,,M,Y,,,20220316,,MD,SG,SG,2022,Q1,Adult
206036241,20603624,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, OTHER (OM)",,,U,,,,,10.0,MG,,,2022,Q1,Blood creatine increased,,2022,Q1,1,I,20210101.0,20220308.0,20220316,20220316,EXP,,NVSC2022SG056013,NOVARTIS,,63.0,YR,,M,Y,,,20220316,,MD,SG,SG,2022,Q1,Adult
206036241,20603624,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, OTHER (OM)",,,U,,,,,10.0,MG,,,2022,Q1,Cardiac failure,,2022,Q1,1,I,20210101.0,20220308.0,20220316,20220316,EXP,,NVSC2022SG056013,NOVARTIS,,63.0,YR,,M,Y,,,20220316,,MD,SG,SG,2022,Q1,Adult
206036241,20603624,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, OTHER (OM)",,,U,,,,,10.0,MG,,,2022,Q1,Incorrect dose administered,,2022,Q1,1,I,20210101.0,20220308.0,20220316,20220316,EXP,,NVSC2022SG056013,NOVARTIS,,63.0,YR,,M,Y,,,20220316,,MD,SG,SG,2022,Q1,Adult
206036241,20603624,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, OTHER (OM)",,,U,,,,,10.0,MG,,,2022,Q1,Chest discomfort,,2022,Q1,1,I,20210101.0,20220308.0,20220316,20220316,EXP,,NVSC2022SG056013,NOVARTIS,,63.0,YR,,M,Y,,,20220316,,MD,SG,SG,2022,Q1,Adult
206036241,20603624,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, OTHER (OM)",,,U,,,,,10.0,MG,,,2022,Q1,Wrong technique in product usage process,,2022,Q1,1,I,20210101.0,20220308.0,20220316,20220316,EXP,,NVSC2022SG056013,NOVARTIS,,63.0,YR,,M,Y,,,20220316,,MD,SG,SG,2022,Q1,Adult
206036241,20603624,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, OTHER (OM)",,,U,,,,,10.0,MG,,,2022,Q1,Blood pressure decreased,,2022,Q1,1,I,20210101.0,20220308.0,20220316,20220316,EXP,,NVSC2022SG056013,NOVARTIS,,63.0,YR,,M,Y,,,20220316,,MD,SG,SG,2022,Q1,Adult
206036241,20603624,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, OTHER (OM)",,,U,,,,,10.0,MG,,,2022,Q1,Dyspnoea,,2022,Q1,1,I,20210101.0,20220308.0,20220316,20220316,EXP,,NVSC2022SG056013,NOVARTIS,,63.0,YR,,M,Y,,,20220316,,MD,SG,SG,2022,Q1,Adult
206036241,20603624,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, OTHER (OM)",,,U,,,,,10.0,MG,,,2022,Q1,Left ventricular dilatation,,2022,Q1,1,I,20210101.0,20220308.0,20220316,20220316,EXP,,NVSC2022SG056013,NOVARTIS,,63.0,YR,,M,Y,,,20220316,,MD,SG,SG,2022,Q1,Adult
206036241,20603624,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, OTHER (OM)",,,U,,,,,10.0,MG,,,2022,Q1,Iron deficiency anaemia,,2022,Q1,1,I,20210101.0,20220308.0,20220316,20220316,EXP,,NVSC2022SG056013,NOVARTIS,,63.0,YR,,M,Y,,,20220316,,MD,SG,SG,2022,Q1,Adult
206036661,20603666,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,,,,QD,2022,Q1,Acidosis,,2022,Q1,1,I,20211221.0,,20220316,20220316,DIR,FDA-CDER-CTU-2022-20840,,FDA-CTU,,49.0,YR,,M,N,,,20220218,N,PH,US,,2022,Q1,Adult
206037731,20603773,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,Y,Y,,,,12.5,MG,,QD,2022,Q1,Transient ischaemic attack,,2022,Q1,1,I,20211108.0,,20220316,20220316,DIR,FDA-CDER-CTU-2022-20858,,FDA-CTU,,52.0,YR,,M,N,106.0,KG,20220119,N,HP,US,,2022,Q1,Adult
206037731,20603773,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,Y,Y,,,,12.5,MG,,QD,2022,Q1,Feeling abnormal,,2022,Q1,1,I,20211108.0,,20220316,20220316,DIR,FDA-CDER-CTU-2022-20858,,FDA-CTU,,52.0,YR,,M,N,106.0,KG,20220119,N,HP,US,,2022,Q1,Adult
206037731,20603773,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,Y,Y,,,,12.5,MG,,QD,2022,Q1,Dysarthria,,2022,Q1,1,I,20211108.0,,20220316,20220316,DIR,FDA-CDER-CTU-2022-20858,,FDA-CTU,,52.0,YR,,M,N,106.0,KG,20220119,N,HP,US,,2022,Q1,Adult
206037731,20603773,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,Y,Y,,,,12.5,MG,,QD,2022,Q1,Paraesthesia,,2022,Q1,1,I,20211108.0,,20220316,20220316,DIR,FDA-CDER-CTU-2022-20858,,FDA-CTU,,52.0,YR,,M,N,106.0,KG,20220119,N,HP,US,,2022,Q1,Adult
206037771,20603777,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q1,Pneumonia,,2022,Q1,1,I,20211130.0,,20220316,20220316,DIR,FDA-CDER-CTU-2022-20862,,FDA-CTU,,50.0,YR,,F,N,68.0,KG,20220119,N,HP,US,,2022,Q1,Adult
206037771,20603777,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q1,Lethargy,,2022,Q1,1,I,20211130.0,,20220316,20220316,DIR,FDA-CDER-CTU-2022-20862,,FDA-CTU,,50.0,YR,,F,N,68.0,KG,20220119,N,HP,US,,2022,Q1,Adult
206037771,20603777,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q1,Oxygen saturation decreased,,2022,Q1,1,I,20211130.0,,20220316,20220316,DIR,FDA-CDER-CTU-2022-20862,,FDA-CTU,,50.0,YR,,F,N,68.0,KG,20220119,N,HP,US,,2022,Q1,Adult
206037771,20603777,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q1,Treatment noncompliance,,2022,Q1,1,I,20211130.0,,20220316,20220316,DIR,FDA-CDER-CTU-2022-20862,,FDA-CTU,,50.0,YR,,F,N,68.0,KG,20220119,N,HP,US,,2022,Q1,Adult
206055481,20605548,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Mean cell haemoglobin decreased,,2022,Q1,1,I,,20220304.0,20220317,20220317,EXP,2022-HC-04831253,CA-ALVOGEN-2022-ALVOGEN-118530,ALVOGEN,,52.0,YR,,M,Y,,,20220317,,HP,CA,CA,2022,Q1,Adult
206055481,20605548,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Headache,,2022,Q1,1,I,,20220304.0,20220317,20220317,EXP,2022-HC-04831253,CA-ALVOGEN-2022-ALVOGEN-118530,ALVOGEN,,52.0,YR,,M,Y,,,20220317,,HP,CA,CA,2022,Q1,Adult
206055481,20605548,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Disease recurrence,,2022,Q1,1,I,,20220304.0,20220317,20220317,EXP,2022-HC-04831253,CA-ALVOGEN-2022-ALVOGEN-118530,ALVOGEN,,52.0,YR,,M,Y,,,20220317,,HP,CA,CA,2022,Q1,Adult
206055481,20605548,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Product use in unapproved indication,,2022,Q1,1,I,,20220304.0,20220317,20220317,EXP,2022-HC-04831253,CA-ALVOGEN-2022-ALVOGEN-118530,ALVOGEN,,52.0,YR,,M,Y,,,20220317,,HP,CA,CA,2022,Q1,Adult
206055481,20605548,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Platelet count decreased,,2022,Q1,1,I,,20220304.0,20220317,20220317,EXP,2022-HC-04831253,CA-ALVOGEN-2022-ALVOGEN-118530,ALVOGEN,,52.0,YR,,M,Y,,,20220317,,HP,CA,CA,2022,Q1,Adult
206055481,20605548,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Ecchymosis,,2022,Q1,1,I,,20220304.0,20220317,20220317,EXP,2022-HC-04831253,CA-ALVOGEN-2022-ALVOGEN-118530,ALVOGEN,,52.0,YR,,M,Y,,,20220317,,HP,CA,CA,2022,Q1,Adult
206055481,20605548,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Monocyte count increased,,2022,Q1,1,I,,20220304.0,20220317,20220317,EXP,2022-HC-04831253,CA-ALVOGEN-2022-ALVOGEN-118530,ALVOGEN,,52.0,YR,,M,Y,,,20220317,,HP,CA,CA,2022,Q1,Adult
206055481,20605548,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Immune thrombocytopenia,,2022,Q1,1,I,,20220304.0,20220317,20220317,EXP,2022-HC-04831253,CA-ALVOGEN-2022-ALVOGEN-118530,ALVOGEN,,52.0,YR,,M,Y,,,20220317,,HP,CA,CA,2022,Q1,Adult
206055481,20605548,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Mean platelet volume increased,,2022,Q1,1,I,,20220304.0,20220317,20220317,EXP,2022-HC-04831253,CA-ALVOGEN-2022-ALVOGEN-118530,ALVOGEN,,52.0,YR,,M,Y,,,20220317,,HP,CA,CA,2022,Q1,Adult
206058022,20605802,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Cardiac failure acute,,2022,Q1,2,F,20210101.0,20220318.0,20220317,20220329,EXP,,NVSC2022GB060731,NOVARTIS,,63.0,YR,,M,Y,,,20220329,,MD,GB,GB,2022,Q1,Adult
206058022,20605802,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Blood lactic acid decreased,,2022,Q1,2,F,20210101.0,20220318.0,20220317,20220329,EXP,,NVSC2022GB060731,NOVARTIS,,63.0,YR,,M,Y,,,20220329,,MD,GB,GB,2022,Q1,Adult
206058022,20605802,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Blood bicarbonate decreased,,2022,Q1,2,F,20210101.0,20220318.0,20220317,20220329,EXP,,NVSC2022GB060731,NOVARTIS,,63.0,YR,,M,Y,,,20220329,,MD,GB,GB,2022,Q1,Adult
206058022,20605802,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Inappropriate schedule of product administration,,2022,Q1,2,F,20210101.0,20220318.0,20220317,20220329,EXP,,NVSC2022GB060731,NOVARTIS,,63.0,YR,,M,Y,,,20220329,,MD,GB,GB,2022,Q1,Adult
206058022,20605802,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Troponin T increased,,2022,Q1,2,F,20210101.0,20220318.0,20220317,20220329,EXP,,NVSC2022GB060731,NOVARTIS,,63.0,YR,,M,Y,,,20220329,,MD,GB,GB,2022,Q1,Adult
206058022,20605802,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Wrong technique in product usage process,,2022,Q1,2,F,20210101.0,20220318.0,20220317,20220329,EXP,,NVSC2022GB060731,NOVARTIS,,63.0,YR,,M,Y,,,20220329,,MD,GB,GB,2022,Q1,Adult
206058022,20605802,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Blood creatine increased,,2022,Q1,2,F,20210101.0,20220318.0,20220317,20220329,EXP,,NVSC2022GB060731,NOVARTIS,,63.0,YR,,M,Y,,,20220329,,MD,GB,GB,2022,Q1,Adult
206058022,20605802,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Condition aggravated,,2022,Q1,2,F,20210101.0,20220318.0,20220317,20220329,EXP,,NVSC2022GB060731,NOVARTIS,,63.0,YR,,M,Y,,,20220329,,MD,GB,GB,2022,Q1,Adult
206058022,20605802,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Chest discomfort,,2022,Q1,2,F,20210101.0,20220318.0,20220317,20220329,EXP,,NVSC2022GB060731,NOVARTIS,,63.0,YR,,M,Y,,,20220329,,MD,GB,GB,2022,Q1,Adult
206058022,20605802,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Cardiac failure chronic,,2022,Q1,2,F,20210101.0,20220318.0,20220317,20220329,EXP,,NVSC2022GB060731,NOVARTIS,,63.0,YR,,M,Y,,,20220329,,MD,GB,GB,2022,Q1,Adult
206058022,20605802,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Serum ferritin decreased,,2022,Q1,2,F,20210101.0,20220318.0,20220317,20220329,EXP,,NVSC2022GB060731,NOVARTIS,,63.0,YR,,M,Y,,,20220329,,MD,GB,GB,2022,Q1,Adult
206058022,20605802,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,N-terminal prohormone brain natriuretic peptide increased,,2022,Q1,2,F,20210101.0,20220318.0,20220317,20220329,EXP,,NVSC2022GB060731,NOVARTIS,,63.0,YR,,M,Y,,,20220329,,MD,GB,GB,2022,Q1,Adult
206058022,20605802,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Transferrin saturation decreased,,2022,Q1,2,F,20210101.0,20220318.0,20220317,20220329,EXP,,NVSC2022GB060731,NOVARTIS,,63.0,YR,,M,Y,,,20220329,,MD,GB,GB,2022,Q1,Adult
206058022,20605802,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Dyspnoea,,2022,Q1,2,F,20210101.0,20220318.0,20220317,20220329,EXP,,NVSC2022GB060731,NOVARTIS,,63.0,YR,,M,Y,,,20220329,,MD,GB,GB,2022,Q1,Adult
206058022,20605802,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Blood pressure decreased,,2022,Q1,2,F,20210101.0,20220318.0,20220317,20220329,EXP,,NVSC2022GB060731,NOVARTIS,,63.0,YR,,M,Y,,,20220329,,MD,GB,GB,2022,Q1,Adult
206063191,20606319,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,Powder for infusion,QD,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,20220208.0,20220315.0,20220317,20220317,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-159643",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,,,20220317,,PH,GB,GB,2022,Q1,Adult
206113421,20611342,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",80.0,MG,,,154211203,,,10.0,MG,,QD,2022,Q1,Upper gastrointestinal haemorrhage,,2022,Q1,1,I,20220208.0,20220316.0,20220318,20220318,EXP,,CN-BAYER-2022A039279,BAYER,,72.0,YR,E,F,Y,78.0,KG,20220318,,HP,CN,CN,2022,Q1,Elderly
206113421,20611342,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",80.0,MG,,,154211203,,,10.0,MG,,QD,2022,Q1,Decreased appetite,,2022,Q1,1,I,20220208.0,20220316.0,20220318,20220318,EXP,,CN-BAYER-2022A039279,BAYER,,72.0,YR,E,F,Y,78.0,KG,20220318,,HP,CN,CN,2022,Q1,Elderly
206113421,20611342,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",80.0,MG,,,154211203,,,10.0,MG,,QD,2022,Q1,Fatigue,,2022,Q1,1,I,20220208.0,20220316.0,20220318,20220318,EXP,,CN-BAYER-2022A039279,BAYER,,72.0,YR,E,F,Y,78.0,KG,20220318,,HP,CN,CN,2022,Q1,Elderly
206113421,20611342,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",80.0,MG,,,154211203,,,10.0,MG,,QD,2022,Q1,Asthenia,,2022,Q1,1,I,20220208.0,20220316.0,20220318,20220318,EXP,,CN-BAYER-2022A039279,BAYER,,72.0,YR,E,F,Y,78.0,KG,20220318,,HP,CN,CN,2022,Q1,Elderly
206113421,20611342,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",80.0,MG,,,154211203,,,10.0,MG,,QD,2022,Q1,Melaena,,2022,Q1,1,I,20220208.0,20220316.0,20220318,20220318,EXP,,CN-BAYER-2022A039279,BAYER,,72.0,YR,E,F,Y,78.0,KG,20220318,,HP,CN,CN,2022,Q1,Elderly
206119471,20611947,64,C,LINAGLIPTIN/EMPAGLIFLOZIN,,2,Unknown,"25/5mg every, every morning, UNK",,,,,UNKNOWN,,,,,,,2022,Q1,Myelitis,,2022,Q1,1,I,20220213.0,20220308.0,20220318,20220318,EXP,,US-Fresenius Kabi-FK202203113,FRESENIUS KABI,,53.0,YR,,M,Y,75.7,KG,20220318,,MD,US,US,2022,Q1,Adult
206151341,20615134,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q1,Psoriasis,,2022,Q1,1,I,,20220308.0,20220321,20220321,EXP,,CA-AUROBINDO-AUR-APL-2022-008393,AUROBINDO,,40.0,YR,,F,Y,,,20220321,,HP,CA,CA,2022,Q1,Adult
206151341,20615134,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q1,C-reactive protein increased,,2022,Q1,1,I,,20220308.0,20220321,20220321,EXP,,CA-AUROBINDO-AUR-APL-2022-008393,AUROBINDO,,40.0,YR,,F,Y,,,20220321,,HP,CA,CA,2022,Q1,Adult
206151341,20615134,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q1,Drug ineffective,,2022,Q1,1,I,,20220308.0,20220321,20220321,EXP,,CA-AUROBINDO-AUR-APL-2022-008393,AUROBINDO,,40.0,YR,,F,Y,,,20220321,,HP,CA,CA,2022,Q1,Adult
206151341,20615134,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q1,Hepatotoxicity,,2022,Q1,1,I,,20220308.0,20220321,20220321,EXP,,CA-AUROBINDO-AUR-APL-2022-008393,AUROBINDO,,40.0,YR,,F,Y,,,20220321,,HP,CA,CA,2022,Q1,Adult
206151341,20615134,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q1,Weight decreased,,2022,Q1,1,I,,20220308.0,20220321,20220321,EXP,,CA-AUROBINDO-AUR-APL-2022-008393,AUROBINDO,,40.0,YR,,F,Y,,,20220321,,HP,CA,CA,2022,Q1,Adult
206155611,20615561,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,,20220314.0,20220321,20220321,EXP,,CA-SA-2022SA091411,SANOFI AVENTIS,,60.0,YR,A,M,Y,,,20220321,,CN,CA,CA,2022,Q1,Adult
206157332,20615733,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,Unknown,,2022,Q1,Hypotension,,2022,Q1,2,F,20220217.0,20220318.0,20220321,20220325,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20220325,,MD,GB,GB,2022,Q1,Adult
206157332,20615733,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,Unknown,,2022,Q1,Pyrexia,,2022,Q1,2,F,20220217.0,20220318.0,20220321,20220325,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20220325,,MD,GB,GB,2022,Q1,Adult
206157332,20615733,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,Unknown,,2022,Q1,Diarrhoea,,2022,Q1,2,F,20220217.0,20220318.0,20220321,20220325,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20220325,,MD,GB,GB,2022,Q1,Adult
206157332,20615733,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,Unknown,,2022,Q1,Vomiting,,2022,Q1,2,F,20220217.0,20220318.0,20220321,20220325,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20220325,,MD,GB,GB,2022,Q1,Adult
206157332,20615733,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,Unknown,,2022,Q1,Sepsis,,2022,Q1,2,F,20220217.0,20220318.0,20220321,20220325,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20220325,,MD,GB,GB,2022,Q1,Adult
206157332,20615733,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,Unknown,,2022,Q1,Infusion related reaction,,2022,Q1,2,F,20220217.0,20220318.0,20220321,20220325,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20220325,,MD,GB,GB,2022,Q1,Adult
206161701,20616170,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,206111.0,,,,,2022,Q1,Skin necrosis,,2022,Q1,1,I,,20220318.0,20220321,20220321,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-160075",BOEHRINGER INGELHEIM,,7.0,DEC,E,F,Y,,,20220321,,MD,AU,AU,2022,Q1,Child
206161802,20616180,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"UNK, bid",,,,,,,,,,,BID,2022,Q1,Abdominal pain,,2022,Q1,2,F,,20220322.0,20220321,20220329,EXP,,IL-ELI_LILLY_AND_COMPANY-IL202203002984,ELI LILLY AND CO,,64.0,YR,,M,Y,,,20220329,,CN,IL,IL,2022,Q1,Adult
206161802,20616180,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"UNK, bid",,,,,,,,,,,BID,2022,Q1,Myocardial infarction,,2022,Q1,2,F,,20220322.0,20220321,20220329,EXP,,IL-ELI_LILLY_AND_COMPANY-IL202203002984,ELI LILLY AND CO,,64.0,YR,,M,Y,,,20220329,,CN,IL,IL,2022,Q1,Adult
206161802,20616180,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"UNK, bid",,,,,,,,,,,BID,2022,Q1,Weight decreased,,2022,Q1,2,F,,20220322.0,20220321,20220329,EXP,,IL-ELI_LILLY_AND_COMPANY-IL202203002984,ELI LILLY AND CO,,64.0,YR,,M,Y,,,20220329,,CN,IL,IL,2022,Q1,Adult
206186261,20618626,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,Powder for infusion,QD,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20220316.0,20220318.0,20220322,20220322,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-160469",BOEHRINGER INGELHEIM,,44.0,YR,A,M,Y,,,20220322,,MD,GB,GB,2022,Q1,Adult
206186441,20618644,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q1,Fournier's gangrene,,2022,Q1,1,I,20220316.0,20220318.0,20220322,20220322,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-160461",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,166.0,KG,20220322,,PH,GB,GB,2022,Q1,Adult
206195801,20619580,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20220313.0,20220318.0,20220322,20220322,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-160474",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,,,20220322,,MD,GB,GB,2022,Q1,Elderly
206233341,20623334,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20220226.0,20220322.0,20220322,20220322,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-160657",BOEHRINGER INGELHEIM,,54.0,YR,A,F,Y,,,20220322,,HP,SG,SG,2022,Q1,Adult
206287781,20628778,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,,20220316.0,20220323,20220323,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-159924",BOEHRINGER INGELHEIM,"Rodrigues S, Esteves V. EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Revista Portuguesa de Diabetes. 2022 Mar; 17(1): 74-74.",82.0,YR,E,F,Y,,,20220323,,HP,PT,PT,2022,Q1,Elderly
206312181,20631218,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2022,Q1,Dyspnoea,,2022,Q1,1,I,,20220323.0,20220324,20220324,EXP,,"PH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161168",BOEHRINGER INGELHEIM,,56.0,YR,A,M,Y,,,20220324,,MD,PH,PH,2022,Q1,Adult
206312181,20631218,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,,20220323.0,20220324,20220324,EXP,,"PH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161168",BOEHRINGER INGELHEIM,,56.0,YR,A,M,Y,,,20220324,,MD,PH,PH,2022,Q1,Adult
206349341,20634934,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q1,Anxiety,,2022,Q1,1,I,20220321.0,20220323.0,20220325,20220325,EXP,GB-MHRA-TPP1306017C579002YC1647873729608,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161251",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,76.0,KG,20220325,,MD,GB,GB,2022,Q1,Adult
206349341,20634934,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q1,Lower urinary tract symptoms,,2022,Q1,1,I,20220321.0,20220323.0,20220325,20220325,EXP,GB-MHRA-TPP1306017C579002YC1647873729608,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161251",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,76.0,KG,20220325,,MD,GB,GB,2022,Q1,Adult
206349341,20634934,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q1,Alopecia,,2022,Q1,1,I,20220321.0,20220323.0,20220325,20220325,EXP,GB-MHRA-TPP1306017C579002YC1647873729608,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161251",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,76.0,KG,20220325,,MD,GB,GB,2022,Q1,Adult
206349341,20634934,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,,,,,,,QD,2022,Q1,Anxiety,,2022,Q1,1,I,20220321.0,20220323.0,20220325,20220325,EXP,GB-MHRA-TPP1306017C579002YC1647873729608,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161251",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,76.0,KG,20220325,,MD,GB,GB,2022,Q1,Adult
206349341,20634934,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,,,,,,,QD,2022,Q1,Lower urinary tract symptoms,,2022,Q1,1,I,20220321.0,20220323.0,20220325,20220325,EXP,GB-MHRA-TPP1306017C579002YC1647873729608,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161251",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,76.0,KG,20220325,,MD,GB,GB,2022,Q1,Adult
206349341,20634934,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,,,,,,,QD,2022,Q1,Alopecia,,2022,Q1,1,I,20220321.0,20220323.0,20220325,20220325,EXP,GB-MHRA-TPP1306017C579002YC1647873729608,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161251",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,76.0,KG,20220325,,MD,GB,GB,2022,Q1,Adult
206360631,20636063,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Abdominal pain,,2022,Q1,1,I,20210531.0,20220311.0,20220325,20220325,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-330755,RANBAXY,,38.0,YR,,M,Y,123.8,KG,20220325,,HP,GB,GB,2022,Q1,Adult
206360631,20636063,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,20210531.0,20220311.0,20220325,20220325,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-330755,RANBAXY,,38.0,YR,,M,Y,123.8,KG,20220325,,HP,GB,GB,2022,Q1,Adult
206366901,20636690,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q1,Infusion related reaction,,2022,Q1,1,I,20220217.0,20220316.0,20220325,20220325,EXP,,GB-TEVA-2022-GB-2017685,TEVA,,62.0,YR,A,M,Y,115.9,KG,20220325,,MD,GB,GB,2022,Q1,Adult
206411191,20641119,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,Tablet,,2022,Q1,Renal failure,,2022,Q1,1,I,,20220322.0,20220327,20220327,EXP,,NVSJ2022JP004270,NOVARTIS,,71.0,YR,,F,Y,,,20220328,,PH,JP,JP,2022,Q1,Elderly
206411191,20641119,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,Tablet,,2022,Q1,Blood pressure decreased,,2022,Q1,1,I,,20220322.0,20220327,20220327,EXP,,NVSJ2022JP004270,NOVARTIS,,71.0,YR,,F,Y,,,20220328,,PH,JP,JP,2022,Q1,Elderly
206427381,20642738,2,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,N,,Unknown,,206073.0,,,Tablet,,2022,Q1,Gangrene,,2022,Q1,1,I,20210801.0,20220325.0,20220328,20220328,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161827",BOEHRINGER INGELHEIM,,77.0,YR,E,M,Y,,,20220328,,MD,JP,JP,2022,Q1,Elderly
206430521,20643052,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2022,Q1,Glomerular filtration rate decreased,,2022,Q1,1,I,,20220323.0,20220328,20220328,EXP,,"HU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161526",BOEHRINGER INGELHEIM,,48.0,YR,A,M,Y,119.0,KG,20220328,,MD,HU,HU,2022,Q1,Adult
206430521,20643052,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2022,Q1,Ketonuria,,2022,Q1,1,I,,20220323.0,20220328,20220328,EXP,,"HU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161526",BOEHRINGER INGELHEIM,,48.0,YR,A,M,Y,119.0,KG,20220328,,MD,HU,HU,2022,Q1,Adult
206430521,20643052,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,In combined form with metformin,,,,,Unknown,,204629.0,12.5,MG,,Q12H,2022,Q1,Glomerular filtration rate decreased,,2022,Q1,1,I,,20220323.0,20220328,20220328,EXP,,"HU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161526",BOEHRINGER INGELHEIM,,48.0,YR,A,M,Y,119.0,KG,20220328,,MD,HU,HU,2022,Q1,Adult
206430521,20643052,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,In combined form with metformin,,,,,Unknown,,204629.0,12.5,MG,,Q12H,2022,Q1,Ketonuria,,2022,Q1,1,I,,20220323.0,20220328,20220328,EXP,,"HU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161526",BOEHRINGER INGELHEIM,,48.0,YR,A,M,Y,119.0,KG,20220328,,MD,HU,HU,2022,Q1,Adult
206456141,20645614,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,,,,,2022,Q1,Pneumonia aspiration,,2022,Q1,1,I,,20220318.0,20220328,20220328,EXP,,JP-BAUSCH-BL-2022-007492,BAUSCH AND LOMB,,9.0,DEC,,F,Y,,,20220328,,MD,JP,JP,2022,Q1,Child
206460111,20646011,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,Powder for infusion,QD,2022,Q1,Abdominal pain,,2022,Q1,1,I,,20220327.0,20220329,20220329,EXP,GB-MHRA-TPP8416955C9436403YC1648141849384,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161809",BOEHRINGER INGELHEIM,,76.0,YR,E,F,Y,106.0,KG,20220329,,MD,GB,GB,2022,Q1,Elderly
206460111,20646011,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,Powder for infusion,QD,2022,Q1,Ketonuria,,2022,Q1,1,I,,20220327.0,20220329,20220329,EXP,GB-MHRA-TPP8416955C9436403YC1648141849384,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161809",BOEHRINGER INGELHEIM,,76.0,YR,E,F,Y,106.0,KG,20220329,,MD,GB,GB,2022,Q1,Elderly
206461411,20646141,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,380.0,MG,Y,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q1,Headache,,2022,Q1,1,I,20220324.0,20220327.0,20220329,20220329,EXP,GB-MHRA-TPP8293644C5336534YC1648117609099,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161815",BOEHRINGER INGELHEIM,,51.0,YR,A,F,Y,94.0,KG,20220329,,PH,GB,GB,2022,Q1,Adult
206464811,20646481,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, od",,,U,,,,,25.0,MG,,QD,2022,Q1,Therapy cessation,,2022,Q1,1,I,,20220316.0,20220329,20220329,EXP,,AE-GLENMARK PHARMACEUTICALS-2022GMK071432,GLENMARK,"Alhemeiri M, Alseddeeqi E.. Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor.. Case Reports in Endocrinology.. 2022;2022:1-4",45.0,YR,,M,Y,115.0,KG,20220329,,HP,AE,AE,2022,Q1,Adult
206469481,20646948,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q1,Hyperglycaemia,,2022,Q1,1,I,,20220324.0,20220329,20220329,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161622",BOEHRINGER INGELHEIM,"Leung M, Roitman D. PIK3CA Inhibitor, Alpelisib, and Diabetic Ketoacidosis: A Lesson on Choosing Wisely. Canadian Journal of Diabetes. 2021; 45: 29-",58.0,YR,A,F,Y,,,20220329,,HP,CA,CA,2022,Q1,Adult
206469481,20646948,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,,20220324.0,20220329,20220329,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161622",BOEHRINGER INGELHEIM,"Leung M, Roitman D. PIK3CA Inhibitor, Alpelisib, and Diabetic Ketoacidosis: A Lesson on Choosing Wisely. Canadian Journal of Diabetes. 2021; 45: 29-",58.0,YR,A,F,Y,,,20220329,,HP,CA,CA,2022,Q1,Adult
206469481,20646948,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,,20220324.0,20220329,20220329,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161622",BOEHRINGER INGELHEIM,"Leung M, Roitman D. PIK3CA Inhibitor, Alpelisib, and Diabetic Ketoacidosis: A Lesson on Choosing Wisely. Canadian Journal of Diabetes. 2021; 45: 29-",58.0,YR,A,F,Y,,,20220329,,HP,CA,CA,2022,Q1,Adult
206541981,20654198,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(AMBER 3- as per Nottinghamshires APC Diabetes ...,,,,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q1,"Hallucination, visual",,2022,Q1,1,I,20220323.0,20220325.0,20220330,20220330,EXP,GB-MHRA-TPP6972520C8344973YC1648052956324,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161846",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,103.0,KG,20220330,,MD,GB,GB,2022,Q1,Elderly
206573211,20657321,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Fall,,2022,Q1,1,I,20211019.0,20220329.0,20220331,20220331,EXP,,GB-ABBVIE-22K-167-4338739-00,ABBVIE,,62.0,YR,,M,Y,108.0,KG,20220331,,HP,COUNTRY NOT SPECIFIED,GB,2022,Q1,Adult
206573211,20657321,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Lumbar vertebral fracture,,2022,Q1,1,I,20211019.0,20220329.0,20220331,20220331,EXP,,GB-ABBVIE-22K-167-4338739-00,ABBVIE,,62.0,YR,,M,Y,108.0,KG,20220331,,HP,COUNTRY NOT SPECIFIED,GB,2022,Q1,Adult
206573211,20657321,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Arthralgia,,2022,Q1,1,I,20211019.0,20220329.0,20220331,20220331,EXP,,GB-ABBVIE-22K-167-4338739-00,ABBVIE,,62.0,YR,,M,Y,108.0,KG,20220331,,HP,COUNTRY NOT SPECIFIED,GB,2022,Q1,Adult
206573211,20657321,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q1,Plasmacytoma,,2022,Q1,1,I,20211019.0,20220329.0,20220331,20220331,EXP,,GB-ABBVIE-22K-167-4338739-00,ABBVIE,,62.0,YR,,M,Y,108.0,KG,20220331,,HP,COUNTRY NOT SPECIFIED,GB,2022,Q1,Adult
206573321,20657332,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,Powder for infusion,QD,2022,Q1,Diabetic ketoacidosis,,2022,Q1,1,I,20220323.0,20220330.0,20220331,20220331,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-162404",BOEHRINGER INGELHEIM,,79.0,YR,E,M,Y,,,20220331,,HP,GB,GB,2022,Q1,Elderly
206599381,20659938,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg,,,,,Unknown,,,,,,,2022,Q1,Fall,,2022,Q1,1,I,20200101.0,20201026.0,20220331,20220331,EXP,,BR-NOVOPROD-813931,NOVO NORDISK,,69.0,YR,,M,Y,62.0,KG,20220331,,MD,BR,BR,2022,Q1,Elderly
206599381,20659938,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg,,,,,Unknown,,,,,,,2022,Q1,Adenocarcinoma of colon,,2022,Q1,1,I,20200101.0,20201026.0,20220331,20220331,EXP,,BR-NOVOPROD-813931,NOVO NORDISK,,69.0,YR,,M,Y,62.0,KG,20220331,,MD,BR,BR,2022,Q1,Elderly
206599381,20659938,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg,,,,,Unknown,,,,,,,2022,Q1,Head injury,,2022,Q1,1,I,20200101.0,20201026.0,20220331,20220331,EXP,,BR-NOVOPROD-813931,NOVO NORDISK,,69.0,YR,,M,Y,62.0,KG,20220331,,MD,BR,BR,2022,Q1,Elderly
206609131,20660913,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Dosage of 12.5/850mg,,,U,,Unknown,,208658.0,,,,QD,2022,Q1,Off label use,,2022,Q1,1,I,20200517.0,20220331.0,20220331,20220331,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-162643",BOEHRINGER INGELHEIM,,44.0,YR,A,M,Y,,,20220331,,CN,IL,IL,2022,Q1,Adult
206609131,20660913,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Dosage of 12.5/850mg,,,U,,Unknown,,208658.0,,,,QD,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,20200517.0,20220331.0,20220331,20220331,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-162643",BOEHRINGER INGELHEIM,,44.0,YR,A,M,Y,,,20220331,,CN,IL,IL,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Fatigue,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Brain neoplasm,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Nausea,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,COVID-19,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Needle issue,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Cerebrospinal fluid leakage,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Hormone level abnormal,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Cough,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Injection site pain,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Abdominal pain upper,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Diabetes mellitus,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Heart rate decreased,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Food allergy,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Memory impairment,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Urinary tract infection,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Abdominal pain,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Blood pressure systolic increased,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
911685111,9116851,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 OT,,,U,,,,,,,,,2022,Q1,Blood prolactin abnormal,,2022,Q1,11,F,20130201.0,20220113.0,20130225,20220120,EXP,,PHHY2013CA010870,NOVARTIS,,53.0,YR,,M,Y,,,20220120,,HP,CA,CA,2022,Q1,Adult
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Malaise,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Nasopharyngitis,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Weight decreased,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Anxiety,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Cataract,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Blood urine present,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Pancreatic carcinoma,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Neck pain,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Vision blurred,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Basal cell carcinoma,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Gastrooesophageal reflux disease,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Vomiting,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Blood pressure systolic increased,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Influenza,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Cough,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Nausea,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Blood pressure increased,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Dyspepsia,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Skin mass,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Blood pressure diastolic decreased,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Nasal congestion,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Arthralgia,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Second primary malignancy,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
946404955,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,Unknown,,,,,,QD,2022,Q1,Pyrexia,,2022,Q1,55,F,20141127.0,20220208.0,20130819,20220212,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20220212,,CN,CA,CA,2022,Q1,Elderly
163058783,16305878,117,C,METFORMIN/LINAGLIPTIN/EMPAGLIFLOZIN,,2,,,,,,,,,,,,,,2022,Q2,Chronic kidney disease,,2022,Q2,3,F,20140101.0,20220509.0,20190513,20220517,EXP,,US-AstraZeneca-2019SE64135,ASTRAZENECA,,66.0,YR,,F,Y,91.2,KG,20220517,,LW,US,,2022,Q2,Elderly
163058783,16305878,117,C,METFORMIN/LINAGLIPTIN/EMPAGLIFLOZIN,,2,,,,,,,,,,,,,,2022,Q2,Acute kidney injury,,2022,Q2,3,F,20140101.0,20220509.0,20190513,20220517,EXP,,US-AstraZeneca-2019SE64135,ASTRAZENECA,,66.0,YR,,F,Y,91.2,KG,20220517,,LW,US,,2022,Q2,Elderly
163058783,16305878,117,C,METFORMIN/LINAGLIPTIN/EMPAGLIFLOZIN,,2,,,,,,,,,,,,,,2022,Q2,Nephrogenic anaemia,,2022,Q2,3,F,20140101.0,20220509.0,20190513,20220517,EXP,,US-AstraZeneca-2019SE64135,ASTRAZENECA,,66.0,YR,,F,Y,91.2,KG,20220517,,LW,US,,2022,Q2,Elderly
163058783,16305878,117,C,METFORMIN/LINAGLIPTIN/EMPAGLIFLOZIN,,2,,,,,,,,,,,,,,2022,Q2,Renal failure,,2022,Q2,3,F,20140101.0,20220509.0,20190513,20220517,EXP,,US-AstraZeneca-2019SE64135,ASTRAZENECA,,66.0,YR,,F,Y,91.2,KG,20220517,,LW,US,,2022,Q2,Elderly
163058783,16305878,117,C,METFORMIN/LINAGLIPTIN/EMPAGLIFLOZIN,,2,,,,,,,,,,,,,,2022,Q2,Renal tubular necrosis,,2022,Q2,3,F,20140101.0,20220509.0,20190513,20220517,EXP,,US-AstraZeneca-2019SE64135,ASTRAZENECA,,66.0,YR,,F,Y,91.2,KG,20220517,,LW,US,,2022,Q2,Elderly
180000765,18000076,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, unknown",,,U,,,,,,,,,2022,Q2,Dizziness postural,,2022,Q2,5,F,20200601.0,20220405.0,20200709,20220411,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202007002636,ELI LILLY AND CO,,73.0,YR,,F,Y,,,20220411,,CN,JP,JP,2022,Q2,Elderly
180000765,18000076,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, unknown",,,U,,,,,,,,,2022,Q2,Pulmonary arterial hypertension,,2022,Q2,5,F,20200601.0,20220405.0,20200709,20220411,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202007002636,ELI LILLY AND CO,,73.0,YR,,F,Y,,,20220411,,CN,JP,JP,2022,Q2,Elderly
1845526410,18455264,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,10,F,20200423.0,20220502.0,20201102,20220505,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20220505,,CN,CO,CO,2022,Q2,Elderly
1845526410,18455264,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q2,Hypothyroidism,,2022,Q2,10,F,20200423.0,20220502.0,20201102,20220505,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20220505,,CN,CO,CO,2022,Q2,Elderly
1845526410,18455264,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q2,Weight decreased,,2022,Q2,10,F,20200423.0,20220502.0,20201102,20220505,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20220505,,CN,CO,CO,2022,Q2,Elderly
1845526410,18455264,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q2,Expired product administered,,2022,Q2,10,F,20200423.0,20220502.0,20201102,20220505,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20220505,,CN,CO,CO,2022,Q2,Elderly
1845526410,18455264,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q2,Body height increased,,2022,Q2,10,F,20200423.0,20220502.0,20201102,20220505,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20220505,,CN,CO,CO,2022,Q2,Elderly
1845526410,18455264,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q2,Chronic obstructive pulmonary disease,,2022,Q2,10,F,20200423.0,20220502.0,20201102,20220505,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20220505,,CN,CO,CO,2022,Q2,Elderly
1845526410,18455264,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q2,Hyperthyroidism,,2022,Q2,10,F,20200423.0,20220502.0,20201102,20220505,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20220505,,CN,CO,CO,2022,Q2,Elderly
1845526410,18455264,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q2,Weight increased,,2022,Q2,10,F,20200423.0,20220502.0,20201102,20220505,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20220505,,CN,CO,CO,2022,Q2,Elderly
184821758,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2022,Q2,Angina pectoris,,2022,Q2,8,F,20201019.0,20220420.0,20201110,20220426,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20220426,,MD,COUNTRY NOT SPECIFIED,JP,2022,Q2,Adult
184821758,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2022,Q2,Cataract,,2022,Q2,8,F,20201019.0,20220420.0,20201110,20220426,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20220426,,MD,COUNTRY NOT SPECIFIED,JP,2022,Q2,Adult
184821758,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2022,Q2,Rash pruritic,,2022,Q2,8,F,20201019.0,20220420.0,20201110,20220426,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20220426,,MD,COUNTRY NOT SPECIFIED,JP,2022,Q2,Adult
184821758,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2022,Q2,Eczema asteatotic,,2022,Q2,8,F,20201019.0,20220420.0,20201110,20220426,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20220426,,MD,COUNTRY NOT SPECIFIED,JP,2022,Q2,Adult
184821758,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2022,Q2,Arthralgia,,2022,Q2,8,F,20201019.0,20220420.0,20201110,20220426,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20220426,,MD,COUNTRY NOT SPECIFIED,JP,2022,Q2,Adult
185782252,18578225,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,SARS-CoV-2 test positive,,2022,Q2,2,F,20200503.0,20220518.0,20201204,20220613,PER,,GB-AMGEN-GBRSP2020194253,AMGEN,,50.0,YR,A,F,Y,113.0,KG,20220612,,HP,GB,GB,2022,Q2,Adult
185840213,18584021,8,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,,,,,,,Unknown,,2022,Q2,Pulmonary embolism,,2022,Q2,3,F,20201101.0,20220513.0,20201207,20220520,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-102045,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,,,20220520,,PH,CH,CH,2022,Q2,Elderly
185840213,18584021,8,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,,,,,,,Unknown,,2022,Q2,Cardiac failure,,2022,Q2,3,F,20201101.0,20220513.0,20201207,20220520,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-102045,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,,,20220520,,PH,CH,CH,2022,Q2,Elderly
185840213,18584021,8,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,,,,,,,Unknown,,2022,Q2,Cardio-respiratory arrest,,2022,Q2,3,F,20201101.0,20220513.0,20201207,20220520,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-102045,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,,,20220520,,PH,CH,CH,2022,Q2,Elderly
185840213,18584021,8,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,,,,,,,Unknown,,2022,Q2,COVID-19,,2022,Q2,3,F,20201101.0,20220513.0,20201207,20220520,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-102045,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,,,20220520,,PH,CH,CH,2022,Q2,Elderly
185930274,18593027,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,,,,,,,,,,2022,Q2,Cardiac failure,,2022,Q2,4,F,20201101.0,20220513.0,20201208,20220526,EXP,,CH-PFIZER INC-2020484303,PFIZER,,85.0,YR,,M,Y,,,20220526,,PH,CH,CH,2022,Q2,Elderly
185930274,18593027,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,,,,,,,,,,2022,Q2,Cardio-respiratory arrest,,2022,Q2,4,F,20201101.0,20220513.0,20201208,20220526,EXP,,CH-PFIZER INC-2020484303,PFIZER,,85.0,YR,,M,Y,,,20220526,,PH,CH,CH,2022,Q2,Elderly
185930274,18593027,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,,,,,,,,,,2022,Q2,COVID-19,,2022,Q2,4,F,20201101.0,20220513.0,20201208,20220526,EXP,,CH-PFIZER INC-2020484303,PFIZER,,85.0,YR,,M,Y,,,20220526,,PH,CH,CH,2022,Q2,Elderly
185930274,18593027,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,,,,,,,,,,2022,Q2,Pulmonary embolism,,2022,Q2,4,F,20201101.0,20220513.0,20201208,20220526,EXP,,CH-PFIZER INC-2020484303,PFIZER,,85.0,YR,,M,Y,,,20220526,,PH,CH,CH,2022,Q2,Elderly
187500812,18750081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q2,Respiratory failure,,2022,Q2,2,F,20210111.0,20220113.0,20210118,20220530,EXP,GB-MHRA-WEBCOVID-20210113134901,GB-ROCHE-2750159,ROCHE,,70.0,YR,,M,Y,72.0,KG,20220530,,PH,GB,GB,2022,Q2,Elderly
187500812,18750081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q2,Epigastric discomfort,,2022,Q2,2,F,20210111.0,20220113.0,20210118,20220530,EXP,GB-MHRA-WEBCOVID-20210113134901,GB-ROCHE-2750159,ROCHE,,70.0,YR,,M,Y,72.0,KG,20220530,,PH,GB,GB,2022,Q2,Elderly
187500812,18750081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q2,COVID-19 pneumonia,,2022,Q2,2,F,20210111.0,20220113.0,20210118,20220530,EXP,GB-MHRA-WEBCOVID-20210113134901,GB-ROCHE-2750159,ROCHE,,70.0,YR,,M,Y,72.0,KG,20220530,,PH,GB,GB,2022,Q2,Elderly
187500812,18750081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q2,Chest discomfort,,2022,Q2,2,F,20210111.0,20220113.0,20210118,20220530,EXP,GB-MHRA-WEBCOVID-20210113134901,GB-ROCHE-2750159,ROCHE,,70.0,YR,,M,Y,72.0,KG,20220530,,PH,GB,GB,2022,Q2,Elderly
187500812,18750081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q2,Sudden cardiac death,,2022,Q2,2,F,20210111.0,20220113.0,20210118,20220530,EXP,GB-MHRA-WEBCOVID-20210113134901,GB-ROCHE-2750159,ROCHE,,70.0,YR,,M,Y,72.0,KG,20220530,,PH,GB,GB,2022,Q2,Elderly
187500812,18750081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q2,Pain,,2022,Q2,2,F,20210111.0,20220113.0,20210118,20220530,EXP,GB-MHRA-WEBCOVID-20210113134901,GB-ROCHE-2750159,ROCHE,,70.0,YR,,M,Y,72.0,KG,20220530,,PH,GB,GB,2022,Q2,Elderly
190509652,19050965,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,COVID-19,,2022,Q2,2,F,20200320.0,20220518.0,20210324,20220527,EXP,,GB-SAMSUNG BIOEPIS-SB-2021-07155,SAMSUNG BIOEPIS,,57.0,YR,A,M,Y,129.5,KG,20220527,,HP,GB,GB,2022,Q2,Adult
190999878,19099987,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Injection site pruritus,,2022,Q2,8,F,20201201.0,20220608.0,20210407,20220616,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20220616,,CN,US,US,2022,Q2,Youth
190999878,19099987,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Off label use,,2022,Q2,8,F,20201201.0,20220608.0,20210407,20220616,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20220616,,CN,US,US,2022,Q2,Youth
190999878,19099987,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Injection site reaction,,2022,Q2,8,F,20201201.0,20220608.0,20210407,20220616,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20220616,,CN,US,US,2022,Q2,Youth
190999878,19099987,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Back pain,,2022,Q2,8,F,20201201.0,20220608.0,20210407,20220616,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20220616,,CN,US,US,2022,Q2,Youth
190999878,19099987,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Drug ineffective,,2022,Q2,8,F,20201201.0,20220608.0,20210407,20220616,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20220616,,CN,US,US,2022,Q2,Youth
190999878,19099987,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Blood glucose increased,,2022,Q2,8,F,20201201.0,20220608.0,20210407,20220616,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20220616,,CN,US,US,2022,Q2,Youth
190999878,19099987,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Hypertriglyceridaemia,,2022,Q2,8,F,20201201.0,20220608.0,20210407,20220616,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20220616,,CN,US,US,2022,Q2,Youth
190999878,19099987,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Chlamydial infection,,2022,Q2,8,F,20201201.0,20220608.0,20210407,20220616,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20220616,,CN,US,US,2022,Q2,Youth
190999878,19099987,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Hyperkeratosis,,2022,Q2,8,F,20201201.0,20220608.0,20210407,20220616,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20220616,,CN,US,US,2022,Q2,Youth
190999878,19099987,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Psychogenic seizure,,2022,Q2,8,F,20201201.0,20220608.0,20210407,20220616,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20220616,,CN,US,US,2022,Q2,Youth
190999878,19099987,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Injection site irritation,,2022,Q2,8,F,20201201.0,20220608.0,20210407,20220616,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20220616,,CN,US,US,2022,Q2,Youth
190999878,19099987,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Diabetic retinopathy,,2022,Q2,8,F,20201201.0,20220608.0,20210407,20220616,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20220616,,CN,US,US,2022,Q2,Youth
190999878,19099987,30,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Seizure,,2022,Q2,8,F,20201201.0,20220608.0,20210407,20220616,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20220616,,CN,US,US,2022,Q2,Youth
191940362,19194036,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,2,F,20220519.0,20220529.0,20210429,20220602,EXP,GB-MHRA-EYC 00249043,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-100454",BOEHRINGER INGELHEIM,,37.0,YR,A,F,Y,83.0,KG,20220602,,MD,GB,GB,2022,Q2,Adult
191940362,19194036,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,,,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,2,F,20220519.0,20220529.0,20210429,20220602,EXP,GB-MHRA-EYC 00249043,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-100454",BOEHRINGER INGELHEIM,,37.0,YR,A,F,Y,83.0,KG,20220602,,MD,GB,GB,2022,Q2,Adult
192651873,19265187,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2022,Q2,Blood pressure decreased,,2022,Q2,3,F,20210315.0,20220421.0,20210517,20220504,PER,,JP-AMGEN-JPNSP2021074308,AMGEN,,63.0,YR,A,M,Y,68.0,KG,20220503,,MD,JP,JP,2022,Q2,Adult
192651873,19265187,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2022,Q2,Renal impairment,,2022,Q2,3,F,20210315.0,20220421.0,20210517,20220504,PER,,JP-AMGEN-JPNSP2021074308,AMGEN,,63.0,YR,A,M,Y,68.0,KG,20220503,,MD,JP,JP,2022,Q2,Adult
196467622,19646762,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Emphysematous pyelonephritis,,2022,Q2,2,F,,20220323.0,20210802,20220405,EXP,,ES-PFIZER INC-202100913656,PFIZER,Cases-Corona C. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. Nephron clinical practice. 2020;144(6):304-9,53.0,YR,,F,Y,,,20220405,,MD,ES,ES,2022,Q2,Adult
197283772,19728377,4,C,"EMPAGLIFLOZIN, LINAGLIPTIN",,2,,,,,U,,,,,,,,,2022,Q2,Gait disturbance,,2022,Q2,2,F,,20220510.0,20210820,20220516,EXP,CA-MHPD-000924219,CA-Accord-235280,ACCORD,,79.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Elderly
197283772,19728377,4,C,"EMPAGLIFLOZIN, LINAGLIPTIN",,2,,,,,U,,,,,,,,,2022,Q2,Dysphagia,,2022,Q2,2,F,,20220510.0,20210820,20220516,EXP,CA-MHPD-000924219,CA-Accord-235280,ACCORD,,79.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Elderly
197283772,19728377,4,C,"EMPAGLIFLOZIN, LINAGLIPTIN",,2,,,,,U,,,,,,,,,2022,Q2,Dropped head syndrome,,2022,Q2,2,F,,20220510.0,20210820,20220516,EXP,CA-MHPD-000924219,CA-Accord-235280,ACCORD,,79.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Elderly
197283772,19728377,4,C,"EMPAGLIFLOZIN, LINAGLIPTIN",,2,,,,,U,,,,,,,,,2022,Q2,Muscular weakness,,2022,Q2,2,F,,20220510.0,20210820,20220516,EXP,CA-MHPD-000924219,CA-Accord-235280,ACCORD,,79.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Elderly
197283772,19728377,4,C,"EMPAGLIFLOZIN, LINAGLIPTIN",,2,,,,,U,,,,,,,,,2022,Q2,Asthenia,,2022,Q2,2,F,,20220510.0,20210820,20220516,EXP,CA-MHPD-000924219,CA-Accord-235280,ACCORD,,79.0,YR,,M,Y,,,20220516,,HP,CA,CA,2022,Q2,Elderly
198083943,19808394,13,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q2,Iliac artery stenosis,,2022,Q2,3,F,20201201.0,20220415.0,20210909,20220421,PER,,JP-AMGEN-JPNNI2021136912,AMGEN,,46.0,YR,A,F,Y,51.0,KG,20220421,,MD,JP,JP,2022,Q2,Adult
198083943,19808394,13,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q2,Pruritus,,2022,Q2,3,F,20201201.0,20220415.0,20210909,20220421,PER,,JP-AMGEN-JPNNI2021136912,AMGEN,,46.0,YR,A,F,Y,51.0,KG,20220421,,MD,JP,JP,2022,Q2,Adult
198083943,19808394,13,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q2,Scleroderma,,2022,Q2,3,F,20201201.0,20220415.0,20210909,20220421,PER,,JP-AMGEN-JPNNI2021136912,AMGEN,,46.0,YR,A,F,Y,51.0,KG,20220421,,MD,JP,JP,2022,Q2,Adult
198083943,19808394,13,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q2,Peripheral ischaemia,,2022,Q2,3,F,20201201.0,20220415.0,20210909,20220421,PER,,JP-AMGEN-JPNNI2021136912,AMGEN,,46.0,YR,A,F,Y,51.0,KG,20220421,,MD,JP,JP,2022,Q2,Adult
198990882,19899088,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,1 DF,,,Y,U,Unknown,,206073.0,,,Tablet,,2022,Q2,Pneumonia,,2022,Q2,2,F,20210908.0,20220513.0,20210930,20220516,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-129974",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,,,20220516,,PH,JP,JP,2022,Q2,Elderly
198990882,19899088,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,1 DF,,,Y,U,Unknown,,206073.0,,,Tablet,,2022,Q2,Pyrexia,,2022,Q2,2,F,20210908.0,20220513.0,20210930,20220516,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-129974",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,,,20220516,,PH,JP,JP,2022,Q2,Elderly
198990882,19899088,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,1 DF,,,Y,U,Unknown,,206073.0,,,Tablet,,2022,Q2,Urinary tract infection,,2022,Q2,2,F,20210908.0,20220513.0,20210930,20220516,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-129974",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,,,20220516,,PH,JP,JP,2022,Q2,Elderly
199605093,19960509,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,,,Film-coated tablet,,2022,Q2,Glaucoma,,2022,Q2,3,F,20210823.0,20220413.0,20211015,20220415,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-131968",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,84.7,KG,20220415,,MD,JP,JP,2022,Q2,Elderly
199713053,19971305,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2022,Q2,Arthralgia,,2022,Q2,3,F,,20220531.0,20211020,20220614,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19",70.0,YR,,F,Y,80.0,KG,20220614,,MD,DE,DE,2022,Q2,Elderly
199713053,19971305,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2022,Q2,Inappropriate schedule of product administration,,2022,Q2,3,F,,20220531.0,20211020,20220614,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19",70.0,YR,,F,Y,80.0,KG,20220614,,MD,DE,DE,2022,Q2,Elderly
199713053,19971305,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2022,Q2,Hypophagia,,2022,Q2,3,F,,20220531.0,20211020,20220614,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19",70.0,YR,,F,Y,80.0,KG,20220614,,MD,DE,DE,2022,Q2,Elderly
199713053,19971305,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2022,Q2,Nausea,,2022,Q2,3,F,,20220531.0,20211020,20220614,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19",70.0,YR,,F,Y,80.0,KG,20220614,,MD,DE,DE,2022,Q2,Elderly
199713053,19971305,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2022,Q2,Fall,,2022,Q2,3,F,,20220531.0,20211020,20220614,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19",70.0,YR,,F,Y,80.0,KG,20220614,,MD,DE,DE,2022,Q2,Elderly
199713053,19971305,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2022,Q2,Gastrointestinal disorder,,2022,Q2,3,F,,20220531.0,20211020,20220614,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19",70.0,YR,,F,Y,80.0,KG,20220614,,MD,DE,DE,2022,Q2,Elderly
199713053,19971305,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2022,Q2,Hypoglycaemia,,2022,Q2,3,F,,20220531.0,20211020,20220614,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19",70.0,YR,,F,Y,80.0,KG,20220614,,MD,DE,DE,2022,Q2,Elderly
199713053,19971305,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2022,Q2,Drug intolerance,,2022,Q2,3,F,,20220531.0,20211020,20220614,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19",70.0,YR,,F,Y,80.0,KG,20220614,,MD,DE,DE,2022,Q2,Elderly
199713053,19971305,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2022,Q2,Incorrect product formulation administered,,2022,Q2,3,F,,20220531.0,20211020,20220614,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19",70.0,YR,,F,Y,80.0,KG,20220614,,MD,DE,DE,2022,Q2,Elderly
199713053,19971305,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2022,Q2,Back pain,,2022,Q2,3,F,,20220531.0,20211020,20220614,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19",70.0,YR,,F,Y,80.0,KG,20220614,,MD,DE,DE,2022,Q2,Elderly
199713053,19971305,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2022,Q2,Impaired quality of life,,2022,Q2,3,F,,20220531.0,20211020,20220614,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19",70.0,YR,,F,Y,80.0,KG,20220614,,MD,DE,DE,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Acidosis,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Tachycardia,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Orthopnoea,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Metabolic acidosis,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Venous pressure jugular,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Multiple organ dysfunction syndrome,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Acute kidney injury,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Hyperhidrosis,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Renal artery thrombosis,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Renal disorder,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Bronchospasm,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Shock,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Oliguria,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Acute abdomen,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Tachypnoea,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Asthenia,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Mesenteric artery thrombosis,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
200313156,20031315,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Aortic thrombosis,,2022,Q2,6,F,,20220503.0,20211103,20220505,EXP,,PT-MYLANLABS-2021M1079708,MYLAN,"Fontes J, Falcao M, Paes de Faria V, et al.. PL 0559 Euglycemic diabetic ketoacidosis by iSGLT2- a potentially fatal entity. Journal of the Portuguese Society of Internal Medicine. 2021;28:567",73.0,YR,,M,Y,,,20220505,,MD,PT,PT,2022,Q2,Elderly
2004410417,20044104,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,1.0,MG,Tablet,,2022,Q2,Pancreatitis acute,,2022,Q2,17,F,20211024.0,20220623.0,20211108,20220628,EXP,,RU-ASTELLAS-2021US042176,ASTELLAS,,70.0,YR,,F,Y,,,20220628,,CN,RU,RU,2022,Q2,Elderly
2004410417,20044104,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,1.0,MG,Tablet,,2022,Q2,Gastrooesophageal reflux disease,,2022,Q2,17,F,20211024.0,20220623.0,20211108,20220628,EXP,,RU-ASTELLAS-2021US042176,ASTELLAS,,70.0,YR,,F,Y,,,20220628,,CN,RU,RU,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Acute kidney injury,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Acidosis,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Death,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Shock,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Venous pressure jugular,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Multiple organ dysfunction syndrome,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Orthopnoea,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Hyperhidrosis,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Renal disorder,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Asthenia,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Aortic thrombosis,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Oliguria,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Bronchospasm,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Acute abdomen,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Tachycardia,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Renal artery thrombosis,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Metabolic acidosis,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Mesenteric artery thrombosis,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,D,,,,,10.0,MG,,QD,2022,Q2,Tachypnoea,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Acute kidney injury,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Acidosis,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Death,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Shock,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Venous pressure jugular,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Multiple organ dysfunction syndrome,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Orthopnoea,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Hyperhidrosis,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Renal disorder,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Asthenia,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Aortic thrombosis,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Oliguria,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Bronchospasm,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Acute abdomen,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Tachycardia,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Renal artery thrombosis,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Metabolic acidosis,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Mesenteric artery thrombosis,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200475744,20047574,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1000 milligram, Once a Day",,,D,,,,,1000.0,MG,,QD,2022,Q2,Tachypnoea,,2022,Q2,4,F,,20220413.0,20211109,20220428,EXP,,PT-AUROBINDO-AUR-APL-2021-045339,AUROBINDO,"Fontes J, Falcao M, Paes de Faria V, Leal N, Ferreira P, Rocha P. et al.. Cetoacidose diab?tica euglic?mica por iSGLT2 - uma entidade potencialmente fatal. Medicina Interna /  Portuguese(Euglycemic Diabetic Ketoacidosis by iSGLT2 - a potentially fatal entity). Journal of Internal Medicine. 2021;28(Congresso):567-567",73.0,YR,,M,Y,,,20220428,,MD,PT,PT,2022,Q2,Elderly
200638992,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2022,Q2,Wheezing,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2022,Q2,Full blood count abnormal,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2022,Q2,Nasal congestion,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2022,Q2,Bronchiectasis,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2022,Q2,Cough,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2022,Q2,Malignant mediastinal neoplasm,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2022,Q2,Rhinorrhoea,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2022,Q2,Asthma,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2022,Q2,Dyspnoea,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200638992,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2022,Q2,Blood immunoglobulin E increased,,2022,Q2,2,F,,20220615.0,20211112,20220624,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20220624,,CN,CA,CA,2022,Q2,Elderly
200931302,20093130,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2022,Q2,Laboratory test abnormal,,2022,Q2,2,F,20211115.0,20220428.0,20211120,20220502,EXP,,CO-ABBVIE-21K-036-4169863-00,ABBVIE,,57.0,YR,,F,Y,53.0,KG,20220502,,CN,COUNTRY NOT SPECIFIED,CO,2022,Q2,Adult
200931302,20093130,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2022,Q2,Myocardial infarction,,2022,Q2,2,F,20211115.0,20220428.0,20211120,20220502,EXP,,CO-ABBVIE-21K-036-4169863-00,ABBVIE,,57.0,YR,,F,Y,53.0,KG,20220502,,CN,COUNTRY NOT SPECIFIED,CO,2022,Q2,Adult
200931302,20093130,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,,2022,Q2,Cardiovascular disorder,,2022,Q2,2,F,20211115.0,20220428.0,20211120,20220502,EXP,,CO-ABBVIE-21K-036-4169863-00,ABBVIE,,57.0,YR,,F,Y,53.0,KG,20220502,,CN,COUNTRY NOT SPECIFIED,CO,2022,Q2,Adult
200957174,20095717,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q2,Off label use,,2022,Q2,4,F,20200309.0,20220425.0,20211122,20220504,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20220504,,MD,CA,CA,2022,Q2,Adult
200957174,20095717,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q2,Psoriasis,,2022,Q2,4,F,20200309.0,20220425.0,20211122,20220504,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20220504,,MD,CA,CA,2022,Q2,Adult
200957174,20095717,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,4,F,20200309.0,20220425.0,20211122,20220504,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20220504,,MD,CA,CA,2022,Q2,Adult
200957174,20095717,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q2,C-reactive protein increased,,2022,Q2,4,F,20200309.0,20220425.0,20211122,20220504,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20220504,,MD,CA,CA,2022,Q2,Adult
200957174,20095717,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q2,Hepatotoxicity,,2022,Q2,4,F,20200309.0,20220425.0,20211122,20220504,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20220504,,MD,CA,CA,2022,Q2,Adult
200957174,20095717,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q2,Weight decreased,,2022,Q2,4,F,20200309.0,20220425.0,20211122,20220504,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20220504,,MD,CA,CA,2022,Q2,Adult
200957174,20095717,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q2,Condition aggravated,,2022,Q2,4,F,20200309.0,20220425.0,20211122,20220504,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20220504,,MD,CA,CA,2022,Q2,Adult
201162334,20116233,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2022,Q2,Diarrhoea,,2022,Q2,4,F,20210716.0,20220505.0,20211126,20220513,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220512,,MD,GB,GB,2022,Q2,Elderly
201162334,20116233,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2022,Q2,Glycosuria,,2022,Q2,4,F,20210716.0,20220505.0,20211126,20220513,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220512,,MD,GB,GB,2022,Q2,Elderly
201162334,20116233,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2022,Q2,Hypothyroidism,,2022,Q2,4,F,20210716.0,20220505.0,20211126,20220513,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220512,,MD,GB,GB,2022,Q2,Elderly
201162334,20116233,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2022,Q2,Hyperthyroidism,,2022,Q2,4,F,20210716.0,20220505.0,20211126,20220513,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220512,,MD,GB,GB,2022,Q2,Elderly
201162334,20116233,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,,,,,,,,,QD,2022,Q2,Haematuria,,2022,Q2,4,F,20210716.0,20220505.0,20211126,20220513,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220512,,MD,GB,GB,2022,Q2,Elderly
201162334,20116233,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,4,F,20210716.0,20220505.0,20211126,20220513,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220512,,MD,GB,GB,2022,Q2,Elderly
201162334,20116233,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Glycosuria,,2022,Q2,4,F,20210716.0,20220505.0,20211126,20220513,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220512,,MD,GB,GB,2022,Q2,Elderly
201162334,20116233,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Hypothyroidism,,2022,Q2,4,F,20210716.0,20220505.0,20211126,20220513,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220512,,MD,GB,GB,2022,Q2,Elderly
201162334,20116233,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Hyperthyroidism,,2022,Q2,4,F,20210716.0,20220505.0,20211126,20220513,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220512,,MD,GB,GB,2022,Q2,Elderly
201162334,20116233,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Haematuria,,2022,Q2,4,F,20210716.0,20220505.0,20211126,20220513,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220512,,MD,GB,GB,2022,Q2,Elderly
201162334,20116233,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,4,F,20210716.0,20220505.0,20211126,20220513,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220512,,MD,GB,GB,2022,Q2,Elderly
201162334,20116233,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Glycosuria,,2022,Q2,4,F,20210716.0,20220505.0,20211126,20220513,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220512,,MD,GB,GB,2022,Q2,Elderly
201162334,20116233,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Hypothyroidism,,2022,Q2,4,F,20210716.0,20220505.0,20211126,20220513,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220512,,MD,GB,GB,2022,Q2,Elderly
201162334,20116233,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Hyperthyroidism,,2022,Q2,4,F,20210716.0,20220505.0,20211126,20220513,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220512,,MD,GB,GB,2022,Q2,Elderly
201162334,20116233,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Haematuria,,2022,Q2,4,F,20210716.0,20220505.0,20211126,20220513,PER,,GB-AMGEN-GBRNI2021185238,AMGEN,,69.0,YR,E,F,Y,76.4,KG,20220512,,MD,GB,GB,2022,Q2,Elderly
201337772,20133777,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,290.416666,MG,U,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q2,Vulvovaginal discomfort,,2022,Q2,2,F,20211123.0,20220401.0,20211201,20220406,EXP,GB-MHRA-TPP36098686C963037YC1637670841905,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140360",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,94.0,KG,20220406,,MD,GB,GB,2022,Q2,Adult
201337772,20133777,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,290.416666,MG,U,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q2,Vulvovaginal pain,,2022,Q2,2,F,20211123.0,20220401.0,20211201,20220406,EXP,GB-MHRA-TPP36098686C963037YC1637670841905,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140360",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,94.0,KG,20220406,,MD,GB,GB,2022,Q2,Adult
201337772,20133777,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,290.416666,MG,U,U,,,204629.0,,,,,2022,Q2,Vulvovaginal discomfort,,2022,Q2,2,F,20211123.0,20220401.0,20211201,20220406,EXP,GB-MHRA-TPP36098686C963037YC1637670841905,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140360",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,94.0,KG,20220406,,MD,GB,GB,2022,Q2,Adult
201337772,20133777,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,290.416666,MG,U,U,,,204629.0,,,,,2022,Q2,Vulvovaginal pain,,2022,Q2,2,F,20211123.0,20220401.0,20211201,20220406,EXP,GB-MHRA-TPP36098686C963037YC1637670841905,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140360",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,94.0,KG,20220406,,MD,GB,GB,2022,Q2,Adult
201418382,20141838,45,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,Acute kidney injury,,2022,Q2,2,F,20210301.0,20220413.0,20211202,20220418,EXP,,NVSC2021PL267813,NOVARTIS,,71.0,YR,,M,Y,,,20220418,,MD,PL,PL,2022,Q2,Elderly
201418382,20141838,45,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,Congestive cardiomyopathy,,2022,Q2,2,F,20210301.0,20220413.0,20211202,20220418,EXP,,NVSC2021PL267813,NOVARTIS,,71.0,YR,,M,Y,,,20220418,,MD,PL,PL,2022,Q2,Elderly
201418382,20141838,45,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,Cardiac failure,,2022,Q2,2,F,20210301.0,20220413.0,20211202,20220418,EXP,,NVSC2021PL267813,NOVARTIS,,71.0,YR,,M,Y,,,20220418,,MD,PL,PL,2022,Q2,Elderly
201418382,20141838,45,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,N-terminal prohormone brain natriuretic peptide increased,,2022,Q2,2,F,20210301.0,20220413.0,20211202,20220418,EXP,,NVSC2021PL267813,NOVARTIS,,71.0,YR,,M,Y,,,20220418,,MD,PL,PL,2022,Q2,Elderly
201418382,20141838,45,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,Glomerular filtration rate abnormal,,2022,Q2,2,F,20210301.0,20220413.0,20211202,20220418,EXP,,NVSC2021PL267813,NOVARTIS,,71.0,YR,,M,Y,,,20220418,,MD,PL,PL,2022,Q2,Elderly
201418382,20141838,45,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,Lung disorder,,2022,Q2,2,F,20210301.0,20220413.0,20211202,20220418,EXP,,NVSC2021PL267813,NOVARTIS,,71.0,YR,,M,Y,,,20220418,,MD,PL,PL,2022,Q2,Elderly
201418382,20141838,45,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,Wrong technique in product usage process,,2022,Q2,2,F,20210301.0,20220413.0,20211202,20220418,EXP,,NVSC2021PL267813,NOVARTIS,,71.0,YR,,M,Y,,,20220418,,MD,PL,PL,2022,Q2,Elderly
201685087,20168508,25,C,EMPAGLIFLOZIN;METFORMIN HYDROCHLORIDE,,1,Oral,"1000/12,5 milligram, Two Times a Day",,,U,,,,,,,,BID,2022,Q2,Neutropenia,,2022,Q2,7,F,20211117.0,20220511.0,20211210,20220517,EXP,,ES-AUROBINDO-AUR-APL-2021-050572,AUROBINDO,,56.0,YR,,M,Y,,,20220517,,MD,ES,ES,2022,Q2,Adult
201685087,20168508,25,C,EMPAGLIFLOZIN;METFORMIN HYDROCHLORIDE,,1,Oral,"1000/12,5 milligram, Two Times a Day",,,U,,,,,,,,BID,2022,Q2,Intestinal obstruction,,2022,Q2,7,F,20211117.0,20220511.0,20211210,20220517,EXP,,ES-AUROBINDO-AUR-APL-2021-050572,AUROBINDO,,56.0,YR,,M,Y,,,20220517,,MD,ES,ES,2022,Q2,Adult
201685087,20168508,26,C,EMPAGLIFLOZIN;METFORMIN HYDROCHLORIDE,,1,Oral,"UNK, Once a Day (2x/day)",,,U,,,,,,,,QD,2022,Q2,Neutropenia,,2022,Q2,7,F,20211117.0,20220511.0,20211210,20220517,EXP,,ES-AUROBINDO-AUR-APL-2021-050572,AUROBINDO,,56.0,YR,,M,Y,,,20220517,,MD,ES,ES,2022,Q2,Adult
201685087,20168508,26,C,EMPAGLIFLOZIN;METFORMIN HYDROCHLORIDE,,1,Oral,"UNK, Once a Day (2x/day)",,,U,,,,,,,,QD,2022,Q2,Intestinal obstruction,,2022,Q2,7,F,20211117.0,20220511.0,20211210,20220517,EXP,,ES-AUROBINDO-AUR-APL-2021-050572,AUROBINDO,,56.0,YR,,M,Y,,,20220517,,MD,ES,ES,2022,Q2,Adult
201741047,20174104,30,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,U,Unknown,,,10.0,MG,Unknown,QD,2022,Q2,Glomerular filtration rate abnormal,,2022,Q2,7,F,20210301.0,20220513.0,20211213,20220520,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-132439,BRISTOL MYERS SQUIBB,,71.0,YR,E,M,Y,,,20220520,,CN,PL,PL,2022,Q2,Elderly
201741047,20174104,30,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,U,Unknown,,,10.0,MG,Unknown,QD,2022,Q2,Wrong technique in product usage process,,2022,Q2,7,F,20210301.0,20220513.0,20211213,20220520,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-132439,BRISTOL MYERS SQUIBB,,71.0,YR,E,M,Y,,,20220520,,CN,PL,PL,2022,Q2,Elderly
201741047,20174104,30,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,U,Unknown,,,10.0,MG,Unknown,QD,2022,Q2,Lung disorder,,2022,Q2,7,F,20210301.0,20220513.0,20211213,20220520,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-132439,BRISTOL MYERS SQUIBB,,71.0,YR,E,M,Y,,,20220520,,CN,PL,PL,2022,Q2,Elderly
201741047,20174104,30,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,U,Unknown,,,10.0,MG,Unknown,QD,2022,Q2,Acute kidney injury,,2022,Q2,7,F,20210301.0,20220513.0,20211213,20220520,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-132439,BRISTOL MYERS SQUIBB,,71.0,YR,E,M,Y,,,20220520,,CN,PL,PL,2022,Q2,Elderly
201741047,20174104,30,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,U,Unknown,,,10.0,MG,Unknown,QD,2022,Q2,N-terminal prohormone brain natriuretic peptide increased,,2022,Q2,7,F,20210301.0,20220513.0,20211213,20220520,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-132439,BRISTOL MYERS SQUIBB,,71.0,YR,E,M,Y,,,20220520,,CN,PL,PL,2022,Q2,Elderly
201741047,20174104,30,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,U,Unknown,,,10.0,MG,Unknown,QD,2022,Q2,Congestive cardiomyopathy,,2022,Q2,7,F,20210301.0,20220513.0,20211213,20220520,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-132439,BRISTOL MYERS SQUIBB,,71.0,YR,E,M,Y,,,20220520,,CN,PL,PL,2022,Q2,Elderly
201741047,20174104,30,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,U,Unknown,,,10.0,MG,Unknown,QD,2022,Q2,Cardiac failure,,2022,Q2,7,F,20210301.0,20220513.0,20211213,20220520,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-132439,BRISTOL MYERS SQUIBB,,71.0,YR,E,M,Y,,,20220520,,CN,PL,PL,2022,Q2,Elderly
201812323,20181232,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Congestive cardiomyopathy,,2022,Q2,3,F,20210301.0,20220413.0,20211214,20220420,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-142296",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20220420,,CN,PL,PL,2022,Q2,Elderly
201812323,20181232,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Wrong technique in product usage process,,2022,Q2,3,F,20210301.0,20220413.0,20211214,20220420,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-142296",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20220420,,CN,PL,PL,2022,Q2,Elderly
201812323,20181232,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Lung disorder,,2022,Q2,3,F,20210301.0,20220413.0,20211214,20220420,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-142296",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20220420,,CN,PL,PL,2022,Q2,Elderly
201812323,20181232,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Acute kidney injury,,2022,Q2,3,F,20210301.0,20220413.0,20211214,20220420,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-142296",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20220420,,CN,PL,PL,2022,Q2,Elderly
201812323,20181232,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Glomerular filtration rate abnormal,,2022,Q2,3,F,20210301.0,20220413.0,20211214,20220420,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-142296",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20220420,,CN,PL,PL,2022,Q2,Elderly
201812323,20181232,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Cardiac failure,,2022,Q2,3,F,20210301.0,20220413.0,20211214,20220420,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-142296",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20220420,,CN,PL,PL,2022,Q2,Elderly
201812323,20181232,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,N-terminal prohormone brain natriuretic peptide increased,,2022,Q2,3,F,20210301.0,20220413.0,20211214,20220420,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-142296",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20220420,,CN,PL,PL,2022,Q2,Elderly
201897612,20189761,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Toxicity to various agents,,2022,Q2,2,F,,20220404.0,20211215,20220411,EXP,,"GB-Breckenridge Pharmaceutical, Inc.-2123049",BRECKENRIDGE,,49.0,YR,,M,Y,176.0,KG,20220411,,HP,ES,GB,2022,Q2,Adult
201897612,20189761,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Death,,2022,Q2,2,F,,20220404.0,20211215,20220411,EXP,,"GB-Breckenridge Pharmaceutical, Inc.-2123049",BRECKENRIDGE,,49.0,YR,,M,Y,176.0,KG,20220411,,HP,ES,GB,2022,Q2,Adult
201897612,20189761,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Cardiomegaly,,2022,Q2,2,F,,20220404.0,20211215,20220411,EXP,,"GB-Breckenridge Pharmaceutical, Inc.-2123049",BRECKENRIDGE,,49.0,YR,,M,Y,176.0,KG,20220411,,HP,ES,GB,2022,Q2,Adult
201897612,20189761,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Malaise,,2022,Q2,2,F,,20220404.0,20211215,20220411,EXP,,"GB-Breckenridge Pharmaceutical, Inc.-2123049",BRECKENRIDGE,,49.0,YR,,M,Y,176.0,KG,20220411,,HP,ES,GB,2022,Q2,Adult
201922355,20192235,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q2,Glomerular filtration rate abnormal,,2022,Q2,5,F,20210301.0,20220513.0,20211216,20220527,EXP,,PL-AUROBINDO-AUR-APL-2021-051139,AUROBINDO,,71.0,YR,,M,Y,,,20220527,,MD,PL,PL,2022,Q2,Elderly
201922355,20192235,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q2,Cardiac failure,,2022,Q2,5,F,20210301.0,20220513.0,20211216,20220527,EXP,,PL-AUROBINDO-AUR-APL-2021-051139,AUROBINDO,,71.0,YR,,M,Y,,,20220527,,MD,PL,PL,2022,Q2,Elderly
201922355,20192235,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q2,N-terminal prohormone brain natriuretic peptide increased,,2022,Q2,5,F,20210301.0,20220513.0,20211216,20220527,EXP,,PL-AUROBINDO-AUR-APL-2021-051139,AUROBINDO,,71.0,YR,,M,Y,,,20220527,,MD,PL,PL,2022,Q2,Elderly
201922355,20192235,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q2,Wrong technique in product usage process,,2022,Q2,5,F,20210301.0,20220513.0,20211216,20220527,EXP,,PL-AUROBINDO-AUR-APL-2021-051139,AUROBINDO,,71.0,YR,,M,Y,,,20220527,,MD,PL,PL,2022,Q2,Elderly
201922355,20192235,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q2,Acute kidney injury,,2022,Q2,5,F,20210301.0,20220513.0,20211216,20220527,EXP,,PL-AUROBINDO-AUR-APL-2021-051139,AUROBINDO,,71.0,YR,,M,Y,,,20220527,,MD,PL,PL,2022,Q2,Elderly
201922355,20192235,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q2,Congestive cardiomyopathy,,2022,Q2,5,F,20210301.0,20220513.0,20211216,20220527,EXP,,PL-AUROBINDO-AUR-APL-2021-051139,AUROBINDO,,71.0,YR,,M,Y,,,20220527,,MD,PL,PL,2022,Q2,Elderly
201922355,20192235,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q2,Lung disorder,,2022,Q2,5,F,20210301.0,20220513.0,20211216,20220527,EXP,,PL-AUROBINDO-AUR-APL-2021-051139,AUROBINDO,,71.0,YR,,M,Y,,,20220527,,MD,PL,PL,2022,Q2,Elderly
201950477,20195047,22,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1000/12,5 milligram, bid",,,,,"UNKNOWNS,UNKNOWN",,,,,Unknown,,2022,Q2,Intestinal obstruction,,2022,Q2,7,F,20211117.0,20220516.0,20211216,20220524,EXP,,ES-Fresenius Kabi-FK202113930,FRESENIUS KABI,,56.0,YR,,M,Y,,,20220524,,HP,NL,,2022,Q2,Adult
201950477,20195047,22,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1000/12,5 milligram, bid",,,,,"UNKNOWNS,UNKNOWN",,,,,Unknown,,2022,Q2,Neutropenia,,2022,Q2,7,F,20211117.0,20220516.0,20211216,20220524,EXP,,ES-Fresenius Kabi-FK202113930,FRESENIUS KABI,,56.0,YR,,M,Y,,,20220524,,HP,NL,,2022,Q2,Adult
201950477,20195047,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK,2x/day",,,,,"UNKNOWNS,UNKNOWN",,,,,,,2022,Q2,Intestinal obstruction,,2022,Q2,7,F,20211117.0,20220516.0,20211216,20220524,EXP,,ES-Fresenius Kabi-FK202113930,FRESENIUS KABI,,56.0,YR,,M,Y,,,20220524,,HP,NL,,2022,Q2,Adult
201950477,20195047,23,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK,2x/day",,,,,"UNKNOWNS,UNKNOWN",,,,,,,2022,Q2,Neutropenia,,2022,Q2,7,F,20211117.0,20220516.0,20211216,20220524,EXP,,ES-Fresenius Kabi-FK202113930,FRESENIUS KABI,,56.0,YR,,M,Y,,,20220524,,HP,NL,,2022,Q2,Adult
2019610413,20196104,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,Unknown,,,10.0,MG,,QD,2022,Q2,Lung disorder,,2022,Q2,13,F,20210301.0,20220627.0,20211216,20220630,EXP,,PL-PFIZER INC-202101733614,PFIZER,,71.0,YR,,M,Y,,,20220630,,MD,PL,PL,2022,Q2,Elderly
2019610413,20196104,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,Unknown,,,10.0,MG,,QD,2022,Q2,Cardiac failure,,2022,Q2,13,F,20210301.0,20220627.0,20211216,20220630,EXP,,PL-PFIZER INC-202101733614,PFIZER,,71.0,YR,,M,Y,,,20220630,,MD,PL,PL,2022,Q2,Elderly
2019610413,20196104,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,Unknown,,,10.0,MG,,QD,2022,Q2,Congestive cardiomyopathy,,2022,Q2,13,F,20210301.0,20220627.0,20211216,20220630,EXP,,PL-PFIZER INC-202101733614,PFIZER,,71.0,YR,,M,Y,,,20220630,,MD,PL,PL,2022,Q2,Elderly
2019610413,20196104,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,Unknown,,,10.0,MG,,QD,2022,Q2,Acute kidney injury,,2022,Q2,13,F,20210301.0,20220627.0,20211216,20220630,EXP,,PL-PFIZER INC-202101733614,PFIZER,,71.0,YR,,M,Y,,,20220630,,MD,PL,PL,2022,Q2,Elderly
2019610413,20196104,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,Unknown,,,10.0,MG,,QD,2022,Q2,N-terminal prohormone brain natriuretic peptide increased,,2022,Q2,13,F,20210301.0,20220627.0,20211216,20220630,EXP,,PL-PFIZER INC-202101733614,PFIZER,,71.0,YR,,M,Y,,,20220630,,MD,PL,PL,2022,Q2,Elderly
2019610413,20196104,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,Unknown,,,10.0,MG,,QD,2022,Q2,Wrong technique in product usage process,,2022,Q2,13,F,20210301.0,20220627.0,20211216,20220630,EXP,,PL-PFIZER INC-202101733614,PFIZER,,71.0,YR,,M,Y,,,20220630,,MD,PL,PL,2022,Q2,Elderly
2019610413,20196104,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,Unknown,,,10.0,MG,,QD,2022,Q2,Glomerular filtration rate abnormal,,2022,Q2,13,F,20210301.0,20220627.0,20211216,20220630,EXP,,PL-PFIZER INC-202101733614,PFIZER,,71.0,YR,,M,Y,,,20220630,,MD,PL,PL,2022,Q2,Elderly
202795004,20279500,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,Wrong technique in product usage process,,2022,Q2,4,F,20210301.0,20220505.0,20220103,20220509,EXP,,PL-MYLANLABS-2021M1096293,MYLAN,,71.0,YR,,M,Y,,,20220509,,MD,PL,PL,2022,Q2,Elderly
202795004,20279500,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,Acute kidney injury,,2022,Q2,4,F,20210301.0,20220505.0,20220103,20220509,EXP,,PL-MYLANLABS-2021M1096293,MYLAN,,71.0,YR,,M,Y,,,20220509,,MD,PL,PL,2022,Q2,Elderly
202795004,20279500,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,Lung disorder,,2022,Q2,4,F,20210301.0,20220505.0,20220103,20220509,EXP,,PL-MYLANLABS-2021M1096293,MYLAN,,71.0,YR,,M,Y,,,20220509,,MD,PL,PL,2022,Q2,Elderly
202795004,20279500,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,Glomerular filtration rate abnormal,,2022,Q2,4,F,20210301.0,20220505.0,20220103,20220509,EXP,,PL-MYLANLABS-2021M1096293,MYLAN,,71.0,YR,,M,Y,,,20220509,,MD,PL,PL,2022,Q2,Elderly
202795004,20279500,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,Cardiac failure,,2022,Q2,4,F,20210301.0,20220505.0,20220103,20220509,EXP,,PL-MYLANLABS-2021M1096293,MYLAN,,71.0,YR,,M,Y,,,20220509,,MD,PL,PL,2022,Q2,Elderly
202795004,20279500,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,Congestive cardiomyopathy,,2022,Q2,4,F,20210301.0,20220505.0,20220103,20220509,EXP,,PL-MYLANLABS-2021M1096293,MYLAN,,71.0,YR,,M,Y,,,20220509,,MD,PL,PL,2022,Q2,Elderly
202795004,20279500,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,N-terminal prohormone brain natriuretic peptide increased,,2022,Q2,4,F,20210301.0,20220505.0,20220103,20220509,EXP,,PL-MYLANLABS-2021M1096293,MYLAN,,71.0,YR,,M,Y,,,20220509,,MD,PL,PL,2022,Q2,Elderly
203238902,20323890,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Pain in extremity,,2022,Q2,2,F,20210801.0,20220405.0,20220111,20220421,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-053366,BRISTOL MYERS SQUIBB,,66.0,YR,E,F,Y,,,20220418,,HP,CA,CA,2022,Q2,Elderly
203238902,20323890,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Arthralgia,,2022,Q2,2,F,20210801.0,20220405.0,20220111,20220421,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-053366,BRISTOL MYERS SQUIBB,,66.0,YR,E,F,Y,,,20220418,,HP,CA,CA,2022,Q2,Elderly
203238902,20323890,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Asthenia,,2022,Q2,2,F,20210801.0,20220405.0,20220111,20220421,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-053366,BRISTOL MYERS SQUIBB,,66.0,YR,E,F,Y,,,20220418,,HP,CA,CA,2022,Q2,Elderly
203238902,20323890,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Fatigue,,2022,Q2,2,F,20210801.0,20220405.0,20220111,20220421,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-053366,BRISTOL MYERS SQUIBB,,66.0,YR,E,F,Y,,,20220418,,HP,CA,CA,2022,Q2,Elderly
203238902,20323890,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Nodule,,2022,Q2,2,F,20210801.0,20220405.0,20220111,20220421,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-053366,BRISTOL MYERS SQUIBB,,66.0,YR,E,F,Y,,,20220418,,HP,CA,CA,2022,Q2,Elderly
203238902,20323890,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Somnolence,,2022,Q2,2,F,20210801.0,20220405.0,20220111,20220421,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-053366,BRISTOL MYERS SQUIBB,,66.0,YR,E,F,Y,,,20220418,,HP,CA,CA,2022,Q2,Elderly
203238902,20323890,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Pain,,2022,Q2,2,F,20210801.0,20220405.0,20220111,20220421,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-053366,BRISTOL MYERS SQUIBB,,66.0,YR,E,F,Y,,,20220418,,HP,CA,CA,2022,Q2,Elderly
203238902,20323890,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Rash,,2022,Q2,2,F,20210801.0,20220405.0,20220111,20220421,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-053366,BRISTOL MYERS SQUIBB,,66.0,YR,E,F,Y,,,20220418,,HP,CA,CA,2022,Q2,Elderly
203238902,20323890,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,COVID-19,,2022,Q2,2,F,20210801.0,20220405.0,20220111,20220421,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-053366,BRISTOL MYERS SQUIBB,,66.0,YR,E,F,Y,,,20220418,,HP,CA,CA,2022,Q2,Elderly
203369387,20336938,20,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Intestinal obstruction,,2022,Q2,7,F,20211117.0,20211119.0,20220114,20220516,EXP,,ES-JAZZ-2021-ES-023900,JAZZ,,56.0,YR,,M,Y,,,20220516,,MD,ES,ES,2022,Q2,Adult
203369387,20336938,20,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Neutropenia,,2022,Q2,7,F,20211117.0,20211119.0,20220114,20220516,EXP,,ES-JAZZ-2021-ES-023900,JAZZ,,56.0,YR,,M,Y,,,20220516,,MD,ES,ES,2022,Q2,Adult
203737963,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,,,2022,Q2,Adrenal insufficiency,,2022,Q2,3,F,,20220607.0,20220125,20220613,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220613,,MD,CA,CA,2022,Q2,Elderly
203737963,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,,,2022,Q2,Hypotension,,2022,Q2,3,F,,20220607.0,20220125,20220613,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220613,,MD,CA,CA,2022,Q2,Elderly
203737963,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,,,2022,Q2,Hyperthyroidism,,2022,Q2,3,F,,20220607.0,20220125,20220613,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220613,,MD,CA,CA,2022,Q2,Elderly
203737963,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,,,2022,Q2,Troponin increased,,2022,Q2,3,F,,20220607.0,20220125,20220613,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220613,,MD,CA,CA,2022,Q2,Elderly
2037504412,20375044,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q2,Weight decreased,Weight decreased,2022,Q2,12,F,20220117.0,20220524.0,20220125,20220531,PER,,CH-Eisai Medical Research-EC-2022-107259,EISAI,,80.0,YR,E,M,Y,67.6,KG,20220531,,MD,CH,,2022,Q2,Elderly
203821443,20382144,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Fatigue,,2022,Q2,3,F,20210930.0,20220512.0,20220127,20220518,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20220518,,CN,CA,CA,2022,Q2,Adult
203821443,20382144,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Product dose omission issue,,2022,Q2,3,F,20210930.0,20220512.0,20220127,20220518,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20220518,,CN,CA,CA,2022,Q2,Adult
203821443,20382144,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Blood pressure increased,,2022,Q2,3,F,20210930.0,20220512.0,20220127,20220518,EXP,,CA-BAUSCH-BL-2021-034002,BAUSCH AND LOMB,,55.0,YR,,M,Y,,,20220518,,CN,CA,CA,2022,Q2,Adult
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Hepatic steatosis,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Frustration tolerance decreased,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Upper limb fracture,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Product prescribing issue,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Facial pain,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Facial pain,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Diabetes mellitus,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Swelling,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Pleural effusion,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Swelling face,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Malaise,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Deafness neurosensory,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Fall,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Liver disorder,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Flushing,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Gallbladder operation,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Vitamin D deficiency,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Procedural complication,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Carcinoid heart disease,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Carcinoid tumour of the small bowel,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Swelling,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Papillary thyroid cancer,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Sialoadenitis,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Condition aggravated,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Vertigo positional,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Hypothyroidism,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204148532,20414853,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/850,,,,,,,,,,,,2022,Q2,Dysphagia,,2022,Q2,2,F,20130101.0,20220411.0,20220202,20220413,EXP,,"IL-Ipsen Biopharmaceuticals, Inc.-2019-26073",IPSEN,,66.0,YR,E,F,Y,,,20220413,,HP,IL,IL,2022,Q2,Elderly
204277432,20427743,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,,,Tablet,,2022,Q2,Basal ganglia haemorrhage,,2022,Q2,2,F,20220120.0,20220421.0,20220204,20220502,EXP,,CN-ROCHE-3015536,ROCHE,,75.0,YR,,F,Y,77.5,KG,20220502,,MD,CN,CN,2022,Q2,Elderly
204277432,20427743,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,,,Tablet,,2022,Q2,Atrial flutter,,2022,Q2,2,F,20220120.0,20220421.0,20220204,20220502,EXP,,CN-ROCHE-3015536,ROCHE,,75.0,YR,,F,Y,77.5,KG,20220502,,MD,CN,CN,2022,Q2,Elderly
204303605,20430360,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Tablets,,2022,Q2,Pancreatitis acute,,2022,Q2,5,F,20211201.0,20220610.0,20220204,20220617,PER,,CN-Eisai Medical Research-EC-2021-104476,EISAI,,51.0,YR,A,F,Y,48.0,KG,20220617,,MD,CN,,2022,Q2,Adult
205179124,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Nausea,,2022,Q2,4,F,20201201.0,20220607.0,20220225,20220620,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220620,,CN,US,,2022,Q2,Elderly
205179124,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Diabetes mellitus,,2022,Q2,4,F,20201201.0,20220607.0,20220225,20220620,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220620,,CN,US,,2022,Q2,Elderly
205179124,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,4,F,20201201.0,20220607.0,20220225,20220620,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220620,,CN,US,,2022,Q2,Elderly
205179124,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Abdominal discomfort,,2022,Q2,4,F,20201201.0,20220607.0,20220225,20220620,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220620,,CN,US,,2022,Q2,Elderly
205179124,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Respiratory rate decreased,,2022,Q2,4,F,20201201.0,20220607.0,20220225,20220620,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220620,,CN,US,,2022,Q2,Elderly
205179124,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Sleep apnoea syndrome,,2022,Q2,4,F,20201201.0,20220607.0,20220225,20220620,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220620,,CN,US,,2022,Q2,Elderly
205179124,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Paranasal sinus hyposecretion,,2022,Q2,4,F,20201201.0,20220607.0,20220225,20220620,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220620,,CN,US,,2022,Q2,Elderly
205179124,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Dizziness,,2022,Q2,4,F,20201201.0,20220607.0,20220225,20220620,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220620,,CN,US,,2022,Q2,Elderly
205179124,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Sinus congestion,,2022,Q2,4,F,20201201.0,20220607.0,20220225,20220620,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220620,,CN,US,,2022,Q2,Elderly
205179124,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Cardiac disorder,,2022,Q2,4,F,20201201.0,20220607.0,20220225,20220620,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220620,,CN,US,,2022,Q2,Elderly
205179124,20517912,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Hypoacusis,,2022,Q2,4,F,20201201.0,20220607.0,20220225,20220620,EXP,,US-ROCHE-2831344,ROCHE,,68.0,YR,,M,Y,,,20220620,,CN,US,,2022,Q2,Elderly
205845323,20584532,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Malignant neoplasm progression,,2022,Q2,3,F,20220502.0,20220503.0,20220311,20220510,EXP,,PT-009507513-2203PRT002934,MERCK,,57.0,YR,,F,Y,,,20220510,,MD,PT,PT,2022,Q2,Adult
205845323,20584532,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Thrombocytopenia,,2022,Q2,3,F,20220502.0,20220503.0,20220311,20220510,EXP,,PT-009507513-2203PRT002934,MERCK,,57.0,YR,,F,Y,,,20220510,,MD,PT,PT,2022,Q2,Adult
205845323,20584532,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Pulmonary oedema,,2022,Q2,3,F,20220502.0,20220503.0,20220311,20220510,EXP,,PT-009507513-2203PRT002934,MERCK,,57.0,YR,,F,Y,,,20220510,,MD,PT,PT,2022,Q2,Adult
206157333,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,Unknown,,2022,Q2,Infusion related reaction,,2022,Q2,3,F,20220217.0,20220415.0,20220321,20220429,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20220429,,MD,GB,GB,2022,Q2,Adult
206157333,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,Unknown,,2022,Q2,Vomiting,,2022,Q2,3,F,20220217.0,20220415.0,20220321,20220429,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20220429,,MD,GB,GB,2022,Q2,Adult
206157333,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,Unknown,,2022,Q2,Hypotension,,2022,Q2,3,F,20220217.0,20220415.0,20220321,20220429,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20220429,,MD,GB,GB,2022,Q2,Adult
206157333,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,Unknown,,2022,Q2,Diarrhoea,,2022,Q2,3,F,20220217.0,20220415.0,20220321,20220429,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20220429,,MD,GB,GB,2022,Q2,Adult
206157333,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,Unknown,,2022,Q2,Sepsis,,2022,Q2,3,F,20220217.0,20220415.0,20220321,20220429,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20220429,,MD,GB,GB,2022,Q2,Adult
206157333,20615733,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,Unknown,,2022,Q2,Pyrexia,,2022,Q2,3,F,20220217.0,20220415.0,20220321,20220429,EXP,,GB-Hikma Pharmaceuticals USA Inc.-GB-H14001-22-57076,HIKMA,,62.0,YR,,M,Y,115.9,KG,20220429,,MD,GB,GB,2022,Q2,Adult
206293964,20629396,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2022,Q2,Decreased appetite,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2022,Q2,Ketoacidosis,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2022,Q2,Vomiting,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2022,Q2,Pallor,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2022,Q2,Dysphagia,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2022,Q2,Nausea,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2022,Q2,Oliguria,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2022,Q2,Dehydration,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2022,Q2,Normochromic normocytic anaemia,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2022,Q2,Breast cancer,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2022,Q2,Acetonaemia,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2022,Q2,Dry skin,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,U,,,,25.0,MG,,QD,2022,Q2,Blood lactic acid increased,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q2,Decreased appetite,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q2,Ketoacidosis,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q2,Vomiting,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q2,Pallor,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q2,Dysphagia,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q2,Nausea,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q2,Oliguria,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q2,Dehydration,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q2,Normochromic normocytic anaemia,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q2,Breast cancer,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q2,Acetonaemia,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q2,Dry skin,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,Y,U,,,,25.0,MG,,,2022,Q2,Blood lactic acid increased,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2022,Q2,Decreased appetite,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2022,Q2,Ketoacidosis,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2022,Q2,Vomiting,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2022,Q2,Pallor,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2022,Q2,Dysphagia,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2022,Q2,Nausea,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2022,Q2,Oliguria,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2022,Q2,Dehydration,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2022,Q2,Normochromic normocytic anaemia,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2022,Q2,Breast cancer,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2022,Q2,Acetonaemia,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2022,Q2,Dry skin,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206293964,20629396,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,U,U,,,,25.0,MG,,QD,2022,Q2,Blood lactic acid increased,,2022,Q2,4,F,,20220518.0,20220323,20220524,EXP,,PT-MYLANLABS-2022M1020906,MYLAN,"Rodrigues S, Esteves VL. P065 ? Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN. Portuguese Journal of Diabetes. 2022;17 (1) Suppl:74",82.0,YR,,F,Y,,,20220524,,MD,PT,PT,2022,Q2,Elderly
206295342,20629534,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Cardiac failure chronic,,2022,Q2,2,F,20210101.0,20220330.0,20220323,20220404,EXP,,GB-MYLANLABS-2022M1021324,MYLAN,,63.0,YR,,M,Y,,,20220404,,MD,GB,GB,2022,Q2,Adult
206295342,20629534,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Condition aggravated,,2022,Q2,2,F,20210101.0,20220330.0,20220323,20220404,EXP,,GB-MYLANLABS-2022M1021324,MYLAN,,63.0,YR,,M,Y,,,20220404,,MD,GB,GB,2022,Q2,Adult
206295342,20629534,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Cardiac failure acute,,2022,Q2,2,F,20210101.0,20220330.0,20220323,20220404,EXP,,GB-MYLANLABS-2022M1021324,MYLAN,,63.0,YR,,M,Y,,,20220404,,MD,GB,GB,2022,Q2,Adult
206295342,20629534,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Inappropriate schedule of product administration,,2022,Q2,2,F,20210101.0,20220330.0,20220323,20220404,EXP,,GB-MYLANLABS-2022M1021324,MYLAN,,63.0,YR,,M,Y,,,20220404,,MD,GB,GB,2022,Q2,Adult
206295342,20629534,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Dyspnoea,,2022,Q2,2,F,20210101.0,20220330.0,20220323,20220404,EXP,,GB-MYLANLABS-2022M1021324,MYLAN,,63.0,YR,,M,Y,,,20220404,,MD,GB,GB,2022,Q2,Adult
206295342,20629534,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Blood creatine increased,,2022,Q2,2,F,20210101.0,20220330.0,20220323,20220404,EXP,,GB-MYLANLABS-2022M1021324,MYLAN,,63.0,YR,,M,Y,,,20220404,,MD,GB,GB,2022,Q2,Adult
206295342,20629534,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Blood pressure decreased,,2022,Q2,2,F,20210101.0,20220330.0,20220323,20220404,EXP,,GB-MYLANLABS-2022M1021324,MYLAN,,63.0,YR,,M,Y,,,20220404,,MD,GB,GB,2022,Q2,Adult
206295342,20629534,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Wrong technique in product usage process,,2022,Q2,2,F,20210101.0,20220330.0,20220323,20220404,EXP,,GB-MYLANLABS-2022M1021324,MYLAN,,63.0,YR,,M,Y,,,20220404,,MD,GB,GB,2022,Q2,Adult
206295342,20629534,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Chest discomfort,,2022,Q2,2,F,20210101.0,20220330.0,20220323,20220404,EXP,,GB-MYLANLABS-2022M1021324,MYLAN,,63.0,YR,,M,Y,,,20220404,,MD,GB,GB,2022,Q2,Adult
206295342,20629534,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Transferrin saturation decreased,,2022,Q2,2,F,20210101.0,20220330.0,20220323,20220404,EXP,,GB-MYLANLABS-2022M1021324,MYLAN,,63.0,YR,,M,Y,,,20220404,,MD,GB,GB,2022,Q2,Adult
206295342,20629534,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,N-terminal prohormone brain natriuretic peptide increased,,2022,Q2,2,F,20210101.0,20220330.0,20220323,20220404,EXP,,GB-MYLANLABS-2022M1021324,MYLAN,,63.0,YR,,M,Y,,,20220404,,MD,GB,GB,2022,Q2,Adult
206295342,20629534,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Blood lactic acid decreased,,2022,Q2,2,F,20210101.0,20220330.0,20220323,20220404,EXP,,GB-MYLANLABS-2022M1021324,MYLAN,,63.0,YR,,M,Y,,,20220404,,MD,GB,GB,2022,Q2,Adult
206295342,20629534,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Serum ferritin decreased,,2022,Q2,2,F,20210101.0,20220330.0,20220323,20220404,EXP,,GB-MYLANLABS-2022M1021324,MYLAN,,63.0,YR,,M,Y,,,20220404,,MD,GB,GB,2022,Q2,Adult
206295342,20629534,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Blood bicarbonate decreased,,2022,Q2,2,F,20210101.0,20220330.0,20220323,20220404,EXP,,GB-MYLANLABS-2022M1021324,MYLAN,,63.0,YR,,M,Y,,,20220404,,MD,GB,GB,2022,Q2,Adult
206295342,20629534,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Troponin T increased,,2022,Q2,2,F,20210101.0,20220330.0,20220323,20220404,EXP,,GB-MYLANLABS-2022M1021324,MYLAN,,63.0,YR,,M,Y,,,20220404,,MD,GB,GB,2022,Q2,Adult
206366902,20636690,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Infusion related reaction,,2022,Q2,2,F,20220217.0,20220415.0,20220325,20220425,EXP,,GB-TEVA-2022-GB-2017685,TEVA,,62.0,YR,A,M,Y,115.9,KG,20220425,,MD,GB,GB,2022,Q2,Adult
206427383,20642738,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,1 dosage form,,,Y,U,Unknown,,206073.0,,,,,2022,Q2,Extremity necrosis,,2022,Q2,3,F,20210712.0,20220603.0,20220328,20220610,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161827",BOEHRINGER INGELHEIM,,77.0,YR,E,M,Y,62.3,KG,20220610,,MD,JP,JP,2022,Q2,Elderly
206427383,20642738,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,1 dosage form,,,Y,U,Unknown,,206073.0,,,,,2022,Q2,Lumbar vertebral fracture,,2022,Q2,3,F,20210712.0,20220603.0,20220328,20220610,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161827",BOEHRINGER INGELHEIM,,77.0,YR,E,M,Y,62.3,KG,20220610,,MD,JP,JP,2022,Q2,Elderly
206427383,20642738,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,1 dosage form,,,Y,U,Unknown,,206073.0,,,,,2022,Q2,Metastases to liver,,2022,Q2,3,F,20210712.0,20220603.0,20220328,20220610,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161827",BOEHRINGER INGELHEIM,,77.0,YR,E,M,Y,62.3,KG,20220610,,MD,JP,JP,2022,Q2,Elderly
206427383,20642738,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,1 dosage form,,,Y,U,Unknown,,206073.0,,,,,2022,Q2,Rectosigmoid cancer,,2022,Q2,3,F,20210712.0,20220603.0,20220328,20220610,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161827",BOEHRINGER INGELHEIM,,77.0,YR,E,M,Y,62.3,KG,20220610,,MD,JP,JP,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Pericardial fibrosis,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Dyspnoea at rest,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Rhonchi,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Coronary artery disease,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Lung disorder,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Ejection fraction decreased,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Ventricular tachycardia,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Palpitations,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Acute myocardial infarction,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Chest pain,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Cardiac failure,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Ventricular extrasystoles,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Rales,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Cough,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Angina pectoris,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Oedema peripheral,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206436042,20643604,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Atrial fibrillation,,2022,Q2,2,F,20210101.0,20220320.0,20220328,20220401,EXP,,NVSC2022PL068408,NOVARTIS,,72.0,YR,,M,Y,,,20220401,,MD,PL,PL,2022,Q2,Elderly
206456142,20645614,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,,,,,2022,Q2,Pneumonia aspiration,,2022,Q2,2,F,20201112.0,20220427.0,20220328,20220505,EXP,,JP-BAUSCH-BL-2022-007492,BAUSCH AND LOMB,,88.0,YR,,F,Y,,,20220505,,MD,JP,JP,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Pallor,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Dysphagia,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Oliguria,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Dry skin,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Nausea,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Drug interaction,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Decreased appetite,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Ketoacidosis,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Acetonaemia,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Dehydration,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Blood lactic acid increased,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Breast cancer,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Vomiting,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206466257,20646625,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2022,Q2,Normochromic normocytic anaemia,,2022,Q2,7,F,,20220518.0,20220329,20220601,EXP,,PT-AUROBINDO-AUR-APL-2022-009438,AUROBINDO,"Rodrigues S,Esteves VL.. Cetoacidose euglicemica em doente idoso sob empagliflozina e metformina (Clinical Cases euglycemic ketoacidosis in elderly patient on empagliflozin and metformin). Revista Portuguesa de Diabetes (Portuguese Journal of diabetes). 2022;17(1):69-74",82.0,YR,,F,Y,,,20220601,,MD,PT,PT,2022,Q2,Elderly
206473477,20647347,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD",,,Y,,,,,25.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,7,F,,20220513.0,20220329,20220517,EXP,,NVSC2022PT069983,NOVARTIS,"Rodrigues S, Esteves VL. Cetoacidose euglicemia em doente idoso sob empagliflozina E metformina [Euglycemic ketoacidosis in an elderly patient on empagliflozin and metformin]. PORTUGUESE JOURNAL OF DIABETES. 2022;17(1):69-74",82.0,YR,,F,Y,,,20220517,,HP,PT,PT,2022,Q2,Elderly
206517232,20651723,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Serum ferritin decreased,,2022,Q2,2,F,20210101.0,20220330.0,20220330,20220413,EXP,,GB-AUROBINDO-AUR-APL-2022-010249,AUROBINDO,,63.0,YR,,M,Y,,,20220413,,MD,GB,GB,2022,Q2,Adult
206517232,20651723,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Chest discomfort,,2022,Q2,2,F,20210101.0,20220330.0,20220330,20220413,EXP,,GB-AUROBINDO-AUR-APL-2022-010249,AUROBINDO,,63.0,YR,,M,Y,,,20220413,,MD,GB,GB,2022,Q2,Adult
206517232,20651723,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood pressure decreased,,2022,Q2,2,F,20210101.0,20220330.0,20220330,20220413,EXP,,GB-AUROBINDO-AUR-APL-2022-010249,AUROBINDO,,63.0,YR,,M,Y,,,20220413,,MD,GB,GB,2022,Q2,Adult
206517232,20651723,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood creatine increased,,2022,Q2,2,F,20210101.0,20220330.0,20220330,20220413,EXP,,GB-AUROBINDO-AUR-APL-2022-010249,AUROBINDO,,63.0,YR,,M,Y,,,20220413,,MD,GB,GB,2022,Q2,Adult
206517232,20651723,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Troponin T increased,,2022,Q2,2,F,20210101.0,20220330.0,20220330,20220413,EXP,,GB-AUROBINDO-AUR-APL-2022-010249,AUROBINDO,,63.0,YR,,M,Y,,,20220413,,MD,GB,GB,2022,Q2,Adult
206517232,20651723,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Inappropriate schedule of product administration,,2022,Q2,2,F,20210101.0,20220330.0,20220330,20220413,EXP,,GB-AUROBINDO-AUR-APL-2022-010249,AUROBINDO,,63.0,YR,,M,Y,,,20220413,,MD,GB,GB,2022,Q2,Adult
206517232,20651723,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood bicarbonate decreased,,2022,Q2,2,F,20210101.0,20220330.0,20220330,20220413,EXP,,GB-AUROBINDO-AUR-APL-2022-010249,AUROBINDO,,63.0,YR,,M,Y,,,20220413,,MD,GB,GB,2022,Q2,Adult
206517232,20651723,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood lactic acid decreased,,2022,Q2,2,F,20210101.0,20220330.0,20220330,20220413,EXP,,GB-AUROBINDO-AUR-APL-2022-010249,AUROBINDO,,63.0,YR,,M,Y,,,20220413,,MD,GB,GB,2022,Q2,Adult
206517232,20651723,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Cardiac failure chronic,,2022,Q2,2,F,20210101.0,20220330.0,20220330,20220413,EXP,,GB-AUROBINDO-AUR-APL-2022-010249,AUROBINDO,,63.0,YR,,M,Y,,,20220413,,MD,GB,GB,2022,Q2,Adult
206517232,20651723,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Dyspnoea,,2022,Q2,2,F,20210101.0,20220330.0,20220330,20220413,EXP,,GB-AUROBINDO-AUR-APL-2022-010249,AUROBINDO,,63.0,YR,,M,Y,,,20220413,,MD,GB,GB,2022,Q2,Adult
206517232,20651723,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Condition aggravated,,2022,Q2,2,F,20210101.0,20220330.0,20220330,20220413,EXP,,GB-AUROBINDO-AUR-APL-2022-010249,AUROBINDO,,63.0,YR,,M,Y,,,20220413,,MD,GB,GB,2022,Q2,Adult
206517232,20651723,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Cardiac failure acute,,2022,Q2,2,F,20210101.0,20220330.0,20220330,20220413,EXP,,GB-AUROBINDO-AUR-APL-2022-010249,AUROBINDO,,63.0,YR,,M,Y,,,20220413,,MD,GB,GB,2022,Q2,Adult
206517232,20651723,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,N-terminal prohormone brain natriuretic peptide increased,,2022,Q2,2,F,20210101.0,20220330.0,20220330,20220413,EXP,,GB-AUROBINDO-AUR-APL-2022-010249,AUROBINDO,,63.0,YR,,M,Y,,,20220413,,MD,GB,GB,2022,Q2,Adult
206517232,20651723,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Wrong technique in product usage process,,2022,Q2,2,F,20210101.0,20220330.0,20220330,20220413,EXP,,GB-AUROBINDO-AUR-APL-2022-010249,AUROBINDO,,63.0,YR,,M,Y,,,20220413,,MD,GB,GB,2022,Q2,Adult
206517232,20651723,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Transferrin saturation decreased,,2022,Q2,2,F,20210101.0,20220330.0,20220330,20220413,EXP,,GB-AUROBINDO-AUR-APL-2022-010249,AUROBINDO,,63.0,YR,,M,Y,,,20220413,,MD,GB,GB,2022,Q2,Adult
206575104,20657510,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Cardiac failure,,2022,Q2,4,F,20220325.0,20220426.0,20220331,20220427,EXP,,NVSC2022CA071280,NOVARTIS,,59.0,YR,,M,Y,105.2,KG,20220427,,MD,CA,CA,2022,Q2,Adult
206575104,20657510,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Renal failure,,2022,Q2,4,F,20220325.0,20220426.0,20220331,20220427,EXP,,NVSC2022CA071280,NOVARTIS,,59.0,YR,,M,Y,105.2,KG,20220427,,MD,CA,CA,2022,Q2,Adult
206575104,20657510,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Cardiac failure,,2022,Q2,4,F,20220325.0,20220426.0,20220331,20220427,EXP,,NVSC2022CA071280,NOVARTIS,,59.0,YR,,M,Y,105.2,KG,20220427,,MD,CA,CA,2022,Q2,Adult
206575104,20657510,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Renal failure,,2022,Q2,4,F,20220325.0,20220426.0,20220331,20220427,EXP,,NVSC2022CA071280,NOVARTIS,,59.0,YR,,M,Y,105.2,KG,20220427,,MD,CA,CA,2022,Q2,Adult
206586202,20658620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Inappropriate schedule of product administration,,2022,Q2,2,F,20210101.0,20220404.0,20220331,20220416,EXP,,GB-MICRO LABS LIMITED-ML2022-01170,MICRO LABS,,63.0,YR,A,M,Y,,,20220416,,MD,GB,GB,2022,Q2,Adult
206586202,20658620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Transferrin saturation decreased,,2022,Q2,2,F,20210101.0,20220404.0,20220331,20220416,EXP,,GB-MICRO LABS LIMITED-ML2022-01170,MICRO LABS,,63.0,YR,A,M,Y,,,20220416,,MD,GB,GB,2022,Q2,Adult
206586202,20658620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Condition aggravated,,2022,Q2,2,F,20210101.0,20220404.0,20220331,20220416,EXP,,GB-MICRO LABS LIMITED-ML2022-01170,MICRO LABS,,63.0,YR,A,M,Y,,,20220416,,MD,GB,GB,2022,Q2,Adult
206586202,20658620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Blood bicarbonate decreased,,2022,Q2,2,F,20210101.0,20220404.0,20220331,20220416,EXP,,GB-MICRO LABS LIMITED-ML2022-01170,MICRO LABS,,63.0,YR,A,M,Y,,,20220416,,MD,GB,GB,2022,Q2,Adult
206586202,20658620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Blood lactic acid decreased,,2022,Q2,2,F,20210101.0,20220404.0,20220331,20220416,EXP,,GB-MICRO LABS LIMITED-ML2022-01170,MICRO LABS,,63.0,YR,A,M,Y,,,20220416,,MD,GB,GB,2022,Q2,Adult
206586202,20658620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Troponin T increased,,2022,Q2,2,F,20210101.0,20220404.0,20220331,20220416,EXP,,GB-MICRO LABS LIMITED-ML2022-01170,MICRO LABS,,63.0,YR,A,M,Y,,,20220416,,MD,GB,GB,2022,Q2,Adult
206586202,20658620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Dyspnoea,,2022,Q2,2,F,20210101.0,20220404.0,20220331,20220416,EXP,,GB-MICRO LABS LIMITED-ML2022-01170,MICRO LABS,,63.0,YR,A,M,Y,,,20220416,,MD,GB,GB,2022,Q2,Adult
206586202,20658620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Blood pressure decreased,,2022,Q2,2,F,20210101.0,20220404.0,20220331,20220416,EXP,,GB-MICRO LABS LIMITED-ML2022-01170,MICRO LABS,,63.0,YR,A,M,Y,,,20220416,,MD,GB,GB,2022,Q2,Adult
206586202,20658620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Cardiac failure chronic,,2022,Q2,2,F,20210101.0,20220404.0,20220331,20220416,EXP,,GB-MICRO LABS LIMITED-ML2022-01170,MICRO LABS,,63.0,YR,A,M,Y,,,20220416,,MD,GB,GB,2022,Q2,Adult
206586202,20658620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Blood creatine increased,,2022,Q2,2,F,20210101.0,20220404.0,20220331,20220416,EXP,,GB-MICRO LABS LIMITED-ML2022-01170,MICRO LABS,,63.0,YR,A,M,Y,,,20220416,,MD,GB,GB,2022,Q2,Adult
206586202,20658620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,N-terminal prohormone brain natriuretic peptide increased,,2022,Q2,2,F,20210101.0,20220404.0,20220331,20220416,EXP,,GB-MICRO LABS LIMITED-ML2022-01170,MICRO LABS,,63.0,YR,A,M,Y,,,20220416,,MD,GB,GB,2022,Q2,Adult
206586202,20658620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Cardiac failure acute,,2022,Q2,2,F,20210101.0,20220404.0,20220331,20220416,EXP,,GB-MICRO LABS LIMITED-ML2022-01170,MICRO LABS,,63.0,YR,A,M,Y,,,20220416,,MD,GB,GB,2022,Q2,Adult
206586202,20658620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Wrong technique in product usage process,,2022,Q2,2,F,20210101.0,20220404.0,20220331,20220416,EXP,,GB-MICRO LABS LIMITED-ML2022-01170,MICRO LABS,,63.0,YR,A,M,Y,,,20220416,,MD,GB,GB,2022,Q2,Adult
206586202,20658620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Serum ferritin decreased,,2022,Q2,2,F,20210101.0,20220404.0,20220331,20220416,EXP,,GB-MICRO LABS LIMITED-ML2022-01170,MICRO LABS,,63.0,YR,A,M,Y,,,20220416,,MD,GB,GB,2022,Q2,Adult
206586202,20658620,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Chest discomfort,,2022,Q2,2,F,20210101.0,20220404.0,20220331,20220416,EXP,,GB-MICRO LABS LIMITED-ML2022-01170,MICRO LABS,,63.0,YR,A,M,Y,,,20220416,,MD,GB,GB,2022,Q2,Adult
206598632,20659863,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,COVID-19,,2022,Q2,2,F,20180101.0,20220406.0,20220331,20220413,EXP,,SK-EMD Serono-9308686,EMD SERONO INC,,66.0,YR,E,M,Y,,,20220413,,MD,SK,,2022,Q2,Elderly
206598632,20659863,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Contraindicated product administered,,2022,Q2,2,F,20180101.0,20220406.0,20220331,20220413,EXP,,SK-EMD Serono-9308686,EMD SERONO INC,,66.0,YR,E,M,Y,,,20220413,,MD,SK,,2022,Q2,Elderly
206598632,20659863,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Mitral valve replacement,,2022,Q2,2,F,20180101.0,20220406.0,20220331,20220413,EXP,,SK-EMD Serono-9308686,EMD SERONO INC,,66.0,YR,E,M,Y,,,20220413,,MD,SK,,2022,Q2,Elderly
206598632,20659863,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Acute kidney injury,,2022,Q2,2,F,20180101.0,20220406.0,20220331,20220413,EXP,,SK-EMD Serono-9308686,EMD SERONO INC,,66.0,YR,E,M,Y,,,20220413,,MD,SK,,2022,Q2,Elderly
206598632,20659863,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Cardiac failure,,2022,Q2,2,F,20180101.0,20220406.0,20220331,20220413,EXP,,SK-EMD Serono-9308686,EMD SERONO INC,,66.0,YR,E,M,Y,,,20220413,,MD,SK,,2022,Q2,Elderly
206598632,20659863,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,COVID-19,,2022,Q2,2,F,20180101.0,20220406.0,20220331,20220413,EXP,,SK-EMD Serono-9308686,EMD SERONO INC,,66.0,YR,E,M,Y,,,20220413,,MD,SK,,2022,Q2,Elderly
206598632,20659863,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Contraindicated product administered,,2022,Q2,2,F,20180101.0,20220406.0,20220331,20220413,EXP,,SK-EMD Serono-9308686,EMD SERONO INC,,66.0,YR,E,M,Y,,,20220413,,MD,SK,,2022,Q2,Elderly
206598632,20659863,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Mitral valve replacement,,2022,Q2,2,F,20180101.0,20220406.0,20220331,20220413,EXP,,SK-EMD Serono-9308686,EMD SERONO INC,,66.0,YR,E,M,Y,,,20220413,,MD,SK,,2022,Q2,Elderly
206598632,20659863,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Acute kidney injury,,2022,Q2,2,F,20180101.0,20220406.0,20220331,20220413,EXP,,SK-EMD Serono-9308686,EMD SERONO INC,,66.0,YR,E,M,Y,,,20220413,,MD,SK,,2022,Q2,Elderly
206598632,20659863,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Cardiac failure,,2022,Q2,2,F,20180101.0,20220406.0,20220331,20220413,EXP,,SK-EMD Serono-9308686,EMD SERONO INC,,66.0,YR,E,M,Y,,,20220413,,MD,SK,,2022,Q2,Elderly
206598632,20659863,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,COVID-19,,2022,Q2,2,F,20180101.0,20220406.0,20220331,20220413,EXP,,SK-EMD Serono-9308686,EMD SERONO INC,,66.0,YR,E,M,Y,,,20220413,,MD,SK,,2022,Q2,Elderly
206598632,20659863,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Contraindicated product administered,,2022,Q2,2,F,20180101.0,20220406.0,20220331,20220413,EXP,,SK-EMD Serono-9308686,EMD SERONO INC,,66.0,YR,E,M,Y,,,20220413,,MD,SK,,2022,Q2,Elderly
206598632,20659863,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Mitral valve replacement,,2022,Q2,2,F,20180101.0,20220406.0,20220331,20220413,EXP,,SK-EMD Serono-9308686,EMD SERONO INC,,66.0,YR,E,M,Y,,,20220413,,MD,SK,,2022,Q2,Elderly
206598632,20659863,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Acute kidney injury,,2022,Q2,2,F,20180101.0,20220406.0,20220331,20220413,EXP,,SK-EMD Serono-9308686,EMD SERONO INC,,66.0,YR,E,M,Y,,,20220413,,MD,SK,,2022,Q2,Elderly
206598632,20659863,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Cardiac failure,,2022,Q2,2,F,20180101.0,20220406.0,20220331,20220413,EXP,,SK-EMD Serono-9308686,EMD SERONO INC,,66.0,YR,E,M,Y,,,20220413,,MD,SK,,2022,Q2,Elderly
206606162,20660616,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q2,Atrial fibrillation,,2022,Q2,2,F,20220309.0,20220406.0,20220331,20220420,EXP,,CO-BAYER-2022A046169,BAYER,,86.0,YR,E,M,Y,48.0,KG,20220420,,HP,CO,CO,2022,Q2,Elderly
206606162,20660616,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q2,Paraesthesia,,2022,Q2,2,F,20220309.0,20220406.0,20220331,20220420,EXP,,CO-BAYER-2022A046169,BAYER,,86.0,YR,E,M,Y,48.0,KG,20220420,,HP,CO,CO,2022,Q2,Elderly
206606162,20660616,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q2,Mobility decreased,,2022,Q2,2,F,20220309.0,20220406.0,20220331,20220420,EXP,,CO-BAYER-2022A046169,BAYER,,86.0,YR,E,M,Y,48.0,KG,20220420,,HP,CO,CO,2022,Q2,Elderly
206606162,20660616,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q2,Dyspnoea,,2022,Q2,2,F,20220309.0,20220406.0,20220331,20220420,EXP,,CO-BAYER-2022A046169,BAYER,,86.0,YR,E,M,Y,48.0,KG,20220420,,HP,CO,CO,2022,Q2,Elderly
206606162,20660616,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q2,Mouth haemorrhage,,2022,Q2,2,F,20220309.0,20220406.0,20220331,20220420,EXP,,CO-BAYER-2022A046169,BAYER,,86.0,YR,E,M,Y,48.0,KG,20220420,,HP,CO,CO,2022,Q2,Elderly
206606162,20660616,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q2,Contrast media reaction,,2022,Q2,2,F,20220309.0,20220406.0,20220331,20220420,EXP,,CO-BAYER-2022A046169,BAYER,,86.0,YR,E,M,Y,48.0,KG,20220420,,HP,CO,CO,2022,Q2,Elderly
206606162,20660616,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q2,Atrial flutter,,2022,Q2,2,F,20220309.0,20220406.0,20220331,20220420,EXP,,CO-BAYER-2022A046169,BAYER,,86.0,YR,E,M,Y,48.0,KG,20220420,,HP,CO,CO,2022,Q2,Elderly
206606162,20660616,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q2,Oedema mouth,,2022,Q2,2,F,20220309.0,20220406.0,20220331,20220420,EXP,,CO-BAYER-2022A046169,BAYER,,86.0,YR,E,M,Y,48.0,KG,20220420,,HP,CO,CO,2022,Q2,Elderly
206613981,20661398,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Acute myocardial infarction,,2022,Q2,1,I,20200615.0,20220322.0,20220401,20220401,PER,,GB-AMGEN-GBRSP2022051509,AMGEN,,46.0,YR,A,M,Y,104.0,KG,20220331,,HP,GB,GB,2022,Q2,Adult
206615452,20661545,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Acute respiratory distress syndrome,,2022,Q2,2,F,20220318.0,20220406.0,20220401,20220408,EXP,,JP-SA-2022SA104197,SANOFI AVENTIS,,70.0,YR,E,F,Y,59.0,KG,20220408,,MD,JP,JP,2022,Q2,Elderly
206615452,20661545,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Disseminated intravascular coagulation,,2022,Q2,2,F,20220318.0,20220406.0,20220401,20220408,EXP,,JP-SA-2022SA104197,SANOFI AVENTIS,,70.0,YR,E,F,Y,59.0,KG,20220408,,MD,JP,JP,2022,Q2,Elderly
206622611,20662261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Dyspnoea,,2022,Q2,1,I,,20220318.0,20220401,20220401,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331569,RANBAXY,,63.0,YR,,M,Y,,,20220401,,MD,GB,GB,2022,Q2,Adult
206622611,20662261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Transferrin saturation decreased,,2022,Q2,1,I,,20220318.0,20220401,20220401,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331569,RANBAXY,,63.0,YR,,M,Y,,,20220401,,MD,GB,GB,2022,Q2,Adult
206622611,20662261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Chest discomfort,,2022,Q2,1,I,,20220318.0,20220401,20220401,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331569,RANBAXY,,63.0,YR,,M,Y,,,20220401,,MD,GB,GB,2022,Q2,Adult
206622611,20662261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood creatine increased,,2022,Q2,1,I,,20220318.0,20220401,20220401,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331569,RANBAXY,,63.0,YR,,M,Y,,,20220401,,MD,GB,GB,2022,Q2,Adult
206622611,20662261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Cardiac failure acute,,2022,Q2,1,I,,20220318.0,20220401,20220401,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331569,RANBAXY,,63.0,YR,,M,Y,,,20220401,,MD,GB,GB,2022,Q2,Adult
206622611,20662261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,N-terminal prohormone brain natriuretic peptide increased,,2022,Q2,1,I,,20220318.0,20220401,20220401,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331569,RANBAXY,,63.0,YR,,M,Y,,,20220401,,MD,GB,GB,2022,Q2,Adult
206622611,20662261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Condition aggravated,,2022,Q2,1,I,,20220318.0,20220401,20220401,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331569,RANBAXY,,63.0,YR,,M,Y,,,20220401,,MD,GB,GB,2022,Q2,Adult
206622611,20662261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Serum ferritin decreased,,2022,Q2,1,I,,20220318.0,20220401,20220401,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331569,RANBAXY,,63.0,YR,,M,Y,,,20220401,,MD,GB,GB,2022,Q2,Adult
206622611,20662261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Troponin T increased,,2022,Q2,1,I,,20220318.0,20220401,20220401,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331569,RANBAXY,,63.0,YR,,M,Y,,,20220401,,MD,GB,GB,2022,Q2,Adult
206622611,20662261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood pressure decreased,,2022,Q2,1,I,,20220318.0,20220401,20220401,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331569,RANBAXY,,63.0,YR,,M,Y,,,20220401,,MD,GB,GB,2022,Q2,Adult
206622611,20662261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood bicarbonate decreased,,2022,Q2,1,I,,20220318.0,20220401,20220401,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331569,RANBAXY,,63.0,YR,,M,Y,,,20220401,,MD,GB,GB,2022,Q2,Adult
206622611,20662261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Inappropriate schedule of product administration,,2022,Q2,1,I,,20220318.0,20220401,20220401,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331569,RANBAXY,,63.0,YR,,M,Y,,,20220401,,MD,GB,GB,2022,Q2,Adult
206622611,20662261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Wrong technique in product usage process,,2022,Q2,1,I,,20220318.0,20220401,20220401,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331569,RANBAXY,,63.0,YR,,M,Y,,,20220401,,MD,GB,GB,2022,Q2,Adult
206622611,20662261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Cardiac failure chronic,,2022,Q2,1,I,,20220318.0,20220401,20220401,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331569,RANBAXY,,63.0,YR,,M,Y,,,20220401,,MD,GB,GB,2022,Q2,Adult
206622611,20662261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood lactic acid decreased,,2022,Q2,1,I,,20220318.0,20220401,20220401,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331569,RANBAXY,,63.0,YR,,M,Y,,,20220401,,MD,GB,GB,2022,Q2,Adult
206631802,20663180,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood creatinine increased,,2022,Q2,2,F,,20220326.0,20220401,20220406,EXP,,NVSC2022TH070140,NOVARTIS,,57.0,YR,,M,Y,,,20220406,,MD,TH,TH,2022,Q2,Adult
206631802,20663180,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Weight decreased,,2022,Q2,2,F,,20220326.0,20220401,20220406,EXP,,NVSC2022TH070140,NOVARTIS,,57.0,YR,,M,Y,,,20220406,,MD,TH,TH,2022,Q2,Adult
206631802,20663180,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Underdose,,2022,Q2,2,F,,20220326.0,20220401,20220406,EXP,,NVSC2022TH070140,NOVARTIS,,57.0,YR,,M,Y,,,20220406,,MD,TH,TH,2022,Q2,Adult
206631802,20663180,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Cardiac failure,,2022,Q2,2,F,,20220326.0,20220401,20220406,EXP,,NVSC2022TH070140,NOVARTIS,,57.0,YR,,M,Y,,,20220406,,MD,TH,TH,2022,Q2,Adult
206631802,20663180,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Creatinine renal clearance decreased,,2022,Q2,2,F,,20220326.0,20220401,20220406,EXP,,NVSC2022TH070140,NOVARTIS,,57.0,YR,,M,Y,,,20220406,,MD,TH,TH,2022,Q2,Adult
206631802,20663180,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Pneumonia,,2022,Q2,2,F,,20220326.0,20220401,20220406,EXP,,NVSC2022TH070140,NOVARTIS,,57.0,YR,,M,Y,,,20220406,,MD,TH,TH,2022,Q2,Adult
206631802,20663180,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Left ventricular dysfunction,,2022,Q2,2,F,,20220326.0,20220401,20220406,EXP,,NVSC2022TH070140,NOVARTIS,,57.0,YR,,M,Y,,,20220406,,MD,TH,TH,2022,Q2,Adult
206631802,20663180,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Dyspnoea exertional,,2022,Q2,2,F,,20220326.0,20220401,20220406,EXP,,NVSC2022TH070140,NOVARTIS,,57.0,YR,,M,Y,,,20220406,,MD,TH,TH,2022,Q2,Adult
206631802,20663180,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,N-terminal prohormone brain natriuretic peptide increased,,2022,Q2,2,F,,20220326.0,20220401,20220406,EXP,,NVSC2022TH070140,NOVARTIS,,57.0,YR,,M,Y,,,20220406,,MD,TH,TH,2022,Q2,Adult
206631802,20663180,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Ejection fraction decreased,,2022,Q2,2,F,,20220326.0,20220401,20220406,EXP,,NVSC2022TH070140,NOVARTIS,,57.0,YR,,M,Y,,,20220406,,MD,TH,TH,2022,Q2,Adult
206631802,20663180,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Mitral valve incompetence,,2022,Q2,2,F,,20220326.0,20220401,20220406,EXP,,NVSC2022TH070140,NOVARTIS,,57.0,YR,,M,Y,,,20220406,,MD,TH,TH,2022,Q2,Adult
206633554,20663355,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0,,,Y,,Asked But Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,4,F,20211231.0,20220520.0,20220401,20220523,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-162853",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20220523,,MD,DE,DE,2022,Q2,Elderly
206633554,20663355,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0,,,Y,,Asked But Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2022,Q2,Pneumonia aspiration,,2022,Q2,4,F,20211231.0,20220520.0,20220401,20220523,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-162853",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20220523,,MD,DE,DE,2022,Q2,Elderly
206633554,20663355,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0,,,Y,,Asked But Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2022,Q2,Hemiparesis,,2022,Q2,4,F,20211231.0,20220520.0,20220401,20220523,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-162853",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20220523,,MD,DE,DE,2022,Q2,Elderly
206633554,20663355,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0,,,Y,,Asked But Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2022,Q2,Cerebral infarction,,2022,Q2,4,F,20211231.0,20220520.0,20220401,20220523,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-162853",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20220523,,MD,DE,DE,2022,Q2,Elderly
206633554,20663355,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0,,,Y,,Asked But Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2022,Q2,Disease complication,,2022,Q2,4,F,20211231.0,20220520.0,20220401,20220523,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-162853",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20220523,,MD,DE,DE,2022,Q2,Elderly
206633554,20663355,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0,,,Y,,Asked But Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2022,Q2,Hyperventilation,,2022,Q2,4,F,20211231.0,20220520.0,20220401,20220523,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-162853",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20220523,,MD,DE,DE,2022,Q2,Elderly
206633554,20663355,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0,,,Y,,Asked But Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2022,Q2,Peripheral artery occlusion,,2022,Q2,4,F,20211231.0,20220520.0,20220401,20220523,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-162853",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20220523,,MD,DE,DE,2022,Q2,Elderly
206633554,20663355,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0,,,Y,,Asked But Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2022,Q2,Somnolence,,2022,Q2,4,F,20211231.0,20220520.0,20220401,20220523,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-162853",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20220523,,MD,DE,DE,2022,Q2,Elderly
206642632,20664263,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Pulmonary arterial hypertension,,2022,Q2,2,F,20200601.0,20220405.0,20220401,20220412,EXP,,JP-JNJFOC-A-CH2020-206915,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20220412,,MD,JP,JP,2022,Q2,Elderly
206642632,20664263,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Dizziness postural,,2022,Q2,2,F,20200601.0,20220405.0,20220401,20220412,EXP,,JP-JNJFOC-A-CH2020-206915,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20220412,,MD,JP,JP,2022,Q2,Elderly
206673151,20667315,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220330.0,20220404,20220404,EXP,,"AE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-162438",BOEHRINGER INGELHEIM,"Alhemeiri M, Alseddeeqi E. Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor. Case Reports in Endocrinology. 2022 Mar 02; 2022: 4101975-",45.0,YR,A,M,Y,115.0,KG,20220404,,HP,AE,AE,2022,Q2,Adult
206675452,20667545,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,C-reactive protein increased,,2022,Q2,2,F,,20220427.0,20220404,20220504,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20220504,,CN,CA,CA,2022,Q2,Adult
206675452,20667545,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Psoriasis,,2022,Q2,2,F,,20220427.0,20220404,20220504,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20220504,,CN,CA,CA,2022,Q2,Adult
206675452,20667545,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Condition aggravated,,2022,Q2,2,F,,20220427.0,20220404,20220504,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20220504,,CN,CA,CA,2022,Q2,Adult
206675452,20667545,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,2,F,,20220427.0,20220404,20220504,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20220504,,CN,CA,CA,2022,Q2,Adult
206675452,20667545,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Weight decreased,,2022,Q2,2,F,,20220427.0,20220404,20220504,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20220504,,CN,CA,CA,2022,Q2,Adult
206675452,20667545,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q2,Hepatotoxicity,,2022,Q2,2,F,,20220427.0,20220404,20220504,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20220504,,CN,CA,CA,2022,Q2,Adult
206683682,20668368,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Drug: empagliflozin 12.5/metformin 1g,,,Y,U,Asked But Unknown,,208658.0,,,Tablet,,2022,Q2,Septic shock,,2022,Q2,2,F,20220324.0,20220406.0,20220404,20220411,EXP,,"PH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163155",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,65.0,KG,20220411,,MD,PH,PH,2022,Q2,Adult
206683682,20668368,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Drug: empagliflozin 12.5/metformin 1g,,,Y,U,Asked But Unknown,,208658.0,,,Tablet,,2022,Q2,Pyelonephritis acute,,2022,Q2,2,F,20220324.0,20220406.0,20220404,20220411,EXP,,"PH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163155",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,65.0,KG,20220411,,MD,PH,PH,2022,Q2,Adult
206689861,20668986,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Renal tubular injury,,2022,Q2,1,I,20220217.0,20220330.0,20220404,20220404,EXP,,DE-GLAXOSMITHKLINE-DE2022057581,GLAXOSMITHKLINE,,63.0,YR,,M,Y,74.0,KG,20220404,,MD,DE,DE,2022,Q2,Adult
206689861,20668986,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Renal transplant failure,,2022,Q2,1,I,20220217.0,20220330.0,20220404,20220404,EXP,,DE-GLAXOSMITHKLINE-DE2022057581,GLAXOSMITHKLINE,,63.0,YR,,M,Y,74.0,KG,20220404,,MD,DE,DE,2022,Q2,Adult
206697341,20669734,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,Powder for infusion,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20220328.0,20220401.0,20220404,20220404,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163209",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,127.0,KG,20220404,,HP,GB,GB,2022,Q2,Elderly
206704401,20670440,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Decreased appetite,,2022,Q2,1,I,,20220329.0,20220404,20220404,EXP,,PT-AstraZeneca-2022A130050,ASTRAZENECA,"Rodrigues S, Esteves VL. P065 Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN.. Portuguese Journal of Diabetes. 2022;17(1):",82.0,YR,,F,Y,,,20220404,,MD,PT,,2022,Q2,Elderly
206704401,20670440,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220329.0,20220404,20220404,EXP,,PT-AstraZeneca-2022A130050,ASTRAZENECA,"Rodrigues S, Esteves VL. P065 Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN.. Portuguese Journal of Diabetes. 2022;17(1):",82.0,YR,,F,Y,,,20220404,,MD,PT,,2022,Q2,Elderly
206704401,20670440,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Oliguria,,2022,Q2,1,I,,20220329.0,20220404,20220404,EXP,,PT-AstraZeneca-2022A130050,ASTRAZENECA,"Rodrigues S, Esteves VL. P065 Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN.. Portuguese Journal of Diabetes. 2022;17(1):",82.0,YR,,F,Y,,,20220404,,MD,PT,,2022,Q2,Elderly
206704401,20670440,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Nausea,,2022,Q2,1,I,,20220329.0,20220404,20220404,EXP,,PT-AstraZeneca-2022A130050,ASTRAZENECA,"Rodrigues S, Esteves VL. P065 Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN.. Portuguese Journal of Diabetes. 2022;17(1):",82.0,YR,,F,Y,,,20220404,,MD,PT,,2022,Q2,Elderly
206704401,20670440,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Vomiting,,2022,Q2,1,I,,20220329.0,20220404,20220404,EXP,,PT-AstraZeneca-2022A130050,ASTRAZENECA,"Rodrigues S, Esteves VL. P065 Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN.. Portuguese Journal of Diabetes. 2022;17(1):",82.0,YR,,F,Y,,,20220404,,MD,PT,,2022,Q2,Elderly
206704401,20670440,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood lactic acid increased,,2022,Q2,1,I,,20220329.0,20220404,20220404,EXP,,PT-AstraZeneca-2022A130050,ASTRAZENECA,"Rodrigues S, Esteves VL. P065 Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN.. Portuguese Journal of Diabetes. 2022;17(1):",82.0,YR,,F,Y,,,20220404,,MD,PT,,2022,Q2,Elderly
206704401,20670440,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Pallor,,2022,Q2,1,I,,20220329.0,20220404,20220404,EXP,,PT-AstraZeneca-2022A130050,ASTRAZENECA,"Rodrigues S, Esteves VL. P065 Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN.. Portuguese Journal of Diabetes. 2022;17(1):",82.0,YR,,F,Y,,,20220404,,MD,PT,,2022,Q2,Elderly
206704401,20670440,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Dehydration,,2022,Q2,1,I,,20220329.0,20220404,20220404,EXP,,PT-AstraZeneca-2022A130050,ASTRAZENECA,"Rodrigues S, Esteves VL. P065 Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN.. Portuguese Journal of Diabetes. 2022;17(1):",82.0,YR,,F,Y,,,20220404,,MD,PT,,2022,Q2,Elderly
206704401,20670440,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Dysphagia,,2022,Q2,1,I,,20220329.0,20220404,20220404,EXP,,PT-AstraZeneca-2022A130050,ASTRAZENECA,"Rodrigues S, Esteves VL. P065 Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN.. Portuguese Journal of Diabetes. 2022;17(1):",82.0,YR,,F,Y,,,20220404,,MD,PT,,2022,Q2,Elderly
206704401,20670440,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Acetonaemia,,2022,Q2,1,I,,20220329.0,20220404,20220404,EXP,,PT-AstraZeneca-2022A130050,ASTRAZENECA,"Rodrigues S, Esteves VL. P065 Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN.. Portuguese Journal of Diabetes. 2022;17(1):",82.0,YR,,F,Y,,,20220404,,MD,PT,,2022,Q2,Elderly
206704401,20670440,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Dry skin,,2022,Q2,1,I,,20220329.0,20220404,20220404,EXP,,PT-AstraZeneca-2022A130050,ASTRAZENECA,"Rodrigues S, Esteves VL. P065 Clinical Cases EUGLYCEMIC KETOACIDOSIS IN ELDERLY PATIENT ON EMPAGLIFLOZIN AND METFORMIN.. Portuguese Journal of Diabetes. 2022;17(1):",82.0,YR,,F,Y,,,20220404,,MD,PT,,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Pyrexia,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Bundle branch block right,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Weight decreased,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Malaise,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Osteoarthritis,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Hyperglycaemia,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Chronic obstructive pulmonary disease,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Left ventricular hypertrophy,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Aortic dilatation,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Aerococcus urinae infection,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Chills,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Prosthetic valve endocarditis,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Right ventricular dysfunction,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Micturition urgency,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Aortic dilatation,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Aortic stenosis,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Fatigue,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Cardiac valve abscess,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Dyspnoea,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Pain,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Aortic valve incompetence,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206715031,20671503,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Pollakiuria,,2022,Q2,1,I,,20220401.0,20220404,20220404,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163103",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,114.0,KG,20220405,,MD,CA,CA,2022,Q2,Elderly
206731071,20673107,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Hepatic lesion,,2022,Q2,1,I,,20220329.0,20220405,20220405,EXP,,US-BAUSCH-BL-2022-008241,BAUSCH AND LOMB,,74.0,YR,,F,Y,,,20220405,,HP,US,US,2022,Q2,Elderly
206734331,20673433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MB EVERY DAY PO?,,,,,,,,12.5,MG,,QD,2022,Q2,Fall,,2022,Q2,1,I,20220214.0,,20220403,20220403,DIR,FDA-CDER-CTU-2022-25504,,FDA-CTU,,63.0,YR,,M,N,75.0,KG,20220318,N,PH,US,,2022,Q2,Adult
206734331,20673433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MB EVERY DAY PO?,,,,,,,,12.5,MG,,QD,2022,Q2,Acute kidney injury,,2022,Q2,1,I,20220214.0,,20220403,20220403,DIR,FDA-CDER-CTU-2022-25504,,FDA-CTU,,63.0,YR,,M,N,75.0,KG,20220318,N,PH,US,,2022,Q2,Adult
206734331,20673433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MB EVERY DAY PO?,,,,,,,,12.5,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20220214.0,,20220403,20220403,DIR,FDA-CDER-CTU-2022-25504,,FDA-CTU,,63.0,YR,,M,N,75.0,KG,20220318,N,PH,US,,2022,Q2,Adult
206734331,20673433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MB EVERY DAY PO?,,,,,,,,12.5,MG,,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220214.0,,20220403,20220403,DIR,FDA-CDER-CTU-2022-25504,,FDA-CTU,,63.0,YR,,M,N,75.0,KG,20220318,N,PH,US,,2022,Q2,Adult
206734331,20673433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MB EVERY DAY PO?,,,,,,,,12.5,MG,,QD,2022,Q2,Rhabdomyolysis,,2022,Q2,1,I,20220214.0,,20220403,20220403,DIR,FDA-CDER-CTU-2022-25504,,FDA-CTU,,63.0,YR,,M,N,75.0,KG,20220318,N,PH,US,,2022,Q2,Adult
206735021,20673502,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 0.5 TAB;?Frequency : Daily;?,,,,,,,,,,TABLET,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20211212.0,,20220403,20220403,DIR,FDA-CDER-CTU-2022-25529,,FDA-CTU,,59.0,YR,,M,N,95.71,KG,20220115,N,PH,US,,2022,Q2,Adult
206789791,20678979,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,10.0,MG,,,2022,Q2,Drug interaction,,2022,Q2,1,I,20220201.0,20220328.0,20220406,20220406,EXP,NO-NOMAADVRE-RELISSO-2022-Vkb58q,NO-Fresenius Kabi-FK202203939,FRESENIUS KABI,,69.0,YR,,F,Y,,,20220406,,HP,NL,,2022,Q2,Elderly
206789791,20678979,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,10.0,MG,,,2022,Q2,Thrombocytopenia,,2022,Q2,1,I,20220201.0,20220328.0,20220406,20220406,EXP,NO-NOMAADVRE-RELISSO-2022-Vkb58q,NO-Fresenius Kabi-FK202203939,FRESENIUS KABI,,69.0,YR,,F,Y,,,20220406,,HP,NL,,2022,Q2,Elderly
206797842,20679784,10,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,Dose unknown,,,,,,,,,,Tablets,,2022,Q2,Hepatic encephalopathy,,2022,Q2,2,F,20220307.0,20220426.0,20220406,20220504,PER,,JP-Eisai Medical Research-EC-2022-112116,EISAI,,81.0,YR,E,M,Y,54.0,KG,20220504,,PH,JP,JP,2022,Q2,Elderly
206798261,20679826,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,206111.0,,,,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20220318.0,20220405.0,20220406,20220406,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163381",BOEHRINGER INGELHEIM,,5.0,DEC,A,F,Y,,,20220406,,MD,AU,AU,2022,Q2,Child
206805071,20680507,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1/2 TAB EVERY DAY PO?,,,Y,,,,,,,,QD,2022,Q2,Blood glucose increased,,2022,Q2,1,I,20220323.0,,20220405,20220405,DIR,FDA-CDER-CTU-2022-25872,,FDA-CTU,,76.0,YR,,M,N,94.0,KG,20220330,N,PH,US,,2022,Q2,Elderly
206805071,20680507,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1/2 TAB EVERY DAY PO?,,,Y,,,,,,,,QD,2022,Q2,Blood creatinine increased,,2022,Q2,1,I,20220323.0,,20220405,20220405,DIR,FDA-CDER-CTU-2022-25872,,FDA-CTU,,76.0,YR,,M,N,94.0,KG,20220330,N,PH,US,,2022,Q2,Elderly
206805071,20680507,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1/2 TAB EVERY DAY PO?,,,Y,,,,,,,,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220323.0,,20220405,20220405,DIR,FDA-CDER-CTU-2022-25872,,FDA-CTU,,76.0,YR,,M,N,94.0,KG,20220330,N,PH,US,,2022,Q2,Elderly
206805071,20680507,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1/2 TAB EVERY DAY PO?,,,Y,,,,,,,,QD,2022,Q2,Malaise,,2022,Q2,1,I,20220323.0,,20220405,20220405,DIR,FDA-CDER-CTU-2022-25872,,FDA-CTU,,76.0,YR,,M,N,94.0,KG,20220330,N,PH,US,,2022,Q2,Elderly
206805071,20680507,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1/2 TAB EVERY DAY PO?,,,Y,,,,,,,,QD,2022,Q2,Blood urea increased,,2022,Q2,1,I,20220323.0,,20220405,20220405,DIR,FDA-CDER-CTU-2022-25872,,FDA-CTU,,76.0,YR,,M,N,94.0,KG,20220330,N,PH,US,,2022,Q2,Elderly
206805071,20680507,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1/2 TAB EVERY DAY PO?,,,Y,,,,,,,,QD,2022,Q2,Dehydration,,2022,Q2,1,I,20220323.0,,20220405,20220405,DIR,FDA-CDER-CTU-2022-25872,,FDA-CTU,,76.0,YR,,M,N,94.0,KG,20220330,N,PH,US,,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Ventricular extrasystoles,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Chest pain,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Ventricular tachycardia,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Ejection fraction decreased,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Acute myocardial infarction,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Rhonchi,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Lung disorder,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Pericardial fibrosis,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Coronary artery disease,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Atrial fibrillation,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Oedema peripheral,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Angina pectoris,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Dyspnoea at rest,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Rales,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Palpitations,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Cough,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206830272,20683027,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2022,Q2,Cardiac failure,,2022,Q2,2,F,20210101.0,20220406.0,20220407,20220414,EXP,,PL-BAUSCH-BL-2022-008187,BAUSCH AND LOMB,,72.0,YR,,M,Y,,,20220414,,MD,PL,PL,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Cough,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Obstructive airways disorder,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Respiratory symptom,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Wheezing,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Wrong technique in product usage process,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Condition aggravated,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Therapeutic product effect incomplete,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Productive cough,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Bronchial hyperreactivity,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Aspiration,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Asthma,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Lung disorder,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Pneumonia,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Pneumonitis,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Dyspnoea,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Left ventricular dysfunction,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Loss of personal independence in daily activities,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Sputum discoloured,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Rales,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Sleep disorder due to a general medical condition,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206832101,20683210,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10.0 Milligram 1 every 1 Days )",,,U,U,,,,10.0,MG,,QD,2022,Q2,Full blood count abnormal,,2022,Q2,1,I,,20220328.0,20220407,20220407,EXP,,CA-MYLANLABS-2022M1024266,MYLAN,,80.0,YR,,M,Y,,,20220407,,HP,CA,CA,2022,Q2,Elderly
206843861,20684386,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Thrombocytopenia,,2022,Q2,1,I,,20220401.0,20220407,20220407,EXP,,PT-009507513-2204PRT000452,MERCK,,57.0,YR,,F,Y,,,20220407,,MD,PT,PT,2022,Q2,Adult
206872541,20687254,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Pruritus,,2022,Q2,1,I,20220217.0,20220407.0,20220408,20220408,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164041",BOEHRINGER INGELHEIM,,44.0,YR,A,F,Y,,,20220408,,HP,SG,SG,2022,Q2,Adult
206872541,20687254,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Rash,,2022,Q2,1,I,20220217.0,20220407.0,20220408,20220408,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164041",BOEHRINGER INGELHEIM,,44.0,YR,A,F,Y,,,20220408,,HP,SG,SG,2022,Q2,Adult
206873041,20687304,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Dizziness,,2022,Q2,1,I,20220101.0,20220407.0,20220408,20220408,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164046",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220408,,HP,SG,SG,2022,Q2,Adult
206873571,20687357,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Rash,,2022,Q2,1,I,20220216.0,20220407.0,20220408,20220408,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164052",BOEHRINGER INGELHEIM,,54.0,YR,A,F,Y,,,20220408,,HP,SG,SG,2022,Q2,Adult
206873571,20687357,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Pruritus,,2022,Q2,1,I,20220216.0,20220407.0,20220408,20220408,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164052",BOEHRINGER INGELHEIM,,54.0,YR,A,F,Y,,,20220408,,HP,SG,SG,2022,Q2,Adult
206874791,20687479,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Dizziness,,2022,Q2,1,I,20210101.0,20220407.0,20220408,20220408,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164167",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220408,,HP,SG,SG,2022,Q2,Elderly
206875902,20687590,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2022,Q2,Diabetes mellitus inadequate control,,2022,Q2,2,F,,20220413.0,20220408,20220419,EXP,,SK-EMD Serono-9310644,EMD SERONO INC,,56.0,YR,A,M,Y,127.0,KG,20220419,,MD,SK,,2022,Q2,Adult
206884651,20688465,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Contraindicated product administered,,2022,Q2,1,I,20180101.0,20220404.0,20220408,20220408,PER,,SK-BAUSCH-BL-2022-008407,BAUSCH AND LOMB,,66.0,YR,,M,Y,,,20220408,,MD,SK,SK,2022,Q2,Elderly
206884651,20688465,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Acute kidney injury,,2022,Q2,1,I,20180101.0,20220404.0,20220408,20220408,PER,,SK-BAUSCH-BL-2022-008407,BAUSCH AND LOMB,,66.0,YR,,M,Y,,,20220408,,MD,SK,SK,2022,Q2,Elderly
206884651,20688465,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Cardiac failure,,2022,Q2,1,I,20180101.0,20220404.0,20220408,20220408,PER,,SK-BAUSCH-BL-2022-008407,BAUSCH AND LOMB,,66.0,YR,,M,Y,,,20220408,,MD,SK,SK,2022,Q2,Elderly
206884651,20688465,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,COVID-19,,2022,Q2,1,I,20180101.0,20220404.0,20220408,20220408,PER,,SK-BAUSCH-BL-2022-008407,BAUSCH AND LOMB,,66.0,YR,,M,Y,,,20220408,,MD,SK,SK,2022,Q2,Elderly
206884651,20688465,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Mitral valve replacement,,2022,Q2,1,I,20180101.0,20220404.0,20220408,20220408,PER,,SK-BAUSCH-BL-2022-008407,BAUSCH AND LOMB,,66.0,YR,,M,Y,,,20220408,,MD,SK,SK,2022,Q2,Elderly
206884651,20688465,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Contraindicated product administered,,2022,Q2,1,I,20180101.0,20220404.0,20220408,20220408,PER,,SK-BAUSCH-BL-2022-008407,BAUSCH AND LOMB,,66.0,YR,,M,Y,,,20220408,,MD,SK,SK,2022,Q2,Elderly
206884651,20688465,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Acute kidney injury,,2022,Q2,1,I,20180101.0,20220404.0,20220408,20220408,PER,,SK-BAUSCH-BL-2022-008407,BAUSCH AND LOMB,,66.0,YR,,M,Y,,,20220408,,MD,SK,SK,2022,Q2,Elderly
206884651,20688465,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Cardiac failure,,2022,Q2,1,I,20180101.0,20220404.0,20220408,20220408,PER,,SK-BAUSCH-BL-2022-008407,BAUSCH AND LOMB,,66.0,YR,,M,Y,,,20220408,,MD,SK,SK,2022,Q2,Elderly
206884651,20688465,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,COVID-19,,2022,Q2,1,I,20180101.0,20220404.0,20220408,20220408,PER,,SK-BAUSCH-BL-2022-008407,BAUSCH AND LOMB,,66.0,YR,,M,Y,,,20220408,,MD,SK,SK,2022,Q2,Elderly
206884651,20688465,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Mitral valve replacement,,2022,Q2,1,I,20180101.0,20220404.0,20220408,20220408,PER,,SK-BAUSCH-BL-2022-008407,BAUSCH AND LOMB,,66.0,YR,,M,Y,,,20220408,,MD,SK,SK,2022,Q2,Elderly
206884651,20688465,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Contraindicated product administered,,2022,Q2,1,I,20180101.0,20220404.0,20220408,20220408,PER,,SK-BAUSCH-BL-2022-008407,BAUSCH AND LOMB,,66.0,YR,,M,Y,,,20220408,,MD,SK,SK,2022,Q2,Elderly
206884651,20688465,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Acute kidney injury,,2022,Q2,1,I,20180101.0,20220404.0,20220408,20220408,PER,,SK-BAUSCH-BL-2022-008407,BAUSCH AND LOMB,,66.0,YR,,M,Y,,,20220408,,MD,SK,SK,2022,Q2,Elderly
206884651,20688465,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Cardiac failure,,2022,Q2,1,I,20180101.0,20220404.0,20220408,20220408,PER,,SK-BAUSCH-BL-2022-008407,BAUSCH AND LOMB,,66.0,YR,,M,Y,,,20220408,,MD,SK,SK,2022,Q2,Elderly
206884651,20688465,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,COVID-19,,2022,Q2,1,I,20180101.0,20220404.0,20220408,20220408,PER,,SK-BAUSCH-BL-2022-008407,BAUSCH AND LOMB,,66.0,YR,,M,Y,,,20220408,,MD,SK,SK,2022,Q2,Elderly
206884651,20688465,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2022,Q2,Mitral valve replacement,,2022,Q2,1,I,20180101.0,20220404.0,20220408,20220408,PER,,SK-BAUSCH-BL-2022-008407,BAUSCH AND LOMB,,66.0,YR,,M,Y,,,20220408,,MD,SK,SK,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Cardiac failure,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Coronary artery disease,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Ejection fraction decreased,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Dyspnoea at rest,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Palpitations,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Cough,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Pericardial fibrosis,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Chest pain,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Atrial fibrillation,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Ventricular tachycardia,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Angina pectoris,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Ventricular extrasystoles,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Oedema peripheral,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Lung disorder,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Rales,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Rhonchi,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206887091,20688709,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,D,,,,,,,,,2022,Q2,Acute myocardial infarction,,2022,Q2,1,I,20210101.0,20220401.0,20220408,20220408,EXP,PL-002147023-NVSC2022PL068408,PL-STRIDES ARCOLAB LIMITED-2022SP003357,STRIDES,,72.0,YR,,M,Y,,,20220408,,MD,PL,PL,2022,Q2,Elderly
206893875,20689387,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Subcutaneous,,,,,,,,,25.0,MG,Injection,,2022,Q2,Hepatic encephalopathy,,2022,Q2,5,F,20220331.0,20220506.0,20220408,20220512,PER,,CL-Eisai Medical Research-EC-2022-112519,EISAI,,58.0,YR,A,F,Y,86.3,KG,20220512,,MD,CL,,2022,Q2,Adult
206916881,20691688,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Pruritus,,2022,Q2,1,I,20220224.0,20220407.0,20220408,20220408,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164056",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20220408,,HP,SG,SG,2022,Q2,Elderly
206916881,20691688,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Polycythaemia vera,,2022,Q2,1,I,20220224.0,20220407.0,20220408,20220408,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164056",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20220408,,HP,SG,SG,2022,Q2,Elderly
206917772,20691777,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,U,,unknown,,,10.0,MG,Unknown,,2022,Q2,Neutropenic sepsis,,2022,Q2,2,F,20220120.0,20220426.0,20220408,20220512,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-AUT-20220106085,BRISTOL MYERS SQUIBB,,71.0,YR,E,M,Y,88.0,KG,20220512,,MD,AT,AT,2022,Q2,Elderly
206920781,20692078,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Rectal haemorrhage,,2022,Q2,1,I,,20220401.0,20220409,20220409,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20220409,,HP,CA,CA,2022,Q2,Adult
206920781,20692078,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220401.0,20220409,20220409,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20220409,,HP,CA,CA,2022,Q2,Adult
206920781,20692078,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Condition aggravated,,2022,Q2,1,I,,20220401.0,20220409,20220409,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20220409,,HP,CA,CA,2022,Q2,Adult
206925882,20692588,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, daily",,,,,,,,10.0,MG,,QD,2022,Q2,Ischaemic stroke,,2022,Q2,2,F,20220324.0,20220506.0,20220409,20220516,EXP,,PL-009507513-2204POL002624,MERCK,,45.0,YR,,M,Y,,,20220516,,MD,PL,PL,2022,Q2,Adult
206925882,20692588,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, daily",,,,,,,,10.0,MG,,QD,2022,Q2,Cerebral microangiopathy,,2022,Q2,2,F,20220324.0,20220506.0,20220409,20220516,EXP,,PL-009507513-2204POL002624,MERCK,,45.0,YR,,M,Y,,,20220516,,MD,PL,PL,2022,Q2,Adult
206925882,20692588,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, daily",,,,,,,,10.0,MG,,QD,2022,Q2,Central nervous system lesion,,2022,Q2,2,F,20220324.0,20220506.0,20220409,20220516,EXP,,PL-009507513-2204POL002624,MERCK,,45.0,YR,,M,Y,,,20220516,,MD,PL,PL,2022,Q2,Adult
206926071,20692607,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg per day,,,U,,,,,10.0,MG,Tablet,,2022,Q2,Malaise,,2022,Q2,1,I,,20220329.0,20220409,20220409,EXP,GB-MHRA-EYC 00268653,GB-TORRENT-00027805,TORRENT,,49.0,YR,A,M,Y,176.0,KG,20220409,,MD,GB,GB,2022,Q2,Adult
206926071,20692607,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg per day,,,U,,,,,10.0,MG,Tablet,,2022,Q2,Cardiomegaly,,2022,Q2,1,I,,20220329.0,20220409,20220409,EXP,GB-MHRA-EYC 00268653,GB-TORRENT-00027805,TORRENT,,49.0,YR,A,M,Y,176.0,KG,20220409,,MD,GB,GB,2022,Q2,Adult
206926071,20692607,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg per day,,,U,,,,,10.0,MG,Tablet,,2022,Q2,Toxicity to various agents,,2022,Q2,1,I,,20220329.0,20220409,20220409,EXP,GB-MHRA-EYC 00268653,GB-TORRENT-00027805,TORRENT,,49.0,YR,A,M,Y,176.0,KG,20220409,,MD,GB,GB,2022,Q2,Adult
206941831,20694183,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,N,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220218.0,20220408.0,20220411,20220411,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164314",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20220411,,MD,PT,PT,2022,Q2,Elderly
206943871,20694387,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2022,Q2,Malaise,,2022,Q2,1,I,,20220329.0,20220411,20220411,EXP,,GB-AUROBINDO-AUR-APL-2021-051848,AUROBINDO,,49.0,YR,,M,Y,176.0,KG,20220411,,MD,GB,GB,2022,Q2,Adult
206943871,20694387,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2022,Q2,Cardiomegaly,,2022,Q2,1,I,,20220329.0,20220411,20220411,EXP,,GB-AUROBINDO-AUR-APL-2021-051848,AUROBINDO,,49.0,YR,,M,Y,176.0,KG,20220411,,MD,GB,GB,2022,Q2,Adult
206943871,20694387,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2022,Q2,Toxicity to various agents,,2022,Q2,1,I,,20220329.0,20220411,20220411,EXP,,GB-AUROBINDO-AUR-APL-2021-051848,AUROBINDO,,49.0,YR,,M,Y,176.0,KG,20220411,,MD,GB,GB,2022,Q2,Adult
206944361,20694436,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,12.5,MG,,QD,2022,Q2,Large intestinal obstruction,,2022,Q2,1,I,,20220406.0,20220411,20220411,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163758",BOEHRINGER INGELHEIM,"Shah M, Pathrose E, Bhagwat N, Chandy D. ^The Bitter Truth of Sugar??Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series. Indian Journal of Critical Care Medicine. 2022; 26:1: 123-126.",71.0,YR,E,F,Y,,,20220411,,HP,IN,IN,2022,Q2,Elderly
206944361,20694436,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,12.5,MG,,QD,2022,Q2,Hydronephrosis,,2022,Q2,1,I,,20220406.0,20220411,20220411,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163758",BOEHRINGER INGELHEIM,"Shah M, Pathrose E, Bhagwat N, Chandy D. ^The Bitter Truth of Sugar??Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series. Indian Journal of Critical Care Medicine. 2022; 26:1: 123-126.",71.0,YR,E,F,Y,,,20220411,,HP,IN,IN,2022,Q2,Elderly
206944361,20694436,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,12.5,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220406.0,20220411,20220411,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163758",BOEHRINGER INGELHEIM,"Shah M, Pathrose E, Bhagwat N, Chandy D. ^The Bitter Truth of Sugar??Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series. Indian Journal of Critical Care Medicine. 2022; 26:1: 123-126.",71.0,YR,E,F,Y,,,20220411,,HP,IN,IN,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Lung disorder,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Coronary artery disease,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Ejection fraction decreased,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Oedema peripheral,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Rhonchi,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Cough,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Rales,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Chest pain,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Atrial fibrillation,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Ventricular tachycardia,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Ventricular extrasystoles,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Angina pectoris,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Cardiac failure,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Acute myocardial infarction,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Pericardial fibrosis,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Palpitations,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206947151,20694715,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, QD",,,,,,,,,,,,2022,Q2,Dyspnoea at rest,,2022,Q2,1,I,20210101.0,20220331.0,20220411,20220411,EXP,,PL-AstraZeneca-2022A133288,ASTRAZENECA,,72.0,YR,,M,Y,,,20220411,,MD,PL,,2022,Q2,Elderly
206958403,20695840,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,LAST ADMINISTRATION DATE BEFORE EVENT: 6 APR 2022,,,,,Unknown,,204629.0,10.0,MG,Tablet,,2022,Q2,Pancreatitis,,2022,Q2,3,F,20220406.0,20220420.0,20220411,20220421,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164476",BOEHRINGER INGELHEIM,,89.0,YR,E,F,Y,68.0,KG,20220421,,MD,DE,DE,2022,Q2,Elderly
206978941,20697894,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Viral disease carrier,,2022,Q2,1,I,,20220405.0,20220412,20220412,EXP,,"BR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163562",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20220412,,CN,BR,BR,2022,Q2,Elderly
206978941,20697894,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Decreased appetite,,2022,Q2,1,I,,20220405.0,20220412,20220412,EXP,,"BR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163562",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20220412,,CN,BR,BR,2022,Q2,Elderly
206978941,20697894,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220405.0,20220412,20220412,EXP,,"BR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163562",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20220412,,CN,BR,BR,2022,Q2,Elderly
206978941,20697894,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Hypotension,,2022,Q2,1,I,,20220405.0,20220412,20220412,EXP,,"BR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163562",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20220412,,CN,BR,BR,2022,Q2,Elderly
206978941,20697894,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Abdominal pain,,2022,Q2,1,I,,20220405.0,20220412,20220412,EXP,,"BR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163562",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20220412,,CN,BR,BR,2022,Q2,Elderly
206978941,20697894,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,General physical health deterioration,,2022,Q2,1,I,,20220405.0,20220412,20220412,EXP,,"BR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163562",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20220412,,CN,BR,BR,2022,Q2,Elderly
206978941,20697894,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Somnolence,,2022,Q2,1,I,,20220405.0,20220412,20220412,EXP,,"BR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163562",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20220412,,CN,BR,BR,2022,Q2,Elderly
206978941,20697894,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Blood ketone body,,2022,Q2,1,I,,20220405.0,20220412,20220412,EXP,,"BR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163562",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20220412,,CN,BR,BR,2022,Q2,Elderly
206978941,20697894,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Vomiting,,2022,Q2,1,I,,20220405.0,20220412,20220412,EXP,,"BR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163562",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20220412,,CN,BR,BR,2022,Q2,Elderly
206992561,20699256,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Dizziness,,2022,Q2,1,I,20220331.0,20220412.0,20220412,20220412,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164778",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,,,20220412,,HP,SG,SG,2022,Q2,Elderly
206996431,20699643,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1000 Milligram Daily;,,,,,,,,1000.0,MG,,,2022,Q2,Multiple organ dysfunction syndrome,,2022,Q2,1,I,,20220328.0,20220412,20220412,EXP,,PT-TEVA-2022-PT-2023770,TEVA,Fontes J. Cetoacidose diabetica euglicemica por iSGLT2 - uma entidade potencialmente fatal. Revista Portuguesa de Medicina Interna. 567-567.,73.0,YR,E,M,Y,,,20220412,,MD,PT,PT,2022,Q2,Elderly
206996431,20699643,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1000 Milligram Daily;,,,,,,,,1000.0,MG,,,2022,Q2,Acute abdomen,,2022,Q2,1,I,,20220328.0,20220412,20220412,EXP,,PT-TEVA-2022-PT-2023770,TEVA,Fontes J. Cetoacidose diabetica euglicemica por iSGLT2 - uma entidade potencialmente fatal. Revista Portuguesa de Medicina Interna. 567-567.,73.0,YR,E,M,Y,,,20220412,,MD,PT,PT,2022,Q2,Elderly
206996431,20699643,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1000 Milligram Daily;,,,,,,,,1000.0,MG,,,2022,Q2,Shock,,2022,Q2,1,I,,20220328.0,20220412,20220412,EXP,,PT-TEVA-2022-PT-2023770,TEVA,Fontes J. Cetoacidose diabetica euglicemica por iSGLT2 - uma entidade potencialmente fatal. Revista Portuguesa de Medicina Interna. 567-567.,73.0,YR,E,M,Y,,,20220412,,MD,PT,PT,2022,Q2,Elderly
206996431,20699643,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1000 Milligram Daily;,,,,,,,,1000.0,MG,,,2022,Q2,Renal disorder,,2022,Q2,1,I,,20220328.0,20220412,20220412,EXP,,PT-TEVA-2022-PT-2023770,TEVA,Fontes J. Cetoacidose diabetica euglicemica por iSGLT2 - uma entidade potencialmente fatal. Revista Portuguesa de Medicina Interna. 567-567.,73.0,YR,E,M,Y,,,20220412,,MD,PT,PT,2022,Q2,Elderly
206996431,20699643,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1000 Milligram Daily;,,,,,,,,1000.0,MG,,,2022,Q2,Renal artery thrombosis,,2022,Q2,1,I,,20220328.0,20220412,20220412,EXP,,PT-TEVA-2022-PT-2023770,TEVA,Fontes J. Cetoacidose diabetica euglicemica por iSGLT2 - uma entidade potencialmente fatal. Revista Portuguesa de Medicina Interna. 567-567.,73.0,YR,E,M,Y,,,20220412,,MD,PT,PT,2022,Q2,Elderly
206996431,20699643,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1000 Milligram Daily;,,,,,,,,1000.0,MG,,,2022,Q2,Aortic thrombosis,,2022,Q2,1,I,,20220328.0,20220412,20220412,EXP,,PT-TEVA-2022-PT-2023770,TEVA,Fontes J. Cetoacidose diabetica euglicemica por iSGLT2 - uma entidade potencialmente fatal. Revista Portuguesa de Medicina Interna. 567-567.,73.0,YR,E,M,Y,,,20220412,,MD,PT,PT,2022,Q2,Elderly
206996431,20699643,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1000 Milligram Daily;,,,,,,,,1000.0,MG,,,2022,Q2,Mesenteric artery thrombosis,,2022,Q2,1,I,,20220328.0,20220412,20220412,EXP,,PT-TEVA-2022-PT-2023770,TEVA,Fontes J. Cetoacidose diabetica euglicemica por iSGLT2 - uma entidade potencialmente fatal. Revista Portuguesa de Medicina Interna. 567-567.,73.0,YR,E,M,Y,,,20220412,,MD,PT,PT,2022,Q2,Elderly
206996431,20699643,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1000 Milligram Daily;,,,,,,,,1000.0,MG,,,2022,Q2,Metabolic acidosis,,2022,Q2,1,I,,20220328.0,20220412,20220412,EXP,,PT-TEVA-2022-PT-2023770,TEVA,Fontes J. Cetoacidose diabetica euglicemica por iSGLT2 - uma entidade potencialmente fatal. Revista Portuguesa de Medicina Interna. 567-567.,73.0,YR,E,M,Y,,,20220412,,MD,PT,PT,2022,Q2,Elderly
206996431,20699643,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1000 Milligram Daily;,,,,,,,,1000.0,MG,,,2022,Q2,Death,,2022,Q2,1,I,,20220328.0,20220412,20220412,EXP,,PT-TEVA-2022-PT-2023770,TEVA,Fontes J. Cetoacidose diabetica euglicemica por iSGLT2 - uma entidade potencialmente fatal. Revista Portuguesa de Medicina Interna. 567-567.,73.0,YR,E,M,Y,,,20220412,,MD,PT,PT,2022,Q2,Elderly
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Pain in extremity,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Joint swelling,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Pain,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Musculoskeletal stiffness,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Joint effusion,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Abdominal discomfort,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Psoriasis,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Arthropathy,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Arthralgia,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Paraesthesia,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Synovitis,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Joint range of motion decreased,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Mobility decreased,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Enthesopathy,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Weight increased,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Spinal pain,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206996512,20699651,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Psoriatic arthropathy,,2022,Q2,2,F,,20220616.0,20220412,20220625,EXP,CA-MHPD-E2B_03840580,CA-Accord-260293,ACCORD,,60.0,YR,,M,Y,,,20220625,,HP,CA,CA,2022,Q2,Adult
206997181,20699718,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220407.0,20220412,20220412,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164113",BOEHRINGER INGELHEIM,"Lehenbauer K, Tsangaris A, Bart B. EUGLYCEMIC DKA IN THE SETTING OF SGLT2 INHIBITOR THERAPY DEMANDS CARDIOLOGISTS?  AWARENESS AND REVISION OF STANDARDIZED TREATMENT PROTOCOLS. Journal of the American College of Cardiology. 2022; 79(2871):",52.0,YR,A,M,Y,,,20220412,,HP,US,US,2022,Q2,Adult
206997181,20699718,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Acute myocardial infarction,,2022,Q2,1,I,,20220407.0,20220412,20220412,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164113",BOEHRINGER INGELHEIM,"Lehenbauer K, Tsangaris A, Bart B. EUGLYCEMIC DKA IN THE SETTING OF SGLT2 INHIBITOR THERAPY DEMANDS CARDIOLOGISTS?  AWARENESS AND REVISION OF STANDARDIZED TREATMENT PROTOCOLS. Journal of the American College of Cardiology. 2022; 79(2871):",52.0,YR,A,M,Y,,,20220412,,HP,US,US,2022,Q2,Adult
207001351,20700135,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Cardiac failure,,2022,Q2,1,I,20180101.0,20220405.0,20220412,20220412,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163417",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220412,,MD,SK,SK,2022,Q2,Elderly
207001351,20700135,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Mitral valve replacement,,2022,Q2,1,I,20180101.0,20220405.0,20220412,20220412,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163417",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220412,,MD,SK,SK,2022,Q2,Elderly
207001351,20700135,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Contraindicated product administered,,2022,Q2,1,I,20180101.0,20220405.0,20220412,20220412,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163417",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220412,,MD,SK,SK,2022,Q2,Elderly
207001351,20700135,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Acute kidney injury,,2022,Q2,1,I,20180101.0,20220405.0,20220412,20220412,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163417",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220412,,MD,SK,SK,2022,Q2,Elderly
207001351,20700135,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,COVID-19,,2022,Q2,1,I,20180101.0,20220405.0,20220412,20220412,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163417",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220412,,MD,SK,SK,2022,Q2,Elderly
207001351,20700135,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Cardiac failure,,2022,Q2,1,I,20180101.0,20220405.0,20220412,20220412,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163417",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220412,,MD,SK,SK,2022,Q2,Elderly
207001351,20700135,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Mitral valve replacement,,2022,Q2,1,I,20180101.0,20220405.0,20220412,20220412,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163417",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220412,,MD,SK,SK,2022,Q2,Elderly
207001351,20700135,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Contraindicated product administered,,2022,Q2,1,I,20180101.0,20220405.0,20220412,20220412,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163417",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220412,,MD,SK,SK,2022,Q2,Elderly
207001351,20700135,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Acute kidney injury,,2022,Q2,1,I,20180101.0,20220405.0,20220412,20220412,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163417",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220412,,MD,SK,SK,2022,Q2,Elderly
207001351,20700135,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,COVID-19,,2022,Q2,1,I,20180101.0,20220405.0,20220412,20220412,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163417",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220412,,MD,SK,SK,2022,Q2,Elderly
207001351,20700135,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Cardiac failure,,2022,Q2,1,I,20180101.0,20220405.0,20220412,20220412,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163417",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220412,,MD,SK,SK,2022,Q2,Elderly
207001351,20700135,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Mitral valve replacement,,2022,Q2,1,I,20180101.0,20220405.0,20220412,20220412,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163417",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220412,,MD,SK,SK,2022,Q2,Elderly
207001351,20700135,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Contraindicated product administered,,2022,Q2,1,I,20180101.0,20220405.0,20220412,20220412,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163417",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220412,,MD,SK,SK,2022,Q2,Elderly
207001351,20700135,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Acute kidney injury,,2022,Q2,1,I,20180101.0,20220405.0,20220412,20220412,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163417",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220412,,MD,SK,SK,2022,Q2,Elderly
207001351,20700135,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,COVID-19,,2022,Q2,1,I,20180101.0,20220405.0,20220412,20220412,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163417",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220412,,MD,SK,SK,2022,Q2,Elderly
207003634,20700363,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,Tablet,,2022,Q2,Acute kidney injury,,2022,Q2,4,F,20210820.0,20220512.0,20220412,20220513,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-127601",BOEHRINGER INGELHEIM,,76.0,YR,E,F,Y,60.0,KG,20220513,,MD,DE,DE,2022,Q2,Elderly
207003634,20700363,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,Tablet,,2022,Q2,Acute kidney injury,,2022,Q2,4,F,20210820.0,20220512.0,20220412,20220513,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-127601",BOEHRINGER INGELHEIM,,76.0,YR,E,F,Y,60.0,KG,20220513,,MD,DE,DE,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Ejection fraction decreased,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Chest pain,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Ventricular tachycardia,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Oedema peripheral,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Dyspnoea at rest,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Acute myocardial infarction,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Palpitations,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Rhonchi,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Coronary artery disease,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Angina pectoris,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Pericardial fibrosis,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Cardiac failure,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Lung disorder,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Rales,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Ventricular extrasystoles,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Atrial fibrillation,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207010971,20701097,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,,,,,,,QD,2022,Q2,Cough,,2022,Q2,1,I,20210101.0,20220401.0,20220412,20220412,EXP,,PL-PFIZER INC-202200523617,PFIZER,,72.0,YR,,M,Y,,,20220412,,MD,PL,PL,2022,Q2,Elderly
207013461,20701346,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,empagliflozin 25 mg + linagliptin 5 mg,,,Y,U,Unknown,,206073.0,,,,QD,2022,Q2,Coronary artery bypass,,2022,Q2,1,I,,20220406.0,20220412,20220412,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163757",BOEHRINGER INGELHEIM,"Shah M, Pathrose E, Bhagwat N, Chandy D. ?The Bitter Truth of Sugar??Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series. Indian Journal of Critical Care Medicine. 2022; 26 (1): 123-126.",74.0,YR,E,M,Y,,,20220412,,HP,IN,IN,2022,Q2,Elderly
207013461,20701346,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,empagliflozin 25 mg + linagliptin 5 mg,,,Y,U,Unknown,,206073.0,,,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220406.0,20220412,20220412,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163757",BOEHRINGER INGELHEIM,"Shah M, Pathrose E, Bhagwat N, Chandy D. ?The Bitter Truth of Sugar??Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series. Indian Journal of Critical Care Medicine. 2022; 26 (1): 123-126.",74.0,YR,E,M,Y,,,20220412,,HP,IN,IN,2022,Q2,Elderly
207020771,20702077,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, qd",,,,,Unknown,,,,,Tablet,QD,2022,Q2,Palpitations,,2022,Q2,1,I,20211209.0,20220408.0,20220412,20220412,EXP,,GB-TAKEDA-2022TEU002513,TAKEDA,,66.0,YR,,F,Y,61.0,KG,20220412,,HP,GB,GB,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Cardiac failure,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Cough,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Ejection fraction decreased,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Coronary artery disease,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Acute myocardial infarction,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Atrial fibrillation,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Angina pectoris,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Lung disorder,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Ventricular tachycardia,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Oedema peripheral,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Palpitations,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Chest pain,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Ventricular extrasystoles,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Rhonchi,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Pericardial fibrosis,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Rales,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207033171,20703317,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, Once a Day",,,U,,,,,,,,QD,2022,Q2,Dyspnoea at rest,,2022,Q2,1,I,20210101.0,20220330.0,20220413,20220413,EXP,,PL-AUROBINDO-AUR-APL-2022-011800,AUROBINDO,,72.0,YR,,M,Y,,,20220413,,MD,PL,PL,2022,Q2,Elderly
207034921,20703492,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Subdural haemorrhage,,2022,Q2,1,I,,20220406.0,20220413,20220413,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163756",BOEHRINGER INGELHEIM,"Shah M, Pathrose E, Bhagwat N, Chandy D. ?The Bitter Truth of Sugar??Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series. Indian Journal of Critical Care Medicine. 2022; 26 (1): 123-126.",66.0,YR,E,M,Y,,,20220413,,HP,IN,IN,2022,Q2,Elderly
207034921,20703492,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Starvation,,2022,Q2,1,I,,20220406.0,20220413,20220413,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163756",BOEHRINGER INGELHEIM,"Shah M, Pathrose E, Bhagwat N, Chandy D. ?The Bitter Truth of Sugar??Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series. Indian Journal of Critical Care Medicine. 2022; 26 (1): 123-126.",66.0,YR,E,M,Y,,,20220413,,HP,IN,IN,2022,Q2,Elderly
207034921,20703492,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Meningitis aseptic,,2022,Q2,1,I,,20220406.0,20220413,20220413,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163756",BOEHRINGER INGELHEIM,"Shah M, Pathrose E, Bhagwat N, Chandy D. ?The Bitter Truth of Sugar??Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series. Indian Journal of Critical Care Medicine. 2022; 26 (1): 123-126.",66.0,YR,E,M,Y,,,20220413,,HP,IN,IN,2022,Q2,Elderly
207034921,20703492,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Subarachnoid haemorrhage,,2022,Q2,1,I,,20220406.0,20220413,20220413,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163756",BOEHRINGER INGELHEIM,"Shah M, Pathrose E, Bhagwat N, Chandy D. ?The Bitter Truth of Sugar??Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series. Indian Journal of Critical Care Medicine. 2022; 26 (1): 123-126.",66.0,YR,E,M,Y,,,20220413,,HP,IN,IN,2022,Q2,Elderly
207034921,20703492,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Skull fractured base,,2022,Q2,1,I,,20220406.0,20220413,20220413,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163756",BOEHRINGER INGELHEIM,"Shah M, Pathrose E, Bhagwat N, Chandy D. ?The Bitter Truth of Sugar??Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series. Indian Journal of Critical Care Medicine. 2022; 26 (1): 123-126.",66.0,YR,E,M,Y,,,20220413,,HP,IN,IN,2022,Q2,Elderly
207034921,20703492,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220406.0,20220413,20220413,EXP,,"IN-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-163756",BOEHRINGER INGELHEIM,"Shah M, Pathrose E, Bhagwat N, Chandy D. ?The Bitter Truth of Sugar??Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series. Indian Journal of Critical Care Medicine. 2022; 26 (1): 123-126.",66.0,YR,E,M,Y,,,20220413,,HP,IN,IN,2022,Q2,Elderly
207037071,20703707,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2022,Q2,Vomiting,,2022,Q2,1,I,,20220401.0,20220413,20220413,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-332385,RANBAXY,"Yasuma T, Okano Y, Tanaka S, Nishihama K, Eguchi K, Inoue C, et al. Sodium-glucose cotransporter- 2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report. World J Clin Cases. 2021;9(13):3163-3169",43.0,YR,,F,Y,58.6,KG,20220413,,HP,JP,JP,2022,Q2,Adult
207037071,20703707,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2022,Q2,Fatigue,,2022,Q2,1,I,,20220401.0,20220413,20220413,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-332385,RANBAXY,"Yasuma T, Okano Y, Tanaka S, Nishihama K, Eguchi K, Inoue C, et al. Sodium-glucose cotransporter- 2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report. World J Clin Cases. 2021;9(13):3163-3169",43.0,YR,,F,Y,58.6,KG,20220413,,HP,JP,JP,2022,Q2,Adult
207037071,20703707,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2022,Q2,Dry mouth,,2022,Q2,1,I,,20220401.0,20220413,20220413,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-332385,RANBAXY,"Yasuma T, Okano Y, Tanaka S, Nishihama K, Eguchi K, Inoue C, et al. Sodium-glucose cotransporter- 2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report. World J Clin Cases. 2021;9(13):3163-3169",43.0,YR,,F,Y,58.6,KG,20220413,,HP,JP,JP,2022,Q2,Adult
207037071,20703707,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220401.0,20220413,20220413,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-332385,RANBAXY,"Yasuma T, Okano Y, Tanaka S, Nishihama K, Eguchi K, Inoue C, et al. Sodium-glucose cotransporter- 2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report. World J Clin Cases. 2021;9(13):3163-3169",43.0,YR,,F,Y,58.6,KG,20220413,,HP,JP,JP,2022,Q2,Adult
207046551,20704655,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,QD,2022,Q2,Palpitations,,2022,Q2,1,I,20211209.0,20220403.0,20220413,20220413,EXP,GB-MHRA-ADR 26779708,GB-Accord-260353,ACCORD,,66.0,YR,,F,Y,61.0,KG,20220413,,HP,GB,GB,2022,Q2,Elderly
207049621,20704962,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 dosage form per day,,,U,,,,,,,Tablet,,2022,Q2,Palpitations,,2022,Q2,1,I,20211209.0,20220403.0,20220413,20220413,EXP,GB-MHRA-TPP14496314C312473YC1639054424331,GB-TORRENT-00027848,TORRENT,,66.0,YR,E,F,Y,61.0,KG,20220413,,HP,GB,GB,2022,Q2,Elderly
207078912,20707891,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,2,F,20220412.0,20220415.0,20220414,20220418,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165275",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,,,20220418,,PH,JP,JP,2022,Q2,Adult
207090141,20709014,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"(12.5 mg/1 g) 1 dosage form, bid",,,,,,,,,,Tablet,BID,2022,Q2,Bronchospasm,,2022,Q2,1,I,,20220404.0,20220414,20220414,PER,,AU-LUPIN PHARMACEUTICALS INC.-2022-05219,LUPIN,"Gan J, Rheault H, Wong YW. Who ^nose^, is it the angiotensin receptor neprilysin inhibitor?: A case series of persistent nasal pruritus in heart failure patients receiving sacubitril/valsartan. European Heart Journal. 2021;5(12):1-7",73.0,YR,,F,Y,,,20220414,,HP,AU,AU,2022,Q2,Elderly
207090141,20709014,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"(12.5 mg/1 g) 1 dosage form, bid",,,,,,,,,,Tablet,BID,2022,Q2,Visual impairment,,2022,Q2,1,I,,20220404.0,20220414,20220414,PER,,AU-LUPIN PHARMACEUTICALS INC.-2022-05219,LUPIN,"Gan J, Rheault H, Wong YW. Who ^nose^, is it the angiotensin receptor neprilysin inhibitor?: A case series of persistent nasal pruritus in heart failure patients receiving sacubitril/valsartan. European Heart Journal. 2021;5(12):1-7",73.0,YR,,F,Y,,,20220414,,HP,AU,AU,2022,Q2,Elderly
207098561,20709856,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Diabetes mellitus inadequate control,,2022,Q2,1,I,,20220412.0,20220414,20220414,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164806",BOEHRINGER INGELHEIM,,56.0,YR,A,M,Y,127.0,KG,20220414,,MD,SK,SK,2022,Q2,Adult
207117912,20711791,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,Film-coated tablet,QD,2022,Q2,Dialysis device insertion,,2022,Q2,2,F,20211112.0,20220530.0,20220414,20220601,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164828",BOEHRINGER INGELHEIM,,45.0,YR,A,M,Y,,,20220601,,MD,DE,DE,2022,Q2,Adult
207117912,20711791,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,Film-coated tablet,QD,2022,Q2,Glomerulonephritis membranous,,2022,Q2,2,F,20211112.0,20220530.0,20220414,20220601,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164828",BOEHRINGER INGELHEIM,,45.0,YR,A,M,Y,,,20220601,,MD,DE,DE,2022,Q2,Adult
207119852,20711985,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,2,F,20220403.0,20220414.0,20220414,20220419,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165410",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220419,,HP,GB,GB,2022,Q2,Adult
207121162,20712116,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2022,Q2,Lacunar infarction,,2022,Q2,2,F,20220301.0,20220603.0,20220414,20220606,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165526",BOEHRINGER INGELHEIM,,54.0,YR,A,F,Y,58.7,KG,20220606,,MD,JP,JP,2022,Q2,Adult
207144501,20714450,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,,2022,Q2,Diabetes mellitus inadequate control,,2022,Q2,1,I,,20220411.0,20220415,20220415,EXP,,SK-BAUSCH-BL-2022-009024,BAUSCH AND LOMB,,56.0,YR,,M,Y,127.0,KG,20220415,,MD,SK,SK,2022,Q2,Adult
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Discouragement,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Vertigo,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Panic disorder,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Neuropathy peripheral,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Weight decreased,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Fall,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Depression,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Ear disorder,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Dizziness,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Pain,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Tension headache,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Nervous system disorder,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Sacral pain,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Wrong product administered,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Perineal injury,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Anxiety,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Dyspepsia,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Muscle rigidity,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Visual impairment,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Urinary tract infection,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Vaginal haemorrhage,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Oedema peripheral,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Red blood cell sedimentation rate increased,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207146062,20714606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q2,Decreased appetite,,2022,Q2,2,F,20201216.0,20220525.0,20220415,20220604,PER,,CO-AMGEN-COLSL2021015933,AMGEN,,67.0,YR,E,F,Y,61.0,KG,20220604,,CN,CO,CO,2022,Q2,Elderly
207168051,20716805,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Invasive ductal breast carcinoma,,2022,Q2,1,I,20220223.0,20220407.0,20220416,20220416,PER,,GB-AMGEN-GBRSP2022061889,AMGEN,,61.0,YR,A,F,Y,93.0,KG,20220416,,HP,GB,GB,2022,Q2,Adult
207169871,20716987,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Acute myocardial infarction,,2022,Q2,1,I,20210516.0,20220407.0,20220417,20220417,PER,,GB-AMGEN-GBRSP2022063065,AMGEN,,61.0,YR,A,F,Y,93.0,KG,20220416,,HP,GB,GB,2022,Q2,Adult
207206611,20720661,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2022,Q2,Muscle spasms,,2022,Q2,1,I,20220408.0,20220409.0,20220418,20220418,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165485",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220418,,CN,CO,CO,2022,Q2,Adult
207206611,20720661,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2022,Q2,Dizziness,,2022,Q2,1,I,20220408.0,20220409.0,20220418,20220418,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165485",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220418,,CN,CO,CO,2022,Q2,Adult
207206611,20720661,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2022,Q2,Loss of consciousness,,2022,Q2,1,I,20220408.0,20220409.0,20220418,20220418,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165485",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220418,,CN,CO,CO,2022,Q2,Adult
207206611,20720661,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2022,Q2,Discomfort,,2022,Q2,1,I,20220408.0,20220409.0,20220418,20220418,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165485",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220418,,CN,CO,CO,2022,Q2,Adult
207206611,20720661,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,208658.0,,,,,2022,Q2,Headache,,2022,Q2,1,I,20220408.0,20220409.0,20220418,20220418,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165485",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220418,,CN,CO,CO,2022,Q2,Adult
207208251,20720825,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Cardiac failure,,2022,Q2,1,I,20211201.0,20220410.0,20220418,20220418,EXP,,NVSC2022RS084876,NOVARTIS,,50.0,YR,,M,Y,120.0,KG,20220418,,MD,RS,RS,2022,Q2,Adult
207208251,20720825,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood potassium increased,,2022,Q2,1,I,20211201.0,20220410.0,20220418,20220418,EXP,,NVSC2022RS084876,NOVARTIS,,50.0,YR,,M,Y,120.0,KG,20220418,,MD,RS,RS,2022,Q2,Adult
207208251,20720825,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Off label use,,2022,Q2,1,I,20211201.0,20220410.0,20220418,20220418,EXP,,NVSC2022RS084876,NOVARTIS,,50.0,YR,,M,Y,120.0,KG,20220418,,MD,RS,RS,2022,Q2,Adult
207208251,20720825,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood urea increased,,2022,Q2,1,I,20211201.0,20220410.0,20220418,20220418,EXP,,NVSC2022RS084876,NOVARTIS,,50.0,YR,,M,Y,120.0,KG,20220418,,MD,RS,RS,2022,Q2,Adult
207208251,20720825,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Localised oedema,,2022,Q2,1,I,20211201.0,20220410.0,20220418,20220418,EXP,,NVSC2022RS084876,NOVARTIS,,50.0,YR,,M,Y,120.0,KG,20220418,,MD,RS,RS,2022,Q2,Adult
207208251,20720825,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Dyspnoea,,2022,Q2,1,I,20211201.0,20220410.0,20220418,20220418,EXP,,NVSC2022RS084876,NOVARTIS,,50.0,YR,,M,Y,120.0,KG,20220418,,MD,RS,RS,2022,Q2,Adult
207208251,20720825,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Blood creatinine increased,,2022,Q2,1,I,20211201.0,20220410.0,20220418,20220418,EXP,,NVSC2022RS084876,NOVARTIS,,50.0,YR,,M,Y,120.0,KG,20220418,,MD,RS,RS,2022,Q2,Adult
207208251,20720825,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Fatigue,,2022,Q2,1,I,20211201.0,20220410.0,20220418,20220418,EXP,,NVSC2022RS084876,NOVARTIS,,50.0,YR,,M,Y,120.0,KG,20220418,,MD,RS,RS,2022,Q2,Adult
207208251,20720825,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Oedema peripheral,,2022,Q2,1,I,20211201.0,20220410.0,20220418,20220418,EXP,,NVSC2022RS084876,NOVARTIS,,50.0,YR,,M,Y,120.0,KG,20220418,,MD,RS,RS,2022,Q2,Adult
207213121,20721312,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q2,Palpitations,,2022,Q2,1,I,20211209.0,20220412.0,20220418,20220418,EXP,GB-MHRA-TPP14496314C312473YC1639054424331,GB-MYLANLABS-2022M1024991,MYLAN,,66.0,YR,,F,Y,61.0,KG,20220418,,HP,GB,GB,2022,Q2,Elderly
207227144,20722714,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,Underdose,,2022,Q2,4,F,20220128.0,20220530.0,20220419,20220603,EXP,,NVSJ2022JP006171,NOVARTIS,,82.0,YR,,M,Y,63.3,KG,20220603,,MD,JP,JP,2022,Q2,Elderly
207227144,20722714,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,Pyrexia,,2022,Q2,4,F,20220128.0,20220530.0,20220419,20220603,EXP,,NVSJ2022JP006171,NOVARTIS,,82.0,YR,,M,Y,63.3,KG,20220603,,MD,JP,JP,2022,Q2,Elderly
207227144,20722714,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,Hypotension,,2022,Q2,4,F,20220128.0,20220530.0,20220419,20220603,EXP,,NVSJ2022JP006171,NOVARTIS,,82.0,YR,,M,Y,63.3,KG,20220603,,MD,JP,JP,2022,Q2,Elderly
207227144,20722714,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q2,COVID-19,,2022,Q2,4,F,20220128.0,20220530.0,20220419,20220603,EXP,,NVSJ2022JP006171,NOVARTIS,,82.0,YR,,M,Y,63.3,KG,20220603,,MD,JP,JP,2022,Q2,Elderly
207240841,20724084,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220412.0,20220419,20220419,EXP,,"QA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164912",BOEHRINGER INGELHEIM,"Ata F, Razok A, Ahmed S, Al Mohanadi D. Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation. World Journal of Diabetes. 2022; 13(3): 272-274.",45.0,YR,A,F,Y,,,20220419,,MD,QA,QA,2022,Q2,Adult
207254062,20725406,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1,,,,,,,,,,,,2022,Q2,Vulvovaginal pruritus,,2022,Q2,2,F,20220330.0,20220407.0,20220419,20220421,EXP,,GB-AstraZeneca-2022A143421,ASTRAZENECA,,38.0,YR,,F,Y,82.0,KG,20220421,,MD,GB,,2022,Q2,Adult
207271211,20727121,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Taking for months to years,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Ketoacidosis,,2022,Q2,1,I,20220406.0,20220419.0,20220419,20220419,EXP,DE-BFARM-22002597,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165992",BOEHRINGER INGELHEIM,,65.0,YR,E,M,Y,60.0,KG,20220419,,MD,DE,DE,2022,Q2,Elderly
207310243,20731024,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 T, qd",,,,,,,,,,,QD,2022,Q2,Hypotension,,2022,Q2,3,F,20220129.0,20220530.0,20220420,20220603,EXP,,JP-OTSUKA-2022_023865,OTSUKA,,82.0,YR,,M,Y,63.3,KG,20220603,,MD,JP,JP,2022,Q2,Elderly
207310243,20731024,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 T, qd",,,,,,,,,,,QD,2022,Q2,N-terminal prohormone brain natriuretic peptide increased,,2022,Q2,3,F,20220129.0,20220530.0,20220420,20220603,EXP,,JP-OTSUKA-2022_023865,OTSUKA,,82.0,YR,,M,Y,63.3,KG,20220603,,MD,JP,JP,2022,Q2,Elderly
207310243,20731024,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 T, qd",,,,,,,,,,,QD,2022,Q2,SARS-CoV-2 test positive,,2022,Q2,3,F,20220129.0,20220530.0,20220420,20220603,EXP,,JP-OTSUKA-2022_023865,OTSUKA,,82.0,YR,,M,Y,63.3,KG,20220603,,MD,JP,JP,2022,Q2,Elderly
207340901,20734090,5,C,"EMPAGLIFLOZIN, METFORMIN",,2,Oral,strength: 12.5 mg / 850 mg,,,,,,,,,,Film-coated tablet,,2022,Q2,Tachycardia,,2022,Q2,1,I,20210902.0,20220416.0,20220421,20220421,EXP,IT-MINISAL02-852451,IT-Accord-261428,ACCORD,,79.0,YR,,F,Y,73.0,KG,20220421,,MD,IT,IT,2022,Q2,Elderly
207347262,20734726,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, unknown",,,,,,,,10.0,MG,,,2022,Q2,Diabetes mellitus inadequate control,,2022,Q2,2,F,,20220420.0,20220421,20220502,EXP,,SK-ELI_LILLY_AND_COMPANY-SK202204005326,ELI LILLY AND CO,,56.0,YR,,M,Y,127.0,KG,20220502,,CN,SK,SK,2022,Q2,Adult
207377291,20737729,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Vomiting,,2022,Q2,1,I,20220401.0,20220421.0,20220422,20220422,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-166487",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20220422,,HP,SG,SG,2022,Q2,Elderly
207377291,20737729,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Nausea,,2022,Q2,1,I,20220401.0,20220421.0,20220422,20220422,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-166487",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20220422,,HP,SG,SG,2022,Q2,Elderly
207383911,20738391,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 Dosage forms Daily; Frequency Time :1 days,,,,,,,,,,Tablet,,2022,Q2,Palpitations,,2022,Q2,1,I,20211209.0,20220412.0,20220422,20220422,EXP,GB-MHRA-TPP14496314C312473YC1639054424331,GB-TEVA-2022-GB-2027714,TEVA,,66.0,YR,E,F,Y,61.0,KG,20220422,,HP,GB,GB,2022,Q2,Elderly
207388971,20738897,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Off label use,,2022,Q2,1,I,,20220419.0,20220422,20220422,PER,,AU-AMGEN-AUSSP2022069105,AMGEN,,53.0,YR,A,M,Y,80.0,KG,20220422,,MD,AU,AU,2022,Q2,Adult
207388971,20738897,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Diffuse large B-cell lymphoma,,2022,Q2,1,I,,20220419.0,20220422,20220422,PER,,AU-AMGEN-AUSSP2022069105,AMGEN,,53.0,YR,A,M,Y,80.0,KG,20220422,,MD,AU,AU,2022,Q2,Adult
207388971,20738897,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220419.0,20220422,20220422,PER,,AU-AMGEN-AUSSP2022069105,AMGEN,,53.0,YR,A,M,Y,80.0,KG,20220422,,MD,AU,AU,2022,Q2,Adult
207432571,20743257,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Asked But Unknown,,204629.0,5.0,MG,Tablet,Q12H,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20211206.0,20220419.0,20220425,20220425,EXP,NL-LRB-00804741,"NL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165975",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,69.0,KG,20220425,,PH,NL,NL,2022,Q2,Adult
207432571,20743257,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Asked But Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20211206.0,20220419.0,20220425,20220425,EXP,NL-LRB-00804741,"NL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165975",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,69.0,KG,20220425,,PH,NL,NL,2022,Q2,Adult
207432571,20743257,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Asked But Unknown,,204629.0,10.0,MG,,/HR,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20211206.0,20220419.0,20220425,20220425,EXP,NL-LRB-00804741,"NL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165975",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,69.0,KG,20220425,,PH,NL,NL,2022,Q2,Adult
207433562,20743356,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,2,F,,20220503.0,20220425,20220516,EXP,,AU-NOVOPROD-912033,NOVO NORDISK,,58.0,YR,,F,Y,,,20220516,,HP,AU,AU,2022,Q2,Adult
207433562,20743356,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Decreased appetite,,2022,Q2,2,F,,20220503.0,20220425,20220516,EXP,,AU-NOVOPROD-912033,NOVO NORDISK,,58.0,YR,,F,Y,,,20220516,,HP,AU,AU,2022,Q2,Adult
207433562,20743356,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Vomiting,,2022,Q2,2,F,,20220503.0,20220425,20220516,EXP,,AU-NOVOPROD-912033,NOVO NORDISK,,58.0,YR,,F,Y,,,20220516,,HP,AU,AU,2022,Q2,Adult
207433562,20743356,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Headache,,2022,Q2,2,F,,20220503.0,20220425,20220516,EXP,,AU-NOVOPROD-912033,NOVO NORDISK,,58.0,YR,,F,Y,,,20220516,,HP,AU,AU,2022,Q2,Adult
207433562,20743356,3,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Nausea,,2022,Q2,2,F,,20220503.0,20220425,20220516,EXP,,AU-NOVOPROD-912033,NOVO NORDISK,,58.0,YR,,F,Y,,,20220516,,HP,AU,AU,2022,Q2,Adult
207447661,20744766,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Weight decreased,,2022,Q2,1,I,20210808.0,20220425.0,20220425,20220425,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-167020",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,90.0,KG,20220425,,MD,DE,DE,2022,Q2,Elderly
207447661,20744766,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Polyuria,,2022,Q2,1,I,20210808.0,20220425.0,20220425,20220425,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-167020",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,90.0,KG,20220425,,MD,DE,DE,2022,Q2,Elderly
207447661,20744766,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Ketoacidosis,,2022,Q2,1,I,20210808.0,20220425.0,20220425,20220425,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-167020",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,90.0,KG,20220425,,MD,DE,DE,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Angina pectoris,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Cough,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Atrial fibrillation,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Palpitations,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Pericardial fibrosis,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Ejection fraction decreased,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Chest pain,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Oedema peripheral,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Ventricular tachycardia,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Cardiac failure,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Rhonchi,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Acute myocardial infarction,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Rales,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Lung disorder,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Ventricular extrasystoles,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Coronary artery disease,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207454381,20745438,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd",,,U,U,,,,,,,QD,2022,Q2,Dyspnoea at rest,,2022,Q2,1,I,20210101.0,20220419.0,20220425,20220425,EXP,,PL-MYLANLABS-2022M1029347,MYLAN,,72.0,YR,,M,Y,,,20220425,,MD,PL,PL,2022,Q2,Elderly
207485281,20748528,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220419.0,20220426,20220426,EXP,,NVSC2022SI093312,NOVARTIS,,56.0,YR,,F,Y,,,20220426,,MD,SI,SI,2022,Q2,Adult
207485281,20748528,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q2,Ejection fraction abnormal,,2022,Q2,1,I,,20220419.0,20220426,20220426,EXP,,NVSC2022SI093312,NOVARTIS,,56.0,YR,,F,Y,,,20220426,,MD,SI,SI,2022,Q2,Adult
207485281,20748528,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q2,Dyspnoea,,2022,Q2,1,I,,20220419.0,20220426,20220426,EXP,,NVSC2022SI093312,NOVARTIS,,56.0,YR,,F,Y,,,20220426,,MD,SI,SI,2022,Q2,Adult
207517452,20751745,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Contraindicated product administered,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Cardiac failure,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Mitral valve replacement,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,COVID-19,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Medication error,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Acute kidney injury,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Contraindicated product administered,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Cardiac failure,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Mitral valve replacement,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,COVID-19,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Medication error,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Acute kidney injury,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Contraindicated product administered,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Cardiac failure,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Mitral valve replacement,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,COVID-19,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Medication error,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207517452,20751745,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,U,,,,10.0,MG,,,2022,Q2,Acute kidney injury,,2022,Q2,2,F,20180101.0,20220504.0,20220426,20220509,EXP,,SK-MYLANLABS-2022M1030059,MYLAN,,66.0,YR,,M,Y,,,20220509,,MD,SK,SK,2022,Q2,Elderly
207550401,20755040,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,,,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,,20220422.0,20220427,20220427,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-166843",BOEHRINGER INGELHEIM,"Afrahimi S, Pham C, Guirguis H. The Use of SGLT-2 Inhibitors Coupled With a Strict Low-Carbohydrate Diet: A Set-Up for Inducing Severe Diabetic Ketoacidosis. Clinical Medicine Insights. Case Reports. 2022; volume 15: 1-3.",58.0,YR,A,M,Y,,,20220427,,MD,US,US,2022,Q2,Adult
207550401,20755040,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,,,,,2022,Q2,Weight decreased,,2022,Q2,1,I,,20220422.0,20220427,20220427,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-166843",BOEHRINGER INGELHEIM,"Afrahimi S, Pham C, Guirguis H. The Use of SGLT-2 Inhibitors Coupled With a Strict Low-Carbohydrate Diet: A Set-Up for Inducing Severe Diabetic Ketoacidosis. Clinical Medicine Insights. Case Reports. 2022; volume 15: 1-3.",58.0,YR,A,M,Y,,,20220427,,MD,US,US,2022,Q2,Adult
207608891,20760889,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,Tablet,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,,20220426.0,20220428,20220428,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-167625",BOEHRINGER INGELHEIM,,65.0,YR,E,M,Y,,,20220428,,PH,GB,GB,2022,Q2,Elderly
207646681,20764668,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2022,Q2,Malaise,,2022,Q2,1,I,20220420.0,20220426.0,20220428,20220428,EXP,GB-MHRA-TPP37281447C1127181YC1650455496985,GB-TAKEDA-2022TEU002868,TAKEDA,,71.0,YR,,M,Y,87.0,KG,20220428,,HP,GB,GB,2022,Q2,Elderly
207646681,20764668,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK UNK, qd",,,,,,,,,,Tablet,QD,2022,Q2,Dizziness,,2022,Q2,1,I,20220420.0,20220426.0,20220428,20220428,EXP,GB-MHRA-TPP37281447C1127181YC1650455496985,GB-TAKEDA-2022TEU002868,TAKEDA,,71.0,YR,,M,Y,87.0,KG,20220428,,HP,GB,GB,2022,Q2,Elderly
207669591,20766959,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Aplastic anaemia,,2022,Q2,1,I,20210721.0,20220421.0,20220429,20220429,EXP,,DE-TEVA-2022-DE-2031782,TEVA,,78.0,YR,E,M,Y,70.0,KG,20220429,,MD,DE,DE,2022,Q2,Elderly
207680221,20768022,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Vascular device infection,,2022,Q2,1,I,20220201.0,20220422.0,20220429,20220429,EXP,,NVSC2022GB094922,NOVARTIS,,62.0,YR,,M,Y,113.0,KG,20220429,,MD,GB,GB,2022,Q2,Adult
207688151,20768815,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Infusion related reaction,,2022,Q2,1,I,20220217.0,20220415.0,20220429,20220429,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-335014,RANBAXY,,62.0,YR,,M,Y,115.9,KG,20220429,,MD,GB,GB,2022,Q2,Adult
207689551,20768955,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,,,,QD,2022,Q2,Fournier's gangrene,,2022,Q2,1,I,,,20220428,20220428,DIR,612413,,FDA-CTU,,68.0,YR,,M,N,,,20220428,N,,US,,2022,Q2,Elderly
207716861,20771686,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,Powder for infusion,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220422.0,20220426.0,20220430,20220430,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-167668",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20220430,,HP,GB,GB,2022,Q2,Elderly
207719523,20771952,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Vitreous haemorrhage,,2022,Q2,3,F,20220418.0,20220527.0,20220501,20220602,EXP,,NVSC2022CN095120,NOVARTIS,,22.0,YR,,F,Y,,,20220603,,MD,CN,CN,2022,Q2,Youth
207762341,20776234,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220428.0,20220502,20220502,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-168017",BOEHRINGER INGELHEIM,"Mistry S, Eschler D. euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a Ketogenic Diet: A Case Series and Review of Literature. AACE clinical case reports. 2021; 7:1: 17-19.",47.0,YR,A,F,Y,,,20220502,,MD,US,US,2022,Q2,Adult
207770501,20777050,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Strength: 10 Mg,,,,,,,,10.0,MG,,,2022,Q2,Drug interaction,,2022,Q2,1,I,20220201.0,20220420.0,20220503,20220503,EXP,NO-NOMAADVRE-E2B00080154,NO-Accord-262334,ACCORD,,69.0,YR,,F,Y,,,20220430,,MD,NO,NO,2022,Q2,Elderly
207770501,20777050,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Strength: 10 Mg,,,,,,,,10.0,MG,,,2022,Q2,Off label use,,2022,Q2,1,I,20220201.0,20220420.0,20220503,20220503,EXP,NO-NOMAADVRE-E2B00080154,NO-Accord-262334,ACCORD,,69.0,YR,,F,Y,,,20220430,,MD,NO,NO,2022,Q2,Elderly
207770501,20777050,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Strength: 10 Mg,,,,,,,,10.0,MG,,,2022,Q2,Thrombocytopenia,,2022,Q2,1,I,20220201.0,20220420.0,20220503,20220503,EXP,NO-NOMAADVRE-E2B00080154,NO-Accord-262334,ACCORD,,69.0,YR,,F,Y,,,20220430,,MD,NO,NO,2022,Q2,Elderly
207776551,20777655,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2022,Q2,Adverse drug reaction,,2022,Q2,1,I,20220428.0,20220429.0,20220503,20220503,EXP,GB-MHRA-TPP20557936C5273244YC1651133960719,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-168556",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,65.0,KG,20220503,,HP,GB,GB,2022,Q2,Adult
207776811,20777681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q2,Necrosis,,2022,Q2,1,I,20220428.0,20220429.0,20220503,20220503,EXP,GB-MHRA-WEBRADR-202204281640365260-Z0UVN,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-168559",BOEHRINGER INGELHEIM,,87.0,YR,E,M,Y,,,20220503,,HP,GB,GB,2022,Q2,Elderly
207777381,20777738,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,25.0,MG,Powder for infusion,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20220428.0,20220501.0,20220503,20220503,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-168568",BOEHRINGER INGELHEIM,,56.0,YR,A,M,Y,93.0,KG,20220503,,HP,GB,GB,2022,Q2,Adult
207778941,20777894,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2022,Q2,Hypoaesthesia,,2022,Q2,1,I,,20220426.0,20220503,20220503,EXP,CA-MHPD-E2B_03864168,CA-Accord-262260,ACCORD,,77.0,YR,,F,Y,,,20220503,,CN,CA,CA,2022,Q2,Elderly
207778941,20777894,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2022,Q2,Transient ischaemic attack,,2022,Q2,1,I,,20220426.0,20220503,20220503,EXP,CA-MHPD-E2B_03864168,CA-Accord-262260,ACCORD,,77.0,YR,,F,Y,,,20220503,,CN,CA,CA,2022,Q2,Elderly
207781812,20778181,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 milligram,,,,,,,,10.0,MG,,,2022,Q2,Diabetes mellitus inadequate control,,2022,Q2,2,F,,20220505.0,20220503,20220510,EXP,,SK-MYLANLABS-2022M1032133,MYLAN,,56.0,YR,,M,Y,127.0,KG,20220510,,MD,SK,SK,2022,Q2,Adult
207805401,20780540,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,Asked But Unknown,,206111.0,,,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,,20220503.0,20220504,20220504,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-168701",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,,,20220504,,MD,AU,AU,2022,Q2,Young Adult
207875531,20787553,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20200116.0,20220428.0,20220505,20220505,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-168004",BOEHRINGER INGELHEIM,"Osafehinti D, Okoli O, Karam J. a case of SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis following coronary artery bypass surgery. AACE clinical case reports. 2021; 7:1: 20-22.",60.0,YR,A,M,Y,,,20220505,,MD,US,US,2022,Q2,Adult
207921091,20792109,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,U,Unknown,,204629.0,,,Powder for infusion,,2022,Q2,Visual impairment,,2022,Q2,1,I,,20220505.0,20220505,20220505,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-169019",BOEHRINGER INGELHEIM,,35.0,YR,A,F,Y,,,20220505,,CN,GB,GB,2022,Q2,Adult
207939571,20793957,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Vascular device infection,,2022,Q2,1,I,20220201.0,20220422.0,20220506,20220506,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-335828,RANBAXY,,62.0,YR,,M,Y,113.0,KG,20220506,,MD,GB,GB,2022,Q2,Adult
207954404,20795440,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2022,Q2,Ocular vasculitis,,2022,Q2,4,F,20220427.0,20220614.0,20220506,20220620,EXP,,US-ROCHE-3087474,ROCHE,,76.0,YR,,F,Y,70.9,KG,20220620,,MD,US,,2022,Q2,Elderly
207964661,20796466,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Atrioventricular block,,2022,Q2,1,I,,20220504.0,20220506,20220506,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-168944",BOEHRINGER INGELHEIM,Koudelka M. The challenge of polypharmacy. Haus ?rzt:in. 2022 Apr; 45-48.,72.0,YR,E,F,Y,,,20220506,,HP,AT,AT,2022,Q2,Elderly
207964661,20796466,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Intestinal haemorrhage,,2022,Q2,1,I,,20220504.0,20220506,20220506,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-168944",BOEHRINGER INGELHEIM,Koudelka M. The challenge of polypharmacy. Haus ?rzt:in. 2022 Apr; 45-48.,72.0,YR,E,F,Y,,,20220506,,HP,AT,AT,2022,Q2,Elderly
207964661,20796466,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Internal haemorrhage,,2022,Q2,1,I,,20220504.0,20220506,20220506,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-168944",BOEHRINGER INGELHEIM,Koudelka M. The challenge of polypharmacy. Haus ?rzt:in. 2022 Apr; 45-48.,72.0,YR,E,F,Y,,,20220506,,HP,AT,AT,2022,Q2,Elderly
207964661,20796466,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Loss of consciousness,,2022,Q2,1,I,,20220504.0,20220506,20220506,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-168944",BOEHRINGER INGELHEIM,Koudelka M. The challenge of polypharmacy. Haus ?rzt:in. 2022 Apr; 45-48.,72.0,YR,E,F,Y,,,20220506,,HP,AT,AT,2022,Q2,Elderly
207964661,20796466,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,unknown,,204629.0,,,,,2022,Q2,Atrioventricular block,,2022,Q2,1,I,,20220504.0,20220506,20220506,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-168944",BOEHRINGER INGELHEIM,Koudelka M. The challenge of polypharmacy. Haus ?rzt:in. 2022 Apr; 45-48.,72.0,YR,E,F,Y,,,20220506,,HP,AT,AT,2022,Q2,Elderly
207964661,20796466,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,unknown,,204629.0,,,,,2022,Q2,Intestinal haemorrhage,,2022,Q2,1,I,,20220504.0,20220506,20220506,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-168944",BOEHRINGER INGELHEIM,Koudelka M. The challenge of polypharmacy. Haus ?rzt:in. 2022 Apr; 45-48.,72.0,YR,E,F,Y,,,20220506,,HP,AT,AT,2022,Q2,Elderly
207964661,20796466,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,unknown,,204629.0,,,,,2022,Q2,Internal haemorrhage,,2022,Q2,1,I,,20220504.0,20220506,20220506,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-168944",BOEHRINGER INGELHEIM,Koudelka M. The challenge of polypharmacy. Haus ?rzt:in. 2022 Apr; 45-48.,72.0,YR,E,F,Y,,,20220506,,HP,AT,AT,2022,Q2,Elderly
207964661,20796466,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,unknown,,204629.0,,,,,2022,Q2,Loss of consciousness,,2022,Q2,1,I,,20220504.0,20220506,20220506,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-168944",BOEHRINGER INGELHEIM,Koudelka M. The challenge of polypharmacy. Haus ?rzt:in. 2022 Apr; 45-48.,72.0,YR,E,F,Y,,,20220506,,HP,AT,AT,2022,Q2,Elderly
207969851,20796985,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q2,Hyperglycaemia,,2022,Q2,1,I,20220401.0,20220504.0,20220506,20220506,EXP,,NVSC2022KE104348,NOVARTIS,,57.0,YR,,F,Y,,,20220506,,HP,KE,KE,2022,Q2,Adult
207969851,20796985,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q2,Dysarthria,,2022,Q2,1,I,20220401.0,20220504.0,20220506,20220506,EXP,,NVSC2022KE104348,NOVARTIS,,57.0,YR,,F,Y,,,20220506,,HP,KE,KE,2022,Q2,Adult
207969851,20796985,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q2,Tachycardia,,2022,Q2,1,I,20220401.0,20220504.0,20220506,20220506,EXP,,NVSC2022KE104348,NOVARTIS,,57.0,YR,,F,Y,,,20220506,,HP,KE,KE,2022,Q2,Adult
207976881,20797688,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,,,,,,10.0,MG,,,2022,Q2,Dyspnoea,,2022,Q2,1,I,,20220429.0,20220506,20220506,EXP,,SI-AstraZeneca-2022A167203,ASTRAZENECA,,56.0,YR,,F,Y,,,20220506,,MD,SI,,2022,Q2,Adult
207976881,20797688,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,,,,,,10.0,MG,,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220429.0,20220506,20220506,EXP,,SI-AstraZeneca-2022A167203,ASTRAZENECA,,56.0,YR,,F,Y,,,20220506,,MD,SI,,2022,Q2,Adult
207976881,20797688,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,,,,,,10.0,MG,,,2022,Q2,Ejection fraction abnormal,,2022,Q2,1,I,,20220429.0,20220506,20220506,EXP,,SI-AstraZeneca-2022A167203,ASTRAZENECA,,56.0,YR,,F,Y,,,20220506,,MD,SI,,2022,Q2,Adult
207979742,20797974,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg,,,U,,,,,25.0,MG,,,2022,Q2,Diabetes mellitus inadequate control,,2022,Q2,2,F,,20220519.0,20220506,20220525,EXP,,CO-SA-2022SA142703,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20220525,,CN,CO,CO,2022,Q2,Elderly
207979742,20797974,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg,,,U,,,,,25.0,MG,,,2022,Q2,Dry mouth,,2022,Q2,2,F,,20220519.0,20220506,20220525,EXP,,CO-SA-2022SA142703,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20220525,,CN,CO,CO,2022,Q2,Elderly
207979742,20797974,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg,,,U,,,,,25.0,MG,,,2022,Q2,Abdominal pain upper,,2022,Q2,2,F,,20220519.0,20220506,20220525,EXP,,CO-SA-2022SA142703,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20220525,,CN,CO,CO,2022,Q2,Elderly
207979742,20797974,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg,,,U,,,,,25.0,MG,,,2022,Q2,Discomfort,,2022,Q2,2,F,,20220519.0,20220506,20220525,EXP,,CO-SA-2022SA142703,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20220525,,CN,CO,CO,2022,Q2,Elderly
207979742,20797974,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg,,,U,,,,,25.0,MG,,,2022,Q2,Product dose omission issue,,2022,Q2,2,F,,20220519.0,20220506,20220525,EXP,,CO-SA-2022SA142703,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20220525,,CN,CO,CO,2022,Q2,Elderly
207979742,20797974,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg,,,U,,,,,25.0,MG,,,2022,Q2,Pain,,2022,Q2,2,F,,20220519.0,20220506,20220525,EXP,,CO-SA-2022SA142703,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20220525,,CN,CO,CO,2022,Q2,Elderly
207979742,20797974,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg,,,U,,,,,25.0,MG,,,2022,Q2,Visual impairment,,2022,Q2,2,F,,20220519.0,20220506,20220525,EXP,,CO-SA-2022SA142703,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20220525,,CN,CO,CO,2022,Q2,Elderly
207979742,20797974,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg,,,U,,,,,25.0,MG,,,2022,Q2,Asthenia,,2022,Q2,2,F,,20220519.0,20220506,20220525,EXP,,CO-SA-2022SA142703,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20220525,,CN,CO,CO,2022,Q2,Elderly
207979742,20797974,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg,,,U,,,,,25.0,MG,,,2022,Q2,Malaise,,2022,Q2,2,F,,20220519.0,20220506,20220525,EXP,,CO-SA-2022SA142703,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20220525,,CN,CO,CO,2022,Q2,Elderly
207979742,20797974,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg,,,U,,,,,25.0,MG,,,2022,Q2,Blood glucose decreased,,2022,Q2,2,F,,20220519.0,20220506,20220525,EXP,,CO-SA-2022SA142703,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20220525,,CN,CO,CO,2022,Q2,Elderly
207979742,20797974,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg,,,U,,,,,25.0,MG,,,2022,Q2,Vulvovaginal burning sensation,,2022,Q2,2,F,,20220519.0,20220506,20220525,EXP,,CO-SA-2022SA142703,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20220525,,CN,CO,CO,2022,Q2,Elderly
207979742,20797974,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg,,,U,,,,,25.0,MG,,,2022,Q2,Tongue discolouration,,2022,Q2,2,F,,20220519.0,20220506,20220525,EXP,,CO-SA-2022SA142703,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20220525,,CN,CO,CO,2022,Q2,Elderly
207980241,20798024,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Potentiating drug interaction,,2022,Q2,1,I,,20220429.0,20220506,20220506,EXP,,AT-JNJFOC-20220507236,JOHNSON AND JOHNSON,,72.0,YR,E,F,Y,,,20220507,,HP,AT,AT,2022,Q2,Elderly
207980241,20798024,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Intestinal haemorrhage,,2022,Q2,1,I,,20220429.0,20220506,20220506,EXP,,AT-JNJFOC-20220507236,JOHNSON AND JOHNSON,,72.0,YR,E,F,Y,,,20220507,,HP,AT,AT,2022,Q2,Elderly
207980241,20798024,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Loss of consciousness,,2022,Q2,1,I,,20220429.0,20220506,20220506,EXP,,AT-JNJFOC-20220507236,JOHNSON AND JOHNSON,,72.0,YR,E,F,Y,,,20220507,,HP,AT,AT,2022,Q2,Elderly
207980241,20798024,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Labelled drug-drug interaction medication error,,2022,Q2,1,I,,20220429.0,20220506,20220506,EXP,,AT-JNJFOC-20220507236,JOHNSON AND JOHNSON,,72.0,YR,E,F,Y,,,20220507,,HP,AT,AT,2022,Q2,Elderly
208023051,20802305,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,Powder for infusion,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20211104.0,20220506.0,20220509,20220509,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-169262",BOEHRINGER INGELHEIM,,60.0,YR,A,F,Y,75.0,KG,20220509,,CN,GB,GB,2022,Q2,Adult
208024021,20802402,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,,,,,25.0,MG,,QD,2022,Q2,Urinary tract infection,,2022,Q2,1,I,20220422.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35212,,FDA-CTU,,71.0,YR,,M,N,116.0,KG,20220503,N,PH,US,,2022,Q2,Elderly
208024021,20802402,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,,,,,25.0,MG,,QD,2022,Q2,Penile erythema,,2022,Q2,1,I,20220422.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35212,,FDA-CTU,,71.0,YR,,M,N,116.0,KG,20220503,N,PH,US,,2022,Q2,Elderly
208024021,20802402,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,,,,,25.0,MG,,QD,2022,Q2,Cough,,2022,Q2,1,I,20220422.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35212,,FDA-CTU,,71.0,YR,,M,N,116.0,KG,20220503,N,PH,US,,2022,Q2,Elderly
208024021,20802402,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,,,,,25.0,MG,,QD,2022,Q2,Penile oedema,,2022,Q2,1,I,20220422.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35212,,FDA-CTU,,71.0,YR,,M,N,116.0,KG,20220503,N,PH,US,,2022,Q2,Elderly
208024021,20802402,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,,,,,25.0,MG,,QD,2022,Q2,Chills,,2022,Q2,1,I,20220422.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35212,,FDA-CTU,,71.0,YR,,M,N,116.0,KG,20220503,N,PH,US,,2022,Q2,Elderly
208024021,20802402,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,,,,,25.0,MG,,QD,2022,Q2,Dizziness,,2022,Q2,1,I,20220422.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35212,,FDA-CTU,,71.0,YR,,M,N,116.0,KG,20220503,N,PH,US,,2022,Q2,Elderly
208024021,20802402,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,,,,,25.0,MG,,QD,2022,Q2,Syncope,,2022,Q2,1,I,20220422.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35212,,FDA-CTU,,71.0,YR,,M,N,116.0,KG,20220503,N,PH,US,,2022,Q2,Elderly
208024021,20802402,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,,,,,25.0,MG,,QD,2022,Q2,Hypoglycaemia,,2022,Q2,1,I,20220422.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35212,,FDA-CTU,,71.0,YR,,M,N,116.0,KG,20220503,N,PH,US,,2022,Q2,Elderly
208024021,20802402,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,,,,,25.0,MG,,QD,2022,Q2,Influenza,,2022,Q2,1,I,20220422.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35212,,FDA-CTU,,71.0,YR,,M,N,116.0,KG,20220503,N,PH,US,,2022,Q2,Elderly
208024021,20802402,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,,,,,25.0,MG,,QD,2022,Q2,Nightmare,,2022,Q2,1,I,20220422.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35212,,FDA-CTU,,71.0,YR,,M,N,116.0,KG,20220503,N,PH,US,,2022,Q2,Elderly
208024021,20802402,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,,,,,25.0,MG,,QD,2022,Q2,Pulmonary mass,,2022,Q2,1,I,20220422.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35212,,FDA-CTU,,71.0,YR,,M,N,116.0,KG,20220503,N,PH,US,,2022,Q2,Elderly
208024021,20802402,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,,,,,25.0,MG,,QD,2022,Q2,Hyperhidrosis,,2022,Q2,1,I,20220422.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35212,,FDA-CTU,,71.0,YR,,M,N,116.0,KG,20220503,N,PH,US,,2022,Q2,Elderly
208024021,20802402,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,Y,,,,,25.0,MG,,QD,2022,Q2,Loss of consciousness,,2022,Q2,1,I,20220422.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35212,,FDA-CTU,,71.0,YR,,M,N,116.0,KG,20220503,N,PH,US,,2022,Q2,Elderly
208024091,20802409,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG AM PO?,,,Y,D,,,,25.0,MG,,999,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220328.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35220,,FDA-CTU,,72.0,YR,,M,N,85.0,KG,20220429,N,HP,US,,2022,Q2,Elderly
208025751,20802575,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 12.5 MG;?Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2022,Q2,Oxygen saturation decreased,,2022,Q2,1,I,20220224.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35372,,FDA-CTU,,75.0,YR,,M,N,123.0,KG,20220418,N,PH,US,,2022,Q2,Elderly
208025751,20802575,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 12.5 MG;?Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2022,Q2,Respiratory depression,,2022,Q2,1,I,20220224.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35372,,FDA-CTU,,75.0,YR,,M,N,123.0,KG,20220418,N,PH,US,,2022,Q2,Elderly
208025751,20802575,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 12.5 MG;?Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2022,Q2,Palpitations,,2022,Q2,1,I,20220224.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35372,,FDA-CTU,,75.0,YR,,M,N,123.0,KG,20220418,N,PH,US,,2022,Q2,Elderly
208026021,20802602,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1.25 MG;?Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q2,Hypotension,,2022,Q2,1,I,20220210.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35379,,FDA-CTU,,74.0,YR,,M,N,86.64,KG,20220418,N,PH,US,,2022,Q2,Elderly
208026021,20802602,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1.25 MG;?Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q2,Hypovolaemia,,2022,Q2,1,I,20220210.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35379,,FDA-CTU,,74.0,YR,,M,N,86.64,KG,20220418,N,PH,US,,2022,Q2,Elderly
208026021,20802602,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1.25 MG;?Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q2,Urinary tract infection,,2022,Q2,1,I,20220210.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35379,,FDA-CTU,,74.0,YR,,M,N,86.64,KG,20220418,N,PH,US,,2022,Q2,Elderly
208026021,20802602,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1.25 MG;?Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q2,Acute kidney injury,,2022,Q2,1,I,20220210.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35379,,FDA-CTU,,74.0,YR,,M,N,86.64,KG,20220418,N,PH,US,,2022,Q2,Elderly
208042971,20804297,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q2,Upper gastrointestinal haemorrhage,,2022,Q2,1,I,,20220427.0,20220509,20220509,EXP,IL-DEXPHARM-20220614,IL-DEXPHARM-20220614,DEXCEL,,62.0,YR,,F,Y,,,20220508,,PH,IL,,2022,Q2,Adult
208042971,20804297,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220427.0,20220509,20220509,EXP,IL-DEXPHARM-20220614,IL-DEXPHARM-20220614,DEXCEL,,62.0,YR,,F,Y,,,20220508,,PH,IL,,2022,Q2,Adult
208043121,20804312,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,unknown,,,25.0,MG,,QD,2022,Q2,Cardio-respiratory arrest,,2022,Q2,1,I,20210101.0,20220427.0,20220509,20220509,EXP,,BR-NOVOPROD-914459,NOVO NORDISK,,78.0,YR,,M,Y,105.0,KG,20220509,,MD,BR,BR,2022,Q2,Elderly
208043121,20804312,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,unknown,,,25.0,MG,,QD,2022,Q2,Acute myocardial infarction,,2022,Q2,1,I,20210101.0,20220427.0,20220509,20220509,EXP,,BR-NOVOPROD-914459,NOVO NORDISK,,78.0,YR,,M,Y,105.0,KG,20220509,,MD,BR,BR,2022,Q2,Elderly
208074011,20807401,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER FREQUENCY : AM;?,,,Y,D,,,,12.5,MG,,999,2022,Q2,Bladder disorder,,2022,Q2,1,I,20220325.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35537,,FDA-CTU,,60.0,YR,,M,N,132.0,KG,20220330,N,PH,US,,2022,Q2,Adult
208074011,20807401,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER FREQUENCY : AM;?,,,Y,D,,,,12.5,MG,,999,2022,Q2,Dysuria,,2022,Q2,1,I,20220325.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35537,,FDA-CTU,,60.0,YR,,M,N,132.0,KG,20220330,N,PH,US,,2022,Q2,Adult
208086411,20808641,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q2,Fournier's gangrene,,2022,Q2,1,I,20211017.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35726,,FDA-CTU,,66.0,YR,,M,N,107.0,KG,20211220,N,PH,US,,2022,Q2,Elderly
208092941,20809294,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,D,D,,,,12.5,MG,,QD,2022,Q2,Urticaria,,2022,Q2,1,I,20200407.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35769,,FDA-CTU,,66.0,YR,,M,N,70.0,KG,20200504,N,HP,US,,2022,Q2,Elderly
208092941,20809294,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,D,D,,,,12.5,MG,,QD,2022,Q2,Penile discomfort,,2022,Q2,1,I,20200407.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35769,,FDA-CTU,,66.0,YR,,M,N,70.0,KG,20200504,N,HP,US,,2022,Q2,Elderly
208092941,20809294,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,D,D,,,,12.5,MG,,QD,2022,Q2,Glucose urine,,2022,Q2,1,I,20200407.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35769,,FDA-CTU,,66.0,YR,,M,N,70.0,KG,20200504,N,HP,US,,2022,Q2,Elderly
208092941,20809294,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,D,D,,,,12.5,MG,,QD,2022,Q2,Pruritus genital,,2022,Q2,1,I,20200407.0,,20220509,20220509,DIR,FDA-CDER-CTU-2022-35769,,FDA-CTU,,66.0,YR,,M,N,70.0,KG,20200504,N,HP,US,,2022,Q2,Elderly
208117161,20811716,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Pruritus,,2022,Q2,1,I,20220101.0,20220510.0,20220511,20220511,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-169699",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20220511,,HP,SG,SG,2022,Q2,Elderly
208130941,20813094,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,Oral,10-5 1000 mg,,,U,,Unknown,,122138.0,,,Tablet,QD,2022,Q2,Vision blurred,,2022,Q2,1,I,,20220510.0,20220511,20220511,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-169918",BOEHRINGER INGELHEIM,,70.0,YR,E,F,Y,,,20220511,,CN,US,US,2022,Q2,Elderly
208151182,20815118,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,25.0,MG,Unknown,QD,2022,Q2,Atrial fibrillation,,2022,Q2,2,F,20220429.0,20220504.0,20220511,20220513,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-033748,BRISTOL MYERS SQUIBB,,74.0,YR,E,M,Y,84.5,KG,20220513,,HP,US,US,2022,Q2,Elderly
208152581,20815258,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2022,Q2,Influenza like illness,,2022,Q2,1,I,20191028.0,20220505.0,20220511,20220511,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-036507,BRISTOL MYERS SQUIBB,,77.0,YR,E,M,Y,73.4,KG,20220511,,HP,CA,CA,2022,Q2,Elderly
208153101,20815310,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Dehydration,,2022,Q2,1,I,20220401.0,20220505.0,20220511,20220511,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202205003046,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20220511,,CN,CO,CO,2022,Q2,Adult
208153101,20815310,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Abdominal pain upper,,2022,Q2,1,I,20220401.0,20220505.0,20220511,20220511,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202205003046,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20220511,,CN,CO,CO,2022,Q2,Adult
208153101,20815310,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Headache,,2022,Q2,1,I,20220401.0,20220505.0,20220511,20220511,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202205003046,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20220511,,CN,CO,CO,2022,Q2,Adult
208153101,20815310,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,1,I,20220401.0,20220505.0,20220511,20220511,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202205003046,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20220511,,CN,CO,CO,2022,Q2,Adult
208153101,20815310,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Vomiting,,2022,Q2,1,I,20220401.0,20220505.0,20220511,20220511,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202205003046,ELI LILLY AND CO,,63.0,YR,,F,Y,,,20220511,,CN,CO,CO,2022,Q2,Adult
208193121,20819312,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Ketoacidosis,,2022,Q2,1,I,,20220505.0,20220512,20220512,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-169236",BOEHRINGER INGELHEIM,,23.0,YR,A,,Y,,,20220512,,MD,DE,DE,2022,Q2,Youth
208193121,20819312,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Dehydration,,2022,Q2,1,I,,20220505.0,20220512,20220512,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-169236",BOEHRINGER INGELHEIM,,23.0,YR,A,,Y,,,20220512,,MD,DE,DE,2022,Q2,Youth
208193121,20819312,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Gastroenteritis,,2022,Q2,1,I,,20220505.0,20220512,20220512,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-169236",BOEHRINGER INGELHEIM,,23.0,YR,A,,Y,,,20220512,,MD,DE,DE,2022,Q2,Youth
208193121,20819312,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Off label use,,2022,Q2,1,I,,20220505.0,20220512,20220512,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-169236",BOEHRINGER INGELHEIM,,23.0,YR,A,,Y,,,20220512,,MD,DE,DE,2022,Q2,Youth
208193121,20819312,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2022,Q2,Ketoacidosis,,2022,Q2,1,I,,20220505.0,20220512,20220512,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-169236",BOEHRINGER INGELHEIM,,23.0,YR,A,,Y,,,20220512,,MD,DE,DE,2022,Q2,Youth
208193121,20819312,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2022,Q2,Dehydration,,2022,Q2,1,I,,20220505.0,20220512,20220512,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-169236",BOEHRINGER INGELHEIM,,23.0,YR,A,,Y,,,20220512,,MD,DE,DE,2022,Q2,Youth
208193121,20819312,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2022,Q2,Gastroenteritis,,2022,Q2,1,I,,20220505.0,20220512,20220512,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-169236",BOEHRINGER INGELHEIM,,23.0,YR,A,,Y,,,20220512,,MD,DE,DE,2022,Q2,Youth
208193121,20819312,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2022,Q2,Off label use,,2022,Q2,1,I,,20220505.0,20220512,20220512,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-169236",BOEHRINGER INGELHEIM,,23.0,YR,A,,Y,,,20220512,,MD,DE,DE,2022,Q2,Youth
208229341,20822934,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,,Unknown,,122138.0,,,,,2022,Q2,Cardiac disorder,,2022,Q2,1,I,20220512.0,20220512.0,20220512,20220512,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170441",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220513,,CN,US,US,2022,Q2,Adult
208235152,20823515,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Potentiating drug interaction,,2022,Q2,2,F,,20220516.0,20220513,20220517,EXP,,NVSC2022AT107394,NOVARTIS,Koudelka M. Herausforderung Polypharmazie Vor allem bei alteren Menschen: Ein Medikament kommt selten allein. HAUSARZT. 2022;9:45-8,72.0,YR,,F,Y,,,20220517,,HP,AT,AT,2022,Q2,Elderly
208235152,20823515,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Internal haemorrhage,,2022,Q2,2,F,,20220516.0,20220513,20220517,EXP,,NVSC2022AT107394,NOVARTIS,Koudelka M. Herausforderung Polypharmazie Vor allem bei alteren Menschen: Ein Medikament kommt selten allein. HAUSARZT. 2022;9:45-8,72.0,YR,,F,Y,,,20220517,,HP,AT,AT,2022,Q2,Elderly
208235152,20823515,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Loss of consciousness,,2022,Q2,2,F,,20220516.0,20220513,20220517,EXP,,NVSC2022AT107394,NOVARTIS,Koudelka M. Herausforderung Polypharmazie Vor allem bei alteren Menschen: Ein Medikament kommt selten allein. HAUSARZT. 2022;9:45-8,72.0,YR,,F,Y,,,20220517,,HP,AT,AT,2022,Q2,Elderly
208235152,20823515,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Atrioventricular block,,2022,Q2,2,F,,20220516.0,20220513,20220517,EXP,,NVSC2022AT107394,NOVARTIS,Koudelka M. Herausforderung Polypharmazie Vor allem bei alteren Menschen: Ein Medikament kommt selten allein. HAUSARZT. 2022;9:45-8,72.0,YR,,F,Y,,,20220517,,HP,AT,AT,2022,Q2,Elderly
208235152,20823515,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Labelled drug-drug interaction medication error,,2022,Q2,2,F,,20220516.0,20220513,20220517,EXP,,NVSC2022AT107394,NOVARTIS,Koudelka M. Herausforderung Polypharmazie Vor allem bei alteren Menschen: Ein Medikament kommt selten allein. HAUSARZT. 2022;9:45-8,72.0,YR,,F,Y,,,20220517,,HP,AT,AT,2022,Q2,Elderly
208235152,20823515,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Intestinal haemorrhage,,2022,Q2,2,F,,20220516.0,20220513,20220517,EXP,,NVSC2022AT107394,NOVARTIS,Koudelka M. Herausforderung Polypharmazie Vor allem bei alteren Menschen: Ein Medikament kommt selten allein. HAUSARZT. 2022;9:45-8,72.0,YR,,F,Y,,,20220517,,HP,AT,AT,2022,Q2,Elderly
208278701,20827870,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 UNK, qd",,,,,,,,,,,QD,2022,Q2,Tooth extraction,,2022,Q2,1,I,20220104.0,20220505.0,20220513,20220513,EXP,,DE-DSJP-DSE-2022-115440,DAIICHI,,78.0,YR,,M,Y,75.0,KG,20220513,,MD,DE,DE,2022,Q2,Elderly
208278701,20827870,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 UNK, qd",,,,,,,,,,,QD,2022,Q2,Dyspnoea,,2022,Q2,1,I,20220104.0,20220505.0,20220513,20220513,EXP,,DE-DSJP-DSE-2022-115440,DAIICHI,,78.0,YR,,M,Y,75.0,KG,20220513,,MD,DE,DE,2022,Q2,Elderly
208278701,20827870,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 UNK, qd",,,,,,,,,,,QD,2022,Q2,Abdominal pain,,2022,Q2,1,I,20220104.0,20220505.0,20220513,20220513,EXP,,DE-DSJP-DSE-2022-115440,DAIICHI,,78.0,YR,,M,Y,75.0,KG,20220513,,MD,DE,DE,2022,Q2,Elderly
208278701,20827870,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 UNK, qd",,,,,,,,,,,QD,2022,Q2,Haemorrhage,,2022,Q2,1,I,20220104.0,20220505.0,20220513,20220513,EXP,,DE-DSJP-DSE-2022-115440,DAIICHI,,78.0,YR,,M,Y,75.0,KG,20220513,,MD,DE,DE,2022,Q2,Elderly
208308451,20830845,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q2,Headache,,2022,Q2,1,I,20220508.0,20220512.0,20220515,20220515,EXP,GB-MHRA-EYC 00273117,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170332",BOEHRINGER INGELHEIM,,56.0,YR,A,F,Y,94.0,KG,20220515,,HP,GB,GB,2022,Q2,Adult
208308451,20830845,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q2,Fatigue,,2022,Q2,1,I,20220508.0,20220512.0,20220515,20220515,EXP,GB-MHRA-EYC 00273117,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170332",BOEHRINGER INGELHEIM,,56.0,YR,A,F,Y,94.0,KG,20220515,,HP,GB,GB,2022,Q2,Adult
208308451,20830845,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q2,Nausea,,2022,Q2,1,I,20220508.0,20220512.0,20220515,20220515,EXP,GB-MHRA-EYC 00273117,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170332",BOEHRINGER INGELHEIM,,56.0,YR,A,F,Y,94.0,KG,20220515,,HP,GB,GB,2022,Q2,Adult
208308451,20830845,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q2,Cold sweat,,2022,Q2,1,I,20220508.0,20220512.0,20220515,20220515,EXP,GB-MHRA-EYC 00273117,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170332",BOEHRINGER INGELHEIM,,56.0,YR,A,F,Y,94.0,KG,20220515,,HP,GB,GB,2022,Q2,Adult
208308451,20830845,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q2,Tachycardia,,2022,Q2,1,I,20220508.0,20220512.0,20220515,20220515,EXP,GB-MHRA-EYC 00273117,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170332",BOEHRINGER INGELHEIM,,56.0,YR,A,F,Y,94.0,KG,20220515,,HP,GB,GB,2022,Q2,Adult
208308451,20830845,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q2,Dysgeusia,,2022,Q2,1,I,20220508.0,20220512.0,20220515,20220515,EXP,GB-MHRA-EYC 00273117,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170332",BOEHRINGER INGELHEIM,,56.0,YR,A,F,Y,94.0,KG,20220515,,HP,GB,GB,2022,Q2,Adult
208308451,20830845,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Powder for infusion,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20220508.0,20220512.0,20220515,20220515,EXP,GB-MHRA-EYC 00273117,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170332",BOEHRINGER INGELHEIM,,56.0,YR,A,F,Y,94.0,KG,20220515,,HP,GB,GB,2022,Q2,Adult
208331601,20833160,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,unknown,,,,,,,2022,Q2,Atrioventricular block,,2022,Q2,1,I,,20220511.0,20220516,20220516,EXP,,AT-BAUSCH-BL-2022-011712,BAUSCH AND LOMB,Koudelka M. The challenge of polypharmacy. Haus Arzt:in. 2022 APR;45-48.,72.0,YR,,F,Y,,,20220516,,HP,AT,AT,2022,Q2,Elderly
208331601,20833160,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,unknown,,,,,,,2022,Q2,Intestinal haemorrhage,,2022,Q2,1,I,,20220511.0,20220516,20220516,EXP,,AT-BAUSCH-BL-2022-011712,BAUSCH AND LOMB,Koudelka M. The challenge of polypharmacy. Haus Arzt:in. 2022 APR;45-48.,72.0,YR,,F,Y,,,20220516,,HP,AT,AT,2022,Q2,Elderly
208331601,20833160,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,unknown,,,,,,,2022,Q2,Loss of consciousness,,2022,Q2,1,I,,20220511.0,20220516,20220516,EXP,,AT-BAUSCH-BL-2022-011712,BAUSCH AND LOMB,Koudelka M. The challenge of polypharmacy. Haus Arzt:in. 2022 APR;45-48.,72.0,YR,,F,Y,,,20220516,,HP,AT,AT,2022,Q2,Elderly
208331601,20833160,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,unknown,,,,,,,2022,Q2,Internal haemorrhage,,2022,Q2,1,I,,20220511.0,20220516,20220516,EXP,,AT-BAUSCH-BL-2022-011712,BAUSCH AND LOMB,Koudelka M. The challenge of polypharmacy. Haus Arzt:in. 2022 APR;45-48.,72.0,YR,,F,Y,,,20220516,,HP,AT,AT,2022,Q2,Elderly
208337611,20833761,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1 Tablet(s);?,,,N,D,,,,,,,,2022,Q2,Anorectal swelling,,2022,Q2,1,I,20220507.0,,20220513,20220513,DIR,614204,,FDA-CTU,,80.0,YR,,M,N,90.9,KG,20220513,N,CN,US,,2022,Q2,Elderly
208337611,20833761,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1 Tablet(s);?,,,N,D,,,,,,,,2022,Q2,Dysuria,,2022,Q2,1,I,20220507.0,,20220513,20220513,DIR,614204,,FDA-CTU,,80.0,YR,,M,N,90.9,KG,20220513,N,CN,US,,2022,Q2,Elderly
208337611,20833761,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1 Tablet(s);?,,,N,D,,,,,,,,2022,Q2,Penile rash,,2022,Q2,1,I,20220507.0,,20220513,20220513,DIR,614204,,FDA-CTU,,80.0,YR,,M,N,90.9,KG,20220513,N,CN,US,,2022,Q2,Elderly
208337611,20833761,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1 Tablet(s);?,,,N,D,,,,,,,,2022,Q2,Anal rash,,2022,Q2,1,I,20220507.0,,20220513,20220513,DIR,614204,,FDA-CTU,,80.0,YR,,M,N,90.9,KG,20220513,N,CN,US,,2022,Q2,Elderly
208337611,20833761,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1 Tablet(s);?,,,N,D,,,,,,,,2022,Q2,Nonspecific reaction,,2022,Q2,1,I,20220507.0,,20220513,20220513,DIR,614204,,FDA-CTU,,80.0,YR,,M,N,90.9,KG,20220513,N,CN,US,,2022,Q2,Elderly
208337611,20833761,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1 Tablet(s);?,,,N,D,,,,,,,,2022,Q2,Renal pain,,2022,Q2,1,I,20220507.0,,20220513,20220513,DIR,614204,,FDA-CTU,,80.0,YR,,M,N,90.9,KG,20220513,N,CN,US,,2022,Q2,Elderly
208337611,20833761,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1 Tablet(s);?,,,N,D,,,,,,,,2022,Q2,Urinary tract infection,,2022,Q2,1,I,20220507.0,,20220513,20220513,DIR,614204,,FDA-CTU,,80.0,YR,,M,N,90.9,KG,20220513,N,CN,US,,2022,Q2,Elderly
208337611,20833761,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1 Tablet(s);?,,,N,D,,,,,,,,2022,Q2,Pain,,2022,Q2,1,I,20220507.0,,20220513,20220513,DIR,614204,,FDA-CTU,,80.0,YR,,M,N,90.9,KG,20220513,N,CN,US,,2022,Q2,Elderly
208341631,20834163,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Anxiety,,2022,Q2,1,I,20220514.0,,20220514,20220514,DIR,614245,,FDA-CTU,,77.0,YR,,M,N,69.75,KG,20220514,N,CN,US,,2022,Q2,Elderly
208341631,20834163,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Abnormal dreams,,2022,Q2,1,I,20220514.0,,20220514,20220514,DIR,614245,,FDA-CTU,,77.0,YR,,M,N,69.75,KG,20220514,N,CN,US,,2022,Q2,Elderly
208341631,20834163,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Fear,,2022,Q2,1,I,20220514.0,,20220514,20220514,DIR,614245,,FDA-CTU,,77.0,YR,,M,N,69.75,KG,20220514,N,CN,US,,2022,Q2,Elderly
208341631,20834163,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Feeling abnormal,,2022,Q2,1,I,20220514.0,,20220514,20220514,DIR,614245,,FDA-CTU,,77.0,YR,,M,N,69.75,KG,20220514,N,CN,US,,2022,Q2,Elderly
208341631,20834163,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Job dissatisfaction,,2022,Q2,1,I,20220514.0,,20220514,20220514,DIR,614245,,FDA-CTU,,77.0,YR,,M,N,69.75,KG,20220514,N,CN,US,,2022,Q2,Elderly
208341631,20834163,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Anxiety,,2022,Q2,1,I,20220514.0,,20220514,20220514,DIR,614245,,FDA-CTU,,77.0,YR,,M,N,69.75,KG,20220514,N,CN,US,,2022,Q2,Elderly
208341631,20834163,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Memory impairment,,2022,Q2,1,I,20220514.0,,20220514,20220514,DIR,614245,,FDA-CTU,,77.0,YR,,M,N,69.75,KG,20220514,N,CN,US,,2022,Q2,Elderly
208341631,20834163,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Muscular weakness,,2022,Q2,1,I,20220514.0,,20220514,20220514,DIR,614245,,FDA-CTU,,77.0,YR,,M,N,69.75,KG,20220514,N,CN,US,,2022,Q2,Elderly
208341631,20834163,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Laziness,,2022,Q2,1,I,20220514.0,,20220514,20220514,DIR,614245,,FDA-CTU,,77.0,YR,,M,N,69.75,KG,20220514,N,CN,US,,2022,Q2,Elderly
208341631,20834163,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Pain,,2022,Q2,1,I,20220514.0,,20220514,20220514,DIR,614245,,FDA-CTU,,77.0,YR,,M,N,69.75,KG,20220514,N,CN,US,,2022,Q2,Elderly
208341631,20834163,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Acute stress disorder,,2022,Q2,1,I,20220514.0,,20220514,20220514,DIR,614245,,FDA-CTU,,77.0,YR,,M,N,69.75,KG,20220514,N,CN,US,,2022,Q2,Elderly
208341631,20834163,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Mental impairment,,2022,Q2,1,I,20220514.0,,20220514,20220514,DIR,614245,,FDA-CTU,,77.0,YR,,M,N,69.75,KG,20220514,N,CN,US,,2022,Q2,Elderly
208341631,20834163,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Myalgia,,2022,Q2,1,I,20220514.0,,20220514,20220514,DIR,614245,,FDA-CTU,,77.0,YR,,M,N,69.75,KG,20220514,N,CN,US,,2022,Q2,Elderly
208341631,20834163,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Hypoaesthesia,,2022,Q2,1,I,20220514.0,,20220514,20220514,DIR,614245,,FDA-CTU,,77.0,YR,,M,N,69.75,KG,20220514,N,CN,US,,2022,Q2,Elderly
208366812,20836681,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,25+5mg per day,,,,,unknown,,,,,,,2022,Q2,Bradycardia,,2022,Q2,2,F,,20220510.0,20220517,20220524,EXP,,BR-NOVOPROD-916936,NOVO NORDISK,,77.0,YR,,M,Y,88.0,KG,20220524,,MD,BR,BR,2022,Q2,Elderly
208423142,20842314,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,Unknown,,206073.0,,,Tablet,,2022,Q2,Cerebral infarction,,2022,Q2,2,F,20220506.0,20220602.0,20220518,20220603,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170227",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220603,,PH,JP,JP,2022,Q2,Elderly
208423142,20842314,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,Unknown,,206073.0,,,Tablet,,2022,Q2,Rash,,2022,Q2,2,F,20220506.0,20220602.0,20220518,20220603,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170227",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220603,,PH,JP,JP,2022,Q2,Elderly
208452541,20845254,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Dose or Amount: 1 Tab ,,,Y,,,,,,,,QD,2022,Q2,Therapy interrupted,,2022,Q2,1,I,20220418.0,,20220518,20220518,DIR,FDA-CDER-CTU-2022-38046,,FDA-CTU,,72.0,YR,,M,N,76.0,KG,20220514,N,PH,US,,2022,Q2,Elderly
208452541,20845254,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Dose or Amount: 1 Tab ,,,Y,,,,,,,,QD,2022,Q2,Urinary tract infection,,2022,Q2,1,I,20220418.0,,20220518,20220518,DIR,FDA-CDER-CTU-2022-38046,,FDA-CTU,,72.0,YR,,M,N,76.0,KG,20220514,N,PH,US,,2022,Q2,Elderly
208452541,20845254,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Dose or Amount: 1 Tab ,,,Y,,,,,,,,QD,2022,Q2,Prostatomegaly,,2022,Q2,1,I,20220418.0,,20220518,20220518,DIR,FDA-CDER-CTU-2022-38046,,FDA-CTU,,72.0,YR,,M,N,76.0,KG,20220514,N,PH,US,,2022,Q2,Elderly
208452541,20845254,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Dose or Amount: 1 Tab ,,,Y,,,,,,,,QD,2022,Q2,Nephrolithiasis,,2022,Q2,1,I,20220418.0,,20220518,20220518,DIR,FDA-CDER-CTU-2022-38046,,FDA-CTU,,72.0,YR,,M,N,76.0,KG,20220514,N,PH,US,,2022,Q2,Elderly
208468722,20846872,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000 mg,,,N,,Unknown,,206111.0,,,,QD,2022,Q2,Fungaemia,,2022,Q2,2,F,20211129.0,20220620.0,20220519,20220627,EXP,CH-SM-2022-15075,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170552",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20220627,,MD,CH,CH,2022,Q2,Elderly
208468722,20846872,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000 mg,,,N,,Unknown,,206111.0,,,,QD,2022,Q2,Urinary tract candidiasis,,2022,Q2,2,F,20211129.0,20220620.0,20220519,20220627,EXP,CH-SM-2022-15075,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170552",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20220627,,MD,CH,CH,2022,Q2,Elderly
208468722,20846872,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000 mg,,,N,,Unknown,,206111.0,,,,QD,2022,Q2,Pyelonephritis,,2022,Q2,2,F,20211129.0,20220620.0,20220519,20220627,EXP,CH-SM-2022-15075,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170552",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20220627,,MD,CH,CH,2022,Q2,Elderly
208476721,20847672,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Product prescribing error,,2022,Q2,1,I,20220302.0,20220519.0,20220519,20220519,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171459",BOEHRINGER INGELHEIM,,83.0,YR,E,M,Y,,,20220519,,MD,DE,DE,2022,Q2,Elderly
208476721,20847672,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Metabolic acidosis,,2022,Q2,1,I,20220302.0,20220519.0,20220519,20220519,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171459",BOEHRINGER INGELHEIM,,83.0,YR,E,M,Y,,,20220519,,MD,DE,DE,2022,Q2,Elderly
208476721,20847672,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Failure to suspend medication,,2022,Q2,1,I,20220302.0,20220519.0,20220519,20220519,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171459",BOEHRINGER INGELHEIM,,83.0,YR,E,M,Y,,,20220519,,MD,DE,DE,2022,Q2,Elderly
208518151,20851815,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/500 mg,,,N,,Unknown,,206111.0,,,,,2022,Q2,Lethargy,,2022,Q2,1,I,20220502.0,20220513.0,20220520,20220520,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170489",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220520,,MD,AU,AU,2022,Q2,Adult
208518151,20851815,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/500 mg,,,N,,Unknown,,206111.0,,,,,2022,Q2,Nocturia,,2022,Q2,1,I,20220502.0,20220513.0,20220520,20220520,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170489",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220520,,MD,AU,AU,2022,Q2,Adult
208518151,20851815,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/500 mg,,,N,,Unknown,,206111.0,,,,,2022,Q2,Seizure,,2022,Q2,1,I,20220502.0,20220513.0,20220520,20220520,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170489",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220520,,MD,AU,AU,2022,Q2,Adult
208518151,20851815,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/500 mg,,,N,,Unknown,,206111.0,,,,,2022,Q2,Feeling abnormal,,2022,Q2,1,I,20220502.0,20220513.0,20220520,20220520,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170489",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220520,,MD,AU,AU,2022,Q2,Adult
208518151,20851815,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/500 mg,,,N,,Unknown,,206111.0,,,,,2022,Q2,Fatigue,,2022,Q2,1,I,20220502.0,20220513.0,20220520,20220520,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170489",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220520,,MD,AU,AU,2022,Q2,Adult
208518151,20851815,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/500 mg,,,N,,Unknown,,206111.0,,,,,2022,Q2,Confusional state,,2022,Q2,1,I,20220502.0,20220513.0,20220520,20220520,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170489",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220520,,MD,AU,AU,2022,Q2,Adult
208518151,20851815,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/500 mg,,,N,,Unknown,,206111.0,,,,,2022,Q2,Mental impairment,,2022,Q2,1,I,20220502.0,20220513.0,20220520,20220520,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170489",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220520,,MD,AU,AU,2022,Q2,Adult
208518151,20851815,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/500 mg,,,N,,Unknown,,206111.0,,,,,2022,Q2,Dizziness,,2022,Q2,1,I,20220502.0,20220513.0,20220520,20220520,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170489",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220520,,MD,AU,AU,2022,Q2,Adult
208518151,20851815,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/500 mg,,,N,,Unknown,,206111.0,,,,,2022,Q2,Cognitive disorder,,2022,Q2,1,I,20220502.0,20220513.0,20220520,20220520,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170489",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220520,,MD,AU,AU,2022,Q2,Adult
208518151,20851815,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/500 mg,,,N,,Unknown,,206111.0,,,,,2022,Q2,Dysarthria,,2022,Q2,1,I,20220502.0,20220513.0,20220520,20220520,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170489",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220520,,MD,AU,AU,2022,Q2,Adult
208518151,20851815,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/500 mg,,,N,,Unknown,,206111.0,,,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220502.0,20220513.0,20220520,20220520,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170489",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220520,,MD,AU,AU,2022,Q2,Adult
208518151,20851815,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/500 mg,,,N,,Unknown,,206111.0,,,,,2022,Q2,Malaise,,2022,Q2,1,I,20220502.0,20220513.0,20220520,20220520,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170489",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220520,,MD,AU,AU,2022,Q2,Adult
208518151,20851815,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/500 mg,,,N,,Unknown,,206111.0,,,,,2022,Q2,Dehydration,,2022,Q2,1,I,20220502.0,20220513.0,20220520,20220520,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-170489",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220520,,MD,AU,AU,2022,Q2,Adult
208526391,20852639,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,,20220519.0,20220520,20220520,EXP,GB-MHRA-MIDB-2867bd7a-3291-4a07-ae3f-14f52dabe2e4,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171533",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20220520,,PH,GB,GB,2022,Q2,Elderly
208529791,20852979,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2022,Q2,Intestinal haemorrhage,,2022,Q2,1,I,,20220513.0,20220520,20220520,EXP,,AT-MYLANLABS-2022M1036252,MYLAN,Koudelka M.. The challenge : Polypharmacy especially in the case of older people: A drug rarely comes alone.. general physician. 2022;9:45-48,72.0,YR,,F,Y,,,20220520,,HP,AT,AT,2022,Q2,Elderly
208529791,20852979,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2022,Q2,Atrioventricular block,,2022,Q2,1,I,,20220513.0,20220520,20220520,EXP,,AT-MYLANLABS-2022M1036252,MYLAN,Koudelka M.. The challenge : Polypharmacy especially in the case of older people: A drug rarely comes alone.. general physician. 2022;9:45-48,72.0,YR,,F,Y,,,20220520,,HP,AT,AT,2022,Q2,Elderly
208529791,20852979,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2022,Q2,Potentiating drug interaction,,2022,Q2,1,I,,20220513.0,20220520,20220520,EXP,,AT-MYLANLABS-2022M1036252,MYLAN,Koudelka M.. The challenge : Polypharmacy especially in the case of older people: A drug rarely comes alone.. general physician. 2022;9:45-48,72.0,YR,,F,Y,,,20220520,,HP,AT,AT,2022,Q2,Elderly
208529791,20852979,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2022,Q2,Internal haemorrhage,,2022,Q2,1,I,,20220513.0,20220520,20220520,EXP,,AT-MYLANLABS-2022M1036252,MYLAN,Koudelka M.. The challenge : Polypharmacy especially in the case of older people: A drug rarely comes alone.. general physician. 2022;9:45-48,72.0,YR,,F,Y,,,20220520,,HP,AT,AT,2022,Q2,Elderly
208529791,20852979,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2022,Q2,Labelled drug-drug interaction medication error,,2022,Q2,1,I,,20220513.0,20220520,20220520,EXP,,AT-MYLANLABS-2022M1036252,MYLAN,Koudelka M.. The challenge : Polypharmacy especially in the case of older people: A drug rarely comes alone.. general physician. 2022;9:45-48,72.0,YR,,F,Y,,,20220520,,HP,AT,AT,2022,Q2,Elderly
208529791,20852979,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2022,Q2,Loss of consciousness,,2022,Q2,1,I,,20220513.0,20220520,20220520,EXP,,AT-MYLANLABS-2022M1036252,MYLAN,Koudelka M.. The challenge : Polypharmacy especially in the case of older people: A drug rarely comes alone.. general physician. 2022;9:45-48,72.0,YR,,F,Y,,,20220520,,HP,AT,AT,2022,Q2,Elderly
208530972,20853097,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Labelled drug-drug interaction medication error,,2022,Q2,2,F,,20220518.0,20220520,20220524,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8,72.0,YR,E,F,Y,,,20220524,,HP,AT,AT,2022,Q2,Elderly
208530972,20853097,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Intestinal haemorrhage,,2022,Q2,2,F,,20220518.0,20220520,20220524,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8,72.0,YR,E,F,Y,,,20220524,,HP,AT,AT,2022,Q2,Elderly
208530972,20853097,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Internal haemorrhage,,2022,Q2,2,F,,20220518.0,20220520,20220524,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8,72.0,YR,E,F,Y,,,20220524,,HP,AT,AT,2022,Q2,Elderly
208530972,20853097,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Loss of consciousness,,2022,Q2,2,F,,20220518.0,20220520,20220524,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8,72.0,YR,E,F,Y,,,20220524,,HP,AT,AT,2022,Q2,Elderly
208530972,20853097,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Atrioventricular block,,2022,Q2,2,F,,20220518.0,20220520,20220524,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8,72.0,YR,E,F,Y,,,20220524,,HP,AT,AT,2022,Q2,Elderly
208530972,20853097,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q2,Labelled drug-drug interaction medication error,,2022,Q2,2,F,,20220518.0,20220520,20220524,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8,72.0,YR,E,F,Y,,,20220524,,HP,AT,AT,2022,Q2,Elderly
208530972,20853097,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q2,Intestinal haemorrhage,,2022,Q2,2,F,,20220518.0,20220520,20220524,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8,72.0,YR,E,F,Y,,,20220524,,HP,AT,AT,2022,Q2,Elderly
208530972,20853097,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q2,Internal haemorrhage,,2022,Q2,2,F,,20220518.0,20220520,20220524,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8,72.0,YR,E,F,Y,,,20220524,,HP,AT,AT,2022,Q2,Elderly
208530972,20853097,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q2,Loss of consciousness,,2022,Q2,2,F,,20220518.0,20220520,20220524,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8,72.0,YR,E,F,Y,,,20220524,,HP,AT,AT,2022,Q2,Elderly
208530972,20853097,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q2,Atrioventricular block,,2022,Q2,2,F,,20220518.0,20220520,20220524,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8,72.0,YR,E,F,Y,,,20220524,,HP,AT,AT,2022,Q2,Elderly
208541501,20854150,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,,,,,2022,Q2,Delirium,,2022,Q2,1,I,,20220518.0,20220520,20220520,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171316",BOEHRINGER INGELHEIM,"Edwards N, Munshi M. Diet DKA: euglycemic Diabetic Ketoacidosis (eDKA) caused by SGLT2 inhibitors in an elderly male. Epidemiology. 2022; 70:",90.0,YR,E,M,Y,,,20220520,,HP,US,US,2022,Q2,Elderly
208541501,20854150,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,,,,,2022,Q2,Death,,2022,Q2,1,I,,20220518.0,20220520,20220520,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171316",BOEHRINGER INGELHEIM,"Edwards N, Munshi M. Diet DKA: euglycemic Diabetic Ketoacidosis (eDKA) caused by SGLT2 inhibitors in an elderly male. Epidemiology. 2022; 70:",90.0,YR,E,M,Y,,,20220520,,HP,US,US,2022,Q2,Elderly
208541501,20854150,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,,,,,2022,Q2,Pneumonia aspiration,,2022,Q2,1,I,,20220518.0,20220520,20220520,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171316",BOEHRINGER INGELHEIM,"Edwards N, Munshi M. Diet DKA: euglycemic Diabetic Ketoacidosis (eDKA) caused by SGLT2 inhibitors in an elderly male. Epidemiology. 2022; 70:",90.0,YR,E,M,Y,,,20220520,,HP,US,US,2022,Q2,Elderly
208541501,20854150,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,,,,,2022,Q2,Pancreatic atrophy,,2022,Q2,1,I,,20220518.0,20220520,20220520,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171316",BOEHRINGER INGELHEIM,"Edwards N, Munshi M. Diet DKA: euglycemic Diabetic Ketoacidosis (eDKA) caused by SGLT2 inhibitors in an elderly male. Epidemiology. 2022; 70:",90.0,YR,E,M,Y,,,20220520,,HP,US,US,2022,Q2,Elderly
208541501,20854150,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,,,,,2022,Q2,Acute kidney injury,,2022,Q2,1,I,,20220518.0,20220520,20220520,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171316",BOEHRINGER INGELHEIM,"Edwards N, Munshi M. Diet DKA: euglycemic Diabetic Ketoacidosis (eDKA) caused by SGLT2 inhibitors in an elderly male. Epidemiology. 2022; 70:",90.0,YR,E,M,Y,,,20220520,,HP,US,US,2022,Q2,Elderly
208541501,20854150,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,,,,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220518.0,20220520,20220520,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171316",BOEHRINGER INGELHEIM,"Edwards N, Munshi M. Diet DKA: euglycemic Diabetic Ketoacidosis (eDKA) caused by SGLT2 inhibitors in an elderly male. Epidemiology. 2022; 70:",90.0,YR,E,M,Y,,,20220520,,HP,US,US,2022,Q2,Elderly
208582411,20858241,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,,,,,,,,,QD,2022,Q2,Abdominal discomfort,,2022,Q2,1,I,,20220510.0,20220521,20220521,PER,,IE-LUPIN PHARMACEUTICALS INC.-2022-07295,LUPIN,"Ahmed MSO, Rafey M, McDonnell T, Smith D. HIST1H1E syndrome with type 2 diabetes. British medical journal Case Reports. 2021;14:e241907:1-3",20.0,YR,,F,Y,,,20220521,,MD,IE,IE,2022,Q2,Youth
208612521,20861252,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q2,Thrombocytopenia,,2022,Q2,1,I,20220502.0,20220516.0,20220523,20220523,EXP,,PT-Fresenius Kabi-FK202203680,FRESENIUS KABI,,57.0,YR,,F,Y,,,20220523,,HP,NL,,2022,Q2,Adult
208612521,20861252,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q2,Malignant neoplasm progression,,2022,Q2,1,I,20220502.0,20220516.0,20220523,20220523,EXP,,PT-Fresenius Kabi-FK202203680,FRESENIUS KABI,,57.0,YR,,F,Y,,,20220523,,HP,NL,,2022,Q2,Adult
208612521,20861252,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q2,Pulmonary oedema,,2022,Q2,1,I,20220502.0,20220516.0,20220523,20220523,EXP,,PT-Fresenius Kabi-FK202203680,FRESENIUS KABI,,57.0,YR,,F,Y,,,20220523,,HP,NL,,2022,Q2,Adult
208624181,20862418,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, qd (UNK UNK, BID (5/1000 mg))",,,D,,,,,,,,QD,2022,Q2,Cardiac failure,,2022,Q2,1,I,,20220520.0,20220523,20220523,EXP,,HU-MYLANLABS-2022M1038236,MYLAN,,71.0,YR,,M,Y,,,20220523,,HP,HU,HU,2022,Q2,Elderly
208624192,20862419,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd, 1 dosage form, BID (5/1000 mg)",,,D,,,,,,,,QD,2022,Q2,Myocardial infarction,,2022,Q2,2,F,,20220523.0,20220523,20220526,EXP,,HU-MYLANLABS-2022M1038210,MYLAN,,54.0,YR,,M,Y,,,20220526,,HP,HU,HU,2022,Q2,Adult
208624192,20862419,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd, 1 dosage form, BID (5/1000 mg)",,,D,,,,,,,,QD,2022,Q2,Cor pulmonale acute,,2022,Q2,2,F,,20220523.0,20220523,20220526,EXP,,HU-MYLANLABS-2022M1038210,MYLAN,,54.0,YR,,M,Y,,,20220526,,HP,HU,HU,2022,Q2,Adult
208624192,20862419,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd, 1 dosage form, BID (5/1000 mg)",,,D,,,,,,,,QD,2022,Q2,Hypertension,,2022,Q2,2,F,,20220523.0,20220523,20220526,EXP,,HU-MYLANLABS-2022M1038210,MYLAN,,54.0,YR,,M,Y,,,20220526,,HP,HU,HU,2022,Q2,Adult
208624192,20862419,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd, 1 dosage form, BID (5/1000 mg)",,,D,,,,,,,,QD,2022,Q2,Cardiac failure,,2022,Q2,2,F,,20220523.0,20220523,20220526,EXP,,HU-MYLANLABS-2022M1038210,MYLAN,,54.0,YR,,M,Y,,,20220526,,HP,HU,HU,2022,Q2,Adult
208624192,20862419,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd, 1 dosage form, BID (5/1000 mg)",,,D,,,,,,,,QD,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,2,F,,20220523.0,20220523,20220526,EXP,,HU-MYLANLABS-2022M1038210,MYLAN,,54.0,YR,,M,Y,,,20220526,,HP,HU,HU,2022,Q2,Adult
208624192,20862419,10,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd, 1 dosage form, BID (5/1000 mg)",,,D,,,,,,,,QD,2022,Q2,Mitral valve incompetence,,2022,Q2,2,F,,20220523.0,20220523,20220526,EXP,,HU-MYLANLABS-2022M1038210,MYLAN,,54.0,YR,,M,Y,,,20220526,,HP,HU,HU,2022,Q2,Adult
208625432,20862543,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,2,F,20210701.0,20220601.0,20220523,20220606,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171071",BOEHRINGER INGELHEIM,"Stratigou T, Diamantopoulos A, Sambanioti E, Mouchtouris P, Antonopoulou D, Tsagkarakis S. et al. DIABETIC KETOACIDOSIS IN THE CONTEXT OF SGLT2  INHIBITOR ADMINISTRATION: REFERENCE TO THE CASES  FOLLOWED AT THE ENDOCRINOLOGY CLINIC OF A TERTIARY  HOSPITAL OVER THE LAST THREE YEARS. 49th Panhellenic congress of Endocrinology, Metabolism and Diabetes mellitus, 28-30 April 2022. 2022 Apr 28;",62.0,YR,A,F,Y,,,20220606,,MD,GR,GR,2022,Q2,Adult
208625432,20862543,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Altered state of consciousness,,2022,Q2,2,F,20210701.0,20220601.0,20220523,20220606,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171071",BOEHRINGER INGELHEIM,"Stratigou T, Diamantopoulos A, Sambanioti E, Mouchtouris P, Antonopoulou D, Tsagkarakis S. et al. DIABETIC KETOACIDOSIS IN THE CONTEXT OF SGLT2  INHIBITOR ADMINISTRATION: REFERENCE TO THE CASES  FOLLOWED AT THE ENDOCRINOLOGY CLINIC OF A TERTIARY  HOSPITAL OVER THE LAST THREE YEARS. 49th Panhellenic congress of Endocrinology, Metabolism and Diabetes mellitus, 28-30 April 2022. 2022 Apr 28;",62.0,YR,A,F,Y,,,20220606,,MD,GR,GR,2022,Q2,Adult
208627701,20862770,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220414.0,,20220523,20220523,DIR,FDA-CDER-CTU-2022-39971,,FDA-CTU,,87.0,YR,,M,N,,,20220508,N,PH,US,,2022,Q2,Elderly
208627701,20862770,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2022,Q2,Hyperglycaemia,,2022,Q2,1,I,20220414.0,,20220523,20220523,DIR,FDA-CDER-CTU-2022-39971,,FDA-CTU,,87.0,YR,,M,N,,,20220508,N,PH,US,,2022,Q2,Elderly
208627701,20862770,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2022,Q2,Pruritus,,2022,Q2,1,I,20220414.0,,20220523,20220523,DIR,FDA-CDER-CTU-2022-39971,,FDA-CTU,,87.0,YR,,M,N,,,20220508,N,PH,US,,2022,Q2,Elderly
208627701,20862770,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2022,Q2,Eczema,,2022,Q2,1,I,20220414.0,,20220523,20220523,DIR,FDA-CDER-CTU-2022-39971,,FDA-CTU,,87.0,YR,,M,N,,,20220508,N,PH,US,,2022,Q2,Elderly
208627701,20862770,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2022,Q2,Skin abrasion,,2022,Q2,1,I,20220414.0,,20220523,20220523,DIR,FDA-CDER-CTU-2022-39971,,FDA-CTU,,87.0,YR,,M,N,,,20220508,N,PH,US,,2022,Q2,Elderly
208628531,20862853,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,d32980,20240531.0,,25.0,MG,,QD,2022,Q2,Nausea,,2022,Q2,1,I,20220120.0,,20220523,20220523,DIR,FDA-CDER-CTU-2022-40007,,FDA-CTU,,69.0,YR,,M,N,69.0,KG,20220425,N,PH,US,,2022,Q2,Elderly
208628531,20862853,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,d32980,20240531.0,,25.0,MG,,QD,2022,Q2,Hypertension,,2022,Q2,1,I,20220120.0,,20220523,20220523,DIR,FDA-CDER-CTU-2022-40007,,FDA-CTU,,69.0,YR,,M,N,69.0,KG,20220425,N,PH,US,,2022,Q2,Elderly
208628531,20862853,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,d32980,20240531.0,,25.0,MG,,QD,2022,Q2,Tachycardia,,2022,Q2,1,I,20220120.0,,20220523,20220523,DIR,FDA-CDER-CTU-2022-40007,,FDA-CTU,,69.0,YR,,M,N,69.0,KG,20220425,N,PH,US,,2022,Q2,Elderly
208628531,20862853,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,d32980,20240531.0,,25.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20220120.0,,20220523,20220523,DIR,FDA-CDER-CTU-2022-40007,,FDA-CTU,,69.0,YR,,M,N,69.0,KG,20220425,N,PH,US,,2022,Q2,Elderly
208628531,20862853,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,d32980,20240531.0,,25.0,MG,,QD,2022,Q2,Hyperglycaemia,,2022,Q2,1,I,20220120.0,,20220523,20220523,DIR,FDA-CDER-CTU-2022-40007,,FDA-CTU,,69.0,YR,,M,N,69.0,KG,20220425,N,PH,US,,2022,Q2,Elderly
208628531,20862853,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,d32980,20240531.0,,25.0,MG,,QD,2022,Q2,Vomiting,,2022,Q2,1,I,20220120.0,,20220523,20220523,DIR,FDA-CDER-CTU-2022-40007,,FDA-CTU,,69.0,YR,,M,N,69.0,KG,20220425,N,PH,US,,2022,Q2,Elderly
208635602,20863560,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,2,F,20210101.0,20220601.0,20220523,20220608,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171075",BOEHRINGER INGELHEIM,,45.0,YR,A,M,Y,,,20220608,,MD,GR,GR,2022,Q2,Adult
208635602,20863560,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Abdominal pain,,2022,Q2,2,F,20210101.0,20220601.0,20220523,20220608,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171075",BOEHRINGER INGELHEIM,,45.0,YR,A,M,Y,,,20220608,,MD,GR,GR,2022,Q2,Adult
208635968,20863596,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2022,Q2,Angina pectoris,,2022,Q2,8,F,20201201.0,20220622.0,20220523,20220624,EXP,,HR-PFIZER INC-202200731782,PFIZER,,85.0,YR,,M,Y,,,20220624,,MD,HR,HR,2022,Q2,Elderly
208635968,20863596,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2022,Q2,Aortic valve incompetence,,2022,Q2,8,F,20201201.0,20220622.0,20220523,20220624,EXP,,HR-PFIZER INC-202200731782,PFIZER,,85.0,YR,,M,Y,,,20220624,,MD,HR,HR,2022,Q2,Elderly
208635968,20863596,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2022,Q2,Angina unstable,,2022,Q2,8,F,20201201.0,20220622.0,20220523,20220624,EXP,,HR-PFIZER INC-202200731782,PFIZER,,85.0,YR,,M,Y,,,20220624,,MD,HR,HR,2022,Q2,Elderly
208635968,20863596,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2022,Q2,Mitral valve incompetence,,2022,Q2,8,F,20201201.0,20220622.0,20220523,20220624,EXP,,HR-PFIZER INC-202200731782,PFIZER,,85.0,YR,,M,Y,,,20220624,,MD,HR,HR,2022,Q2,Elderly
208635968,20863596,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2022,Q2,Ischaemic cardiomyopathy,,2022,Q2,8,F,20201201.0,20220622.0,20220523,20220624,EXP,,HR-PFIZER INC-202200731782,PFIZER,,85.0,YR,,M,Y,,,20220624,,MD,HR,HR,2022,Q2,Elderly
208635968,20863596,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q2,Angina pectoris,,2022,Q2,8,F,20201201.0,20220622.0,20220523,20220624,EXP,,HR-PFIZER INC-202200731782,PFIZER,,85.0,YR,,M,Y,,,20220624,,MD,HR,HR,2022,Q2,Elderly
208635968,20863596,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q2,Aortic valve incompetence,,2022,Q2,8,F,20201201.0,20220622.0,20220523,20220624,EXP,,HR-PFIZER INC-202200731782,PFIZER,,85.0,YR,,M,Y,,,20220624,,MD,HR,HR,2022,Q2,Elderly
208635968,20863596,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q2,Angina unstable,,2022,Q2,8,F,20201201.0,20220622.0,20220523,20220624,EXP,,HR-PFIZER INC-202200731782,PFIZER,,85.0,YR,,M,Y,,,20220624,,MD,HR,HR,2022,Q2,Elderly
208635968,20863596,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q2,Mitral valve incompetence,,2022,Q2,8,F,20201201.0,20220622.0,20220523,20220624,EXP,,HR-PFIZER INC-202200731782,PFIZER,,85.0,YR,,M,Y,,,20220624,,MD,HR,HR,2022,Q2,Elderly
208635968,20863596,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q2,Ischaemic cardiomyopathy,,2022,Q2,8,F,20201201.0,20220622.0,20220523,20220624,EXP,,HR-PFIZER INC-202200731782,PFIZER,,85.0,YR,,M,Y,,,20220624,,MD,HR,HR,2022,Q2,Elderly
208644631,20864463,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,,20220522.0,20220524,20220524,EXP,GB-MHRA-MIDB-bf485e6a-3cc3-4a73-a216-42b987c70cb7,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172105",BOEHRINGER INGELHEIM,,50.0,YR,A,F,Y,,,20220524,,PH,GB,GB,2022,Q2,Adult
208657201,20865720,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,EVERY MORNING,,,,,,,,12.5,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20220128.0,,20220523,20220523,DIR,FDA-CDER-CTU-2022-40111,,FDA-CTU,,44.0,YR,,M,N,110.0,KG,20220319,N,PH,US,,2022,Q2,Adult
208659531,20865953,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20211220.0,,20220523,20220523,DIR,FDA-CDER-CTU-2022-40170,,FDA-CTU,,65.0,YR,,M,N,,,20220218,N,PH,US,,2022,Q2,Elderly
208665952,20866595,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10mg, UNK",,,,,,,,,,,,2022,Q2,Cardiac failure chronic,,2022,Q2,2,F,20171101.0,20220623.0,20220524,20220628,EXP,,JP-OTSUKA-2022_028248,OTSUKA,,7.0,DEC,,M,Y,,,20220628,,MD,JP,JP,2022,Q2,Child
208665952,20866595,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10mg, UNK",,,,,,,,,,,,2022,Q2,Renal impairment,,2022,Q2,2,F,20171101.0,20220623.0,20220524,20220628,EXP,,JP-OTSUKA-2022_028248,OTSUKA,,7.0,DEC,,M,Y,,,20220628,,MD,JP,JP,2022,Q2,Child
208665952,20866595,27,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10mg, UNK",,,,,,,,,,,,2022,Q2,Therapy non-responder,,2022,Q2,2,F,20171101.0,20220623.0,20220524,20220628,EXP,,JP-OTSUKA-2022_028248,OTSUKA,,7.0,DEC,,M,Y,,,20220628,,MD,JP,JP,2022,Q2,Child
208697341,20869734,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,,,Unknown,,,,,,,2022,Q2,Hypoglycaemia,,2022,Q2,1,I,20220404.0,20220515.0,20220525,20220525,EXP,,BR-NOVOPROD-919439,NOVO NORDISK,,62.0,YR,,M,Y,81.5,KG,20220525,,MD,BR,BR,2022,Q2,Adult
208697341,20869734,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,,,Unknown,,,,,,,2022,Q2,Sleep disorder,,2022,Q2,1,I,20220404.0,20220515.0,20220525,20220525,EXP,,BR-NOVOPROD-919439,NOVO NORDISK,,62.0,YR,,M,Y,81.5,KG,20220525,,MD,BR,BR,2022,Q2,Adult
208697341,20869734,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,,,Unknown,,,,,,,2022,Q2,Arteriosclerosis,,2022,Q2,1,I,20220404.0,20220515.0,20220525,20220525,EXP,,BR-NOVOPROD-919439,NOVO NORDISK,,62.0,YR,,M,Y,81.5,KG,20220525,,MD,BR,BR,2022,Q2,Adult
208697341,20869734,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,,,Unknown,,,,,,,2022,Q2,Hyperglycaemia,,2022,Q2,1,I,20220404.0,20220515.0,20220525,20220525,EXP,,BR-NOVOPROD-919439,NOVO NORDISK,,62.0,YR,,M,Y,81.5,KG,20220525,,MD,BR,BR,2022,Q2,Adult
208697341,20869734,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,,,Unknown,,,,,,,2022,Q2,Depression,,2022,Q2,1,I,20220404.0,20220515.0,20220525,20220525,EXP,,BR-NOVOPROD-919439,NOVO NORDISK,,62.0,YR,,M,Y,81.5,KG,20220525,,MD,BR,BR,2022,Q2,Adult
208697341,20869734,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,,,Unknown,,,,,,,2022,Q2,Decreased appetite,,2022,Q2,1,I,20220404.0,20220515.0,20220525,20220525,EXP,,BR-NOVOPROD-919439,NOVO NORDISK,,62.0,YR,,M,Y,81.5,KG,20220525,,MD,BR,BR,2022,Q2,Adult
208705471,20870547,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220504.0,20220524.0,20220525,20220525,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172332",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220525,,HP,SG,SG,2022,Q2,Elderly
208713011,20871301,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Treatment failure,,2022,Q2,1,I,,20220518.0,20220525,20220525,EXP,,ES-MYLANLABS-2022M1038794,MYLAN,"Diana DLF, Miguel RJ, Sergio R, Anna F, Elena D-M, Natalia C, et al. SECUKINUMAB and ALITHIASIC PANCREATITIS in A PATIENT with PSORIATIC ARTHRITIS. Eur-J-Clin-Pham 2021;23(3):201-202.",50.0,YR,,M,Y,,,20220525,,HP,ES,ES,2022,Q2,Adult
208715921,20871592,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,U,,,,,,,,,2022,Q2,Limb discomfort,,2022,Q2,1,I,20220513.0,20220517.0,20220525,20220525,EXP,GB-MHRA-TPP2144607C34180YC1652422440700,GB-TORRENT-00028171,TORRENT,,63.0,YR,A,F,Y,94.0,KG,20220525,,MD,GB,GB,2022,Q2,Adult
208715921,20871592,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,U,,,,,,,,,2022,Q2,Nausea,,2022,Q2,1,I,20220513.0,20220517.0,20220525,20220525,EXP,GB-MHRA-TPP2144607C34180YC1652422440700,GB-TORRENT-00028171,TORRENT,,63.0,YR,A,F,Y,94.0,KG,20220525,,MD,GB,GB,2022,Q2,Adult
208715921,20871592,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,U,,,,,,,,,2022,Q2,Constipation,,2022,Q2,1,I,20220513.0,20220517.0,20220525,20220525,EXP,GB-MHRA-TPP2144607C34180YC1652422440700,GB-TORRENT-00028171,TORRENT,,63.0,YR,A,F,Y,94.0,KG,20220525,,MD,GB,GB,2022,Q2,Adult
208715921,20871592,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,U,,,,,,,,,2022,Q2,Dyspnoea,,2022,Q2,1,I,20220513.0,20220517.0,20220525,20220525,EXP,GB-MHRA-TPP2144607C34180YC1652422440700,GB-TORRENT-00028171,TORRENT,,63.0,YR,A,F,Y,94.0,KG,20220525,,MD,GB,GB,2022,Q2,Adult
208715921,20871592,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,U,,,,,,,,,2022,Q2,Headache,,2022,Q2,1,I,20220513.0,20220517.0,20220525,20220525,EXP,GB-MHRA-TPP2144607C34180YC1652422440700,GB-TORRENT-00028171,TORRENT,,63.0,YR,A,F,Y,94.0,KG,20220525,,MD,GB,GB,2022,Q2,Adult
208719412,20871941,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,Unknown,,206111.0,,,,,2022,Q2,Treatment noncompliance,,2022,Q2,2,F,20190701.0,20220531.0,20220525,20220608,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171491",BOEHRINGER INGELHEIM,"Kriz J, Bem R. Case report ? a combined effect of education and motivation of  the patient with the support of dulaglutide. Aktu?ln? medic?na. 61-62.",51.0,YR,A,M,Y,,,20220608,,MD,CZ,CZ,2022,Q2,Adult
208722202,20872220,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Subarachnoid haemorrhage,,2022,Q2,2,F,,20220601.0,20220525,20220608,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171530",BOEHRINGER INGELHEIM,"Bellou I, Karyofylli-Tamisoglou I, Tychalas A, Lazaridis A, Tzatzagou G. OCCURRENCE OF DIABETIC KETOACIDOSIS ON GROUNDS OF VESICOINTESTINAL FISTULA AND INFECTION OF THE URINARY TRACT WITH CANDIDA ALBICANS. 20th Panhellenic Diabetological Conference, 18-21 May 2022. 2022 May 18;",63.0,YR,A,M,Y,,,20220608,,MD,GR,GR,2022,Q2,Adult
208722202,20872220,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Candida infection,,2022,Q2,2,F,,20220601.0,20220525,20220608,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171530",BOEHRINGER INGELHEIM,"Bellou I, Karyofylli-Tamisoglou I, Tychalas A, Lazaridis A, Tzatzagou G. OCCURRENCE OF DIABETIC KETOACIDOSIS ON GROUNDS OF VESICOINTESTINAL FISTULA AND INFECTION OF THE URINARY TRACT WITH CANDIDA ALBICANS. 20th Panhellenic Diabetological Conference, 18-21 May 2022. 2022 May 18;",63.0,YR,A,M,Y,,,20220608,,MD,GR,GR,2022,Q2,Adult
208722202,20872220,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Bladder hypertrophy,,2022,Q2,2,F,,20220601.0,20220525,20220608,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171530",BOEHRINGER INGELHEIM,"Bellou I, Karyofylli-Tamisoglou I, Tychalas A, Lazaridis A, Tzatzagou G. OCCURRENCE OF DIABETIC KETOACIDOSIS ON GROUNDS OF VESICOINTESTINAL FISTULA AND INFECTION OF THE URINARY TRACT WITH CANDIDA ALBICANS. 20th Panhellenic Diabetological Conference, 18-21 May 2022. 2022 May 18;",63.0,YR,A,M,Y,,,20220608,,MD,GR,GR,2022,Q2,Adult
208722202,20872220,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Pyelonephritis,,2022,Q2,2,F,,20220601.0,20220525,20220608,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171530",BOEHRINGER INGELHEIM,"Bellou I, Karyofylli-Tamisoglou I, Tychalas A, Lazaridis A, Tzatzagou G. OCCURRENCE OF DIABETIC KETOACIDOSIS ON GROUNDS OF VESICOINTESTINAL FISTULA AND INFECTION OF THE URINARY TRACT WITH CANDIDA ALBICANS. 20th Panhellenic Diabetological Conference, 18-21 May 2022. 2022 May 18;",63.0,YR,A,M,Y,,,20220608,,MD,GR,GR,2022,Q2,Adult
208722202,20872220,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Acinetobacter bacteraemia,,2022,Q2,2,F,,20220601.0,20220525,20220608,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171530",BOEHRINGER INGELHEIM,"Bellou I, Karyofylli-Tamisoglou I, Tychalas A, Lazaridis A, Tzatzagou G. OCCURRENCE OF DIABETIC KETOACIDOSIS ON GROUNDS OF VESICOINTESTINAL FISTULA AND INFECTION OF THE URINARY TRACT WITH CANDIDA ALBICANS. 20th Panhellenic Diabetological Conference, 18-21 May 2022. 2022 May 18;",63.0,YR,A,M,Y,,,20220608,,MD,GR,GR,2022,Q2,Adult
208722202,20872220,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Acute kidney injury,,2022,Q2,2,F,,20220601.0,20220525,20220608,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171530",BOEHRINGER INGELHEIM,"Bellou I, Karyofylli-Tamisoglou I, Tychalas A, Lazaridis A, Tzatzagou G. OCCURRENCE OF DIABETIC KETOACIDOSIS ON GROUNDS OF VESICOINTESTINAL FISTULA AND INFECTION OF THE URINARY TRACT WITH CANDIDA ALBICANS. 20th Panhellenic Diabetological Conference, 18-21 May 2022. 2022 May 18;",63.0,YR,A,M,Y,,,20220608,,MD,GR,GR,2022,Q2,Adult
208722202,20872220,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Enterovesical fistula,,2022,Q2,2,F,,20220601.0,20220525,20220608,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171530",BOEHRINGER INGELHEIM,"Bellou I, Karyofylli-Tamisoglou I, Tychalas A, Lazaridis A, Tzatzagou G. OCCURRENCE OF DIABETIC KETOACIDOSIS ON GROUNDS OF VESICOINTESTINAL FISTULA AND INFECTION OF THE URINARY TRACT WITH CANDIDA ALBICANS. 20th Panhellenic Diabetological Conference, 18-21 May 2022. 2022 May 18;",63.0,YR,A,M,Y,,,20220608,,MD,GR,GR,2022,Q2,Adult
208722202,20872220,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Hydronephrosis,,2022,Q2,2,F,,20220601.0,20220525,20220608,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171530",BOEHRINGER INGELHEIM,"Bellou I, Karyofylli-Tamisoglou I, Tychalas A, Lazaridis A, Tzatzagou G. OCCURRENCE OF DIABETIC KETOACIDOSIS ON GROUNDS OF VESICOINTESTINAL FISTULA AND INFECTION OF THE URINARY TRACT WITH CANDIDA ALBICANS. 20th Panhellenic Diabetological Conference, 18-21 May 2022. 2022 May 18;",63.0,YR,A,M,Y,,,20220608,,MD,GR,GR,2022,Q2,Adult
208722202,20872220,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,2,F,,20220601.0,20220525,20220608,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171530",BOEHRINGER INGELHEIM,"Bellou I, Karyofylli-Tamisoglou I, Tychalas A, Lazaridis A, Tzatzagou G. OCCURRENCE OF DIABETIC KETOACIDOSIS ON GROUNDS OF VESICOINTESTINAL FISTULA AND INFECTION OF THE URINARY TRACT WITH CANDIDA ALBICANS. 20th Panhellenic Diabetological Conference, 18-21 May 2022. 2022 May 18;",63.0,YR,A,M,Y,,,20220608,,MD,GR,GR,2022,Q2,Adult
208722202,20872220,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Cystitis,,2022,Q2,2,F,,20220601.0,20220525,20220608,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171530",BOEHRINGER INGELHEIM,"Bellou I, Karyofylli-Tamisoglou I, Tychalas A, Lazaridis A, Tzatzagou G. OCCURRENCE OF DIABETIC KETOACIDOSIS ON GROUNDS OF VESICOINTESTINAL FISTULA AND INFECTION OF THE URINARY TRACT WITH CANDIDA ALBICANS. 20th Panhellenic Diabetological Conference, 18-21 May 2022. 2022 May 18;",63.0,YR,A,M,Y,,,20220608,,MD,GR,GR,2022,Q2,Adult
208722202,20872220,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Leukocytosis,,2022,Q2,2,F,,20220601.0,20220525,20220608,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171530",BOEHRINGER INGELHEIM,"Bellou I, Karyofylli-Tamisoglou I, Tychalas A, Lazaridis A, Tzatzagou G. OCCURRENCE OF DIABETIC KETOACIDOSIS ON GROUNDS OF VESICOINTESTINAL FISTULA AND INFECTION OF THE URINARY TRACT WITH CANDIDA ALBICANS. 20th Panhellenic Diabetological Conference, 18-21 May 2022. 2022 May 18;",63.0,YR,A,M,Y,,,20220608,,MD,GR,GR,2022,Q2,Adult
208722202,20872220,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Metabolic acidosis,,2022,Q2,2,F,,20220601.0,20220525,20220608,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-171530",BOEHRINGER INGELHEIM,"Bellou I, Karyofylli-Tamisoglou I, Tychalas A, Lazaridis A, Tzatzagou G. OCCURRENCE OF DIABETIC KETOACIDOSIS ON GROUNDS OF VESICOINTESTINAL FISTULA AND INFECTION OF THE URINARY TRACT WITH CANDIDA ALBICANS. 20th Panhellenic Diabetological Conference, 18-21 May 2022. 2022 May 18;",63.0,YR,A,M,Y,,,20220608,,MD,GR,GR,2022,Q2,Adult
208722411,20872241,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q2,Nausea,,2022,Q2,1,I,20220513.0,20220517.0,20220525,20220525,EXP,GB-MHRA-ADR 26923321,GB-Accord-264049,ACCORD,,63.0,YR,,F,Y,94.0,KG,20220525,,MD,GB,GB,2022,Q2,Adult
208722411,20872241,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q2,Dyspnoea,,2022,Q2,1,I,20220513.0,20220517.0,20220525,20220525,EXP,GB-MHRA-ADR 26923321,GB-Accord-264049,ACCORD,,63.0,YR,,F,Y,94.0,KG,20220525,,MD,GB,GB,2022,Q2,Adult
208722411,20872241,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q2,Limb discomfort,,2022,Q2,1,I,20220513.0,20220517.0,20220525,20220525,EXP,GB-MHRA-ADR 26923321,GB-Accord-264049,ACCORD,,63.0,YR,,F,Y,94.0,KG,20220525,,MD,GB,GB,2022,Q2,Adult
208722411,20872241,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q2,Headache,,2022,Q2,1,I,20220513.0,20220517.0,20220525,20220525,EXP,GB-MHRA-ADR 26923321,GB-Accord-264049,ACCORD,,63.0,YR,,F,Y,94.0,KG,20220525,,MD,GB,GB,2022,Q2,Adult
208722411,20872241,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q2,Constipation,,2022,Q2,1,I,20220513.0,20220517.0,20220525,20220525,EXP,GB-MHRA-ADR 26923321,GB-Accord-264049,ACCORD,,63.0,YR,,F,Y,94.0,KG,20220525,,MD,GB,GB,2022,Q2,Adult
208725421,20872542,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Unknown,,2022,Q2,Thrombocytopenia,,2022,Q2,1,I,20220502.0,20220512.0,20220525,20220525,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-040151,BRISTOL MYERS SQUIBB,,57.0,YR,A,F,Y,,,20220525,,MD,PT,PT,2022,Q2,Adult
208725421,20872542,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Unknown,,2022,Q2,Malignant neoplasm progression,,2022,Q2,1,I,20220502.0,20220512.0,20220525,20220525,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-040151,BRISTOL MYERS SQUIBB,,57.0,YR,A,F,Y,,,20220525,,MD,PT,PT,2022,Q2,Adult
208725421,20872542,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Unknown,,2022,Q2,Pulmonary oedema,,2022,Q2,1,I,20220502.0,20220512.0,20220525,20220525,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-040151,BRISTOL MYERS SQUIBB,,57.0,YR,A,F,Y,,,20220525,,MD,PT,PT,2022,Q2,Adult
208725421,20872542,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Thrombocytopenia,,2022,Q2,1,I,20220502.0,20220512.0,20220525,20220525,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-040151,BRISTOL MYERS SQUIBB,,57.0,YR,A,F,Y,,,20220525,,MD,PT,PT,2022,Q2,Adult
208725421,20872542,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Malignant neoplasm progression,,2022,Q2,1,I,20220502.0,20220512.0,20220525,20220525,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-040151,BRISTOL MYERS SQUIBB,,57.0,YR,A,F,Y,,,20220525,,MD,PT,PT,2022,Q2,Adult
208725421,20872542,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Pulmonary oedema,,2022,Q2,1,I,20220502.0,20220512.0,20220525,20220525,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-040151,BRISTOL MYERS SQUIBB,,57.0,YR,A,F,Y,,,20220525,,MD,PT,PT,2022,Q2,Adult
208725421,20872542,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Unknown,,2022,Q2,Thrombocytopenia,,2022,Q2,1,I,20220502.0,20220512.0,20220525,20220525,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-040151,BRISTOL MYERS SQUIBB,,57.0,YR,A,F,Y,,,20220525,,MD,PT,PT,2022,Q2,Adult
208725421,20872542,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Unknown,,2022,Q2,Malignant neoplasm progression,,2022,Q2,1,I,20220502.0,20220512.0,20220525,20220525,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-040151,BRISTOL MYERS SQUIBB,,57.0,YR,A,F,Y,,,20220525,,MD,PT,PT,2022,Q2,Adult
208725421,20872542,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,Unknown,,2022,Q2,Pulmonary oedema,,2022,Q2,1,I,20220502.0,20220512.0,20220525,20220525,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-040151,BRISTOL MYERS SQUIBB,,57.0,YR,A,F,Y,,,20220525,,MD,PT,PT,2022,Q2,Adult
208728401,20872840,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK (Dosage form: Unknown),,,U,U,,,,,,,,2022,Q2,Malignant neoplasm progression,,2022,Q2,1,I,20220502.0,20220519.0,20220525,20220525,EXP,,PT-MYLANLABS-2022M1029632,MYLAN,,57.0,YR,,F,Y,,,20220525,,MD,PT,PT,2022,Q2,Adult
208728401,20872840,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK (Dosage form: Unknown),,,U,U,,,,,,,,2022,Q2,Thrombocytopenia,,2022,Q2,1,I,20220502.0,20220519.0,20220525,20220525,EXP,,PT-MYLANLABS-2022M1029632,MYLAN,,57.0,YR,,F,Y,,,20220525,,MD,PT,PT,2022,Q2,Adult
208728401,20872840,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK (Dosage form: Unknown),,,U,U,,,,,,,,2022,Q2,Pulmonary oedema,,2022,Q2,1,I,20220502.0,20220519.0,20220525,20220525,EXP,,PT-MYLANLABS-2022M1029632,MYLAN,,57.0,YR,,F,Y,,,20220525,,MD,PT,PT,2022,Q2,Adult
208736214,20873621,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q2,Ischaemic cardiomyopathy,,2022,Q2,4,F,20201201.0,20220622.0,20220525,20220623,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2022-045637,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,,,20220623,,MD,HR,HR,2022,Q2,Elderly
208736214,20873621,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q2,Aortic valve incompetence,,2022,Q2,4,F,20201201.0,20220622.0,20220525,20220623,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2022-045637,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,,,20220623,,MD,HR,HR,2022,Q2,Elderly
208736214,20873621,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q2,Angina pectoris,,2022,Q2,4,F,20201201.0,20220622.0,20220525,20220623,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2022-045637,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,,,20220623,,MD,HR,HR,2022,Q2,Elderly
208736214,20873621,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q2,Angina unstable,,2022,Q2,4,F,20201201.0,20220622.0,20220525,20220623,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2022-045637,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,,,20220623,,MD,HR,HR,2022,Q2,Elderly
208736214,20873621,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q2,Mitral valve incompetence,,2022,Q2,4,F,20201201.0,20220622.0,20220525,20220623,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2022-045637,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,,,20220623,,MD,HR,HR,2022,Q2,Elderly
208736214,20873621,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Ischaemic cardiomyopathy,,2022,Q2,4,F,20201201.0,20220622.0,20220525,20220623,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2022-045637,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,,,20220623,,MD,HR,HR,2022,Q2,Elderly
208736214,20873621,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Aortic valve incompetence,,2022,Q2,4,F,20201201.0,20220622.0,20220525,20220623,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2022-045637,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,,,20220623,,MD,HR,HR,2022,Q2,Elderly
208736214,20873621,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Angina pectoris,,2022,Q2,4,F,20201201.0,20220622.0,20220525,20220623,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2022-045637,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,,,20220623,,MD,HR,HR,2022,Q2,Elderly
208736214,20873621,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Angina unstable,,2022,Q2,4,F,20201201.0,20220622.0,20220525,20220623,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2022-045637,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,,,20220623,,MD,HR,HR,2022,Q2,Elderly
208736214,20873621,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Mitral valve incompetence,,2022,Q2,4,F,20201201.0,20220622.0,20220525,20220623,EXP,,HR-BRISTOL-MYERS SQUIBB COMPANY-2022-045637,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,,,20220623,,MD,HR,HR,2022,Q2,Elderly
208768111,20876811,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,UNKNOWN,,,,,,,2022,Q2,Sepsis,,2022,Q2,1,I,20220301.0,20220513.0,20220526,20220526,EXP,,JP-ROCHE-3101575,ROCHE,,70.0,YR,,F,Y,59.0,KG,20220526,,MD,JP,JP,2022,Q2,Elderly
208768111,20876811,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,UNKNOWN,,,,,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220301.0,20220513.0,20220526,20220526,EXP,,JP-ROCHE-3101575,ROCHE,,70.0,YR,,F,Y,59.0,KG,20220526,,MD,JP,JP,2022,Q2,Elderly
208768111,20876811,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,UNKNOWN,,,,,,,2022,Q2,Anaemia,,2022,Q2,1,I,20220301.0,20220513.0,20220526,20220526,EXP,,JP-ROCHE-3101575,ROCHE,,70.0,YR,,F,Y,59.0,KG,20220526,,MD,JP,JP,2022,Q2,Elderly
208768111,20876811,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,UNKNOWN,,,,,,,2022,Q2,Acute respiratory distress syndrome,,2022,Q2,1,I,20220301.0,20220513.0,20220526,20220526,EXP,,JP-ROCHE-3101575,ROCHE,,70.0,YR,,F,Y,59.0,KG,20220526,,MD,JP,JP,2022,Q2,Elderly
208768111,20876811,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,UNKNOWN,,,,,,,2022,Q2,Disseminated intravascular coagulation,,2022,Q2,1,I,20220301.0,20220513.0,20220526,20220526,EXP,,JP-ROCHE-3101575,ROCHE,,70.0,YR,,F,Y,59.0,KG,20220526,,MD,JP,JP,2022,Q2,Elderly
208770751,20877075,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,D63643,20240630.0,,,,,QD,2022,Q2,Vomiting,,2022,Q2,1,I,20220521.0,,20220526,20220526,DIR,FDA-CDER-CTU-2022-41614,,FDA-CTU,,75.0,YR,,F,N,78.0,KG,20220525,N,PH,US,,2022,Q2,Elderly
208770751,20877075,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,D63643,20240630.0,,,,,QD,2022,Q2,Nausea,,2022,Q2,1,I,20220521.0,,20220526,20220526,DIR,FDA-CDER-CTU-2022-41614,,FDA-CTU,,75.0,YR,,F,N,78.0,KG,20220525,N,PH,US,,2022,Q2,Elderly
208770751,20877075,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,D63643,20240630.0,,,,,QD,2022,Q2,Abdominal pain,,2022,Q2,1,I,20220521.0,,20220526,20220526,DIR,FDA-CDER-CTU-2022-41614,,FDA-CTU,,75.0,YR,,F,N,78.0,KG,20220525,N,PH,US,,2022,Q2,Elderly
208770751,20877075,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,D63643,20240630.0,,,,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20220521.0,,20220526,20220526,DIR,FDA-CDER-CTU-2022-41614,,FDA-CTU,,75.0,YR,,F,N,78.0,KG,20220525,N,PH,US,,2022,Q2,Elderly
208770811,20877081,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2022,Q2,Hypercalcaemia,,2022,Q2,1,I,20220422.0,,20220526,20220526,DIR,FDA-CDER-CTU-2022-41615,,FDA-CTU,,81.0,YR,,M,N,,,20220524,N,HP,US,,2022,Q2,Elderly
208771571,20877157,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q2,Fournier's gangrene,,2022,Q2,1,I,20220519.0,,20220526,20220526,DIR,FDA-CDER-CTU-2022-41627,,FDA-CTU,,79.0,YR,,M,N,,,20220524,N,PH,US,,2022,Q2,Elderly
208772491,20877249,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q2,Therapy interrupted,,2022,Q2,1,I,20220224.0,,20220526,20220526,DIR,FDA-CDER-CTU-2022-41652,,FDA-CTU,,71.0,YR,,M,N,105.0,KG,20220520,N,PH,US,,2022,Q2,Elderly
208772491,20877249,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q2,Culture urine positive,,2022,Q2,1,I,20220224.0,,20220526,20220526,DIR,FDA-CDER-CTU-2022-41652,,FDA-CTU,,71.0,YR,,M,N,105.0,KG,20220520,N,PH,US,,2022,Q2,Elderly
208772491,20877249,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q2,Nephrolithiasis,,2022,Q2,1,I,20220224.0,,20220526,20220526,DIR,FDA-CDER-CTU-2022-41652,,FDA-CTU,,71.0,YR,,M,N,105.0,KG,20220520,N,PH,US,,2022,Q2,Elderly
208772491,20877249,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q2,Urinary tract infection,,2022,Q2,1,I,20220224.0,,20220526,20220526,DIR,FDA-CDER-CTU-2022-41652,,FDA-CTU,,71.0,YR,,M,N,105.0,KG,20220520,N,PH,US,,2022,Q2,Elderly
208772491,20877249,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q2,Cholecystitis,,2022,Q2,1,I,20220224.0,,20220526,20220526,DIR,FDA-CDER-CTU-2022-41652,,FDA-CTU,,71.0,YR,,M,N,105.0,KG,20220520,N,PH,US,,2022,Q2,Elderly
208772491,20877249,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q2,Nephrolithiasis,,2022,Q2,1,I,20220224.0,,20220526,20220526,DIR,FDA-CDER-CTU-2022-41652,,FDA-CTU,,71.0,YR,,M,N,105.0,KG,20220520,N,PH,US,,2022,Q2,Elderly
208779821,20877982,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Sepsis,,2022,Q2,1,I,20211001.0,20220523.0,20220526,20220526,EXP,,CA-MYLANLABS-2021M1073650,MYLAN,,64.0,YR,,F,Y,,,20220526,,PH,CA,CA,2022,Q2,Adult
208779821,20877982,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Death,,2022,Q2,1,I,20211001.0,20220523.0,20220526,20220526,EXP,,CA-MYLANLABS-2021M1073650,MYLAN,,64.0,YR,,F,Y,,,20220526,,PH,CA,CA,2022,Q2,Adult
208779821,20877982,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Megacolon,,2022,Q2,1,I,20211001.0,20220523.0,20220526,20220526,EXP,,CA-MYLANLABS-2021M1073650,MYLAN,,64.0,YR,,F,Y,,,20220526,,PH,CA,CA,2022,Q2,Adult
208782771,20878277,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20220523.0,20220525.0,20220526,20220526,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172711",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20220526,,PH,GB,GB,2022,Q2,Elderly
208785881,20878588,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Atrioventricular block,,2022,Q2,1,I,,20220518.0,20220526,20220526,EXP,,AT-EMD Serono-E2B_90087887,EMD SERONO INC,Koudelka M. Herausforderung Polypharmazie    Vor allem bei alteren Menschen: Ein Medikament kommt selten allein. Hausarzt: in. 2022;9:45-48,72.0,YR,E,F,Y,,,20220526,,HP,AT,AT,2022,Q2,Elderly
208785881,20878588,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Internal haemorrhage,,2022,Q2,1,I,,20220518.0,20220526,20220526,EXP,,AT-EMD Serono-E2B_90087887,EMD SERONO INC,Koudelka M. Herausforderung Polypharmazie    Vor allem bei alteren Menschen: Ein Medikament kommt selten allein. Hausarzt: in. 2022;9:45-48,72.0,YR,E,F,Y,,,20220526,,HP,AT,AT,2022,Q2,Elderly
208785881,20878588,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Intestinal haemorrhage,,2022,Q2,1,I,,20220518.0,20220526,20220526,EXP,,AT-EMD Serono-E2B_90087887,EMD SERONO INC,Koudelka M. Herausforderung Polypharmazie    Vor allem bei alteren Menschen: Ein Medikament kommt selten allein. Hausarzt: in. 2022;9:45-48,72.0,YR,E,F,Y,,,20220526,,HP,AT,AT,2022,Q2,Elderly
208785881,20878588,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Labelled drug-drug interaction medication error,,2022,Q2,1,I,,20220518.0,20220526,20220526,EXP,,AT-EMD Serono-E2B_90087887,EMD SERONO INC,Koudelka M. Herausforderung Polypharmazie    Vor allem bei alteren Menschen: Ein Medikament kommt selten allein. Hausarzt: in. 2022;9:45-48,72.0,YR,E,F,Y,,,20220526,,HP,AT,AT,2022,Q2,Elderly
208785881,20878588,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Loss of consciousness,,2022,Q2,1,I,,20220518.0,20220526,20220526,EXP,,AT-EMD Serono-E2B_90087887,EMD SERONO INC,Koudelka M. Herausforderung Polypharmazie    Vor allem bei alteren Menschen: Ein Medikament kommt selten allein. Hausarzt: in. 2022;9:45-48,72.0,YR,E,F,Y,,,20220526,,HP,AT,AT,2022,Q2,Elderly
208825221,20882522,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Foreign body ingestion,,2022,Q2,1,I,,20220520.0,20220527,20220527,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172195",BOEHRINGER INGELHEIM,"Kang C, Khamooshi P, Pinzon V. An unsuspected case of euglycemic diabetic ketoacidosis with twists. Cureus. 2022 Apr 10; 14;4: 24016-",34.0,YR,A,F,Y,,,20220527,,HP,US,US,2022,Q2,Young Adult
208825221,20882522,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220520.0,20220527,20220527,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172195",BOEHRINGER INGELHEIM,"Kang C, Khamooshi P, Pinzon V. An unsuspected case of euglycemic diabetic ketoacidosis with twists. Cureus. 2022 Apr 10; 14;4: 24016-",34.0,YR,A,F,Y,,,20220527,,HP,US,US,2022,Q2,Young Adult
208825221,20882522,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Hypophagia,,2022,Q2,1,I,,20220520.0,20220527,20220527,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172195",BOEHRINGER INGELHEIM,"Kang C, Khamooshi P, Pinzon V. An unsuspected case of euglycemic diabetic ketoacidosis with twists. Cureus. 2022 Apr 10; 14;4: 24016-",34.0,YR,A,F,Y,,,20220527,,HP,US,US,2022,Q2,Young Adult
208825221,20882522,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Off label use,,2022,Q2,1,I,,20220520.0,20220527,20220527,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172195",BOEHRINGER INGELHEIM,"Kang C, Khamooshi P, Pinzon V. An unsuspected case of euglycemic diabetic ketoacidosis with twists. Cureus. 2022 Apr 10; 14;4: 24016-",34.0,YR,A,F,Y,,,20220527,,HP,US,US,2022,Q2,Young Adult
208825221,20882522,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Sensation of foreign body,,2022,Q2,1,I,,20220520.0,20220527,20220527,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172195",BOEHRINGER INGELHEIM,"Kang C, Khamooshi P, Pinzon V. An unsuspected case of euglycemic diabetic ketoacidosis with twists. Cureus. 2022 Apr 10; 14;4: 24016-",34.0,YR,A,F,Y,,,20220527,,HP,US,US,2022,Q2,Young Adult
208825221,20882522,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Oropharyngeal pain,,2022,Q2,1,I,,20220520.0,20220527,20220527,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172195",BOEHRINGER INGELHEIM,"Kang C, Khamooshi P, Pinzon V. An unsuspected case of euglycemic diabetic ketoacidosis with twists. Cureus. 2022 Apr 10; 14;4: 24016-",34.0,YR,A,F,Y,,,20220527,,HP,US,US,2022,Q2,Young Adult
208856892,20885689,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,Y,U,Unknown,,206111.0,12.5,MG,Tablet,Q12H,2022,Q2,Pollakiuria,,2022,Q2,2,F,20220208.0,20220614.0,20220527,20220617,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173003",BOEHRINGER INGELHEIM,,8.0,DEC,E,F,Y,70.0,KG,20220617,,MD,IL,IL,2022,Q2,Child
208856892,20885689,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,Y,U,Unknown,,206111.0,12.5,MG,Tablet,Q12H,2022,Q2,Face injury,,2022,Q2,2,F,20220208.0,20220614.0,20220527,20220617,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173003",BOEHRINGER INGELHEIM,,8.0,DEC,E,F,Y,70.0,KG,20220617,,MD,IL,IL,2022,Q2,Child
208856892,20885689,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,Y,U,Unknown,,206111.0,12.5,MG,Tablet,Q12H,2022,Q2,Ventricular tachycardia,,2022,Q2,2,F,20220208.0,20220614.0,20220527,20220617,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173003",BOEHRINGER INGELHEIM,,8.0,DEC,E,F,Y,70.0,KG,20220617,,MD,IL,IL,2022,Q2,Child
208856892,20885689,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,Y,U,Unknown,,206111.0,12.5,MG,Tablet,Q12H,2022,Q2,Diabetic ketoacidosis,,2022,Q2,2,F,20220208.0,20220614.0,20220527,20220617,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173003",BOEHRINGER INGELHEIM,,8.0,DEC,E,F,Y,70.0,KG,20220617,,MD,IL,IL,2022,Q2,Child
208856892,20885689,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,Y,U,Unknown,,206111.0,12.5,MG,Tablet,Q12H,2022,Q2,Glucose urine,,2022,Q2,2,F,20220208.0,20220614.0,20220527,20220617,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173003",BOEHRINGER INGELHEIM,,8.0,DEC,E,F,Y,70.0,KG,20220617,,MD,IL,IL,2022,Q2,Child
208856892,20885689,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,Y,U,Unknown,,206111.0,12.5,MG,Tablet,Q12H,2022,Q2,Mechanical ventilation,,2022,Q2,2,F,20220208.0,20220614.0,20220527,20220617,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173003",BOEHRINGER INGELHEIM,,8.0,DEC,E,F,Y,70.0,KG,20220617,,MD,IL,IL,2022,Q2,Child
208856892,20885689,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,Y,U,Unknown,,206111.0,12.5,MG,Tablet,Q12H,2022,Q2,Ventricular fibrillation,,2022,Q2,2,F,20220208.0,20220614.0,20220527,20220617,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173003",BOEHRINGER INGELHEIM,,8.0,DEC,E,F,Y,70.0,KG,20220617,,MD,IL,IL,2022,Q2,Child
208856892,20885689,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,Y,U,Unknown,,206111.0,12.5,MG,Tablet,Q12H,2022,Q2,Dehydration,,2022,Q2,2,F,20220208.0,20220614.0,20220527,20220617,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173003",BOEHRINGER INGELHEIM,,8.0,DEC,E,F,Y,70.0,KG,20220617,,MD,IL,IL,2022,Q2,Child
208859591,20885959,6,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Urticaria,,2022,Q2,1,I,20220301.0,20220523.0,20220527,20220527,EXP,,JP-PFIZER INC-202200405204,PFIZER,,59.0,YR,,F,Y,,,20220527,,PH,JP,JP,2022,Q2,Adult
208859591,20885959,6,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,,,,,,Tablet,,2022,Q2,Anaphylactic shock,,2022,Q2,1,I,20220301.0,20220523.0,20220527,20220527,EXP,,JP-PFIZER INC-202200405204,PFIZER,,59.0,YR,,F,Y,,,20220527,,PH,JP,JP,2022,Q2,Adult
208913731,20891373,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Asked But Unknown,,204629.0,,,Film-coated tablet,,2022,Q2,Nausea,,2022,Q2,1,I,20220502.0,20220530.0,20220530,20220530,EXP,LT-SMCA-4561,"LT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173444",BOEHRINGER INGELHEIM,,46.0,YR,A,F,Y,119.0,KG,20220530,,MD,LT,LT,2022,Q2,Adult
208913731,20891373,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Asked But Unknown,,204629.0,,,Film-coated tablet,,2022,Q2,Ketoacidosis,,2022,Q2,1,I,20220502.0,20220530.0,20220530,20220530,EXP,LT-SMCA-4561,"LT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173444",BOEHRINGER INGELHEIM,,46.0,YR,A,F,Y,119.0,KG,20220530,,MD,LT,LT,2022,Q2,Adult
208913731,20891373,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Asked But Unknown,,204629.0,,,Film-coated tablet,,2022,Q2,Asthenia,,2022,Q2,1,I,20220502.0,20220530.0,20220530,20220530,EXP,LT-SMCA-4561,"LT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173444",BOEHRINGER INGELHEIM,,46.0,YR,A,F,Y,119.0,KG,20220530,,MD,LT,LT,2022,Q2,Adult
208913731,20891373,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Asked But Unknown,,204629.0,,,Film-coated tablet,,2022,Q2,Abdominal pain,,2022,Q2,1,I,20220502.0,20220530.0,20220530,20220530,EXP,LT-SMCA-4561,"LT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173444",BOEHRINGER INGELHEIM,,46.0,YR,A,F,Y,119.0,KG,20220530,,MD,LT,LT,2022,Q2,Adult
208915331,20891533,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q2,Headache,,2022,Q2,1,I,20220513.0,20220517.0,20220530,20220530,EXP,GB-MHRA-TPP2144607C34180YC1652422440700,GB-BIOCON-BCN-2022-000458,BIOCON,,63.0,YR,A,F,Y,94.0,KG,20220530,,MD,GB,GB,2022,Q2,Adult
208915331,20891533,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q2,Nausea,,2022,Q2,1,I,20220513.0,20220517.0,20220530,20220530,EXP,GB-MHRA-TPP2144607C34180YC1652422440700,GB-BIOCON-BCN-2022-000458,BIOCON,,63.0,YR,A,F,Y,94.0,KG,20220530,,MD,GB,GB,2022,Q2,Adult
208915331,20891533,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q2,Dyspnoea,,2022,Q2,1,I,20220513.0,20220517.0,20220530,20220530,EXP,GB-MHRA-TPP2144607C34180YC1652422440700,GB-BIOCON-BCN-2022-000458,BIOCON,,63.0,YR,A,F,Y,94.0,KG,20220530,,MD,GB,GB,2022,Q2,Adult
208915331,20891533,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q2,Constipation,,2022,Q2,1,I,20220513.0,20220517.0,20220530,20220530,EXP,GB-MHRA-TPP2144607C34180YC1652422440700,GB-BIOCON-BCN-2022-000458,BIOCON,,63.0,YR,A,F,Y,94.0,KG,20220530,,MD,GB,GB,2022,Q2,Adult
208915331,20891533,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q2,Limb discomfort,,2022,Q2,1,I,20220513.0,20220517.0,20220530,20220530,EXP,GB-MHRA-TPP2144607C34180YC1652422440700,GB-BIOCON-BCN-2022-000458,BIOCON,,63.0,YR,A,F,Y,94.0,KG,20220530,,MD,GB,GB,2022,Q2,Adult
208915401,20891540,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK, qd",,,,,,,,,,Tablet,QD,2022,Q2,Pruritus,,2022,Q2,1,I,20220429.0,20220525.0,20220530,20220530,EXP,,JP-009507513-2205JPN000202J,MERCK,,83.0,YR,,F,Y,,,20220530,,PH,JP,JP,2022,Q2,Elderly
208915401,20891540,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK, qd",,,,,,,,,,Tablet,QD,2022,Q2,Eczema,,2022,Q2,1,I,20220429.0,20220525.0,20220530,20220530,EXP,,JP-009507513-2205JPN000202J,MERCK,,83.0,YR,,F,Y,,,20220530,,PH,JP,JP,2022,Q2,Elderly
208944861,20894486,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2022,Q2,Acute myocardial infarction,,2022,Q2,1,I,20210101.0,20220520.0,20220531,20220531,EXP,,JP-MYLANLABS-2022M1040101,MYLAN,,87.0,YR,,M,Y,55.0,KG,20220531,,MD,JP,JP,2022,Q2,Elderly
208949001,20894900,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,,,Unknown,,,,,,QD,2022,Q2,Polycythaemia,,2022,Q2,1,I,,20220518.0,20220531,20220531,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-07793,LUPIN,Schumacher K. Hereditary hemochromatosis gene mutation in patients developing erythrocytosis on combined testosterone replacement and sglt-2 inhibitor therapy: a case series. Endocrine Practice. 2022;28:S19-S20,74.0,YR,,M,Y,,,20220531,,HP,US,US,2022,Q2,Elderly
208949001,20894900,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,Unknown,,,,,,QD,2022,Q2,Polycythaemia,,2022,Q2,1,I,,20220518.0,20220531,20220531,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-07793,LUPIN,Schumacher K. Hereditary hemochromatosis gene mutation in patients developing erythrocytosis on combined testosterone replacement and sglt-2 inhibitor therapy: a case series. Endocrine Practice. 2022;28:S19-S20,74.0,YR,,M,Y,,,20220531,,HP,US,US,2022,Q2,Elderly
208949442,20894944,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q2,Renal failure,,2022,Q2,2,F,,20220607.0,20220531,20220616,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173463",BOEHRINGER INGELHEIM,Red . Gliflozins together in the hands of cardiologists and diabetologists. Medical Tribune. 2-4.,72.0,YR,E,M,Y,,,20220616,,HP,CZ,CZ,2022,Q2,Elderly
208952281,20895228,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220523.0,20220531,20220531,EXP,,US-MYLANLABS-2022M1039880,MYLAN,"Yu Htoo ST, Califano T, Kole A. Multifactorial case of Euglycemic Diabetic Ketoacidosis following an initiation of Sodium-glucose Cotransporter 2 Inhibitor. Endocr-Pract 2022;28 (Suppl.)(5):S35 abstr. 1181778.",54.0,YR,,F,Y,,,20220531,,MD,US,US,2022,Q2,Adult
208952281,20895228,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q2,Withdrawal syndrome,,2022,Q2,1,I,,20220523.0,20220531,20220531,EXP,,US-MYLANLABS-2022M1039880,MYLAN,"Yu Htoo ST, Califano T, Kole A. Multifactorial case of Euglycemic Diabetic Ketoacidosis following an initiation of Sodium-glucose Cotransporter 2 Inhibitor. Endocr-Pract 2022;28 (Suppl.)(5):S35 abstr. 1181778.",54.0,YR,,F,Y,,,20220531,,MD,US,US,2022,Q2,Adult
208958011,20895801,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220525.0,20220531,20220531,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172885",BOEHRINGER INGELHEIM,"Shin J, Seger C, Xing H, Wang L. Intraoperative Diagnosis of Sodium-Glucose Cotransporter 2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report. A+A Practice. 2021; 15 (1): 01380-01380.",55.0,YR,A,M,Y,,,20220531,,MD,US,US,2022,Q2,Adult
208958011,20895801,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Metabolic acidosis,,2022,Q2,1,I,,20220525.0,20220531,20220531,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172885",BOEHRINGER INGELHEIM,"Shin J, Seger C, Xing H, Wang L. Intraoperative Diagnosis of Sodium-Glucose Cotransporter 2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report. A+A Practice. 2021; 15 (1): 01380-01380.",55.0,YR,A,M,Y,,,20220531,,MD,US,US,2022,Q2,Adult
208960431,20896043,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20220523.0,20220531.0,20220531,20220531,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173711",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20220531,,PH,GB,GB,2022,Q2,Elderly
208985521,20898552,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,,,,,,,,,QD,2022,Q2,Limb discomfort,,2022,Q2,1,I,20220513.0,20220517.0,20220601,20220601,EXP,,GB-AUROBINDO-AUR-APL-2022-018617,AUROBINDO,,63.0,YR,,F,Y,94.0,KG,20220601,,MD,GB,GB,2022,Q2,Adult
208985521,20898552,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,,,,,,,,,QD,2022,Q2,Constipation,,2022,Q2,1,I,20220513.0,20220517.0,20220601,20220601,EXP,,GB-AUROBINDO-AUR-APL-2022-018617,AUROBINDO,,63.0,YR,,F,Y,94.0,KG,20220601,,MD,GB,GB,2022,Q2,Adult
208985521,20898552,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,,,,,,,,,QD,2022,Q2,Headache,,2022,Q2,1,I,20220513.0,20220517.0,20220601,20220601,EXP,,GB-AUROBINDO-AUR-APL-2022-018617,AUROBINDO,,63.0,YR,,F,Y,94.0,KG,20220601,,MD,GB,GB,2022,Q2,Adult
208985521,20898552,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,,,,,,,,,QD,2022,Q2,Dyspnoea,,2022,Q2,1,I,20220513.0,20220517.0,20220601,20220601,EXP,,GB-AUROBINDO-AUR-APL-2022-018617,AUROBINDO,,63.0,YR,,F,Y,94.0,KG,20220601,,MD,GB,GB,2022,Q2,Adult
208985521,20898552,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day",,,,,,,,,,,QD,2022,Q2,Nausea,,2022,Q2,1,I,20220513.0,20220517.0,20220601,20220601,EXP,,GB-AUROBINDO-AUR-APL-2022-018617,AUROBINDO,,63.0,YR,,F,Y,94.0,KG,20220601,,MD,GB,GB,2022,Q2,Adult
208987961,20898796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2022,Q2,Nocturia,,2022,Q2,1,I,,20220525.0,20220601,20220601,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172804",BOEHRINGER INGELHEIM,"Hester J, Nimmo T, Liu J, Sukpraprut-Braaten S, Pasquel F, Zimmerman S. et al. Euglycemic Diabetic Ketoacidosis Secondary to SGLT2- inhibitor Use in Combination with a Ketogenic Diet: A Case Report. Endocrine Practice. 2021; 27: 25-25.",72.0,YR,E,F,Y,,,20220601,,MD,US,US,2022,Q2,Elderly
208987961,20898796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2022,Q2,Fall,,2022,Q2,1,I,,20220525.0,20220601,20220601,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172804",BOEHRINGER INGELHEIM,"Hester J, Nimmo T, Liu J, Sukpraprut-Braaten S, Pasquel F, Zimmerman S. et al. Euglycemic Diabetic Ketoacidosis Secondary to SGLT2- inhibitor Use in Combination with a Ketogenic Diet: A Case Report. Endocrine Practice. 2021; 27: 25-25.",72.0,YR,E,F,Y,,,20220601,,MD,US,US,2022,Q2,Elderly
208987961,20898796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2022,Q2,Lower limb fracture,,2022,Q2,1,I,,20220525.0,20220601,20220601,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172804",BOEHRINGER INGELHEIM,"Hester J, Nimmo T, Liu J, Sukpraprut-Braaten S, Pasquel F, Zimmerman S. et al. Euglycemic Diabetic Ketoacidosis Secondary to SGLT2- inhibitor Use in Combination with a Ketogenic Diet: A Case Report. Endocrine Practice. 2021; 27: 25-25.",72.0,YR,E,F,Y,,,20220601,,MD,US,US,2022,Q2,Elderly
208987961,20898796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220525.0,20220601,20220601,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172804",BOEHRINGER INGELHEIM,"Hester J, Nimmo T, Liu J, Sukpraprut-Braaten S, Pasquel F, Zimmerman S. et al. Euglycemic Diabetic Ketoacidosis Secondary to SGLT2- inhibitor Use in Combination with a Ketogenic Diet: A Case Report. Endocrine Practice. 2021; 27: 25-25.",72.0,YR,E,F,Y,,,20220601,,MD,US,US,2022,Q2,Elderly
208987961,20898796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,,,,,2022,Q2,Ankle fracture,,2022,Q2,1,I,,20220525.0,20220601,20220601,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-172804",BOEHRINGER INGELHEIM,"Hester J, Nimmo T, Liu J, Sukpraprut-Braaten S, Pasquel F, Zimmerman S. et al. Euglycemic Diabetic Ketoacidosis Secondary to SGLT2- inhibitor Use in Combination with a Ketogenic Diet: A Case Report. Endocrine Practice. 2021; 27: 25-25.",72.0,YR,E,F,Y,,,20220601,,MD,US,US,2022,Q2,Elderly
209002883,20900288,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2022,Q2,Ischaemic cardiomyopathy,,2022,Q2,3,F,20201201.0,20220614.0,20220601,20220621,EXP,,HR-SANOFI US-2022SA201379,SANOFI AVENTIS,,85.0,YR,E,M,Y,,,20220621,,CN,HR,HR,2022,Q2,Elderly
209002883,20900288,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2022,Q2,Angina unstable,,2022,Q2,3,F,20201201.0,20220614.0,20220601,20220621,EXP,,HR-SANOFI US-2022SA201379,SANOFI AVENTIS,,85.0,YR,E,M,Y,,,20220621,,CN,HR,HR,2022,Q2,Elderly
209002883,20900288,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2022,Q2,Aortic valve incompetence,,2022,Q2,3,F,20201201.0,20220614.0,20220601,20220621,EXP,,HR-SANOFI US-2022SA201379,SANOFI AVENTIS,,85.0,YR,E,M,Y,,,20220621,,CN,HR,HR,2022,Q2,Elderly
209002883,20900288,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2022,Q2,Mitral valve incompetence,,2022,Q2,3,F,20201201.0,20220614.0,20220601,20220621,EXP,,HR-SANOFI US-2022SA201379,SANOFI AVENTIS,,85.0,YR,E,M,Y,,,20220621,,CN,HR,HR,2022,Q2,Elderly
209002883,20900288,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2022,Q2,Angina pectoris,,2022,Q2,3,F,20201201.0,20220614.0,20220601,20220621,EXP,,HR-SANOFI US-2022SA201379,SANOFI AVENTIS,,85.0,YR,E,M,Y,,,20220621,,CN,HR,HR,2022,Q2,Elderly
209011941,20901194,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Bradycardia,,2022,Q2,1,I,20220503.0,20220524.0,20220601,20220601,EXP,,US-BRACCO-2022US02011,BRACCO,,72.0,YR,,M,Y,,,20220601,,CN,US,US,2022,Q2,Elderly
209011941,20901194,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Cardiac arrest,,2022,Q2,1,I,20220503.0,20220524.0,20220601,20220601,EXP,,US-BRACCO-2022US02011,BRACCO,,72.0,YR,,M,Y,,,20220601,,CN,US,US,2022,Q2,Elderly
209011941,20901194,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Anaphylactic reaction,,2022,Q2,1,I,20220503.0,20220524.0,20220601,20220601,EXP,,US-BRACCO-2022US02011,BRACCO,,72.0,YR,,M,Y,,,20220601,,CN,US,US,2022,Q2,Elderly
209032211,20903221,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Immune-mediated myocarditis,,2022,Q2,1,I,,20220525.0,20220601,20220601,EXP,,AU-009507513-2206AUS000296,MERCK,"Siu D, O^Neill R, Harris C, Wang J, Ardolino L, Downton T, et al,.. Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review. Immunotherapy. 2022;14 (7):511-20",63.0,YR,,M,Y,,,20220601,,HP,AU,AU,2022,Q2,Adult
209032211,20903221,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Conduction disorder,,2022,Q2,1,I,,20220525.0,20220601,20220601,EXP,,AU-009507513-2206AUS000296,MERCK,"Siu D, O^Neill R, Harris C, Wang J, Ardolino L, Downton T, et al,.. Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review. Immunotherapy. 2022;14 (7):511-20",63.0,YR,,M,Y,,,20220601,,HP,AU,AU,2022,Q2,Adult
209032211,20903221,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Hypertransaminasaemia,,2022,Q2,1,I,,20220525.0,20220601,20220601,EXP,,AU-009507513-2206AUS000296,MERCK,"Siu D, O^Neill R, Harris C, Wang J, Ardolino L, Downton T, et al,.. Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review. Immunotherapy. 2022;14 (7):511-20",63.0,YR,,M,Y,,,20220601,,HP,AU,AU,2022,Q2,Adult
209032211,20903221,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Myasthenia gravis,,2022,Q2,1,I,,20220525.0,20220601,20220601,EXP,,AU-009507513-2206AUS000296,MERCK,"Siu D, O^Neill R, Harris C, Wang J, Ardolino L, Downton T, et al,.. Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review. Immunotherapy. 2022;14 (7):511-20",63.0,YR,,M,Y,,,20220601,,HP,AU,AU,2022,Q2,Adult
209040931,20904093,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"12.5 mg, BID",,,,,,,,12.5,MG,,BID,2022,Q2,Atrial fibrillation,,2022,Q2,1,I,20210101.0,20220528.0,20220602,20220602,EXP,,HR-JNJFOC-20220531035,JOHNSON AND JOHNSON,,66.0,YR,E,M,Y,,,20220602,,MD,HR,HR,2022,Q2,Elderly
209060281,20906028,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220524.0,,20220602,20220602,DIR,FDA-CDER-CTU-2022-43531,,FDA-CTU,,66.0,YR,,M,N,,,20220527,N,PH,US,,2022,Q2,Elderly
209078331,20907833,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/1000 MG,,,U,,Unknown,,206111.0,,,,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220530.0,20220602,20220602,EXP,,"PE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173452",BOEHRINGER INGELHEIM,"Paz-Ibarra J, Diaz R, Quinto F. Euglycemic diabetic ketoacidosis in a young adult associated with the use of SGLT2 inhibitors. Endocrine Practice. 2022; 28: 33-",34.0,YR,A,M,Y,,,20220602,,MD,PE,PE,2022,Q2,Young Adult
209079441,20907944,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Urinary tract infection,,2022,Q2,1,I,,20220530.0,20220602,20220602,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173471",BOEHRINGER INGELHEIM,,54.0,YR,A,F,Y,,,20220602,,MD,US,US,2022,Q2,Adult
209079441,20907944,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220530.0,20220602,20220602,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173471",BOEHRINGER INGELHEIM,,54.0,YR,A,F,Y,,,20220602,,MD,US,US,2022,Q2,Adult
209092321,20909232,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q2,Ketoacidosis,,2022,Q2,1,I,20220523.0,20220603.0,20220603,20220603,EXP,ES-AEMPS-1196727,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-174402",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,,,20220603,,PH,ES,ES,2022,Q2,Adult
209139291,20913929,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2022,Q2,Angina unstable,,2022,Q2,1,I,20201201.0,20220530.0,20220604,20220604,EXP,,NVSC2022HR124209,NOVARTIS,,85.0,YR,,M,Y,,,20220604,,HP,HR,HR,2022,Q2,Elderly
209139291,20913929,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2022,Q2,Ischaemic cardiomyopathy,,2022,Q2,1,I,20201201.0,20220530.0,20220604,20220604,EXP,,NVSC2022HR124209,NOVARTIS,,85.0,YR,,M,Y,,,20220604,,HP,HR,HR,2022,Q2,Elderly
209183741,20918374,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Unknown,,,,,,,,,,,,2022,Q2,Condition aggravated,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-13280,SAMSUNG BIOEPIS,,40.0,YR,A,F,Y,,,20220606,,CN,CA,CA,2022,Q2,Adult
209183741,20918374,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Unknown,,,,,,,,,,,,2022,Q2,Weight decreased,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-13280,SAMSUNG BIOEPIS,,40.0,YR,A,F,Y,,,20220606,,CN,CA,CA,2022,Q2,Adult
209183741,20918374,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Unknown,,,,,,,,,,,,2022,Q2,C-reactive protein increased,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-13280,SAMSUNG BIOEPIS,,40.0,YR,A,F,Y,,,20220606,,CN,CA,CA,2022,Q2,Adult
209183741,20918374,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Unknown,,,,,,,,,,,,2022,Q2,Psoriasis,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-13280,SAMSUNG BIOEPIS,,40.0,YR,A,F,Y,,,20220606,,CN,CA,CA,2022,Q2,Adult
209183741,20918374,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Unknown,,,,,,,,,,,,2022,Q2,Hepatotoxicity,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-13280,SAMSUNG BIOEPIS,,40.0,YR,A,F,Y,,,20220606,,CN,CA,CA,2022,Q2,Adult
209183741,20918374,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Unknown,,,,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-13280,SAMSUNG BIOEPIS,,40.0,YR,A,F,Y,,,20220606,,CN,CA,CA,2022,Q2,Adult
209200731,20920073,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(1-0-0).,,,,,,,,,,Tablet,QD,2022,Q2,Nausea,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,DE-EMD Serono-E2B_90088003,EMD SERONO INC,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220606,,HP,DE,,2022,Q2,Elderly
209200731,20920073,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(1-0-0).,,,,,,,,,,Tablet,QD,2022,Q2,Fall,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,DE-EMD Serono-E2B_90088003,EMD SERONO INC,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220606,,HP,DE,,2022,Q2,Elderly
209200731,20920073,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(1-0-0).,,,,,,,,,,Tablet,QD,2022,Q2,Back pain,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,DE-EMD Serono-E2B_90088003,EMD SERONO INC,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220606,,HP,DE,,2022,Q2,Elderly
209200731,20920073,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(1-0-0).,,,,,,,,,,Tablet,QD,2022,Q2,Inappropriate schedule of product administration,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,DE-EMD Serono-E2B_90088003,EMD SERONO INC,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220606,,HP,DE,,2022,Q2,Elderly
209200731,20920073,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(1-0-0).,,,,,,,,,,Tablet,QD,2022,Q2,Incorrect product formulation administered,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,DE-EMD Serono-E2B_90088003,EMD SERONO INC,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220606,,HP,DE,,2022,Q2,Elderly
209200731,20920073,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(1-0-0).,,,,,,,,,,Tablet,QD,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,DE-EMD Serono-E2B_90088003,EMD SERONO INC,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220606,,HP,DE,,2022,Q2,Elderly
209200731,20920073,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(1-0-0).,,,,,,,,,,Tablet,QD,2022,Q2,Gastrointestinal disorder,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,DE-EMD Serono-E2B_90088003,EMD SERONO INC,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220606,,HP,DE,,2022,Q2,Elderly
209200731,20920073,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(1-0-0).,,,,,,,,,,Tablet,QD,2022,Q2,Impaired quality of life,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,DE-EMD Serono-E2B_90088003,EMD SERONO INC,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220606,,HP,DE,,2022,Q2,Elderly
209200731,20920073,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(1-0-0).,,,,,,,,,,Tablet,QD,2022,Q2,Hypophagia,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,DE-EMD Serono-E2B_90088003,EMD SERONO INC,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220606,,HP,DE,,2022,Q2,Elderly
209200731,20920073,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(1-0-0).,,,,,,,,,,Tablet,QD,2022,Q2,Drug intolerance,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,DE-EMD Serono-E2B_90088003,EMD SERONO INC,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220606,,HP,DE,,2022,Q2,Elderly
209200731,20920073,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(1-0-0).,,,,,,,,,,Tablet,QD,2022,Q2,Hypoglycaemia,,2022,Q2,1,I,,20220530.0,20220606,20220606,EXP,,DE-EMD Serono-E2B_90088003,EMD SERONO INC,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220606,,HP,DE,,2022,Q2,Elderly
209204331,20920433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,,,,,,25.0,MG,,QD,2022,Q2,Fatigue,,2022,Q2,1,I,20220412.0,,20220606,20220606,DIR,FDA-CDER-CTU-2022-44600,,FDA-CTU,,80.0,YR,,M,N,,,20220425,N,HP,US,,2022,Q2,Elderly
209204331,20920433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,,,,,,25.0,MG,,QD,2022,Q2,Constipation,,2022,Q2,1,I,20220412.0,,20220606,20220606,DIR,FDA-CDER-CTU-2022-44600,,FDA-CTU,,80.0,YR,,M,N,,,20220425,N,HP,US,,2022,Q2,Elderly
209204331,20920433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO?,,,,,,,,25.0,MG,,QD,2022,Q2,Tachycardia,,2022,Q2,1,I,20220412.0,,20220606,20220606,DIR,FDA-CDER-CTU-2022-44600,,FDA-CTU,,80.0,YR,,M,N,,,20220425,N,HP,US,,2022,Q2,Elderly
209204931,20920493,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1/2 TAB;?Frequency : Daily;?,,,Y,D,,,,,,TABLET,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220328.0,,20220606,20220606,DIR,FDA-CDER-CTU-2022-44617,,FDA-CTU,,70.0,YR,,M,N,71.0,KG,20220420,N,PH,US,,2022,Q2,Elderly
209216632,20921663,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,204629.0,,,,,2022,Q2,Hypoxia,,2022,Q2,2,F,20220501.0,20220607.0,20220606,20220608,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-174742",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,,,20220608,,HP,CA,CA,2022,Q2,Adult
209216632,20921663,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,204629.0,,,,,2022,Q2,Lung opacity,,2022,Q2,2,F,20220501.0,20220607.0,20220606,20220608,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-174742",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,,,20220608,,HP,CA,CA,2022,Q2,Adult
209216632,20921663,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,204629.0,,,,,2022,Q2,Cardiac failure congestive,,2022,Q2,2,F,20220501.0,20220607.0,20220606,20220608,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-174742",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,,,20220608,,HP,CA,CA,2022,Q2,Adult
209216632,20921663,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,204629.0,,,,,2022,Q2,Drug hypersensitivity,,2022,Q2,2,F,20220501.0,20220607.0,20220606,20220608,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-174742",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,,,20220608,,HP,CA,CA,2022,Q2,Adult
209216632,20921663,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,204629.0,,,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,2,F,20220501.0,20220607.0,20220606,20220608,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-174742",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,,,20220608,,HP,CA,CA,2022,Q2,Adult
209216632,20921663,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,204629.0,,,,,2022,Q2,Lymphadenopathy,,2022,Q2,2,F,20220501.0,20220607.0,20220606,20220608,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-174742",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,,,20220608,,HP,CA,CA,2022,Q2,Adult
209216632,20921663,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,204629.0,,,,,2022,Q2,Traumatic lung injury,,2022,Q2,2,F,20220501.0,20220607.0,20220606,20220608,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-174742",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,,,20220608,,HP,CA,CA,2022,Q2,Adult
209222291,20922229,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Hyperglycaemia,,2022,Q2,1,I,,20220518.0,20220607,20220607,PER,,US-STRIDES ARCOLAB LIMITED-2022SP006035,STRIDES,"Farasat S, McCallum J. Abstract #1161775: Semaglutide-induced leukocytoclastic vasculitis. Endocr-Pract. 2022;28(Suppl.)(5):S21-S22 abstr. 1161775",65.0,YR,,M,Y,,,20220607,,MD,US,US,2022,Q2,Elderly
209222291,20922229,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q2,Condition aggravated,,2022,Q2,1,I,,20220518.0,20220607,20220607,PER,,US-STRIDES ARCOLAB LIMITED-2022SP006035,STRIDES,"Farasat S, McCallum J. Abstract #1161775: Semaglutide-induced leukocytoclastic vasculitis. Endocr-Pract. 2022;28(Suppl.)(5):S21-S22 abstr. 1161775",65.0,YR,,M,Y,,,20220607,,MD,US,US,2022,Q2,Elderly
209235364,20923536,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Febrile neutropenia,,2022,Q2,4,F,20220527.0,20220608.0,20220607,20220623,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2022-051032,BRISTOL MYERS SQUIBB,,75.0,YR,E,M,Y,75.0,KG,20220623,,MD,ES,ES,2022,Q2,Elderly
209236581,20923658,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220531.0,20220607,20220607,EXP,CA-MHPD-E2B_04005287,CA-Accord-265520,ACCORD,,60.0,YR,,F,Y,129.0,KG,20220607,,MD,CA,CA,2022,Q2,Adult
209236581,20923658,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Chest pain,,2022,Q2,1,I,,20220531.0,20220607,20220607,EXP,CA-MHPD-E2B_04005287,CA-Accord-265520,ACCORD,,60.0,YR,,F,Y,129.0,KG,20220607,,MD,CA,CA,2022,Q2,Adult
209236581,20923658,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Illness,,2022,Q2,1,I,,20220531.0,20220607,20220607,EXP,CA-MHPD-E2B_04005287,CA-Accord-265520,ACCORD,,60.0,YR,,F,Y,129.0,KG,20220607,,MD,CA,CA,2022,Q2,Adult
209236581,20923658,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Granulomatosis with polyangiitis,,2022,Q2,1,I,,20220531.0,20220607,20220607,EXP,CA-MHPD-E2B_04005287,CA-Accord-265520,ACCORD,,60.0,YR,,F,Y,129.0,KG,20220607,,MD,CA,CA,2022,Q2,Adult
209236581,20923658,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Shock,,2022,Q2,1,I,,20220531.0,20220607,20220607,EXP,CA-MHPD-E2B_04005287,CA-Accord-265520,ACCORD,,60.0,YR,,F,Y,129.0,KG,20220607,,MD,CA,CA,2022,Q2,Adult
209236581,20923658,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Abdominal pain upper,,2022,Q2,1,I,,20220531.0,20220607,20220607,EXP,CA-MHPD-E2B_04005287,CA-Accord-265520,ACCORD,,60.0,YR,,F,Y,129.0,KG,20220607,,MD,CA,CA,2022,Q2,Adult
209299521,20929952,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q2,Fournier's gangrene,,2022,Q2,1,I,20220504.0,20220607.0,20220608,20220608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-174966",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20220608,,HP,GB,GB,2022,Q2,Adult
209299521,20929952,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q2,Medication error,,2022,Q2,1,I,20220504.0,20220607.0,20220608,20220608,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-174966",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20220608,,HP,GB,GB,2022,Q2,Adult
209312001,20931200,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Ophthalmoplegia,,2022,Q2,1,I,20220410.0,20220601.0,20220608,20220608,EXP,,US-Accord-265421,ACCORD,,75.0,YR,,F,Y,102.9,KG,20220608,,CN,US,US,2022,Q2,Elderly
209312001,20931200,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Arthritis,,2022,Q2,1,I,20220410.0,20220601.0,20220608,20220608,EXP,,US-Accord-265421,ACCORD,,75.0,YR,,F,Y,102.9,KG,20220608,,CN,US,US,2022,Q2,Elderly
209312001,20931200,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Fatigue,,2022,Q2,1,I,20220410.0,20220601.0,20220608,20220608,EXP,,US-Accord-265421,ACCORD,,75.0,YR,,F,Y,102.9,KG,20220608,,CN,US,US,2022,Q2,Elderly
209312001,20931200,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Balance disorder,,2022,Q2,1,I,20220410.0,20220601.0,20220608,20220608,EXP,,US-Accord-265421,ACCORD,,75.0,YR,,F,Y,102.9,KG,20220608,,CN,US,US,2022,Q2,Elderly
209312001,20931200,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Vision blurred,,2022,Q2,1,I,20220410.0,20220601.0,20220608,20220608,EXP,,US-Accord-265421,ACCORD,,75.0,YR,,F,Y,102.9,KG,20220608,,CN,US,US,2022,Q2,Elderly
209312001,20931200,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Muscular weakness,,2022,Q2,1,I,20220410.0,20220601.0,20220608,20220608,EXP,,US-Accord-265421,ACCORD,,75.0,YR,,F,Y,102.9,KG,20220608,,CN,US,US,2022,Q2,Elderly
209312001,20931200,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Arthralgia,,2022,Q2,1,I,20220410.0,20220601.0,20220608,20220608,EXP,,US-Accord-265421,ACCORD,,75.0,YR,,F,Y,102.9,KG,20220608,,CN,US,US,2022,Q2,Elderly
209312001,20931200,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Diplopia,,2022,Q2,1,I,20220410.0,20220601.0,20220608,20220608,EXP,,US-Accord-265421,ACCORD,,75.0,YR,,F,Y,102.9,KG,20220608,,CN,US,US,2022,Q2,Elderly
209312001,20931200,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Blood pressure decreased,,2022,Q2,1,I,20220410.0,20220601.0,20220608,20220608,EXP,,US-Accord-265421,ACCORD,,75.0,YR,,F,Y,102.9,KG,20220608,,CN,US,US,2022,Q2,Elderly
209312001,20931200,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,VIth nerve paralysis,,2022,Q2,1,I,20220410.0,20220601.0,20220608,20220608,EXP,,US-Accord-265421,ACCORD,,75.0,YR,,F,Y,102.9,KG,20220608,,CN,US,US,2022,Q2,Elderly
209312001,20931200,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Dizziness,,2022,Q2,1,I,20220410.0,20220601.0,20220608,20220608,EXP,,US-Accord-265421,ACCORD,,75.0,YR,,F,Y,102.9,KG,20220608,,CN,US,US,2022,Q2,Elderly
209331831,20933183,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q2,Ischaemic cardiomyopathy,,2022,Q2,1,I,20201201.0,20220603.0,20220608,20220608,EXP,,HR-MYLANLABS-2022M1042484,MYLAN,,85.0,YR,,M,Y,,,20220608,,HP,HR,HR,2022,Q2,Elderly
209331831,20933183,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q2,Angina unstable,,2022,Q2,1,I,20201201.0,20220603.0,20220608,20220608,EXP,,HR-MYLANLABS-2022M1042484,MYLAN,,85.0,YR,,M,Y,,,20220608,,HP,HR,HR,2022,Q2,Elderly
209341101,20934110,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Glomerular filtration rate decreased,,2022,Q2,1,I,,20220602.0,20220608,20220608,EXP,,NVSC2022NL130176,NOVARTIS,,80.0,YR,,M,Y,,,20220608,,HP,NL,NL,2022,Q2,Elderly
209341101,20934110,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Product use in unapproved indication,,2022,Q2,1,I,,20220602.0,20220608,20220608,EXP,,NVSC2022NL130176,NOVARTIS,,80.0,YR,,M,Y,,,20220608,,HP,NL,NL,2022,Q2,Elderly
209341101,20934110,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Product use issue,,2022,Q2,1,I,,20220602.0,20220608,20220608,EXP,,NVSC2022NL130176,NOVARTIS,,80.0,YR,,M,Y,,,20220608,,HP,NL,NL,2022,Q2,Elderly
209388042,20938804,4,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"UNK UNK, bid (1-0-1) (0.5 day)",,,,,,,,,,,BID,2022,Q2,Treatment noncompliance,,2022,Q2,2,F,20190701.0,20220615.0,20220609,20220622,EXP,,CZ-MYLANLABS-2022M1042530,MYLAN,"Kriz J, Bem R.. Case report - a combined effect of education and motivation of the patient with the support of dulaglutide.. Current medicine. 61-62",51.0,YR,,M,Y,,,20220622,,MD,CZ,CZ,2022,Q2,Adult
209405352,20940535,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Cutaneous vasculitis,,2022,Q2,2,F,,20220616.0,20220609,20220625,EXP,,US-TEVA-2022-US-2043543,TEVA,"Farasat S, McCallum J. Abstract #1161775: Semaglutide-induced leukocytoclastic vasculitis. Endocr-Pract 2022;28 (Suppl.)(5):S21-S22 abstr. 1161775.",65.0,YR,E,M,Y,,,20220625,,MD,US,US,2022,Q2,Elderly
209405352,20940535,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Hyperglycaemia,,2022,Q2,2,F,,20220616.0,20220609,20220625,EXP,,US-TEVA-2022-US-2043543,TEVA,"Farasat S, McCallum J. Abstract #1161775: Semaglutide-induced leukocytoclastic vasculitis. Endocr-Pract 2022;28 (Suppl.)(5):S21-S22 abstr. 1161775.",65.0,YR,E,M,Y,,,20220625,,MD,US,US,2022,Q2,Elderly
209449181,20944918,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Illness,,2022,Q2,1,I,,20220603.0,20220610,20220610,EXP,CA-MHPD-E2B_04078555,CA-Accord-265831,ACCORD,,60.0,YR,,F,Y,129.0,KG,20220610,,MD,CA,CA,2022,Q2,Adult
209449181,20944918,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Drug intolerance,,2022,Q2,1,I,,20220603.0,20220610,20220610,EXP,CA-MHPD-E2B_04078555,CA-Accord-265831,ACCORD,,60.0,YR,,F,Y,129.0,KG,20220610,,MD,CA,CA,2022,Q2,Adult
209449181,20944918,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Granulomatosis with polyangiitis,,2022,Q2,1,I,,20220603.0,20220610,20220610,EXP,CA-MHPD-E2B_04078555,CA-Accord-265831,ACCORD,,60.0,YR,,F,Y,129.0,KG,20220610,,MD,CA,CA,2022,Q2,Adult
209449181,20944918,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Chest pain,,2022,Q2,1,I,,20220603.0,20220610,20220610,EXP,CA-MHPD-E2B_04078555,CA-Accord-265831,ACCORD,,60.0,YR,,F,Y,129.0,KG,20220610,,MD,CA,CA,2022,Q2,Adult
209449181,20944918,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220603.0,20220610,20220610,EXP,CA-MHPD-E2B_04078555,CA-Accord-265831,ACCORD,,60.0,YR,,F,Y,129.0,KG,20220610,,MD,CA,CA,2022,Q2,Adult
209449181,20944918,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Abdominal pain upper,,2022,Q2,1,I,,20220603.0,20220610,20220610,EXP,CA-MHPD-E2B_04078555,CA-Accord-265831,ACCORD,,60.0,YR,,F,Y,129.0,KG,20220610,,MD,CA,CA,2022,Q2,Adult
209449181,20944918,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q2,Shock,,2022,Q2,1,I,,20220603.0,20220610,20220610,EXP,CA-MHPD-E2B_04078555,CA-Accord-265831,ACCORD,,60.0,YR,,F,Y,129.0,KG,20220610,,MD,CA,CA,2022,Q2,Adult
209467691,20946769,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",30.0,MG,Y,,104099/080,,,10.0,MG,Tablet,QD,2022,Q2,Ketoacidosis,,2022,Q2,1,I,20220525.0,20220601.0,20220610,20220610,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202206000459,ELI LILLY AND CO,,31.0,YR,,M,Y,75.0,KG,20220610,,CN,CN,CN,2022,Q2,Young Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Procedural pain,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Hypoaesthesia,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Blood pressure diastolic decreased,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Blood iron decreased,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Injection site bruising,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Nervousness,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Respiratory tract congestion,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Feeling abnormal,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Injection site pruritus,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Sinus congestion,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Nausea,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Injection site swelling,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Malaise,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Weight increased,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Blood pressure systolic increased,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Bronchitis,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Upper limb fracture,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Decreased appetite,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Respiratory rate decreased,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Acne,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Dizziness,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Asthenia,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Weight decreased,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Loss of consciousness,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Headache,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Fall,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Pneumonia,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209485141,20948514,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Sleep apnoea syndrome,,2022,Q2,1,I,,20220607.0,20220612,20220612,EXP,CA-MHPD-E2B_04159604,CA-Accord-265815,ACCORD,,53.0,YR,A,M,Y,110.0,KG,20220612,,HP,CA,CA,2022,Q2,Adult
209490551,20949055,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,,2022,Q2,Polycythaemia,,2022,Q2,1,I,,20220602.0,20220613,20220613,EXP,,US-drreddys-SPO/USA/22/0150903,DR REDDYS,Schumacher K. Hereditary Hemochromatosis Gene Mutation in Patients Developing Erythrocytosis on Combined Testosterone Replacement and SGLT-2 Inhibitor Therapy: A Case Series. Endocr Pract. 2022;28(5):S19-20. doi:10.1016/j.eprac.2022.03.062,72.0,YR,E,M,Y,,,20220613,,MD,US,US,2022,Q2,Elderly
209490561,20949056,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,"UNKNOWN,UNKNOWN",,,10.0,MG,,,2022,Q2,Polycythaemia,,2022,Q2,1,I,,20220602.0,20220613,20220613,PER,,US-drreddys-SPO/USA/22/0150901,DR REDDYS,Schumacher K. Abstract #1152223: Hereditary Hemochromatosis Gene Mutation in Patients Developing Erythrocytosis on Combined Testosterone Replacement and SGLT-2 Inhibitor Therapy: A Case Series. Endocrine Practice. 2022;28(5)Supplement:S19-20. DOI: 10.1016/j.eprac.2022.03.062,74.0,YR,E,M,Y,,,20220613,,MD,US,US,2022,Q2,Elderly
209490561,20949056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,increase,,,,,"UNKNOWN,UNKNOWN",,,25.0,MG,,,2022,Q2,Polycythaemia,,2022,Q2,1,I,,20220602.0,20220613,20220613,PER,,US-drreddys-SPO/USA/22/0150901,DR REDDYS,Schumacher K. Abstract #1152223: Hereditary Hemochromatosis Gene Mutation in Patients Developing Erythrocytosis on Combined Testosterone Replacement and SGLT-2 Inhibitor Therapy: A Case Series. Endocrine Practice. 2022;28(5)Supplement:S19-20. DOI: 10.1016/j.eprac.2022.03.062,74.0,YR,E,M,Y,,,20220613,,MD,US,US,2022,Q2,Elderly
209490601,20949060,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,increased,,,Y,U,"UNKNOWN,UNKNOWN",,,25.0,MG,,QD,2022,Q2,Polycythaemia,,2022,Q2,1,I,,20220602.0,20220613,20220613,PER,,US-drreddys-SPO/USA/22/0150904,DR REDDYS,Schumacher K. Hereditary Hemochromatosis Gene Mutation in Patients Developing Erythrocytosis on Combined Testosterone Replacement and SGLT-2 Inhibitor Therapy: A Case Series. Endocr Pract. 2022;28(5):19-20. doi:10.1016/j.eprac.2022.03.062,65.0,YR,E,M,Y,,,20220613,,MD,US,US,2022,Q2,Elderly
209490601,20949060,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,"UNKNOWN,UNKNOWN",,,10.0,MG,,QD,2022,Q2,Polycythaemia,,2022,Q2,1,I,,20220602.0,20220613,20220613,PER,,US-drreddys-SPO/USA/22/0150904,DR REDDYS,Schumacher K. Hereditary Hemochromatosis Gene Mutation in Patients Developing Erythrocytosis on Combined Testosterone Replacement and SGLT-2 Inhibitor Therapy: A Case Series. Endocr Pract. 2022;28(5):19-20. doi:10.1016/j.eprac.2022.03.062,65.0,YR,E,M,Y,,,20220613,,MD,US,US,2022,Q2,Elderly
209490691,20949069,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Cardiac failure chronic,,2022,Q2,1,I,20201101.0,20220606.0,20220613,20220613,EXP,,NVSJ2022JP091959,NOVARTIS,,79.0,YR,,F,Y,,,20220613,,MD,JP,JP,2022,Q2,Elderly
209490691,20949069,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Palpitations,,2022,Q2,1,I,20201101.0,20220606.0,20220613,20220613,EXP,,NVSJ2022JP091959,NOVARTIS,,79.0,YR,,F,Y,,,20220613,,MD,JP,JP,2022,Q2,Elderly
209490691,20949069,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Dyspnoea,,2022,Q2,1,I,20201101.0,20220606.0,20220613,20220613,EXP,,NVSJ2022JP091959,NOVARTIS,,79.0,YR,,F,Y,,,20220613,,MD,JP,JP,2022,Q2,Elderly
209490691,20949069,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Weight increased,,2022,Q2,1,I,20201101.0,20220606.0,20220613,20220613,EXP,,NVSJ2022JP091959,NOVARTIS,,79.0,YR,,F,Y,,,20220613,,MD,JP,JP,2022,Q2,Elderly
209490691,20949069,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q2,Blood pressure increased,,2022,Q2,1,I,20201101.0,20220606.0,20220613,20220613,EXP,,NVSJ2022JP091959,NOVARTIS,,79.0,YR,,F,Y,,,20220613,,MD,JP,JP,2022,Q2,Elderly
209493331,20949333,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Metformin 1 g-Empagliflozin 5 mg every 12 h for 39 months,,,U,,Unknown,,206111.0,,,,Q12H,2022,Q2,Fournier's gangrene,,2022,Q2,1,I,20210101.0,20220609.0,20220613,20220613,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-175670",BOEHRINGER INGELHEIM,"Olave A, Banon C, Mesa E, Jimenez Lopez J, Moral A. Fournier?s Gangrene under Sodium?Glucose Cotransporter-2 Inhibitors Therapy in Gynecological Patients. International Journal of Environmental Research and Public Health. 2022 May 21; 19:10: 6261-",68.0,YR,E,F,Y,,,20220613,,HP,ES,ES,2022,Q2,Elderly
209518381,20951838,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,MU,,,,,,,2022,Q2,Metabolic acidosis,,2022,Q2,1,I,20220606.0,,20220611,20220611,DIR,FDA-CDER-CTU-2022-46703,,FDA-CTU,,64.0,YR,,M,N,115.2,KG,20220611,N,PH,US,,2022,Q2,Adult
209518381,20951838,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,MU,,,,,,,2022,Q2,Blood ketone body,,2022,Q2,1,I,20220606.0,,20220611,20220611,DIR,FDA-CDER-CTU-2022-46703,,FDA-CTU,,64.0,YR,,M,N,115.2,KG,20220611,N,PH,US,,2022,Q2,Adult
209518381,20951838,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,MU,,,,,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220606.0,,20220611,20220611,DIR,FDA-CDER-CTU-2022-46703,,FDA-CTU,,64.0,YR,,M,N,115.2,KG,20220611,N,PH,US,,2022,Q2,Adult
209549711,20954971,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220528.0,20220610.0,20220614,20220614,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-175941",BOEHRINGER INGELHEIM,,75.0,YR,E,M,Y,83.0,KG,20220614,,PH,GB,GB,2022,Q2,Elderly
209562321,20956232,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,N,,,,12.5,MG,,QD,2022,Q2,Hypophagia,,2022,Q2,1,I,20220524.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46960,,FDA-CTU,,74.0,YR,,M,N,,,20220609,N,PH,US,,2022,Q2,Elderly
209562321,20956232,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,N,,,,12.5,MG,,QD,2022,Q2,Hypotension,,2022,Q2,1,I,20220524.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46960,,FDA-CTU,,74.0,YR,,M,N,,,20220609,N,PH,US,,2022,Q2,Elderly
209562321,20956232,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,N,,,,12.5,MG,,QD,2022,Q2,Hypovolaemia,,2022,Q2,1,I,20220524.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46960,,FDA-CTU,,74.0,YR,,M,N,,,20220609,N,PH,US,,2022,Q2,Elderly
209562321,20956232,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,N,,,,20.0,MG,,QD,2022,Q2,Hypophagia,,2022,Q2,1,I,20220524.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46960,,FDA-CTU,,74.0,YR,,M,N,,,20220609,N,PH,US,,2022,Q2,Elderly
209562321,20956232,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,N,,,,20.0,MG,,QD,2022,Q2,Hypotension,,2022,Q2,1,I,20220524.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46960,,FDA-CTU,,74.0,YR,,M,N,,,20220609,N,PH,US,,2022,Q2,Elderly
209562321,20956232,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,N,,,,20.0,MG,,QD,2022,Q2,Hypovolaemia,,2022,Q2,1,I,20220524.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46960,,FDA-CTU,,74.0,YR,,M,N,,,20220609,N,PH,US,,2022,Q2,Elderly
209562431,20956243,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO,,,D,,,,,,,Tablet,QD,2022,Q2,Vomiting,,2022,Q2,1,I,20220525.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46971,,FDA-CTU,,69.0,YR,,F,N,96.0,KG,20220607,N,HP,US,,2022,Q2,Elderly
209562431,20956243,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO,,,D,,,,,,,Tablet,QD,2022,Q2,Dehydration,,2022,Q2,1,I,20220525.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46971,,FDA-CTU,,69.0,YR,,F,N,96.0,KG,20220607,N,HP,US,,2022,Q2,Elderly
209562431,20956243,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO,,,D,,,,,,,Tablet,QD,2022,Q2,Chest pain,,2022,Q2,1,I,20220525.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46971,,FDA-CTU,,69.0,YR,,F,N,96.0,KG,20220607,N,HP,US,,2022,Q2,Elderly
209562431,20956243,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO,,,D,,,,,,,Tablet,QD,2022,Q2,Nausea,,2022,Q2,1,I,20220525.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46971,,FDA-CTU,,69.0,YR,,F,N,96.0,KG,20220607,N,HP,US,,2022,Q2,Elderly
209562431,20956243,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO,,,D,,,,,,,Tablet,QD,2022,Q2,Vasospasm,,2022,Q2,1,I,20220525.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46971,,FDA-CTU,,69.0,YR,,F,N,96.0,KG,20220607,N,HP,US,,2022,Q2,Elderly
209563621,20956362,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q2,Blood urea increased,,2022,Q2,1,I,20220311.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46978,,FDA-CTU,,74.0,YR,,M,N,,,20220519,N,PH,US,,2022,Q2,Elderly
209563621,20956362,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q2,Rash,,2022,Q2,1,I,20220311.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46978,,FDA-CTU,,74.0,YR,,M,N,,,20220519,N,PH,US,,2022,Q2,Elderly
209563621,20956362,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q2,Blood creatinine increased,,2022,Q2,1,I,20220311.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46978,,FDA-CTU,,74.0,YR,,M,N,,,20220519,N,PH,US,,2022,Q2,Elderly
209563781,20956378,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5MG AM PO? ?,,,Y,D,,,,12.5,MG,,999,2022,Q2,Toe amputation,,2022,Q2,1,I,20211201.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46990,,FDA-CTU,,73.0,YR,,M,N,115.67,KG,20220218,N,HP,US,,2022,Q2,Elderly
209563781,20956378,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5MG AM PO? ?,,,Y,D,,,,12.5,MG,,999,2022,Q2,Infection,,2022,Q2,1,I,20211201.0,,20220614,20220614,DIR,FDA-CDER-CTU-2022-46990,,FDA-CTU,,73.0,YR,,M,N,115.67,KG,20220218,N,HP,US,,2022,Q2,Elderly
209585141,20958514,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q2,Coronary artery stenosis,,2022,Q2,1,I,20210101.0,20220607.0,20220614,20220614,EXP,,HR-JNJFOC-20220452468,JOHNSON AND JOHNSON,,84.0,YR,E,M,Y,,,20220614,,MD,HR,HR,2022,Q2,Elderly
209639911,20963991,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2022,Q2,Parathyroid tumour benign,,2022,Q2,1,I,,20220607.0,20220615,20220615,EXP,,"LB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-174990",BOEHRINGER INGELHEIM,"Khalaf Z, Awada M, Melhem Z, Hazimeh Y. Masked Primary Hyperparathyroidism Empagliflozin Use. Cureus. 2022 Apr 26; 14:4:",57.0,YR,A,M,Y,,,20220615,,HP,LB,LB,2022,Q2,Adult
209639911,20963991,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2022,Q2,Hyperparathyroidism primary,,2022,Q2,1,I,,20220607.0,20220615,20220615,EXP,,"LB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-174990",BOEHRINGER INGELHEIM,"Khalaf Z, Awada M, Melhem Z, Hazimeh Y. Masked Primary Hyperparathyroidism Empagliflozin Use. Cureus. 2022 Apr 26; 14:4:",57.0,YR,A,M,Y,,,20220615,,HP,LB,LB,2022,Q2,Adult
209649341,20964934,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 dosage form,,,,,Unknown,,204629.0,,,Tablet,QD,2022,Q2,Arthralgia,,2022,Q2,1,I,,20220609.0,20220616,20220616,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-175404",BOEHRINGER INGELHEIM,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220616,,HP,DE,DE,2022,Q2,Elderly
209649341,20964934,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 dosage form,,,,,Unknown,,204629.0,,,Tablet,QD,2022,Q2,Hypophagia,,2022,Q2,1,I,,20220609.0,20220616,20220616,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-175404",BOEHRINGER INGELHEIM,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220616,,HP,DE,DE,2022,Q2,Elderly
209649341,20964934,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 dosage form,,,,,Unknown,,204629.0,,,Tablet,QD,2022,Q2,Incorrect product formulation administered,,2022,Q2,1,I,,20220609.0,20220616,20220616,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-175404",BOEHRINGER INGELHEIM,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220616,,HP,DE,DE,2022,Q2,Elderly
209649341,20964934,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 dosage form,,,,,Unknown,,204629.0,,,Tablet,QD,2022,Q2,Fall,,2022,Q2,1,I,,20220609.0,20220616,20220616,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-175404",BOEHRINGER INGELHEIM,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220616,,HP,DE,DE,2022,Q2,Elderly
209649341,20964934,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 dosage form,,,,,Unknown,,204629.0,,,Tablet,QD,2022,Q2,Drug intolerance,,2022,Q2,1,I,,20220609.0,20220616,20220616,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-175404",BOEHRINGER INGELHEIM,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220616,,HP,DE,DE,2022,Q2,Elderly
209649341,20964934,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 dosage form,,,,,Unknown,,204629.0,,,Tablet,QD,2022,Q2,Impaired quality of life,,2022,Q2,1,I,,20220609.0,20220616,20220616,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-175404",BOEHRINGER INGELHEIM,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220616,,HP,DE,DE,2022,Q2,Elderly
209649341,20964934,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 dosage form,,,,,Unknown,,204629.0,,,Tablet,QD,2022,Q2,Nausea,,2022,Q2,1,I,,20220609.0,20220616,20220616,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-175404",BOEHRINGER INGELHEIM,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220616,,HP,DE,DE,2022,Q2,Elderly
209649341,20964934,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 dosage form,,,,,Unknown,,204629.0,,,Tablet,QD,2022,Q2,Gastrointestinal disorder,,2022,Q2,1,I,,20220609.0,20220616,20220616,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-175404",BOEHRINGER INGELHEIM,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220616,,HP,DE,DE,2022,Q2,Elderly
209649341,20964934,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 dosage form,,,,,Unknown,,204629.0,,,Tablet,QD,2022,Q2,Inappropriate schedule of product administration,,2022,Q2,1,I,,20220609.0,20220616,20220616,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-175404",BOEHRINGER INGELHEIM,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220616,,HP,DE,DE,2022,Q2,Elderly
209649341,20964934,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 dosage form,,,,,Unknown,,204629.0,,,Tablet,QD,2022,Q2,Hypoglycaemia,,2022,Q2,1,I,,20220609.0,20220616,20220616,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-175404",BOEHRINGER INGELHEIM,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220616,,HP,DE,DE,2022,Q2,Elderly
209649341,20964934,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 dosage form,,,,,Unknown,,204629.0,,,Tablet,QD,2022,Q2,Back pain,,2022,Q2,1,I,,20220609.0,20220616,20220616,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-175404",BOEHRINGER INGELHEIM,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):1-19.",70.0,YR,E,F,Y,80.0,KG,20220616,,HP,DE,DE,2022,Q2,Elderly
209660001,20966000,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Asthenia,,2022,Q2,1,I,,20220606.0,20220616,20220616,EXP,,CA-TEVA-2022-CA-2045715,TEVA,,57.0,YR,A,M,Y,103.0,KG,20220616,,HP,CA,CA,2022,Q2,Adult
209660001,20966000,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Loss of consciousness,,2022,Q2,1,I,,20220606.0,20220616,20220616,EXP,,CA-TEVA-2022-CA-2045715,TEVA,,57.0,YR,A,M,Y,103.0,KG,20220616,,HP,CA,CA,2022,Q2,Adult
209660001,20966000,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Off label use,,2022,Q2,1,I,,20220606.0,20220616,20220616,EXP,,CA-TEVA-2022-CA-2045715,TEVA,,57.0,YR,A,M,Y,103.0,KG,20220616,,HP,CA,CA,2022,Q2,Adult
209660001,20966000,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Insomnia,,2022,Q2,1,I,,20220606.0,20220616,20220616,EXP,,CA-TEVA-2022-CA-2045715,TEVA,,57.0,YR,A,M,Y,103.0,KG,20220616,,HP,CA,CA,2022,Q2,Adult
209660001,20966000,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Cardiac pacemaker insertion,,2022,Q2,1,I,,20220606.0,20220616,20220616,EXP,,CA-TEVA-2022-CA-2045715,TEVA,,57.0,YR,A,M,Y,103.0,KG,20220616,,HP,CA,CA,2022,Q2,Adult
209662761,20966276,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,3698.95833,MG,U,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q2,Hypervolaemia,,2022,Q2,1,I,20220608.0,20220614.0,20220616,20220616,EXP,GB-MHRA-TPP20334560C2182674YC1654685803920,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-176279",BOEHRINGER INGELHEIM,,60.0,YR,A,F,Y,98.0,KG,20220616,,MD,GB,GB,2022,Q2,Adult
209680182,20968018,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2022,Q2,Hypotension,,2022,Q2,2,F,,20220610.0,20220616,20220622,EXP,,NVSC2022TH134065,NOVARTIS,,76.0,YR,,F,Y,,,20220622,,MD,TH,TH,2022,Q2,Elderly
209680182,20968018,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2022,Q2,Left ventricular hypertrophy,,2022,Q2,2,F,,20220610.0,20220616,20220622,EXP,,NVSC2022TH134065,NOVARTIS,,76.0,YR,,F,Y,,,20220622,,MD,TH,TH,2022,Q2,Elderly
209680182,20968018,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2022,Q2,Wrong technique in product usage process,,2022,Q2,2,F,,20220610.0,20220616,20220622,EXP,,NVSC2022TH134065,NOVARTIS,,76.0,YR,,F,Y,,,20220622,,MD,TH,TH,2022,Q2,Elderly
209680182,20968018,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2022,Q2,Blood potassium increased,,2022,Q2,2,F,,20220610.0,20220616,20220622,EXP,,NVSC2022TH134065,NOVARTIS,,76.0,YR,,F,Y,,,20220622,,MD,TH,TH,2022,Q2,Elderly
209680182,20968018,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2022,Q2,Incorrect dose administered,,2022,Q2,2,F,,20220610.0,20220616,20220622,EXP,,NVSC2022TH134065,NOVARTIS,,76.0,YR,,F,Y,,,20220622,,MD,TH,TH,2022,Q2,Elderly
209680182,20968018,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2022,Q2,Blood creatinine increased,,2022,Q2,2,F,,20220610.0,20220616,20220622,EXP,,NVSC2022TH134065,NOVARTIS,,76.0,YR,,F,Y,,,20220622,,MD,TH,TH,2022,Q2,Elderly
209686301,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q2,Hypercalcaemia,,2022,Q2,1,I,,20220602.0,20220616,20220616,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220616,,MD,CA,CA,2022,Q2,Adult
209686301,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q2,Normocytic anaemia,,2022,Q2,1,I,,20220602.0,20220616,20220616,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220616,,MD,CA,CA,2022,Q2,Adult
209686301,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q2,Acute kidney injury,,2022,Q2,1,I,,20220602.0,20220616,20220616,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220616,,MD,CA,CA,2022,Q2,Adult
209686301,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q2,Weight decreased,,2022,Q2,1,I,,20220602.0,20220616,20220616,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220616,,MD,CA,CA,2022,Q2,Adult
209686301,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q2,Back pain,,2022,Q2,1,I,,20220602.0,20220616,20220616,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220616,,MD,CA,CA,2022,Q2,Adult
209686301,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q2,Fall,,2022,Q2,1,I,,20220602.0,20220616,20220616,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220616,,MD,CA,CA,2022,Q2,Adult
209686301,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q2,Pancytopenia,,2022,Q2,1,I,,20220602.0,20220616,20220616,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220616,,MD,CA,CA,2022,Q2,Adult
209686301,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q2,Plasma cell myeloma,,2022,Q2,1,I,,20220602.0,20220616,20220616,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220616,,MD,CA,CA,2022,Q2,Adult
209686301,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q2,Blood immunoglobulin G increased,,2022,Q2,1,I,,20220602.0,20220616,20220616,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220616,,MD,CA,CA,2022,Q2,Adult
209686301,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q2,Mobility decreased,,2022,Q2,1,I,,20220602.0,20220616,20220616,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220616,,MD,CA,CA,2022,Q2,Adult
209762182,20976218,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Acute kidney injury,,2022,Q2,2,F,20220224.0,20220617.0,20220617,20220620,EXP,,US-PFIZER INC-202200691680,PFIZER,,47.0,YR,,F,Y,90.9,KG,20220620,,HP,US,US,2022,Q2,Adult
209762182,20976218,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q2,Dizziness,,2022,Q2,2,F,20220224.0,20220617.0,20220617,20220620,EXP,,US-PFIZER INC-202200691680,PFIZER,,47.0,YR,,F,Y,90.9,KG,20220620,,HP,US,US,2022,Q2,Adult
209762721,20976272,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Loss of consciousness,,2022,Q2,1,I,,20220608.0,20220617,20220617,EXP,,CA-JNJFOC-20220621900,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,103.0,KG,20220617,,HP,CA,CA,2022,Q2,Adult
209762721,20976272,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Off label use,,2022,Q2,1,I,,20220608.0,20220617,20220617,EXP,,CA-JNJFOC-20220621900,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,103.0,KG,20220617,,HP,CA,CA,2022,Q2,Adult
209762721,20976272,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Insomnia,,2022,Q2,1,I,,20220608.0,20220617,20220617,EXP,,CA-JNJFOC-20220621900,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,103.0,KG,20220617,,HP,CA,CA,2022,Q2,Adult
209762721,20976272,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Cardiac pacemaker insertion,,2022,Q2,1,I,,20220608.0,20220617,20220617,EXP,,CA-JNJFOC-20220621900,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,103.0,KG,20220617,,HP,CA,CA,2022,Q2,Adult
209762721,20976272,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,Asthenia,,2022,Q2,1,I,,20220608.0,20220617,20220617,EXP,,CA-JNJFOC-20220621900,JOHNSON AND JOHNSON,,57.0,YR,A,M,Y,103.0,KG,20220617,,HP,CA,CA,2022,Q2,Adult
209790301,20979030,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Probably 5/1000mg,,,U,,Unknown,,206111.0,,,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,,20220619.0,20220619,20220619,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177099",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220620,,HP,IL,IL,2022,Q2,Elderly
209808261,20980826,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q2,Fournier's gangrene,,2022,Q2,1,I,20220531.0,20220619.0,20220620,20220620,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177225",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,96.0,KG,20220620,,HP,GB,GB,2022,Q2,Adult
209813421,20981342,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2022,Q2,Incontinence,,2022,Q2,1,I,,20220619.0,20220620,20220620,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177220",BOEHRINGER INGELHEIM,,32.0,YR,A,F,Y,,,20220620,,CN,GB,GB,2022,Q2,Young Adult
209813871,20981387,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Acute myocardial infarction,,2022,Q2,1,I,20070101.0,20220613.0,20220620,20220620,EXP,,NVSC2022DE140437,NOVARTIS,,74.0,YR,,M,Y,,,20220620,,MD,DE,DE,2022,Q2,Elderly
209813871,20981387,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q2,Hyperlipidaemia,,2022,Q2,1,I,20070101.0,20220613.0,20220620,20220620,EXP,,NVSC2022DE140437,NOVARTIS,,74.0,YR,,M,Y,,,20220620,,MD,DE,DE,2022,Q2,Elderly
209830891,20983089,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Ischaemia,,2022,Q2,1,I,20210101.0,20220613.0,20220620,20220620,EXP,,NVSC2022DE140693,NOVARTIS,,74.0,YR,,M,Y,,,20220620,,MD,DE,DE,2022,Q2,Elderly
209830891,20983089,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Coronary artery disease,,2022,Q2,1,I,20210101.0,20220613.0,20220620,20220620,EXP,,NVSC2022DE140693,NOVARTIS,,74.0,YR,,M,Y,,,20220620,,MD,DE,DE,2022,Q2,Elderly
209830891,20983089,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,Low density lipoprotein abnormal,,2022,Q2,1,I,20210101.0,20220613.0,20220620,20220620,EXP,,NVSC2022DE140693,NOVARTIS,,74.0,YR,,M,Y,,,20220620,,MD,DE,DE,2022,Q2,Elderly
209830891,20983089,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q2,High density lipoprotein decreased,,2022,Q2,1,I,20210101.0,20220613.0,20220620,20220620,EXP,,NVSC2022DE140693,NOVARTIS,,74.0,YR,,M,Y,,,20220620,,MD,DE,DE,2022,Q2,Elderly
209835201,20983520,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Ketoacidosis,,2022,Q2,1,I,20220601.0,20220620.0,20220620,20220620,EXP,DE-CADRBFARM-2022298814,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177266",BOEHRINGER INGELHEIM,,39.0,YR,A,F,Y,70.0,KG,20220620,,MD,DE,DE,2022,Q2,Adult
209835201,20983520,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2022,Q2,Coma scale abnormal,,2022,Q2,1,I,20220601.0,20220620.0,20220620,20220620,EXP,DE-CADRBFARM-2022298814,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177266",BOEHRINGER INGELHEIM,,39.0,YR,A,F,Y,70.0,KG,20220620,,MD,DE,DE,2022,Q2,Adult
209837461,20983746,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,QD,2022,Q2,Drug intolerance,,2022,Q2,1,I,20220606.0,20220612.0,20220620,20220620,EXP,,GB-drreddys-SPO/UKI/22/0151265,DR REDDYS,,80.0,YR,E,M,Y,93.0,KG,20220621,,MD,GB,GB,2022,Q2,Elderly
209837461,20983746,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,QD,2022,Q2,Hallucination,,2022,Q2,1,I,20220606.0,20220612.0,20220620,20220620,EXP,,GB-drreddys-SPO/UKI/22/0151265,DR REDDYS,,80.0,YR,E,M,Y,93.0,KG,20220621,,MD,GB,GB,2022,Q2,Elderly
209841541,20984154,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20220618.0,20220620.0,20220621,20220621,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177288",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,129.0,KG,20220621,,MD,GB,GB,2022,Q2,Adult
209856461,20985646,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,204629.0,10.0,MG,Tablet,QD,2022,Q2,Mitral valve incompetence,,2022,Q2,1,I,20201201.0,20220614.0,20220621,20220621,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173468",BOEHRINGER INGELHEIM,,85.0,YR,E,M,Y,,,20220621,,MD,HR,HR,2022,Q2,Elderly
209856461,20985646,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,204629.0,10.0,MG,Tablet,QD,2022,Q2,Aortic valve incompetence,,2022,Q2,1,I,20201201.0,20220614.0,20220621,20220621,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173468",BOEHRINGER INGELHEIM,,85.0,YR,E,M,Y,,,20220621,,MD,HR,HR,2022,Q2,Elderly
209856461,20985646,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,204629.0,10.0,MG,Tablet,QD,2022,Q2,Angina pectoris,,2022,Q2,1,I,20201201.0,20220614.0,20220621,20220621,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173468",BOEHRINGER INGELHEIM,,85.0,YR,E,M,Y,,,20220621,,MD,HR,HR,2022,Q2,Elderly
209856461,20985646,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,204629.0,10.0,MG,Tablet,QD,2022,Q2,Angina unstable,,2022,Q2,1,I,20201201.0,20220614.0,20220621,20220621,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173468",BOEHRINGER INGELHEIM,,85.0,YR,E,M,Y,,,20220621,,MD,HR,HR,2022,Q2,Elderly
209856461,20985646,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,204629.0,10.0,MG,Tablet,QD,2022,Q2,Ischaemic cardiomyopathy,,2022,Q2,1,I,20201201.0,20220614.0,20220621,20220621,EXP,,"HR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173468",BOEHRINGER INGELHEIM,,85.0,YR,E,M,Y,,,20220621,,MD,HR,HR,2022,Q2,Elderly
209885841,20988584,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2022,Q2,Epistaxis,,2022,Q2,1,I,,20220603.0,20220621,20220621,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-052710,BRISTOL MYERS SQUIBB,,81.0,YR,E,M,Y,,,20220621,,HP,US,US,2022,Q2,Elderly
209921021,20992102,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Alkalosis,,2022,Q2,1,I,20210601.0,20220617.0,20220622,20220622,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177205",BOEHRINGER INGELHEIM,"Fernandez Felix D, Loria G, Sharma S, Sharma S, Arias Morales C. A Rare Case of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis Obscured by Alkalosis. Cureus. 2022 Jun 10; 14 (6):",37.0,YR,A,M,Y,,,20220622,,HP,US,US,2022,Q2,Adult
209921021,20992102,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20210601.0,20220617.0,20220622,20220622,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177205",BOEHRINGER INGELHEIM,"Fernandez Felix D, Loria G, Sharma S, Sharma S, Arias Morales C. A Rare Case of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis Obscured by Alkalosis. Cureus. 2022 Jun 10; 14 (6):",37.0,YR,A,M,Y,,,20220622,,HP,US,US,2022,Q2,Adult
209937031,20993703,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2022,Q2,Oxygen saturation decreased,,2022,Q2,1,I,20220620.0,20220621.0,20220622,20220622,EXP,,US-PFIZER INC-202200865830,PFIZER,,64.0,YR,,M,Y,,,20220622,,PH,US,US,2022,Q2,Adult
209937031,20993703,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2022,Q2,Dyspnoea,,2022,Q2,1,I,20220620.0,20220621.0,20220622,20220622,EXP,,US-PFIZER INC-202200865830,PFIZER,,64.0,YR,,M,Y,,,20220622,,PH,US,US,2022,Q2,Adult
209975601,20997560,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q2,COVID-19,,2022,Q2,1,I,20220421.0,20220531.0,20220623,20220623,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-2022-050653,BRISTOL MYERS SQUIBB,,76.0,YR,E,M,Y,,,20220623,,HP,AU,AU,2022,Q2,Elderly
209975601,20997560,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q2,COVID-19,,2022,Q2,1,I,20220421.0,20220531.0,20220623,20220623,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-2022-050653,BRISTOL MYERS SQUIBB,,76.0,YR,E,M,Y,,,20220623,,HP,AU,AU,2022,Q2,Elderly
210052461,21005246,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Sepsis,,2022,Q2,1,I,,20220621.0,20220624,20220624,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177597",BOEHRINGER INGELHEIM,"Sukor N, Wan Azman S, Shamsi M, Ismail I, Kamaruddin N. Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis. Frontiers in Endocrinology. 2022 May 30; 13: 867647-",60.0,YR,A,M,Y,,,20220624,,HP,MY,MY,2022,Q2,Adult
210052461,21005246,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Acute kidney injury,,2022,Q2,1,I,,20220621.0,20220624,20220624,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177597",BOEHRINGER INGELHEIM,"Sukor N, Wan Azman S, Shamsi M, Ismail I, Kamaruddin N. Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis. Frontiers in Endocrinology. 2022 May 30; 13: 867647-",60.0,YR,A,M,Y,,,20220624,,HP,MY,MY,2022,Q2,Adult
210052461,21005246,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,General physical health deterioration,,2022,Q2,1,I,,20220621.0,20220624,20220624,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177597",BOEHRINGER INGELHEIM,"Sukor N, Wan Azman S, Shamsi M, Ismail I, Kamaruddin N. Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis. Frontiers in Endocrinology. 2022 May 30; 13: 867647-",60.0,YR,A,M,Y,,,20220624,,HP,MY,MY,2022,Q2,Adult
210052461,21005246,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,,20220621.0,20220624,20220624,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177597",BOEHRINGER INGELHEIM,"Sukor N, Wan Azman S, Shamsi M, Ismail I, Kamaruddin N. Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis. Frontiers in Endocrinology. 2022 May 30; 13: 867647-",60.0,YR,A,M,Y,,,20220624,,HP,MY,MY,2022,Q2,Adult
210052461,21005246,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Acute coronary syndrome,,2022,Q2,1,I,,20220621.0,20220624,20220624,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177597",BOEHRINGER INGELHEIM,"Sukor N, Wan Azman S, Shamsi M, Ismail I, Kamaruddin N. Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis. Frontiers in Endocrinology. 2022 May 30; 13: 867647-",60.0,YR,A,M,Y,,,20220624,,HP,MY,MY,2022,Q2,Adult
210052461,21005246,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q2,Pituitary apoplexy,,2022,Q2,1,I,,20220621.0,20220624,20220624,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177597",BOEHRINGER INGELHEIM,"Sukor N, Wan Azman S, Shamsi M, Ismail I, Kamaruddin N. Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis. Frontiers in Endocrinology. 2022 May 30; 13: 867647-",60.0,YR,A,M,Y,,,20220624,,HP,MY,MY,2022,Q2,Adult
210092681,21009268,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20220513.0,,20220624,20220624,DIR,620607,,FDA-CTU,,62.0,YR,,F,N,66.5,KG,20220624,N,PH,US,,2022,Q2,Adult
210122181,21012218,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q2,C-reactive protein increased,,2022,Q2,1,I,,20220613.0,20220627,20220627,EXP,,DE-PFIZER INC-PV202200001698,PFIZER,,75.0,YR,,M,Y,,,20220627,,MD,DE,DE,2022,Q2,Elderly
210155641,21015564,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20200901.0,20220627.0,20220628,20220628,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178657",BOEHRINGER INGELHEIM,"Chiew K, Raja Nurazni R, Zakaria M. SIMILAR BUT DIFFERENT: A TALE OF 2 CASES OF EUGLYCEMIC DIABETIC KETOACIDOSIS. Journal of the ASEAN Federation of Endocrine Societies. 2021; 36: 45-",41.0,YR,A,F,Y,,,20220628,,HP,MY,MY,2022,Q2,Adult
210160881,21016088,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg 1 time / day,,,,,,,,,,Film-coated tablet,,2022,Q2,Contusion,,2022,Q2,1,I,20210415.0,20220618.0,20220628,20220628,EXP,SE-MPA-2022-014315,SE-Accord-267558,ACCORD,,73.0,YR,,F,Y,67.0,KG,20220628,,CN,SE,SE,2022,Q2,Elderly
210160881,21016088,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg 1 time / day,,,,,,,,,,Film-coated tablet,,2022,Q2,Pain in extremity,,2022,Q2,1,I,20210415.0,20220618.0,20220628,20220628,EXP,SE-MPA-2022-014315,SE-Accord-267558,ACCORD,,73.0,YR,,F,Y,67.0,KG,20220628,,CN,SE,SE,2022,Q2,Elderly
210162721,21016272,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,1,I,20170101.0,20220624.0,20220628,20220628,EXP,,DE-MYLANLABS-2022M1048400,MYLAN,,74.0,YR,,M,Y,,,20220628,,MD,DE,DE,2022,Q2,Elderly
210162721,21016272,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Hyperuricaemia,,2022,Q2,1,I,20170101.0,20220624.0,20220628,20220628,EXP,,DE-MYLANLABS-2022M1048400,MYLAN,,74.0,YR,,M,Y,,,20220628,,MD,DE,DE,2022,Q2,Elderly
210164181,21016418,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,10.0,MG,,QD,2022,Q2,Fungal infection,,2022,Q2,1,I,20220607.0,,20220627,20220627,DIR,FDA-CDER-CTU-2022-50496,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20220614,N,PH,US,,2022,Q2,Elderly
210164181,21016418,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,10.0,MG,,QD,2022,Q2,Penile rash,,2022,Q2,1,I,20220607.0,,20220627,20220627,DIR,FDA-CDER-CTU-2022-50496,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20220614,N,PH,US,,2022,Q2,Elderly
210173311,21017331,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q2,Vomiting,,2022,Q2,1,I,20211119.0,,20220627,20220627,DIR,FDA-CDER-CTU-2022-50600,,FDA-CTU,,34.0,YR,,M,N,125.64,KG,20220118,N,PH,US,,2022,Q2,Young Adult
210173311,21017331,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q2,Fatigue,,2022,Q2,1,I,20211119.0,,20220627,20220627,DIR,FDA-CDER-CTU-2022-50600,,FDA-CTU,,34.0,YR,,M,N,125.64,KG,20220118,N,PH,US,,2022,Q2,Young Adult
210173311,21017331,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20211119.0,,20220627,20220627,DIR,FDA-CDER-CTU-2022-50600,,FDA-CTU,,34.0,YR,,M,N,125.64,KG,20220118,N,PH,US,,2022,Q2,Young Adult
210173311,21017331,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q2,Dehydration,,2022,Q2,1,I,20211119.0,,20220627,20220627,DIR,FDA-CDER-CTU-2022-50600,,FDA-CTU,,34.0,YR,,M,N,125.64,KG,20220118,N,PH,US,,2022,Q2,Young Adult
210173311,21017331,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q2,Dyspnoea,,2022,Q2,1,I,20211119.0,,20220627,20220627,DIR,FDA-CDER-CTU-2022-50600,,FDA-CTU,,34.0,YR,,M,N,125.64,KG,20220118,N,PH,US,,2022,Q2,Young Adult
210173311,21017331,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q2,Tachycardia,,2022,Q2,1,I,20211119.0,,20220627,20220627,DIR,FDA-CDER-CTU-2022-50600,,FDA-CTU,,34.0,YR,,M,N,125.64,KG,20220118,N,PH,US,,2022,Q2,Young Adult
210173311,21017331,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q2,Nausea,,2022,Q2,1,I,20211119.0,,20220627,20220627,DIR,FDA-CDER-CTU-2022-50600,,FDA-CTU,,34.0,YR,,M,N,125.64,KG,20220118,N,PH,US,,2022,Q2,Young Adult
210173311,21017331,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q2,Tachypnoea,,2022,Q2,1,I,20211119.0,,20220627,20220627,DIR,FDA-CDER-CTU-2022-50600,,FDA-CTU,,34.0,YR,,M,N,125.64,KG,20220118,N,PH,US,,2022,Q2,Young Adult
210173311,21017331,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q2,Pain,,2022,Q2,1,I,20211119.0,,20220627,20220627,DIR,FDA-CDER-CTU-2022-50600,,FDA-CTU,,34.0,YR,,M,N,125.64,KG,20220118,N,PH,US,,2022,Q2,Young Adult
210173311,21017331,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q2,Vertigo,,2022,Q2,1,I,20211119.0,,20220627,20220627,DIR,FDA-CDER-CTU-2022-50600,,FDA-CTU,,34.0,YR,,M,N,125.64,KG,20220118,N,PH,US,,2022,Q2,Young Adult
210173311,21017331,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q2,Chest pain,,2022,Q2,1,I,20211119.0,,20220627,20220627,DIR,FDA-CDER-CTU-2022-50600,,FDA-CTU,,34.0,YR,,M,N,125.64,KG,20220118,N,PH,US,,2022,Q2,Young Adult
210203631,21020363,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q2,Type 2 diabetes mellitus,,2022,Q2,1,I,20170101.0,20220627.0,20220629,20220629,EXP,,DE-ORGANON-O2206DEU002339,ORGANON,,74.0,YR,,M,Y,,,20220629,,MD,DE,DE,2022,Q2,Elderly
210203631,21020363,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q2,Hyperuricaemia,,2022,Q2,1,I,20170101.0,20220627.0,20220629,20220629,EXP,,DE-ORGANON-O2206DEU002339,ORGANON,,74.0,YR,,M,Y,,,20220629,,MD,DE,DE,2022,Q2,Elderly
210216691,21021669,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,U,,,,,10.0,MG,Unknown,,2022,Q2,Neurotoxicity,,2022,Q2,1,I,20211225.0,20220621.0,20220629,20220629,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-AUT-20211208544,BRISTOL MYERS SQUIBB,,71.0,YR,E,M,Y,88.0,KG,20220629,,MD,AT,AT,2022,Q2,Elderly
210217061,21021706,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2022,Q2,Interstitial lung disease,,2022,Q2,1,I,,20220621.0,20220629,20220629,EXP,,US-JNJFOC-20220646099,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,45.0,KG,20220629,,HP,US,US,2022,Q2,Elderly
210217061,21021706,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2022,Q2,Cardiomyopathy,,2022,Q2,1,I,,20220621.0,20220629,20220629,EXP,,US-JNJFOC-20220646099,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,45.0,KG,20220629,,HP,US,US,2022,Q2,Elderly
210217061,21021706,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2022,Q2,Cardiac failure,,2022,Q2,1,I,,20220621.0,20220629,20220629,EXP,,US-JNJFOC-20220646099,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,45.0,KG,20220629,,HP,US,US,2022,Q2,Elderly
210229371,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Feeling drunk,,2022,Q2,1,I,,20220627.0,20220629,20220629,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220629,,CN,US,US,2022,Q2,Adult
210229371,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Hangover,,2022,Q2,1,I,,20220627.0,20220629,20220629,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220629,,CN,US,US,2022,Q2,Adult
210229371,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Disturbance in attention,,2022,Q2,1,I,,20220627.0,20220629,20220629,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220629,,CN,US,US,2022,Q2,Adult
210229371,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Constipation,,2022,Q2,1,I,,20220627.0,20220629,20220629,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220629,,CN,US,US,2022,Q2,Adult
210229371,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Incoherent,,2022,Q2,1,I,,20220627.0,20220629,20220629,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220629,,CN,US,US,2022,Q2,Adult
210229371,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Dizziness,,2022,Q2,1,I,,20220627.0,20220629,20220629,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220629,,CN,US,US,2022,Q2,Adult
210229371,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Bradyphrenia,,2022,Q2,1,I,,20220627.0,20220629,20220629,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220629,,CN,US,US,2022,Q2,Adult
210229371,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Feeling abnormal,,2022,Q2,1,I,,20220627.0,20220629,20220629,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220629,,CN,US,US,2022,Q2,Adult
210229371,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Insomnia,,2022,Q2,1,I,,20220627.0,20220629,20220629,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220629,,CN,US,US,2022,Q2,Adult
210229371,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Dysgeusia,,2022,Q2,1,I,,20220627.0,20220629,20220629,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220629,,CN,US,US,2022,Q2,Adult
210230991,21023099,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 12.5 MG;?Frequency : Daily;?,,,,,,,,,,,QD,2022,Q2,Pruritus,,2022,Q2,1,I,,,20220629,20220629,DIR,FDA-CDER-CTU-2022-51267,,FDA-CTU,,41.0,YR,,M,N,90.0,KG,20220614,N,PH,US,,2022,Q2,Adult
210230991,21023099,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 12.5 MG;?Frequency : Daily;?,,,,,,,,,,,QD,2022,Q2,Rash,,2022,Q2,1,I,,,20220629,20220629,DIR,FDA-CDER-CTU-2022-51267,,FDA-CTU,,41.0,YR,,M,N,90.0,KG,20220614,N,PH,US,,2022,Q2,Adult
210230991,21023099,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 12.5 MG;?Frequency : Daily;?,,,,,,,,,,,QD,2022,Q2,Therapy interrupted,,2022,Q2,1,I,,,20220629,20220629,DIR,FDA-CDER-CTU-2022-51267,,FDA-CTU,,41.0,YR,,M,N,90.0,KG,20220614,N,PH,US,,2022,Q2,Adult
210230991,21023099,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 12.5 MG;?Frequency : Daily;?,,,,,,,,,,,QD,2022,Q2,Urticaria,,2022,Q2,1,I,,,20220629,20220629,DIR,FDA-CDER-CTU-2022-51267,,FDA-CTU,,41.0,YR,,M,N,90.0,KG,20220614,N,PH,US,,2022,Q2,Adult
210231891,21023189,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,Tablet,,2022,Q2,Necrotising fasciitis,,2022,Q2,1,I,20220530.0,20220628.0,20220629,20220629,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-179041",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,51.0,KG,20220629,,MD,GB,GB,2022,Q2,Elderly
210242231,21024223,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Acute myocardial infarction,,2022,Q2,1,I,20070101.0,20220624.0,20220629,20220629,EXP,,DE-MYLANLABS-2022M1048392,MYLAN,,74.0,YR,,M,Y,,,20220629,,MD,DE,DE,2022,Q2,Elderly
210242231,21024223,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q2,Hyperlipidaemia,,2022,Q2,1,I,20070101.0,20220624.0,20220629,20220629,EXP,,DE-MYLANLABS-2022M1048392,MYLAN,,74.0,YR,,M,Y,,,20220629,,MD,DE,DE,2022,Q2,Elderly
210257041,21025704,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Acute myocardial infarction,,2022,Q2,1,I,20070101.0,20220623.0,20220630,20220630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177949",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20220630,,MD,DE,DE,2022,Q2,Elderly
210257041,21025704,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Hyperlipidaemia,,2022,Q2,1,I,20070101.0,20220623.0,20220630,20220630,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177949",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20220630,,MD,DE,DE,2022,Q2,Elderly
210262231,21026223,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Loss of consciousness,,2022,Q2,1,I,20220101.0,20220628.0,20220630,20220630,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178728",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20220630,,HP,AU,AU,2022,Q2,Elderly
210262231,21026223,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Dehydration,,2022,Q2,1,I,20220101.0,20220628.0,20220630,20220630,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178728",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20220630,,HP,AU,AU,2022,Q2,Elderly
210262231,21026223,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q2,Circulatory collapse,,2022,Q2,1,I,20220101.0,20220628.0,20220630,20220630,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178728",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20220630,,HP,AU,AU,2022,Q2,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Bradycardia,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Heart rate irregular,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Arrhythmia,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Skin disorder,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Left atrial dilatation,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Atrial fibrillation,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Acute kidney injury,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Dehydration,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Dizziness,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Haemoglobin increased,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Presyncope,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Renal disorder,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Hypotension,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Hypovolaemia,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Syncope,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Pulmonary congestion,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Renal injury,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Drug interaction,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Mucosal dryness,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Haematocrit increased,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1608836713,16088367,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,,,,,,10.0,MG,,QD,2022,Q3,Oedema peripheral,,2022,Q3,13,F,20180101.0,20220727.0,20190319,20220810,EXP,,PT-AUROBINDO-AUR-APL-2019-015280,AUROBINDO,"Gouveia CC, Duque S, Campos L. Lipotymia by hypovolemia-A case of IATROGENIA to EMPAGLIFLOZINA. By Mariana Rocha. 2019;14(1):74P050",71.0,YR,,M,Y,,,20220810,,MD,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Renal disorder,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Drug interaction,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Acute kidney injury,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Oedema peripheral,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Pulmonary congestion,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Hypovolaemia,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Haemoglobin increased,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Heart rate irregular,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Arrhythmia,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Bradycardia,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Atrial fibrillation,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Hypotension,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Syncope,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Skin disorder,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Left atrial dilatation,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Haematocrit increased,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Mucosal dryness,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Dehydration,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Presyncope,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,18,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Dizziness,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Renal disorder,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Drug interaction,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Acute kidney injury,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Oedema peripheral,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Pulmonary congestion,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Hypovolaemia,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Haemoglobin increased,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Heart rate irregular,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Arrhythmia,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Bradycardia,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Atrial fibrillation,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Hypotension,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Syncope,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Skin disorder,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Left atrial dilatation,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Haematocrit increased,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Mucosal dryness,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Dehydration,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Presyncope,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1612368811,16123688,19,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q3,Dizziness,,2022,Q3,11,F,20180101.0,20220818.0,20190327,20220825,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20220825,,HP,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Mucosal dryness,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Hypovolaemia,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Renal disorder,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Drug interaction,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Syncope,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Oedema peripheral,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Pulmonary congestion,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Skin disorder,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Hypotension,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Hypovolaemia,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Atrial fibrillation,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Hypovolaemia,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Haemoglobin increased,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Arrhythmia,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Bradycardia,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Presyncope,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Dizziness,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Left atrial dilatation,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Syncope,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Haematocrit increased,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Dehydration,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1616373313,16163733,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q3,Acute kidney injury,,2022,Q3,13,F,20180101.0,20220728.0,20190405,20220803,EXP,,PT-PFIZER INC-2019149489,PFIZER,"Gouveia, C.. Lipothymia by hypovolaemia - a case of iatrogeny to empagliflozin?. Revista Portuguesa de Diabtes. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,MD,PT,PT,2022,Q3,Elderly
1652766612,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q3,Enuresis,,2022,Q3,12,F,20170929.0,20220704.0,20190703,20220711,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20220711,,MD,JP,JP,2022,Q3,Young Adult
1652766612,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q3,Gastroenteritis,,2022,Q3,12,F,20170929.0,20220704.0,20190703,20220711,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20220711,,MD,JP,JP,2022,Q3,Young Adult
1652766612,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q3,Schizophrenia,,2022,Q3,12,F,20170929.0,20220704.0,20190703,20220711,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20220711,,MD,JP,JP,2022,Q3,Young Adult
1652766612,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q3,Pruritus genital,,2022,Q3,12,F,20170929.0,20220704.0,20190703,20220711,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20220711,,MD,JP,JP,2022,Q3,Young Adult
1652766612,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q3,Electrocardiogram abnormal,,2022,Q3,12,F,20170929.0,20220704.0,20190703,20220711,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20220711,,MD,JP,JP,2022,Q3,Young Adult
1652766612,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q3,Insomnia,,2022,Q3,12,F,20170929.0,20220704.0,20190703,20220711,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20220711,,MD,JP,JP,2022,Q3,Young Adult
1652766612,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q3,Stomatitis,,2022,Q3,12,F,20170929.0,20220704.0,20190703,20220711,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20220711,,MD,JP,JP,2022,Q3,Young Adult
1652766612,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q3,Diabetes mellitus,,2022,Q3,12,F,20170929.0,20220704.0,20190703,20220711,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20220711,,MD,JP,JP,2022,Q3,Young Adult
1652766612,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q3,Bronchitis,,2022,Q3,12,F,20170929.0,20220704.0,20190703,20220711,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20220711,,MD,JP,JP,2022,Q3,Young Adult
178773078,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,Unknown,,2022,Q3,Oedema peripheral,,2022,Q3,8,F,20200303.0,20220623.0,20200609,20220706,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,E,M,Y,,,20220706,,HP,DE,DE,2022,Q3,Elderly
178773078,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,Unknown,,2022,Q3,Arteriosclerosis coronary artery,,2022,Q3,8,F,20200303.0,20220623.0,20200609,20220706,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,E,M,Y,,,20220706,,HP,DE,DE,2022,Q3,Elderly
178773078,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,Unknown,,2022,Q3,Pneumonia,,2022,Q3,8,F,20200303.0,20220623.0,20200609,20220706,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,E,M,Y,,,20220706,,HP,DE,DE,2022,Q3,Elderly
178773078,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,Unknown,,2022,Q3,Pulmonary hypertension,,2022,Q3,8,F,20200303.0,20220623.0,20200609,20220706,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,E,M,Y,,,20220706,,HP,DE,DE,2022,Q3,Elderly
178773078,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,Unknown,,2022,Q3,Tricuspid valve incompetence,,2022,Q3,8,F,20200303.0,20220623.0,20200609,20220706,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,E,M,Y,,,20220706,,HP,DE,DE,2022,Q3,Elderly
178773078,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,Unknown,,2022,Q3,Aortic valve stenosis,,2022,Q3,8,F,20200303.0,20220623.0,20200609,20220706,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,E,M,Y,,,20220706,,HP,DE,DE,2022,Q3,Elderly
178773078,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,Unknown,,2022,Q3,Chronic obstructive pulmonary disease,,2022,Q3,8,F,20200303.0,20220623.0,20200609,20220706,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,E,M,Y,,,20220706,,HP,DE,DE,2022,Q3,Elderly
178773078,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,Unknown,,2022,Q3,Lipase increased,,2022,Q3,8,F,20200303.0,20220623.0,20200609,20220706,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,E,M,Y,,,20220706,,HP,DE,DE,2022,Q3,Elderly
178773078,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,Unknown,,2022,Q3,Aortic valve sclerosis,,2022,Q3,8,F,20200303.0,20220623.0,20200609,20220706,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,E,M,Y,,,20220706,,HP,DE,DE,2022,Q3,Elderly
178773078,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,Unknown,,2022,Q3,Angina pectoris,,2022,Q3,8,F,20200303.0,20220623.0,20200609,20220706,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,E,M,Y,,,20220706,,HP,DE,DE,2022,Q3,Elderly
178773078,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,Unknown,,2022,Q3,Diarrhoea,,2022,Q3,8,F,20200303.0,20220623.0,20200609,20220706,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,E,M,Y,,,20220706,,HP,DE,DE,2022,Q3,Elderly
178773078,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,Unknown,,2022,Q3,Chronic kidney disease,,2022,Q3,8,F,20200303.0,20220623.0,20200609,20220706,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,E,M,Y,,,20220706,,HP,DE,DE,2022,Q3,Elderly
178773078,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,Unknown,,2022,Q3,Mitral valve incompetence,,2022,Q3,8,F,20200303.0,20220623.0,20200609,20220706,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,E,M,Y,,,20220706,,HP,DE,DE,2022,Q3,Elderly
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Hypotension,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Coagulation test abnormal,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Emphysematous pyelonephritis,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Candida infection,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Perinephric abscess,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Urinary tract infection,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Coagulopathy,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Pyelonephritis fungal,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Urinary tract candidiasis,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Urinary tract infection enterococcal,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Candida sepsis,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Systemic candida,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Drug ineffective,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Product use in unapproved indication,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Oliguria,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Septic shock,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Vesicoureteric reflux,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Therapy non-responder,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
1805907210,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Renal impairment,,2022,Q3,10,F,,20220826.0,20200723,20220829,EXP,,NVSC2020ES206671,NOVARTIS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al.. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft. NEPHRON CLINICAL PRACTICE. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
181028814,18102881,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,,,,,,Formulation unknown,,2022,Q3,Perinephric abscess,,2022,Q3,4,F,20181217.0,20220907.0,20200803,20220913,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20220913,,CN,ES,ES,2022,Q3,Adult
181028814,18102881,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,,,,,,Formulation unknown,,2022,Q3,Emphysematous pyelonephritis,,2022,Q3,4,F,20181217.0,20220907.0,20200803,20220913,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20220913,,CN,ES,ES,2022,Q3,Adult
181028814,18102881,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,,,,,,Formulation unknown,,2022,Q3,Drug ineffective,,2022,Q3,4,F,20181217.0,20220907.0,20200803,20220913,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20220913,,CN,ES,ES,2022,Q3,Adult
181028814,18102881,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,,,,,,Formulation unknown,,2022,Q3,Urinary tract infection,,2022,Q3,4,F,20181217.0,20220907.0,20200803,20220913,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20220913,,CN,ES,ES,2022,Q3,Adult
181028814,18102881,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,,,,,,Formulation unknown,,2022,Q3,Septic shock,,2022,Q3,4,F,20181217.0,20220907.0,20200803,20220913,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20220913,,CN,ES,ES,2022,Q3,Adult
181028814,18102881,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,,,,,,Formulation unknown,,2022,Q3,Candida sepsis,,2022,Q3,4,F,20181217.0,20220907.0,20200803,20220913,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20220913,,CN,ES,ES,2022,Q3,Adult
181028814,18102881,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,,,,,,Formulation unknown,,2022,Q3,Candida infection,,2022,Q3,4,F,20181217.0,20220907.0,20200803,20220913,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20220913,,CN,ES,ES,2022,Q3,Adult
181028814,18102881,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,,,,,,Formulation unknown,,2022,Q3,Urinary tract infection enterococcal,,2022,Q3,4,F,20181217.0,20220907.0,20200803,20220913,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20220913,,CN,ES,ES,2022,Q3,Adult
181028814,18102881,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,,,,,,,,Formulation unknown,,2022,Q3,Urinary tract candidiasis,,2022,Q3,4,F,20181217.0,20220907.0,20200803,20220913,EXP,,ES-ASTELLAS-2020US023850,ASTELLAS,,53.0,YR,,F,Y,,,20220913,,CN,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Vesicoureteric reflux,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Septic shock,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Perinephric abscess,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Coagulation test abnormal,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Candida infection,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Urinary tract candidiasis,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Product use in unapproved indication,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Coagulopathy,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Oliguria,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Urinary tract infection enterococcal,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Systemic candida,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Candida sepsis,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Renal impairment,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Emphysematous pyelonephritis,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Therapy non-responder,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Urinary tract infection enterococcal,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Hypotension,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
181423285,18142328,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,ASKED BUT UNKNOWN,,,,,,,2022,Q3,Pyelonephritis fungal,,2022,Q3,5,F,,20220822.0,20200813,20220830,EXP,,ES-ROCHE-2657950,ROCHE,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144(6):304-309.",56.0,YR,,F,Y,,,20220830,,HP,ES,ES,2022,Q3,Adult
183641944,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Chronic obstructive pulmonary disease,,2022,Q3,4,F,20200303.0,20220718.0,20201009,20220730,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20220730,,PH,DE,DE,2022,Q3,Elderly
183641944,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Pulmonary hypertension,,2022,Q3,4,F,20200303.0,20220718.0,20201009,20220730,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20220730,,PH,DE,DE,2022,Q3,Elderly
183641944,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Mitral valve incompetence,,2022,Q3,4,F,20200303.0,20220718.0,20201009,20220730,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20220730,,PH,DE,DE,2022,Q3,Elderly
183641944,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Aortic valve stenosis,,2022,Q3,4,F,20200303.0,20220718.0,20201009,20220730,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20220730,,PH,DE,DE,2022,Q3,Elderly
183641944,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Aortic valve sclerosis,,2022,Q3,4,F,20200303.0,20220718.0,20201009,20220730,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20220730,,PH,DE,DE,2022,Q3,Elderly
183641944,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Angina pectoris,,2022,Q3,4,F,20200303.0,20220718.0,20201009,20220730,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20220730,,PH,DE,DE,2022,Q3,Elderly
183641944,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Tricuspid valve incompetence,,2022,Q3,4,F,20200303.0,20220718.0,20201009,20220730,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20220730,,PH,DE,DE,2022,Q3,Elderly
183641944,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Chronic kidney disease,,2022,Q3,4,F,20200303.0,20220718.0,20201009,20220730,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20220730,,PH,DE,DE,2022,Q3,Elderly
183641944,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Lipase increased,,2022,Q3,4,F,20200303.0,20220718.0,20201009,20220730,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20220730,,PH,DE,DE,2022,Q3,Elderly
183641944,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Arteriosclerosis coronary artery,,2022,Q3,4,F,20200303.0,20220718.0,20201009,20220730,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20220730,,PH,DE,DE,2022,Q3,Elderly
183641944,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Infection,,2022,Q3,4,F,20200303.0,20220718.0,20201009,20220730,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20220730,,PH,DE,DE,2022,Q3,Elderly
183641944,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Oedema peripheral,,2022,Q3,4,F,20200303.0,20220718.0,20201009,20220730,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20220730,,PH,DE,DE,2022,Q3,Elderly
183641944,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Pneumonia,,2022,Q3,4,F,20200303.0,20220718.0,20201009,20220730,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20220730,,PH,DE,DE,2022,Q3,Elderly
183641944,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Diarrhoea,,2022,Q3,4,F,20200303.0,20220718.0,20201009,20220730,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20220730,,PH,DE,DE,2022,Q3,Elderly
1848217510,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q3,Cataract,,2022,Q3,10,F,20201019.0,20220922.0,20201110,20220928,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20220928,,MD,JP,JP,2022,Q3,Adult
1848217510,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q3,Rash pruritic,,2022,Q3,10,F,20201019.0,20220922.0,20201110,20220928,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20220928,,MD,JP,JP,2022,Q3,Adult
1848217510,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q3,Eczema asteatotic,,2022,Q3,10,F,20201019.0,20220922.0,20201110,20220928,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20220928,,MD,JP,JP,2022,Q3,Adult
1848217510,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q3,Angina pectoris,,2022,Q3,10,F,20201019.0,20220922.0,20201110,20220928,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20220928,,MD,JP,JP,2022,Q3,Adult
1848217510,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q3,Arthralgia,,2022,Q3,10,F,20201019.0,20220922.0,20201110,20220928,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20220928,,MD,JP,JP,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Candida sepsis,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Pyrexia,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Perinephric abscess,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Urinary tract infection enterococcal,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Hypotension,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Urinary tract candidiasis,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Coagulation test abnormal,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Oliguria,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Tachycardia,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Septic shock,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Emphysematous pyelonephritis,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Abdominal pain,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Pyelonephritis acute,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Vesicoureteric reflux,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Chills,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Pyelonephritis fungal,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Tenderness,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Malaise,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Dysuria,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Pain,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Pyelonephritis acute,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Drug ineffective,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Renal impairment,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Pyuria,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Urinary tract infection,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
184839363,18483936,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Candida infection,,2022,Q3,3,F,,20220905.0,20201110,20220913,EXP,,ES-SA-2020SA311347,SANOFI AVENTIS,,56.0,YR,A,F,Y,,,20220913,,MD,ES,ES,2022,Q3,Adult
185440832,18544083,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q3,Chills,,2022,Q3,2,F,,20220902.0,20201125,20220909,EXP,,CA-APOTEX-2019AP017387,APOTEX,,66.0,YR,,M,Y,,,20220909,,HP,CA,CA,2022,Q3,Elderly
185440832,18544083,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q3,Sepsis,,2022,Q3,2,F,,20220902.0,20201125,20220909,EXP,,CA-APOTEX-2019AP017387,APOTEX,,66.0,YR,,M,Y,,,20220909,,HP,CA,CA,2022,Q3,Elderly
185440832,18544083,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q3,Hospitalisation,,2022,Q3,2,F,,20220902.0,20201125,20220909,EXP,,CA-APOTEX-2019AP017387,APOTEX,,66.0,YR,,M,Y,,,20220909,,HP,CA,CA,2022,Q3,Elderly
185440832,18544083,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q3,Vomiting,,2022,Q3,2,F,,20220902.0,20201125,20220909,EXP,,CA-APOTEX-2019AP017387,APOTEX,,66.0,YR,,M,Y,,,20220909,,HP,CA,CA,2022,Q3,Elderly
1858639417,18586394,36,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hypotension,,2022,Q3,17,F,20201101.0,20220725.0,20201207,20220803,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20220803,,MD,CA,CA,2022,Q3,Elderly
1858639417,18586394,36,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hypotension,,2022,Q3,17,F,20201101.0,20220725.0,20201207,20220803,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20220803,,MD,CA,CA,2022,Q3,Elderly
1858639417,18586394,36,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q3,Adrenal insufficiency,,2022,Q3,17,F,20201101.0,20220725.0,20201207,20220803,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20220803,,MD,CA,CA,2022,Q3,Elderly
1858639417,18586394,36,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q3,Hyperthyroidism,,2022,Q3,17,F,20201101.0,20220725.0,20201207,20220803,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20220803,,MD,CA,CA,2022,Q3,Elderly
1858639417,18586394,36,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,Tablet,,2022,Q3,Troponin increased,,2022,Q3,17,F,20201101.0,20220725.0,20201207,20220803,EXP,,CA-SA-2020SA349303,SANOFI AVENTIS,,75.0,YR,E,M,Y,,,20220803,,MD,CA,CA,2022,Q3,Elderly
1864170513,18641705,10,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Malignant neoplasm progression,,2022,Q3,13,F,20200720.0,20220830.0,20201221,20220911,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-108892,BRISTOL MYERS SQUIBB,"Goto A, Takai R, Yahiro T, Sakamoto H, Nakatani S. A case of acute generalized exanthematous pustulosis during administration of immune checkpoint inhibitors. The 114th Academic Assembly of Kinki Region of Japanese Dermatological Association. 2021; 9",73.0,YR,E,M,Y,,,20220912,,MD,JP,JP,2022,Q3,Elderly
1864170513,18641705,10,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Colitis,,2022,Q3,13,F,20200720.0,20220830.0,20201221,20220911,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-108892,BRISTOL MYERS SQUIBB,"Goto A, Takai R, Yahiro T, Sakamoto H, Nakatani S. A case of acute generalized exanthematous pustulosis during administration of immune checkpoint inhibitors. The 114th Academic Assembly of Kinki Region of Japanese Dermatological Association. 2021; 9",73.0,YR,E,M,Y,,,20220912,,MD,JP,JP,2022,Q3,Elderly
1864170513,18641705,10,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Acute generalised exanthematous pustulosis,,2022,Q3,13,F,20200720.0,20220830.0,20201221,20220911,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-108892,BRISTOL MYERS SQUIBB,"Goto A, Takai R, Yahiro T, Sakamoto H, Nakatani S. A case of acute generalized exanthematous pustulosis during administration of immune checkpoint inhibitors. The 114th Academic Assembly of Kinki Region of Japanese Dermatological Association. 2021; 9",73.0,YR,E,M,Y,,,20220912,,MD,JP,JP,2022,Q3,Elderly
1864170513,18641705,10,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2022,Q3,Pyrexia,,2022,Q3,13,F,20200720.0,20220830.0,20201221,20220911,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-108892,BRISTOL MYERS SQUIBB,"Goto A, Takai R, Yahiro T, Sakamoto H, Nakatani S. A case of acute generalized exanthematous pustulosis during administration of immune checkpoint inhibitors. The 114th Academic Assembly of Kinki Region of Japanese Dermatological Association. 2021; 9",73.0,YR,E,M,Y,,,20220912,,MD,JP,JP,2022,Q3,Elderly
1864170513,18641705,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,U,,,,,,,,,2022,Q3,Malignant neoplasm progression,,2022,Q3,13,F,20200720.0,20220830.0,20201221,20220911,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-108892,BRISTOL MYERS SQUIBB,"Goto A, Takai R, Yahiro T, Sakamoto H, Nakatani S. A case of acute generalized exanthematous pustulosis during administration of immune checkpoint inhibitors. The 114th Academic Assembly of Kinki Region of Japanese Dermatological Association. 2021; 9",73.0,YR,E,M,Y,,,20220912,,MD,JP,JP,2022,Q3,Elderly
1864170513,18641705,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,U,,,,,,,,,2022,Q3,Colitis,,2022,Q3,13,F,20200720.0,20220830.0,20201221,20220911,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-108892,BRISTOL MYERS SQUIBB,"Goto A, Takai R, Yahiro T, Sakamoto H, Nakatani S. A case of acute generalized exanthematous pustulosis during administration of immune checkpoint inhibitors. The 114th Academic Assembly of Kinki Region of Japanese Dermatological Association. 2021; 9",73.0,YR,E,M,Y,,,20220912,,MD,JP,JP,2022,Q3,Elderly
1864170513,18641705,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,U,,,,,,,,,2022,Q3,Acute generalised exanthematous pustulosis,,2022,Q3,13,F,20200720.0,20220830.0,20201221,20220911,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-108892,BRISTOL MYERS SQUIBB,"Goto A, Takai R, Yahiro T, Sakamoto H, Nakatani S. A case of acute generalized exanthematous pustulosis during administration of immune checkpoint inhibitors. The 114th Academic Assembly of Kinki Region of Japanese Dermatological Association. 2021; 9",73.0,YR,E,M,Y,,,20220912,,MD,JP,JP,2022,Q3,Elderly
1864170513,18641705,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,U,,,,,,,,,2022,Q3,Pyrexia,,2022,Q3,13,F,20200720.0,20220830.0,20201221,20220911,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-108892,BRISTOL MYERS SQUIBB,"Goto A, Takai R, Yahiro T, Sakamoto H, Nakatani S. A case of acute generalized exanthematous pustulosis during administration of immune checkpoint inhibitors. The 114th Academic Assembly of Kinki Region of Japanese Dermatological Association. 2021; 9",73.0,YR,E,M,Y,,,20220912,,MD,JP,JP,2022,Q3,Elderly
191553878,19155387,59,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Hyperthyroidism,,2022,Q3,8,F,20201101.0,20220728.0,20210419,20220805,EXP,,CA-BAUSCH-BL-2021-012331,BAUSCH AND LOMB,,75.0,YR,,M,Y,,,20220805,,MD,CA,CA,2022,Q3,Elderly
191553878,19155387,59,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Hypotension,,2022,Q3,8,F,20201101.0,20220728.0,20210419,20220805,EXP,,CA-BAUSCH-BL-2021-012331,BAUSCH AND LOMB,,75.0,YR,,M,Y,,,20220805,,MD,CA,CA,2022,Q3,Elderly
191553878,19155387,59,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Troponin increased,,2022,Q3,8,F,20201101.0,20220728.0,20210419,20220805,EXP,,CA-BAUSCH-BL-2021-012331,BAUSCH AND LOMB,,75.0,YR,,M,Y,,,20220805,,MD,CA,CA,2022,Q3,Elderly
191553878,19155387,59,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Adrenal insufficiency,,2022,Q3,8,F,20201101.0,20220728.0,20210419,20220805,EXP,,CA-BAUSCH-BL-2021-012331,BAUSCH AND LOMB,,75.0,YR,,M,Y,,,20220805,,MD,CA,CA,2022,Q3,Elderly
191553878,19155387,59,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q3,Hypotension,,2022,Q3,8,F,20201101.0,20220728.0,20210419,20220805,EXP,,CA-BAUSCH-BL-2021-012331,BAUSCH AND LOMB,,75.0,YR,,M,Y,,,20220805,,MD,CA,CA,2022,Q3,Elderly
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Urinary tract infection,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Coagulopathy,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Product use in unapproved indication,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Candida sepsis,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Perinephric abscess,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Oliguria,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Pyelonephritis fungal,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Vesicoureteric reflux,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Candida infection,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Urinary tract candidiasis,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Therapy non-responder,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Drug ineffective,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Emphysematous pyelonephritis,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Septic shock,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Systemic candida,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Renal impairment,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Urinary tract infection enterococcal,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
195673523,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,Unknown,,,,,,,2022,Q3,Hypotension,,2022,Q3,3,F,20181217.0,20220902.0,20210716,20220912,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R et al. Fulminant ephysematous pyelonephritis by candida glabrata in a kidney allograft.. Nephron clinical practice. 2020;144(6):304-9",56.0,YR,,F,Y,,,20220912,,MD,ES,ES,2022,Q3,Adult
196116697,19611669,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2022,Q3,Hepatitis,,2022,Q3,7,F,20210123.0,20220719.0,20210726,20220720,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220720,,MD,CN,CN,2022,Q3,Elderly
196116697,19611669,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2022,Q3,Liver injury,,2022,Q3,7,F,20210123.0,20220719.0,20210726,20220720,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220720,,MD,CN,CN,2022,Q3,Elderly
196116697,19611669,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2022,Q3,Hepatic cirrhosis,,2022,Q3,7,F,20210123.0,20220719.0,20210726,20220720,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220720,,MD,CN,CN,2022,Q3,Elderly
196116697,19611669,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2022,Q3,Hepatic cirrhosis,,2022,Q3,7,F,20210123.0,20220719.0,20210726,20220720,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220720,,MD,CN,CN,2022,Q3,Elderly
196116697,19611669,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2022,Q3,Hepatic cirrhosis,,2022,Q3,7,F,20210123.0,20220719.0,20210726,20220720,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220720,,MD,CN,CN,2022,Q3,Elderly
196116697,19611669,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2022,Q3,Hepatic cirrhosis,,2022,Q3,7,F,20210123.0,20220719.0,20210726,20220720,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220720,,MD,CN,CN,2022,Q3,Elderly
196116697,19611669,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2022,Q3,Hepatic cirrhosis,,2022,Q3,7,F,20210123.0,20220719.0,20210726,20220720,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20220720,,MD,CN,CN,2022,Q3,Elderly
197034064,19703406,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,25.0,MG,Tablet,,2022,Q3,Anxiety disorder,,2022,Q3,4,F,,20220914.0,20210816,20220923,EXP,CA-MHPD-E2B-03454054,CA-Accord-235247,ACCORD,,49.0,YR,A,M,Y,,,20220923,,CN,CA,CA,2022,Q3,Adult
197034064,19703406,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,25.0,MG,Tablet,,2022,Q3,Headache,,2022,Q3,4,F,,20220914.0,20210816,20220923,EXP,CA-MHPD-E2B-03454054,CA-Accord-235247,ACCORD,,49.0,YR,A,M,Y,,,20220923,,CN,CA,CA,2022,Q3,Adult
197034064,19703406,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,25.0,MG,Tablet,,2022,Q3,Off label use,,2022,Q3,4,F,,20220914.0,20210816,20220923,EXP,CA-MHPD-E2B-03454054,CA-Accord-235247,ACCORD,,49.0,YR,A,M,Y,,,20220923,,CN,CA,CA,2022,Q3,Adult
197034064,19703406,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,25.0,MG,Tablet,,2022,Q3,Suicidal ideation,,2022,Q3,4,F,,20220914.0,20210816,20220923,EXP,CA-MHPD-E2B-03454054,CA-Accord-235247,ACCORD,,49.0,YR,A,M,Y,,,20220923,,CN,CA,CA,2022,Q3,Adult
197034064,19703406,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,25.0,MG,Tablet,,2022,Q3,Drug ineffective,,2022,Q3,4,F,,20220914.0,20210816,20220923,EXP,CA-MHPD-E2B-03454054,CA-Accord-235247,ACCORD,,49.0,YR,A,M,Y,,,20220923,,CN,CA,CA,2022,Q3,Adult
197979772,19797977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Alcoholic pancreatitis,,2022,Q3,2,F,,20220627.0,20210907,20220704,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-124473",BOEHRINGER INGELHEIM,"Bloom M, Sattari M. Empagliflozin and diabetes- Dr. Jekyll or Mr. Hyde. Journal of general internal medicine. 2021; 36:1: 327-",53.0,YR,A,M,Y,,,20220704,,MD,US,US,2022,Q3,Adult
197979772,19797977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,2,F,,20220627.0,20210907,20220704,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-124473",BOEHRINGER INGELHEIM,"Bloom M, Sattari M. Empagliflozin and diabetes- Dr. Jekyll or Mr. Hyde. Journal of general internal medicine. 2021; 36:1: 327-",53.0,YR,A,M,Y,,,20220704,,MD,US,US,2022,Q3,Adult
198083944,19808394,13,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q3,Peripheral ischaemia,,2022,Q3,4,F,20201201.0,20220818.0,20210909,20220823,PER,,JP-AMGEN-JPNNI2021136912,AMGEN,,46.0,YR,A,F,Y,51.0,KG,20220823,,MD,JP,JP,2022,Q3,Adult
198083944,19808394,13,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q3,Scleroderma,,2022,Q3,4,F,20201201.0,20220818.0,20210909,20220823,PER,,JP-AMGEN-JPNNI2021136912,AMGEN,,46.0,YR,A,F,Y,51.0,KG,20220823,,MD,JP,JP,2022,Q3,Adult
198083944,19808394,13,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q3,Iliac artery stenosis,,2022,Q3,4,F,20201201.0,20220818.0,20210909,20220823,PER,,JP-AMGEN-JPNNI2021136912,AMGEN,,46.0,YR,A,F,Y,51.0,KG,20220823,,MD,JP,JP,2022,Q3,Adult
198083944,19808394,13,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2022,Q3,Pruritus,,2022,Q3,4,F,20201201.0,20220818.0,20210909,20220823,PER,,JP-AMGEN-JPNNI2021136912,AMGEN,,46.0,YR,A,F,Y,51.0,KG,20220823,,MD,JP,JP,2022,Q3,Adult
199562943,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2022,Q3,Incorrect product formulation administered,,2022,Q3,3,F,,20220913.0,20211014,20220926,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
199562943,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2022,Q3,Back pain,,2022,Q3,3,F,,20220913.0,20211014,20220926,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
199562943,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2022,Q3,Hypoglycaemia,,2022,Q3,3,F,,20220913.0,20211014,20220926,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
199562943,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2022,Q3,Arthralgia,,2022,Q3,3,F,,20220913.0,20211014,20220926,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
199562943,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2022,Q3,Gastrointestinal disorder,,2022,Q3,3,F,,20220913.0,20211014,20220926,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
199562943,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2022,Q3,Impaired quality of life,,2022,Q3,3,F,,20220913.0,20211014,20220926,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
199562943,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2022,Q3,Inappropriate schedule of product administration,,2022,Q3,3,F,,20220913.0,20211014,20220926,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
199562943,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2022,Q3,Hypophagia,,2022,Q3,3,F,,20220913.0,20211014,20220926,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
199562943,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2022,Q3,Nausea,,2022,Q3,3,F,,20220913.0,20211014,20220926,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
199562943,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2022,Q3,Fall,,2022,Q3,3,F,,20220913.0,20211014,20220926,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
200638994,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Cough,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Asthma,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Bronchiectasis,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Malignant mediastinal neoplasm,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Full blood count abnormal,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Nasal congestion,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Wheezing,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Blood immunoglobulin E increased,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Rhinorrhoea,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200638994,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,4,F,,20220802.0,20211112,20220813,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,E,F,Y,101.0,KG,20220813,,CN,CA,CA,2022,Q3,Elderly
200709212,20070921,19,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Pancytopenia,,2022,Q3,2,F,20211001.0,20220815.0,20211115,20220825,EXP,CH-SM-2021-26833,CH-TEVA-2021-CH-1977053,TEVA,,53.0,YR,A,M,Y,,,20220825,,MD,CH,CH,2022,Q3,Adult
200709212,20070921,19,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Agranulocytosis,,2022,Q3,2,F,20211001.0,20220815.0,20211115,20220825,EXP,CH-SM-2021-26833,CH-TEVA-2021-CH-1977053,TEVA,,53.0,YR,A,M,Y,,,20220825,,MD,CH,CH,2022,Q3,Adult
200709212,20070921,19,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Thrombocytopenia,,2022,Q3,2,F,20211001.0,20220815.0,20211115,20220825,EXP,CH-SM-2021-26833,CH-TEVA-2021-CH-1977053,TEVA,,53.0,YR,A,M,Y,,,20220825,,MD,CH,CH,2022,Q3,Adult
200709212,20070921,19,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Leukopenia,,2022,Q3,2,F,20211001.0,20220815.0,20211115,20220825,EXP,CH-SM-2021-26833,CH-TEVA-2021-CH-1977053,TEVA,,53.0,YR,A,M,Y,,,20220825,,MD,CH,CH,2022,Q3,Adult
200709212,20070921,19,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Anaemia,,2022,Q3,2,F,20211001.0,20220815.0,20211115,20220825,EXP,CH-SM-2021-26833,CH-TEVA-2021-CH-1977053,TEVA,,53.0,YR,A,M,Y,,,20220825,,MD,CH,CH,2022,Q3,Adult
200709212,20070921,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2022,Q3,Pancytopenia,,2022,Q3,2,F,20211001.0,20220815.0,20211115,20220825,EXP,CH-SM-2021-26833,CH-TEVA-2021-CH-1977053,TEVA,,53.0,YR,A,M,Y,,,20220825,,MD,CH,CH,2022,Q3,Adult
200709212,20070921,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2022,Q3,Agranulocytosis,,2022,Q3,2,F,20211001.0,20220815.0,20211115,20220825,EXP,CH-SM-2021-26833,CH-TEVA-2021-CH-1977053,TEVA,,53.0,YR,A,M,Y,,,20220825,,MD,CH,CH,2022,Q3,Adult
200709212,20070921,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2022,Q3,Thrombocytopenia,,2022,Q3,2,F,20211001.0,20220815.0,20211115,20220825,EXP,CH-SM-2021-26833,CH-TEVA-2021-CH-1977053,TEVA,,53.0,YR,A,M,Y,,,20220825,,MD,CH,CH,2022,Q3,Adult
200709212,20070921,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2022,Q3,Leukopenia,,2022,Q3,2,F,20211001.0,20220815.0,20211115,20220825,EXP,CH-SM-2021-26833,CH-TEVA-2021-CH-1977053,TEVA,,53.0,YR,A,M,Y,,,20220825,,MD,CH,CH,2022,Q3,Adult
200709212,20070921,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2022,Q3,Anaemia,,2022,Q3,2,F,20211001.0,20220815.0,20211115,20220825,EXP,CH-SM-2021-26833,CH-TEVA-2021-CH-1977053,TEVA,,53.0,YR,A,M,Y,,,20220825,,MD,CH,CH,2022,Q3,Adult
201889312,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Diarrhoea,,2022,Q3,2,F,20200303.0,20220721.0,20211215,20220728,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20220728,,HP,DE,DE,2022,Q3,Elderly
201889312,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Pulmonary hypertension,,2022,Q3,2,F,20200303.0,20220721.0,20211215,20220728,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20220728,,HP,DE,DE,2022,Q3,Elderly
201889312,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Chronic obstructive pulmonary disease,,2022,Q3,2,F,20200303.0,20220721.0,20211215,20220728,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20220728,,HP,DE,DE,2022,Q3,Elderly
201889312,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Pneumonia,,2022,Q3,2,F,20200303.0,20220721.0,20211215,20220728,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20220728,,HP,DE,DE,2022,Q3,Elderly
201889312,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Aortic valve sclerosis,,2022,Q3,2,F,20200303.0,20220721.0,20211215,20220728,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20220728,,HP,DE,DE,2022,Q3,Elderly
201889312,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Chronic kidney disease,,2022,Q3,2,F,20200303.0,20220721.0,20211215,20220728,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20220728,,HP,DE,DE,2022,Q3,Elderly
201889312,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Arteriosclerosis coronary artery,,2022,Q3,2,F,20200303.0,20220721.0,20211215,20220728,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20220728,,HP,DE,DE,2022,Q3,Elderly
201889312,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Oedema peripheral,,2022,Q3,2,F,20200303.0,20220721.0,20211215,20220728,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20220728,,HP,DE,DE,2022,Q3,Elderly
201889312,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Mitral valve incompetence,,2022,Q3,2,F,20200303.0,20220721.0,20211215,20220728,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20220728,,HP,DE,DE,2022,Q3,Elderly
201889312,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Aortic valve stenosis,,2022,Q3,2,F,20200303.0,20220721.0,20211215,20220728,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20220728,,HP,DE,DE,2022,Q3,Elderly
201889312,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Angina pectoris,,2022,Q3,2,F,20200303.0,20220721.0,20211215,20220728,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20220728,,HP,DE,DE,2022,Q3,Elderly
201889312,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Tricuspid valve incompetence,,2022,Q3,2,F,20200303.0,20220721.0,20211215,20220728,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20220728,,HP,DE,DE,2022,Q3,Elderly
201889312,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Infection,,2022,Q3,2,F,20200303.0,20220721.0,20211215,20220728,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20220728,,HP,DE,DE,2022,Q3,Elderly
201889312,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Lipase increased,,2022,Q3,2,F,20200303.0,20220721.0,20211215,20220728,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20220728,,HP,DE,DE,2022,Q3,Elderly
203039046,20303904,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Drug Dose First Administered is 10 TABLET ;Ongoing: Yes,,,,,,,,,,Tablet,QD,2022,Q3,Uveitis,,2022,Q3,6,F,20211225.0,20220829.0,20220106,20220831,EXP,,US-ROCHE-2992171,ROCHE,,58.0,YR,,M,Y,94.0,KG,20220831,,MD,US,,2022,Q3,Adult
203160213,20316021,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 - 1000 mg, bid",,,,,UNKNOWN,,,,,"Tablet, coated",,2022,Q3,Constipation,,2022,Q3,3,F,20211001.0,20220622.0,20220110,20220704,EXP,,CO-NOVOPROD-870068,NOVO NORDISK,,73.0,YR,,M,Y,58.0,KG,20220704,,CN,CO,CO,2022,Q3,Elderly
203160213,20316021,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 - 1000 mg, bid",,,,,UNKNOWN,,,,,"Tablet, coated",,2022,Q3,Discouragement,,2022,Q3,3,F,20211001.0,20220622.0,20220110,20220704,EXP,,CO-NOVOPROD-870068,NOVO NORDISK,,73.0,YR,,M,Y,58.0,KG,20220704,,CN,CO,CO,2022,Q3,Elderly
203160213,20316021,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 - 1000 mg, bid",,,,,UNKNOWN,,,,,"Tablet, coated",,2022,Q3,Diarrhoea,,2022,Q3,3,F,20211001.0,20220622.0,20220110,20220704,EXP,,CO-NOVOPROD-870068,NOVO NORDISK,,73.0,YR,,M,Y,58.0,KG,20220704,,CN,CO,CO,2022,Q3,Elderly
203160213,20316021,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 - 1000 mg, bid",,,,,UNKNOWN,,,,,"Tablet, coated",,2022,Q3,Vomiting,,2022,Q3,3,F,20211001.0,20220622.0,20220110,20220704,EXP,,CO-NOVOPROD-870068,NOVO NORDISK,,73.0,YR,,M,Y,58.0,KG,20220704,,CN,CO,CO,2022,Q3,Elderly
203160213,20316021,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 - 1000 mg, bid",,,,,UNKNOWN,,,,,"Tablet, coated",,2022,Q3,Decreased appetite,,2022,Q3,3,F,20211001.0,20220622.0,20220110,20220704,EXP,,CO-NOVOPROD-870068,NOVO NORDISK,,73.0,YR,,M,Y,58.0,KG,20220704,,CN,CO,CO,2022,Q3,Elderly
203160213,20316021,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5 - 1000 mg, bid",,,,,UNKNOWN,,,,,"Tablet, coated",,2022,Q3,Weight decreased,,2022,Q3,3,F,20211001.0,20220622.0,20220110,20220704,EXP,,CO-NOVOPROD-870068,NOVO NORDISK,,73.0,YR,,M,Y,58.0,KG,20220704,,CN,CO,CO,2022,Q3,Elderly
203737964,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Tablet,,2022,Q3,Adrenal insufficiency,,2022,Q3,4,F,,20220824.0,20220125,20220828,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220828,,MD,CA,CA,2022,Q3,Elderly
203737964,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Tablet,,2022,Q3,Troponin increased,,2022,Q3,4,F,,20220824.0,20220125,20220828,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220828,,MD,CA,CA,2022,Q3,Elderly
203737964,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Tablet,,2022,Q3,Hyperthyroidism,,2022,Q3,4,F,,20220824.0,20220125,20220828,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220828,,MD,CA,CA,2022,Q3,Elderly
203737964,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Tablet,,2022,Q3,Hypotension,,2022,Q3,4,F,,20220824.0,20220125,20220828,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220828,,MD,CA,CA,2022,Q3,Elderly
203737964,20373796,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Film-coated tablet,,2022,Q3,Adrenal insufficiency,,2022,Q3,4,F,,20220824.0,20220125,20220828,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220828,,MD,CA,CA,2022,Q3,Elderly
203737964,20373796,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Film-coated tablet,,2022,Q3,Troponin increased,,2022,Q3,4,F,,20220824.0,20220125,20220828,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220828,,MD,CA,CA,2022,Q3,Elderly
203737964,20373796,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Film-coated tablet,,2022,Q3,Hyperthyroidism,,2022,Q3,4,F,,20220824.0,20220125,20220828,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220828,,MD,CA,CA,2022,Q3,Elderly
203737964,20373796,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Film-coated tablet,,2022,Q3,Hypotension,,2022,Q3,4,F,,20220824.0,20220125,20220828,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220828,,MD,CA,CA,2022,Q3,Elderly
203737964,20373796,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,200.0,MG,,,2022,Q3,Adrenal insufficiency,,2022,Q3,4,F,,20220824.0,20220125,20220828,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220828,,MD,CA,CA,2022,Q3,Elderly
203737964,20373796,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,200.0,MG,,,2022,Q3,Troponin increased,,2022,Q3,4,F,,20220824.0,20220125,20220828,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220828,,MD,CA,CA,2022,Q3,Elderly
203737964,20373796,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,200.0,MG,,,2022,Q3,Hyperthyroidism,,2022,Q3,4,F,,20220824.0,20220125,20220828,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220828,,MD,CA,CA,2022,Q3,Elderly
203737964,20373796,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,200.0,MG,,,2022,Q3,Hypotension,,2022,Q3,4,F,,20220824.0,20220125,20220828,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,,M,Y,,,20220828,,MD,CA,CA,2022,Q3,Elderly
204219394,20421939,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,Tablet,QD,2022,Q3,Skin toxicity,,2022,Q3,4,F,20220123.0,20220711.0,20220203,20220714,EXP,,GB-ROCHE-3011313,ROCHE,,62.0,YR,,M,Y,70.3,KG,20220714,,MD,GB,,2022,Q3,Adult
204219394,20421939,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,Tablet,QD,2022,Q3,Metastatic renal cell carcinoma,,2022,Q3,4,F,20220123.0,20220711.0,20220203,20220714,EXP,,GB-ROCHE-3011313,ROCHE,,62.0,YR,,M,Y,70.3,KG,20220714,,MD,GB,,2022,Q3,Adult
204277433,20427743,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,,,Tablet,,2022,Q3,Atrial flutter,,2022,Q3,3,F,20220120.0,20220714.0,20220204,20220722,EXP,,CN-ROCHE-3015536,ROCHE,,75.0,YR,,F,Y,77.5,KG,20220722,,MD,CN,CN,2022,Q3,Elderly
204277433,20427743,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,,,Tablet,,2022,Q3,Haemorrhagic cerebral infarction,,2022,Q3,3,F,20220120.0,20220714.0,20220204,20220722,EXP,,CN-ROCHE-3015536,ROCHE,,75.0,YR,,F,Y,77.5,KG,20220722,,MD,CN,CN,2022,Q3,Elderly
204277433,20427743,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,UNKNOWN,,,,,Tablet,,2022,Q3,Basal ganglia haemorrhage,,2022,Q3,3,F,20220120.0,20220714.0,20220204,20220722,EXP,,CN-ROCHE-3015536,ROCHE,,75.0,YR,,F,Y,77.5,KG,20220722,,MD,CN,CN,2022,Q3,Elderly
2051220510,20512205,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2022,Q3,Infection,,2022,Q3,10,F,20220209.0,20220923.0,20220224,20220930,EXP,,BR-Eisai Medical Research-EC-2022-109187,EISAI,,65.0,YR,E,F,Y,61.5,KG,20220930,,MD,BR,,2022,Q3,Elderly
205814292,20581429,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q3,Condition aggravated,,2022,Q3,2,F,,20220719.0,20220311,20220725,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20220725,,HP,CA,CA,2022,Q3,Adult
205814292,20581429,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q3,Weight decreased,,2022,Q3,2,F,,20220719.0,20220311,20220725,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20220725,,HP,CA,CA,2022,Q3,Adult
205814292,20581429,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q3,Hepatotoxicity,,2022,Q3,2,F,,20220719.0,20220311,20220725,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20220725,,HP,CA,CA,2022,Q3,Adult
205814292,20581429,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q3,Drug ineffective,,2022,Q3,2,F,,20220719.0,20220311,20220725,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20220725,,HP,CA,CA,2022,Q3,Adult
205814292,20581429,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q3,Psoriasis,,2022,Q3,2,F,,20220719.0,20220311,20220725,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20220725,,HP,CA,CA,2022,Q3,Adult
205814292,20581429,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q3,C-reactive protein increased,,2022,Q3,2,F,,20220719.0,20220311,20220725,EXP,,CA-APOTEX-2022AP004206,APOTEX,,40.0,YR,,F,Y,,,20220725,,HP,CA,CA,2022,Q3,Adult
205876063,20587606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Drug ineffective,,2022,Q3,3,F,20200309.0,20220909.0,20220314,20220916,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20220916,,MD,CA,CA,2022,Q3,Adult
205876063,20587606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Psoriasis,,2022,Q3,3,F,20200309.0,20220909.0,20220314,20220916,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20220916,,MD,CA,CA,2022,Q3,Adult
205876063,20587606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Hepatotoxicity,,2022,Q3,3,F,20200309.0,20220909.0,20220314,20220916,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20220916,,MD,CA,CA,2022,Q3,Adult
205876063,20587606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Weight decreased,,2022,Q3,3,F,20200309.0,20220909.0,20220314,20220916,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20220916,,MD,CA,CA,2022,Q3,Adult
205876063,20587606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Condition aggravated,,2022,Q3,3,F,20200309.0,20220909.0,20220314,20220916,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20220916,,MD,CA,CA,2022,Q3,Adult
205876063,20587606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Pustular psoriasis,,2022,Q3,3,F,20200309.0,20220909.0,20220314,20220916,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20220916,,MD,CA,CA,2022,Q3,Adult
205876063,20587606,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,C-reactive protein increased,,2022,Q3,3,F,20200309.0,20220909.0,20220314,20220916,EXP,,CA-SA-2022SA081665,SANOFI AVENTIS,,40.0,YR,A,F,Y,,,20220916,,MD,CA,CA,2022,Q3,Adult
205979005,20597900,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, daily (mane)",,,U,,,,,10.0,MG,,,2022,Q3,Dizziness,,2022,Q3,5,F,,20220726.0,20220315,20220801,EXP,,AU-PFIZER INC-202200398004,PFIZER,,48.0,YR,,M,Y,90.0,KG,20220801,,MD,AU,AU,2022,Q3,Adult
205979005,20597900,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, daily (mane)",,,U,,,,,10.0,MG,,,2022,Q3,Schizophrenia,,2022,Q3,5,F,,20220726.0,20220315,20220801,EXP,,AU-PFIZER INC-202200398004,PFIZER,,48.0,YR,,M,Y,90.0,KG,20220801,,MD,AU,AU,2022,Q3,Adult
205979005,20597900,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, daily (mane)",,,U,,,,,10.0,MG,,,2022,Q3,Blood pressure decreased,,2022,Q3,5,F,,20220726.0,20220315,20220801,EXP,,AU-PFIZER INC-202200398004,PFIZER,,48.0,YR,,M,Y,90.0,KG,20220801,,MD,AU,AU,2022,Q3,Adult
205979005,20597900,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, daily (mane)",,,U,,,,,10.0,MG,,,2022,Q3,Dyspnoea,,2022,Q3,5,F,,20220726.0,20220315,20220801,EXP,,AU-PFIZER INC-202200398004,PFIZER,,48.0,YR,,M,Y,90.0,KG,20220801,,MD,AU,AU,2022,Q3,Adult
205979005,20597900,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, daily (mane)",,,U,,,,,10.0,MG,,,2022,Q3,Mental disorder,,2022,Q3,5,F,,20220726.0,20220315,20220801,EXP,,AU-PFIZER INC-202200398004,PFIZER,,48.0,YR,,M,Y,90.0,KG,20220801,,MD,AU,AU,2022,Q3,Adult
206151342,20615134,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,C-reactive protein increased,,2022,Q3,2,F,,20220721.0,20220321,20220803,EXP,,CA-AUROBINDO-AUR-APL-2022-008393,AUROBINDO,,40.0,YR,,F,Y,,,20220803,,HP,CA,CA,2022,Q3,Adult
206151342,20615134,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Hepatotoxicity,,2022,Q3,2,F,,20220721.0,20220321,20220803,EXP,,CA-AUROBINDO-AUR-APL-2022-008393,AUROBINDO,,40.0,YR,,F,Y,,,20220803,,HP,CA,CA,2022,Q3,Adult
206151342,20615134,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Psoriasis,,2022,Q3,2,F,,20220721.0,20220321,20220803,EXP,,CA-AUROBINDO-AUR-APL-2022-008393,AUROBINDO,,40.0,YR,,F,Y,,,20220803,,HP,CA,CA,2022,Q3,Adult
206151342,20615134,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Weight decreased,,2022,Q3,2,F,,20220721.0,20220321,20220803,EXP,,CA-AUROBINDO-AUR-APL-2022-008393,AUROBINDO,,40.0,YR,,F,Y,,,20220803,,HP,CA,CA,2022,Q3,Adult
206151342,20615134,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Drug ineffective,,2022,Q3,2,F,,20220721.0,20220321,20220803,EXP,,CA-AUROBINDO-AUR-APL-2022-008393,AUROBINDO,,40.0,YR,,F,Y,,,20220803,,HP,CA,CA,2022,Q3,Adult
206151342,20615134,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2022,Q3,Condition aggravated,,2022,Q3,2,F,,20220721.0,20220321,20220803,EXP,,CA-AUROBINDO-AUR-APL-2022-008393,AUROBINDO,,40.0,YR,,F,Y,,,20220803,,HP,CA,CA,2022,Q3,Adult
206675454,20667545,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q3,Weight decreased,,2022,Q3,4,F,,20220928.0,20220404,20220930,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20220930,,CN,CA,CA,2022,Q3,Adult
206675454,20667545,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q3,C-reactive protein increased,,2022,Q3,4,F,,20220928.0,20220404,20220930,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20220930,,CN,CA,CA,2022,Q3,Adult
206675454,20667545,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q3,Psoriasis,,2022,Q3,4,F,,20220928.0,20220404,20220930,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20220930,,CN,CA,CA,2022,Q3,Adult
206675454,20667545,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q3,Drug ineffective,,2022,Q3,4,F,,20220928.0,20220404,20220930,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20220930,,CN,CA,CA,2022,Q3,Adult
206675454,20667545,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q3,Hepatotoxicity,,2022,Q3,4,F,,20220928.0,20220404,20220930,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20220930,,CN,CA,CA,2022,Q3,Adult
206675454,20667545,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q3,Off label use,,2022,Q3,4,F,,20220928.0,20220404,20220930,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20220930,,CN,CA,CA,2022,Q3,Adult
206675454,20667545,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q3,Condition aggravated,,2022,Q3,4,F,,20220928.0,20220404,20220930,EXP,,CA-BAUSCH-BL-2022-008136,BAUSCH AND LOMB,,40.0,YR,,F,Y,,,20220930,,CN,CA,CA,2022,Q3,Adult
206958404,20695840,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,102145.0,,,Tablet,,2022,Q3,Pancreatitis,,2022,Q3,4,F,20220406.0,20220906.0,20220411,20220907,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-164476",BOEHRINGER INGELHEIM,,89.0,YR,E,F,Y,68.0,KG,20220907,,MD,DE,DE,2022,Q3,Elderly
207062173,20706217,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,Unknown,,2022,Q3,Urinary tract infection,,2022,Q3,3,F,20220319.0,20220711.0,20220413,20220715,EXP,,IN-JNJFOC-20220350714,JOHNSON AND JOHNSON,,47.0,YR,A,M,Y,81.2,KG,20220715,,MD,IN,IN,2022,Q3,Adult
207078915,20707891,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2022,Q3,Appendicitis,,2022,Q3,5,F,20220412.0,20220901.0,20220414,20220906,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165275",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,61.1,KG,20220906,,MD,JP,JP,2022,Q3,Adult
207078915,20707891,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,5,F,20220412.0,20220901.0,20220414,20220906,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165275",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,61.1,KG,20220906,,MD,JP,JP,2022,Q3,Adult
207255824,20725582,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Prostatomegaly,,2022,Q3,4,F,20220101.0,20220810.0,20220419,20220818,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-021099,BRISTOL MYERS SQUIBB,,80.0,YR,E,M,Y,83.0,KG,20220818,,MD,DE,DE,2022,Q3,Elderly
207255824,20725582,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Gastritis,,2022,Q3,4,F,20220101.0,20220810.0,20220419,20220818,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-021099,BRISTOL MYERS SQUIBB,,80.0,YR,E,M,Y,83.0,KG,20220818,,MD,DE,DE,2022,Q3,Elderly
207255824,20725582,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Vena cava thrombosis,,2022,Q3,4,F,20220101.0,20220810.0,20220419,20220818,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-021099,BRISTOL MYERS SQUIBB,,80.0,YR,E,M,Y,83.0,KG,20220818,,MD,DE,DE,2022,Q3,Elderly
207255824,20725582,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Diverticulum,,2022,Q3,4,F,20220101.0,20220810.0,20220419,20220818,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-021099,BRISTOL MYERS SQUIBB,,80.0,YR,E,M,Y,83.0,KG,20220818,,MD,DE,DE,2022,Q3,Elderly
207255824,20725582,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Duodenogastric reflux,,2022,Q3,4,F,20220101.0,20220810.0,20220419,20220818,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-021099,BRISTOL MYERS SQUIBB,,80.0,YR,E,M,Y,83.0,KG,20220818,,MD,DE,DE,2022,Q3,Elderly
207255824,20725582,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Prostatic calcification,,2022,Q3,4,F,20220101.0,20220810.0,20220419,20220818,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-021099,BRISTOL MYERS SQUIBB,,80.0,YR,E,M,Y,83.0,KG,20220818,,MD,DE,DE,2022,Q3,Elderly
207255824,20725582,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Subclavian vein thrombosis,,2022,Q3,4,F,20220101.0,20220810.0,20220419,20220818,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-021099,BRISTOL MYERS SQUIBB,,80.0,YR,E,M,Y,83.0,KG,20220818,,MD,DE,DE,2022,Q3,Elderly
207255824,20725582,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Rash erythematous,,2022,Q3,4,F,20220101.0,20220810.0,20220419,20220818,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-021099,BRISTOL MYERS SQUIBB,,80.0,YR,E,M,Y,83.0,KG,20220818,,MD,DE,DE,2022,Q3,Elderly
207255824,20725582,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Device defective,,2022,Q3,4,F,20220101.0,20220810.0,20220419,20220818,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-021099,BRISTOL MYERS SQUIBB,,80.0,YR,E,M,Y,83.0,KG,20220818,,MD,DE,DE,2022,Q3,Elderly
207255824,20725582,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Arteriosclerosis coronary artery,,2022,Q3,4,F,20220101.0,20220810.0,20220419,20220818,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-021099,BRISTOL MYERS SQUIBB,,80.0,YR,E,M,Y,83.0,KG,20220818,,MD,DE,DE,2022,Q3,Elderly
207255824,20725582,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Face oedema,,2022,Q3,4,F,20220101.0,20220810.0,20220419,20220818,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-021099,BRISTOL MYERS SQUIBB,,80.0,YR,E,M,Y,83.0,KG,20220818,,MD,DE,DE,2022,Q3,Elderly
207255824,20725582,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Small intestinal anastomosis,,2022,Q3,4,F,20220101.0,20220810.0,20220419,20220818,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-021099,BRISTOL MYERS SQUIBB,,80.0,YR,E,M,Y,83.0,KG,20220818,,MD,DE,DE,2022,Q3,Elderly
207255824,20725582,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Goitre,,2022,Q3,4,F,20220101.0,20220810.0,20220419,20220818,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-021099,BRISTOL MYERS SQUIBB,,80.0,YR,E,M,Y,83.0,KG,20220818,,MD,DE,DE,2022,Q3,Elderly
207255824,20725582,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Spinal osteoarthritis,,2022,Q3,4,F,20220101.0,20220810.0,20220419,20220818,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-021099,BRISTOL MYERS SQUIBB,,80.0,YR,E,M,Y,83.0,KG,20220818,,MD,DE,DE,2022,Q3,Elderly
207361544,20736154,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Pyrexia,,2022,Q3,4,F,20220331.0,20220722.0,20220421,20220727,EXP,,AU-ROCHE-3074103,ROCHE,,67.0,YR,,M,Y,,,20220727,,HP,AU,,2022,Q3,Elderly
207719526,20771952,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Vitreous haemorrhage,,2022,Q3,6,F,20220418.0,20220804.0,20220501,20220810,EXP,,NVSC2022CN095120,NOVARTIS,,22.0,YR,,F,Y,,,20220810,,MD,CN,CN,2022,Q3,Youth
207778942,20777894,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2022,Q3,Hypoaesthesia,,2022,Q3,2,F,,20220803.0,20220503,20220816,EXP,CA-MHPD-E2B_03864168,CA-Accord-262260,ACCORD,,77.0,YR,E,F,Y,,,20220816,,CN,CA,CA,2022,Q3,Elderly
207778942,20777894,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2022,Q3,Transient ischaemic attack,,2022,Q3,2,F,,20220803.0,20220503,20220816,EXP,CA-MHPD-E2B_03864168,CA-Accord-262260,ACCORD,,77.0,YR,E,F,Y,,,20220816,,CN,CA,CA,2022,Q3,Elderly
207954405,20795440,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2022,Q3,Ocular vasculitis,,2022,Q3,5,F,20220427.0,20220730.0,20220506,20220805,EXP,,US-ROCHE-3087474,ROCHE,,76.0,YR,,F,Y,70.9,KG,20220805,,MD,US,,2022,Q3,Elderly
207969852,20796985,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Dysarthria,,2022,Q3,2,F,20220401.0,20220720.0,20220506,20220722,EXP,,NVSC2022KE104348,NOVARTIS,,57.0,YR,,F,Y,,,20220722,,HP,KE,KE,2022,Q3,Adult
207969852,20796985,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Tachycardia,,2022,Q3,2,F,20220401.0,20220720.0,20220506,20220722,EXP,,NVSC2022KE104348,NOVARTIS,,57.0,YR,,F,Y,,,20220722,,HP,KE,KE,2022,Q3,Adult
207969852,20796985,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Hyperglycaemia,,2022,Q3,2,F,20220401.0,20220720.0,20220506,20220722,EXP,,NVSC2022KE104348,NOVARTIS,,57.0,YR,,F,Y,,,20220722,,HP,KE,KE,2022,Q3,Adult
208454492,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Renal disorder,,2022,Q3,2,F,20211008.0,20220626.0,20220518,20220702,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20220702,,CN,AR,AR,2022,Q3,Elderly
208454492,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Product quality issue,,2022,Q3,2,F,20211008.0,20220626.0,20220518,20220702,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20220702,,CN,AR,AR,2022,Q3,Elderly
208454492,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Varicose vein,,2022,Q3,2,F,20211008.0,20220626.0,20220518,20220702,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20220702,,CN,AR,AR,2022,Q3,Elderly
208454492,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Mobility decreased,,2022,Q3,2,F,20211008.0,20220626.0,20220518,20220702,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20220702,,CN,AR,AR,2022,Q3,Elderly
208454492,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Ejection fraction decreased,,2022,Q3,2,F,20211008.0,20220626.0,20220518,20220702,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20220702,,CN,AR,AR,2022,Q3,Elderly
208454492,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Hypotension,,2022,Q3,2,F,20211008.0,20220626.0,20220518,20220702,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20220702,,CN,AR,AR,2022,Q3,Elderly
208454492,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Wrong technique in product usage process,,2022,Q3,2,F,20211008.0,20220626.0,20220518,20220702,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20220702,,CN,AR,AR,2022,Q3,Elderly
208454492,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Atrial fibrillation,,2022,Q3,2,F,20211008.0,20220626.0,20220518,20220702,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20220702,,CN,AR,AR,2022,Q3,Elderly
208454492,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Arrhythmia,,2022,Q3,2,F,20211008.0,20220626.0,20220518,20220702,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20220702,,CN,AR,AR,2022,Q3,Elderly
208454492,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Amnesia,,2022,Q3,2,F,20211008.0,20220626.0,20220518,20220702,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20220702,,CN,AR,AR,2022,Q3,Elderly
208454492,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Hypokinesia,,2022,Q3,2,F,20211008.0,20220626.0,20220518,20220702,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20220702,,CN,AR,AR,2022,Q3,Elderly
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Anhedonia,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Arthralgia,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Pain in extremity,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Abdominal pain lower,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Quality of life decreased,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Periarthritis,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Pain,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Emotional distress,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Depression,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Anxiety,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Back pain,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Bone demineralisation,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Osteonecrosis,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Back pain,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Muscular weakness,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208591312,20859131,25,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q3,Osteoporosis,,2022,Q3,2,F,20120101.0,20220818.0,20220523,20220823,EXP,,US-GILEAD-2022-0582477,GILEAD,,57.0,YR,A,F,Y,103.86,KG,20220823,,LW,US,US,2022,Q3,Adult
208625394,20862539,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500mg,,,D,,,,,,,,,2022,Q3,Nausea,,2022,Q3,4,F,20220504.0,20220804.0,20220523,20220810,EXP,,AU-NALPROPION PHARMACEUTICALS INC.-AU-2022CUR021660,CURRAX PHARMACEUTICALS,,62.0,YR,,F,Y,67.0,KG,20220810,,CN,AU,AU,2022,Q3,Adult
208625394,20862539,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500mg,,,D,,,,,,,,,2022,Q3,Dyspnoea,,2022,Q3,4,F,20220504.0,20220804.0,20220523,20220810,EXP,,AU-NALPROPION PHARMACEUTICALS INC.-AU-2022CUR021660,CURRAX PHARMACEUTICALS,,62.0,YR,,F,Y,67.0,KG,20220810,,CN,AU,AU,2022,Q3,Adult
208625394,20862539,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500mg,,,D,,,,,,,,,2022,Q3,Gastrooesophageal reflux disease,,2022,Q3,4,F,20220504.0,20220804.0,20220523,20220810,EXP,,AU-NALPROPION PHARMACEUTICALS INC.-AU-2022CUR021660,CURRAX PHARMACEUTICALS,,62.0,YR,,F,Y,67.0,KG,20220810,,CN,AU,AU,2022,Q3,Adult
208625394,20862539,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500mg,,,D,,,,,,,,,2022,Q3,Tremor,,2022,Q3,4,F,20220504.0,20220804.0,20220523,20220810,EXP,,AU-NALPROPION PHARMACEUTICALS INC.-AU-2022CUR021660,CURRAX PHARMACEUTICALS,,62.0,YR,,F,Y,67.0,KG,20220810,,CN,AU,AU,2022,Q3,Adult
208625394,20862539,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500mg,,,D,,,,,,,,,2022,Q3,Taste disorder,,2022,Q3,4,F,20220504.0,20220804.0,20220523,20220810,EXP,,AU-NALPROPION PHARMACEUTICALS INC.-AU-2022CUR021660,CURRAX PHARMACEUTICALS,,62.0,YR,,F,Y,67.0,KG,20220810,,CN,AU,AU,2022,Q3,Adult
208625394,20862539,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500mg,,,D,,,,,,,,,2022,Q3,Thirst,,2022,Q3,4,F,20220504.0,20220804.0,20220523,20220810,EXP,,AU-NALPROPION PHARMACEUTICALS INC.-AU-2022CUR021660,CURRAX PHARMACEUTICALS,,62.0,YR,,F,Y,67.0,KG,20220810,,CN,AU,AU,2022,Q3,Adult
208625394,20862539,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500mg,,,D,,,,,,,,,2022,Q3,Anxiety,,2022,Q3,4,F,20220504.0,20220804.0,20220523,20220810,EXP,,AU-NALPROPION PHARMACEUTICALS INC.-AU-2022CUR021660,CURRAX PHARMACEUTICALS,,62.0,YR,,F,Y,67.0,KG,20220810,,CN,AU,AU,2022,Q3,Adult
208930055,20893005,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2022,Q3,Pyrexia,,2022,Q3,5,F,20220329.0,20220923.0,20220531,20220927,EXP,,US-ROCHE-3071236,ROCHE,,61.0,YR,,M,Y,150.57,KG,20220926,,MD,US,,2022,Q3,Adult
208930055,20893005,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2022,Q3,Cardiac failure congestive,,2022,Q3,5,F,20220329.0,20220923.0,20220531,20220927,EXP,,US-ROCHE-3071236,ROCHE,,61.0,YR,,M,Y,150.57,KG,20220926,,MD,US,,2022,Q3,Adult
209068193,20906819,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Ischaemic cardiomyopathy,,2022,Q3,3,F,20201201.0,20220624.0,20220602,20220630,EXP,,NVSC2022HR123097,NOVARTIS,,85.0,YR,,M,Y,,,20220630,,MD,HR,HR,2022,Q3,Elderly
209068193,20906819,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Mitral valve incompetence,,2022,Q3,3,F,20201201.0,20220624.0,20220602,20220630,EXP,,NVSC2022HR123097,NOVARTIS,,85.0,YR,,M,Y,,,20220630,,MD,HR,HR,2022,Q3,Elderly
209068193,20906819,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Aortic valve incompetence,,2022,Q3,3,F,20201201.0,20220624.0,20220602,20220630,EXP,,NVSC2022HR123097,NOVARTIS,,85.0,YR,,M,Y,,,20220630,,MD,HR,HR,2022,Q3,Elderly
209068193,20906819,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Angina unstable,,2022,Q3,3,F,20201201.0,20220624.0,20220602,20220630,EXP,,NVSC2022HR123097,NOVARTIS,,85.0,YR,,M,Y,,,20220630,,MD,HR,HR,2022,Q3,Elderly
209068193,20906819,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Angina pectoris,,2022,Q3,3,F,20201201.0,20220624.0,20220602,20220630,EXP,,NVSC2022HR123097,NOVARTIS,,85.0,YR,,M,Y,,,20220630,,MD,HR,HR,2022,Q3,Elderly
209068193,20906819,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Ischaemic cardiomyopathy,,2022,Q3,3,F,20201201.0,20220624.0,20220602,20220630,EXP,,NVSC2022HR123097,NOVARTIS,,85.0,YR,,M,Y,,,20220630,,MD,HR,HR,2022,Q3,Elderly
209068193,20906819,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Mitral valve incompetence,,2022,Q3,3,F,20201201.0,20220624.0,20220602,20220630,EXP,,NVSC2022HR123097,NOVARTIS,,85.0,YR,,M,Y,,,20220630,,MD,HR,HR,2022,Q3,Elderly
209068193,20906819,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Aortic valve incompetence,,2022,Q3,3,F,20201201.0,20220624.0,20220602,20220630,EXP,,NVSC2022HR123097,NOVARTIS,,85.0,YR,,M,Y,,,20220630,,MD,HR,HR,2022,Q3,Elderly
209068193,20906819,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Angina unstable,,2022,Q3,3,F,20201201.0,20220624.0,20220602,20220630,EXP,,NVSC2022HR123097,NOVARTIS,,85.0,YR,,M,Y,,,20220630,,MD,HR,HR,2022,Q3,Elderly
209068193,20906819,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q3,Angina pectoris,,2022,Q3,3,F,20201201.0,20220624.0,20220602,20220630,EXP,,NVSC2022HR123097,NOVARTIS,,85.0,YR,,M,Y,,,20220630,,MD,HR,HR,2022,Q3,Elderly
209204475,20920447,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2022,Q3,Ischaemic cardiomyopathy,,2022,Q3,5,F,20201201.0,20220627.0,20220606,20220706,EXP,,HR-MYLANLABS-2022M1041930,MYLAN,,85.0,YR,,M,Y,,,20220706,,MD,HR,HR,2022,Q3,Elderly
209204475,20920447,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2022,Q3,Angina unstable,,2022,Q3,5,F,20201201.0,20220627.0,20220606,20220706,EXP,,HR-MYLANLABS-2022M1041930,MYLAN,,85.0,YR,,M,Y,,,20220706,,MD,HR,HR,2022,Q3,Elderly
209204475,20920447,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2022,Q3,Aortic valve incompetence,,2022,Q3,5,F,20201201.0,20220627.0,20220606,20220706,EXP,,HR-MYLANLABS-2022M1041930,MYLAN,,85.0,YR,,M,Y,,,20220706,,MD,HR,HR,2022,Q3,Elderly
209204475,20920447,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2022,Q3,Angina pectoris,,2022,Q3,5,F,20201201.0,20220627.0,20220606,20220706,EXP,,HR-MYLANLABS-2022M1041930,MYLAN,,85.0,YR,,M,Y,,,20220706,,MD,HR,HR,2022,Q3,Elderly
209204475,20920447,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2022,Q3,Mitral valve incompetence,,2022,Q3,5,F,20201201.0,20220627.0,20220606,20220706,EXP,,HR-MYLANLABS-2022M1041930,MYLAN,,85.0,YR,,M,Y,,,20220706,,MD,HR,HR,2022,Q3,Elderly
209204475,20920447,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Ischaemic cardiomyopathy,,2022,Q3,5,F,20201201.0,20220627.0,20220606,20220706,EXP,,HR-MYLANLABS-2022M1041930,MYLAN,,85.0,YR,,M,Y,,,20220706,,MD,HR,HR,2022,Q3,Elderly
209204475,20920447,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Angina unstable,,2022,Q3,5,F,20201201.0,20220627.0,20220606,20220706,EXP,,HR-MYLANLABS-2022M1041930,MYLAN,,85.0,YR,,M,Y,,,20220706,,MD,HR,HR,2022,Q3,Elderly
209204475,20920447,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Aortic valve incompetence,,2022,Q3,5,F,20201201.0,20220627.0,20220606,20220706,EXP,,HR-MYLANLABS-2022M1041930,MYLAN,,85.0,YR,,M,Y,,,20220706,,MD,HR,HR,2022,Q3,Elderly
209204475,20920447,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Angina pectoris,,2022,Q3,5,F,20201201.0,20220627.0,20220606,20220706,EXP,,HR-MYLANLABS-2022M1041930,MYLAN,,85.0,YR,,M,Y,,,20220706,,MD,HR,HR,2022,Q3,Elderly
209204475,20920447,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,Tablet,,2022,Q3,Mitral valve incompetence,,2022,Q3,5,F,20201201.0,20220627.0,20220606,20220706,EXP,,HR-MYLANLABS-2022M1041930,MYLAN,,85.0,YR,,M,Y,,,20220706,,MD,HR,HR,2022,Q3,Elderly
209296142,20929614,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Vitreal cells,,2022,Q3,2,F,20220602.0,20220622.0,20220608,20220623,EXP,,NVSC2022DE128004,NOVARTIS,,74.0,YR,,M,Y,,,20220623,,MD,DE,DE,2022,Q3,Elderly
209480963,20948096,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD",,,U,,,,,,,,QD,2022,Q3,Nocturia,,2022,Q3,3,F,20220501.0,20220826.0,20220611,20220830,EXP,,NVSC2022KE133497,NOVARTIS,,59.0,YR,,M,Y,,,20220830,,HP,KE,KE,2022,Q3,Adult
209686302,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q3,Pancytopenia,,2022,Q3,2,F,,20220711.0,20220616,20220725,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220725,,MD,CA,CA,2022,Q3,Adult
209686302,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q3,Weight decreased,,2022,Q3,2,F,,20220711.0,20220616,20220725,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220725,,MD,CA,CA,2022,Q3,Adult
209686302,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q3,Blood immunoglobulin G increased,,2022,Q3,2,F,,20220711.0,20220616,20220725,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220725,,MD,CA,CA,2022,Q3,Adult
209686302,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q3,Fall,,2022,Q3,2,F,,20220711.0,20220616,20220725,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220725,,MD,CA,CA,2022,Q3,Adult
209686302,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q3,Acute kidney injury,,2022,Q3,2,F,,20220711.0,20220616,20220725,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220725,,MD,CA,CA,2022,Q3,Adult
209686302,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q3,Mobility decreased,,2022,Q3,2,F,,20220711.0,20220616,20220725,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220725,,MD,CA,CA,2022,Q3,Adult
209686302,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q3,Normocytic anaemia,,2022,Q3,2,F,,20220711.0,20220616,20220725,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220725,,MD,CA,CA,2022,Q3,Adult
209686302,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q3,Plasma cell myeloma,,2022,Q3,2,F,,20220711.0,20220616,20220725,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220725,,MD,CA,CA,2022,Q3,Adult
209686302,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q3,Back pain,,2022,Q3,2,F,,20220711.0,20220616,20220725,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220725,,MD,CA,CA,2022,Q3,Adult
209686302,20968630,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,20.0,MG,Tablet,,2022,Q3,Hypercalcaemia,,2022,Q3,2,F,,20220711.0,20220616,20220725,EXP,,CA-HLS-202201122,HLS THERAPEUTICS,,62.0,YR,A,M,Y,,,20220725,,MD,CA,CA,2022,Q3,Adult
209762184,20976218,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Acute kidney injury,,2022,Q3,4,F,20220224.0,20220912.0,20220617,20220913,EXP,,US-PFIZER INC-202200691680,PFIZER,,47.0,YR,,F,Y,90.9,KG,20220913,,HP,US,US,2022,Q3,Adult
209762184,20976218,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Dizziness,,2022,Q3,4,F,20220224.0,20220912.0,20220617,20220913,EXP,,US-PFIZER INC-202200691680,PFIZER,,47.0,YR,,F,Y,90.9,KG,20220913,,HP,US,US,2022,Q3,Adult
209793272,20979327,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg/day,,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q3,Cerebral infarction,,2022,Q3,2,F,20191224.0,20220707.0,20220620,20220713,EXP,,JP-ROCHE-3117402,ROCHE,"PRIVACY P, Temmoku J, Asano T, Saito K, Matsumoto H, Fujita Y, Furuya-Yashiro M, et al.. Case Report Effect of a multitarget therapy with prednisolone,mycophenolate mofetil,and tacrolimus in a patient with type B insulin resistance syndrome complicated by lupus nephritis.. Journal of Modern Rheumatology Case Reports. 2022;6(1):41-46.",59.0,YR,,M,Y,68.1,KG,20220713,,MD,JP,JP,2022,Q3,Adult
209967914,20996791,3,C,EMPAGLIFLOZINE,,2,Oral,ongoing,,,U,,,,,10.0,MG,Unknown,,2022,Q3,Acute hepatic failure,,2022,Q3,4,F,20220608.0,20220826.0,20220623,20220901,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-2022-055622,BRISTOL MYERS SQUIBB,,49.0,YR,A,M,Y,99.0,KG,20220901,,HP,PL,PL,2022,Q3,Adult
209979296,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2022,Q3,Systemic lupus erythematosus,,2022,Q3,6,F,20220501.0,20220912.0,20220623,20220917,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20220917,,CN,US,US,2022,Q3,Adult
209979296,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2022,Q3,Epistaxis,,2022,Q3,6,F,20220501.0,20220912.0,20220623,20220917,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20220917,,CN,US,US,2022,Q3,Adult
209979296,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2022,Q3,Cough,,2022,Q3,6,F,20220501.0,20220912.0,20220623,20220917,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20220917,,CN,US,US,2022,Q3,Adult
209979296,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2022,Q3,Photosensitivity reaction,,2022,Q3,6,F,20220501.0,20220912.0,20220623,20220917,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20220917,,CN,US,US,2022,Q3,Adult
209979296,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2022,Q3,Fatigue,,2022,Q3,6,F,20220501.0,20220912.0,20220623,20220917,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20220917,,CN,US,US,2022,Q3,Adult
209979296,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2022,Q3,Inappropriate schedule of product administration,,2022,Q3,6,F,20220501.0,20220912.0,20220623,20220917,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20220917,,CN,US,US,2022,Q3,Adult
209979296,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2022,Q3,Wrong technique in product usage process,,2022,Q3,6,F,20220501.0,20220912.0,20220623,20220917,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20220917,,CN,US,US,2022,Q3,Adult
209979296,20997929,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 mg, qd",,,,,,,,12.5,MG,,QD,2022,Q3,Headache,,2022,Q3,6,F,20220501.0,20220912.0,20220623,20220917,EXP,,US-UNITED THERAPEUTICS-UNT-2022-011002,UNITED THERAPEUTICS,,48.0,YR,,F,Y,98.866,KG,20220917,,CN,US,US,2022,Q3,Adult
210047983,21004798,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (at the morning)",,,U,,,,,,,Tablet,QD,2022,Q3,Hyperkalaemia,,2022,Q3,3,F,,20220617.0,20220624,20220630,EXP,,NVSC2022TH140864,NOVARTIS,,60.0,YR,,M,Y,,,20220630,,MD,TH,TH,2022,Q3,Adult
210047983,21004798,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (at the morning)",,,U,,,,,,,Tablet,QD,2022,Q3,Product use issue,,2022,Q3,3,F,,20220617.0,20220624,20220630,EXP,,NVSC2022TH140864,NOVARTIS,,60.0,YR,,M,Y,,,20220630,,MD,TH,TH,2022,Q3,Adult
210047983,21004798,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (at the morning)",,,U,,,,,,,Tablet,QD,2022,Q3,N-terminal prohormone brain natriuretic peptide increased,,2022,Q3,3,F,,20220617.0,20220624,20220630,EXP,,NVSC2022TH140864,NOVARTIS,,60.0,YR,,M,Y,,,20220630,,MD,TH,TH,2022,Q3,Adult
210047983,21004798,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (at the morning)",,,U,,,,,,,Tablet,QD,2022,Q3,Wrong technique in product usage process,,2022,Q3,3,F,,20220617.0,20220624,20220630,EXP,,NVSC2022TH140864,NOVARTIS,,60.0,YR,,M,Y,,,20220630,,MD,TH,TH,2022,Q3,Adult
210047983,21004798,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (at the morning)",,,U,,,,,,,Tablet,QD,2022,Q3,Hyperkalaemia,,2022,Q3,3,F,,20220617.0,20220624,20220630,EXP,,NVSC2022TH140864,NOVARTIS,,60.0,YR,,M,Y,,,20220630,,MD,TH,TH,2022,Q3,Adult
210047983,21004798,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (at the morning)",,,U,,,,,,,Tablet,QD,2022,Q3,Product use issue,,2022,Q3,3,F,,20220617.0,20220624,20220630,EXP,,NVSC2022TH140864,NOVARTIS,,60.0,YR,,M,Y,,,20220630,,MD,TH,TH,2022,Q3,Adult
210047983,21004798,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (at the morning)",,,U,,,,,,,Tablet,QD,2022,Q3,N-terminal prohormone brain natriuretic peptide increased,,2022,Q3,3,F,,20220617.0,20220624,20220630,EXP,,NVSC2022TH140864,NOVARTIS,,60.0,YR,,M,Y,,,20220630,,MD,TH,TH,2022,Q3,Adult
210047983,21004798,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD (at the morning)",,,U,,,,,,,Tablet,QD,2022,Q3,Wrong technique in product usage process,,2022,Q3,3,F,,20220617.0,20220624,20220630,EXP,,NVSC2022TH140864,NOVARTIS,,60.0,YR,,M,Y,,,20220630,,MD,TH,TH,2022,Q3,Adult
210075602,21007560,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,Tablet,,2022,Q3,Hypotension,,2022,Q3,2,F,20220201.0,20220627.0,20220626,20220705,EXP,,NVSJ2022JP092886,NOVARTIS,,46.0,YR,,F,Y,,,20220706,,MD,JP,JP,2022,Q3,Adult
210075602,21007560,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,Tablet,,2022,Q3,Renal impairment,,2022,Q3,2,F,20220201.0,20220627.0,20220626,20220705,EXP,,NVSJ2022JP092886,NOVARTIS,,46.0,YR,,F,Y,,,20220706,,MD,JP,JP,2022,Q3,Adult
210075602,21007560,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,Tablet,,2022,Q3,Dizziness,,2022,Q3,2,F,20220201.0,20220627.0,20220626,20220705,EXP,,NVSJ2022JP092886,NOVARTIS,,46.0,YR,,F,Y,,,20220706,,MD,JP,JP,2022,Q3,Adult
210157102,21015710,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Metabolic acidosis,,2022,Q3,2,F,20201130.0,20220707.0,20220628,20220708,EXP,ES-AEMPS-766262,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178756",BOEHRINGER INGELHEIM,,85.0,YR,E,M,Y,84.0,KG,20220708,,PH,ES,ES,2022,Q3,Elderly
210157102,21015710,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Hyperkalaemia,,2022,Q3,2,F,20201130.0,20220707.0,20220628,20220708,EXP,ES-AEMPS-766262,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178756",BOEHRINGER INGELHEIM,,85.0,YR,E,M,Y,84.0,KG,20220708,,PH,ES,ES,2022,Q3,Elderly
210157102,21015710,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Chronic kidney disease,,2022,Q3,2,F,20201130.0,20220707.0,20220628,20220708,EXP,ES-AEMPS-766262,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178756",BOEHRINGER INGELHEIM,,85.0,YR,E,M,Y,84.0,KG,20220708,,PH,ES,ES,2022,Q3,Elderly
210227672,21022767,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Low density lipoprotein abnormal,,2022,Q3,2,F,20210101.0,20220630.0,20220629,20220708,EXP,,DE-PFIZER INC-202200891511,PFIZER,,74.0,YR,,M,Y,,,20220708,,MD,DE,DE,2022,Q3,Elderly
210227672,21022767,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Ischaemia,,2022,Q3,2,F,20210101.0,20220630.0,20220629,20220708,EXP,,DE-PFIZER INC-202200891511,PFIZER,,74.0,YR,,M,Y,,,20220708,,MD,DE,DE,2022,Q3,Elderly
210227672,21022767,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,High density lipoprotein decreased,,2022,Q3,2,F,20210101.0,20220630.0,20220629,20220708,EXP,,DE-PFIZER INC-202200891511,PFIZER,,74.0,YR,,M,Y,,,20220708,,MD,DE,DE,2022,Q3,Elderly
210227672,21022767,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Coronary artery disease,,2022,Q3,2,F,20210101.0,20220630.0,20220629,20220708,EXP,,DE-PFIZER INC-202200891511,PFIZER,,74.0,YR,,M,Y,,,20220708,,MD,DE,DE,2022,Q3,Elderly
210229372,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Bradyphrenia,,2022,Q3,2,F,20220625.0,20220817.0,20220629,20220819,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220819,,CN,US,US,2022,Q3,Adult
210229372,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Dysgeusia,,2022,Q3,2,F,20220625.0,20220817.0,20220629,20220819,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220819,,CN,US,US,2022,Q3,Adult
210229372,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Dizziness,,2022,Q3,2,F,20220625.0,20220817.0,20220629,20220819,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220819,,CN,US,US,2022,Q3,Adult
210229372,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Hangover,,2022,Q3,2,F,20220625.0,20220817.0,20220629,20220819,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220819,,CN,US,US,2022,Q3,Adult
210229372,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Feeling drunk,,2022,Q3,2,F,20220625.0,20220817.0,20220629,20220819,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220819,,CN,US,US,2022,Q3,Adult
210229372,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Insomnia,,2022,Q3,2,F,20220625.0,20220817.0,20220629,20220819,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220819,,CN,US,US,2022,Q3,Adult
210229372,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Disturbance in attention,,2022,Q3,2,F,20220625.0,20220817.0,20220629,20220819,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220819,,CN,US,US,2022,Q3,Adult
210229372,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Feeling abnormal,,2022,Q3,2,F,20220625.0,20220817.0,20220629,20220819,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220819,,CN,US,US,2022,Q3,Adult
210229372,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Incoherent,,2022,Q3,2,F,20220625.0,20220817.0,20220629,20220819,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220819,,CN,US,US,2022,Q3,Adult
210229372,21022937,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Constipation,,2022,Q3,2,F,20220625.0,20220817.0,20220629,20220819,PER,,US-PFIZER INC-202200902455,PFIZER,,61.0,YR,,M,Y,107.95,KG,20220819,,CN,US,US,2022,Q3,Adult
210254542,21025454,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2022,Q3,Circulatory collapse,,2022,Q3,2,F,,20220704.0,20220630,20220711,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177757",BOEHRINGER INGELHEIM,"Spahiou A. Handling of an Implantable Cardioverter Defibrillator dysfunction case.. Hippocratic days of cardiology, 3-4 June 2022. 2022 Jun;",50.0,YR,A,M,Y,,,20220711,,MD,GR,GR,2022,Q3,Adult
210254542,21025454,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2022,Q3,Axillary vein thrombosis,,2022,Q3,2,F,,20220704.0,20220630,20220711,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177757",BOEHRINGER INGELHEIM,"Spahiou A. Handling of an Implantable Cardioverter Defibrillator dysfunction case.. Hippocratic days of cardiology, 3-4 June 2022. 2022 Jun;",50.0,YR,A,M,Y,,,20220711,,MD,GR,GR,2022,Q3,Adult
210254542,21025454,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2022,Q3,Device malfunction,,2022,Q3,2,F,,20220704.0,20220630,20220711,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177757",BOEHRINGER INGELHEIM,"Spahiou A. Handling of an Implantable Cardioverter Defibrillator dysfunction case.. Hippocratic days of cardiology, 3-4 June 2022. 2022 Jun;",50.0,YR,A,M,Y,,,20220711,,MD,GR,GR,2022,Q3,Adult
210254542,21025454,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2022,Q3,Implantable defibrillator insertion,,2022,Q3,2,F,,20220704.0,20220630,20220711,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177757",BOEHRINGER INGELHEIM,"Spahiou A. Handling of an Implantable Cardioverter Defibrillator dysfunction case.. Hippocratic days of cardiology, 3-4 June 2022. 2022 Jun;",50.0,YR,A,M,Y,,,20220711,,MD,GR,GR,2022,Q3,Adult
210254542,21025454,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2022,Q3,Subclavian vein thrombosis,,2022,Q3,2,F,,20220704.0,20220630,20220711,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177757",BOEHRINGER INGELHEIM,"Spahiou A. Handling of an Implantable Cardioverter Defibrillator dysfunction case.. Hippocratic days of cardiology, 3-4 June 2022. 2022 Jun;",50.0,YR,A,M,Y,,,20220711,,MD,GR,GR,2022,Q3,Adult
210254542,21025454,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2022,Q3,Supraventricular tachycardia,,2022,Q3,2,F,,20220704.0,20220630,20220711,EXP,,"GR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-177757",BOEHRINGER INGELHEIM,"Spahiou A. Handling of an Implantable Cardioverter Defibrillator dysfunction case.. Hippocratic days of cardiology, 3-4 June 2022. 2022 Jun;",50.0,YR,A,M,Y,,,20220711,,MD,GR,GR,2022,Q3,Adult
210262232,21026223,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg in the morning,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Thoracic vertebral fracture,,2022,Q3,2,F,20220422.0,20220802.0,20220630,20220803,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178728",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,100.0,KG,20220803,,HP,AU,AU,2022,Q3,Elderly
210262232,21026223,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg in the morning,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Cervical vertebral fracture,,2022,Q3,2,F,20220422.0,20220802.0,20220630,20220803,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178728",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,100.0,KG,20220803,,HP,AU,AU,2022,Q3,Elderly
210262232,21026223,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg in the morning,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Syncope,,2022,Q3,2,F,20220422.0,20220802.0,20220630,20220803,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178728",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,100.0,KG,20220803,,HP,AU,AU,2022,Q3,Elderly
210262232,21026223,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg in the morning,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Dehydration,,2022,Q3,2,F,20220422.0,20220802.0,20220630,20220803,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178728",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,100.0,KG,20220803,,HP,AU,AU,2022,Q3,Elderly
210262232,21026223,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg in the morning,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Thoracic vertebral fracture,,2022,Q3,2,F,20220422.0,20220802.0,20220630,20220803,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178728",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,100.0,KG,20220803,,HP,AU,AU,2022,Q3,Elderly
210262232,21026223,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg in the morning,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Cervical vertebral fracture,,2022,Q3,2,F,20220422.0,20220802.0,20220630,20220803,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178728",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,100.0,KG,20220803,,HP,AU,AU,2022,Q3,Elderly
210262232,21026223,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg in the morning,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Syncope,,2022,Q3,2,F,20220422.0,20220802.0,20220630,20220803,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178728",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,100.0,KG,20220803,,HP,AU,AU,2022,Q3,Elderly
210262232,21026223,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25mg in the morning,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Dehydration,,2022,Q3,2,F,20220422.0,20220802.0,20220630,20220803,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178728",BOEHRINGER INGELHEIM,,81.0,YR,E,M,Y,100.0,KG,20220803,,HP,AU,AU,2022,Q3,Elderly
210312632,21031263,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,,,,,,2022,Q3,Hyperuricaemia,,2022,Q3,2,F,20170101.0,20220701.0,20220701,20220708,EXP,,DE-PFIZER INC-202200884814,PFIZER,,74.0,YR,,M,Y,,,20220708,,MD,DE,DE,2022,Q3,Elderly
210312632,21031263,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,,,,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,2,F,20170101.0,20220701.0,20220701,20220708,EXP,,DE-PFIZER INC-202200884814,PFIZER,,74.0,YR,,M,Y,,,20220708,,MD,DE,DE,2022,Q3,Elderly
210313891,21031389,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,,,Unknown,,,,,,,2022,Q3,COVID-19,,2022,Q3,1,I,20220101.0,20220620.0,20220701,20220701,EXP,,BR-NOVOPROD-927528,NOVO NORDISK,,56.0,YR,,M,Y,108.0,KG,20220701,,MD,BR,BR,2022,Q3,Adult
210313891,21031389,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,,,Unknown,,,,,,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,20220101.0,20220620.0,20220701,20220701,EXP,,BR-NOVOPROD-927528,NOVO NORDISK,,56.0,YR,,M,Y,108.0,KG,20220701,,MD,BR,BR,2022,Q3,Adult
210320991,21032099,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,100.0,MG,Tablet,QD,2022,Q3,Necrotising fasciitis,,2022,Q3,1,I,,20220629.0,20220701,20220701,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-179284",BOEHRINGER INGELHEIM,,53.0,YR,A,F,Y,,,20220701,,PH,GB,GB,2022,Q3,Adult
210325871,21032587,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Low density lipoprotein abnormal,,2022,Q3,1,I,20210101.0,20220629.0,20220701,20220701,EXP,,DE-ORGANON-O2206DEU002578,ORGANON,,74.0,YR,,M,Y,,,20220701,,MD,DE,DE,2022,Q3,Elderly
210325871,21032587,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,High density lipoprotein decreased,,2022,Q3,1,I,20210101.0,20220629.0,20220701,20220701,EXP,,DE-ORGANON-O2206DEU002578,ORGANON,,74.0,YR,,M,Y,,,20220701,,MD,DE,DE,2022,Q3,Elderly
210325871,21032587,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Coronary artery disease,,2022,Q3,1,I,20210101.0,20220629.0,20220701,20220701,EXP,,DE-ORGANON-O2206DEU002578,ORGANON,,74.0,YR,,M,Y,,,20220701,,MD,DE,DE,2022,Q3,Elderly
210325871,21032587,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q3,Ischaemia,,2022,Q3,1,I,20210101.0,20220629.0,20220701,20220701,EXP,,DE-ORGANON-O2206DEU002578,ORGANON,,74.0,YR,,M,Y,,,20220701,,MD,DE,DE,2022,Q3,Elderly
210341111,21034111,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Low density lipoprotein abnormal,,2022,Q3,1,I,20210101.0,20220627.0,20220701,20220701,EXP,,DE-MYLANLABS-2022M1049279,MYLAN,,74.0,YR,,M,Y,,,20220701,,MD,DE,DE,2022,Q3,Elderly
210341111,21034111,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Coronary artery disease,,2022,Q3,1,I,20210101.0,20220627.0,20220701,20220701,EXP,,DE-MYLANLABS-2022M1049279,MYLAN,,74.0,YR,,M,Y,,,20220701,,MD,DE,DE,2022,Q3,Elderly
210341111,21034111,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,High density lipoprotein decreased,,2022,Q3,1,I,20210101.0,20220627.0,20220701,20220701,EXP,,DE-MYLANLABS-2022M1049279,MYLAN,,74.0,YR,,M,Y,,,20220701,,MD,DE,DE,2022,Q3,Elderly
210341111,21034111,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Ischaemia,,2022,Q3,1,I,20210101.0,20220627.0,20220701,20220701,EXP,,DE-MYLANLABS-2022M1049279,MYLAN,,74.0,YR,,M,Y,,,20220701,,MD,DE,DE,2022,Q3,Elderly
210377201,21037720,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Acute myocardial infarction,,2022,Q3,1,I,20070101.0,20220621.0,20220704,20220704,EXP,,DE-AUROBINDO-AUR-APL-2022-023906,AUROBINDO,,74.0,YR,,M,Y,,,20220704,,MD,DE,DE,2022,Q3,Elderly
210377201,21037720,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Hyperlipidaemia,,2022,Q3,1,I,20070101.0,20220621.0,20220704,20220704,EXP,,DE-AUROBINDO-AUR-APL-2022-023906,AUROBINDO,,74.0,YR,,M,Y,,,20220704,,MD,DE,DE,2022,Q3,Elderly
210381623,21038162,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg 2x/day,,,,,,,,,,,,2022,Q3,Myalgia,,2022,Q3,3,F,20220211.0,20220905.0,20220704,20220914,EXP,CH-SM-2022-12861,CH-NOVOPROD-931130,NOVO NORDISK,,65.0,YR,,F,Y,94.0,KG,20220914,,MD,CH,CH,2022,Q3,Elderly
210381623,21038162,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg 2x/day,,,,,,,,,,,,2022,Q3,Injection site pain,,2022,Q3,3,F,20220211.0,20220905.0,20220704,20220914,EXP,CH-SM-2022-12861,CH-NOVOPROD-931130,NOVO NORDISK,,65.0,YR,,F,Y,94.0,KG,20220914,,MD,CH,CH,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Renal impairment,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Acute kidney injury,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Cardiac failure chronic,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Ejection fraction abnormal,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Chronic kidney disease,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Inappropriate schedule of product administration,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Chronic coronary syndrome,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Pleural disorder,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Hypotension,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Dyspnoea exertional,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Diabetic neuropathy,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Oedema peripheral,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Weight increased,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Mitral valve incompetence,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210394351,21039435,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Hypervolaemia,,2022,Q3,1,I,,20220628.0,20220704,20220704,EXP,,NVSC2022PL150727,NOVARTIS,,67.0,YR,,M,Y,,,20220704,,MD,PL,PL,2022,Q3,Elderly
210413181,21041318,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Hyperuricaemia,,2022,Q3,1,I,20170101.0,20220621.0,20220705,20220705,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-06577,ALKEM,,74.0,YR,,M,Y,,,20220705,,MD,DE,DE,2022,Q3,Elderly
210413181,21041318,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,20170101.0,20220621.0,20220705,20220705,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-06577,ALKEM,,74.0,YR,,M,Y,,,20220705,,MD,DE,DE,2022,Q3,Elderly
210416741,21041674,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q3,Pancreatitis necrotising,,2022,Q3,1,I,,20220628.0,20220705,20220705,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178907",BOEHRINGER INGELHEIM,"Foster P, Jha P, Pandit S. Empagliflozin-induced pancreatitis: A Case Report Pattern. Cureus. 2022 May 21; 14:5: e25189",73.0,YR,E,F,Y,,,20220705,,HP,US,US,2022,Q3,Elderly
210416741,21041674,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q3,Pancreatitis,,2022,Q3,1,I,,20220628.0,20220705,20220705,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178907",BOEHRINGER INGELHEIM,"Foster P, Jha P, Pandit S. Empagliflozin-induced pancreatitis: A Case Report Pattern. Cureus. 2022 May 21; 14:5: e25189",73.0,YR,E,F,Y,,,20220705,,HP,US,US,2022,Q3,Elderly
210416741,21041674,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q3,Pancreatitis,,2022,Q3,1,I,,20220628.0,20220705,20220705,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178907",BOEHRINGER INGELHEIM,"Foster P, Jha P, Pandit S. Empagliflozin-induced pancreatitis: A Case Report Pattern. Cureus. 2022 May 21; 14:5: e25189",73.0,YR,E,F,Y,,,20220705,,HP,US,US,2022,Q3,Elderly
210431311,21043131,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Pancreatic fistula,,2022,Q3,1,I,,20220628.0,20220705,20220705,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178870",BOEHRINGER INGELHEIM,"Murteira F, Costa T, Francisco E, Pinto S, Gomes A. Pancreaticopleural fistula: An insidious cause of pleural effusion-case report. Journal of cardiovascular and throracic research. 2022; 14:1: 67-70.",61.0,YR,A,M,Y,,,20220705,,HP,PT,PT,2022,Q3,Adult
210431311,21043131,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220628.0,20220705,20220705,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-178870",BOEHRINGER INGELHEIM,"Murteira F, Costa T, Francisco E, Pinto S, Gomes A. Pancreaticopleural fistula: An insidious cause of pleural effusion-case report. Journal of cardiovascular and throracic research. 2022; 14:1: 67-70.",61.0,YR,A,M,Y,,,20220705,,HP,PT,PT,2022,Q3,Adult
210444832,21044483,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Peripheral arterial occlusive disease,,2022,Q3,2,F,20220629.0,20220707.0,20220705,20220710,PER,,PL-AMGEN-POLCT2022112052,AMGEN,,72.0,YR,E,F,Y,102.0,KG,20220710,,MD,PL,PL,2022,Q3,Elderly
210449971,21044997,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,Y,U,Unknown,,204629.0,,,,QD,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,20220628.0,20220701.0,20220705,20220705,EXP,GB-MHRA-TPP21615921C7015522YC1656410564198,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-179811",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,67.0,KG,20220705,,MD,GB,GB,2022,Q3,Adult
210449971,21044997,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,20220628.0,20220701.0,20220705,20220705,EXP,GB-MHRA-TPP21615921C7015522YC1656410564198,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-179811",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,67.0,KG,20220705,,MD,GB,GB,2022,Q3,Adult
210456151,21045615,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Low density lipoprotein abnormal,,2022,Q3,1,I,20210101.0,20220622.0,20220706,20220706,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-06610,ALKEM,,74.0,YR,,M,Y,,,20220706,,MD,DE,DE,2022,Q3,Elderly
210456151,21045615,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,High density lipoprotein decreased,,2022,Q3,1,I,20210101.0,20220622.0,20220706,20220706,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-06610,ALKEM,,74.0,YR,,M,Y,,,20220706,,MD,DE,DE,2022,Q3,Elderly
210456151,21045615,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Ischaemia,,2022,Q3,1,I,20210101.0,20220622.0,20220706,20220706,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-06610,ALKEM,,74.0,YR,,M,Y,,,20220706,,MD,DE,DE,2022,Q3,Elderly
210456151,21045615,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Coronary artery disease,,2022,Q3,1,I,20210101.0,20220622.0,20220706,20220706,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-06610,ALKEM,,74.0,YR,,M,Y,,,20220706,,MD,DE,DE,2022,Q3,Elderly
210462781,21046278,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,50.0,MG,Capsule,QD,2022,Q3,Dizziness,,2022,Q3,1,I,20220124.0,20220701.0,20220706,20220706,EXP,GB-MHRA-TPP30583970C177956YC1656433165256,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-179814",BOEHRINGER INGELHEIM,,49.0,YR,A,F,Y,58.0,KG,20220706,,MD,GB,GB,2022,Q3,Adult
210487831,21048783,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,,20220630.0,20220706,20220706,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-179387",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20220706,,MD,US,US,2022,Q3,Elderly
210490881,21049088,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,20220630.0,20220706.0,20220706,20220706,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180223",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20220706,,HP,GB,GB,2022,Q3,Elderly
210497951,21049795,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,,20220630.0,20220706,20220706,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-179390",BOEHRINGER INGELHEIM,,46.0,YR,A,F,Y,,,20220706,,MD,US,US,2022,Q3,Adult
210497961,21049796,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,,20220630.0,20220706,20220706,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-179389",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,,,20220706,,MD,US,US,2022,Q3,Elderly
210504141,21050414,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,,20220630.0,20220707,20220707,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-179388",BOEHRINGER INGELHEIM,,50.0,YR,A,F,Y,,,20220707,,MD,US,US,2022,Q3,Adult
210520611,21052061,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Dyspnoea,,2022,Q3,1,I,20220610.0,20220629.0,20220707,20220707,EXP,,NVSC2022ZA150596,NOVARTIS,,75.0,YR,,M,Y,,,20220707,,MD,ZA,ZA,2022,Q3,Elderly
210520611,21052061,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Fatigue,,2022,Q3,1,I,20220610.0,20220629.0,20220707,20220707,EXP,,NVSC2022ZA150596,NOVARTIS,,75.0,YR,,M,Y,,,20220707,,MD,ZA,ZA,2022,Q3,Elderly
210520611,21052061,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Orthopnoea,,2022,Q3,1,I,20220610.0,20220629.0,20220707,20220707,EXP,,NVSC2022ZA150596,NOVARTIS,,75.0,YR,,M,Y,,,20220707,,MD,ZA,ZA,2022,Q3,Elderly
210520611,21052061,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Oedema peripheral,,2022,Q3,1,I,20220610.0,20220629.0,20220707,20220707,EXP,,NVSC2022ZA150596,NOVARTIS,,75.0,YR,,M,Y,,,20220707,,MD,ZA,ZA,2022,Q3,Elderly
210520611,21052061,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Ejection fraction decreased,,2022,Q3,1,I,20220610.0,20220629.0,20220707,20220707,EXP,,NVSC2022ZA150596,NOVARTIS,,75.0,YR,,M,Y,,,20220707,,MD,ZA,ZA,2022,Q3,Elderly
210520611,21052061,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Cardiac failure,,2022,Q3,1,I,20220610.0,20220629.0,20220707,20220707,EXP,,NVSC2022ZA150596,NOVARTIS,,75.0,YR,,M,Y,,,20220707,,MD,ZA,ZA,2022,Q3,Elderly
210535422,21053542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Total daily dose: 25,,,U,,,,,,,,,2022,Q3,Pleural effusion,,2022,Q3,2,F,20210623.0,20220812.0,20220707,20220816,EXP,,PH-SA-2021SA407010,SANOFI AVENTIS,,62.0,YR,A,M,Y,57.8,KG,20220816,,MD,PH,PH,2022,Q3,Adult
210573962,21057396,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Asked But Unknown,,204629.0,25.0,MG,"Capsule, soft",QD,2022,Q3,Hypertension,,2022,Q3,2,F,20220627.0,20220719.0,20220708,20220725,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180673",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,104.0,KG,20220725,,MD,DE,DE,2022,Q3,Young Adult
210573962,21057396,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Asked But Unknown,,204629.0,25.0,MG,"Capsule, soft",QD,2022,Q3,Hyperventilation,,2022,Q3,2,F,20220627.0,20220719.0,20220708,20220725,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180673",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,104.0,KG,20220725,,MD,DE,DE,2022,Q3,Young Adult
210573962,21057396,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Asked But Unknown,,204629.0,25.0,MG,"Capsule, soft",QD,2022,Q3,Hypoglycaemia,,2022,Q3,2,F,20220627.0,20220719.0,20220708,20220725,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180673",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,104.0,KG,20220725,,MD,DE,DE,2022,Q3,Young Adult
210573962,21057396,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Asked But Unknown,,204629.0,25.0,MG,"Capsule, soft",QD,2022,Q3,Ketoacidosis,,2022,Q3,2,F,20220627.0,20220719.0,20220708,20220725,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180673",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,104.0,KG,20220725,,MD,DE,DE,2022,Q3,Young Adult
210573962,21057396,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Asked But Unknown,,204629.0,25.0,MG,"Capsule, soft",QD,2022,Q3,Dyspnoea,,2022,Q3,2,F,20220627.0,20220719.0,20220708,20220725,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180673",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,104.0,KG,20220725,,MD,DE,DE,2022,Q3,Young Adult
210573962,21057396,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Asked But Unknown,,204629.0,25.0,MG,"Capsule, soft",QD,2022,Q3,Nausea,,2022,Q3,2,F,20220627.0,20220719.0,20220708,20220725,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180673",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,104.0,KG,20220725,,MD,DE,DE,2022,Q3,Young Adult
210573962,21057396,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Asked But Unknown,,204629.0,25.0,MG,"Capsule, soft",QD,2022,Q3,Asthenia,,2022,Q3,2,F,20220627.0,20220719.0,20220708,20220725,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180673",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,104.0,KG,20220725,,MD,DE,DE,2022,Q3,Young Adult
210582661,21058266,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Asthenia,,2022,Q3,1,I,20220706.0,,20220708,20220708,DIR,622276,,FDA-CTU,,75.0,YR,,F,N,88.2,KG,20220708,Y,HP,US,,2022,Q3,Elderly
210582661,21058266,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Fall,,2022,Q3,1,I,20220706.0,,20220708,20220708,DIR,622276,,FDA-CTU,,75.0,YR,,F,N,88.2,KG,20220708,Y,HP,US,,2022,Q3,Elderly
210582661,21058266,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Urinary tract infection,,2022,Q3,1,I,20220706.0,,20220708,20220708,DIR,622276,,FDA-CTU,,75.0,YR,,F,N,88.2,KG,20220708,Y,HP,US,,2022,Q3,Elderly
210653291,21065329,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Facial paralysis,,2022,Q3,1,I,20220605.0,20220630.0,20220711,20220711,EXP,,GB-JNJFOC-20220664467,JOHNSON AND JOHNSON,,54.0,YR,A,M,Y,,,20220711,,HP,GB,GB,2022,Q3,Adult
210653291,21065329,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Facial pain,,2022,Q3,1,I,20220605.0,20220630.0,20220711,20220711,EXP,,GB-JNJFOC-20220664467,JOHNSON AND JOHNSON,,54.0,YR,A,M,Y,,,20220711,,HP,GB,GB,2022,Q3,Adult
210653291,21065329,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Swelling face,,2022,Q3,1,I,20220605.0,20220630.0,20220711,20220711,EXP,,GB-JNJFOC-20220664467,JOHNSON AND JOHNSON,,54.0,YR,A,M,Y,,,20220711,,HP,GB,GB,2022,Q3,Adult
210653291,21065329,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Toothache,,2022,Q3,1,I,20220605.0,20220630.0,20220711,20220711,EXP,,GB-JNJFOC-20220664467,JOHNSON AND JOHNSON,,54.0,YR,A,M,Y,,,20220711,,HP,GB,GB,2022,Q3,Adult
210653411,21065341,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Swelling face,,2022,Q3,1,I,20220704.0,20220707.0,20220711,20220711,EXP,GB-MHRA-TPP26644736C1315940YC1656922383704,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180713",BOEHRINGER INGELHEIM,,60.0,YR,A,F,Y,76.0,KG,20220711,,MD,GB,GB,2022,Q3,Adult
210653411,21065341,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Dry skin,,2022,Q3,1,I,20220704.0,20220707.0,20220711,20220711,EXP,GB-MHRA-TPP26644736C1315940YC1656922383704,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180713",BOEHRINGER INGELHEIM,,60.0,YR,A,F,Y,76.0,KG,20220711,,MD,GB,GB,2022,Q3,Adult
210654031,21065403,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Drug ineffective,,2022,Q3,1,I,20210201.0,20220705.0,20220711,20220711,EXP,,NVSC2022AT156598,NOVARTIS,,54.0,YR,,M,Y,,,20220711,,MD,AT,AT,2022,Q3,Adult
210654031,21065403,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Coronary artery disease,,2022,Q3,1,I,20210201.0,20220705.0,20220711,20220711,EXP,,NVSC2022AT156598,NOVARTIS,,54.0,YR,,M,Y,,,20220711,,MD,AT,AT,2022,Q3,Adult
210669952,21066995,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,unknown,,,,,,,2022,Q3,Hepatic steatosis,,2022,Q3,2,F,20220519.0,20220712.0,20220712,20220725,EXP,JP-MHLW-I2210002195,JP-NOVOPROD-935809,NOVO NORDISK,,38.0,YR,,F,Y,115.0,KG,20220725,,MD,JP,JP,2022,Q3,Adult
210669952,21066995,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,unknown,,,,,,,2022,Q3,Hepatic enzyme increased,,2022,Q3,2,F,20220519.0,20220712.0,20220712,20220725,EXP,JP-MHLW-I2210002195,JP-NOVOPROD-935809,NOVO NORDISK,,38.0,YR,,F,Y,115.0,KG,20220725,,MD,JP,JP,2022,Q3,Adult
210669952,21066995,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,unknown,,,,,,,2022,Q3,Weight increased,,2022,Q3,2,F,20220519.0,20220712.0,20220712,20220725,EXP,JP-MHLW-I2210002195,JP-NOVOPROD-935809,NOVO NORDISK,,38.0,YR,,F,Y,115.0,KG,20220725,,MD,JP,JP,2022,Q3,Adult
210669952,21066995,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,unknown,,,,,,,2022,Q3,Condition aggravated,,2022,Q3,2,F,20220519.0,20220712.0,20220712,20220725,EXP,JP-MHLW-I2210002195,JP-NOVOPROD-935809,NOVO NORDISK,,38.0,YR,,F,Y,115.0,KG,20220725,,MD,JP,JP,2022,Q3,Adult
210669952,21066995,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,unknown,,,,,,,2022,Q3,Increased appetite,,2022,Q3,2,F,20220519.0,20220712.0,20220712,20220725,EXP,JP-MHLW-I2210002195,JP-NOVOPROD-935809,NOVO NORDISK,,38.0,YR,,F,Y,115.0,KG,20220725,,MD,JP,JP,2022,Q3,Adult
210670051,21067005,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Asphyxia,,2022,Q3,1,I,,20220627.0,20220712,20220712,EXP,,SI-JNJFOC-20220720071,JOHNSON AND JOHNSON,,72.0,YR,E,F,Y,,,20220712,,MD,SI,SI,2022,Q3,Elderly
210725391,21072539,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5mg  2 tablets every morning with a meal,,,Y,U,Unknown,,212614.0,,,Tablet,QD,2022,Q3,Diarrhoea,,2022,Q3,1,I,,20220711.0,20220712,20220712,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-181100",BOEHRINGER INGELHEIM,,83.0,YR,E,M,Y,,,20220712,,CN,US,US,2022,Q3,Elderly
210736201,21073620,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q3,Abdominal distension,,2022,Q3,1,I,20220427.0,20220629.0,20220713,20220713,EXP,,GB-NOVOPROD-929785,NOVO NORDISK,,37.0,YR,,M,Y,127.0,KG,20220713,,HP,GB,GB,2022,Q3,Adult
210736201,21073620,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q3,Nausea,,2022,Q3,1,I,20220427.0,20220629.0,20220713,20220713,EXP,,GB-NOVOPROD-929785,NOVO NORDISK,,37.0,YR,,M,Y,127.0,KG,20220713,,HP,GB,GB,2022,Q3,Adult
210736201,21073620,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q3,Glycosylated haemoglobin abnormal,,2022,Q3,1,I,20220427.0,20220629.0,20220713,20220713,EXP,,GB-NOVOPROD-929785,NOVO NORDISK,,37.0,YR,,M,Y,127.0,KG,20220713,,HP,GB,GB,2022,Q3,Adult
210736201,21073620,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,unknown,,,25.0,MG,,QD,2022,Q3,Headache,,2022,Q3,1,I,20220427.0,20220629.0,20220713,20220713,EXP,,GB-NOVOPROD-929785,NOVO NORDISK,,37.0,YR,,M,Y,127.0,KG,20220713,,HP,GB,GB,2022,Q3,Adult
210749891,21074989,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Off label use,,2022,Q3,1,I,20220527.0,20220711.0,20220713,20220713,EXP,,ES-MYLANLABS-2022M1049260,MYLAN,,75.0,YR,,M,Y,75.0,KG,20220713,,MD,ES,ES,2022,Q3,Elderly
210749891,21074989,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Febrile neutropenia,,2022,Q3,1,I,20220527.0,20220711.0,20220713,20220713,EXP,,ES-MYLANLABS-2022M1049260,MYLAN,,75.0,YR,,M,Y,75.0,KG,20220713,,MD,ES,ES,2022,Q3,Elderly
210757661,21075766,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/1000mg,,,U,,Unknown,,206111.0,,,,QD,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,,20220712.0,20220713,20220713,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-181424",BOEHRINGER INGELHEIM,,49.0,YR,A,M,Y,,,20220713,,PH,IL,IL,2022,Q3,Adult
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Mitral valve incompetence,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Renal impairment,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Diabetic neuropathy,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Ejection fraction abnormal,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Pleural disorder,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Oedema peripheral,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Weight increased,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Hypotension,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Cardiac failure chronic,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Acute kidney injury,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Chronic kidney disease,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Chronic coronary syndrome,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Inappropriate schedule of product administration,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Dyspnoea exertional,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210763191,21076319,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Hypervolaemia,,2022,Q3,1,I,,20220707.0,20220713,20220713,EXP,,PL-PFIZER INC-202200936320,PFIZER,,67.0,YR,,M,Y,,,20220713,,MD,PL,PL,2022,Q3,Elderly
210772241,21077224,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Urinary tract infection,,2022,Q3,1,I,20220107.0,20220710.0,20220713,20220713,EXP,,DE-ABBVIE-22K-062-4463676-00,ABBVIE,,49.0,YR,,M,Y,76.0,KG,20220713,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
210772241,21077224,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Leukocyturia,,2022,Q3,1,I,20220107.0,20220710.0,20220713,20220713,EXP,,DE-ABBVIE-22K-062-4463676-00,ABBVIE,,49.0,YR,,M,Y,76.0,KG,20220713,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
210772241,21077224,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Cerebral microangiopathy,,2022,Q3,1,I,20220107.0,20220710.0,20220713,20220713,EXP,,DE-ABBVIE-22K-062-4463676-00,ABBVIE,,49.0,YR,,M,Y,76.0,KG,20220713,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
210772241,21077224,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Lacunar infarction,,2022,Q3,1,I,20220107.0,20220710.0,20220713,20220713,EXP,,DE-ABBVIE-22K-062-4463676-00,ABBVIE,,49.0,YR,,M,Y,76.0,KG,20220713,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
210772241,21077224,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Inflammatory marker increased,,2022,Q3,1,I,20220107.0,20220710.0,20220713,20220713,EXP,,DE-ABBVIE-22K-062-4463676-00,ABBVIE,,49.0,YR,,M,Y,76.0,KG,20220713,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
210772241,21077224,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Hypertension,,2022,Q3,1,I,20220107.0,20220710.0,20220713,20220713,EXP,,DE-ABBVIE-22K-062-4463676-00,ABBVIE,,49.0,YR,,M,Y,76.0,KG,20220713,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
210793252,21079325,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,the treatment is still ongoing,,,,,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Urosepsis,,2022,Q3,2,F,20200101.0,20220804.0,20220714,20220810,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180518",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220810,,MD,PL,PL,2022,Q3,Elderly
210793252,21079325,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,the treatment is still ongoing,,,,,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Escherichia infection,,2022,Q3,2,F,20200101.0,20220804.0,20220714,20220810,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180518",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220810,,MD,PL,PL,2022,Q3,Elderly
210793252,21079325,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,the treatment is still ongoing,,,,,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Cardiac failure,,2022,Q3,2,F,20200101.0,20220804.0,20220714,20220810,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180518",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220810,,MD,PL,PL,2022,Q3,Elderly
210793252,21079325,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,the treatment is still ongoing,,,,,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Metabolic function test abnormal,,2022,Q3,2,F,20200101.0,20220804.0,20220714,20220810,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180518",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220810,,MD,PL,PL,2022,Q3,Elderly
210793252,21079325,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,the treatment is still ongoing,,,,,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Cardiac failure,,2022,Q3,2,F,20200101.0,20220804.0,20220714,20220810,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180518",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220810,,MD,PL,PL,2022,Q3,Elderly
210793252,21079325,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,the treatment is still ongoing,,,,,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Cardiac failure,,2022,Q3,2,F,20200101.0,20220804.0,20220714,20220810,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180518",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220810,,MD,PL,PL,2022,Q3,Elderly
210793252,21079325,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,the treatment is still ongoing,,,,,Asked But Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Urosepsis,,2022,Q3,2,F,20200101.0,20220804.0,20220714,20220810,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180518",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220810,,MD,PL,PL,2022,Q3,Elderly
210793252,21079325,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,therapy ongoing,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Urosepsis,,2022,Q3,2,F,20200101.0,20220804.0,20220714,20220810,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180518",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220810,,MD,PL,PL,2022,Q3,Elderly
210793252,21079325,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,therapy ongoing,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Escherichia infection,,2022,Q3,2,F,20200101.0,20220804.0,20220714,20220810,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180518",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220810,,MD,PL,PL,2022,Q3,Elderly
210793252,21079325,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,therapy ongoing,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Cardiac failure,,2022,Q3,2,F,20200101.0,20220804.0,20220714,20220810,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180518",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220810,,MD,PL,PL,2022,Q3,Elderly
210793252,21079325,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,therapy ongoing,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Metabolic function test abnormal,,2022,Q3,2,F,20200101.0,20220804.0,20220714,20220810,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180518",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220810,,MD,PL,PL,2022,Q3,Elderly
210793252,21079325,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,therapy ongoing,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Cardiac failure,,2022,Q3,2,F,20200101.0,20220804.0,20220714,20220810,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180518",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220810,,MD,PL,PL,2022,Q3,Elderly
210793252,21079325,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,therapy ongoing,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Cardiac failure,,2022,Q3,2,F,20200101.0,20220804.0,20220714,20220810,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180518",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220810,,MD,PL,PL,2022,Q3,Elderly
210793252,21079325,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,therapy ongoing,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Urosepsis,,2022,Q3,2,F,20200101.0,20220804.0,20220714,20220810,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180518",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220810,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Inappropriate schedule of product administration,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Dyspnoea exertional,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Cardiac failure chronic,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Oedema peripheral,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Chronic coronary syndrome,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Ejection fraction abnormal,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Pleural disorder,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Acute kidney injury,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Mitral valve incompetence,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Weight increased,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Diabetic neuropathy,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Hypotension,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Hypervolaemia,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Renal impairment,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210799211,21079921,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Chronic kidney disease,,2022,Q3,1,I,,20220707.0,20220714,20220714,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-180509",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Acute kidney injury,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Off label use,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Mitral valve incompetence,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Hypervolaemia,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Diabetic neuropathy,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Chronic coronary syndrome,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Ejection fraction abnormal,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Pleural disorder,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Oedema peripheral,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Renal impairment,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Cardiac failure chronic,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Inappropriate schedule of product administration,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Dyspnoea exertional,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Weight increased,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Chronic kidney disease,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210810791,21081079,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (10 mg),,,U,U,,,,10.0,MG,,,2022,Q3,Hypotension,,2022,Q3,1,I,,20220708.0,20220714,20220714,EXP,,PL-MYLANLABS-2022M1052100,MYLAN,,67.0,YR,,M,Y,,,20220714,,MD,PL,PL,2022,Q3,Elderly
210820841,21082084,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,20220506.0,,20220714,20220714,DIR,FDA-CDER-CTU-2022-55413,,FDA-CTU,,73.0,YR,,M,N,,,20220705,N,PH,US,,2022,Q3,Elderly
210820841,21082084,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Visual impairment,,2022,Q3,1,I,20220506.0,,20220714,20220714,DIR,FDA-CDER-CTU-2022-55413,,FDA-CTU,,73.0,YR,,M,N,,,20220705,N,PH,US,,2022,Q3,Elderly
210820841,21082084,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Dizziness,,2022,Q3,1,I,20220506.0,,20220714,20220714,DIR,FDA-CDER-CTU-2022-55413,,FDA-CTU,,73.0,YR,,M,N,,,20220705,N,PH,US,,2022,Q3,Elderly
210820841,21082084,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,20220506.0,,20220714,20220714,DIR,FDA-CDER-CTU-2022-55413,,FDA-CTU,,73.0,YR,,M,N,,,20220705,N,PH,US,,2022,Q3,Elderly
210838171,21083817,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2022,Q3,Urinary tract infection,,2022,Q3,1,I,20220407.0,,20220714,20220714,DIR,FDA-CDER-CTU-2022-55668,,FDA-CTU,,73.0,YR,,M,N,108.0,KG,20220615,N,PH,US,,2022,Q3,Elderly
210838171,21083817,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2022,Q3,Fungal infection,,2022,Q3,1,I,20220407.0,,20220714,20220714,DIR,FDA-CDER-CTU-2022-55668,,FDA-CTU,,73.0,YR,,M,N,108.0,KG,20220615,N,PH,US,,2022,Q3,Elderly
210869801,21086980,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Urinary tract infection,,2022,Q3,1,I,20220528.0,,20220714,20220714,DIR,FDA-CDER-CTU-2022-55766,,FDA-CTU,,75.0,YR,,F,N,,,20220613,N,PH,US,,2022,Q3,Elderly
210869881,21086988,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Vomiting,,2022,Q3,1,I,20220606.0,,20220714,20220714,DIR,FDA-CDER-CTU-2022-55768,,FDA-CTU,,73.0,YR,,M,N,,,20220610,N,HP,US,,2022,Q3,Elderly
210869881,21086988,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Nausea,,2022,Q3,1,I,20220606.0,,20220714,20220714,DIR,FDA-CDER-CTU-2022-55768,,FDA-CTU,,73.0,YR,,M,N,,,20220610,N,HP,US,,2022,Q3,Elderly
210869941,21086994,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Urinary tract infection,,2022,Q3,1,I,20220515.0,,20220714,20220714,DIR,FDA-CDER-CTU-2022-55776,,FDA-CTU,,73.0,YR,,M,N,,,20220609,N,PH,US,,2022,Q3,Elderly
210869941,21086994,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Septic shock,,2022,Q3,1,I,20220515.0,,20220714,20220714,DIR,FDA-CDER-CTU-2022-55776,,FDA-CTU,,73.0,YR,,M,N,,,20220609,N,PH,US,,2022,Q3,Elderly
210873761,21087376,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5MG EVERY DAY PO? ?,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Hypoglycaemia,,2022,Q3,1,I,20220203.0,,20220714,20220714,DIR,FDA-CDER-CTU-2022-55827,,FDA-CTU,,59.0,YR,,M,N,,,20220208,N,HP,US,,2022,Q3,Adult
210877741,21087774,6,C,Empagliflozin 10 mg once daily,,2,,,,,,,,,,,,,,2022,Q3,Obstructive airways disorder,,2022,Q3,1,I,20220711.0,,20220714,20220714,DIR,623136,,FDA-CTU,,66.0,YR,,M,N,88.7,KG,20220714,N,PH,US,,2022,Q3,Elderly
210877741,21087774,6,C,Empagliflozin 10 mg once daily,,2,,,,,,,,,,,,,,2022,Q3,Rash,,2022,Q3,1,I,20220711.0,,20220714,20220714,DIR,623136,,FDA-CTU,,66.0,YR,,M,N,88.7,KG,20220714,N,PH,US,,2022,Q3,Elderly
210877741,21087774,6,C,Empagliflozin 10 mg once daily,,2,,,,,,,,,,,,,,2022,Q3,Swollen tongue,,2022,Q3,1,I,20220711.0,,20220714,20220714,DIR,623136,,FDA-CTU,,66.0,YR,,M,N,88.7,KG,20220714,N,PH,US,,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Mitral valve incompetence,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Pleural disorder,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Renal impairment,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Chronic coronary syndrome,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Hypotension,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Cardiac failure chronic,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Ejection fraction abnormal,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Inappropriate schedule of product administration,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Dyspnoea exertional,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Diabetic neuropathy,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Weight increased,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Oedema peripheral,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Hypervolaemia,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Acute kidney injury,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Chronic kidney disease,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210878361,21087836,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily;,,,U,,UNKNOWN,,,,,,,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220707.0,20220715,20220715,EXP,,PL-TEVA-2022-PL-2055904,TEVA,,67.0,YR,E,M,Y,,,20220715,,MD,PL,PL,2022,Q3,Elderly
210884784,21088478,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2022,Q3,Fatigue,,2022,Q3,4,F,20220106.0,20220902.0,20220715,20220909,PER,,BR-Eisai Medical Research-EC-2022-111558,EISAI,,64.0,YR,A,F,Y,63.4,KG,20220909,,MD,BR,,2022,Q3,Adult
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Dyspnoea exertional,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Acute kidney injury,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Inappropriate schedule of product administration,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Cardiac failure chronic,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Pleural disorder,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Diabetic neuropathy,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Hypervolaemia,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Mitral valve incompetence,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Weight increased,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Renal impairment,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Oedema peripheral,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Ejection fraction abnormal,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Hypotension,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Chronic kidney disease,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Chronic coronary syndrome,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210922901,21092290,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,PL-AUROBINDO-AUR-APL-2022-026111,AUROBINDO,,67.0,YR,,M,Y,,,20220718,,MD,PL,PL,2022,Q3,Elderly
210925011,21092501,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/1000mg,,,U,,Unknown,,206111.0,,,,QD,2022,Q3,Off label use,,2022,Q3,1,I,,20220714.0,20220718,20220718,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-182126",BOEHRINGER INGELHEIM,,54.0,YR,A,M,Y,,,20220718,,MD,IL,IL,2022,Q3,Adult
210925011,21092501,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/1000mg,,,U,,Unknown,,206111.0,,,,QD,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220714.0,20220718,20220718,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-182126",BOEHRINGER INGELHEIM,,54.0,YR,A,M,Y,,,20220718,,MD,IL,IL,2022,Q3,Adult
210925011,21092501,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/1000mg,,,U,,Unknown,,206111.0,,,,QD,2022,Q3,COVID-19,,2022,Q3,1,I,,20220714.0,20220718,20220718,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-182126",BOEHRINGER INGELHEIM,,54.0,YR,A,M,Y,,,20220718,,MD,IL,IL,2022,Q3,Adult
210925531,21092553,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,,20220711.0,20220718,20220718,EXP,,"TR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-181163",BOEHRINGER INGELHEIM,"Bilgin S, Duman T, Kurtkulagi O, Yilmaz F, Aktas G. A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus. Journal of the College of Physicians and Surgeons Pakistan. 2022; 32:7: 928-930.",36.0,YR,A,F,Y,,,20220718,,MD,TR,TR,2022,Q3,Adult
210925531,21092553,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Off label use,,2022,Q3,1,I,,20220711.0,20220718,20220718,EXP,,"TR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-181163",BOEHRINGER INGELHEIM,"Bilgin S, Duman T, Kurtkulagi O, Yilmaz F, Aktas G. A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus. Journal of the College of Physicians and Surgeons Pakistan. 2022; 32:7: 928-930.",36.0,YR,A,F,Y,,,20220718,,MD,TR,TR,2022,Q3,Adult
210935901,21093590,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,,U,,,,25.0,MG,,,2022,Q3,Drug ineffective,,2022,Q3,1,I,,20220705.0,20220718,20220718,EXP,,US-MYLANLABS-2022M1077457,MYLAN,"Woloshuk A, Lee M, Assmus M, Agarwal D, Krambeck A, Large T. A case of ureteral fungal mass removal in a patient taking empagliflozin. CEN-Case-Rep 2021;10(4):603-607.",67.0,YR,,F,Y,,,20220718,,HP,US,US,2022,Q3,Elderly
210956451,21095645,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Pyrexia,,2022,Q3,1,I,20211204.0,20220714.0,20220718,20220718,EXP,,AU-ABBVIE-21P-008-4187646-00,ABBVIE,,81.0,YR,,M,Y,87.0,KG,20220718,,HP,COUNTRY NOT SPECIFIED,AU,2022,Q3,Elderly
210956451,21095645,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Pulmonary oedema,,2022,Q3,1,I,20211204.0,20220714.0,20220718,20220718,EXP,,AU-ABBVIE-21P-008-4187646-00,ABBVIE,,81.0,YR,,M,Y,87.0,KG,20220718,,HP,COUNTRY NOT SPECIFIED,AU,2022,Q3,Elderly
210967451,21096745,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000mg,,,Y,U,Unknown,,208658.0,,,,QD,2022,Q3,Asthenia,,2022,Q3,1,I,,20220718.0,20220718,20220718,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-182226",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,,,20220718,,MD,IL,IL,2022,Q3,Adult
210967451,21096745,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000mg,,,Y,U,Unknown,,208658.0,,,,QD,2022,Q3,Vomiting,,2022,Q3,1,I,,20220718.0,20220718,20220718,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-182226",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,,,20220718,,MD,IL,IL,2022,Q3,Adult
210967451,21096745,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5/1000mg,,,Y,U,Unknown,,208658.0,,,,QD,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220718.0,20220718,20220718,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-182226",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,,,20220718,,MD,IL,IL,2022,Q3,Adult
210988853,21098885,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0)",,,,,,,,10.0,MG,,QD,2022,Q3,Coronary artery disease,,2022,Q3,3,F,20210201.0,20220718.0,20220719,20220726,EXP,,AT-AstraZeneca-2022A256423,ASTRAZENECA,,54.0,YR,,M,Y,,,20220726,,MD,AT,,2022,Q3,Adult
210988853,21098885,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0)",,,,,,,,10.0,MG,,QD,2022,Q3,Drug ineffective,,2022,Q3,3,F,20210201.0,20220718.0,20220719,20220726,EXP,,AT-AstraZeneca-2022A256423,ASTRAZENECA,,54.0,YR,,M,Y,,,20220726,,MD,AT,,2022,Q3,Adult
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Hypervolaemia,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Hypotension,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Inappropriate schedule of product administration,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Dyspnoea exertional,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Pleural disorder,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Acute kidney injury,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Mitral valve incompetence,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Chronic coronary syndrome,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Oedema peripheral,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Chronic kidney disease,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Diabetic neuropathy,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Weight increased,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Renal impairment,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Cardiac failure chronic,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Ejection fraction abnormal,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
210992031,21099203,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,Unknown,,,10.0,MG,,,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220711.0,20220719,20220719,EXP,,PL-FreseniusKabi-FK202209898,FRESENIUS KABI,,67.0,YR,E,M,Y,,,20220719,,MD,PL,PL,2022,Q3,Elderly
211021281,21102128,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,,2022,Q3,Skin exfoliation,,2022,Q3,1,I,20220427.0,20220719.0,20220719,20220719,EXP,GB-MHRA-TPP506059C5466271YC1657710069721,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-182514",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,99.0,KG,20220719,,PH,GB,GB,2022,Q3,Adult
211021281,21102128,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,,2022,Q3,Pain,,2022,Q3,1,I,20220427.0,20220719.0,20220719,20220719,EXP,GB-MHRA-TPP506059C5466271YC1657710069721,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-182514",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,99.0,KG,20220719,,PH,GB,GB,2022,Q3,Adult
211021281,21102128,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,,2022,Q3,Chapped lips,,2022,Q3,1,I,20220427.0,20220719.0,20220719,20220719,EXP,GB-MHRA-TPP506059C5466271YC1657710069721,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-182514",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,99.0,KG,20220719,,PH,GB,GB,2022,Q3,Adult
211050801,21105080,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg DAILY,,,,N,,,,,,,,2022,Q3,Drug ineffective,,2022,Q3,1,I,20210201.0,20220715.0,20220720,20220720,EXP,,AT-ANIPHARMA-2022-AT-000009,ANI,,54.0,YR,,M,Y,,,20220720,,MD,AT,AT,2022,Q3,Adult
211050801,21105080,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg DAILY,,,,N,,,,,,,,2022,Q3,Coronary artery disease,,2022,Q3,1,I,20210201.0,20220715.0,20220720,20220720,EXP,,AT-ANIPHARMA-2022-AT-000009,ANI,,54.0,YR,,M,Y,,,20220720,,MD,AT,AT,2022,Q3,Adult
211065271,21106527,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (10 mg, QD (1-0-0))",,,U,U,,,,10.0,MG,,QD,2022,Q3,Drug ineffective,,2022,Q3,1,I,20210201.0,20220718.0,20220720,20220720,EXP,,AT-MYLANLABS-2022M1079461,MYLAN,,54.0,YR,,M,Y,,,20220720,,MD,AT,AT,2022,Q3,Adult
211065271,21106527,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd (10 mg, QD (1-0-0))",,,U,U,,,,10.0,MG,,QD,2022,Q3,Coronary artery disease,,2022,Q3,1,I,20210201.0,20220718.0,20220720,20220720,EXP,,AT-MYLANLABS-2022M1079461,MYLAN,,54.0,YR,,M,Y,,,20220720,,MD,AT,AT,2022,Q3,Adult
211076901,21107690,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Sepsis,,2022,Q3,1,I,,20220719.0,20220720,20220720,EXP,,"NP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-182582",BOEHRINGER INGELHEIM,"Bhattarai A, Pathak B, Dhakal B, Regmi B, Mandal S, Panta P. et al. Euglycemic diabetic ketoacidosis in a patient with acute stroke taking sodium glucose co-transporter 2 inhibitor. Annals of Medicine and Surgery. 2022; 79: 104118-",64.0,YR,A,M,Y,,,20220720,,HP,NP,NP,2022,Q3,Adult
211076901,21107690,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Facial paralysis,,2022,Q3,1,I,,20220719.0,20220720,20220720,EXP,,"NP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-182582",BOEHRINGER INGELHEIM,"Bhattarai A, Pathak B, Dhakal B, Regmi B, Mandal S, Panta P. et al. Euglycemic diabetic ketoacidosis in a patient with acute stroke taking sodium glucose co-transporter 2 inhibitor. Annals of Medicine and Surgery. 2022; 79: 104118-",64.0,YR,A,M,Y,,,20220720,,HP,NP,NP,2022,Q3,Adult
211076901,21107690,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Ischaemic stroke,,2022,Q3,1,I,,20220719.0,20220720,20220720,EXP,,"NP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-182582",BOEHRINGER INGELHEIM,"Bhattarai A, Pathak B, Dhakal B, Regmi B, Mandal S, Panta P. et al. Euglycemic diabetic ketoacidosis in a patient with acute stroke taking sodium glucose co-transporter 2 inhibitor. Annals of Medicine and Surgery. 2022; 79: 104118-",64.0,YR,A,M,Y,,,20220720,,HP,NP,NP,2022,Q3,Adult
211076901,21107690,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,,20220719.0,20220720,20220720,EXP,,"NP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-182582",BOEHRINGER INGELHEIM,"Bhattarai A, Pathak B, Dhakal B, Regmi B, Mandal S, Panta P. et al. Euglycemic diabetic ketoacidosis in a patient with acute stroke taking sodium glucose co-transporter 2 inhibitor. Annals of Medicine and Surgery. 2022; 79: 104118-",64.0,YR,A,M,Y,,,20220720,,HP,NP,NP,2022,Q3,Adult
211105391,21110539,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg od; ;,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Fournier's gangrene,,2022,Q3,1,I,20220619.0,20220720.0,20220721,20220721,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-182758",BOEHRINGER INGELHEIM,,49.0,YR,A,M,Y,,,20220721,,CN,GB,GB,2022,Q3,Adult
211127611,21112761,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Testicular abscess,,2022,Q3,1,I,,20220714.0,20220721,20220721,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-181829",BOEHRINGER INGELHEIM,"Raj R, Mishra R, Elshimy G, Kannan L. Sodium?glucose cotransporter 2 inhibitor- associated severe epididymo- orchitis. BMJ Case Reports. 2022; 15:7:",6.0,DEC,A,M,Y,,,20220721,,MD,US,US,2022,Q3,Child
211127611,21112761,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Orchitis,,2022,Q3,1,I,,20220714.0,20220721,20220721,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-181829",BOEHRINGER INGELHEIM,"Raj R, Mishra R, Elshimy G, Kannan L. Sodium?glucose cotransporter 2 inhibitor- associated severe epididymo- orchitis. BMJ Case Reports. 2022; 15:7:",6.0,DEC,A,M,Y,,,20220721,,MD,US,US,2022,Q3,Child
211129971,21112997,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,D,D,,,,12.5,MG,,QD,2022,Q3,Acute kidney injury,,2022,Q3,1,I,20220518.0,,20220721,20220721,DIR,FDA-CDER-CTU-2022-57704,,FDA-CTU,,68.0,YR,,M,N,,,20220630,N,HP,US,,2022,Q3,Elderly
211129971,21112997,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,D,D,,,,12.5,MG,,QD,2022,Q3,Dehydration,,2022,Q3,1,I,20220518.0,,20220721,20220721,DIR,FDA-CDER-CTU-2022-57704,,FDA-CTU,,68.0,YR,,M,N,,,20220630,N,HP,US,,2022,Q3,Elderly
211130011,21113001,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,12.5MG EVERY DAY ,,,Y,D,,,,12.5,MG,,,2022,Q3,Abdominal pain,,2022,Q3,1,I,20220501.0,,20220721,20220721,DIR,FDA-CDER-CTU-2022-57719,,FDA-CTU,,52.0,YR,,M,N,,,20220629,N,HP,US,,2022,Q3,Adult
211130011,21113001,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,12.5MG EVERY DAY ,,,Y,D,,,,12.5,MG,,,2022,Q3,Vomiting,,2022,Q3,1,I,20220501.0,,20220721,20220721,DIR,FDA-CDER-CTU-2022-57719,,FDA-CTU,,52.0,YR,,M,N,,,20220629,N,HP,US,,2022,Q3,Adult
211130011,21113001,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,12.5MG EVERY DAY ,,,Y,D,,,,12.5,MG,,,2022,Q3,Nausea,,2022,Q3,1,I,20220501.0,,20220721,20220721,DIR,FDA-CDER-CTU-2022-57719,,FDA-CTU,,52.0,YR,,M,N,,,20220629,N,HP,US,,2022,Q3,Adult
211130011,21113001,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,12.5MG EVERY DAY ,,,Y,D,,,,12.5,MG,,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,20220501.0,,20220721,20220721,DIR,FDA-CDER-CTU-2022-57719,,FDA-CTU,,52.0,YR,,M,N,,,20220629,N,HP,US,,2022,Q3,Adult
211134331,21113433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,D60520,20240831.0,,,,,QD,2022,Q3,Acidosis,,2022,Q3,1,I,20220419.0,,20220721,20220721,DIR,FDA-CDER-CTU-2022-57742,,FDA-CTU,,57.0,YR,,M,N,94.8,KG,20220615,N,PH,US,,2022,Q3,Adult
211152291,21115229,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Ketosis,,2022,Q3,1,I,20200301.0,20220712.0,20220721,20220721,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-181413",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,65.0,KG,20220721,,PH,AU,AU,2022,Q3,Adult
211152291,21115229,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Hypoglycaemia,,2022,Q3,1,I,20200301.0,20220712.0,20220721,20220721,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-181413",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,65.0,KG,20220721,,PH,AU,AU,2022,Q3,Adult
211152291,21115229,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Medication error,,2022,Q3,1,I,20200301.0,20220712.0,20220721,20220721,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-181413",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,65.0,KG,20220721,,PH,AU,AU,2022,Q3,Adult
211165702,21116570,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,Tablet,,2022,Q3,Aphasia,,2022,Q3,2,F,20201020.0,20220825.0,20220722,20220901,EXP,,JP-TAKEDA-2022TUS049042,TAKEDA,Umaba K. A case of vidarabine-induced encephalopathy which developed during therapy with febuxostat (in Japanese). Clinical Neurology (Web). 2021;61(11): 790(41),75.0,YR,,M,Y,,,20220901,,MD,JP,JP,2022,Q3,Elderly
211165702,21116570,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,Tablet,,2022,Q3,Tremor,,2022,Q3,2,F,20201020.0,20220825.0,20220722,20220901,EXP,,JP-TAKEDA-2022TUS049042,TAKEDA,Umaba K. A case of vidarabine-induced encephalopathy which developed during therapy with febuxostat (in Japanese). Clinical Neurology (Web). 2021;61(11): 790(41),75.0,YR,,M,Y,,,20220901,,MD,JP,JP,2022,Q3,Elderly
211165702,21116570,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,Tablet,,2022,Q3,Toxic encephalopathy,,2022,Q3,2,F,20201020.0,20220825.0,20220722,20220901,EXP,,JP-TAKEDA-2022TUS049042,TAKEDA,Umaba K. A case of vidarabine-induced encephalopathy which developed during therapy with febuxostat (in Japanese). Clinical Neurology (Web). 2021;61(11): 790(41),75.0,YR,,M,Y,,,20220901,,MD,JP,JP,2022,Q3,Elderly
211165702,21116570,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,Tablet,,2022,Q3,Drug interaction,,2022,Q3,2,F,20201020.0,20220825.0,20220722,20220901,EXP,,JP-TAKEDA-2022TUS049042,TAKEDA,Umaba K. A case of vidarabine-induced encephalopathy which developed during therapy with febuxostat (in Japanese). Clinical Neurology (Web). 2021;61(11): 790(41),75.0,YR,,M,Y,,,20220901,,MD,JP,JP,2022,Q3,Elderly
211165702,21116570,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,Tablet,,2022,Q3,Gait disturbance,,2022,Q3,2,F,20201020.0,20220825.0,20220722,20220901,EXP,,JP-TAKEDA-2022TUS049042,TAKEDA,Umaba K. A case of vidarabine-induced encephalopathy which developed during therapy with febuxostat (in Japanese). Clinical Neurology (Web). 2021;61(11): 790(41),75.0,YR,,M,Y,,,20220901,,MD,JP,JP,2022,Q3,Elderly
211165702,21116570,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,Tablet,,2022,Q3,Disorientation,,2022,Q3,2,F,20201020.0,20220825.0,20220722,20220901,EXP,,JP-TAKEDA-2022TUS049042,TAKEDA,Umaba K. A case of vidarabine-induced encephalopathy which developed during therapy with febuxostat (in Japanese). Clinical Neurology (Web). 2021;61(11): 790(41),75.0,YR,,M,Y,,,20220901,,MD,JP,JP,2022,Q3,Elderly
211181681,21118168,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,12.5,MG,,QD,2022,Q3,Fournier's gangrene,,2022,Q3,1,I,,20220714.0,20220722,20220722,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-181806",BOEHRINGER INGELHEIM,"Khokhar F, Hernandez C, Mahapatra R. Fournier^s Gangrene in an HIV-Positive Patient on Empagliflozin for the Treatment of Diabetes Mellitus. Cureus. 2022 Jun 19; 14:6: 26083-",55.0,YR,A,M,Y,,,20220722,,HP,US,US,2022,Q3,Adult
211195501,21119550,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD (1-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Drug ineffective,,2022,Q3,1,I,20210201.0,20220719.0,20220722,20220722,EXP,,AT-ORGANON-O2207AUT001537,ORGANON,,54.0,YR,,M,Y,,,20220722,,MD,AT,AT,2022,Q3,Adult
211195501,21119550,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, QD (1-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Coronary artery disease,,2022,Q3,1,I,20210201.0,20220719.0,20220722,20220722,EXP,,AT-ORGANON-O2207AUT001537,ORGANON,,54.0,YR,,M,Y,,,20220722,,MD,AT,AT,2022,Q3,Adult
211204252,21120425,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1T1x,,,,,,,,,,,,2022,Q3,Dyspnoea,,2022,Q3,2,F,,20220729.0,20220722,20220803,EXP,,JP-OTSUKA-2022_037112,OTSUKA,,9.0,DEC,,F,Y,59.2,KG,20220803,,MD,JP,JP,2022,Q3,Child
211204252,21120425,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1T1x,,,,,,,,,,,,2022,Q3,Hypotension,,2022,Q3,2,F,,20220729.0,20220722,20220803,EXP,,JP-OTSUKA-2022_037112,OTSUKA,,9.0,DEC,,F,Y,59.2,KG,20220803,,MD,JP,JP,2022,Q3,Child
211204252,21120425,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1T1x,,,,,,,,,,,,2022,Q3,Polyuria,,2022,Q3,2,F,,20220729.0,20220722,20220803,EXP,,JP-OTSUKA-2022_037112,OTSUKA,,9.0,DEC,,F,Y,59.2,KG,20220803,,MD,JP,JP,2022,Q3,Child
211204252,21120425,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1T1x,,,,,,,,,,,,2022,Q3,Dyspnoea,,2022,Q3,2,F,,20220729.0,20220722,20220803,EXP,,JP-OTSUKA-2022_037112,OTSUKA,,9.0,DEC,,F,Y,59.2,KG,20220803,,MD,JP,JP,2022,Q3,Child
211204252,21120425,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1T1x,,,,,,,,,,,,2022,Q3,Product use in unapproved indication,,2022,Q3,2,F,,20220729.0,20220722,20220803,EXP,,JP-OTSUKA-2022_037112,OTSUKA,,9.0,DEC,,F,Y,59.2,KG,20220803,,MD,JP,JP,2022,Q3,Child
211204252,21120425,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1T1x,,,,,,,,,,,,2022,Q3,Hypokalaemia,,2022,Q3,2,F,,20220729.0,20220722,20220803,EXP,,JP-OTSUKA-2022_037112,OTSUKA,,9.0,DEC,,F,Y,59.2,KG,20220803,,MD,JP,JP,2022,Q3,Child
211204252,21120425,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10,,,,,,,,,,,,2022,Q3,Dyspnoea,,2022,Q3,2,F,,20220729.0,20220722,20220803,EXP,,JP-OTSUKA-2022_037112,OTSUKA,,9.0,DEC,,F,Y,59.2,KG,20220803,,MD,JP,JP,2022,Q3,Child
211204252,21120425,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10,,,,,,,,,,,,2022,Q3,Hypotension,,2022,Q3,2,F,,20220729.0,20220722,20220803,EXP,,JP-OTSUKA-2022_037112,OTSUKA,,9.0,DEC,,F,Y,59.2,KG,20220803,,MD,JP,JP,2022,Q3,Child
211204252,21120425,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10,,,,,,,,,,,,2022,Q3,Polyuria,,2022,Q3,2,F,,20220729.0,20220722,20220803,EXP,,JP-OTSUKA-2022_037112,OTSUKA,,9.0,DEC,,F,Y,59.2,KG,20220803,,MD,JP,JP,2022,Q3,Child
211204252,21120425,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10,,,,,,,,,,,,2022,Q3,Dyspnoea,,2022,Q3,2,F,,20220729.0,20220722,20220803,EXP,,JP-OTSUKA-2022_037112,OTSUKA,,9.0,DEC,,F,Y,59.2,KG,20220803,,MD,JP,JP,2022,Q3,Child
211204252,21120425,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10,,,,,,,,,,,,2022,Q3,Product use in unapproved indication,,2022,Q3,2,F,,20220729.0,20220722,20220803,EXP,,JP-OTSUKA-2022_037112,OTSUKA,,9.0,DEC,,F,Y,59.2,KG,20220803,,MD,JP,JP,2022,Q3,Child
211204252,21120425,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10,,,,,,,,,,,,2022,Q3,Hypokalaemia,,2022,Q3,2,F,,20220729.0,20220722,20220803,EXP,,JP-OTSUKA-2022_037112,OTSUKA,,9.0,DEC,,F,Y,59.2,KG,20220803,,MD,JP,JP,2022,Q3,Child
211206761,21120676,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg per day,,,,,,,,,,,,2022,Q3,Depression,,2022,Q3,1,I,20220531.0,20220711.0,20220722,20220722,EXP,,US-UCBSA-2022031861,UCB,,41.0,YR,,F,Y,74.83,KG,20220722,,CN,US,US,2022,Q3,Adult
211206761,21120676,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg per day,,,,,,,,,,,,2022,Q3,Product availability issue,,2022,Q3,1,I,20220531.0,20220711.0,20220722,20220722,EXP,,US-UCBSA-2022031861,UCB,,41.0,YR,,F,Y,74.83,KG,20220722,,CN,US,US,2022,Q3,Adult
211206761,21120676,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg per day,,,,,,,,,,,,2022,Q3,Cognitive disorder,,2022,Q3,1,I,20220531.0,20220711.0,20220722,20220722,EXP,,US-UCBSA-2022031861,UCB,,41.0,YR,,F,Y,74.83,KG,20220722,,CN,US,US,2022,Q3,Adult
211206761,21120676,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg per day,,,,,,,,,,,,2022,Q3,Therapy interrupted,,2022,Q3,1,I,20220531.0,20220711.0,20220722,20220722,EXP,,US-UCBSA-2022031861,UCB,,41.0,YR,,F,Y,74.83,KG,20220722,,CN,US,US,2022,Q3,Adult
211206761,21120676,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg per day,,,,,,,,,,,,2022,Q3,Seizure,,2022,Q3,1,I,20220531.0,20220711.0,20220722,20220722,EXP,,US-UCBSA-2022031861,UCB,,41.0,YR,,F,Y,74.83,KG,20220722,,CN,US,US,2022,Q3,Adult
211213551,21121355,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Drug ineffective,,2022,Q3,1,I,20211001.0,20220715.0,20220722,20220722,PER,,US-MYLANLABS-2022M1079488,MYLAN,,79.0,YR,,M,Y,95.238,KG,20220722,,CN,US,US,2022,Q3,Elderly
211234611,21123461,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,550.0,MG,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Myalgia,,2022,Q3,1,I,20220719.0,20220722.0,20220724,20220724,EXP,GB-MHRA-TPP15306418C5962349YC1658229038369,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-183272",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,73.0,KG,20220724,,HP,GB,GB,2022,Q3,Adult
211299561,21129956,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Drug ineffective,,2022,Q3,1,I,20210201.0,20220717.0,20220726,20220726,EXP,,AT-BAUSCH-BL-2022-018161,BAUSCH AND LOMB,,54.0,YR,,M,Y,,,20220726,,MD,AT,AT,2022,Q3,Adult
211299561,21129956,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Coronary artery disease,,2022,Q3,1,I,20210201.0,20220717.0,20220726,20220726,EXP,,AT-BAUSCH-BL-2022-018161,BAUSCH AND LOMB,,54.0,YR,,M,Y,,,20220726,,MD,AT,AT,2022,Q3,Adult
211304811,21130481,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,,,,12.5,MG,,,2022,Q3,Drug ineffective,,2022,Q3,1,I,,20220713.0,20220726,20220726,EXP,,"US-Oxford Pharmaceuticals, LLC-2131240",OXFORD PHARMACEUTICALS,"Khokhar F, Hernandez C, Mahapatra R. Fournier Gangrene in an HIV-Positive Patient on Empagliflozin for the Treatment of Diabetes Mellitus. Cureus. 2022 Jun 19;14(6):e26083. doi: 10.7759/cureus.26083.",55.0,YR,,M,Y,,,20220726,,MD,US,US,2022,Q3,Adult
211304811,21130481,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,,,,12.5,MG,,,2022,Q3,Fournier's gangrene,,2022,Q3,1,I,,20220713.0,20220726,20220726,EXP,,"US-Oxford Pharmaceuticals, LLC-2131240",OXFORD PHARMACEUTICALS,"Khokhar F, Hernandez C, Mahapatra R. Fournier Gangrene in an HIV-Positive Patient on Empagliflozin for the Treatment of Diabetes Mellitus. Cureus. 2022 Jun 19;14(6):e26083. doi: 10.7759/cureus.26083.",55.0,YR,,M,Y,,,20220726,,MD,US,US,2022,Q3,Adult
211304811,21130481,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,,,,12.5,MG,,,2022,Q3,Glycosylated haemoglobin increased,,2022,Q3,1,I,,20220713.0,20220726,20220726,EXP,,"US-Oxford Pharmaceuticals, LLC-2131240",OXFORD PHARMACEUTICALS,"Khokhar F, Hernandez C, Mahapatra R. Fournier Gangrene in an HIV-Positive Patient on Empagliflozin for the Treatment of Diabetes Mellitus. Cureus. 2022 Jun 19;14(6):e26083. doi: 10.7759/cureus.26083.",55.0,YR,,M,Y,,,20220726,,MD,US,US,2022,Q3,Adult
211336141,21133614,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG  AM PO?,,,D,,,,,12.5,MG,,999,2022,Q3,Genital rash,,2022,Q3,1,I,20220722.0,,20220726,20220726,DIR,FDA-CDER-CTU-2022-59027,,FDA-CTU,,63.0,YR,,M,N,127.0,KG,20220722,N,HP,US,,2022,Q3,Adult
211336141,21133614,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG  AM PO?,,,D,,,,,12.5,MG,,999,2022,Q3,Urticaria,,2022,Q3,1,I,20220722.0,,20220726,20220726,DIR,FDA-CDER-CTU-2022-59027,,FDA-CTU,,63.0,YR,,M,N,127.0,KG,20220722,N,HP,US,,2022,Q3,Adult
211336141,21133614,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG  AM PO?,,,D,,,,,12.5,MG,,999,2022,Q3,Pruritus,,2022,Q3,1,I,20220722.0,,20220726,20220726,DIR,FDA-CDER-CTU-2022-59027,,FDA-CTU,,63.0,YR,,M,N,127.0,KG,20220722,N,HP,US,,2022,Q3,Adult
211336141,21133614,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG  AM PO?,,,D,,,,,12.5,MG,,999,2022,Q3,Urinary tract infection,,2022,Q3,1,I,20220722.0,,20220726,20220726,DIR,FDA-CDER-CTU-2022-59027,,FDA-CTU,,63.0,YR,,M,N,127.0,KG,20220722,N,HP,US,,2022,Q3,Adult
211343491,21134349,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Necrotising fasciitis,,2022,Q3,1,I,20220717.0,20220725.0,20220726,20220726,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-183702",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,60.0,KG,20220726,,PH,GB,GB,2022,Q3,Adult
211343981,21134398,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Diabetic ketosis,,2022,Q3,1,I,20220706.0,20220726.0,20220726,20220726,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-183754",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20220727,,PH,GB,GB,2022,Q3,Elderly
211350151,21135015,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,20220624.0,20220726.0,20220727,20220727,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-183715",BOEHRINGER INGELHEIM,,85.0,YR,E,F,Y,,,20220727,,HP,SG,SG,2022,Q3,Elderly
211357741,21135774,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Urinary incontinence,,2022,Q3,1,I,20220706.0,20220726.0,20220727,20220727,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-183717",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20220727,,HP,SG,SG,2022,Q3,Elderly
211366481,21136648,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,D,,,,,,,,2022,Q3,Flushing,,2022,Q3,1,I,20220524.0,,20220726,20220726,DIR,FDA-CDER-CTU-2022-59172,,FDA-CTU,,73.0,YR,,M,N,,,20220719,N,PH,US,,2022,Q3,Elderly
211366481,21136648,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,D,,,,,,,,2022,Q3,Urosepsis,,2022,Q3,1,I,20220524.0,,20220726,20220726,DIR,FDA-CDER-CTU-2022-59172,,FDA-CTU,,73.0,YR,,M,N,,,20220719,N,PH,US,,2022,Q3,Elderly
211366481,21136648,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,D,,,,,,,,2022,Q3,Bacteraemia,,2022,Q3,1,I,20220524.0,,20220726,20220726,DIR,FDA-CDER-CTU-2022-59172,,FDA-CTU,,73.0,YR,,M,N,,,20220719,N,PH,US,,2022,Q3,Elderly
211366481,21136648,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,D,,,,,,,,2022,Q3,Septic shock,,2022,Q3,1,I,20220524.0,,20220726,20220726,DIR,FDA-CDER-CTU-2022-59172,,FDA-CTU,,73.0,YR,,M,N,,,20220719,N,PH,US,,2022,Q3,Elderly
211366481,21136648,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,D,,,,,,,,2022,Q3,Drug hypersensitivity,,2022,Q3,1,I,20220524.0,,20220726,20220726,DIR,FDA-CDER-CTU-2022-59172,,FDA-CTU,,73.0,YR,,M,N,,,20220719,N,PH,US,,2022,Q3,Elderly
211382571,21138257,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Pruritus,,2022,Q3,1,I,20220324.0,20220726.0,20220727,20220727,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-183725",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220727,,HP,SG,SG,2022,Q3,Adult
211382571,21138257,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Pruritus,,2022,Q3,1,I,20220324.0,20220726.0,20220727,20220727,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-183725",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220727,,HP,SG,SG,2022,Q3,Adult
211472631,21147263,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,170.0,MG,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Hypotension,,2022,Q3,1,I,20220725.0,20220728.0,20220729,20220729,EXP,GB-MHRA-TPP4209479C37091YC1658743966087,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-184239",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,82.0,KG,20220729,,MD,GB,GB,2022,Q3,Elderly
211472631,21147263,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,170.0,MG,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Somnolence,,2022,Q3,1,I,20220725.0,20220728.0,20220729,20220729,EXP,GB-MHRA-TPP4209479C37091YC1658743966087,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-184239",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,82.0,KG,20220729,,MD,GB,GB,2022,Q3,Elderly
211472631,21147263,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,170.0,MG,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Hypotension,,2022,Q3,1,I,20220725.0,20220728.0,20220729,20220729,EXP,GB-MHRA-TPP4209479C37091YC1658743966087,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-184239",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,82.0,KG,20220729,,MD,GB,GB,2022,Q3,Elderly
211479631,21147963,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2022,Q3,Abdominal pain upper,,2022,Q3,1,I,20220414.0,,20220729,20220729,DIR,625142,,FDA-CTU,,85.0,YR,,M,N,86.2,KG,20220729,N,,US,,2022,Q3,Elderly
211479631,21147963,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2022,Q3,Pancreatitis acute,,2022,Q3,1,I,20220414.0,,20220729,20220729,DIR,625142,,FDA-CTU,,85.0,YR,,M,N,86.2,KG,20220729,N,,US,,2022,Q3,Elderly
211479631,21147963,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2022,Q3,Vomiting,,2022,Q3,1,I,20220414.0,,20220729,20220729,DIR,625142,,FDA-CTU,,85.0,YR,,M,N,86.2,KG,20220729,N,,US,,2022,Q3,Elderly
211479631,21147963,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2022,Q3,Nausea,,2022,Q3,1,I,20220414.0,,20220729,20220729,DIR,625142,,FDA-CTU,,85.0,YR,,M,N,86.2,KG,20220729,N,,US,,2022,Q3,Elderly
211479631,21147963,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2022,Q3,Therapy interrupted,,2022,Q3,1,I,20220414.0,,20220729,20220729,DIR,625142,,FDA-CTU,,85.0,YR,,M,N,86.2,KG,20220729,N,,US,,2022,Q3,Elderly
211483173,21148317,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Circulatory collapse,,2022,Q3,3,F,20220524.0,20220728.0,20220729,20220804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-077562,BRISTOL MYERS SQUIBB,,67.0,YR,E,M,Y,90.0,KG,20220804,,MD,DE,DE,2022,Q3,Elderly
211483173,21148317,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Pulmonary sepsis,,2022,Q3,3,F,20220524.0,20220728.0,20220729,20220804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-077562,BRISTOL MYERS SQUIBB,,67.0,YR,E,M,Y,90.0,KG,20220804,,MD,DE,DE,2022,Q3,Elderly
211483173,21148317,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,General physical health deterioration,,2022,Q3,3,F,20220524.0,20220728.0,20220729,20220804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-077562,BRISTOL MYERS SQUIBB,,67.0,YR,E,M,Y,90.0,KG,20220804,,MD,DE,DE,2022,Q3,Elderly
211483173,21148317,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Malignant neoplasm progression,,2022,Q3,3,F,20220524.0,20220728.0,20220729,20220804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-077562,BRISTOL MYERS SQUIBB,,67.0,YR,E,M,Y,90.0,KG,20220804,,MD,DE,DE,2022,Q3,Elderly
211483173,21148317,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Prescribed overdose,,2022,Q3,3,F,20220524.0,20220728.0,20220729,20220804,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-077562,BRISTOL MYERS SQUIBB,,67.0,YR,E,M,Y,90.0,KG,20220804,,MD,DE,DE,2022,Q3,Elderly
211483321,21148332,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,N-terminal prohormone brain natriuretic peptide,,2022,Q3,1,I,,20220725.0,20220729,20220729,EXP,,NVSC2022TH168076,NOVARTIS,,55.0,YR,,M,Y,,,20220729,,MD,TH,TH,2022,Q3,Adult
211483321,21148332,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Hypotension,,2022,Q3,1,I,,20220725.0,20220729,20220729,EXP,,NVSC2022TH168076,NOVARTIS,,55.0,YR,,M,Y,,,20220729,,MD,TH,TH,2022,Q3,Adult
211483321,21148332,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Wrong technique in product usage process,,2022,Q3,1,I,,20220725.0,20220729,20220729,EXP,,NVSC2022TH168076,NOVARTIS,,55.0,YR,,M,Y,,,20220729,,MD,TH,TH,2022,Q3,Adult
211483321,21148332,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Blood creatinine increased,,2022,Q3,1,I,,20220725.0,20220729,20220729,EXP,,NVSC2022TH168076,NOVARTIS,,55.0,YR,,M,Y,,,20220729,,MD,TH,TH,2022,Q3,Adult
211483321,21148332,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Weight increased,,2022,Q3,1,I,,20220725.0,20220729,20220729,EXP,,NVSC2022TH168076,NOVARTIS,,55.0,YR,,M,Y,,,20220729,,MD,TH,TH,2022,Q3,Adult
211483321,21148332,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Cardiac failure chronic,,2022,Q3,1,I,,20220725.0,20220729,20220729,EXP,,NVSC2022TH168076,NOVARTIS,,55.0,YR,,M,Y,,,20220729,,MD,TH,TH,2022,Q3,Adult
211483321,21148332,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220725.0,20220729,20220729,EXP,,NVSC2022TH168076,NOVARTIS,,55.0,YR,,M,Y,,,20220729,,MD,TH,TH,2022,Q3,Adult
211483321,21148332,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Underdose,,2022,Q3,1,I,,20220725.0,20220729,20220729,EXP,,NVSC2022TH168076,NOVARTIS,,55.0,YR,,M,Y,,,20220729,,MD,TH,TH,2022,Q3,Adult
211483321,21148332,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q3,Heart rate decreased,,2022,Q3,1,I,,20220725.0,20220729,20220729,EXP,,NVSC2022TH168076,NOVARTIS,,55.0,YR,,M,Y,,,20220729,,MD,TH,TH,2022,Q3,Adult
211493312,21149331,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,Tablet,,2022,Q3,Diarrhoea,,2022,Q3,2,F,20220101.0,20220902.0,20220729,20220906,PER,,US-PFIZER INC-202201014470,PFIZER,,75.0,YR,,M,Y,65.32,KG,20220906,,CN,US,US,2022,Q3,Elderly
211493312,21149331,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,Tablet,,2022,Q3,Muscle tightness,,2022,Q3,2,F,20220101.0,20220902.0,20220729,20220906,PER,,US-PFIZER INC-202201014470,PFIZER,,75.0,YR,,M,Y,65.32,KG,20220906,,CN,US,US,2022,Q3,Elderly
211493312,21149331,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,Tablet,,2022,Q3,Nightmare,,2022,Q3,2,F,20220101.0,20220902.0,20220729,20220906,PER,,US-PFIZER INC-202201014470,PFIZER,,75.0,YR,,M,Y,65.32,KG,20220906,,CN,US,US,2022,Q3,Elderly
211598231,21159823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2022,Q3,Headache,,2022,Q3,1,I,20220623.0,20220728.0,20220802,20220802,EXP,GB-MHRA-INP8CA66647-792A-4BA2-9336-CCCDEEA31693,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-184246",BOEHRINGER INGELHEIM,,46.0,YR,A,F,Y,121.0,KG,20220802,,MD,GB,GB,2022,Q3,Adult
211598231,21159823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2022,Q3,Nausea,,2022,Q3,1,I,20220623.0,20220728.0,20220802,20220802,EXP,GB-MHRA-INP8CA66647-792A-4BA2-9336-CCCDEEA31693,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-184246",BOEHRINGER INGELHEIM,,46.0,YR,A,F,Y,121.0,KG,20220802,,MD,GB,GB,2022,Q3,Adult
211598231,21159823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2022,Q3,Dizziness,,2022,Q3,1,I,20220623.0,20220728.0,20220802,20220802,EXP,GB-MHRA-INP8CA66647-792A-4BA2-9336-CCCDEEA31693,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-184246",BOEHRINGER INGELHEIM,,46.0,YR,A,F,Y,121.0,KG,20220802,,MD,GB,GB,2022,Q3,Adult
211598231,21159823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2022,Q3,Vomiting,,2022,Q3,1,I,20220623.0,20220728.0,20220802,20220802,EXP,GB-MHRA-INP8CA66647-792A-4BA2-9336-CCCDEEA31693,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-184246",BOEHRINGER INGELHEIM,,46.0,YR,A,F,Y,121.0,KG,20220802,,MD,GB,GB,2022,Q3,Adult
211598231,21159823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2022,Q3,Decreased appetite,,2022,Q3,1,I,20220623.0,20220728.0,20220802,20220802,EXP,GB-MHRA-INP8CA66647-792A-4BA2-9336-CCCDEEA31693,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-184246",BOEHRINGER INGELHEIM,,46.0,YR,A,F,Y,121.0,KG,20220802,,MD,GB,GB,2022,Q3,Adult
211598231,21159823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2022,Q3,Musculoskeletal stiffness,,2022,Q3,1,I,20220623.0,20220728.0,20220802,20220802,EXP,GB-MHRA-INP8CA66647-792A-4BA2-9336-CCCDEEA31693,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-184246",BOEHRINGER INGELHEIM,,46.0,YR,A,F,Y,121.0,KG,20220802,,MD,GB,GB,2022,Q3,Adult
211598231,21159823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2022,Q3,Hypotension,,2022,Q3,1,I,20220623.0,20220728.0,20220802,20220802,EXP,GB-MHRA-INP8CA66647-792A-4BA2-9336-CCCDEEA31693,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-184246",BOEHRINGER INGELHEIM,,46.0,YR,A,F,Y,121.0,KG,20220802,,MD,GB,GB,2022,Q3,Adult
211607421,21160742,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q3,Gastrointestinal bacterial overgrowth,,2022,Q3,1,I,20220530.0,,20220801,20220801,DIR,FDA-CDER-CTU-2022-60957,,FDA-CTU,,69.0,YR,,M,N,83.91,KG,20220728,N,PH,US,,2022,Q3,Elderly
211607421,21160742,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q3,Toxicity to various agents,,2022,Q3,1,I,20220530.0,,20220801,20220801,DIR,FDA-CDER-CTU-2022-60957,,FDA-CTU,,69.0,YR,,M,N,83.91,KG,20220728,N,PH,US,,2022,Q3,Elderly
211607421,21160742,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q3,Metabolic acidosis,,2022,Q3,1,I,20220530.0,,20220801,20220801,DIR,FDA-CDER-CTU-2022-60957,,FDA-CTU,,69.0,YR,,M,N,83.91,KG,20220728,N,PH,US,,2022,Q3,Elderly
211607421,21160742,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q3,Dehydration,,2022,Q3,1,I,20220530.0,,20220801,20220801,DIR,FDA-CDER-CTU-2022-60957,,FDA-CTU,,69.0,YR,,M,N,83.91,KG,20220728,N,PH,US,,2022,Q3,Elderly
211607421,21160742,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,20220530.0,,20220801,20220801,DIR,FDA-CDER-CTU-2022-60957,,FDA-CTU,,69.0,YR,,M,N,83.91,KG,20220728,N,PH,US,,2022,Q3,Elderly
211607421,21160742,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q3,Lactic acidosis,,2022,Q3,1,I,20220530.0,,20220801,20220801,DIR,FDA-CDER-CTU-2022-60957,,FDA-CTU,,69.0,YR,,M,N,83.91,KG,20220728,N,PH,US,,2022,Q3,Elderly
211607421,21160742,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q3,Acute kidney injury,,2022,Q3,1,I,20220530.0,,20220801,20220801,DIR,FDA-CDER-CTU-2022-60957,,FDA-CTU,,69.0,YR,,M,N,83.91,KG,20220728,N,PH,US,,2022,Q3,Elderly
211607421,21160742,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q3,Hyperkalaemia,,2022,Q3,1,I,20220530.0,,20220801,20220801,DIR,FDA-CDER-CTU-2022-60957,,FDA-CTU,,69.0,YR,,M,N,83.91,KG,20220728,N,PH,US,,2022,Q3,Elderly
211634091,21163409,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,Unknown,,208658.0,,,,,2022,Q3,Blood creatinine increased,,2022,Q3,1,I,20220401.0,20220729.0,20220802,20220802,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-184891",BOEHRINGER INGELHEIM,,65.0,YR,E,F,Y,,,20220802,,MD,AU,AU,2022,Q3,Elderly
211634091,21163409,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,Unknown,,208658.0,,,,,2022,Q3,Rhabdomyolysis,,2022,Q3,1,I,20220401.0,20220729.0,20220802,20220802,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-184891",BOEHRINGER INGELHEIM,,65.0,YR,E,F,Y,,,20220802,,MD,AU,AU,2022,Q3,Elderly
211636982,21163698,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,N,,Unknown,,206073.0,,,Tablet,QD,2022,Q3,Prostate cancer,,2022,Q3,2,F,20220301.0,20220803.0,20220802,20220805,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185105",BOEHRINGER INGELHEIM,,74.0,YR,E,M,Y,,,20220805,,MD,JP,JP,2022,Q3,Elderly
211656031,21165603,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg,,,,,,,,,,,Q12H,2022,Q3,Urinary tract infection,,2022,Q3,1,I,20220629.0,20220725.0,20220803,20220803,EXP,,ES-EMD Serono-9339931,EMD SERONO INC,,54.0,YR,A,M,Y,,,20220803,,MD,ES,,2022,Q3,Adult
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Atrial fibrillation,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Drug interaction,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Acute kidney injury,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Oedema peripheral,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Hypotension,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Skin disorder,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Arrhythmia,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Bradycardia,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Dehydration,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Dizziness,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Haematocrit increased,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Pulmonary congestion,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Mucosal dryness,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Syncope,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Haemoglobin increased,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Renal disorder,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Hypovolaemia,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Left atrial dilatation,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211656901,21165690,17,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,Unknown,,,10.0,MG,,QD,2022,Q3,Presyncope,,2022,Q3,1,I,20180101.0,20220729.0,20220803,20220803,EXP,,NVSC2019PT097027,NOVARTIS,"Gouveia C, Duque S, Campos L. Lipotymia by hypovolemia-a case of iatrogenia to empagliflozina. PORTUGUESE JOURNAL OF DIABTES. 2019;14(1):74",71.0,YR,,M,Y,,,20220803,,HP,PT,PT,2022,Q3,Elderly
211693131,21169313,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Cardiac pacemaker insertion,,2022,Q3,1,I,,20220726.0,20220804,20220804,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-18614,SAMSUNG BIOEPIS,,57.0,YR,A,M,Y,103.0,KG,20220804,,HP,CA,CA,2022,Q3,Adult
211693131,21169313,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Loss of consciousness,,2022,Q3,1,I,,20220726.0,20220804,20220804,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-18614,SAMSUNG BIOEPIS,,57.0,YR,A,M,Y,103.0,KG,20220804,,HP,CA,CA,2022,Q3,Adult
211693131,21169313,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Product use in unapproved indication,,2022,Q3,1,I,,20220726.0,20220804,20220804,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-18614,SAMSUNG BIOEPIS,,57.0,YR,A,M,Y,103.0,KG,20220804,,HP,CA,CA,2022,Q3,Adult
211693131,21169313,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Insomnia,,2022,Q3,1,I,,20220726.0,20220804,20220804,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-18614,SAMSUNG BIOEPIS,,57.0,YR,A,M,Y,103.0,KG,20220804,,HP,CA,CA,2022,Q3,Adult
211693131,21169313,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Off label use,,2022,Q3,1,I,,20220726.0,20220804,20220804,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-18614,SAMSUNG BIOEPIS,,57.0,YR,A,M,Y,103.0,KG,20220804,,HP,CA,CA,2022,Q3,Adult
211693131,21169313,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q3,Asthenia,,2022,Q3,1,I,,20220726.0,20220804,20220804,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-18614,SAMSUNG BIOEPIS,,57.0,YR,A,M,Y,103.0,KG,20220804,,HP,CA,CA,2022,Q3,Adult
211697741,21169774,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,180 dosage form per day,,,,,Unknown,,,,,,,2022,Q3,Hallucination,,2022,Q3,1,I,20220606.0,20220613.0,20220804,20220804,EXP,GB-MHRA-ADR 26997528,GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2022-06375,ALKEM,,80.0,YR,,M,Y,93.0,KG,20220804,,MD,GB,GB,2022,Q3,Elderly
211697741,21169774,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,180 dosage form per day,,,,,Unknown,,,,,,,2022,Q3,Drug intolerance,,2022,Q3,1,I,20220606.0,20220613.0,20220804,20220804,EXP,GB-MHRA-ADR 26997528,GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2022-06375,ALKEM,,80.0,YR,,M,Y,93.0,KG,20220804,,MD,GB,GB,2022,Q3,Elderly
211725111,21172511,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Micturition urgency,,2022,Q3,1,I,20220729.0,20220804.0,20220804,20220804,EXP,GB-MHRA-TPP980539C579002YC1659113302132,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185451",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,130.0,KG,20220804,,MD,GB,GB,2022,Q3,Elderly
211725111,21172511,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Pollakiuria,,2022,Q3,1,I,20220729.0,20220804.0,20220804,20220804,EXP,GB-MHRA-TPP980539C579002YC1659113302132,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185451",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,130.0,KG,20220804,,MD,GB,GB,2022,Q3,Elderly
211787472,21178747,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Dry throat,,2022,Q3,2,F,20220802.0,20220914.0,20220805,20220915,EXP,GB-MHRA-WEBCOVID-202208030754173880-BWLTJ,GB-PFIZER INC-202201037727,PFIZER,,70.0,YR,,M,Y,78.0,KG,20220915,,CN,GB,GB,2022,Q3,Elderly
211787472,21178747,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Dyspnoea,,2022,Q3,2,F,20220802.0,20220914.0,20220805,20220915,EXP,GB-MHRA-WEBCOVID-202208030754173880-BWLTJ,GB-PFIZER INC-202201037727,PFIZER,,70.0,YR,,M,Y,78.0,KG,20220915,,CN,GB,GB,2022,Q3,Elderly
211787472,21178747,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Throat tightness,,2022,Q3,2,F,20220802.0,20220914.0,20220805,20220915,EXP,GB-MHRA-WEBCOVID-202208030754173880-BWLTJ,GB-PFIZER INC-202201037727,PFIZER,,70.0,YR,,M,Y,78.0,KG,20220915,,CN,GB,GB,2022,Q3,Elderly
211797291,21179729,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2022,Q3,Urinary tract infection,,2022,Q3,1,I,20220603.0,,20220805,20220805,DIR,FDA-CDER-CTU-2022-62447,,FDA-CTU,,72.0,YR,,M,N,,,20220729,N,PH,US,,2022,Q3,Elderly
211799541,21179954,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q3,Hyperkalaemia,,2022,Q3,1,I,20220513.0,,20220805,20220805,DIR,FDA-CDER-CTU-2022-62480,,FDA-CTU,,62.0,YR,,M,N,,,20220719,N,PH,US,,2022,Q3,Adult
211799541,21179954,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q3,Therapy change,,2022,Q3,1,I,20220513.0,,20220805,20220805,DIR,FDA-CDER-CTU-2022-62480,,FDA-CTU,,62.0,YR,,M,N,,,20220719,N,PH,US,,2022,Q3,Adult
211799571,21179957,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q3,Renal impairment,,2022,Q3,1,I,20190927.0,,20220805,20220805,DIR,FDA-CDER-CTU-2022-62481,,FDA-CTU,,69.0,YR,,M,N,,,20220711,N,PH,US,,2022,Q3,Elderly
211799571,21179957,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q3,Acute kidney injury,,2022,Q3,1,I,20190927.0,,20220805,20220805,DIR,FDA-CDER-CTU-2022-62481,,FDA-CTU,,69.0,YR,,M,N,,,20220711,N,PH,US,,2022,Q3,Elderly
211799631,21179963,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg,,,Y,U,Unknown,,206111.0,,,,Q12H,2022,Q3,Eczema,,2022,Q3,1,I,20210101.0,20220727.0,20220805,20220805,EXP,CH-SM-2022-14501,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185461",BOEHRINGER INGELHEIM,,50.0,YR,A,F,Y,,,20220805,,MD,CH,CH,2022,Q3,Adult
211799631,21179963,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg,,,Y,U,Unknown,,206111.0,,,,Q12H,2022,Q3,Collagen disorder,,2022,Q3,1,I,20210101.0,20220727.0,20220805,20220805,EXP,CH-SM-2022-14501,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185461",BOEHRINGER INGELHEIM,,50.0,YR,A,F,Y,,,20220805,,MD,CH,CH,2022,Q3,Adult
211799631,21179963,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,5/1000 mg,,,Y,U,Unknown,,206111.0,,,,Q12H,2022,Q3,Pruritus,,2022,Q3,1,I,20210101.0,20220727.0,20220805,20220805,EXP,CH-SM-2022-14501,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185461",BOEHRINGER INGELHEIM,,50.0,YR,A,F,Y,,,20220805,,MD,CH,CH,2022,Q3,Adult
211800511,21180051,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Diarrhoea,,2022,Q3,1,I,20220305.0,,20220805,20220805,DIR,FDA-CDER-CTU-2022-62499,,FDA-CTU,,62.0,YR,,M,N,93.44,KG,20220519,N,HP,US,,2022,Q3,Adult
211800511,21180051,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Vision blurred,,2022,Q3,1,I,20220305.0,,20220805,20220805,DIR,FDA-CDER-CTU-2022-62499,,FDA-CTU,,62.0,YR,,M,N,93.44,KG,20220519,N,HP,US,,2022,Q3,Adult
211800771,21180077,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG AM PO?,,,,,,,,12.5,MG,,999,2022,Q3,Rash,,2022,Q3,1,I,20200702.0,,20220805,20220805,DIR,FDA-CDER-CTU-2022-62539,,FDA-CTU,,73.0,YR,,M,N,120.2,KG,20200708,N,HP,US,,2022,Q3,Elderly
211800771,21180077,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG AM PO?,,,,,,,,12.5,MG,,999,2022,Q3,Adverse drug reaction,,2022,Q3,1,I,20200702.0,,20220805,20220805,DIR,FDA-CDER-CTU-2022-62539,,FDA-CTU,,73.0,YR,,M,N,120.2,KG,20200708,N,HP,US,,2022,Q3,Elderly
211835751,21183575,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q3,Dizziness,,2022,Q3,1,I,,20220727.0,20220808,20220808,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2022-07995,ALKEM,,48.0,YR,,M,Y,,,20220808,,HP,AU,AU,2022,Q3,Adult
211835751,21183575,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q3,Mental disorder,,2022,Q3,1,I,,20220727.0,20220808,20220808,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2022-07995,ALKEM,,48.0,YR,,M,Y,,,20220808,,HP,AU,AU,2022,Q3,Adult
211835751,21183575,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q3,Blood pressure decreased,,2022,Q3,1,I,,20220727.0,20220808,20220808,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2022-07995,ALKEM,,48.0,YR,,M,Y,,,20220808,,HP,AU,AU,2022,Q3,Adult
211835751,21183575,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220727.0,20220808,20220808,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2022-07995,ALKEM,,48.0,YR,,M,Y,,,20220808,,HP,AU,AU,2022,Q3,Adult
211835751,21183575,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q3,Schizophrenia,,2022,Q3,1,I,,20220727.0,20220808,20220808,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2022-07995,ALKEM,,48.0,YR,,M,Y,,,20220808,,HP,AU,AU,2022,Q3,Adult
211842741,21184274,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Acute kidney injury,,2022,Q3,1,I,,20220729.0,20220808,20220808,EXP,,CA-TEVA-2022-CA-2060968,TEVA,,73.0,YR,E,M,Y,,,20220808,,PH,CA,CA,2022,Q3,Elderly
211842741,21184274,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Hyperkalaemia,,2022,Q3,1,I,,20220729.0,20220808,20220808,EXP,,CA-TEVA-2022-CA-2060968,TEVA,,73.0,YR,E,M,Y,,,20220808,,PH,CA,CA,2022,Q3,Elderly
211842741,21184274,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Hypotension,,2022,Q3,1,I,,20220729.0,20220808,20220808,EXP,,CA-TEVA-2022-CA-2060968,TEVA,,73.0,YR,E,M,Y,,,20220808,,PH,CA,CA,2022,Q3,Elderly
211847101,21184710,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Loss of consciousness,,2022,Q3,1,I,,20220730.0,20220808,20220808,EXP,CA-MHPD-E2B_05112338,CA-Accord-272461,ACCORD,,57.0,YR,A,M,Y,103.0,KG,20220808,,HP,CA,CA,2022,Q3,Adult
211847101,21184710,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Asthenia,,2022,Q3,1,I,,20220730.0,20220808,20220808,EXP,CA-MHPD-E2B_05112338,CA-Accord-272461,ACCORD,,57.0,YR,A,M,Y,103.0,KG,20220808,,HP,CA,CA,2022,Q3,Adult
211847101,21184710,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Cardiac pacemaker insertion,,2022,Q3,1,I,,20220730.0,20220808,20220808,EXP,CA-MHPD-E2B_05112338,CA-Accord-272461,ACCORD,,57.0,YR,A,M,Y,103.0,KG,20220808,,HP,CA,CA,2022,Q3,Adult
211847101,21184710,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Insomnia,,2022,Q3,1,I,,20220730.0,20220808,20220808,EXP,CA-MHPD-E2B_05112338,CA-Accord-272461,ACCORD,,57.0,YR,A,M,Y,103.0,KG,20220808,,HP,CA,CA,2022,Q3,Adult
211848891,21184889,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, daily",107.143,MG,U,,,,,25.0,MG,"Capsule, soft",QD,2022,Q3,Hyperventilation,,2022,Q3,1,I,20220627.0,20220726.0,20220808,20220808,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202207011508,ELI LILLY AND CO,,34.0,YR,,M,Y,104.0,KG,20220808,,CN,DE,DE,2022,Q3,Young Adult
211848891,21184889,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, daily",107.143,MG,U,,,,,25.0,MG,"Capsule, soft",QD,2022,Q3,Asthenia,,2022,Q3,1,I,20220627.0,20220726.0,20220808,20220808,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202207011508,ELI LILLY AND CO,,34.0,YR,,M,Y,104.0,KG,20220808,,CN,DE,DE,2022,Q3,Young Adult
211848891,21184889,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, daily",107.143,MG,U,,,,,25.0,MG,"Capsule, soft",QD,2022,Q3,Ketoacidosis,,2022,Q3,1,I,20220627.0,20220726.0,20220808,20220808,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202207011508,ELI LILLY AND CO,,34.0,YR,,M,Y,104.0,KG,20220808,,CN,DE,DE,2022,Q3,Young Adult
211848891,21184889,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, daily",107.143,MG,U,,,,,25.0,MG,"Capsule, soft",QD,2022,Q3,Dyspnoea,,2022,Q3,1,I,20220627.0,20220726.0,20220808,20220808,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202207011508,ELI LILLY AND CO,,34.0,YR,,M,Y,104.0,KG,20220808,,CN,DE,DE,2022,Q3,Young Adult
211848891,21184889,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, daily",107.143,MG,U,,,,,25.0,MG,"Capsule, soft",QD,2022,Q3,Hypoglycaemia,,2022,Q3,1,I,20220627.0,20220726.0,20220808,20220808,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202207011508,ELI LILLY AND CO,,34.0,YR,,M,Y,104.0,KG,20220808,,CN,DE,DE,2022,Q3,Young Adult
211848891,21184889,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, daily",107.143,MG,U,,,,,25.0,MG,"Capsule, soft",QD,2022,Q3,Hypertension,,2022,Q3,1,I,20220627.0,20220726.0,20220808,20220808,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202207011508,ELI LILLY AND CO,,34.0,YR,,M,Y,104.0,KG,20220808,,CN,DE,DE,2022,Q3,Young Adult
211848891,21184889,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, daily",107.143,MG,U,,,,,25.0,MG,"Capsule, soft",QD,2022,Q3,Nausea,,2022,Q3,1,I,20220627.0,20220726.0,20220808,20220808,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202207011508,ELI LILLY AND CO,,34.0,YR,,M,Y,104.0,KG,20220808,,CN,DE,DE,2022,Q3,Young Adult
211866721,21186672,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Dose: 10,,,Y,U,Unknown,,204629.0,,,Tablet,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,19591121.0,20220807.0,20220808,20220808,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185871",BOEHRINGER INGELHEIM,,1.0,HR,N,M,Y,,,20220808,,HP,GB,GB,2022,Q3,Child
211882331,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220802.0,20220809,20220809,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,89.0,KG,20220809,,HP,CA,CA,2022,Q3,Elderly
211882331,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Blood pressure fluctuation,,2022,Q3,1,I,,20220802.0,20220809,20220809,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,89.0,KG,20220809,,HP,CA,CA,2022,Q3,Elderly
211882331,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Blood pressure diastolic abnormal,,2022,Q3,1,I,,20220802.0,20220809,20220809,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,89.0,KG,20220809,,HP,CA,CA,2022,Q3,Elderly
211882331,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Blood pressure systolic increased,,2022,Q3,1,I,,20220802.0,20220809,20220809,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,89.0,KG,20220809,,HP,CA,CA,2022,Q3,Elderly
211882331,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Blood glucose increased,,2022,Q3,1,I,,20220802.0,20220809,20220809,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,89.0,KG,20220809,,HP,CA,CA,2022,Q3,Elderly
211882331,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,1,I,,20220802.0,20220809,20220809,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,89.0,KG,20220809,,HP,CA,CA,2022,Q3,Elderly
211882331,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Weight increased,,2022,Q3,1,I,,20220802.0,20220809,20220809,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,89.0,KG,20220809,,HP,CA,CA,2022,Q3,Elderly
211882331,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220802.0,20220809,20220809,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,89.0,KG,20220809,,HP,CA,CA,2022,Q3,Elderly
211882331,21188233,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Blood pressure increased,,2022,Q3,1,I,,20220802.0,20220809,20220809,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185417",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,89.0,KG,20220809,,HP,CA,CA,2022,Q3,Elderly
211903241,21190324,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,,,,,,,QD,2022,Q3,Drug ineffective for unapproved indication,,2022,Q3,1,I,,20220802.0,20220809,20220809,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-10174,LUPIN,"Mishra R, Elshimy G, Kannan L, Raj R. Sodium-glucose cotransporter 2 inhibitor-associated severe epididymoorchitis. British medical journal Case Reports. 2022;15:1-3",6.0,DEC,,M,Y,,,20220809,,HP,US,US,2022,Q3,Child
211903241,21190324,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,,,,,,,QD,2022,Q3,Drug ineffective,,2022,Q3,1,I,,20220802.0,20220809,20220809,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-10174,LUPIN,"Mishra R, Elshimy G, Kannan L, Raj R. Sodium-glucose cotransporter 2 inhibitor-associated severe epididymoorchitis. British medical journal Case Reports. 2022;15:1-3",6.0,DEC,,M,Y,,,20220809,,HP,US,US,2022,Q3,Child
211903241,21190324,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,,,,,,,QD,2022,Q3,Off label use,,2022,Q3,1,I,,20220802.0,20220809,20220809,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-10174,LUPIN,"Mishra R, Elshimy G, Kannan L, Raj R. Sodium-glucose cotransporter 2 inhibitor-associated severe epididymoorchitis. British medical journal Case Reports. 2022;15:1-3",6.0,DEC,,M,Y,,,20220809,,HP,US,US,2022,Q3,Child
211917871,21191787,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,Tablet,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,20220806.0,20220809.0,20220809,20220809,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186129",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,93.0,KG,20220809,,HP,GB,GB,2022,Q3,Adult
211963671,21196367,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, daily",,,,,,,,,,,QD,2022,Q3,Anaphylactic reaction,,2022,Q3,1,I,20220713.0,20220804.0,20220810,20220810,EXP,GB-MHRA-EMIS-9993-c7f679ca-a1ee-40e5-8239-30d3f093d599,GB-ELI_LILLY_AND_COMPANY-GB202208003172,ELI LILLY AND CO,,64.0,YR,,M,Y,87.4,KG,20220810,,CN,GB,GB,2022,Q3,Adult
211963671,21196367,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, daily",,,,,,,,,,,QD,2022,Q3,Hypersensitivity,,2022,Q3,1,I,20220713.0,20220804.0,20220810,20220810,EXP,GB-MHRA-EMIS-9993-c7f679ca-a1ee-40e5-8239-30d3f093d599,GB-ELI_LILLY_AND_COMPANY-GB202208003172,ELI LILLY AND CO,,64.0,YR,,M,Y,87.4,KG,20220810,,CN,GB,GB,2022,Q3,Adult
211963671,21196367,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, daily",,,,,,,,,,,QD,2022,Q3,Anaphylactic reaction,,2022,Q3,1,I,20220713.0,20220804.0,20220810,20220810,EXP,GB-MHRA-EMIS-9993-c7f679ca-a1ee-40e5-8239-30d3f093d599,GB-ELI_LILLY_AND_COMPANY-GB202208003172,ELI LILLY AND CO,,64.0,YR,,M,Y,87.4,KG,20220810,,CN,GB,GB,2022,Q3,Adult
211963671,21196367,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"UNK, daily",,,,,,,,,,,QD,2022,Q3,Oral candidiasis,,2022,Q3,1,I,20220713.0,20220804.0,20220810,20220810,EXP,GB-MHRA-EMIS-9993-c7f679ca-a1ee-40e5-8239-30d3f093d599,GB-ELI_LILLY_AND_COMPANY-GB202208003172,ELI LILLY AND CO,,64.0,YR,,M,Y,87.4,KG,20220810,,CN,GB,GB,2022,Q3,Adult
211972481,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,1,I,,20220805.0,20220810,20220810,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20220810,,HP,CA,CA,2022,Q3,Elderly
211972481,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220805.0,20220810,20220810,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20220810,,HP,CA,CA,2022,Q3,Elderly
211972481,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2022,Q3,Blood pressure systolic increased,,2022,Q3,1,I,,20220805.0,20220810,20220810,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20220810,,HP,CA,CA,2022,Q3,Elderly
211972481,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2022,Q3,Blood pressure increased,,2022,Q3,1,I,,20220805.0,20220810,20220810,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20220810,,HP,CA,CA,2022,Q3,Elderly
211972481,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2022,Q3,Blood glucose increased,,2022,Q3,1,I,,20220805.0,20220810,20220810,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20220810,,HP,CA,CA,2022,Q3,Elderly
211972481,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2022,Q3,Blood pressure fluctuation,,2022,Q3,1,I,,20220805.0,20220810,20220810,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20220810,,HP,CA,CA,2022,Q3,Elderly
211972481,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2022,Q3,Blood pressure diastolic abnormal,,2022,Q3,1,I,,20220805.0,20220810,20220810,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20220810,,HP,CA,CA,2022,Q3,Elderly
211972481,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2022,Q3,Weight increased,,2022,Q3,1,I,,20220805.0,20220810,20220810,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20220810,,HP,CA,CA,2022,Q3,Elderly
211972481,21197248,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220805.0,20220810,20220810,EXP,,CA-PFIZER INC-202201041435,PFIZER,,66.0,YR,,F,Y,89.0,KG,20220810,,HP,CA,CA,2022,Q3,Elderly
211988741,21198874,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,,20220804.0,20220811,20220811,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-185471",BOEHRINGER INGELHEIM,"Mahfooz R, Khan M, Al Hennawi H, Khedr A. SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review. Cureus. 2022 Jun 23; 14:6: 26267-",45.0,YR,A,F,Y,,,20220811,,HP,US,US,2022,Q3,Adult
211996461,21199646,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,N,,Unknown,,,,,,,2022,Q3,Adenocarcinoma pancreas,,2022,Q3,1,I,,20220802.0,20220811,20220811,EXP,,RU-NOVOPROD-946163,NOVO NORDISK,,59.0,YR,,M,Y,,,20220811,,MD,RU,RU,2022,Q3,Adult
212022841,21202284,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,Unknown,,206111.0,,,,,2022,Q3,Blood ketone body increased,,2022,Q3,1,I,,20220811.0,20220811,20220811,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186601",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20220811,,MD,IL,IL,2022,Q3,Elderly
212022841,21202284,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,Unknown,,206111.0,,,,,2022,Q3,Renal impairment,,2022,Q3,1,I,,20220811.0,20220811,20220811,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186601",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20220811,,MD,IL,IL,2022,Q3,Elderly
212022841,21202284,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,Unknown,,206111.0,,,,,2022,Q3,Diarrhoea,,2022,Q3,1,I,,20220811.0,20220811,20220811,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186601",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20220811,,MD,IL,IL,2022,Q3,Elderly
212022841,21202284,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,Unknown,,206111.0,,,,,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220811.0,20220811,20220811,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186601",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20220811,,MD,IL,IL,2022,Q3,Elderly
212022841,21202284,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,Unknown,,206111.0,,,,,2022,Q3,Blood lactic acid increased,,2022,Q3,1,I,,20220811.0,20220811,20220811,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186601",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20220811,,MD,IL,IL,2022,Q3,Elderly
212022841,21202284,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,Unknown,,206111.0,,,,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220811.0,20220811,20220811,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186601",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20220811,,MD,IL,IL,2022,Q3,Elderly
212025751,21202575,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1 Tablet(s);?,,,,D,,20230711.0,,,,Tablet,,2022,Q3,Blood creatine increased,,2022,Q3,1,I,20220809.0,,20220811,20220811,DIR,627072,,FDA-CTU,,77.0,YR,,M,N,92.25,KG,20220811,N,CN,US,,2022,Q3,Elderly
212025751,21202575,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1 Tablet(s);?,,,,D,,20230711.0,,,,Tablet,,2022,Q3,Renal disorder,,2022,Q3,1,I,20220809.0,,20220811,20220811,DIR,627072,,FDA-CTU,,77.0,YR,,M,N,92.25,KG,20220811,N,CN,US,,2022,Q3,Elderly
212025751,21202575,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1 Tablet(s);?,,,,D,,20230711.0,,,,Tablet,,2022,Q3,Blood urea,,2022,Q3,1,I,20220809.0,,20220811,20220811,DIR,627072,,FDA-CTU,,77.0,YR,,M,N,92.25,KG,20220811,N,CN,US,,2022,Q3,Elderly
212025751,21202575,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1 Tablet(s);?,,,,D,,20230711.0,,,,Tablet,,2022,Q3,Weight decreased,,2022,Q3,1,I,20220809.0,,20220811,20220811,DIR,627072,,FDA-CTU,,77.0,YR,,M,N,92.25,KG,20220811,N,CN,US,,2022,Q3,Elderly
212025751,21202575,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER QUANTITY : 1 Tablet(s);?,,,,D,,20230711.0,,,,Tablet,,2022,Q3,Glomerular filtration rate decreased,,2022,Q3,1,I,20220809.0,,20220811,20220811,DIR,627072,,FDA-CTU,,77.0,YR,,M,N,92.25,KG,20220811,N,CN,US,,2022,Q3,Elderly
212086892,21208689,6,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,dose and frequency unknown,,,,,,,,,,Unknown,,2022,Q3,Interstitial lung disease,,2022,Q3,2,F,20220805.0,20220830.0,20220812,20220907,PER,,JP-Eisai Medical Research-EC-2022-120925,EISAI,,64.0,YR,A,F,Y,,,20220907,,MD,JP,JP,2022,Q3,Adult
212095451,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood creatinine increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood potassium increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Body mass index increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood pressure systolic increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Creatinine renal clearance decreased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Weight increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood glucose increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Haemolysis,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Glycosylated haemoglobin increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood creatinine increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood potassium increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Body mass index increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood pressure systolic increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Creatinine renal clearance decreased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Weight increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood glucose increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Haemolysis,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Glycosylated haemoglobin increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood creatinine increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood potassium increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Body mass index increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood pressure systolic increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Creatinine renal clearance decreased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Weight increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood glucose increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Haemolysis,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Glycosylated haemoglobin increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood creatinine increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood potassium increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Body mass index increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood pressure systolic increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Creatinine renal clearance decreased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Weight increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood glucose increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Haemolysis,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Glycosylated haemoglobin increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood creatinine increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood potassium increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Body mass index increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood pressure systolic increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Creatinine renal clearance decreased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Weight increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Blood glucose increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Haemolysis,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212095451,21209545,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, BID",,,U,,,,,10.0,MG,,BID,2022,Q3,Glycosylated haemoglobin increased,,2022,Q3,1,I,,20220808.0,20220813,20220813,EXP,,NVSC2022TH180125,NOVARTIS,,66.0,YR,,F,Y,,,20220813,,MD,TH,TH,2022,Q3,Elderly
212117911,21211791,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2022,Q3,Delirium,,2022,Q3,1,I,20220413.0,,20220812,20220812,DIR,FDA-CDER-CTU-2022-64777,,FDA-CTU,,74.0,YR,,M,N,110.0,KG,20220719,N,PH,US,,2022,Q3,Elderly
212117911,21211791,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2022,Q3,Mental status changes,,2022,Q3,1,I,20220413.0,,20220812,20220812,DIR,FDA-CDER-CTU-2022-64777,,FDA-CTU,,74.0,YR,,M,N,110.0,KG,20220719,N,PH,US,,2022,Q3,Elderly
212117911,21211791,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2022,Q3,Blood glucose increased,,2022,Q3,1,I,20220413.0,,20220812,20220812,DIR,FDA-CDER-CTU-2022-64777,,FDA-CTU,,74.0,YR,,M,N,110.0,KG,20220719,N,PH,US,,2022,Q3,Elderly
212124581,21212458,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO?,,,D,D,,,,,,Tablet,QD,2022,Q3,Therapy cessation,,2022,Q3,1,I,20220207.0,,20220812,20220812,DIR,FDA-CDER-CTU-2022-64808,,FDA-CTU,,75.0,YR,,M,N,66.68,KG,20220418,N,HP,US,,2022,Q3,Elderly
212124581,21212458,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO?,,,D,D,,,,,,Tablet,QD,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,20220207.0,,20220812,20220812,DIR,FDA-CDER-CTU-2022-64808,,FDA-CTU,,75.0,YR,,M,N,66.68,KG,20220418,N,HP,US,,2022,Q3,Elderly
212129771,21212977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Bundle branch block left,,2022,Q3,1,I,,20220810.0,20220815,20220815,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186600",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20220815,,MD,DE,DE,2022,Q3,Elderly
212129771,21212977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220810.0,20220815,20220815,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-186600",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20220815,,MD,DE,DE,2022,Q3,Elderly
212131071,21213107,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2022,Q3,Polycythaemia,,2022,Q3,1,I,20220308.0,,20220815,20220815,DIR,627538,,FDA-CTU,,77.0,YR,,M,N,91.0,KG,20220815,N,MD,US,,2022,Q3,Elderly
212131071,21213107,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Polycythaemia,,2022,Q3,1,I,20220308.0,,20220815,20220815,DIR,627538,,FDA-CTU,,77.0,YR,,M,N,91.0,KG,20220815,N,MD,US,,2022,Q3,Elderly
212192011,21219201,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q3,Renal failure,,2022,Q3,1,I,20220811.0,20220812.0,20220816,20220816,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-089845,BRISTOL MYERS SQUIBB,,77.0,YR,E,F,Y,,,20220817,,CN,US,US,2022,Q3,Elderly
212202661,21220266,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Pruritus genital,,2022,Q3,1,I,20220729.0,20220816.0,20220817,20220817,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187280",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,,,20220817,,HP,SG,SG,2022,Q3,Adult
212203201,21220320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,20220713.0,20220816.0,20220817,20220817,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187278",BOEHRINGER INGELHEIM,,83.0,YR,E,M,Y,,,20220817,,HP,SG,SG,2022,Q3,Elderly
212226651,21222665,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Anaemia,,2022,Q3,1,I,20220801.0,20220815.0,20220817,20220817,PER,,US-PFIZER INC-PV202200044317,PFIZER,,68.0,YR,,F,Y,,,20220817,,CN,US,US,2022,Q3,Elderly
212227661,21222766,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG  AM PO?,,,Y,,,,,10.0,MG,,999,2022,Q3,Rash,,2022,Q3,1,I,20220810.0,,20220816,20220816,DIR,FDA-CDER-CTU-2022-65703,,FDA-CTU,,74.0,YR,,M,N,84.0,KG,20220815,N,HP,US,,2022,Q3,Elderly
212229061,21222906,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO?,,,Y,D,,,,,,,QD,2022,Q3,Oxygen saturation decreased,,2022,Q3,1,I,20220607.0,,20220816,20220816,DIR,FDA-CDER-CTU-2022-65725,,FDA-CTU,,70.0,YR,,M,N,92.08,KG,20220812,N,HP,US,,2022,Q3,Elderly
212229061,21222906,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO?,,,Y,D,,,,,,,QD,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,20220607.0,,20220816,20220816,DIR,FDA-CDER-CTU-2022-65725,,FDA-CTU,,70.0,YR,,M,N,92.08,KG,20220812,N,HP,US,,2022,Q3,Elderly
212229061,21222906,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO?,,,Y,D,,,,,,,QD,2022,Q3,Lung opacity,,2022,Q3,1,I,20220607.0,,20220816,20220816,DIR,FDA-CDER-CTU-2022-65725,,FDA-CTU,,70.0,YR,,M,N,92.08,KG,20220812,N,HP,US,,2022,Q3,Elderly
212229061,21222906,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO?,,,Y,D,,,,,,,QD,2022,Q3,Infection,,2022,Q3,1,I,20220607.0,,20220816,20220816,DIR,FDA-CDER-CTU-2022-65725,,FDA-CTU,,70.0,YR,,M,N,92.08,KG,20220812,N,HP,US,,2022,Q3,Elderly
212229801,21222980,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Infection,,2022,Q3,1,I,,20220808.0,20220817,20220817,PER,,BE-AMGEN-TURSP2022138187,AMGEN,Veiga-da-cunha M.. Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5. Journal of Inherited Metabolic Disease. 2022;45(4):759-768,2.0,MON,I,M,Y,,,20220817,,HP,BE,TR,2022,Q3,Child
212229801,21222980,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,"Ear, nose and throat infection",,2022,Q3,1,I,,20220808.0,20220817,20220817,PER,,BE-AMGEN-TURSP2022138187,AMGEN,Veiga-da-cunha M.. Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5. Journal of Inherited Metabolic Disease. 2022;45(4):759-768,2.0,MON,I,M,Y,,,20220817,,HP,BE,TR,2022,Q3,Child
212229801,21222980,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Therapeutic product effect incomplete,,2022,Q3,1,I,,20220808.0,20220817,20220817,PER,,BE-AMGEN-TURSP2022138187,AMGEN,Veiga-da-cunha M.. Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5. Journal of Inherited Metabolic Disease. 2022;45(4):759-768,2.0,MON,I,M,Y,,,20220817,,HP,BE,TR,2022,Q3,Child
212229801,21222980,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Sinusitis,,2022,Q3,1,I,,20220808.0,20220817,20220817,PER,,BE-AMGEN-TURSP2022138187,AMGEN,Veiga-da-cunha M.. Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5. Journal of Inherited Metabolic Disease. 2022;45(4):759-768,2.0,MON,I,M,Y,,,20220817,,HP,BE,TR,2022,Q3,Child
212229801,21222980,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Neutrophil count decreased,,2022,Q3,1,I,,20220808.0,20220817,20220817,PER,,BE-AMGEN-TURSP2022138187,AMGEN,Veiga-da-cunha M.. Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5. Journal of Inherited Metabolic Disease. 2022;45(4):759-768,2.0,MON,I,M,Y,,,20220817,,HP,BE,TR,2022,Q3,Child
212229801,21222980,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Mastoiditis,,2022,Q3,1,I,,20220808.0,20220817,20220817,PER,,BE-AMGEN-TURSP2022138187,AMGEN,Veiga-da-cunha M.. Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5. Journal of Inherited Metabolic Disease. 2022;45(4):759-768,2.0,MON,I,M,Y,,,20220817,,HP,BE,TR,2022,Q3,Child
212229801,21222980,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Gastroenteritis,,2022,Q3,1,I,,20220808.0,20220817,20220817,PER,,BE-AMGEN-TURSP2022138187,AMGEN,Veiga-da-cunha M.. Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5. Journal of Inherited Metabolic Disease. 2022;45(4):759-768,2.0,MON,I,M,Y,,,20220817,,HP,BE,TR,2022,Q3,Child
212231301,21223130,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,Y,N,,,,12.5,MG,,QD,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,20220516.0,,20220816,20220816,DIR,FDA-CDER-CTU-2022-65744,,FDA-CTU,,49.0,YR,,M,N,118.0,KG,20220719,N,HP,US,,2022,Q3,Adult
212232251,21223225,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Debridement,,2022,Q3,1,I,20220304.0,,20220816,20220816,DIR,FDA-CDER-CTU-2022-65747,,FDA-CTU,,67.0,YR,,M,N,,,20220519,N,PH,US,,2022,Q3,Elderly
212232251,21223225,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Fournier's gangrene,,2022,Q3,1,I,20220304.0,,20220816,20220816,DIR,FDA-CDER-CTU-2022-65747,,FDA-CTU,,67.0,YR,,M,N,,,20220519,N,PH,US,,2022,Q3,Elderly
212297231,21229723,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Dyskinesia,,2022,Q3,1,I,20220806.0,20220818.0,20220818,20220818,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187745",BOEHRINGER INGELHEIM,,89.0,YR,E,F,Y,,,20220818,,PH,GB,GB,2022,Q3,Elderly
212297761,21229776,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Fournier's gangrene,,2022,Q3,1,I,20220717.0,20220818.0,20220818,20220818,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187749",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,,,20220818,,PH,GB,GB,2022,Q3,Adult
212303261,21230326,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Vulvovaginal pruritus,,2022,Q3,1,I,20220802.0,20220816.0,20220818,20220818,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187524",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,,,20220818,,HP,GB,GB,2022,Q3,Elderly
212303261,21230326,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Nausea,,2022,Q3,1,I,20220802.0,20220816.0,20220818,20220818,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187524",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,,,20220818,,HP,GB,GB,2022,Q3,Elderly
212303261,21230326,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Vomiting,,2022,Q3,1,I,20220802.0,20220816.0,20220818,20220818,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187524",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,,,20220818,,HP,GB,GB,2022,Q3,Elderly
212303261,21230326,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Urinary tract disorder,,2022,Q3,1,I,20220802.0,20220816.0,20220818,20220818,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187524",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,,,20220818,,HP,GB,GB,2022,Q3,Elderly
212339583,21233958,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2022,Q3,Psoriasis,,2022,Q3,3,F,20220517.0,20220923.0,20220819,20220928,EXP,PT-INFARMED-T202208-981,PT-PFIZER INC-202201055167,PFIZER,,70.0,YR,,M,Y,61.0,KG,20220928,,PH,PT,PT,2022,Q3,Elderly
212380861,21238086,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, qd",,,U,U,UNK,,,,,,QD,2022,Q3,Fall,,2022,Q3,1,I,,20220809.0,20220822,20220822,EXP,,US-MYLANLABS-2022M1086532,MYLAN,"Meyer KS, Roberts J, Sasser Croley K. Part Four: Identifying, Managing, and Preventing Adverse Effects of Diabetes Medications. Sr-Care-Pharm 2022;37(8):310-316.",81.0,YR,,F,Y,,,20220822,,PH,US,US,2022,Q3,Elderly
212380861,21238086,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, qd",,,U,U,UNK,,,,,,QD,2022,Q3,Hypoglycaemia,,2022,Q3,1,I,,20220809.0,20220822,20220822,EXP,,US-MYLANLABS-2022M1086532,MYLAN,"Meyer KS, Roberts J, Sasser Croley K. Part Four: Identifying, Managing, and Preventing Adverse Effects of Diabetes Medications. Sr-Care-Pharm 2022;37(8):310-316.",81.0,YR,,F,Y,,,20220822,,PH,US,US,2022,Q3,Elderly
212380861,21238086,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, qd",,,U,U,UNK,,,,,,QD,2022,Q3,Drug ineffective,,2022,Q3,1,I,,20220809.0,20220822,20220822,EXP,,US-MYLANLABS-2022M1086532,MYLAN,"Meyer KS, Roberts J, Sasser Croley K. Part Four: Identifying, Managing, and Preventing Adverse Effects of Diabetes Medications. Sr-Care-Pharm 2022;37(8):310-316.",81.0,YR,,F,Y,,,20220822,,PH,US,US,2022,Q3,Elderly
212382693,21238269,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Unknown,,,,,,,,,,,,2022,Q3,Psoriasis,,2022,Q3,3,F,20220517.0,20220926.0,20220822,20220928,EXP,PT-INFARMED-T202208-981,PT-009507513-2208PRT005951,MERCK,,70.0,YR,,M,Y,61.0,KG,20220928,,PH,PT,PT,2022,Q3,Elderly
212409721,21240972,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,take one daily,,,,,,,,,,,,2022,Q3,Angioedema,,2022,Q3,1,I,20220815.0,20220816.0,20220823,20220823,EXP,,GB-AUROBINDO-AUR-APL-2022-033186,AUROBINDO,,56.0,YR,,M,Y,93.0,KG,20220823,,PH,GB,GB,2022,Q3,Adult
212426581,21242658,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Drug ineffective,,2022,Q3,1,I,,20220819.0,20220823,20220823,EXP,CA-MHPD-E2B_04938746,CA-Accord-274495,ACCORD,,37.0,YR,A,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Adult
212426581,21242658,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Abdominal discomfort,,2022,Q3,1,I,,20220819.0,20220823,20220823,EXP,CA-MHPD-E2B_04938746,CA-Accord-274495,ACCORD,,37.0,YR,A,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Adult
212426581,21242658,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Alopecia,,2022,Q3,1,I,,20220819.0,20220823,20220823,EXP,CA-MHPD-E2B_04938746,CA-Accord-274495,ACCORD,,37.0,YR,A,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Adult
212426581,21242658,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Thrombosis,,2022,Q3,1,I,,20220819.0,20220823,20220823,EXP,CA-MHPD-E2B_04938746,CA-Accord-274495,ACCORD,,37.0,YR,A,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Adult
212426581,21242658,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Mouth haemorrhage,,2022,Q3,1,I,,20220819.0,20220823,20220823,EXP,CA-MHPD-E2B_04938746,CA-Accord-274495,ACCORD,,37.0,YR,A,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Adult
212426581,21242658,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Epistaxis,,2022,Q3,1,I,,20220819.0,20220823,20220823,EXP,CA-MHPD-E2B_04938746,CA-Accord-274495,ACCORD,,37.0,YR,A,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Adult
212446951,21244695,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Off label use,,2022,Q3,1,I,20220101.0,20220819.0,20220823,20220823,EXP,,DE-AstraZeneca-2022A292243,ASTRAZENECA,,69.0,YR,,M,Y,101.0,KG,20220823,,MD,DE,,2022,Q3,Elderly
212446951,21244695,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Intentional product misuse,,2022,Q3,1,I,20220101.0,20220819.0,20220823,20220823,EXP,,DE-AstraZeneca-2022A292243,ASTRAZENECA,,69.0,YR,,M,Y,101.0,KG,20220823,,MD,DE,,2022,Q3,Elderly
212446951,21244695,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Phimosis,,2022,Q3,1,I,20220101.0,20220819.0,20220823,20220823,EXP,,DE-AstraZeneca-2022A292243,ASTRAZENECA,,69.0,YR,,M,Y,101.0,KG,20220823,,MD,DE,,2022,Q3,Elderly
212446951,21244695,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Fungal infection,,2022,Q3,1,I,20220101.0,20220819.0,20220823,20220823,EXP,,DE-AstraZeneca-2022A292243,ASTRAZENECA,,69.0,YR,,M,Y,101.0,KG,20220823,,MD,DE,,2022,Q3,Elderly
212446951,21244695,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Ketoacidosis,,2022,Q3,1,I,20220101.0,20220819.0,20220823,20220823,EXP,,DE-AstraZeneca-2022A292243,ASTRAZENECA,,69.0,YR,,M,Y,101.0,KG,20220823,,MD,DE,,2022,Q3,Elderly
212510682,21251068,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q3,Protein urine present,,2022,Q3,2,F,,20220830.0,20220824,20220904,EXP,,NVSJ2022JP096186,NOVARTIS,,51.0,YR,,M,Y,,,20220905,,MD,JP,JP,2022,Q3,Adult
212518431,21251843,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Vaginal discharge,,2022,Q3,1,I,20220811.0,20220824.0,20220825,20220825,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-188677",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20220825,,HP,SG,SG,2022,Q3,Elderly
212518431,21251843,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Vulvovaginal pruritus,,2022,Q3,1,I,20220811.0,20220824.0,20220825,20220825,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-188677",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20220825,,HP,SG,SG,2022,Q3,Elderly
212551292,21255129,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 Dosage forms Daily;,,,U,,,,,,,,QD,2022,Q3,Hypoglycaemia,,2022,Q3,2,F,,20220901.0,20220825,20220913,EXP,,US-TEVA-2022-US-2066567,TEVA,,81.0,YR,E,F,Y,,,20220913,,PH,US,US,2022,Q3,Elderly
212551292,21255129,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 Dosage forms Daily;,,,U,,,,,,,,QD,2022,Q3,Drug ineffective,,2022,Q3,2,F,,20220901.0,20220825,20220913,EXP,,US-TEVA-2022-US-2066567,TEVA,,81.0,YR,E,F,Y,,,20220913,,PH,US,US,2022,Q3,Elderly
212551292,21255129,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 Dosage forms Daily;,,,U,,,,,,,,QD,2022,Q3,Fall,,2022,Q3,2,F,,20220901.0,20220825,20220913,EXP,,US-TEVA-2022-US-2066567,TEVA,,81.0,YR,E,F,Y,,,20220913,,PH,US,US,2022,Q3,Elderly
212560451,21256045,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,212614.0,,,Tablet,Q12H,2022,Q3,Incorrect dose administered,,2022,Q3,1,I,20220615.0,20220825.0,20220825,20220825,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-189041",BOEHRINGER INGELHEIM,,65.0,YR,E,F,Y,,,20220826,,CN,US,US,2022,Q3,Elderly
212560451,21256045,2,SS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,212614.0,,,Tablet,QD,2022,Q3,Incorrect dose administered,,2022,Q3,1,I,20220615.0,20220825.0,20220825,20220825,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-189041",BOEHRINGER INGELHEIM,,65.0,YR,E,F,Y,,,20220826,,CN,US,US,2022,Q3,Elderly
212568641,21256864,37,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Eosinophilic colitis,,2022,Q3,1,I,20220705.0,20220812.0,20220826,20220826,EXP,,CH-AstraZeneca-2022A292916,ASTRAZENECA,,74.0,YR,,F,Y,,,20220826,,MD,CH,,2022,Q3,Elderly
212568891,21256889,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Urinary retention,,2022,Q3,1,I,20150213.0,20220819.0,20220826,20220826,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187926",BOEHRINGER INGELHEIM,"Brock G, Lane S, Roosevelt T. Emphysematous Cystitis and Urinary Retention in a Male Patient With Diabetes Mellitus Type 2 Treated With Empagliflozin. AACE Clinical Case Reports. 2022; 8:4: 163-165.",62.0,YR,A,M,Y,,,20220826,,MD,US,US,2022,Q3,Adult
212568891,21256889,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Emphysematous cystitis,,2022,Q3,1,I,20150213.0,20220819.0,20220826,20220826,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187926",BOEHRINGER INGELHEIM,"Brock G, Lane S, Roosevelt T. Emphysematous Cystitis and Urinary Retention in a Male Patient With Diabetes Mellitus Type 2 Treated With Empagliflozin. AACE Clinical Case Reports. 2022; 8:4: 163-165.",62.0,YR,A,M,Y,,,20220826,,MD,US,US,2022,Q3,Adult
212599681,21259968,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2022,Q3,Hyponatraemia,,2022,Q3,1,I,,20220824.0,20220826,20220826,EXP,,NVSC2022US190545,NOVARTIS,"Corpuz E, Dean J, Cahill M. Pass the salt? Acute asymptomatic hyponatremia following inpatient initiation of angiotensin receptor-neprilysin inhibitor. JOURNAL OF GENERAL INTERNAL MEDICINE. 2022;37:S497",71.0,YR,,F,Y,,,20220826,,HP,US,US,2022,Q3,Elderly
212613191,21261319,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,,,,,,,QD,2022,Q3,Hyperhidrosis,,2022,Q3,1,I,20220825.0,20220826.0,20220827,20220827,EXP,GB-MHRA-TPP2053137C5336534YC1661415942071,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-189150",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,74.0,KG,20220827,,MD,GB,GB,2022,Q3,Elderly
212613191,21261319,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,,,,,,,QD,2022,Q3,Abdominal distension,,2022,Q3,1,I,20220825.0,20220826.0,20220827,20220827,EXP,GB-MHRA-TPP2053137C5336534YC1661415942071,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-189150",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,74.0,KG,20220827,,MD,GB,GB,2022,Q3,Elderly
212613191,21261319,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,,,,,,,QD,2022,Q3,Nausea,,2022,Q3,1,I,20220825.0,20220826.0,20220827,20220827,EXP,GB-MHRA-TPP2053137C5336534YC1661415942071,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-189150",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,74.0,KG,20220827,,MD,GB,GB,2022,Q3,Elderly
212649191,21264919,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,,,Tablet,QD,2022,Q3,Blood glucose decreased,,2022,Q3,1,I,20220814.0,,20220826,20220826,DIR,FDA-CDER-CTU-2022-68532,,FDA-CTU,,84.0,YR,,M,N,,,20220819,N,PH,US,,2022,Q3,Elderly
212649191,21264919,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,,,Tablet,QD,2022,Q3,Cystitis,,2022,Q3,1,I,20220814.0,,20220826,20220826,DIR,FDA-CDER-CTU-2022-68532,,FDA-CTU,,84.0,YR,,M,N,,,20220819,N,PH,US,,2022,Q3,Elderly
212649191,21264919,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,,,Tablet,QD,2022,Q3,Dysuria,,2022,Q3,1,I,20220814.0,,20220826,20220826,DIR,FDA-CDER-CTU-2022-68532,,FDA-CTU,,84.0,YR,,M,N,,,20220819,N,PH,US,,2022,Q3,Elderly
212649191,21264919,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,,,Tablet,QD,2022,Q3,Urinary tract infection,,2022,Q3,1,I,20220814.0,,20220826,20220826,DIR,FDA-CDER-CTU-2022-68532,,FDA-CTU,,84.0,YR,,M,N,,,20220819,N,PH,US,,2022,Q3,Elderly
212649191,21264919,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,,,Tablet,QD,2022,Q3,Haematuria,,2022,Q3,1,I,20220814.0,,20220826,20220826,DIR,FDA-CDER-CTU-2022-68532,,FDA-CTU,,84.0,YR,,M,N,,,20220819,N,PH,US,,2022,Q3,Elderly
212651651,21265165,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Blood glucose increased,,2022,Q3,1,I,20220824.0,,20220826,20220826,DIR,629140,,FDA-CTU,,63.0,YR,,F,N,83.0,KG,20220826,N,PH,US,,2022,Q3,Adult
212651651,21265165,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Nausea,,2022,Q3,1,I,20220824.0,,20220826,20220826,DIR,629140,,FDA-CTU,,63.0,YR,,F,N,83.0,KG,20220826,N,PH,US,,2022,Q3,Adult
212651651,21265165,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Vaginal discharge,,2022,Q3,1,I,20220824.0,,20220826,20220826,DIR,629140,,FDA-CTU,,63.0,YR,,F,N,83.0,KG,20220826,N,PH,US,,2022,Q3,Adult
212651651,21265165,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,20220824.0,,20220826,20220826,DIR,629140,,FDA-CTU,,63.0,YR,,F,N,83.0,KG,20220826,N,PH,US,,2022,Q3,Adult
212651651,21265165,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Diabetes insipidus,,2022,Q3,1,I,20220824.0,,20220826,20220826,DIR,629140,,FDA-CTU,,63.0,YR,,F,N,83.0,KG,20220826,N,PH,US,,2022,Q3,Adult
212651651,21265165,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Vomiting,,2022,Q3,1,I,20220824.0,,20220826,20220826,DIR,629140,,FDA-CTU,,63.0,YR,,F,N,83.0,KG,20220826,N,PH,US,,2022,Q3,Adult
212651651,21265165,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Polydipsia,,2022,Q3,1,I,20220824.0,,20220826,20220826,DIR,629140,,FDA-CTU,,63.0,YR,,F,N,83.0,KG,20220826,N,PH,US,,2022,Q3,Adult
212841621,21284162,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2022,Q3,Live birth,,2022,Q3,1,I,,20220822.0,20220902,20220902,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-352963,RANBAXY,"Grunert SC, Rosenbaum-Fabian S, Schumann A, Selbitz A-C, Merz W, Gieselmann A, et al. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib. JIMD Rep. 2022;63(4):303-308",35.0,YR,,F,Y,,,20220902,,HP,DE,DE,2022,Q3,Adult
212841621,21284162,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2022,Q3,Therapy non-responder,,2022,Q3,1,I,,20220822.0,20220902,20220902,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-352963,RANBAXY,"Grunert SC, Rosenbaum-Fabian S, Schumann A, Selbitz A-C, Merz W, Gieselmann A, et al. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib. JIMD Rep. 2022;63(4):303-308",35.0,YR,,F,Y,,,20220902,,HP,DE,DE,2022,Q3,Adult
212841621,21284162,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2022,Q3,Oral disorder,,2022,Q3,1,I,,20220822.0,20220902,20220902,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-352963,RANBAXY,"Grunert SC, Rosenbaum-Fabian S, Schumann A, Selbitz A-C, Merz W, Gieselmann A, et al. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib. JIMD Rep. 2022;63(4):303-308",35.0,YR,,F,Y,,,20220902,,HP,DE,DE,2022,Q3,Adult
212841621,21284162,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2022,Q3,Exposure during pregnancy,,2022,Q3,1,I,,20220822.0,20220902,20220902,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-352963,RANBAXY,"Grunert SC, Rosenbaum-Fabian S, Schumann A, Selbitz A-C, Merz W, Gieselmann A, et al. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib. JIMD Rep. 2022;63(4):303-308",35.0,YR,,F,Y,,,20220902,,HP,DE,DE,2022,Q3,Adult
212841621,21284162,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"15 milligram, Daily",,,U,,,,,15.0,MG,,,2022,Q3,Live birth,,2022,Q3,1,I,,20220822.0,20220902,20220902,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-352963,RANBAXY,"Grunert SC, Rosenbaum-Fabian S, Schumann A, Selbitz A-C, Merz W, Gieselmann A, et al. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib. JIMD Rep. 2022;63(4):303-308",35.0,YR,,F,Y,,,20220902,,HP,DE,DE,2022,Q3,Adult
212841621,21284162,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"15 milligram, Daily",,,U,,,,,15.0,MG,,,2022,Q3,Therapy non-responder,,2022,Q3,1,I,,20220822.0,20220902,20220902,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-352963,RANBAXY,"Grunert SC, Rosenbaum-Fabian S, Schumann A, Selbitz A-C, Merz W, Gieselmann A, et al. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib. JIMD Rep. 2022;63(4):303-308",35.0,YR,,F,Y,,,20220902,,HP,DE,DE,2022,Q3,Adult
212841621,21284162,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"15 milligram, Daily",,,U,,,,,15.0,MG,,,2022,Q3,Oral disorder,,2022,Q3,1,I,,20220822.0,20220902,20220902,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-352963,RANBAXY,"Grunert SC, Rosenbaum-Fabian S, Schumann A, Selbitz A-C, Merz W, Gieselmann A, et al. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib. JIMD Rep. 2022;63(4):303-308",35.0,YR,,F,Y,,,20220902,,HP,DE,DE,2022,Q3,Adult
212841621,21284162,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"15 milligram, Daily",,,U,,,,,15.0,MG,,,2022,Q3,Exposure during pregnancy,,2022,Q3,1,I,,20220822.0,20220902,20220902,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-352963,RANBAXY,"Grunert SC, Rosenbaum-Fabian S, Schumann A, Selbitz A-C, Merz W, Gieselmann A, et al. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib. JIMD Rep. 2022;63(4):303-308",35.0,YR,,F,Y,,,20220902,,HP,DE,DE,2022,Q3,Adult
212841621,21284162,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 milligram, Daily",,,U,,,,,20.0,MG,,,2022,Q3,Live birth,,2022,Q3,1,I,,20220822.0,20220902,20220902,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-352963,RANBAXY,"Grunert SC, Rosenbaum-Fabian S, Schumann A, Selbitz A-C, Merz W, Gieselmann A, et al. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib. JIMD Rep. 2022;63(4):303-308",35.0,YR,,F,Y,,,20220902,,HP,DE,DE,2022,Q3,Adult
212841621,21284162,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 milligram, Daily",,,U,,,,,20.0,MG,,,2022,Q3,Therapy non-responder,,2022,Q3,1,I,,20220822.0,20220902,20220902,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-352963,RANBAXY,"Grunert SC, Rosenbaum-Fabian S, Schumann A, Selbitz A-C, Merz W, Gieselmann A, et al. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib. JIMD Rep. 2022;63(4):303-308",35.0,YR,,F,Y,,,20220902,,HP,DE,DE,2022,Q3,Adult
212841621,21284162,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 milligram, Daily",,,U,,,,,20.0,MG,,,2022,Q3,Oral disorder,,2022,Q3,1,I,,20220822.0,20220902,20220902,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-352963,RANBAXY,"Grunert SC, Rosenbaum-Fabian S, Schumann A, Selbitz A-C, Merz W, Gieselmann A, et al. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib. JIMD Rep. 2022;63(4):303-308",35.0,YR,,F,Y,,,20220902,,HP,DE,DE,2022,Q3,Adult
212841621,21284162,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 milligram, Daily",,,U,,,,,20.0,MG,,,2022,Q3,Exposure during pregnancy,,2022,Q3,1,I,,20220822.0,20220902,20220902,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-352963,RANBAXY,"Grunert SC, Rosenbaum-Fabian S, Schumann A, Selbitz A-C, Merz W, Gieselmann A, et al. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib. JIMD Rep. 2022;63(4):303-308",35.0,YR,,F,Y,,,20220902,,HP,DE,DE,2022,Q3,Adult
212868632,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Ileus,,2022,Q3,2,F,,20220824.0,20220902,20220907,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220907,,HP,AU,AU,2022,Q3,Elderly
212868632,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Pneumonia,,2022,Q3,2,F,,20220824.0,20220902,20220907,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220907,,HP,AU,AU,2022,Q3,Elderly
212868632,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Hypernatraemia,,2022,Q3,2,F,,20220824.0,20220902,20220907,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220907,,HP,AU,AU,2022,Q3,Elderly
212868632,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Toxicity to various agents,,2022,Q3,2,F,,20220824.0,20220902,20220907,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220907,,HP,AU,AU,2022,Q3,Elderly
212868632,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Neurotoxicity,,2022,Q3,2,F,,20220824.0,20220902,20220907,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220907,,HP,AU,AU,2022,Q3,Elderly
212868632,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Acute kidney injury,,2022,Q3,2,F,,20220824.0,20220902,20220907,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220907,,HP,AU,AU,2022,Q3,Elderly
212868632,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Nephrogenic diabetes insipidus,,2022,Q3,2,F,,20220824.0,20220902,20220907,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220907,,HP,AU,AU,2022,Q3,Elderly
212868632,21286863,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Hypovolaemia,,2022,Q3,2,F,,20220824.0,20220902,20220907,EXP,,AU-DSJP-DSJ-2022-131393,DAIICHI,"Reimann F, Whyte I. Chronic lithium toxicity. Aust Prescr. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220907,,HP,AU,AU,2022,Q3,Elderly
212898863,21289886,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Hypovolaemia,,2022,Q3,3,F,,20220824.0,20220902,20220914,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
212898863,21289886,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Pneumonia,,2022,Q3,3,F,,20220824.0,20220902,20220914,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
212898863,21289886,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Ileus,,2022,Q3,3,F,,20220824.0,20220902,20220914,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
212898863,21289886,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Acute kidney injury,,2022,Q3,3,F,,20220824.0,20220902,20220914,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
212898863,21289886,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Toxicity to various agents,,2022,Q3,3,F,,20220824.0,20220902,20220914,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
212898863,21289886,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Hypernatraemia,,2022,Q3,3,F,,20220824.0,20220902,20220914,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
212898863,21289886,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Nephrogenic diabetes insipidus,,2022,Q3,3,F,,20220824.0,20220902,20220914,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
212898863,21289886,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q3,Neurotoxicity,,2022,Q3,3,F,,20220824.0,20220902,20220914,EXP,,AU-ORGANON-O2209AUS000148,ORGANON,"Reimann F, Whyte I.. Chronic lithium toxicity.. Aust Prescr.. 2022;45(3):93-94",66.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
212926961,21292696,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12.5x1000, 1 tablet in the morning and another at night",,,U,,D82944,,206111.0,,,Tablet,Q12H,2022,Q3,Bladder catheterisation,,2022,Q3,1,I,20220101.0,20220901.0,20220905,20220905,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-190359",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,70.0,KG,20220905,,CN,MX,MX,2022,Q3,Adult
212926961,21292696,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12.5x1000, 1 tablet in the morning and another at night",,,U,,D82944,,206111.0,,,Tablet,Q12H,2022,Q3,Therapeutic response unexpected,,2022,Q3,1,I,20220101.0,20220901.0,20220905,20220905,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-190359",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,70.0,KG,20220905,,CN,MX,MX,2022,Q3,Adult
212926961,21292696,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12.5x1000, 1 tablet in the morning and another at night",,,U,,D82944,,206111.0,,,Tablet,Q12H,2022,Q3,Prostate cancer,,2022,Q3,1,I,20220101.0,20220901.0,20220905,20220905,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-190359",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,70.0,KG,20220905,,CN,MX,MX,2022,Q3,Adult
212926961,21292696,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,206111.0,,,,,2022,Q3,Bladder catheterisation,,2022,Q3,1,I,20220101.0,20220901.0,20220905,20220905,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-190359",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,70.0,KG,20220905,,CN,MX,MX,2022,Q3,Adult
212926961,21292696,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,206111.0,,,,,2022,Q3,Therapeutic response unexpected,,2022,Q3,1,I,20220101.0,20220901.0,20220905,20220905,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-190359",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,70.0,KG,20220905,,CN,MX,MX,2022,Q3,Adult
212926961,21292696,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,206111.0,,,,,2022,Q3,Prostate cancer,,2022,Q3,1,I,20220101.0,20220901.0,20220905,20220905,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-190359",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,70.0,KG,20220905,,CN,MX,MX,2022,Q3,Adult
212959171,21295917,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Amyloidosis,,2022,Q3,1,I,,20220904.0,20220906,20220906,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-190499",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,,,20220906,,MD,AT,AT,2022,Q3,Elderly
212959171,21295917,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Fatigue,,2022,Q3,1,I,,20220904.0,20220906,20220906,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-190499",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,,,20220906,,MD,AT,AT,2022,Q3,Elderly
212959171,21295917,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220904.0,20220906,20220906,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-190499",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,,,20220906,,MD,AT,AT,2022,Q3,Elderly
212967291,21296729,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,,,,,,12.5,MG,,QD,2022,Q3,Urinary tract infection,,2022,Q3,1,I,20220604.0,,20220902,20220902,DIR,FDA-CDER-CTU-2022-70809,,FDA-CTU,,83.0,YR,,M,N,66.22,KG,20220901,N,HP,US,,2022,Q3,Elderly
212967291,21296729,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,,,,,,12.5,MG,,QD,2022,Q3,Toxic encephalopathy,,2022,Q3,1,I,20220604.0,,20220902,20220902,DIR,FDA-CDER-CTU-2022-70809,,FDA-CTU,,83.0,YR,,M,N,66.22,KG,20220901,N,HP,US,,2022,Q3,Elderly
212967461,21296746,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q3,Genital candidiasis,,2022,Q3,1,I,20220604.0,,20220902,20220902,DIR,FDA-CDER-CTU-2022-70816,,FDA-CTU,,83.0,YR,,M,N,66.22,KG,20220901,N,PH,US,,2022,Q3,Elderly
212967461,21296746,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q3,Urinary tract infection,,2022,Q3,1,I,20220604.0,,20220902,20220902,DIR,FDA-CDER-CTU-2022-70816,,FDA-CTU,,83.0,YR,,M,N,66.22,KG,20220901,N,PH,US,,2022,Q3,Elderly
212967461,21296746,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q3,Toxic encephalopathy,,2022,Q3,1,I,20220604.0,,20220902,20220902,DIR,FDA-CDER-CTU-2022-70816,,FDA-CTU,,83.0,YR,,M,N,66.22,KG,20220901,N,PH,US,,2022,Q3,Elderly
212974501,21297450,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG  EVERY DAY PO?,,,Y,,,,,25.0,MG,,QD,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,20220818.0,,20220902,20220902,DIR,FDA-CDER-CTU-2022-70880,,FDA-CTU,,80.0,YR,,M,N,112.0,KG,20220826,N,HP,US,,2022,Q3,Elderly
212974501,21297450,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG  EVERY DAY PO?,,,Y,,,,,25.0,MG,,QD,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,20220818.0,,20220902,20220902,DIR,FDA-CDER-CTU-2022-70880,,FDA-CTU,,80.0,YR,,M,N,112.0,KG,20220826,N,HP,US,,2022,Q3,Elderly
212974591,21297459,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Sepsis,,2022,Q3,1,I,20220727.0,,20220902,20220902,DIR,FDA-CDER-CTU-2022-70885,,FDA-CTU,,75.0,YR,,M,N,143.0,KG,20220825,N,HP,US,,2022,Q3,Elderly
212974591,21297459,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Glycosuria,,2022,Q3,1,I,20220727.0,,20220902,20220902,DIR,FDA-CDER-CTU-2022-70885,,FDA-CTU,,75.0,YR,,M,N,143.0,KG,20220825,N,HP,US,,2022,Q3,Elderly
212974591,21297459,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Urinary tract infection,,2022,Q3,1,I,20220727.0,,20220902,20220902,DIR,FDA-CDER-CTU-2022-70885,,FDA-CTU,,75.0,YR,,M,N,143.0,KG,20220825,N,HP,US,,2022,Q3,Elderly
212974591,21297459,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Acute kidney injury,,2022,Q3,1,I,20220727.0,,20220902,20220902,DIR,FDA-CDER-CTU-2022-70885,,FDA-CTU,,75.0,YR,,M,N,143.0,KG,20220825,N,HP,US,,2022,Q3,Elderly
212976091,21297609,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG EVERY DAY PO?,,,Y,,,,,10.0,MG,,QD,2022,Q3,Blood urea increased,,2022,Q3,1,I,20220605.0,,20220902,20220902,DIR,FDA-CDER-CTU-2022-70896,,FDA-CTU,,64.0,YR,,F,N,68.0,KG,20220818,N,HP,US,,2022,Q3,Adult
212976091,21297609,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG EVERY DAY PO?,,,Y,,,,,10.0,MG,,QD,2022,Q3,Renal impairment,,2022,Q3,1,I,20220605.0,,20220902,20220902,DIR,FDA-CDER-CTU-2022-70896,,FDA-CTU,,64.0,YR,,F,N,68.0,KG,20220818,N,HP,US,,2022,Q3,Adult
213017091,21301709,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2022,Q3,Urinary tract infection,,2022,Q3,1,I,20220629.0,,20220906,20220906,DIR,FDA-CDER-CTU-2022-71356,,FDA-CTU,,71.0,YR,,M,N,80.29,KG,20220818,N,PH,US,,2022,Q3,Elderly
213018221,21301822,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,D57151,20240831.0,,12.5,MG,,QD,2022,Q3,Urinary incontinence,,2022,Q3,1,I,20220603.0,,20220906,20220906,DIR,FDA-CDER-CTU-2022-71363,,FDA-CTU,,75.0,YR,,M,N,116.0,KG,20220818,N,PH,US,,2022,Q3,Elderly
213028881,21302888,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Atrial fibrillation,,2022,Q3,1,I,20210801.0,20220906.0,20220907,20220907,EXP,GB-MHRA-MED-202208271811388640-RKQMY,GB-PFIZER INC-202201134298,PFIZER,,70.0,YR,,F,Y,,,20220907,,CN,GB,GB,2022,Q3,Elderly
213028881,21302888,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q3,Palpitations,,2022,Q3,1,I,20210801.0,20220906.0,20220907,20220907,EXP,GB-MHRA-MED-202208271811388640-RKQMY,GB-PFIZER INC-202201134298,PFIZER,,70.0,YR,,F,Y,,,20220907,,CN,GB,GB,2022,Q3,Elderly
213052801,21305280,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Hyponatraemia,,2022,Q3,1,I,,20220829.0,20220907,20220907,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00316,PRINSTON PHARMACEUTICAL,"Corpuz E, Dean JHL, Cahill M. Pass The Salt? Acute Asymptomatic Hyponatremia Following Inpatient Initiation of Angiotensin Receptor-Neprilysin Inhibitor. J Gen Intern Med. 2022;37:S497",71.0,YR,,F,Y,,,20220907,,HP,US,US,2022,Q3,Elderly
213055882,21305588,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, in the morning",,,,,,,,10.0,MG,,,2022,Q3,Paresis,,2022,Q3,2,F,,20220908.0,20220908,20220923,EXP,,RU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-353632,RANBAXY,"Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report. Russ J Cardiol. 2021;26(11):4471 (102-103)",60.0,YR,,F,Y,,,20220923,,HP,RU,RU,2022,Q3,Adult
213055882,21305588,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, in the morning",,,,,,,,10.0,MG,,,2022,Q3,Rhabdomyolysis,,2022,Q3,2,F,,20220908.0,20220908,20220923,EXP,,RU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-353632,RANBAXY,"Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report. Russ J Cardiol. 2021;26(11):4471 (102-103)",60.0,YR,,F,Y,,,20220923,,HP,RU,RU,2022,Q3,Adult
213058351,21305835,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd (1 every 1 Day)",,,U,,,,,10.0,MG,,QD,2022,Q3,Blood glucose increased,,2022,Q3,1,I,,20220829.0,20220908,20220908,EXP,CA-HEALTHCANVIG-E2B-05394102,CA-NOVOPROD-955169,NOVO NORDISK,,66.0,YR,,F,Y,89.0,KG,20220908,,HP,CA,CA,2022,Q3,Elderly
213058351,21305835,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd (1 every 1 Day)",,,U,,,,,10.0,MG,,QD,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220829.0,20220908,20220908,EXP,CA-HEALTHCANVIG-E2B-05394102,CA-NOVOPROD-955169,NOVO NORDISK,,66.0,YR,,F,Y,89.0,KG,20220908,,HP,CA,CA,2022,Q3,Elderly
213058351,21305835,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd (1 every 1 Day)",,,U,,,,,10.0,MG,,QD,2022,Q3,Blood pressure fluctuation,,2022,Q3,1,I,,20220829.0,20220908,20220908,EXP,CA-HEALTHCANVIG-E2B-05394102,CA-NOVOPROD-955169,NOVO NORDISK,,66.0,YR,,F,Y,89.0,KG,20220908,,HP,CA,CA,2022,Q3,Elderly
213058351,21305835,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd (1 every 1 Day)",,,U,,,,,10.0,MG,,QD,2022,Q3,Blood pressure diastolic abnormal,,2022,Q3,1,I,,20220829.0,20220908,20220908,EXP,CA-HEALTHCANVIG-E2B-05394102,CA-NOVOPROD-955169,NOVO NORDISK,,66.0,YR,,F,Y,89.0,KG,20220908,,HP,CA,CA,2022,Q3,Elderly
213058351,21305835,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd (1 every 1 Day)",,,U,,,,,10.0,MG,,QD,2022,Q3,Blood pressure diastolic decreased,,2022,Q3,1,I,,20220829.0,20220908,20220908,EXP,CA-HEALTHCANVIG-E2B-05394102,CA-NOVOPROD-955169,NOVO NORDISK,,66.0,YR,,F,Y,89.0,KG,20220908,,HP,CA,CA,2022,Q3,Elderly
213058351,21305835,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd (1 every 1 Day)",,,U,,,,,10.0,MG,,QD,2022,Q3,Blood pressure increased,,2022,Q3,1,I,,20220829.0,20220908,20220908,EXP,CA-HEALTHCANVIG-E2B-05394102,CA-NOVOPROD-955169,NOVO NORDISK,,66.0,YR,,F,Y,89.0,KG,20220908,,HP,CA,CA,2022,Q3,Elderly
213058351,21305835,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd (1 every 1 Day)",,,U,,,,,10.0,MG,,QD,2022,Q3,Blood pressure systolic increased,,2022,Q3,1,I,,20220829.0,20220908,20220908,EXP,CA-HEALTHCANVIG-E2B-05394102,CA-NOVOPROD-955169,NOVO NORDISK,,66.0,YR,,F,Y,89.0,KG,20220908,,HP,CA,CA,2022,Q3,Elderly
213058351,21305835,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd (1 every 1 Day)",,,U,,,,,10.0,MG,,QD,2022,Q3,Weight increased,,2022,Q3,1,I,,20220829.0,20220908,20220908,EXP,CA-HEALTHCANVIG-E2B-05394102,CA-NOVOPROD-955169,NOVO NORDISK,,66.0,YR,,F,Y,89.0,KG,20220908,,HP,CA,CA,2022,Q3,Elderly
213058351,21305835,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd (1 every 1 Day)",,,U,,,,,10.0,MG,,QD,2022,Q3,Type 2 diabetes mellitus,,2022,Q3,1,I,,20220829.0,20220908,20220908,EXP,CA-HEALTHCANVIG-E2B-05394102,CA-NOVOPROD-955169,NOVO NORDISK,,66.0,YR,,F,Y,89.0,KG,20220908,,HP,CA,CA,2022,Q3,Elderly
213058471,21305847,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2022,Q3,Feeling hot,,2022,Q3,1,I,20220723.0,20220830.0,20220908,20220908,EXP,,CO-NOVOPROD-943002,NOVO NORDISK,,81.0,YR,,F,Y,73.0,KG,20220908,,CN,CO,CO,2022,Q3,Elderly
213058471,21305847,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2022,Q3,Back pain,,2022,Q3,1,I,20220723.0,20220830.0,20220908,20220908,EXP,,CO-NOVOPROD-943002,NOVO NORDISK,,81.0,YR,,F,Y,73.0,KG,20220908,,CN,CO,CO,2022,Q3,Elderly
213058471,21305847,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2022,Q3,Dizziness,,2022,Q3,1,I,20220723.0,20220830.0,20220908,20220908,EXP,,CO-NOVOPROD-943002,NOVO NORDISK,,81.0,YR,,F,Y,73.0,KG,20220908,,CN,CO,CO,2022,Q3,Elderly
213058471,21305847,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2022,Q3,Vomiting,,2022,Q3,1,I,20220723.0,20220830.0,20220908,20220908,EXP,,CO-NOVOPROD-943002,NOVO NORDISK,,81.0,YR,,F,Y,73.0,KG,20220908,,CN,CO,CO,2022,Q3,Elderly
213058471,21305847,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2022,Q3,Pruritus,,2022,Q3,1,I,20220723.0,20220830.0,20220908,20220908,EXP,,CO-NOVOPROD-943002,NOVO NORDISK,,81.0,YR,,F,Y,73.0,KG,20220908,,CN,CO,CO,2022,Q3,Elderly
213058471,21305847,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2022,Q3,Headache,,2022,Q3,1,I,20220723.0,20220830.0,20220908,20220908,EXP,,CO-NOVOPROD-943002,NOVO NORDISK,,81.0,YR,,F,Y,73.0,KG,20220908,,CN,CO,CO,2022,Q3,Elderly
213058471,21305847,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2022,Q3,Rash,,2022,Q3,1,I,20220723.0,20220830.0,20220908,20220908,EXP,,CO-NOVOPROD-943002,NOVO NORDISK,,81.0,YR,,F,Y,73.0,KG,20220908,,CN,CO,CO,2022,Q3,Elderly
213058471,21305847,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2022,Q3,Dry throat,,2022,Q3,1,I,20220723.0,20220830.0,20220908,20220908,EXP,,CO-NOVOPROD-943002,NOVO NORDISK,,81.0,YR,,F,Y,73.0,KG,20220908,,CN,CO,CO,2022,Q3,Elderly
213073681,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2022,Q3,Hypovolaemia,,2022,Q3,1,I,,20220824.0,20220908,20220908,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20220908,,HP,AU,AU,2022,Q3,Elderly
213073681,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2022,Q3,Acute kidney injury,,2022,Q3,1,I,,20220824.0,20220908,20220908,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20220908,,HP,AU,AU,2022,Q3,Elderly
213073681,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2022,Q3,Pneumonia,,2022,Q3,1,I,,20220824.0,20220908,20220908,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20220908,,HP,AU,AU,2022,Q3,Elderly
213073681,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2022,Q3,Nephrogenic diabetes insipidus,,2022,Q3,1,I,,20220824.0,20220908,20220908,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20220908,,HP,AU,AU,2022,Q3,Elderly
213073681,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2022,Q3,Toxicity to various agents,,2022,Q3,1,I,,20220824.0,20220908,20220908,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20220908,,HP,AU,AU,2022,Q3,Elderly
213073681,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2022,Q3,Hypernatraemia,,2022,Q3,1,I,,20220824.0,20220908,20220908,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20220908,,HP,AU,AU,2022,Q3,Elderly
213073681,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2022,Q3,Ileus,,2022,Q3,1,I,,20220824.0,20220908,20220908,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20220908,,HP,AU,AU,2022,Q3,Elderly
213073681,21307368,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,,,,,,2022,Q3,Neurotoxicity,,2022,Q3,1,I,,20220824.0,20220908,20220908,EXP,,AU-COSETTE-CP2022AU000268,COSETTE PHARMACEUTICALS,F Reimann.Chronic lithium toxicity.Aust Prescr.2022;45(3):93-94,66.0,YR,A,M,Y,,,20220908,,HP,AU,AU,2022,Q3,Elderly
213114051,21311405,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2022,Q3,Dehydration,,2022,Q3,1,I,,20220826.0,20220909,20220909,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-354150,RANBAXY,"Meyer KS,Roberts J,Croley KS. Identifying, Managing, and Preventing Adverse Effects of Diabetes Medications. Sr Care Pharm. 2022;Aug;37:310-6",81.0,YR,,F,Y,,,20220909,,HP,US,US,2022,Q3,Elderly
213114051,21311405,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2022,Q3,Hypoglycaemia,,2022,Q3,1,I,,20220826.0,20220909,20220909,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-354150,RANBAXY,"Meyer KS,Roberts J,Croley KS. Identifying, Managing, and Preventing Adverse Effects of Diabetes Medications. Sr Care Pharm. 2022;Aug;37:310-6",81.0,YR,,F,Y,,,20220909,,HP,US,US,2022,Q3,Elderly
213114051,21311405,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2022,Q3,Fall,,2022,Q3,1,I,,20220826.0,20220909,20220909,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-354150,RANBAXY,"Meyer KS,Roberts J,Croley KS. Identifying, Managing, and Preventing Adverse Effects of Diabetes Medications. Sr Care Pharm. 2022;Aug;37:310-6",81.0,YR,,F,Y,,,20220909,,HP,US,US,2022,Q3,Elderly
213114051,21311405,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Daily",,,U,,,,,10.0,MG,,,2022,Q3,Hypotension,,2022,Q3,1,I,,20220826.0,20220909,20220909,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-354150,RANBAXY,"Meyer KS,Roberts J,Croley KS. Identifying, Managing, and Preventing Adverse Effects of Diabetes Medications. Sr Care Pharm. 2022;Aug;37:310-6",81.0,YR,,F,Y,,,20220909,,HP,US,US,2022,Q3,Elderly
213123481,21312348,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,U,,,,10.0,MG,,QD,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,,20220829.0,20220909,20220909,EXP,,US-MYLANLABS-2022M1091589,MYLAN,"Sexe J, Mayes C, Tofts P. Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin. Case-Rep-Crit-Care 2020;null:null.",58.0,YR,,M,Y,,,20220909,,HP,US,US,2022,Q3,Adult
213123481,21312348,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,U,,,,10.0,MG,,QD,2022,Q3,Symptom masked,,2022,Q3,1,I,,20220829.0,20220909,20220909,EXP,,US-MYLANLABS-2022M1091589,MYLAN,"Sexe J, Mayes C, Tofts P. Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin. Case-Rep-Crit-Care 2020;null:null.",58.0,YR,,M,Y,,,20220909,,HP,US,US,2022,Q3,Adult
213156141,21315614,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,212614.0,,,,,2022,Q3,Brain operation,,2022,Q3,1,I,20220908.0,20220908.0,20220909,20220909,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191428",BOEHRINGER INGELHEIM,,72.0,YR,E,,Y,,,20220909,,CN,US,US,2022,Q3,Elderly
213215521,21321552,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, qd",,,,,unknown,,,,,,,2022,Q3,Gastrointestinal disorder,,2022,Q3,1,I,20220825.0,20220901.0,20220912,20220912,EXP,GB-MHRA-ADR 27240767,GB-NOVOPROD-955204,NOVO NORDISK,,81.0,YR,,F,Y,74.0,KG,20220912,,HP,GB,GB,2022,Q3,Elderly
213215521,21321552,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, qd",,,,,unknown,,,,,,,2022,Q3,Malaise,,2022,Q3,1,I,20220825.0,20220901.0,20220912,20220912,EXP,GB-MHRA-ADR 27240767,GB-NOVOPROD-955204,NOVO NORDISK,,81.0,YR,,F,Y,74.0,KG,20220912,,HP,GB,GB,2022,Q3,Elderly
213215521,21321552,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, qd",,,,,unknown,,,,,,,2022,Q3,Fatigue,,2022,Q3,1,I,20220825.0,20220901.0,20220912,20220912,EXP,GB-MHRA-ADR 27240767,GB-NOVOPROD-955204,NOVO NORDISK,,81.0,YR,,F,Y,74.0,KG,20220912,,HP,GB,GB,2022,Q3,Elderly
213227261,21322726,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Hyponatraemia,,2022,Q3,1,I,,20220829.0,20220912,20220912,EXP,,US-JUBILANT CADISTA PHARMACEUTICALS-2022JUB00248,JUBILANT,"Corpuz E, Dean JHL, Cahill M. Pass The Salt? Acute Asymptomatic Hyponatremia Following Inpatient Initiation of Angiotensin Receptor-Neprilysin Inhibitor. J Gen Intern Med. 2022;37:S497",71.0,YR,,F,Y,,,20220912,,HP,US,US,2022,Q3,Elderly
213262661,21326266,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2022,Q3,Nausea,,2022,Q3,1,I,20220908.0,20220909.0,20220913,20220913,EXP,GB-MHRA-TPP6580665C8666846YC1662630000600,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191607",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,101.0,KG,20220913,,MD,GB,GB,2022,Q3,Elderly
213262661,21326266,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2022,Q3,Diarrhoea,,2022,Q3,1,I,20220908.0,20220909.0,20220913,20220913,EXP,GB-MHRA-TPP6580665C8666846YC1662630000600,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191607",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,101.0,KG,20220913,,MD,GB,GB,2022,Q3,Elderly
213262661,21326266,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2022,Q3,Abdominal pain,,2022,Q3,1,I,20220908.0,20220909.0,20220913,20220913,EXP,GB-MHRA-TPP6580665C8666846YC1662630000600,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191607",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,101.0,KG,20220913,,MD,GB,GB,2022,Q3,Elderly
213262661,21326266,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,,,,,,,QD,2022,Q3,Nausea,,2022,Q3,1,I,20220908.0,20220909.0,20220913,20220913,EXP,GB-MHRA-TPP6580665C8666846YC1662630000600,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191607",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,101.0,KG,20220913,,MD,GB,GB,2022,Q3,Elderly
213262661,21326266,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,,,,,,,QD,2022,Q3,Diarrhoea,,2022,Q3,1,I,20220908.0,20220909.0,20220913,20220913,EXP,GB-MHRA-TPP6580665C8666846YC1662630000600,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191607",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,101.0,KG,20220913,,MD,GB,GB,2022,Q3,Elderly
213262661,21326266,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,take one daily,,,,,,,,,,,QD,2022,Q3,Abdominal pain,,2022,Q3,1,I,20220908.0,20220909.0,20220913,20220913,EXP,GB-MHRA-TPP6580665C8666846YC1662630000600,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191607",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,101.0,KG,20220913,,MD,GB,GB,2022,Q3,Elderly
213267321,21326732,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Bacteraemia,,2022,Q3,1,I,,20220908.0,20220913,20220913,EXP,,QA-ROCHE-3177883,ROCHE,"Alammora A, Elamin A Intracranial Hemorrhage Associated With Listeria monocytogenes Bacteremia in an Elderly Patient on Mycophenolate Mofetil, DOI-10.7759/cureus.27562. Cureus 2022 Aug 01;14 (8):1-4.",71.0,YR,,M,Y,,,20220913,,MD,QA,,2022,Q3,Elderly
213267321,21326732,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Haemorrhage intracranial,,2022,Q3,1,I,,20220908.0,20220913,20220913,EXP,,QA-ROCHE-3177883,ROCHE,"Alammora A, Elamin A Intracranial Hemorrhage Associated With Listeria monocytogenes Bacteremia in an Elderly Patient on Mycophenolate Mofetil, DOI-10.7759/cureus.27562. Cureus 2022 Aug 01;14 (8):1-4.",71.0,YR,,M,Y,,,20220913,,MD,QA,,2022,Q3,Elderly
213306611,21330661,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,20220418.0,,20220913,20220913,DIR,FDA-CDER-CTU-2022-73106,,FDA-CTU,,64.0,YR,,M,N,,,20220616,N,PH,US,,2022,Q3,Adult
213306611,21330661,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q3,Groin abscess,,2022,Q3,1,I,20220418.0,,20220913,20220913,DIR,FDA-CDER-CTU-2022-73106,,FDA-CTU,,64.0,YR,,M,N,,,20220616,N,PH,US,,2022,Q3,Adult
213309461,21330946,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (strength - 10, 1x1 in morning)",,,U,,,,,,,,QD,2022,Q3,Eructation,,2022,Q3,1,I,,20220907.0,20220914,20220914,EXP,,NVSC2022TH204083,NOVARTIS,,64.0,YR,,,Y,65.0,KG,20220914,,MD,TH,TH,2022,Q3,Adult
213309461,21330946,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (strength - 10, 1x1 in morning)",,,U,,,,,,,,QD,2022,Q3,Weight increased,,2022,Q3,1,I,,20220907.0,20220914,20220914,EXP,,NVSC2022TH204083,NOVARTIS,,64.0,YR,,,Y,65.0,KG,20220914,,MD,TH,TH,2022,Q3,Adult
213309461,21330946,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (strength - 10, 1x1 in morning)",,,U,,,,,,,,QD,2022,Q3,Feeding disorder,,2022,Q3,1,I,,20220907.0,20220914,20220914,EXP,,NVSC2022TH204083,NOVARTIS,,64.0,YR,,,Y,65.0,KG,20220914,,MD,TH,TH,2022,Q3,Adult
213309461,21330946,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (strength - 10, 1x1 in morning)",,,U,,,,,,,,QD,2022,Q3,Peripheral swelling,,2022,Q3,1,I,,20220907.0,20220914,20220914,EXP,,NVSC2022TH204083,NOVARTIS,,64.0,YR,,,Y,65.0,KG,20220914,,MD,TH,TH,2022,Q3,Adult
213309461,21330946,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (strength - 10, 1x1 in morning)",,,U,,,,,,,,QD,2022,Q3,Ejection fraction decreased,,2022,Q3,1,I,,20220907.0,20220914,20220914,EXP,,NVSC2022TH204083,NOVARTIS,,64.0,YR,,,Y,65.0,KG,20220914,,MD,TH,TH,2022,Q3,Adult
213309461,21330946,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (strength - 10, 1x1 in morning)",,,U,,,,,,,,QD,2022,Q3,Cardiac failure chronic,,2022,Q3,1,I,,20220907.0,20220914,20220914,EXP,,NVSC2022TH204083,NOVARTIS,,64.0,YR,,,Y,65.0,KG,20220914,,MD,TH,TH,2022,Q3,Adult
213309461,21330946,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (strength - 10, 1x1 in morning)",,,U,,,,,,,,QD,2022,Q3,Thrombosis,,2022,Q3,1,I,,20220907.0,20220914,20220914,EXP,,NVSC2022TH204083,NOVARTIS,,64.0,YR,,,Y,65.0,KG,20220914,,MD,TH,TH,2022,Q3,Adult
213309461,21330946,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (strength - 10, 1x1 in morning)",,,U,,,,,,,,QD,2022,Q3,Abdominal distension,,2022,Q3,1,I,,20220907.0,20220914,20220914,EXP,,NVSC2022TH204083,NOVARTIS,,64.0,YR,,,Y,65.0,KG,20220914,,MD,TH,TH,2022,Q3,Adult
213309461,21330946,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (strength - 10, 1x1 in morning)",,,U,,,,,,,,QD,2022,Q3,International normalised ratio decreased,,2022,Q3,1,I,,20220907.0,20220914,20220914,EXP,,NVSC2022TH204083,NOVARTIS,,64.0,YR,,,Y,65.0,KG,20220914,,MD,TH,TH,2022,Q3,Adult
213309461,21330946,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, QD (strength - 10, 1x1 in morning)",,,U,,,,,,,,QD,2022,Q3,Constipation,,2022,Q3,1,I,,20220907.0,20220914,20220914,EXP,,NVSC2022TH204083,NOVARTIS,,64.0,YR,,,Y,65.0,KG,20220914,,MD,TH,TH,2022,Q3,Adult
213322111,21332211,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q3,Faeces discoloured,,2022,Q3,1,I,,20220901.0,20220914,20220914,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2022-09393,ALKEM,,74.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
213322111,21332211,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q3,Chromaturia,,2022,Q3,1,I,,20220901.0,20220914,20220914,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2022-09393,ALKEM,,74.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
213322111,21332211,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q3,Acute on chronic liver failure,,2022,Q3,1,I,,20220901.0,20220914,20220914,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2022-09393,ALKEM,,74.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
213322111,21332211,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q3,Hyperbilirubinaemia,,2022,Q3,1,I,,20220901.0,20220914,20220914,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2022-09393,ALKEM,,74.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
213322111,21332211,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q3,Jaundice,,2022,Q3,1,I,,20220901.0,20220914,20220914,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2022-09393,ALKEM,,74.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
213322111,21332211,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q3,Glomerular filtration rate decreased,,2022,Q3,1,I,,20220901.0,20220914,20220914,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2022-09393,ALKEM,,74.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
213322111,21332211,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q3,Acute kidney injury,,2022,Q3,1,I,,20220901.0,20220914,20220914,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2022-09393,ALKEM,,74.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
213322111,21332211,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q3,Cholestasis,,2022,Q3,1,I,,20220901.0,20220914,20220914,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2022-09393,ALKEM,,74.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
213322111,21332211,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q3,Rash pruritic,,2022,Q3,1,I,,20220901.0,20220914,20220914,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2022-09393,ALKEM,,74.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
213322111,21332211,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q3,Pruritus,,2022,Q3,1,I,,20220901.0,20220914,20220914,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2022-09393,ALKEM,,74.0,YR,,M,Y,,,20220914,,HP,AU,AU,2022,Q3,Elderly
213331251,21333125,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Blood glucose fluctuation,,2022,Q3,1,I,,20220913.0,20220914,20220914,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191839",BOEHRINGER INGELHEIM,,54.0,YR,A,M,Y,88.8,KG,20220914,,PH,DE,DE,2022,Q3,Adult
213331251,21333125,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Asthenia,,2022,Q3,1,I,,20220913.0,20220914,20220914,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191839",BOEHRINGER INGELHEIM,,54.0,YR,A,M,Y,88.8,KG,20220914,,PH,DE,DE,2022,Q3,Adult
213331251,21333125,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220913.0,20220914,20220914,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191839",BOEHRINGER INGELHEIM,,54.0,YR,A,M,Y,88.8,KG,20220914,,PH,DE,DE,2022,Q3,Adult
213331251,21333125,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220913.0,20220914,20220914,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191839",BOEHRINGER INGELHEIM,,54.0,YR,A,M,Y,88.8,KG,20220914,,PH,DE,DE,2022,Q3,Adult
213345221,21334522,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,,,,,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,,20220913.0,20220914,20220914,EXP,,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191871",BOEHRINGER INGELHEIM,"Vitacolonna E, Secinaro E, Ciavarella S, Rizzo G, Porreca E. SGLT2-inhibitors and euglycemic diabetic ketoacidosis in COVID-19 pandemic era: a case report. Acta Diabetologica. 2022; 59(10): 1391-1394.",54.0,YR,A,F,Y,73.0,KG,20220914,,HP,IT,IT,2022,Q3,Adult
213345221,21334522,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,,,,,2022,Q3,COVID-19 pneumonia,,2022,Q3,1,I,,20220913.0,20220914,20220914,EXP,,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191871",BOEHRINGER INGELHEIM,"Vitacolonna E, Secinaro E, Ciavarella S, Rizzo G, Porreca E. SGLT2-inhibitors and euglycemic diabetic ketoacidosis in COVID-19 pandemic era: a case report. Acta Diabetologica. 2022; 59(10): 1391-1394.",54.0,YR,A,F,Y,73.0,KG,20220914,,HP,IT,IT,2022,Q3,Adult
213366391,21336639,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Palpitations,,2022,Q3,1,I,20210801.0,20220906.0,20220915,20220915,EXP,GB-MHRA-ADR 27247250,GB-Accord-277322,ACCORD,,70.0,YR,E,F,Y,,,20220915,,CN,GB,GB,2022,Q3,Elderly
213366391,21336639,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Atrial fibrillation,,2022,Q3,1,I,20210801.0,20220906.0,20220915,20220915,EXP,GB-MHRA-ADR 27247250,GB-Accord-277322,ACCORD,,70.0,YR,E,F,Y,,,20220915,,CN,GB,GB,2022,Q3,Elderly
213400421,21340042,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q3,Palpitations,,2022,Q3,1,I,20210801.0,20220906.0,20220915,20220915,EXP,,GB-drreddys-SPO/UKI/22/0154357,DR REDDYS,,70.0,YR,E,F,Y,,,20220916,,CN,GB,GB,2022,Q3,Elderly
213400421,21340042,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q3,Atrial fibrillation,,2022,Q3,1,I,20210801.0,20220906.0,20220915,20220915,EXP,,GB-drreddys-SPO/UKI/22/0154357,DR REDDYS,,70.0,YR,E,F,Y,,,20220916,,CN,GB,GB,2022,Q3,Elderly
213410351,21341035,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Product communication issue,,2022,Q3,1,I,20220801.0,20220908.0,20220916,20220916,EXP,,SI-009507513-2209SVN005788,MERCK,,69.0,YR,,M,Y,,,20220916,,MD,SI,SI,2022,Q3,Elderly
213410351,21341035,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Drug dose titration not performed,,2022,Q3,1,I,20220801.0,20220908.0,20220916,20220916,EXP,,SI-009507513-2209SVN005788,MERCK,,69.0,YR,,M,Y,,,20220916,,MD,SI,SI,2022,Q3,Elderly
213410351,21341035,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Cardiac resynchronisation therapy,,2022,Q3,1,I,20220801.0,20220908.0,20220916,20220916,EXP,,SI-009507513-2209SVN005788,MERCK,,69.0,YR,,M,Y,,,20220916,,MD,SI,SI,2022,Q3,Elderly
213410351,21341035,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Product prescribing error,,2022,Q3,1,I,20220801.0,20220908.0,20220916,20220916,EXP,,SI-009507513-2209SVN005788,MERCK,,69.0,YR,,M,Y,,,20220916,,MD,SI,SI,2022,Q3,Elderly
213411411,21341141,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Cardiac failure acute,,2022,Q3,1,I,,20220912.0,20220916,20220916,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191609",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20220916,,MD,PL,PL,2022,Q3,Elderly
213411411,21341141,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Mitral valve incompetence,,2022,Q3,1,I,,20220912.0,20220916,20220916,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191609",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20220916,,MD,PL,PL,2022,Q3,Elderly
213411411,21341141,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Arrhythmic storm,,2022,Q3,1,I,,20220912.0,20220916,20220916,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191609",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20220916,,MD,PL,PL,2022,Q3,Elderly
213411411,21341141,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Breath sounds abnormal,,2022,Q3,1,I,,20220912.0,20220916,20220916,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191609",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20220916,,MD,PL,PL,2022,Q3,Elderly
213415621,21341562,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Cerebrovascular accident,,2022,Q3,1,I,20220913.0,,20220915,20220915,DIR,631532,,FDA-CTU,,93.0,YR,,F,N,47.9,KG,20220915,N,PH,US,,2022,Q3,Elderly
213415621,21341562,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Drug interaction,,2022,Q3,1,I,20220913.0,,20220915,20220915,DIR,631532,,FDA-CTU,,93.0,YR,,F,N,47.9,KG,20220915,N,PH,US,,2022,Q3,Elderly
213420701,21342070,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q3,Hyponatraemia,,2022,Q3,1,I,,20220909.0,20220916,20220916,EXP,,US-NOVITIUMPHARMA-2022USNVP00168,NOVITIUM PHARMA,Elaine Corpuz.PASS THE SALT? ACUTE ASYMPTOMATIC HYPONATREMIA FOLLOWING INPATIENT INITIATION OF ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR.Journal of General Internal Medicine.17-JUN-2022;37:S497,71.0,YR,E,F,Y,,,20220916,,HP,US,US,2022,Q3,Elderly
213445481,21344548,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 0-2-0-0",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220912.0,20220916,20220916,EXP,,NVSC2022DE206173,NOVARTIS,,68.0,YR,,F,Y,,,20220916,,PH,DE,DE,2022,Q3,Elderly
213445481,21344548,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 0-2-0-0",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Syncope,,2022,Q3,1,I,,20220912.0,20220916,20220916,EXP,,NVSC2022DE206173,NOVARTIS,,68.0,YR,,F,Y,,,20220916,,PH,DE,DE,2022,Q3,Elderly
213445481,21344548,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 0-2-0-0",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Respiratory failure,,2022,Q3,1,I,,20220912.0,20220916,20220916,EXP,,NVSC2022DE206173,NOVARTIS,,68.0,YR,,F,Y,,,20220916,,PH,DE,DE,2022,Q3,Elderly
213445481,21344548,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 0-2-0-0",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Product prescribing error,,2022,Q3,1,I,,20220912.0,20220916,20220916,EXP,,NVSC2022DE206173,NOVARTIS,,68.0,YR,,F,Y,,,20220916,,PH,DE,DE,2022,Q3,Elderly
213468981,21346898,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,102598,,,25.0,MBQ,,QD,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,20220612.0,,20220916,20220916,DIR,FDA-CDER-CTU-2022-74168,,FDA-CTU,,40.0,YR,,M,N,92.0,KG,20220818,N,PH,US,,2022,Q3,Adult
213468981,21346898,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,102598,,,25.0,MBQ,,QD,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,20220612.0,,20220916,20220916,DIR,FDA-CDER-CTU-2022-74168,,FDA-CTU,,40.0,YR,,M,N,92.0,KG,20220818,N,PH,US,,2022,Q3,Adult
213468981,21346898,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,102598,,,25.0,MBQ,,QD,2022,Q3,Vomiting,,2022,Q3,1,I,20220612.0,,20220916,20220916,DIR,FDA-CDER-CTU-2022-74168,,FDA-CTU,,40.0,YR,,M,N,92.0,KG,20220818,N,PH,US,,2022,Q3,Adult
213468981,21346898,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,102598,,,25.0,MBQ,,QD,2022,Q3,Gastrointestinal haemorrhage,,2022,Q3,1,I,20220612.0,,20220916,20220916,DIR,FDA-CDER-CTU-2022-74168,,FDA-CTU,,40.0,YR,,M,N,92.0,KG,20220818,N,PH,US,,2022,Q3,Adult
213468981,21346898,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,102598,,,25.0,MBQ,,QD,2022,Q3,Haematemesis,,2022,Q3,1,I,20220612.0,,20220916,20220916,DIR,FDA-CDER-CTU-2022-74168,,FDA-CTU,,40.0,YR,,M,N,92.0,KG,20220818,N,PH,US,,2022,Q3,Adult
213468981,21346898,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,102598,,,25.0,MBQ,,QD,2022,Q3,Nausea,,2022,Q3,1,I,20220612.0,,20220916,20220916,DIR,FDA-CDER-CTU-2022-74168,,FDA-CTU,,40.0,YR,,M,N,92.0,KG,20220818,N,PH,US,,2022,Q3,Adult
213469531,21346953,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q3,Amputation,,2022,Q3,1,I,20210920.0,,20220916,20220916,DIR,FDA-CDER-CTU-2022-74207,,FDA-CTU,,66.0,YR,,M,N,90.0,KG,20220218,N,PH,US,,2022,Q3,Elderly
213469531,21346953,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q3,Infection,,2022,Q3,1,I,20210920.0,,20220916,20220916,DIR,FDA-CDER-CTU-2022-74207,,FDA-CTU,,66.0,YR,,M,N,90.0,KG,20220218,N,PH,US,,2022,Q3,Elderly
213494641,21349464,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Lipohypertrophy,,2022,Q3,1,I,,20220908.0,20220919,20220919,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,Chwia?kowska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960,64.0,YR,,M,Y,163.0,KG,20220919,,HP,PL,PL,2022,Q3,Adult
213494641,21349464,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Diabetic neuropathy,,2022,Q3,1,I,,20220908.0,20220919,20220919,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,Chwia?kowska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960,64.0,YR,,M,Y,163.0,KG,20220919,,HP,PL,PL,2022,Q3,Adult
213494641,21349464,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Insulin resistance,,2022,Q3,1,I,,20220908.0,20220919,20220919,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,Chwia?kowska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960,64.0,YR,,M,Y,163.0,KG,20220919,,HP,PL,PL,2022,Q3,Adult
213494641,21349464,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Blood glucose increased,,2022,Q3,1,I,,20220908.0,20220919,20220919,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,Chwia?kowska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960,64.0,YR,,M,Y,163.0,KG,20220919,,HP,PL,PL,2022,Q3,Adult
213494641,21349464,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Cholelithiasis,,2022,Q3,1,I,,20220908.0,20220919,20220919,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,Chwia?kowska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960,64.0,YR,,M,Y,163.0,KG,20220919,,HP,PL,PL,2022,Q3,Adult
213494641,21349464,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Hepatic steatosis,,2022,Q3,1,I,,20220908.0,20220919,20220919,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,Chwia?kowska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960,64.0,YR,,M,Y,163.0,KG,20220919,,HP,PL,PL,2022,Q3,Adult
213494641,21349464,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q3,Cardiac failure,,2022,Q3,1,I,,20220908.0,20220919,20220919,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,Chwia?kowska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960,64.0,YR,,M,Y,163.0,KG,20220919,,HP,PL,PL,2022,Q3,Adult
213512731,21351273,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Hypoglycaemia,,2022,Q3,1,I,,20220914.0,20220919,20220919,EXP,,DE-DSJP-DSE-2022-133430,DAIICHI,"Schmidt. H, Schlitt.A. Hypoglycemia in a patient treated with a SGLT2-inhibitor with HFrEF without diabetes mellitus. Dtsch Med Wochenschr. 2022;147:1195-1198",79.0,YR,,M,Y,,,20220919,,MD,DE,DE,2022,Q3,Elderly
213512731,21351273,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Cardiac failure,,2022,Q3,1,I,,20220914.0,20220919,20220919,EXP,,DE-DSJP-DSE-2022-133430,DAIICHI,"Schmidt. H, Schlitt.A. Hypoglycemia in a patient treated with a SGLT2-inhibitor with HFrEF without diabetes mellitus. Dtsch Med Wochenschr. 2022;147:1195-1198",79.0,YR,,M,Y,,,20220919,,MD,DE,DE,2022,Q3,Elderly
213518701,21351870,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Nausea,,2022,Q3,1,I,20220825.0,,20220917,20220917,DIR,FDA-CDER-CTU-2022-74602,,FDA-CTU,,45.0,YR,,M,N,127.0,KG,20220905,N,HP,US,,2022,Q3,Adult
213518701,21351870,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,20220825.0,,20220917,20220917,DIR,FDA-CDER-CTU-2022-74602,,FDA-CTU,,45.0,YR,,M,N,127.0,KG,20220905,N,HP,US,,2022,Q3,Adult
213518701,21351870,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Vomiting,,2022,Q3,1,I,20220825.0,,20220917,20220917,DIR,FDA-CDER-CTU-2022-74602,,FDA-CTU,,45.0,YR,,M,N,127.0,KG,20220905,N,HP,US,,2022,Q3,Adult
213520691,21352069,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10,,,,,,,,,,,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220911.0,20220920,20220920,EXP,,DE-AstraZeneca-2022A317182,ASTRAZENECA,,56.0,YR,,,Y,84.0,KG,20220920,,MD,DE,,2022,Q3,Adult
213520691,21352069,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10,,,,,,,,,,,,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220911.0,20220920,20220920,EXP,,DE-AstraZeneca-2022A317182,ASTRAZENECA,,56.0,YR,,,Y,84.0,KG,20220920,,MD,DE,,2022,Q3,Adult
213528991,21352899,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Blood lactic acid increased,,2022,Q3,1,I,20210328.0,20220913.0,20220920,20220920,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191823",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220920,,PH,AU,AU,2022,Q3,Elderly
213528991,21352899,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Malaise,,2022,Q3,1,I,20210328.0,20220913.0,20220920,20220920,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191823",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220920,,PH,AU,AU,2022,Q3,Elderly
213528991,21352899,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,20210328.0,20220913.0,20220920,20220920,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191823",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220920,,PH,AU,AU,2022,Q3,Elderly
213528991,21352899,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Carbon dioxide abnormal,,2022,Q3,1,I,20210328.0,20220913.0,20220920,20220920,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191823",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220920,,PH,AU,AU,2022,Q3,Elderly
213528991,21352899,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,20210328.0,20220913.0,20220920,20220920,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191823",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220920,,PH,AU,AU,2022,Q3,Elderly
213528991,21352899,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Blood glucose increased,,2022,Q3,1,I,20210328.0,20220913.0,20220920,20220920,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191823",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,,,20220920,,PH,AU,AU,2022,Q3,Elderly
213545851,21354585,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,4373.95833,MG,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q3,Blister,,2022,Q3,1,I,20220913.0,20220916.0,20220920,20220920,EXP,GB-MHRA-TPP33588036C2121577YC1663069187908,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193013",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,103.0,KG,20220920,,MD,GB,GB,2022,Q3,Adult
213545851,21354585,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,4373.95833,MG,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q3,Aphthous ulcer,,2022,Q3,1,I,20220913.0,20220916.0,20220920,20220920,EXP,GB-MHRA-TPP33588036C2121577YC1663069187908,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193013",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,103.0,KG,20220920,,MD,GB,GB,2022,Q3,Adult
213545851,21354585,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,4373.95833,MG,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q3,Dermatitis bullous,,2022,Q3,1,I,20220913.0,20220916.0,20220920,20220920,EXP,GB-MHRA-TPP33588036C2121577YC1663069187908,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193013",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,103.0,KG,20220920,,MD,GB,GB,2022,Q3,Adult
213545851,21354585,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,4373.95833,MG,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q3,Skin lesion,,2022,Q3,1,I,20220913.0,20220916.0,20220920,20220920,EXP,GB-MHRA-TPP33588036C2121577YC1663069187908,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193013",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,103.0,KG,20220920,,MD,GB,GB,2022,Q3,Adult
213554601,21355460,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Wound,,2022,Q3,1,I,,20220919.0,20220920,20220920,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192769",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,84.0,KG,20220920,,PH,DE,DE,2022,Q3,Adult
213554601,21355460,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Product monitoring error,,2022,Q3,1,I,,20220919.0,20220920,20220920,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192769",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,84.0,KG,20220920,,PH,DE,DE,2022,Q3,Adult
213554601,21355460,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Therapeutic drug monitoring analysis not performed,,2022,Q3,1,I,,20220919.0,20220920,20220920,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192769",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,84.0,KG,20220920,,PH,DE,DE,2022,Q3,Adult
213555351,21355535,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Blood glucose increased,,2022,Q3,1,I,,20220918.0,20220920,20220920,EXP,,PL-BAUSCH-BL-2022-022164,BAUSCH AND LOMB,Chwialkowska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960:.,64.0,YR,,M,Y,163.0,KG,20220920,,HP,PL,PL,2022,Q3,Adult
213555351,21355535,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Diabetic neuropathy,,2022,Q3,1,I,,20220918.0,20220920,20220920,EXP,,PL-BAUSCH-BL-2022-022164,BAUSCH AND LOMB,Chwialkowska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960:.,64.0,YR,,M,Y,163.0,KG,20220920,,HP,PL,PL,2022,Q3,Adult
213555351,21355535,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Lipohypertrophy,,2022,Q3,1,I,,20220918.0,20220920,20220920,EXP,,PL-BAUSCH-BL-2022-022164,BAUSCH AND LOMB,Chwialkowska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960:.,64.0,YR,,M,Y,163.0,KG,20220920,,HP,PL,PL,2022,Q3,Adult
213555351,21355535,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Cholelithiasis,,2022,Q3,1,I,,20220918.0,20220920,20220920,EXP,,PL-BAUSCH-BL-2022-022164,BAUSCH AND LOMB,Chwialkowska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960:.,64.0,YR,,M,Y,163.0,KG,20220920,,HP,PL,PL,2022,Q3,Adult
213555351,21355535,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Insulin resistance,,2022,Q3,1,I,,20220918.0,20220920,20220920,EXP,,PL-BAUSCH-BL-2022-022164,BAUSCH AND LOMB,Chwialkowska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960:.,64.0,YR,,M,Y,163.0,KG,20220920,,HP,PL,PL,2022,Q3,Adult
213555351,21355535,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Hepatic steatosis,,2022,Q3,1,I,,20220918.0,20220920,20220920,EXP,,PL-BAUSCH-BL-2022-022164,BAUSCH AND LOMB,Chwialkowska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960:.,64.0,YR,,M,Y,163.0,KG,20220920,,HP,PL,PL,2022,Q3,Adult
213555351,21355535,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q3,Cardiac failure,,2022,Q3,1,I,,20220918.0,20220920,20220920,EXP,,PL-BAUSCH-BL-2022-022164,BAUSCH AND LOMB,Chwialkowska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960:.,64.0,YR,,M,Y,163.0,KG,20220920,,HP,PL,PL,2022,Q3,Adult
213556061,21355606,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD 1-0-0-0",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Hyperkalaemia,,2022,Q3,1,I,20210801.0,20220919.0,20220920,20220920,EXP,,NVSC2022DE211417,NOVARTIS,,64.0,YR,,M,Y,85.0,KG,20220920,,PH,DE,DE,2022,Q3,Adult
213556061,21355606,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD 1-0-0-0",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Haematuria,,2022,Q3,1,I,20210801.0,20220919.0,20220920,20220920,EXP,,NVSC2022DE211417,NOVARTIS,,64.0,YR,,M,Y,85.0,KG,20220920,,PH,DE,DE,2022,Q3,Adult
213595731,21359573,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220919.0,20220921,20220921,EXP,,NVSC2022DE210987,NOVARTIS,,78.0,YR,,M,Y,,,20220921,,PH,DE,DE,2022,Q3,Elderly
213595731,21359573,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Systemic infection,,2022,Q3,1,I,,20220919.0,20220921,20220921,EXP,,NVSC2022DE210987,NOVARTIS,,78.0,YR,,M,Y,,,20220921,,PH,DE,DE,2022,Q3,Elderly
213595731,21359573,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Atrial fibrillation,,2022,Q3,1,I,,20220919.0,20220921,20220921,EXP,,NVSC2022DE210987,NOVARTIS,,78.0,YR,,M,Y,,,20220921,,PH,DE,DE,2022,Q3,Elderly
213595731,21359573,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Tachycardia,,2022,Q3,1,I,,20220919.0,20220921,20220921,EXP,,NVSC2022DE210987,NOVARTIS,,78.0,YR,,M,Y,,,20220921,,PH,DE,DE,2022,Q3,Elderly
213595731,21359573,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220919.0,20220921,20220921,EXP,,NVSC2022DE210987,NOVARTIS,,78.0,YR,,M,Y,,,20220921,,PH,DE,DE,2022,Q3,Elderly
213595731,21359573,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Renal impairment,,2022,Q3,1,I,,20220919.0,20220921,20220921,EXP,,NVSC2022DE210987,NOVARTIS,,78.0,YR,,M,Y,,,20220921,,PH,DE,DE,2022,Q3,Elderly
213595731,21359573,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Acute myocardial infarction,,2022,Q3,1,I,,20220919.0,20220921,20220921,EXP,,NVSC2022DE210987,NOVARTIS,,78.0,YR,,M,Y,,,20220921,,PH,DE,DE,2022,Q3,Elderly
213595731,21359573,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220919.0,20220921,20220921,EXP,,NVSC2022DE210987,NOVARTIS,,78.0,YR,,M,Y,,,20220921,,PH,DE,DE,2022,Q3,Elderly
213595731,21359573,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Acute respiratory failure,,2022,Q3,1,I,,20220919.0,20220921,20220921,EXP,,NVSC2022DE210987,NOVARTIS,,78.0,YR,,M,Y,,,20220921,,PH,DE,DE,2022,Q3,Elderly
213595731,21359573,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Electrocardiogram abnormal,,2022,Q3,1,I,,20220919.0,20220921,20220921,EXP,,NVSC2022DE210987,NOVARTIS,,78.0,YR,,M,Y,,,20220921,,PH,DE,DE,2022,Q3,Elderly
213595731,21359573,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (10 mg, 1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Arrhythmia,,2022,Q3,1,I,,20220919.0,20220921,20220921,EXP,,NVSC2022DE210987,NOVARTIS,,78.0,YR,,M,Y,,,20220921,,PH,DE,DE,2022,Q3,Elderly
213635701,21363570,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, daily, 1-0-0-0",,,U,,,,,25.0,MG,Tablet,QD,2022,Q3,Inflammation,,2022,Q3,1,I,,20220916.0,20220922,20220922,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202209007806,ELI LILLY AND CO,,70.0,YR,,M,Y,100.0,KG,20220922,,CN,DE,DE,2022,Q3,Elderly
213635701,21363570,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, daily, 1-0-0-0",,,U,,,,,25.0,MG,Tablet,QD,2022,Q3,Product monitoring error,,2022,Q3,1,I,,20220916.0,20220922,20220922,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202209007806,ELI LILLY AND CO,,70.0,YR,,M,Y,100.0,KG,20220922,,CN,DE,DE,2022,Q3,Elderly
213635701,21363570,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, daily, 1-0-0-0",,,U,,,,,25.0,MG,Tablet,QD,2022,Q3,Ulcer,,2022,Q3,1,I,,20220916.0,20220922,20220922,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202209007806,ELI LILLY AND CO,,70.0,YR,,M,Y,100.0,KG,20220922,,CN,DE,DE,2022,Q3,Elderly
213641912,21364191,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2022,Q3,Psoriasis,,2022,Q3,2,F,20220830.0,20220921.0,20220922,20220929,EXP,PT-INFARMED-T202209-1239,PT-EXELIXIS-CABO-22056096,EXELIXIS,,70.0,YR,,M,Y,61.0,KG,20220929,,PH,PT,PT,2022,Q3,Elderly
213655851,21365585,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q3,Asthenia,,2022,Q3,1,I,20220401.0,20220901.0,20220922,20220922,PER,,US-MYLANLABS-2022M1091708,MYLAN,,64.0,YR,,M,Y,73.48,KG,20220922,,CN,US,US,2022,Q3,Adult
213655851,21365585,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q3,Pyrexia,,2022,Q3,1,I,20220401.0,20220901.0,20220922,20220922,PER,,US-MYLANLABS-2022M1091708,MYLAN,,64.0,YR,,M,Y,73.48,KG,20220922,,CN,US,US,2022,Q3,Adult
213655851,21365585,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q3,Cough,,2022,Q3,1,I,20220401.0,20220901.0,20220922,20220922,PER,,US-MYLANLABS-2022M1091708,MYLAN,,64.0,YR,,M,Y,73.48,KG,20220922,,CN,US,US,2022,Q3,Adult
213655851,21365585,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q3,Chills,,2022,Q3,1,I,20220401.0,20220901.0,20220922,20220922,PER,,US-MYLANLABS-2022M1091708,MYLAN,,64.0,YR,,M,Y,73.48,KG,20220922,,CN,US,US,2022,Q3,Adult
213655851,21365585,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q3,Breath odour,,2022,Q3,1,I,20220401.0,20220901.0,20220922,20220922,PER,,US-MYLANLABS-2022M1091708,MYLAN,,64.0,YR,,M,Y,73.48,KG,20220922,,CN,US,US,2022,Q3,Adult
213655851,21365585,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q3,Pollakiuria,,2022,Q3,1,I,20220401.0,20220901.0,20220922,20220922,PER,,US-MYLANLABS-2022M1091708,MYLAN,,64.0,YR,,M,Y,73.48,KG,20220922,,CN,US,US,2022,Q3,Adult
213655851,21365585,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q3,Blood urine present,,2022,Q3,1,I,20220401.0,20220901.0,20220922,20220922,PER,,US-MYLANLABS-2022M1091708,MYLAN,,64.0,YR,,M,Y,73.48,KG,20220922,,CN,US,US,2022,Q3,Adult
213655851,21365585,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q3,Fatigue,,2022,Q3,1,I,20220401.0,20220901.0,20220922,20220922,PER,,US-MYLANLABS-2022M1091708,MYLAN,,64.0,YR,,M,Y,73.48,KG,20220922,,CN,US,US,2022,Q3,Adult
213655851,21365585,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q3,Decreased appetite,,2022,Q3,1,I,20220401.0,20220901.0,20220922,20220922,PER,,US-MYLANLABS-2022M1091708,MYLAN,,64.0,YR,,M,Y,73.48,KG,20220922,,CN,US,US,2022,Q3,Adult
213655851,21365585,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q3,Feeling abnormal,,2022,Q3,1,I,20220401.0,20220901.0,20220922,20220922,PER,,US-MYLANLABS-2022M1091708,MYLAN,,64.0,YR,,M,Y,73.48,KG,20220922,,CN,US,US,2022,Q3,Adult
213658911,21365891,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,Unknown,,,10.0,MG,Tablet,QD,2022,Q3,C-reactive protein increased,,2022,Q3,1,I,20210801.0,20220920.0,20220922,20220922,EXP,DE-ADRED-08112-01,DE-PFIZER INC-202201174215,PFIZER,,64.0,YR,,M,Y,85.0,KG,20220922,,PH,DE,DE,2022,Q3,Adult
213658911,21365891,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,Unknown,,,10.0,MG,Tablet,QD,2022,Q3,Red blood cell count decreased,,2022,Q3,1,I,20210801.0,20220920.0,20220922,20220922,EXP,DE-ADRED-08112-01,DE-PFIZER INC-202201174215,PFIZER,,64.0,YR,,M,Y,85.0,KG,20220922,,PH,DE,DE,2022,Q3,Adult
213658911,21365891,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,Unknown,,,10.0,MG,Tablet,QD,2022,Q3,Glomerular filtration rate decreased,,2022,Q3,1,I,20210801.0,20220920.0,20220922,20220922,EXP,DE-ADRED-08112-01,DE-PFIZER INC-202201174215,PFIZER,,64.0,YR,,M,Y,85.0,KG,20220922,,PH,DE,DE,2022,Q3,Adult
213658911,21365891,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,Unknown,,,10.0,MG,Tablet,QD,2022,Q3,Alanine aminotransferase increased,,2022,Q3,1,I,20210801.0,20220920.0,20220922,20220922,EXP,DE-ADRED-08112-01,DE-PFIZER INC-202201174215,PFIZER,,64.0,YR,,M,Y,85.0,KG,20220922,,PH,DE,DE,2022,Q3,Adult
213658911,21365891,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,Unknown,,,10.0,MG,Tablet,QD,2022,Q3,Haematocrit decreased,,2022,Q3,1,I,20210801.0,20220920.0,20220922,20220922,EXP,DE-ADRED-08112-01,DE-PFIZER INC-202201174215,PFIZER,,64.0,YR,,M,Y,85.0,KG,20220922,,PH,DE,DE,2022,Q3,Adult
213658911,21365891,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,Unknown,,,10.0,MG,Tablet,QD,2022,Q3,White blood cell count increased,,2022,Q3,1,I,20210801.0,20220920.0,20220922,20220922,EXP,DE-ADRED-08112-01,DE-PFIZER INC-202201174215,PFIZER,,64.0,YR,,M,Y,85.0,KG,20220922,,PH,DE,DE,2022,Q3,Adult
213658911,21365891,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,Unknown,,,10.0,MG,Tablet,QD,2022,Q3,Hyperkalaemia,,2022,Q3,1,I,20210801.0,20220920.0,20220922,20220922,EXP,DE-ADRED-08112-01,DE-PFIZER INC-202201174215,PFIZER,,64.0,YR,,M,Y,85.0,KG,20220922,,PH,DE,DE,2022,Q3,Adult
213658911,21365891,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,Unknown,,,10.0,MG,Tablet,QD,2022,Q3,Platelet count increased,,2022,Q3,1,I,20210801.0,20220920.0,20220922,20220922,EXP,DE-ADRED-08112-01,DE-PFIZER INC-202201174215,PFIZER,,64.0,YR,,M,Y,85.0,KG,20220922,,PH,DE,DE,2022,Q3,Adult
213658911,21365891,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,Unknown,,,10.0,MG,Tablet,QD,2022,Q3,Blood creatinine increased,,2022,Q3,1,I,20210801.0,20220920.0,20220922,20220922,EXP,DE-ADRED-08112-01,DE-PFIZER INC-202201174215,PFIZER,,64.0,YR,,M,Y,85.0,KG,20220922,,PH,DE,DE,2022,Q3,Adult
213658911,21365891,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,Unknown,,,10.0,MG,Tablet,QD,2022,Q3,International normalised ratio increased,,2022,Q3,1,I,20210801.0,20220920.0,20220922,20220922,EXP,DE-ADRED-08112-01,DE-PFIZER INC-202201174215,PFIZER,,64.0,YR,,M,Y,85.0,KG,20220922,,PH,DE,DE,2022,Q3,Adult
213658911,21365891,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,Unknown,,,10.0,MG,Tablet,QD,2022,Q3,Haemoglobin decreased,,2022,Q3,1,I,20210801.0,20220920.0,20220922,20220922,EXP,DE-ADRED-08112-01,DE-PFIZER INC-202201174215,PFIZER,,64.0,YR,,M,Y,85.0,KG,20220922,,PH,DE,DE,2022,Q3,Adult
213658911,21365891,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,,,Unknown,,,10.0,MG,Tablet,QD,2022,Q3,Haematuria,,2022,Q3,1,I,20210801.0,20220920.0,20220922,20220922,EXP,DE-ADRED-08112-01,DE-PFIZER INC-202201174215,PFIZER,,64.0,YR,,M,Y,85.0,KG,20220922,,PH,DE,DE,2022,Q3,Adult
213660581,21366058,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg,(1-0-0-0) qd",,,,,,,,10.0,MG,Tablet,QD,2022,Q3,Hyperkalaemia,,2022,Q3,1,I,20210801.0,20220919.0,20220922,20220922,EXP,DE-ADRED-08112-01,DE-DSJP-DSE-2022-134043,DAIICHI,,64.0,YR,,M,Y,85.0,KG,20220922,,PH,DE,DE,2022,Q3,Adult
213660581,21366058,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg,(1-0-0-0) qd",,,,,,,,10.0,MG,Tablet,QD,2022,Q3,Haematuria,,2022,Q3,1,I,20210801.0,20220919.0,20220922,20220922,EXP,DE-ADRED-08112-01,DE-DSJP-DSE-2022-134043,DAIICHI,,64.0,YR,,M,Y,85.0,KG,20220922,,PH,DE,DE,2022,Q3,Adult
213676351,21367635,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Vomiting,,2022,Q3,1,I,,20220912.0,20220923,20220923,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-11260,LUPIN,"Ekanayake PS, Gerwer J, McCowen K.. ALPELISIB-INDUCED HYPERGLYCEMIA. Acta-Endocrinol(Buc). 2022;18(1)XVIII:115-117",44.0,YR,,F,Y,,,20220923,,MD,US,US,2022,Q3,Adult
213676351,21367635,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Nausea,,2022,Q3,1,I,,20220912.0,20220923,20220923,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-11260,LUPIN,"Ekanayake PS, Gerwer J, McCowen K.. ALPELISIB-INDUCED HYPERGLYCEMIA. Acta-Endocrinol(Buc). 2022;18(1)XVIII:115-117",44.0,YR,,F,Y,,,20220923,,MD,US,US,2022,Q3,Adult
213686281,21368628,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, tablets",,,U,,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q3,Ulcer,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192789",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,100.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213686281,21368628,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, tablets",,,U,,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q3,Product monitoring error,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192789",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,100.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213686281,21368628,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, tablets",,,U,,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q3,Inflammation,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192789",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,100.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213689921,21368992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Systemic infection,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192786",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,74.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213689921,21368992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Renal impairment,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192786",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,74.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213689921,21368992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Depressed level of consciousness,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192786",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,74.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213689921,21368992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Polyuria,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192786",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,74.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213689921,21368992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192786",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,74.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213689921,21368992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Disorientation,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192786",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,74.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213689921,21368992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192786",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,74.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213689921,21368992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Electrocardiogram abnormal,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192786",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,74.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213689921,21368992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Electrolyte imbalance,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192786",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,74.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213689921,21368992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Vomiting,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192786",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,74.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213689921,21368992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Dysuria,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192786",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,74.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213689921,21368992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Nausea,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192786",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,74.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213689921,21368992,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Pyrexia,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192786",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,74.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213691271,21369127,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Genital tract inflammation,,2022,Q3,1,I,20220601.0,20220922.0,20220923,20220923,EXP,GB-MHRA-TPP9760320C7877741YC1663318644324,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193560",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,112.0,KG,20220923,,PH,GB,GB,2022,Q3,Adult
213691271,21369127,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Throat irritation,,2022,Q3,1,I,20220601.0,20220922.0,20220923,20220923,EXP,GB-MHRA-TPP9760320C7877741YC1663318644324,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193560",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,112.0,KG,20220923,,PH,GB,GB,2022,Q3,Adult
213691271,21369127,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Pyrexia,,2022,Q3,1,I,20220601.0,20220922.0,20220923,20220923,EXP,GB-MHRA-TPP9760320C7877741YC1663318644324,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193560",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,112.0,KG,20220923,,PH,GB,GB,2022,Q3,Adult
213691271,21369127,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Pharyngeal ulceration,,2022,Q3,1,I,20220601.0,20220922.0,20220923,20220923,EXP,GB-MHRA-TPP9760320C7877741YC1663318644324,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193560",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,112.0,KG,20220923,,PH,GB,GB,2022,Q3,Adult
213691271,21369127,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Genital haemorrhage,,2022,Q3,1,I,20220601.0,20220922.0,20220923,20220923,EXP,GB-MHRA-TPP9760320C7877741YC1663318644324,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193560",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,112.0,KG,20220923,,PH,GB,GB,2022,Q3,Adult
213691271,21369127,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Mucosal disorder,,2022,Q3,1,I,20220601.0,20220922.0,20220923,20220923,EXP,GB-MHRA-TPP9760320C7877741YC1663318644324,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193560",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,112.0,KG,20220923,,PH,GB,GB,2022,Q3,Adult
213691271,21369127,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Dry skin,,2022,Q3,1,I,20220601.0,20220922.0,20220923,20220923,EXP,GB-MHRA-TPP9760320C7877741YC1663318644324,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193560",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,112.0,KG,20220923,,PH,GB,GB,2022,Q3,Adult
213691271,21369127,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Genital candidiasis,,2022,Q3,1,I,20220601.0,20220922.0,20220923,20220923,EXP,GB-MHRA-TPP9760320C7877741YC1663318644324,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193560",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,112.0,KG,20220923,,PH,GB,GB,2022,Q3,Adult
213691271,21369127,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Genital blister,,2022,Q3,1,I,20220601.0,20220922.0,20220923,20220923,EXP,GB-MHRA-TPP9760320C7877741YC1663318644324,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193560",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,112.0,KG,20220923,,PH,GB,GB,2022,Q3,Adult
213691271,21369127,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Dry eye,,2022,Q3,1,I,20220601.0,20220922.0,20220923,20220923,EXP,GB-MHRA-TPP9760320C7877741YC1663318644324,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193560",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,112.0,KG,20220923,,PH,GB,GB,2022,Q3,Adult
213713231,21371323,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Product monitoring error,,2022,Q3,1,I,,20220916.0,20220923,20220923,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202209007808,ELI LILLY AND CO,,55.0,YR,,M,Y,84.0,KG,20220923,,CN,DE,DE,2022,Q3,Adult
213713231,21371323,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Therapeutic drug monitoring analysis not performed,,2022,Q3,1,I,,20220916.0,20220923,20220923,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202209007808,ELI LILLY AND CO,,55.0,YR,,M,Y,84.0,KG,20220923,,CN,DE,DE,2022,Q3,Adult
213713231,21371323,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Wound,,2022,Q3,1,I,,20220916.0,20220923,20220923,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202209007808,ELI LILLY AND CO,,55.0,YR,,M,Y,84.0,KG,20220923,,CN,DE,DE,2022,Q3,Adult
213715231,21371523,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q3,Fournier's gangrene,,2022,Q3,1,I,20220815.0,20220923.0,20220923,20220923,EXP,GB-MHRA-WEBRADR-202209221625484660-7YPEX,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193778",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,62.0,KG,20220923,,HP,GB,GB,2022,Q3,Adult
213719811,21371981,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,,,,,,10.0,MG,Tablet,,2022,Q3,Hyperkalaemia,,2022,Q3,1,I,20210801.0,20220920.0,20220923,20220923,EXP,DE-ADRED-08112-01,DE-BAUSCH-BL-2022-022328,BAUSCH AND LOMB,,64.0,YR,,M,Y,85.0,KG,20220923,,PH,DE,DE,2022,Q3,Adult
213719811,21371981,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,,,,,,10.0,MG,Tablet,,2022,Q3,Haematuria,,2022,Q3,1,I,20210801.0,20220920.0,20220923,20220923,EXP,DE-ADRED-08112-01,DE-BAUSCH-BL-2022-022328,BAUSCH AND LOMB,,64.0,YR,,M,Y,85.0,KG,20220923,,PH,DE,DE,2022,Q3,Adult
213722871,21372287,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Pollakiuria,,2022,Q3,1,I,20210907.0,20220919.0,20220924,20220924,EXP,,NVSC2022DE211448,NOVARTIS,,73.0,YR,,M,Y,,,20220924,,PH,DE,DE,2022,Q3,Elderly
213722871,21372287,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Product administration error,,2022,Q3,1,I,20210907.0,20220919.0,20220924,20220924,EXP,,NVSC2022DE211448,NOVARTIS,,73.0,YR,,M,Y,,,20220924,,PH,DE,DE,2022,Q3,Elderly
213722871,21372287,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q3,1,I,20210907.0,20220919.0,20220924,20220924,EXP,,NVSC2022DE211448,NOVARTIS,,73.0,YR,,M,Y,,,20220924,,PH,DE,DE,2022,Q3,Elderly
213722871,21372287,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Labelled drug-drug interaction medication error,,2022,Q3,1,I,20210907.0,20220919.0,20220924,20220924,EXP,,NVSC2022DE211448,NOVARTIS,,73.0,YR,,M,Y,,,20220924,,PH,DE,DE,2022,Q3,Elderly
213722871,21372287,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Urinary hesitation,,2022,Q3,1,I,20210907.0,20220919.0,20220924,20220924,EXP,,NVSC2022DE211448,NOVARTIS,,73.0,YR,,M,Y,,,20220924,,PH,DE,DE,2022,Q3,Elderly
213722871,21372287,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Cystitis,,2022,Q3,1,I,20210907.0,20220919.0,20220924,20220924,EXP,,NVSC2022DE211448,NOVARTIS,,73.0,YR,,M,Y,,,20220924,,PH,DE,DE,2022,Q3,Elderly
213722871,21372287,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Acute kidney injury,,2022,Q3,1,I,20210907.0,20220919.0,20220924,20220924,EXP,,NVSC2022DE211448,NOVARTIS,,73.0,YR,,M,Y,,,20220924,,PH,DE,DE,2022,Q3,Elderly
213722871,21372287,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Product monitoring error,,2022,Q3,1,I,20210907.0,20220919.0,20220924,20220924,EXP,,NVSC2022DE211448,NOVARTIS,,73.0,YR,,M,Y,,,20220924,,PH,DE,DE,2022,Q3,Elderly
213723791,21372379,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Nervous system disorder,,2022,Q3,1,I,20220625.0,20220915.0,20220924,20220924,EXP,,JP-TAKEDA-2022TUS066261,TAKEDA,,39.0,YR,,M,Y,,,20220924,,PH,JP,JP,2022,Q3,Adult
213723791,21372379,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q3,Neuropathy peripheral,,2022,Q3,1,I,20220625.0,20220915.0,20220924,20220924,EXP,,JP-TAKEDA-2022TUS066261,TAKEDA,,39.0,YR,,M,Y,,,20220924,,PH,JP,JP,2022,Q3,Adult
213726351,21372635,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,,,Unknown,,,,,,QD,2022,Q3,Polycythaemia,,2022,Q3,1,I,,20220913.0,20220924,20220924,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-11218,LUPIN,"Schumacher KA, Gosmanov AR. Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy. Journal of Investigative Medicine High Impact Case Reports. 2022;10:1-6",56.0,YR,,M,Y,106.6,KG,20220924,,HP,US,US,2022,Q3,Adult
213726361,21372636,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,,,Unknown,,,,,,QD,2022,Q3,Polycythaemia,,2022,Q3,1,I,,20220913.0,20220924,20220924,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-11217,LUPIN,"Schumacher KA, Gosmanov AR. Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy. Journal of Investigative Medicine High Impact Case Reports. 2022;10:1-6",71.0,YR,,M,Y,102.3,KG,20220924,,HP,US,US,2022,Q3,Elderly
213726361,21372636,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,Unknown,,,,,,QD,2022,Q3,Polycythaemia,,2022,Q3,1,I,,20220913.0,20220924,20220924,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-11217,LUPIN,"Schumacher KA, Gosmanov AR. Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy. Journal of Investigative Medicine High Impact Case Reports. 2022;10:1-6",71.0,YR,,M,Y,102.3,KG,20220924,,HP,US,US,2022,Q3,Elderly
213726371,21372637,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,,,Unknown,,,,,,QD,2022,Q3,Polycythaemia,,2022,Q3,1,I,,20220913.0,20220924,20220924,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-11219,LUPIN,"Schumacher KA, Gosmanov AR. Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy. Journal of Investigative Medicine High Impact Case Reports. 2022;10:1-6",63.0,YR,,M,Y,117.2,KG,20220924,,HP,US,US,2022,Q3,Adult
213736951,21373695,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Asthenia,,2022,Q3,1,I,20211001.0,20220919.0,20220926,20220926,EXP,,NVSC2022DE211794,NOVARTIS,,73.0,YR,,M,Y,,,20220926,,MD,DE,DE,2022,Q3,Elderly
213736951,21373695,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Haematochezia,,2022,Q3,1,I,20211001.0,20220919.0,20220926,20220926,EXP,,NVSC2022DE211794,NOVARTIS,,73.0,YR,,M,Y,,,20220926,,MD,DE,DE,2022,Q3,Elderly
213736951,21373695,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Upper gastrointestinal haemorrhage,,2022,Q3,1,I,20211001.0,20220919.0,20220926,20220926,EXP,,NVSC2022DE211794,NOVARTIS,,73.0,YR,,M,Y,,,20220926,,MD,DE,DE,2022,Q3,Elderly
213736951,21373695,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Melaena,,2022,Q3,1,I,20211001.0,20220919.0,20220926,20220926,EXP,,NVSC2022DE211794,NOVARTIS,,73.0,YR,,M,Y,,,20220926,,MD,DE,DE,2022,Q3,Elderly
213736951,21373695,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Product administration error,,2022,Q3,1,I,20211001.0,20220919.0,20220926,20220926,EXP,,NVSC2022DE211794,NOVARTIS,,73.0,YR,,M,Y,,,20220926,,MD,DE,DE,2022,Q3,Elderly
213736951,21373695,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Haemoglobin decreased,,2022,Q3,1,I,20211001.0,20220919.0,20220926,20220926,EXP,,NVSC2022DE211794,NOVARTIS,,73.0,YR,,M,Y,,,20220926,,MD,DE,DE,2022,Q3,Elderly
213736951,21373695,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Extra dose administered,,2022,Q3,1,I,20211001.0,20220919.0,20220926,20220926,EXP,,NVSC2022DE211794,NOVARTIS,,73.0,YR,,M,Y,,,20220926,,MD,DE,DE,2022,Q3,Elderly
213736991,21373699,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,Tablet,QD,2022,Q3,Product monitoring error,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,NVSC2022DE211080,NOVARTIS,,70.0,YR,,M,Y,100.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213736991,21373699,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,Tablet,QD,2022,Q3,Inflammation,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,NVSC2022DE211080,NOVARTIS,,70.0,YR,,M,Y,100.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213736991,21373699,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,Tablet,QD,2022,Q3,Ulcer,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,NVSC2022DE211080,NOVARTIS,,70.0,YR,,M,Y,100.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213739301,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220920.0,20220926,20220926,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20220926,,MD,JP,JP,2022,Q3,Elderly
213739301,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Mitral valve incompetence,,2022,Q3,1,I,,20220920.0,20220926,20220926,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20220926,,MD,JP,JP,2022,Q3,Elderly
213739301,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Left ventricular dysfunction,,2022,Q3,1,I,,20220920.0,20220926,20220926,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20220926,,MD,JP,JP,2022,Q3,Elderly
213739301,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Hypertension,,2022,Q3,1,I,,20220920.0,20220926,20220926,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20220926,,MD,JP,JP,2022,Q3,Elderly
213739301,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Pleural effusion,,2022,Q3,1,I,,20220920.0,20220926,20220926,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20220926,,MD,JP,JP,2022,Q3,Elderly
213739301,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Left ventricular hypertrophy,,2022,Q3,1,I,,20220920.0,20220926,20220926,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20220926,,MD,JP,JP,2022,Q3,Elderly
213739301,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Electrocardiogram T wave inversion,,2022,Q3,1,I,,20220920.0,20220926,20220926,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20220926,,MD,JP,JP,2022,Q3,Elderly
213739301,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Pulmonary congestion,,2022,Q3,1,I,,20220920.0,20220926,20220926,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20220926,,MD,JP,JP,2022,Q3,Elderly
213739301,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Blood pressure systolic decreased,,2022,Q3,1,I,,20220920.0,20220926,20220926,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20220926,,MD,JP,JP,2022,Q3,Elderly
213739301,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Crepitations,,2022,Q3,1,I,,20220920.0,20220926,20220926,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20220926,,MD,JP,JP,2022,Q3,Elderly
213739301,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Cardiac murmur,,2022,Q3,1,I,,20220920.0,20220926,20220926,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20220926,,MD,JP,JP,2022,Q3,Elderly
213739301,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q3,Ejection fraction decreased,,2022,Q3,1,I,,20220920.0,20220926,20220926,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20220926,,MD,JP,JP,2022,Q3,Elderly
213754391,21375439,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,Unk,,,25.0,MG,,QD,2022,Q3,Palpitations,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,,NVSC2022DE214916,NOVARTIS,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213754391,21375439,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,Unk,,,25.0,MG,,QD,2022,Q3,Chest discomfort,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,,NVSC2022DE214916,NOVARTIS,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213754391,21375439,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,Unk,,,25.0,MG,,QD,2022,Q3,Hypoaesthesia,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,,NVSC2022DE214916,NOVARTIS,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213754391,21375439,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,Unk,,,25.0,MG,,QD,2022,Q3,Tachycardia,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,,NVSC2022DE214916,NOVARTIS,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213754391,21375439,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,Unk,,,25.0,MG,,QD,2022,Q3,Hypoaesthesia,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,,NVSC2022DE214916,NOVARTIS,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213754391,21375439,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,Unk,,,25.0,MG,,QD,2022,Q3,Lactic acidosis,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,,NVSC2022DE214916,NOVARTIS,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213754391,21375439,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,Unk,,,25.0,MG,,QD,2022,Q3,Anion gap increased,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,,NVSC2022DE214916,NOVARTIS,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213754391,21375439,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,Unk,,,25.0,MG,,QD,2022,Q3,Atrial fibrillation,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,,NVSC2022DE214916,NOVARTIS,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213761201,21376120,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,U,,,,,,,Tablet,,2022,Q3,Product administration error,,2022,Q3,1,I,20210907.0,20220921.0,20220926,20220926,EXP,,DE-009507513-2209DEU008008,MERCK,,73.0,YR,,M,Y,,,20220926,,PH,DE,DE,2022,Q3,Elderly
213761201,21376120,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,U,,,,,,,Tablet,,2022,Q3,Urinary hesitation,,2022,Q3,1,I,20210907.0,20220921.0,20220926,20220926,EXP,,DE-009507513-2209DEU008008,MERCK,,73.0,YR,,M,Y,,,20220926,,PH,DE,DE,2022,Q3,Elderly
213761201,21376120,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,U,,,,,,,Tablet,,2022,Q3,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q3,1,I,20210907.0,20220921.0,20220926,20220926,EXP,,DE-009507513-2209DEU008008,MERCK,,73.0,YR,,M,Y,,,20220926,,PH,DE,DE,2022,Q3,Elderly
213761201,21376120,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,U,,,,,,,Tablet,,2022,Q3,Cystitis,,2022,Q3,1,I,20210907.0,20220921.0,20220926,20220926,EXP,,DE-009507513-2209DEU008008,MERCK,,73.0,YR,,M,Y,,,20220926,,PH,DE,DE,2022,Q3,Elderly
213761201,21376120,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,U,,,,,,,Tablet,,2022,Q3,Labelled drug-drug interaction medication error,,2022,Q3,1,I,20210907.0,20220921.0,20220926,20220926,EXP,,DE-009507513-2209DEU008008,MERCK,,73.0,YR,,M,Y,,,20220926,,PH,DE,DE,2022,Q3,Elderly
213761201,21376120,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,U,,,,,,,Tablet,,2022,Q3,Acute kidney injury,,2022,Q3,1,I,20210907.0,20220921.0,20220926,20220926,EXP,,DE-009507513-2209DEU008008,MERCK,,73.0,YR,,M,Y,,,20220926,,PH,DE,DE,2022,Q3,Elderly
213761201,21376120,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,U,,,,,,,Tablet,,2022,Q3,Product monitoring error,,2022,Q3,1,I,20210907.0,20220921.0,20220926,20220926,EXP,,DE-009507513-2209DEU008008,MERCK,,73.0,YR,,M,Y,,,20220926,,PH,DE,DE,2022,Q3,Elderly
213761201,21376120,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,U,,,,,,,Tablet,,2022,Q3,Pollakiuria,,2022,Q3,1,I,20210907.0,20220921.0,20220926,20220926,EXP,,DE-009507513-2209DEU008008,MERCK,,73.0,YR,,M,Y,,,20220926,,PH,DE,DE,2022,Q3,Elderly
213773831,21377383,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Blood urea increased,,2022,Q3,1,I,20220816.0,,20220923,20220923,DIR,FDA-CDER-CTU-2022-76053,,FDA-CTU,,63.0,YR,,M,N,112.0,KG,20220922,N,HP,US,,2022,Q3,Adult
213773831,21377383,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Blood creatinine increased,,2022,Q3,1,I,20220816.0,,20220923,20220923,DIR,FDA-CDER-CTU-2022-76053,,FDA-CTU,,63.0,YR,,M,N,112.0,KG,20220922,N,HP,US,,2022,Q3,Adult
213778521,21377852,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2022,Q3,Ulcer,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,DE-BAUSCH-BL-2022-022267,BAUSCH AND LOMB,,70.0,YR,,M,Y,100.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778521,21377852,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2022,Q3,Product monitoring error,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,DE-BAUSCH-BL-2022-022267,BAUSCH AND LOMB,,70.0,YR,,M,Y,100.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778521,21377852,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2022,Q3,Inflammation,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,DE-BAUSCH-BL-2022-022267,BAUSCH AND LOMB,,70.0,YR,,M,Y,100.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778631,21377863,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,25.0,MG,,,2022,Q3,Hypoaesthesia,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,DE-ADRED-08237-01,DE-BAUSCH-BL-2022-022453,BAUSCH AND LOMB,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778631,21377863,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,25.0,MG,,,2022,Q3,Palpitations,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,DE-ADRED-08237-01,DE-BAUSCH-BL-2022-022453,BAUSCH AND LOMB,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778631,21377863,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,25.0,MG,,,2022,Q3,Hypoaesthesia,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,DE-ADRED-08237-01,DE-BAUSCH-BL-2022-022453,BAUSCH AND LOMB,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778631,21377863,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,25.0,MG,,,2022,Q3,Anion gap increased,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,DE-ADRED-08237-01,DE-BAUSCH-BL-2022-022453,BAUSCH AND LOMB,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778631,21377863,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,25.0,MG,,,2022,Q3,Chest discomfort,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,DE-ADRED-08237-01,DE-BAUSCH-BL-2022-022453,BAUSCH AND LOMB,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778631,21377863,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,25.0,MG,,,2022,Q3,Lactic acidosis,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,DE-ADRED-08237-01,DE-BAUSCH-BL-2022-022453,BAUSCH AND LOMB,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778631,21377863,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,25.0,MG,,,2022,Q3,Tachycardia,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,DE-ADRED-08237-01,DE-BAUSCH-BL-2022-022453,BAUSCH AND LOMB,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778631,21377863,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,25.0,MG,,,2022,Q3,Atrial fibrillation,,2022,Q3,1,I,,20220922.0,20220926,20220926,EXP,DE-ADRED-08237-01,DE-BAUSCH-BL-2022-022453,BAUSCH AND LOMB,,66.0,YR,,M,Y,86.6,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213782321,21378232,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,,,,,,10.0,MG,,,2022,Q3,Polycythaemia,,2022,Q3,1,I,,20220913.0,20220927,20220927,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-355715,RANBAXY,"Schumacher KA, Gosmanov AR. Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy. J Investig Med High Impact Case Rep. 2022;10:1-6",56.0,YR,,M,Y,,,20220927,,HP,US,US,2022,Q3,Adult
213782341,21378234,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,,,,,,10.0,MG,,,2022,Q3,Polycythaemia,,2022,Q3,1,I,,20220913.0,20220927,20220927,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-355712,RANBAXY,"Schumacher KA, Gosmanov AR. Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy. J Investig Med High Impact Case Rep. 2022;10:1-6",63.0,YR,,M,Y,,,20220927,,HP,US,US,2022,Q3,Adult
213782351,21378235,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,,,,,,10.0,MG,,,2022,Q3,Polycythaemia,,2022,Q3,1,I,,20220913.0,20220927,20220927,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-355711,RANBAXY,"Schumacher KA, Gosmanov AR. Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy. J Investig Med High Impact Case Rep. 2022;10:1-6",69.0,YR,,M,Y,,,20220927,,HP,US,US,2022,Q3,Elderly
213782391,21378239,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Daily",,,,,,,,10.0,MG,,,2022,Q3,Polycythaemia,,2022,Q3,1,I,,20220913.0,20220927,20220927,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-355714,RANBAXY,"Schumacher KA, Gosmanov AR. Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy. J Investig Med High Impact Case Rep. 2022;10:1-6",63.0,YR,,M,Y,,,20220927,,HP,US,US,2022,Q3,Adult
213782391,21378239,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Daily",,,,,,,,25.0,MG,,,2022,Q3,Polycythaemia,,2022,Q3,1,I,,20220913.0,20220927,20220927,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-355714,RANBAXY,"Schumacher KA, Gosmanov AR. Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy. J Investig Med High Impact Case Rep. 2022;10:1-6",63.0,YR,,M,Y,,,20220927,,HP,US,US,2022,Q3,Adult
213788111,21378811,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Systemic infection,,2022,Q3,1,I,,20220915.0,20220927,20220927,EXP,,DE-AUROBINDO-AUR-APL-2022-038091,AUROBINDO,,78.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213788111,21378811,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Acute respiratory failure,,2022,Q3,1,I,,20220915.0,20220927,20220927,EXP,,DE-AUROBINDO-AUR-APL-2022-038091,AUROBINDO,,78.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213788111,21378811,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220915.0,20220927,20220927,EXP,,DE-AUROBINDO-AUR-APL-2022-038091,AUROBINDO,,78.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213788111,21378811,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220915.0,20220927,20220927,EXP,,DE-AUROBINDO-AUR-APL-2022-038091,AUROBINDO,,78.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213788111,21378811,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220915.0,20220927,20220927,EXP,,DE-AUROBINDO-AUR-APL-2022-038091,AUROBINDO,,78.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213788111,21378811,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Electrocardiogram abnormal,,2022,Q3,1,I,,20220915.0,20220927,20220927,EXP,,DE-AUROBINDO-AUR-APL-2022-038091,AUROBINDO,,78.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213788111,21378811,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Arrhythmia,,2022,Q3,1,I,,20220915.0,20220927,20220927,EXP,,DE-AUROBINDO-AUR-APL-2022-038091,AUROBINDO,,78.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213788111,21378811,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Atrial fibrillation,,2022,Q3,1,I,,20220915.0,20220927,20220927,EXP,,DE-AUROBINDO-AUR-APL-2022-038091,AUROBINDO,,78.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213788111,21378811,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Acute myocardial infarction,,2022,Q3,1,I,,20220915.0,20220927,20220927,EXP,,DE-AUROBINDO-AUR-APL-2022-038091,AUROBINDO,,78.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213788111,21378811,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Renal impairment,,2022,Q3,1,I,,20220915.0,20220927,20220927,EXP,,DE-AUROBINDO-AUR-APL-2022-038091,AUROBINDO,,78.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213788111,21378811,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Tachycardia,,2022,Q3,1,I,,20220915.0,20220927,20220927,EXP,,DE-AUROBINDO-AUR-APL-2022-038091,AUROBINDO,,78.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213788171,21378817,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q3,Cardiac failure acute,,2022,Q3,1,I,20220912.0,20220920.0,20220927,20220927,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193069",BOEHRINGER INGELHEIM,,54.0,YR,A,M,Y,,,20220927,,MD,SK,SK,2022,Q3,Adult
213796971,21379697,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,,,,QD,2022,Q3,Metabolic acidosis,,2022,Q3,1,I,20220710.0,,20220923,20220923,DIR,FDA-CDER-CTU-2022-76118,,FDA-CTU,,74.0,YR,,M,N,94.0,KG,20220918,N,PH,US,,2022,Q3,Elderly
213796971,21379697,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,,,,QD,2022,Q3,Acute myocardial infarction,,2022,Q3,1,I,20220710.0,,20220923,20220923,DIR,FDA-CDER-CTU-2022-76118,,FDA-CTU,,74.0,YR,,M,N,94.0,KG,20220918,N,PH,US,,2022,Q3,Elderly
213796971,21379697,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,,,,QD,2022,Q3,Cardiogenic shock,,2022,Q3,1,I,20220710.0,,20220923,20220923,DIR,FDA-CDER-CTU-2022-76118,,FDA-CTU,,74.0,YR,,M,N,94.0,KG,20220918,N,PH,US,,2022,Q3,Elderly
213796971,21379697,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,,,,QD,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,20220710.0,,20220923,20220923,DIR,FDA-CDER-CTU-2022-76118,,FDA-CTU,,74.0,YR,,M,N,94.0,KG,20220918,N,PH,US,,2022,Q3,Elderly
213801261,21380126,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2022,Q3,Therapeutic drug monitoring analysis not performed,,2022,Q3,1,I,,20220921.0,20220927,20220927,EXP,,DE-SA-2022SA393530,SANOFI AVENTIS,,55.0,YR,A,M,Y,84.0,KG,20220927,,PH,DE,DE,2022,Q3,Adult
213801261,21380126,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2022,Q3,Wound,,2022,Q3,1,I,,20220921.0,20220927,20220927,EXP,,DE-SA-2022SA393530,SANOFI AVENTIS,,55.0,YR,A,M,Y,84.0,KG,20220927,,PH,DE,DE,2022,Q3,Adult
213801261,21380126,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2022,Q3,Product monitoring error,,2022,Q3,1,I,,20220921.0,20220927,20220927,EXP,,DE-SA-2022SA393530,SANOFI AVENTIS,,55.0,YR,A,M,Y,84.0,KG,20220927,,PH,DE,DE,2022,Q3,Adult
213802081,21380208,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,,DIABETTES MELLITUS,,,10.0,MG,,QD,2022,Q3,Acute kidney injury,,2022,Q3,1,I,,,20220923,20220923,DIR,FDA-CDER-CTU-2022-76199,,FDA-CTU,,74.0,YR,,M,N,,,20220615,N,PH,US,,2022,Q3,Elderly
213803761,21380376,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q3,Dizziness,,2022,Q3,1,I,20211013.0,,20220923,20220923,DIR,FDA-CDER-CTU-2022-76204,,FDA-CTU,,81.0,YR,,M,N,87.54,KG,20220218,N,PH,US,,2022,Q3,Elderly
213803761,21380376,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q3,Syncope,,2022,Q3,1,I,20211013.0,,20220923,20220923,DIR,FDA-CDER-CTU-2022-76204,,FDA-CTU,,81.0,YR,,M,N,87.54,KG,20220218,N,PH,US,,2022,Q3,Elderly
213803761,21380376,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q3,Orthostatic hypotension,,2022,Q3,1,I,20211013.0,,20220923,20220923,DIR,FDA-CDER-CTU-2022-76204,,FDA-CTU,,81.0,YR,,M,N,87.54,KG,20220218,N,PH,US,,2022,Q3,Elderly
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Atrial enlargement,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Glomerular filtration rate increased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Cardiac failure congestive,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Atrial flutter,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Ventricular tachycardia,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Ventricular extrasystoles,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,International normalised ratio fluctuation,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Dyspnoea,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Haemoglobin decreased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Supraventricular extrasystoles,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Glycosylated haemoglobin increased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Sinus arrest,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Bundle branch block left,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Troponin T increased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Blood thyroid stimulating hormone increased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Pancreatitis,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Condition aggravated,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Chest pain,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Fatigue,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Mean cell haemoglobin increased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Heart rate increased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Hydrocholecystis,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Drug effect less than expected,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Congestive cardiomyopathy,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Anaemia,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Extrasystoles,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Electrocardiogram ST segment abnormal,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Atrial flutter,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Heart rate irregular,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Electrocardiogram abnormal,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Atrial fibrillation,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Ejection fraction decreased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Sciatica,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Ventricular fibrillation,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Red cell distribution width increased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Ventricular tachycardia,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Asthenia,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Atrial fibrillation,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Hyperlipidaemia,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Platelet count decreased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Transferrin saturation decreased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Inflammatory marker increased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Cholelithiasis,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Arrhythmia supraventricular,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Arrhythmia,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Mean cell volume increased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Exercise tolerance decreased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Vitamin B12 deficiency,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Weight increased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Ventricular extrasystoles,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213806921,21380692,35,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q3,Electrocardiogram T wave amplitude decreased,,2022,Q3,1,I,20140101.0,20220920.0,20220927,20220927,EXP,,NVSC2022HU216711,NOVARTIS,,53.0,YR,,M,Y,118.0,KG,20220927,,MD,HU,HU,2022,Q3,Adult
213807511,21380751,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0-0,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Product administration error,,2022,Q3,1,I,20210907.0,20220920.0,20220927,20220927,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022329,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213807511,21380751,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0-0,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Cystitis,,2022,Q3,1,I,20210907.0,20220920.0,20220927,20220927,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022329,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213807511,21380751,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0-0,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Urinary hesitation,,2022,Q3,1,I,20210907.0,20220920.0,20220927,20220927,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022329,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213807511,21380751,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0-0,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Product monitoring error,,2022,Q3,1,I,20210907.0,20220920.0,20220927,20220927,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022329,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213807511,21380751,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0-0,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Pollakiuria,,2022,Q3,1,I,20210907.0,20220920.0,20220927,20220927,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022329,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213807511,21380751,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0-0,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Acute kidney injury,,2022,Q3,1,I,20210907.0,20220920.0,20220927,20220927,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022329,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213807511,21380751,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0-0,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Labelled drug-drug interaction medication error,,2022,Q3,1,I,20210907.0,20220920.0,20220927,20220927,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022329,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213807511,21380751,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1-0-0-0,,,U,,,,,10.0,MG,Tablet,,2022,Q3,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q3,1,I,20210907.0,20220920.0,20220927,20220927,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022329,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220927,,PH,DE,DE,2022,Q3,Elderly
213838961,21383896,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"3 Dosage forms Daily; 10 mg, 1-1-1-0, Unit dose : 1 DF , frequency : 3 times a day",,,,,,,,,,,TID,2022,Q3,Abdominal pain,,2022,Q3,1,I,,20220919.0,20220928,20220928,EXP,,DE-TEVA-2022-DE-2076006,TEVA,,82.0,YR,E,M,Y,,,20220928,,MD,DE,DE,2022,Q3,Elderly
213838961,21383896,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"3 Dosage forms Daily; 10 mg, 1-1-1-0, Unit dose : 1 DF , frequency : 3 times a day",,,,,,,,,,,TID,2022,Q3,Dehydration,,2022,Q3,1,I,,20220919.0,20220928,20220928,EXP,,DE-TEVA-2022-DE-2076006,TEVA,,82.0,YR,E,M,Y,,,20220928,,MD,DE,DE,2022,Q3,Elderly
213838961,21383896,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"3 Dosage forms Daily; 10 mg, 1-1-1-0, Unit dose : 1 DF , frequency : 3 times a day",,,,,,,,,,,TID,2022,Q3,Haematuria,,2022,Q3,1,I,,20220919.0,20220928,20220928,EXP,,DE-TEVA-2022-DE-2076006,TEVA,,82.0,YR,E,M,Y,,,20220928,,MD,DE,DE,2022,Q3,Elderly
213838961,21383896,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"3 Dosage forms Daily; 10 mg, 1-1-1-0, Unit dose : 1 DF , frequency : 3 times a day",,,,,,,,,,,TID,2022,Q3,Flatulence,,2022,Q3,1,I,,20220919.0,20220928,20220928,EXP,,DE-TEVA-2022-DE-2076006,TEVA,,82.0,YR,E,M,Y,,,20220928,,MD,DE,DE,2022,Q3,Elderly
213838961,21383896,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"3 Dosage forms Daily; 10 mg, 1-1-1-0, Unit dose : 1 DF , frequency : 3 times a day",,,,,,,,,,,TID,2022,Q3,Constipation,,2022,Q3,1,I,,20220919.0,20220928,20220928,EXP,,DE-TEVA-2022-DE-2076006,TEVA,,82.0,YR,E,M,Y,,,20220928,,MD,DE,DE,2022,Q3,Elderly
213838961,21383896,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"3 Dosage forms Daily; 10 mg, 1-1-1-0, Unit dose : 1 DF , frequency : 3 times a day",,,,,,,,,,,TID,2022,Q3,Micturition disorder,,2022,Q3,1,I,,20220919.0,20220928,20220928,EXP,,DE-TEVA-2022-DE-2076006,TEVA,,82.0,YR,E,M,Y,,,20220928,,MD,DE,DE,2022,Q3,Elderly
213840241,21384024,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Anaemia,,2022,Q3,1,I,,20220923.0,20220928,20220928,EXP,,NVSC2022DE216491,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213840241,21384024,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220923.0,20220928,20220928,EXP,,NVSC2022DE216491,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213840241,21384024,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Urinary hesitation,,2022,Q3,1,I,,20220923.0,20220928,20220928,EXP,,NVSC2022DE216491,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213840241,21384024,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Urogenital haemorrhage,,2022,Q3,1,I,,20220923.0,20220928,20220928,EXP,,NVSC2022DE216491,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213840241,21384024,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Pain,,2022,Q3,1,I,,20220923.0,20220928,20220928,EXP,,NVSC2022DE216491,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213840241,21384024,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Bladder tamponade,,2022,Q3,1,I,,20220923.0,20220928,20220928,EXP,,NVSC2022DE216491,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213840241,21384024,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Systemic infection,,2022,Q3,1,I,,20220923.0,20220928,20220928,EXP,,NVSC2022DE216491,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213840241,21384024,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q3,Condition aggravated,,2022,Q3,1,I,,20220923.0,20220928,20220928,EXP,,NVSC2022DE216491,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213843411,21384341,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2022,Q3,Product monitoring error,,2022,Q3,1,I,,20220920.0,20220928,20220928,EXP,,DE-009507513-2209DEU007183,MERCK,,55.0,YR,,M,Y,84.0,KG,20220928,,PH,DE,DE,2022,Q3,Adult
213843411,21384341,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2022,Q3,Therapeutic drug monitoring analysis not performed,,2022,Q3,1,I,,20220920.0,20220928,20220928,EXP,,DE-009507513-2209DEU007183,MERCK,,55.0,YR,,M,Y,84.0,KG,20220928,,PH,DE,DE,2022,Q3,Adult
213843411,21384341,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2022,Q3,Wound,,2022,Q3,1,I,,20220920.0,20220928,20220928,EXP,,DE-009507513-2209DEU007183,MERCK,,55.0,YR,,M,Y,84.0,KG,20220928,,PH,DE,DE,2022,Q3,Adult
213845521,21384552,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Pruritus,,2022,Q3,1,I,20220101.0,20220927.0,20220928,20220928,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-194410",BOEHRINGER INGELHEIM,,49.0,YR,A,M,Y,,,20220928,,HP,SG,SG,2022,Q3,Adult
213845521,21384552,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Pruritus genital,,2022,Q3,1,I,20220101.0,20220927.0,20220928,20220928,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-194410",BOEHRINGER INGELHEIM,,49.0,YR,A,M,Y,,,20220928,,HP,SG,SG,2022,Q3,Adult
213853881,21385388,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,QD,2022,Q3,Bundle branch block left,,2022,Q3,1,I,20220101.0,20220922.0,20220928,20220928,EXP,,NVSC2022HR216451,NOVARTIS,,53.0,YR,,M,Y,,,20220928,,MD,HR,HR,2022,Q3,Adult
213853881,21385388,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,QD,2022,Q3,N-terminal prohormone brain natriuretic peptide increased,,2022,Q3,1,I,20220101.0,20220922.0,20220928,20220928,EXP,,NVSC2022HR216451,NOVARTIS,,53.0,YR,,M,Y,,,20220928,,MD,HR,HR,2022,Q3,Adult
213853881,21385388,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,QD,2022,Q3,Dizziness postural,,2022,Q3,1,I,20220101.0,20220922.0,20220928,20220928,EXP,,NVSC2022HR216451,NOVARTIS,,53.0,YR,,M,Y,,,20220928,,MD,HR,HR,2022,Q3,Adult
213853881,21385388,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,QD,2022,Q3,Effusion,,2022,Q3,1,I,20220101.0,20220922.0,20220928,20220928,EXP,,NVSC2022HR216451,NOVARTIS,,53.0,YR,,M,Y,,,20220928,,MD,HR,HR,2022,Q3,Adult
213853881,21385388,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,QD,2022,Q3,Cardiomegaly,,2022,Q3,1,I,20220101.0,20220922.0,20220928,20220928,EXP,,NVSC2022HR216451,NOVARTIS,,53.0,YR,,M,Y,,,20220928,,MD,HR,HR,2022,Q3,Adult
213853881,21385388,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,QD,2022,Q3,Dyspnoea exertional,,2022,Q3,1,I,20220101.0,20220922.0,20220928,20220928,EXP,,NVSC2022HR216451,NOVARTIS,,53.0,YR,,M,Y,,,20220928,,MD,HR,HR,2022,Q3,Adult
213853881,21385388,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,QD,2022,Q3,Oedema peripheral,,2022,Q3,1,I,20220101.0,20220922.0,20220928,20220928,EXP,,NVSC2022HR216451,NOVARTIS,,53.0,YR,,M,Y,,,20220928,,MD,HR,HR,2022,Q3,Adult
213853881,21385388,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,QD,2022,Q3,Blood pressure decreased,,2022,Q3,1,I,20220101.0,20220922.0,20220928,20220928,EXP,,NVSC2022HR216451,NOVARTIS,,53.0,YR,,M,Y,,,20220928,,MD,HR,HR,2022,Q3,Adult
213853881,21385388,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,QD,2022,Q3,Ejection fraction decreased,,2022,Q3,1,I,20220101.0,20220922.0,20220928,20220928,EXP,,NVSC2022HR216451,NOVARTIS,,53.0,YR,,M,Y,,,20220928,,MD,HR,HR,2022,Q3,Adult
213853881,21385388,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,QD,2022,Q3,Nocturnal dyspnoea,,2022,Q3,1,I,20220101.0,20220922.0,20220928,20220928,EXP,,NVSC2022HR216451,NOVARTIS,,53.0,YR,,M,Y,,,20220928,,MD,HR,HR,2022,Q3,Adult
213853881,21385388,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,QD,2022,Q3,Blood pressure systolic increased,,2022,Q3,1,I,20220101.0,20220922.0,20220928,20220928,EXP,,NVSC2022HR216451,NOVARTIS,,53.0,YR,,M,Y,,,20220928,,MD,HR,HR,2022,Q3,Adult
213857631,21385763,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Haematuria,,2022,Q3,1,I,20210801.0,20220919.0,20220928,20220928,EXP,DE-ADRED-08112-01,DE-TORRENT-00023313,TORRENT,,64.0,YR,A,M,Y,85.0,KG,20220928,,PH,DE,DE,2022,Q3,Adult
213857631,21385763,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Hyperkalaemia,,2022,Q3,1,I,20210801.0,20220919.0,20220928,20220928,EXP,DE-ADRED-08112-01,DE-TORRENT-00023313,TORRENT,,64.0,YR,A,M,Y,85.0,KG,20220928,,PH,DE,DE,2022,Q3,Adult
213859251,21385925,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Nausea,,2022,Q3,1,I,20220906.0,20220927.0,20220928,20220928,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-194429",BOEHRINGER INGELHEIM,,42.0,YR,A,F,Y,75.6,KG,20220928,,HP,SG,SG,2022,Q3,Adult
213859251,21385925,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Vomiting,,2022,Q3,1,I,20220906.0,20220927.0,20220928,20220928,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-194429",BOEHRINGER INGELHEIM,,42.0,YR,A,F,Y,75.6,KG,20220928,,HP,SG,SG,2022,Q3,Adult
213859251,21385925,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Off label use,,2022,Q3,1,I,20220906.0,20220927.0,20220928,20220928,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-194429",BOEHRINGER INGELHEIM,,42.0,YR,A,F,Y,75.6,KG,20220928,,HP,SG,SG,2022,Q3,Adult
213859251,21385925,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,20220906.0,20220927.0,20220928,20220928,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-194429",BOEHRINGER INGELHEIM,,42.0,YR,A,F,Y,75.6,KG,20220928,,HP,SG,SG,2022,Q3,Adult
213860751,21386075,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,,,,25.0,MG,,QD,2022,Q3,Depressed level of consciousness,,2022,Q3,1,I,,20220926.0,20220928,20220928,EXP,,NVSC2022DE217965,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213860751,21386075,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,,,,25.0,MG,,QD,2022,Q3,Hypertension,,2022,Q3,1,I,,20220926.0,20220928,20220928,EXP,,NVSC2022DE217965,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213860751,21386075,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,,,,25.0,MG,,QD,2022,Q3,Aphasia,,2022,Q3,1,I,,20220926.0,20220928,20220928,EXP,,NVSC2022DE217965,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213860751,21386075,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,,,,25.0,MG,,QD,2022,Q3,Cerebral haemorrhage,,2022,Q3,1,I,,20220926.0,20220928,20220928,EXP,,NVSC2022DE217965,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213860751,21386075,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,,,,25.0,MG,,QD,2022,Q3,Anaemia,,2022,Q3,1,I,,20220926.0,20220928,20220928,EXP,,NVSC2022DE217965,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213860751,21386075,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,,,,25.0,MG,,QD,2022,Q3,Paraesthesia,,2022,Q3,1,I,,20220926.0,20220928,20220928,EXP,,NVSC2022DE217965,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213860751,21386075,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,,,,25.0,MG,,QD,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220926.0,20220928,20220928,EXP,,NVSC2022DE217965,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213860751,21386075,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, QD (1-0-0-0)",,,U,,,,,25.0,MG,,QD,2022,Q3,Restlessness,,2022,Q3,1,I,,20220926.0,20220928,20220928,EXP,,NVSC2022DE217965,NOVARTIS,,77.0,YR,,M,Y,,,20220928,,PH,DE,DE,2022,Q3,Elderly
213862061,21386206,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Asthenia,,2022,Q3,1,I,20220908.0,20220927.0,20220928,20220928,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-194401",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220928,,HP,SG,SG,2022,Q3,Elderly
213862061,21386206,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Back pain,,2022,Q3,1,I,20220908.0,20220927.0,20220928,20220928,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-194401",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220928,,HP,SG,SG,2022,Q3,Elderly
213862061,21386206,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q3,Pain in extremity,,2022,Q3,1,I,20220908.0,20220927.0,20220928,20220928,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-194401",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20220928,,HP,SG,SG,2022,Q3,Elderly
213867451,21386745,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,,,,,,,,,,2022,Q3,Product administration error,,2022,Q3,1,I,20211001.0,20220920.0,20220928,20220928,EXP,,DE-AstraZeneca-2022A322519,ASTRAZENECA,,73.0,YR,,M,Y,,,20220928,,MD,DE,,2022,Q3,Elderly
213867451,21386745,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,,,,,,,,,,2022,Q3,Haemoglobin decreased,,2022,Q3,1,I,20211001.0,20220920.0,20220928,20220928,EXP,,DE-AstraZeneca-2022A322519,ASTRAZENECA,,73.0,YR,,M,Y,,,20220928,,MD,DE,,2022,Q3,Elderly
213867451,21386745,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,,,,,,,,,,2022,Q3,Upper gastrointestinal haemorrhage,,2022,Q3,1,I,20211001.0,20220920.0,20220928,20220928,EXP,,DE-AstraZeneca-2022A322519,ASTRAZENECA,,73.0,YR,,M,Y,,,20220928,,MD,DE,,2022,Q3,Elderly
213867451,21386745,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,,,,,,,,,,2022,Q3,Asthenia,,2022,Q3,1,I,20211001.0,20220920.0,20220928,20220928,EXP,,DE-AstraZeneca-2022A322519,ASTRAZENECA,,73.0,YR,,M,Y,,,20220928,,MD,DE,,2022,Q3,Elderly
213867451,21386745,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,,,,,,,,,,2022,Q3,Haematochezia,,2022,Q3,1,I,20211001.0,20220920.0,20220928,20220928,EXP,,DE-AstraZeneca-2022A322519,ASTRAZENECA,,73.0,YR,,M,Y,,,20220928,,MD,DE,,2022,Q3,Elderly
213867451,21386745,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,,,,,,,,,,2022,Q3,Extra dose administered,,2022,Q3,1,I,20211001.0,20220920.0,20220928,20220928,EXP,,DE-AstraZeneca-2022A322519,ASTRAZENECA,,73.0,YR,,M,Y,,,20220928,,MD,DE,,2022,Q3,Elderly
213867451,21386745,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,,,,,,,,,,2022,Q3,Melaena,,2022,Q3,1,I,20211001.0,20220920.0,20220928,20220928,EXP,,DE-AstraZeneca-2022A322519,ASTRAZENECA,,73.0,YR,,M,Y,,,20220928,,MD,DE,,2022,Q3,Elderly
213884241,21388424,14,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, 1x/day",,,,,,,,,,,QD,2022,Q3,Urosepsis,,2022,Q3,1,I,20220530.0,20220927.0,20220928,20220928,EXP,EE-SAM-9952209151,EE-PFIZER INC-202201188834,PFIZER,,70.0,YR,,F,Y,,,20220928,,MD,EE,EE,2022,Q3,Elderly
213884241,21388424,14,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, 1x/day",,,,,,,,,,,QD,2022,Q3,Pneumonia,,2022,Q3,1,I,20220530.0,20220927.0,20220928,20220928,EXP,EE-SAM-9952209151,EE-PFIZER INC-202201188834,PFIZER,,70.0,YR,,F,Y,,,20220928,,MD,EE,EE,2022,Q3,Elderly
213884241,21388424,14,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, 1x/day",,,,,,,,,,,QD,2022,Q3,Cerebral infarction,,2022,Q3,1,I,20220530.0,20220927.0,20220928,20220928,EXP,EE-SAM-9952209151,EE-PFIZER INC-202201188834,PFIZER,,70.0,YR,,F,Y,,,20220928,,MD,EE,EE,2022,Q3,Elderly
213891641,21389164,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"2 Dosage forms Daily; 10 mg, 0-2-0-0, Unit dose : 2 DF , frequency : OD",,,,,"UNKNOWN,Unknown",,,,,Tablet,QD,2022,Q3,Product prescribing error,,2022,Q3,1,I,,20220919.0,20220929,20220929,EXP,,DE-TEVA-2022-DE-2076494,TEVA,,68.0,YR,E,F,Y,,,20220929,,PH,DE,DE,2022,Q3,Elderly
213891641,21389164,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"2 Dosage forms Daily; 10 mg, 0-2-0-0, Unit dose : 2 DF , frequency : OD",,,,,"UNKNOWN,Unknown",,,,,Tablet,QD,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220919.0,20220929,20220929,EXP,,DE-TEVA-2022-DE-2076494,TEVA,,68.0,YR,E,F,Y,,,20220929,,PH,DE,DE,2022,Q3,Elderly
213891641,21389164,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"2 Dosage forms Daily; 10 mg, 0-2-0-0, Unit dose : 2 DF , frequency : OD",,,,,"UNKNOWN,Unknown",,,,,Tablet,QD,2022,Q3,Syncope,,2022,Q3,1,I,,20220919.0,20220929,20220929,EXP,,DE-TEVA-2022-DE-2076494,TEVA,,68.0,YR,E,F,Y,,,20220929,,PH,DE,DE,2022,Q3,Elderly
213891641,21389164,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"2 Dosage forms Daily; 10 mg, 0-2-0-0, Unit dose : 2 DF , frequency : OD",,,,,"UNKNOWN,Unknown",,,,,Tablet,QD,2022,Q3,Respiratory failure,,2022,Q3,1,I,,20220919.0,20220929,20220929,EXP,,DE-TEVA-2022-DE-2076494,TEVA,,68.0,YR,E,F,Y,,,20220929,,PH,DE,DE,2022,Q3,Elderly
213893071,21389307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once a Day",,,U,,,,,25.0,MG,Tablet,QD,2022,Q3,Product monitoring error,,2022,Q3,1,I,,20220916.0,20220929,20220929,EXP,,DE-AUROBINDO-AUR-APL-2022-038308,AUROBINDO,,70.0,YR,,M,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213893071,21389307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once a Day",,,U,,,,,25.0,MG,Tablet,QD,2022,Q3,Inflammation,,2022,Q3,1,I,,20220916.0,20220929,20220929,EXP,,DE-AUROBINDO-AUR-APL-2022-038308,AUROBINDO,,70.0,YR,,M,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213893071,21389307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once a Day",,,U,,,,,25.0,MG,Tablet,QD,2022,Q3,Ulcer,,2022,Q3,1,I,,20220916.0,20220929,20220929,EXP,,DE-AUROBINDO-AUR-APL-2022-038308,AUROBINDO,,70.0,YR,,M,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213894591,21389459,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram,1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Hyperkalaemia,,2022,Q3,1,I,20210801.0,20220919.0,20220929,20220929,EXP,,DE-AUROBINDO-AUR-APL-2022-038662,AUROBINDO,,64.0,YR,,M,Y,85.0,KG,20220929,,PH,DE,DE,2022,Q3,Adult
213894591,21389459,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram,1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Haematuria,,2022,Q3,1,I,20210801.0,20220919.0,20220929,20220929,EXP,,DE-AUROBINDO-AUR-APL-2022-038662,AUROBINDO,,64.0,YR,,M,Y,85.0,KG,20220929,,PH,DE,DE,2022,Q3,Adult
213899241,21389924,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220915.0,20220929,20220929,EXP,DE-ADRED-07815-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10132,ALKEM,,78.0,YR,,M,Y,,,20220929,,PH,DE,DE,2022,Q3,Elderly
213899241,21389924,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Tachycardia,,2022,Q3,1,I,,20220915.0,20220929,20220929,EXP,DE-ADRED-07815-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10132,ALKEM,,78.0,YR,,M,Y,,,20220929,,PH,DE,DE,2022,Q3,Elderly
213899241,21389924,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220915.0,20220929,20220929,EXP,DE-ADRED-07815-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10132,ALKEM,,78.0,YR,,M,Y,,,20220929,,PH,DE,DE,2022,Q3,Elderly
213899241,21389924,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220915.0,20220929,20220929,EXP,DE-ADRED-07815-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10132,ALKEM,,78.0,YR,,M,Y,,,20220929,,PH,DE,DE,2022,Q3,Elderly
213899241,21389924,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Arrhythmia,,2022,Q3,1,I,,20220915.0,20220929,20220929,EXP,DE-ADRED-07815-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10132,ALKEM,,78.0,YR,,M,Y,,,20220929,,PH,DE,DE,2022,Q3,Elderly
213899241,21389924,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Acute respiratory failure,,2022,Q3,1,I,,20220915.0,20220929,20220929,EXP,DE-ADRED-07815-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10132,ALKEM,,78.0,YR,,M,Y,,,20220929,,PH,DE,DE,2022,Q3,Elderly
213899241,21389924,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Atrial fibrillation,,2022,Q3,1,I,,20220915.0,20220929,20220929,EXP,DE-ADRED-07815-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10132,ALKEM,,78.0,YR,,M,Y,,,20220929,,PH,DE,DE,2022,Q3,Elderly
213899241,21389924,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Acute myocardial infarction,,2022,Q3,1,I,,20220915.0,20220929,20220929,EXP,DE-ADRED-07815-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10132,ALKEM,,78.0,YR,,M,Y,,,20220929,,PH,DE,DE,2022,Q3,Elderly
213899241,21389924,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Electrocardiogram abnormal,,2022,Q3,1,I,,20220915.0,20220929,20220929,EXP,DE-ADRED-07815-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10132,ALKEM,,78.0,YR,,M,Y,,,20220929,,PH,DE,DE,2022,Q3,Elderly
213899241,21389924,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Renal impairment,,2022,Q3,1,I,,20220915.0,20220929,20220929,EXP,DE-ADRED-07815-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10132,ALKEM,,78.0,YR,,M,Y,,,20220929,,PH,DE,DE,2022,Q3,Elderly
213899241,21389924,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q3,Systemic infection,,2022,Q3,1,I,,20220915.0,20220929,20220929,EXP,DE-ADRED-07815-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10132,ALKEM,,78.0,YR,,M,Y,,,20220929,,PH,DE,DE,2022,Q3,Elderly
213916721,21391672,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,NVSC2022DE217188,NOVARTIS,,54.0,YR,,M,Y,98.0,KG,20220929,,PH,DE,DE,2022,Q3,Adult
213916721,21391672,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q3,Electrocardiogram abnormal,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,NVSC2022DE217188,NOVARTIS,,54.0,YR,,M,Y,98.0,KG,20220929,,PH,DE,DE,2022,Q3,Adult
213916721,21391672,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q3,Polyneuropathy,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,NVSC2022DE217188,NOVARTIS,,54.0,YR,,M,Y,98.0,KG,20220929,,PH,DE,DE,2022,Q3,Adult
213916721,21391672,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q3,Condition aggravated,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,NVSC2022DE217188,NOVARTIS,,54.0,YR,,M,Y,98.0,KG,20220929,,PH,DE,DE,2022,Q3,Adult
213916721,21391672,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,NVSC2022DE217188,NOVARTIS,,54.0,YR,,M,Y,98.0,KG,20220929,,PH,DE,DE,2022,Q3,Adult
213916721,21391672,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q3,Chest pain,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,NVSC2022DE217188,NOVARTIS,,54.0,YR,,M,Y,98.0,KG,20220929,,PH,DE,DE,2022,Q3,Adult
213916721,21391672,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q3,Systemic infection,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,NVSC2022DE217188,NOVARTIS,,54.0,YR,,M,Y,98.0,KG,20220929,,PH,DE,DE,2022,Q3,Adult
213916721,21391672,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q3,Labelled drug-drug interaction medication error,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,NVSC2022DE217188,NOVARTIS,,54.0,YR,,M,Y,98.0,KG,20220929,,PH,DE,DE,2022,Q3,Adult
213920161,21392016,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Acute kidney injury,,2022,Q3,1,I,20220215.0,,20220928,20220928,DIR,FDA-CDER-CTU-2022-77240,,FDA-CTU,,81.0,YR,,M,N,90.26,KG,20220918,N,PH,US,,2022,Q3,Elderly
213920161,21392016,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Tubulointerstitial nephritis,,2022,Q3,1,I,20220215.0,,20220928,20220928,DIR,FDA-CDER-CTU-2022-77240,,FDA-CTU,,81.0,YR,,M,N,90.26,KG,20220918,N,PH,US,,2022,Q3,Elderly
213920161,21392016,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Hyperkalaemia,,2022,Q3,1,I,20220215.0,,20220928,20220928,DIR,FDA-CDER-CTU-2022-77240,,FDA-CTU,,81.0,YR,,M,N,90.26,KG,20220918,N,PH,US,,2022,Q3,Elderly
213920161,21392016,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Dehydration,,2022,Q3,1,I,20220215.0,,20220928,20220928,DIR,FDA-CDER-CTU-2022-77240,,FDA-CTU,,81.0,YR,,M,N,90.26,KG,20220918,N,PH,US,,2022,Q3,Elderly
213920161,21392016,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q3,Fatigue,,2022,Q3,1,I,20220215.0,,20220928,20220928,DIR,FDA-CDER-CTU-2022-77240,,FDA-CTU,,81.0,YR,,M,N,90.26,KG,20220918,N,PH,US,,2022,Q3,Elderly
213920431,21392043,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2022,Q3,Acute kidney injury,,2022,Q3,1,I,20211231.0,,20220928,20220928,DIR,FDA-CDER-CTU-2022-77243,,FDA-CTU,,67.0,YR,,M,N,88.9,KG,20220918,N,MD,US,,2022,Q3,Elderly
213920431,21392043,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2022,Q3,Urinary retention,,2022,Q3,1,I,20211231.0,,20220928,20220928,DIR,FDA-CDER-CTU-2022-77243,,FDA-CTU,,67.0,YR,,M,N,88.9,KG,20220918,N,MD,US,,2022,Q3,Elderly
213920431,21392043,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2022,Q3,Dehydration,,2022,Q3,1,I,20211231.0,,20220928,20220928,DIR,FDA-CDER-CTU-2022-77243,,FDA-CTU,,67.0,YR,,M,N,88.9,KG,20220918,N,MD,US,,2022,Q3,Elderly
213939501,21393950,14,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, 1x/day",,,,,,,,,,,QD,2022,Q3,Cerebral infarction,,2022,Q3,1,I,20220530.0,20220927.0,20220930,20220930,PER,EE-SAM-9952209151,EE-AMGEN-ESTSP2022167845,AMGEN,,70.0,YR,E,F,Y,,,20220929,,MD,EE,EE,2022,Q3,Elderly
213939501,21393950,14,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, 1x/day",,,,,,,,,,,QD,2022,Q3,Pneumonia,,2022,Q3,1,I,20220530.0,20220927.0,20220930,20220930,PER,EE-SAM-9952209151,EE-AMGEN-ESTSP2022167845,AMGEN,,70.0,YR,E,F,Y,,,20220929,,MD,EE,EE,2022,Q3,Elderly
213939501,21393950,14,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, 1x/day",,,,,,,,,,,QD,2022,Q3,Urosepsis,,2022,Q3,1,I,20220530.0,20220927.0,20220930,20220930,PER,EE-SAM-9952209151,EE-AMGEN-ESTSP2022167845,AMGEN,,70.0,YR,E,F,Y,,,20220929,,MD,EE,EE,2022,Q3,Elderly
213950521,21395052,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Faeces discoloured,,2022,Q3,1,I,,20220926.0,20220930,20220930,EXP,,NVSC2022DE217377,NOVARTIS,,59.0,YR,,M,Y,93.0,KG,20220930,,PH,DE,DE,2022,Q3,Adult
213950521,21395052,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Abdominal pain,,2022,Q3,1,I,,20220926.0,20220930,20220930,EXP,,NVSC2022DE217377,NOVARTIS,,59.0,YR,,M,Y,93.0,KG,20220930,,PH,DE,DE,2022,Q3,Adult
213950521,21395052,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Hyperhidrosis,,2022,Q3,1,I,,20220926.0,20220930,20220930,EXP,,NVSC2022DE217377,NOVARTIS,,59.0,YR,,M,Y,93.0,KG,20220930,,PH,DE,DE,2022,Q3,Adult
213950521,21395052,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Microcytic anaemia,,2022,Q3,1,I,,20220926.0,20220930,20220930,EXP,,NVSC2022DE217377,NOVARTIS,,59.0,YR,,M,Y,93.0,KG,20220930,,PH,DE,DE,2022,Q3,Adult
213950521,21395052,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Abdominal pain upper,,2022,Q3,1,I,,20220926.0,20220930,20220930,EXP,,NVSC2022DE217377,NOVARTIS,,59.0,YR,,M,Y,93.0,KG,20220930,,PH,DE,DE,2022,Q3,Adult
213950521,21395052,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Dyspnoea exertional,,2022,Q3,1,I,,20220926.0,20220930,20220930,EXP,,NVSC2022DE217377,NOVARTIS,,59.0,YR,,M,Y,93.0,KG,20220930,,PH,DE,DE,2022,Q3,Adult
213950521,21395052,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Fatigue,,2022,Q3,1,I,,20220926.0,20220930,20220930,EXP,,NVSC2022DE217377,NOVARTIS,,59.0,YR,,M,Y,93.0,KG,20220930,,PH,DE,DE,2022,Q3,Adult
213950521,21395052,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Dizziness,,2022,Q3,1,I,,20220926.0,20220930,20220930,EXP,,NVSC2022DE217377,NOVARTIS,,59.0,YR,,M,Y,93.0,KG,20220930,,PH,DE,DE,2022,Q3,Adult
213950521,21395052,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,QD,2022,Q3,Muscular weakness,,2022,Q3,1,I,,20220926.0,20220930,20220930,EXP,,NVSC2022DE217377,NOVARTIS,,59.0,YR,,M,Y,93.0,KG,20220930,,PH,DE,DE,2022,Q3,Adult
213951381,21395138,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,U,,,,,25.0,MG,,QD,2022,Q3,Lactic acidosis,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,DE-AUROBINDO-AUR-APL-2022-039513,AUROBINDO,,66.0,YR,,M,Y,86.6,KG,20220930,,PH,DE,DE,2022,Q3,Elderly
213951381,21395138,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,U,,,,,25.0,MG,,QD,2022,Q3,Chest discomfort,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,DE-AUROBINDO-AUR-APL-2022-039513,AUROBINDO,,66.0,YR,,M,Y,86.6,KG,20220930,,PH,DE,DE,2022,Q3,Elderly
213951381,21395138,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,U,,,,,25.0,MG,,QD,2022,Q3,Atrial fibrillation,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,DE-AUROBINDO-AUR-APL-2022-039513,AUROBINDO,,66.0,YR,,M,Y,86.6,KG,20220930,,PH,DE,DE,2022,Q3,Elderly
213951381,21395138,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,U,,,,,25.0,MG,,QD,2022,Q3,Hypoaesthesia,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,DE-AUROBINDO-AUR-APL-2022-039513,AUROBINDO,,66.0,YR,,M,Y,86.6,KG,20220930,,PH,DE,DE,2022,Q3,Elderly
213951381,21395138,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,U,,,,,25.0,MG,,QD,2022,Q3,Palpitations,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,DE-AUROBINDO-AUR-APL-2022-039513,AUROBINDO,,66.0,YR,,M,Y,86.6,KG,20220930,,PH,DE,DE,2022,Q3,Elderly
213951381,21395138,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,U,,,,,25.0,MG,,QD,2022,Q3,Anion gap increased,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,DE-AUROBINDO-AUR-APL-2022-039513,AUROBINDO,,66.0,YR,,M,Y,86.6,KG,20220930,,PH,DE,DE,2022,Q3,Elderly
213951381,21395138,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,U,,,,,25.0,MG,,QD,2022,Q3,Tachycardia,,2022,Q3,1,I,,20220920.0,20220930,20220930,EXP,,DE-AUROBINDO-AUR-APL-2022-039513,AUROBINDO,,66.0,YR,,M,Y,86.6,KG,20220930,,PH,DE,DE,2022,Q3,Elderly
213985601,21398560,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1-0-0-0,",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q3,1,I,20220907.0,20220922.0,20220930,20220930,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022718,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220930,,PH,DE,DE,2022,Q3,Elderly
213985601,21398560,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1-0-0-0,",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Product administration error,,2022,Q3,1,I,20220907.0,20220922.0,20220930,20220930,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022718,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220930,,PH,DE,DE,2022,Q3,Elderly
213985601,21398560,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1-0-0-0,",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Cystitis,,2022,Q3,1,I,20220907.0,20220922.0,20220930,20220930,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022718,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220930,,PH,DE,DE,2022,Q3,Elderly
213985601,21398560,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1-0-0-0,",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Urinary hesitation,,2022,Q3,1,I,20220907.0,20220922.0,20220930,20220930,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022718,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220930,,PH,DE,DE,2022,Q3,Elderly
213985601,21398560,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1-0-0-0,",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Acute kidney injury,,2022,Q3,1,I,20220907.0,20220922.0,20220930,20220930,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022718,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220930,,PH,DE,DE,2022,Q3,Elderly
213985601,21398560,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1-0-0-0,",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Product monitoring error,,2022,Q3,1,I,20220907.0,20220922.0,20220930,20220930,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022718,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220930,,PH,DE,DE,2022,Q3,Elderly
213985601,21398560,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1-0-0-0,",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Pollakiuria,,2022,Q3,1,I,20220907.0,20220922.0,20220930,20220930,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022718,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220930,,PH,DE,DE,2022,Q3,Elderly
213985601,21398560,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1-0-0-0,",,,U,,,,,10.0,MG,Tablet,,2022,Q3,Labelled drug-drug interaction medication error,,2022,Q3,1,I,20220907.0,20220922.0,20220930,20220930,EXP,DE-ADRED-08158-01,DE-BAUSCH-BL-2022-022718,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20220930,,PH,DE,DE,2022,Q3,Elderly
214048231,21404823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO,,,Y,D,,,,,,Tablet,QD,2022,Q3,Acidosis,,2022,Q3,1,I,20220730.0,,20220930,20220930,DIR,FDA-CDER-CTU-2022-78285,,FDA-CTU,,79.0,YR,,M,N,,,20220918,N,HP,US,,2022,Q3,Elderly
214048231,21404823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO,,,Y,D,,,,,,Tablet,QD,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,20220730.0,,20220930,20220930,DIR,FDA-CDER-CTU-2022-78285,,FDA-CTU,,79.0,YR,,M,N,,,20220918,N,HP,US,,2022,Q3,Elderly
214048231,21404823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO,,,Y,D,,,,,,Tablet,QD,2022,Q3,Decreased appetite,,2022,Q3,1,I,20220730.0,,20220930,20220930,DIR,FDA-CDER-CTU-2022-78285,,FDA-CTU,,79.0,YR,,M,N,,,20220918,N,HP,US,,2022,Q3,Elderly
214048231,21404823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO,,,Y,D,,,,,,Tablet,QD,2022,Q3,Hypophagia,,2022,Q3,1,I,20220730.0,,20220930,20220930,DIR,FDA-CDER-CTU-2022-78285,,FDA-CTU,,79.0,YR,,M,N,,,20220918,N,HP,US,,2022,Q3,Elderly
214048231,21404823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO,,,Y,D,,,,,,Tablet,QD,2022,Q3,Asthenia,,2022,Q3,1,I,20220730.0,,20220930,20220930,DIR,FDA-CDER-CTU-2022-78285,,FDA-CTU,,79.0,YR,,M,N,,,20220918,N,HP,US,,2022,Q3,Elderly
214048231,21404823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO,,,Y,D,,,,,,Tablet,QD,2022,Q3,Urinary tract infection,,2022,Q3,1,I,20220730.0,,20220930,20220930,DIR,FDA-CDER-CTU-2022-78285,,FDA-CTU,,79.0,YR,,M,N,,,20220918,N,HP,US,,2022,Q3,Elderly
1652766613,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q4,Enuresis,,2022,Q4,13,F,20170929.0,20221110.0,20190703,20221117,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20221117,,MD,JP,JP,2022,Q4,Young Adult
1652766613,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q4,Diabetes mellitus,,2022,Q4,13,F,20170929.0,20221110.0,20190703,20221117,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20221117,,MD,JP,JP,2022,Q4,Young Adult
1652766613,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q4,Bronchitis,,2022,Q4,13,F,20170929.0,20221110.0,20190703,20221117,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20221117,,MD,JP,JP,2022,Q4,Young Adult
1652766613,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q4,Electrocardiogram abnormal,,2022,Q4,13,F,20170929.0,20221110.0,20190703,20221117,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20221117,,MD,JP,JP,2022,Q4,Young Adult
1652766613,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q4,Stomatitis,,2022,Q4,13,F,20170929.0,20221110.0,20190703,20221117,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20221117,,MD,JP,JP,2022,Q4,Young Adult
1652766613,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q4,Schizophrenia,,2022,Q4,13,F,20170929.0,20221110.0,20190703,20221117,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20221117,,MD,JP,JP,2022,Q4,Young Adult
1652766613,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q4,Pruritus genital,,2022,Q4,13,F,20170929.0,20221110.0,20190703,20221117,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20221117,,MD,JP,JP,2022,Q4,Young Adult
1652766613,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q4,Insomnia,,2022,Q4,13,F,20170929.0,20221110.0,20190703,20221117,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20221117,,MD,JP,JP,2022,Q4,Young Adult
1652766613,16527666,36,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2022,Q4,Gastroenteritis,,2022,Q4,13,F,20170929.0,20221110.0,20190703,20221117,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20221117,,MD,JP,JP,2022,Q4,Young Adult
166163476,16616347,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Lower respiratory tract infection,,2022,Q4,6,F,20180704.0,20221223.0,20190723,20221227,EXP,,GB-MYLANLABS-2019M1068313,MYLAN,,57.0,YR,,F,Y,,,20221227,,MD,GB,GB,2022,Q4,Adult
166163476,16616347,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Pneumonia,,2022,Q4,6,F,20180704.0,20221223.0,20190723,20221227,EXP,,GB-MYLANLABS-2019M1068313,MYLAN,,57.0,YR,,F,Y,,,20221227,,MD,GB,GB,2022,Q4,Adult
166163476,16616347,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Diabetic ketoacidosis,,2022,Q4,6,F,20180704.0,20221223.0,20190723,20221227,EXP,,GB-MYLANLABS-2019M1068313,MYLAN,,57.0,YR,,F,Y,,,20221227,,MD,GB,GB,2022,Q4,Adult
166163476,16616347,63,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Sepsis,,2022,Q4,6,F,20180704.0,20221223.0,20190723,20221227,EXP,,GB-MYLANLABS-2019M1068313,MYLAN,,57.0,YR,,F,Y,,,20221227,,MD,GB,GB,2022,Q4,Adult
179084922,17908492,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,204629.0,,,,,2022,Q4,Asthenia,,2022,Q4,2,F,,20221220.0,20200617,20221222,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-029197",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20221222,,HP,IL,IL,2022,Q4,Elderly
179084922,17908492,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,204629.0,,,,,2022,Q4,Tubulointerstitial nephritis,,2022,Q4,2,F,,20221220.0,20200617,20221222,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-029197",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20221222,,HP,IL,IL,2022,Q4,Elderly
179084922,17908492,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,204629.0,,,,,2022,Q4,Acute kidney injury,,2022,Q4,2,F,,20221220.0,20200617,20221222,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-029197",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20221222,,HP,IL,IL,2022,Q4,Elderly
179084922,17908492,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,204629.0,,,,,2022,Q4,Renal tubular necrosis,,2022,Q4,2,F,,20221220.0,20200617,20221222,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-029197",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20221222,,HP,IL,IL,2022,Q4,Elderly
179084922,17908492,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,204629.0,,,,,2022,Q4,Dizziness,,2022,Q4,2,F,,20221220.0,20200617,20221222,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-029197",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20221222,,HP,IL,IL,2022,Q4,Elderly
182932732,18293273,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once a Day",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,General physical health deterioration,,2022,Q4,2,F,,20221012.0,20200922,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-048565,AUROBINDO,,60.0,YR,,M,Y,97.0,KG,20221021,,PH,DE,DE,2022,Q4,Adult
182932732,18293273,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once a Day",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,Product monitoring error,,2022,Q4,2,F,,20221012.0,20200922,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-048565,AUROBINDO,,60.0,YR,,M,Y,97.0,KG,20221021,,PH,DE,DE,2022,Q4,Adult
182932732,18293273,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once a Day",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,Cough,,2022,Q4,2,F,,20221012.0,20200922,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-048565,AUROBINDO,,60.0,YR,,M,Y,97.0,KG,20221021,,PH,DE,DE,2022,Q4,Adult
182932732,18293273,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, Once a Day",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221012.0,20200922,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-048565,AUROBINDO,,60.0,YR,,M,Y,97.0,KG,20221021,,PH,DE,DE,2022,Q4,Adult
183067872,18306787,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD  (1-0-0-0)",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,Cough,,2022,Q4,2,F,,20221014.0,20200924,20221019,EXP,,NVSC2020DE254574,NOVARTIS,,60.0,YR,,M,Y,97.0,KG,20221019,,PH,DE,DE,2022,Q4,Adult
183067872,18306787,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD  (1-0-0-0)",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,General physical health deterioration,,2022,Q4,2,F,,20221014.0,20200924,20221019,EXP,,NVSC2020DE254574,NOVARTIS,,60.0,YR,,M,Y,97.0,KG,20221019,,PH,DE,DE,2022,Q4,Adult
183067872,18306787,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD  (1-0-0-0)",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,Product monitoring error,,2022,Q4,2,F,,20221014.0,20200924,20221019,EXP,,NVSC2020DE254574,NOVARTIS,,60.0,YR,,M,Y,97.0,KG,20221019,,PH,DE,DE,2022,Q4,Adult
183067872,18306787,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD  (1-0-0-0)",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221014.0,20200924,20221019,EXP,,NVSC2020DE254574,NOVARTIS,,60.0,YR,,M,Y,97.0,KG,20221019,,PH,DE,DE,2022,Q4,Adult
183080902,18308090,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablet",,,,,,,,25.0,MG,Tablet,QD,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221014.0,20200924,20221019,EXP,DE-ADRED-05421-01,DE-BAUSCH-BL-2020-027072,BAUSCH AND LOMB,,60.0,YR,,M,Y,97.0,KG,20221019,,PH,DE,DE,2022,Q4,Adult
183080902,18308090,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablet",,,,,,,,25.0,MG,Tablet,QD,2022,Q4,Cough,,2022,Q4,2,F,,20221014.0,20200924,20221019,EXP,DE-ADRED-05421-01,DE-BAUSCH-BL-2020-027072,BAUSCH AND LOMB,,60.0,YR,,M,Y,97.0,KG,20221019,,PH,DE,DE,2022,Q4,Adult
183080902,18308090,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablet",,,,,,,,25.0,MG,Tablet,QD,2022,Q4,Product monitoring error,,2022,Q4,2,F,,20221014.0,20200924,20221019,EXP,DE-ADRED-05421-01,DE-BAUSCH-BL-2020-027072,BAUSCH AND LOMB,,60.0,YR,,M,Y,97.0,KG,20221019,,PH,DE,DE,2022,Q4,Adult
183080902,18308090,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablet",,,,,,,,25.0,MG,Tablet,QD,2022,Q4,General physical health deterioration,,2022,Q4,2,F,,20221014.0,20200924,20221019,EXP,DE-ADRED-05421-01,DE-BAUSCH-BL-2020-027072,BAUSCH AND LOMB,,60.0,YR,,M,Y,97.0,KG,20221019,,PH,DE,DE,2022,Q4,Adult
183138433,18313843,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg QD,,,U,N,,,,,,,,2022,Q4,General physical health deterioration,,2022,Q4,3,F,,20221024.0,20200925,20221026,EXP,,DE-ANIPHARMA-2020-DE-000215,ANI,,60.0,YR,,M,Y,97.0,KG,20221026,,PH,DE,DE,2022,Q4,Adult
183138433,18313843,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg QD,,,U,N,,,,,,,,2022,Q4,Pneumonia,,2022,Q4,3,F,,20221024.0,20200925,20221026,EXP,,DE-ANIPHARMA-2020-DE-000215,ANI,,60.0,YR,,M,Y,97.0,KG,20221026,,PH,DE,DE,2022,Q4,Adult
183138433,18313843,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg QD,,,U,N,,,,,,,,2022,Q4,Product monitoring error,,2022,Q4,3,F,,20221024.0,20200925,20221026,EXP,,DE-ANIPHARMA-2020-DE-000215,ANI,,60.0,YR,,M,Y,97.0,KG,20221026,,PH,DE,DE,2022,Q4,Adult
183138433,18313843,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg QD,,,U,N,,,,,,,,2022,Q4,Condition aggravated,,2022,Q4,3,F,,20221024.0,20200925,20221026,EXP,,DE-ANIPHARMA-2020-DE-000215,ANI,,60.0,YR,,M,Y,97.0,KG,20221026,,PH,DE,DE,2022,Q4,Adult
183391782,18339178,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablet",,,,,,,,25.0,MG,Tablet,,2022,Q4,Cough,,2022,Q4,2,F,,20221205.0,20201002,20221212,EXP,,DE-MYLANLABS-2020M1082873,MYLAN,,60.0,YR,,M,Y,97.0,KG,20221212,,PH,DE,DE,2022,Q4,Adult
183391782,18339178,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablet",,,,,,,,25.0,MG,Tablet,,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221205.0,20201002,20221212,EXP,,DE-MYLANLABS-2020M1082873,MYLAN,,60.0,YR,,M,Y,97.0,KG,20221212,,PH,DE,DE,2022,Q4,Adult
183391782,18339178,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablet",,,,,,,,25.0,MG,Tablet,,2022,Q4,Product monitoring error,,2022,Q4,2,F,,20221205.0,20201002,20221212,EXP,,DE-MYLANLABS-2020M1082873,MYLAN,,60.0,YR,,M,Y,97.0,KG,20221212,,PH,DE,DE,2022,Q4,Adult
183391782,18339178,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablet",,,,,,,,25.0,MG,Tablet,,2022,Q4,General physical health deterioration,,2022,Q4,2,F,,20221205.0,20201002,20221212,EXP,,DE-MYLANLABS-2020M1082873,MYLAN,,60.0,YR,,M,Y,97.0,KG,20221212,,PH,DE,DE,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Joint effusion,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Blood uric acid increased,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Arthropathy,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Psoriasis,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Hepatic enzyme increased,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Nephrolithiasis,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Synovitis,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Sepsis,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Incorrect dose administered,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Renal disorder,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Synovial disorder,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Injection site pain,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,C-reactive protein increased,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Urinary tract infection,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Joint swelling,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Blood iron decreased,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Condition aggravated,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Pain,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Injection site warmth,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Oedema,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Tendonitis,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Osteoarthritis,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Arthritis,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Pain in extremity,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Cyst,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Drug ineffective,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Antinuclear antibody positive,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Pyrexia,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Rash,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Alanine aminotransferase increased,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Arthralgia,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Allergic sinusitis,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
184309707,18430970,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2022,Q4,Vitamin B12 decreased,,2022,Q4,7,F,20200110.0,20221011.0,20201027,20221018,EXP,,NVSC2020CA010601,NOVARTIS,,56.0,YR,,F,Y,,,20221018,,CN,CA,CA,2022,Q4,Adult
1845526411,18455264,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q4,Body height increased,,2022,Q4,11,F,20200423.0,20221019.0,20201102,20221021,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20221021,,CN,CO,CO,2022,Q4,Elderly
1845526411,18455264,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q4,Hypothyroidism,,2022,Q4,11,F,20200423.0,20221019.0,20201102,20221021,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20221021,,CN,CO,CO,2022,Q4,Elderly
1845526411,18455264,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q4,Expired product administered,,2022,Q4,11,F,20200423.0,20221019.0,20201102,20221021,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20221021,,CN,CO,CO,2022,Q4,Elderly
1845526411,18455264,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q4,Chronic obstructive pulmonary disease,,2022,Q4,11,F,20200423.0,20221019.0,20201102,20221021,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20221021,,CN,CO,CO,2022,Q4,Elderly
1845526411,18455264,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q4,Hyperthyroidism,,2022,Q4,11,F,20200423.0,20221019.0,20201102,20221021,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20221021,,CN,CO,CO,2022,Q4,Elderly
1845526411,18455264,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,11,F,20200423.0,20221019.0,20201102,20221021,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20221021,,CN,CO,CO,2022,Q4,Elderly
1845526411,18455264,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q4,Weight decreased,,2022,Q4,11,F,20200423.0,20221019.0,20201102,20221021,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20221021,,CN,CO,CO,2022,Q4,Elderly
1845526411,18455264,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2022,Q4,Weight increased,,2022,Q4,11,F,20200423.0,20221019.0,20201102,20221021,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20221021,,CN,CO,CO,2022,Q4,Elderly
184722332,18472233,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablets",,,,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,2,F,,20221119.0,20201106,20221203,EXP,DE-BFARM-20011875,DE-Accord-207482,ACCORD,,68.0,YR,E,M,Y,99.0,KG,20221203,,PH,DE,DE,2022,Q4,Elderly
184722332,18472233,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablets",,,,,,,,,,Tablet,,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221119.0,20201106,20221203,EXP,DE-BFARM-20011875,DE-Accord-207482,ACCORD,,68.0,YR,E,M,Y,99.0,KG,20221203,,PH,DE,DE,2022,Q4,Elderly
184722332,18472233,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablets",,,,,,,,,,Tablet,,2022,Q4,Hyperkalaemia,,2022,Q4,2,F,,20221119.0,20201106,20221203,EXP,DE-BFARM-20011875,DE-Accord-207482,ACCORD,,68.0,YR,E,M,Y,99.0,KG,20221203,,PH,DE,DE,2022,Q4,Elderly
184722332,18472233,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablets",,,,,,,,,,Tablet,,2022,Q4,Acute kidney injury,,2022,Q4,2,F,,20221119.0,20201106,20221203,EXP,DE-BFARM-20011875,DE-Accord-207482,ACCORD,,68.0,YR,E,M,Y,99.0,KG,20221203,,PH,DE,DE,2022,Q4,Elderly
184722332,18472233,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablets",,,,,,,,,,Tablet,,2022,Q4,Infection,,2022,Q4,2,F,,20221119.0,20201106,20221203,EXP,DE-BFARM-20011875,DE-Accord-207482,ACCORD,,68.0,YR,E,M,Y,99.0,KG,20221203,,PH,DE,DE,2022,Q4,Elderly
184722332,18472233,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablets",,,,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221119.0,20201106,20221203,EXP,DE-BFARM-20011875,DE-Accord-207482,ACCORD,,68.0,YR,E,M,Y,99.0,KG,20221203,,PH,DE,DE,2022,Q4,Elderly
1848217511,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Angina pectoris,,2022,Q4,11,F,20201019.0,20221110.0,20201110,20221114,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20221114,,MD,JP,JP,2022,Q4,Adult
1848217511,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Arthralgia,,2022,Q4,11,F,20201019.0,20221110.0,20201110,20221114,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20221114,,MD,JP,JP,2022,Q4,Adult
1848217511,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Rash pruritic,,2022,Q4,11,F,20201019.0,20221110.0,20201110,20221114,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20221114,,MD,JP,JP,2022,Q4,Adult
1848217511,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Cataract,,2022,Q4,11,F,20201019.0,20221110.0,20201110,20221114,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20221114,,MD,JP,JP,2022,Q4,Adult
1848217511,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Eczema asteatotic,,2022,Q4,11,F,20201019.0,20221110.0,20201110,20221114,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20221114,,MD,JP,JP,2022,Q4,Adult
184922112,18492211,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day 1-0-0-0",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Infection,,2022,Q4,2,F,,20221014.0,20201111,20221025,EXP,DE-ADRED-05681-01,DE-PFIZER INC-2020442910,MYLAN,,68.0,YR,,M,Y,99.0,KG,20221025,,PH,DE,DE,2022,Q4,Elderly
184922112,18492211,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day 1-0-0-0",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221014.0,20201111,20221025,EXP,DE-ADRED-05681-01,DE-PFIZER INC-2020442910,MYLAN,,68.0,YR,,M,Y,99.0,KG,20221025,,PH,DE,DE,2022,Q4,Elderly
184922112,18492211,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day 1-0-0-0",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Cough,,2022,Q4,2,F,,20221014.0,20201111,20221025,EXP,DE-ADRED-05681-01,DE-PFIZER INC-2020442910,MYLAN,,68.0,YR,,M,Y,99.0,KG,20221025,,PH,DE,DE,2022,Q4,Elderly
184922112,18492211,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day 1-0-0-0",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Acute kidney injury,,2022,Q4,2,F,,20221014.0,20201111,20221025,EXP,DE-ADRED-05681-01,DE-PFIZER INC-2020442910,MYLAN,,68.0,YR,,M,Y,99.0,KG,20221025,,PH,DE,DE,2022,Q4,Elderly
184922112,18492211,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day 1-0-0-0",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221014.0,20201111,20221025,EXP,DE-ADRED-05681-01,DE-PFIZER INC-2020442910,MYLAN,,68.0,YR,,M,Y,99.0,KG,20221025,,PH,DE,DE,2022,Q4,Elderly
184922112,18492211,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day 1-0-0-0",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Hyperkalaemia,,2022,Q4,2,F,,20221014.0,20201111,20221025,EXP,DE-ADRED-05681-01,DE-PFIZER INC-2020442910,MYLAN,,68.0,YR,,M,Y,99.0,KG,20221025,,PH,DE,DE,2022,Q4,Elderly
184952482,18495248,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-0-0-0, Tabletten)",,,U,,,,,10.0,MG,Tablet,,2022,Q4,Acute kidney injury,,2022,Q4,2,F,,20221012.0,20201112,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-055970,AUROBINDO,,68.0,YR,,M,Y,99.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
184952482,18495248,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-0-0-0, Tabletten)",,,U,,,,,10.0,MG,Tablet,,2022,Q4,Hyperkalaemia,,2022,Q4,2,F,,20221012.0,20201112,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-055970,AUROBINDO,,68.0,YR,,M,Y,99.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
184952482,18495248,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-0-0-0, Tabletten)",,,U,,,,,10.0,MG,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221012.0,20201112,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-055970,AUROBINDO,,68.0,YR,,M,Y,99.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
184952482,18495248,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-0-0-0, Tabletten)",,,U,,,,,10.0,MG,Tablet,,2022,Q4,Infection,,2022,Q4,2,F,,20221012.0,20201112,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-055970,AUROBINDO,,68.0,YR,,M,Y,99.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
184952482,18495248,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-0-0-0, Tabletten)",,,U,,,,,10.0,MG,Tablet,,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221012.0,20201112,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-055970,AUROBINDO,,68.0,YR,,M,Y,99.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
184952482,18495248,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-0-0-0, Tabletten)",,,U,,,,,10.0,MG,Tablet,,2022,Q4,Cough,,2022,Q4,2,F,,20221012.0,20201112,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-055970,AUROBINDO,,68.0,YR,,M,Y,99.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
185002712,18500271,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Hyperkalaemia,,2022,Q4,2,F,,20221114.0,20201113,20221125,EXP,,DE-drreddys-GER/GER/20/0128803,DR REDDYS,,68.0,YR,E,M,Y,99.0,KG,20221125,,PH,DE,DE,2022,Q4,Elderly
185002712,18500271,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Acute kidney injury,,2022,Q4,2,F,,20221114.0,20201113,20221125,EXP,,DE-drreddys-GER/GER/20/0128803,DR REDDYS,,68.0,YR,E,M,Y,99.0,KG,20221125,,PH,DE,DE,2022,Q4,Elderly
185002712,18500271,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221114.0,20201113,20221125,EXP,,DE-drreddys-GER/GER/20/0128803,DR REDDYS,,68.0,YR,E,M,Y,99.0,KG,20221125,,PH,DE,DE,2022,Q4,Elderly
185002712,18500271,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221114.0,20201113,20221125,EXP,,DE-drreddys-GER/GER/20/0128803,DR REDDYS,,68.0,YR,E,M,Y,99.0,KG,20221125,,PH,DE,DE,2022,Q4,Elderly
185002712,18500271,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Cough,,2022,Q4,2,F,,20221114.0,20201113,20221125,EXP,,DE-drreddys-GER/GER/20/0128803,DR REDDYS,,68.0,YR,E,M,Y,99.0,KG,20221125,,PH,DE,DE,2022,Q4,Elderly
185002712,18500271,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Infection,,2022,Q4,2,F,,20221114.0,20201113,20221125,EXP,,DE-drreddys-GER/GER/20/0128803,DR REDDYS,,68.0,YR,E,M,Y,99.0,KG,20221125,,PH,DE,DE,2022,Q4,Elderly
185003642,18500364,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,Unk,,,10.0,MG,Tablet,QD,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221014.0,20201113,20221019,EXP,,NVSC2020DE298565,NOVARTIS,,68.0,YR,,M,Y,99.0,KG,20221019,,PH,DE,DE,2022,Q4,Elderly
185003642,18500364,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,Unk,,,10.0,MG,Tablet,QD,2022,Q4,Infection,,2022,Q4,2,F,,20221014.0,20201113,20221019,EXP,,NVSC2020DE298565,NOVARTIS,,68.0,YR,,M,Y,99.0,KG,20221019,,PH,DE,DE,2022,Q4,Elderly
185003642,18500364,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,Unk,,,10.0,MG,Tablet,QD,2022,Q4,Hyperkalaemia,,2022,Q4,2,F,,20221014.0,20201113,20221019,EXP,,NVSC2020DE298565,NOVARTIS,,68.0,YR,,M,Y,99.0,KG,20221019,,PH,DE,DE,2022,Q4,Elderly
185003642,18500364,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,Unk,,,10.0,MG,Tablet,QD,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221014.0,20201113,20221019,EXP,,NVSC2020DE298565,NOVARTIS,,68.0,YR,,M,Y,99.0,KG,20221019,,PH,DE,DE,2022,Q4,Elderly
185003642,18500364,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,Unk,,,10.0,MG,Tablet,QD,2022,Q4,Cough,,2022,Q4,2,F,,20221014.0,20201113,20221019,EXP,,NVSC2020DE298565,NOVARTIS,,68.0,YR,,M,Y,99.0,KG,20221019,,PH,DE,DE,2022,Q4,Elderly
185003642,18500364,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,Unk,,,10.0,MG,Tablet,QD,2022,Q4,Acute kidney injury,,2022,Q4,2,F,,20221014.0,20201113,20221019,EXP,,NVSC2020DE298565,NOVARTIS,,68.0,YR,,M,Y,99.0,KG,20221019,,PH,DE,DE,2022,Q4,Elderly
185099802,18509980,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 Milligram Daily;  1-0-0-0,",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Infection,,2022,Q4,2,F,,20221019.0,20201117,20221029,EXP,,DE-TEVA-2020-DE-1848290,TEVA,,68.0,YR,E,M,Y,99.0,KG,20221029,,PH,DE,DE,2022,Q4,Elderly
185099802,18509980,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 Milligram Daily;  1-0-0-0,",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Hyperkalaemia,,2022,Q4,2,F,,20221019.0,20201117,20221029,EXP,,DE-TEVA-2020-DE-1848290,TEVA,,68.0,YR,E,M,Y,99.0,KG,20221029,,PH,DE,DE,2022,Q4,Elderly
185099802,18509980,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 Milligram Daily;  1-0-0-0,",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221019.0,20201117,20221029,EXP,,DE-TEVA-2020-DE-1848290,TEVA,,68.0,YR,E,M,Y,99.0,KG,20221029,,PH,DE,DE,2022,Q4,Elderly
185099802,18509980,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 Milligram Daily;  1-0-0-0,",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Acute kidney injury,,2022,Q4,2,F,,20221019.0,20201117,20221029,EXP,,DE-TEVA-2020-DE-1848290,TEVA,,68.0,YR,E,M,Y,99.0,KG,20221029,,PH,DE,DE,2022,Q4,Elderly
185099802,18509980,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 Milligram Daily;  1-0-0-0,",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Cough,,2022,Q4,2,F,,20221019.0,20201117,20221029,EXP,,DE-TEVA-2020-DE-1848290,TEVA,,68.0,YR,E,M,Y,99.0,KG,20221029,,PH,DE,DE,2022,Q4,Elderly
185099802,18509980,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 Milligram Daily;  1-0-0-0,",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221019.0,20201117,20221029,EXP,,DE-TEVA-2020-DE-1848290,TEVA,,68.0,YR,E,M,Y,99.0,KG,20221029,,PH,DE,DE,2022,Q4,Elderly
185100642,18510064,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten ()",,,U,,,,,,,Tablet,,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221018.0,20201117,20221102,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-267739,RANBAXY,,68.0,YR,,M,Y,99.0,KG,20221102,,PH,DE,DE,2022,Q4,Elderly
185100642,18510064,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten ()",,,U,,,,,,,Tablet,,2022,Q4,Acute kidney injury,,2022,Q4,2,F,,20221018.0,20201117,20221102,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-267739,RANBAXY,,68.0,YR,,M,Y,99.0,KG,20221102,,PH,DE,DE,2022,Q4,Elderly
185100642,18510064,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten ()",,,U,,,,,,,Tablet,,2022,Q4,Infection,,2022,Q4,2,F,,20221018.0,20201117,20221102,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-267739,RANBAXY,,68.0,YR,,M,Y,99.0,KG,20221102,,PH,DE,DE,2022,Q4,Elderly
185100642,18510064,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten ()",,,U,,,,,,,Tablet,,2022,Q4,Hyperkalaemia,,2022,Q4,2,F,,20221018.0,20201117,20221102,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-267739,RANBAXY,,68.0,YR,,M,Y,99.0,KG,20221102,,PH,DE,DE,2022,Q4,Elderly
185100642,18510064,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten ()",,,U,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,2,F,,20221018.0,20201117,20221102,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-267739,RANBAXY,,68.0,YR,,M,Y,99.0,KG,20221102,,PH,DE,DE,2022,Q4,Elderly
185100642,18510064,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten ()",,,U,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221018.0,20201117,20221102,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-267739,RANBAXY,,68.0,YR,,M,Y,99.0,KG,20221102,,PH,DE,DE,2022,Q4,Elderly
186570828,18657082,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Hip fracture,,2022,Q4,8,F,20201117.0,20221028.0,20201223,20221104,EXP,,CA-TAKEDA-2020TUS059112,TAKEDA,,77.0,YR,,M,Y,,,20221104,,CN,CA,CA,2022,Q4,Elderly
186570828,18657082,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Off label use,,2022,Q4,8,F,20201117.0,20221028.0,20201223,20221104,EXP,,CA-TAKEDA-2020TUS059112,TAKEDA,,77.0,YR,,M,Y,,,20221104,,CN,CA,CA,2022,Q4,Elderly
186570828,18657082,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Hepatic cirrhosis,,2022,Q4,8,F,20201117.0,20221028.0,20201223,20221104,EXP,,CA-TAKEDA-2020TUS059112,TAKEDA,,77.0,YR,,M,Y,,,20221104,,CN,CA,CA,2022,Q4,Elderly
186570828,18657082,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,8,F,20201117.0,20221028.0,20201223,20221104,EXP,,CA-TAKEDA-2020TUS059112,TAKEDA,,77.0,YR,,M,Y,,,20221104,,CN,CA,CA,2022,Q4,Elderly
186570828,18657082,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Acute kidney injury,,2022,Q4,8,F,20201117.0,20221028.0,20201223,20221104,EXP,,CA-TAKEDA-2020TUS059112,TAKEDA,,77.0,YR,,M,Y,,,20221104,,CN,CA,CA,2022,Q4,Elderly
186570828,18657082,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Infection,,2022,Q4,8,F,20201117.0,20221028.0,20201223,20221104,EXP,,CA-TAKEDA-2020TUS059112,TAKEDA,,77.0,YR,,M,Y,,,20221104,,CN,CA,CA,2022,Q4,Elderly
186570828,18657082,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Fall,,2022,Q4,8,F,20201117.0,20221028.0,20201223,20221104,EXP,,CA-TAKEDA-2020TUS059112,TAKEDA,,77.0,YR,,M,Y,,,20221104,,CN,CA,CA,2022,Q4,Elderly
186570828,18657082,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Hepatic cancer,,2022,Q4,8,F,20201117.0,20221028.0,20201223,20221104,EXP,,CA-TAKEDA-2020TUS059112,TAKEDA,,77.0,YR,,M,Y,,,20221104,,CN,CA,CA,2022,Q4,Elderly
186570828,18657082,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Product dose omission issue,,2022,Q4,8,F,20201117.0,20221028.0,20201223,20221104,EXP,,CA-TAKEDA-2020TUS059112,TAKEDA,,77.0,YR,,M,Y,,,20221104,,CN,CA,CA,2022,Q4,Elderly
186570828,18657082,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Asthenia,,2022,Q4,8,F,20201117.0,20221028.0,20201223,20221104,EXP,,CA-TAKEDA-2020TUS059112,TAKEDA,,77.0,YR,,M,Y,,,20221104,,CN,CA,CA,2022,Q4,Elderly
189227756,18922775,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1x/day",,,,,,,,25.0,MG,,QD,2022,Q4,Product distribution issue,,2022,Q4,6,F,,20221223.0,20210222,20221228,EXP,,US-PFIZER INC-2019538078,PFIZER,,61.0,YR,,F,Y,,,20221228,,MD,US,US,2022,Q4,Adult
189227756,18922775,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1x/day",,,,,,,,25.0,MG,,QD,2022,Q4,Thrombosis,,2022,Q4,6,F,,20221223.0,20210222,20221228,EXP,,US-PFIZER INC-2019538078,PFIZER,,61.0,YR,,F,Y,,,20221228,,MD,US,US,2022,Q4,Adult
189227756,18922775,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1x/day",,,,,,,,25.0,MG,,QD,2022,Q4,Product dispensing error,,2022,Q4,6,F,,20221223.0,20210222,20221228,EXP,,US-PFIZER INC-2019538078,PFIZER,,61.0,YR,,F,Y,,,20221228,,MD,US,US,2022,Q4,Adult
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Hyperkeratosis,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Blood glucose increased,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Back pain,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Chest pain,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Blood magnesium decreased,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Blood test abnormal,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Injection site pruritus,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Chlamydial infection,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Drug ineffective,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Off label use,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Injection site irritation,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Diabetic retinopathy,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Thrombosis,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Seizure,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Psychogenic seizure,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Injection site reaction,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
1909998711,19099987,32,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Hypertriglyceridaemia,,2022,Q4,11,F,20201201.0,20220921.0,20210407,20221004,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005112,AEGERION,,21.0,YR,,F,Y,61.224,KG,20221004,,CN,US,US,2022,Q4,Youth
194891042,19489104,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram,1-0-0-0, tablet",,,,,,,,10.0,MG,Tablet,,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,2,F,,20221012.0,20210703,20221025,EXP,,DE-AUROBINDO-AUR-APL-2021-027373,AUROBINDO,,70.0,YR,,M,Y,95.0,KG,20221025,,PH,DE,DE,2022,Q4,Elderly
194891042,19489104,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram,1-0-0-0, tablet",,,,,,,,10.0,MG,Tablet,,2022,Q4,Toe amputation,,2022,Q4,2,F,,20221012.0,20210703,20221025,EXP,,DE-AUROBINDO-AUR-APL-2021-027373,AUROBINDO,,70.0,YR,,M,Y,95.0,KG,20221025,,PH,DE,DE,2022,Q4,Elderly
194891042,19489104,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram,1-0-0-0, tablet",,,,,,,,10.0,MG,Tablet,,2022,Q4,Decubitus ulcer,,2022,Q4,2,F,,20221012.0,20210703,20221025,EXP,,DE-AUROBINDO-AUR-APL-2021-027373,AUROBINDO,,70.0,YR,,M,Y,95.0,KG,20221025,,PH,DE,DE,2022,Q4,Elderly
194891042,19489104,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram,1-0-0-0, tablet",,,,,,,,10.0,MG,Tablet,,2022,Q4,Skin ulcer,,2022,Q4,2,F,,20221012.0,20210703,20221025,EXP,,DE-AUROBINDO-AUR-APL-2021-027373,AUROBINDO,,70.0,YR,,M,Y,95.0,KG,20221025,,PH,DE,DE,2022,Q4,Elderly
194891042,19489104,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram,1-0-0-0, tablet",,,,,,,,10.0,MG,Tablet,,2022,Q4,Product monitoring error,,2022,Q4,2,F,,20221012.0,20210703,20221025,EXP,,DE-AUROBINDO-AUR-APL-2021-027373,AUROBINDO,,70.0,YR,,M,Y,95.0,KG,20221025,,PH,DE,DE,2022,Q4,Elderly
194891042,19489104,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram,1-0-0-0, tablet",,,,,,,,10.0,MG,Tablet,,2022,Q4,Erythema,,2022,Q4,2,F,,20221012.0,20210703,20221025,EXP,,DE-AUROBINDO-AUR-APL-2021-027373,AUROBINDO,,70.0,YR,,M,Y,95.0,KG,20221025,,PH,DE,DE,2022,Q4,Elderly
194891042,19489104,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram,1-0-0-0, tablet",,,,,,,,10.0,MG,Tablet,,2022,Q4,Product prescribing error,,2022,Q4,2,F,,20221012.0,20210703,20221025,EXP,,DE-AUROBINDO-AUR-APL-2021-027373,AUROBINDO,,70.0,YR,,M,Y,95.0,KG,20221025,,PH,DE,DE,2022,Q4,Elderly
194891042,19489104,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram,1-0-0-0, tablet",,,,,,,,10.0,MG,Tablet,,2022,Q4,Peripheral swelling,,2022,Q4,2,F,,20221012.0,20210703,20221025,EXP,,DE-AUROBINDO-AUR-APL-2021-027373,AUROBINDO,,70.0,YR,,M,Y,95.0,KG,20221025,,PH,DE,DE,2022,Q4,Elderly
194891042,19489104,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram,1-0-0-0, tablet",,,,,,,,10.0,MG,Tablet,,2022,Q4,Pyrexia,,2022,Q4,2,F,,20221012.0,20210703,20221025,EXP,,DE-AUROBINDO-AUR-APL-2021-027373,AUROBINDO,,70.0,YR,,M,Y,95.0,KG,20221025,,PH,DE,DE,2022,Q4,Elderly
194903592,19490359,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd (1-0-0-0)",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Toe amputation,,2022,Q4,2,F,,20221012.0,20210705,20221021,EXP,DE-BFARM-21006057,DE-NOVOPROD-823249,NOVO NORDISK,,70.0,YR,,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
194903592,19490359,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd (1-0-0-0)",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Erythema,,2022,Q4,2,F,,20221012.0,20210705,20221021,EXP,DE-BFARM-21006057,DE-NOVOPROD-823249,NOVO NORDISK,,70.0,YR,,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
194903592,19490359,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd (1-0-0-0)",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Product monitoring error,,2022,Q4,2,F,,20221012.0,20210705,20221021,EXP,DE-BFARM-21006057,DE-NOVOPROD-823249,NOVO NORDISK,,70.0,YR,,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
194903592,19490359,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd (1-0-0-0)",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Peripheral swelling,,2022,Q4,2,F,,20221012.0,20210705,20221021,EXP,DE-BFARM-21006057,DE-NOVOPROD-823249,NOVO NORDISK,,70.0,YR,,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
194903592,19490359,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd (1-0-0-0)",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Product prescribing error,,2022,Q4,2,F,,20221012.0,20210705,20221021,EXP,DE-BFARM-21006057,DE-NOVOPROD-823249,NOVO NORDISK,,70.0,YR,,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
194903592,19490359,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd (1-0-0-0)",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Pyrexia,,2022,Q4,2,F,,20221012.0,20210705,20221021,EXP,DE-BFARM-21006057,DE-NOVOPROD-823249,NOVO NORDISK,,70.0,YR,,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
194903592,19490359,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd (1-0-0-0)",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Skin ulcer,,2022,Q4,2,F,,20221012.0,20210705,20221021,EXP,DE-BFARM-21006057,DE-NOVOPROD-823249,NOVO NORDISK,,70.0,YR,,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
194903592,19490359,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd (1-0-0-0)",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Decubitus ulcer,,2022,Q4,2,F,,20221012.0,20210705,20221021,EXP,DE-BFARM-21006057,DE-NOVOPROD-823249,NOVO NORDISK,,70.0,YR,,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
194903592,19490359,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd (1-0-0-0)",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,2,F,,20221012.0,20210705,20221021,EXP,DE-BFARM-21006057,DE-NOVOPROD-823249,NOVO NORDISK,,70.0,YR,,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
194991522,19499152,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Peripheral swelling,,2022,Q4,2,F,,20221014.0,20210706,20221018,EXP,,NVSC2021DE148696,NOVARTIS,,70.0,YR,,M,Y,95.0,KG,20221018,,PH,DE,DE,2022,Q4,Elderly
194991522,19499152,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Erythema,,2022,Q4,2,F,,20221014.0,20210706,20221018,EXP,,NVSC2021DE148696,NOVARTIS,,70.0,YR,,M,Y,95.0,KG,20221018,,PH,DE,DE,2022,Q4,Elderly
194991522,19499152,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Product monitoring error,,2022,Q4,2,F,,20221014.0,20210706,20221018,EXP,,NVSC2021DE148696,NOVARTIS,,70.0,YR,,M,Y,95.0,KG,20221018,,PH,DE,DE,2022,Q4,Elderly
194991522,19499152,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Decubitus ulcer,,2022,Q4,2,F,,20221014.0,20210706,20221018,EXP,,NVSC2021DE148696,NOVARTIS,,70.0,YR,,M,Y,95.0,KG,20221018,,PH,DE,DE,2022,Q4,Elderly
194991522,19499152,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,2,F,,20221014.0,20210706,20221018,EXP,,NVSC2021DE148696,NOVARTIS,,70.0,YR,,M,Y,95.0,KG,20221018,,PH,DE,DE,2022,Q4,Elderly
194991522,19499152,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Product prescribing error,,2022,Q4,2,F,,20221014.0,20210706,20221018,EXP,,NVSC2021DE148696,NOVARTIS,,70.0,YR,,M,Y,95.0,KG,20221018,,PH,DE,DE,2022,Q4,Elderly
194991522,19499152,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Pyrexia,,2022,Q4,2,F,,20221014.0,20210706,20221018,EXP,,NVSC2021DE148696,NOVARTIS,,70.0,YR,,M,Y,95.0,KG,20221018,,PH,DE,DE,2022,Q4,Elderly
194991522,19499152,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Skin ulcer,,2022,Q4,2,F,,20221014.0,20210706,20221018,EXP,,NVSC2021DE148696,NOVARTIS,,70.0,YR,,M,Y,95.0,KG,20221018,,PH,DE,DE,2022,Q4,Elderly
195109112,19510911,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD,10 mg, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Peripheral swelling,,2022,Q4,2,F,,20221017.0,20210709,20221026,EXP,,DE-SA-2021SA216364,SANOFI AVENTIS,,70.0,YR,E,M,Y,95.0,KG,20221026,,PH,DE,DE,2022,Q4,Elderly
195109112,19510911,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD,10 mg, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Toe amputation,,2022,Q4,2,F,,20221017.0,20210709,20221026,EXP,,DE-SA-2021SA216364,SANOFI AVENTIS,,70.0,YR,E,M,Y,95.0,KG,20221026,,PH,DE,DE,2022,Q4,Elderly
195109112,19510911,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD,10 mg, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,2,F,,20221017.0,20210709,20221026,EXP,,DE-SA-2021SA216364,SANOFI AVENTIS,,70.0,YR,E,M,Y,95.0,KG,20221026,,PH,DE,DE,2022,Q4,Elderly
195109112,19510911,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD,10 mg, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Erythema,,2022,Q4,2,F,,20221017.0,20210709,20221026,EXP,,DE-SA-2021SA216364,SANOFI AVENTIS,,70.0,YR,E,M,Y,95.0,KG,20221026,,PH,DE,DE,2022,Q4,Elderly
195109112,19510911,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD,10 mg, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Pyrexia,,2022,Q4,2,F,,20221017.0,20210709,20221026,EXP,,DE-SA-2021SA216364,SANOFI AVENTIS,,70.0,YR,E,M,Y,95.0,KG,20221026,,PH,DE,DE,2022,Q4,Elderly
195109112,19510911,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD,10 mg, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Decubitus ulcer,,2022,Q4,2,F,,20221017.0,20210709,20221026,EXP,,DE-SA-2021SA216364,SANOFI AVENTIS,,70.0,YR,E,M,Y,95.0,KG,20221026,,PH,DE,DE,2022,Q4,Elderly
195109112,19510911,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD,10 mg, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Product prescribing error,,2022,Q4,2,F,,20221017.0,20210709,20221026,EXP,,DE-SA-2021SA216364,SANOFI AVENTIS,,70.0,YR,E,M,Y,95.0,KG,20221026,,PH,DE,DE,2022,Q4,Elderly
195109112,19510911,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD,10 mg, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Product monitoring error,,2022,Q4,2,F,,20221017.0,20210709,20221026,EXP,,DE-SA-2021SA216364,SANOFI AVENTIS,,70.0,YR,E,M,Y,95.0,KG,20221026,,PH,DE,DE,2022,Q4,Elderly
195109112,19510911,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD,10 mg, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Decubitus ulcer,,2022,Q4,2,F,,20221017.0,20210709,20221026,EXP,,DE-SA-2021SA216364,SANOFI AVENTIS,,70.0,YR,E,M,Y,95.0,KG,20221026,,PH,DE,DE,2022,Q4,Elderly
195109112,19510911,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD,10 mg, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Peripheral swelling,,2022,Q4,2,F,,20221017.0,20210709,20221026,EXP,,DE-SA-2021SA216364,SANOFI AVENTIS,,70.0,YR,E,M,Y,95.0,KG,20221026,,PH,DE,DE,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Off label use,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Cardiac failure,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Fall,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Abdominal pain upper,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Transient ischaemic attack,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Constipation,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Neoplasm skin,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Pneumonia,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Blood pressure increased,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Neuropathy peripheral,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Chest discomfort,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,COVID-19 immunisation,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Cataract,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Product use issue,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Dyspnoea,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Haemorrhoidal haemorrhage,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Haemorrhoids,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Vulvovaginal mycotic infection,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Drug ineffective,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,COVID-19,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
1977202811,19772028,39,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Clostridium difficile colitis,,2022,Q4,11,F,20211024.0,20221110.0,20210831,20221116,EXP,,CA-TAKEDA-2018MPI014438,TAKEDA,,67.0,YR,,F,Y,,,20221116,,CN,CA,CA,2022,Q4,Elderly
198150882,19815088,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, tablets",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Dyspnoea exertional,,2022,Q4,2,F,,20221017.0,20210910,20221028,EXP,DE-ADRED-07051-01,DE-TORRENT-00021058,TORRENT,,79.0,YR,E,F,Y,,,20221028,,MD,DE,DE,2022,Q4,Elderly
198150882,19815088,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, tablets",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Angina pectoris,,2022,Q4,2,F,,20221017.0,20210910,20221028,EXP,DE-ADRED-07051-01,DE-TORRENT-00021058,TORRENT,,79.0,YR,E,F,Y,,,20221028,,MD,DE,DE,2022,Q4,Elderly
198150882,19815088,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, tablets",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Oedema peripheral,,2022,Q4,2,F,,20221017.0,20210910,20221028,EXP,DE-ADRED-07051-01,DE-TORRENT-00021058,TORRENT,,79.0,YR,E,F,Y,,,20221028,,MD,DE,DE,2022,Q4,Elderly
198150882,19815088,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, tablets",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Cough,,2022,Q4,2,F,,20221017.0,20210910,20221028,EXP,DE-ADRED-07051-01,DE-TORRENT-00021058,TORRENT,,79.0,YR,E,F,Y,,,20221028,,MD,DE,DE,2022,Q4,Elderly
198150882,19815088,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, tablets",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221017.0,20210910,20221028,EXP,DE-ADRED-07051-01,DE-TORRENT-00021058,TORRENT,,79.0,YR,E,F,Y,,,20221028,,MD,DE,DE,2022,Q4,Elderly
198154632,19815463,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,Cough,,2022,Q4,2,F,,20221017.0,20210910,20221024,EXP,,NVSC2021DE199854,NOVARTIS,,79.0,YR,,F,Y,,,20221024,,MD,DE,DE,2022,Q4,Elderly
198154632,19815463,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,Dyspnoea exertional,,2022,Q4,2,F,,20221017.0,20210910,20221024,EXP,,NVSC2021DE199854,NOVARTIS,,79.0,YR,,F,Y,,,20221024,,MD,DE,DE,2022,Q4,Elderly
198154632,19815463,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,Oedema peripheral,,2022,Q4,2,F,,20221017.0,20210910,20221024,EXP,,NVSC2021DE199854,NOVARTIS,,79.0,YR,,F,Y,,,20221024,,MD,DE,DE,2022,Q4,Elderly
198154632,19815463,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,Angina pectoris,,2022,Q4,2,F,,20221017.0,20210910,20221024,EXP,,NVSC2021DE199854,NOVARTIS,,79.0,YR,,F,Y,,,20221024,,MD,DE,DE,2022,Q4,Elderly
198154632,19815463,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221017.0,20210910,20221024,EXP,,NVSC2021DE199854,NOVARTIS,,79.0,YR,,F,Y,,,20221024,,MD,DE,DE,2022,Q4,Elderly
198354282,19835428,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, 1-0-0-0, tablets",,,,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221121.0,20210915,20221203,EXP,DE-BFARM-21008377,DE-Accord-238399,ACCORD,,79.0,YR,E,F,Y,,,20221203,,MD,DE,DE,2022,Q4,Elderly
198354282,19835428,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, 1-0-0-0, tablets",,,,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,2,F,,20221121.0,20210915,20221203,EXP,DE-BFARM-21008377,DE-Accord-238399,ACCORD,,79.0,YR,E,F,Y,,,20221203,,MD,DE,DE,2022,Q4,Elderly
198354282,19835428,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, 1-0-0-0, tablets",,,,,,,,,,Tablet,,2022,Q4,Oedema peripheral,,2022,Q4,2,F,,20221121.0,20210915,20221203,EXP,DE-BFARM-21008377,DE-Accord-238399,ACCORD,,79.0,YR,E,F,Y,,,20221203,,MD,DE,DE,2022,Q4,Elderly
198354282,19835428,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, 1-0-0-0, tablets",,,,,,,,,,Tablet,,2022,Q4,Angina pectoris,,2022,Q4,2,F,,20221121.0,20210915,20221203,EXP,DE-BFARM-21008377,DE-Accord-238399,ACCORD,,79.0,YR,E,F,Y,,,20221203,,MD,DE,DE,2022,Q4,Elderly
199460543,19946054,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,3,F,,20221205.0,20211012,20221212,EXP,,DE-MYLANLABS-2021M1070977,MYLAN,,70.0,YR,,M,Y,95.0,KG,20221212,,PH,DE,DE,2022,Q4,Elderly
199460543,19946054,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Pyrexia,,2022,Q4,3,F,,20221205.0,20211012,20221212,EXP,,DE-MYLANLABS-2021M1070977,MYLAN,,70.0,YR,,M,Y,95.0,KG,20221212,,PH,DE,DE,2022,Q4,Elderly
199460543,19946054,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Toe amputation,,2022,Q4,3,F,,20221205.0,20211012,20221212,EXP,,DE-MYLANLABS-2021M1070977,MYLAN,,70.0,YR,,M,Y,95.0,KG,20221212,,PH,DE,DE,2022,Q4,Elderly
199460543,19946054,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Peripheral swelling,,2022,Q4,3,F,,20221205.0,20211012,20221212,EXP,,DE-MYLANLABS-2021M1070977,MYLAN,,70.0,YR,,M,Y,95.0,KG,20221212,,PH,DE,DE,2022,Q4,Elderly
199460543,19946054,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Decubitus ulcer,,2022,Q4,3,F,,20221205.0,20211012,20221212,EXP,,DE-MYLANLABS-2021M1070977,MYLAN,,70.0,YR,,M,Y,95.0,KG,20221212,,PH,DE,DE,2022,Q4,Elderly
199460543,19946054,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Product prescribing error,,2022,Q4,3,F,,20221205.0,20211012,20221212,EXP,,DE-MYLANLABS-2021M1070977,MYLAN,,70.0,YR,,M,Y,95.0,KG,20221212,,PH,DE,DE,2022,Q4,Elderly
199460543,19946054,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Skin ulcer,,2022,Q4,3,F,,20221205.0,20211012,20221212,EXP,,DE-MYLANLABS-2021M1070977,MYLAN,,70.0,YR,,M,Y,95.0,KG,20221212,,PH,DE,DE,2022,Q4,Elderly
199460543,19946054,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Erythema,,2022,Q4,3,F,,20221205.0,20211012,20221212,EXP,,DE-MYLANLABS-2021M1070977,MYLAN,,70.0,YR,,M,Y,95.0,KG,20221212,,PH,DE,DE,2022,Q4,Elderly
199541932,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, tablets)",,,,,,,,10.0,MG,Tablet,,2022,Q4,Constipation,,2022,Q4,2,F,,20221031.0,20211013,20221107,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20221107,,MD,DE,DE,2022,Q4,Elderly
199541932,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, tablets)",,,,,,,,10.0,MG,Tablet,,2022,Q4,Dehydration,,2022,Q4,2,F,,20221031.0,20211013,20221107,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20221107,,MD,DE,DE,2022,Q4,Elderly
199541932,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, tablets)",,,,,,,,10.0,MG,Tablet,,2022,Q4,Abdominal pain,,2022,Q4,2,F,,20221031.0,20211013,20221107,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20221107,,MD,DE,DE,2022,Q4,Elderly
199541932,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, tablets)",,,,,,,,10.0,MG,Tablet,,2022,Q4,Flatulence,,2022,Q4,2,F,,20221031.0,20211013,20221107,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20221107,,MD,DE,DE,2022,Q4,Elderly
199541932,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, tablets)",,,,,,,,10.0,MG,Tablet,,2022,Q4,Haematuria,,2022,Q4,2,F,,20221031.0,20211013,20221107,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20221107,,MD,DE,DE,2022,Q4,Elderly
199541932,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, tablets)",,,,,,,,10.0,MG,Tablet,,2022,Q4,Micturition disorder,,2022,Q4,2,F,,20221031.0,20211013,20221107,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20221107,,MD,DE,DE,2022,Q4,Elderly
2004410423,20044104,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,1.0,MG,Tablet,,2022,Q4,Pancreatitis acute,,2022,Q4,23,F,20211024.0,20221219.0,20211108,20221223,EXP,,RU-ASTELLAS-2021US042176,ASTELLAS,,70.0,YR,,F,Y,,,20221223,,CN,RU,RU,2022,Q4,Elderly
2004410423,20044104,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,1.0,MG,Tablet,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,23,F,20211024.0,20221219.0,20211108,20221223,EXP,,RU-ASTELLAS-2021US042176,ASTELLAS,,70.0,YR,,F,Y,,,20221223,,CN,RU,RU,2022,Q4,Elderly
200826263,20082626,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0, tablet",,,,,,,,25.0,MG,Tablet,,2022,Q4,Angina pectoris,,2022,Q4,3,F,,20221206.0,20211117,20221213,EXP,,DE-MYLANLABS-2021M1083734,MYLAN,,79.0,YR,,F,Y,,,20221213,,MD,DE,DE,2022,Q4,Elderly
200826263,20082626,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0, tablet",,,,,,,,25.0,MG,Tablet,,2022,Q4,Cough,,2022,Q4,3,F,,20221206.0,20211117,20221213,EXP,,DE-MYLANLABS-2021M1083734,MYLAN,,79.0,YR,,F,Y,,,20221213,,MD,DE,DE,2022,Q4,Elderly
200826263,20082626,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0, tablet",,,,,,,,25.0,MG,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,3,F,,20221206.0,20211117,20221213,EXP,,DE-MYLANLABS-2021M1083734,MYLAN,,79.0,YR,,F,Y,,,20221213,,MD,DE,DE,2022,Q4,Elderly
200826263,20082626,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0, tablet",,,,,,,,25.0,MG,Tablet,,2022,Q4,Oedema peripheral,,2022,Q4,3,F,,20221206.0,20211117,20221213,EXP,,DE-MYLANLABS-2021M1083734,MYLAN,,79.0,YR,,F,Y,,,20221213,,MD,DE,DE,2022,Q4,Elderly
200826263,20082626,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0, tablet",,,,,,,,25.0,MG,Tablet,,2022,Q4,Dyspnoea exertional,,2022,Q4,3,F,,20221206.0,20211117,20221213,EXP,,DE-MYLANLABS-2021M1083734,MYLAN,,79.0,YR,,F,Y,,,20221213,,MD,DE,DE,2022,Q4,Elderly
202075392,20207539,44,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Trismus,,2022,Q4,2,F,20211101.0,20221005.0,20211220,20221007,EXP,CH-SM-2021-29093,CH-PFIZER INC-202101766837,PFIZER,,63.0,YR,,M,Y,,,20221007,,MD,CH,CH,2022,Q4,Adult
202075392,20207539,44,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Drug interaction,,2022,Q4,2,F,20211101.0,20221005.0,20211220,20221007,EXP,CH-SM-2021-29093,CH-PFIZER INC-202101766837,PFIZER,,63.0,YR,,M,Y,,,20221007,,MD,CH,CH,2022,Q4,Adult
202075392,20207539,44,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Depressed level of consciousness,,2022,Q4,2,F,20211101.0,20221005.0,20211220,20221007,EXP,CH-SM-2021-29093,CH-PFIZER INC-202101766837,PFIZER,,63.0,YR,,M,Y,,,20221007,,MD,CH,CH,2022,Q4,Adult
202075392,20207539,44,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Confusional state,,2022,Q4,2,F,20211101.0,20221005.0,20211220,20221007,EXP,CH-SM-2021-29093,CH-PFIZER INC-202101766837,PFIZER,,63.0,YR,,M,Y,,,20221007,,MD,CH,CH,2022,Q4,Adult
202075392,20207539,44,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Respiratory failure,,2022,Q4,2,F,20211101.0,20221005.0,20211220,20221007,EXP,CH-SM-2021-29093,CH-PFIZER INC-202101766837,PFIZER,,63.0,YR,,M,Y,,,20221007,,MD,CH,CH,2022,Q4,Adult
202094103,20209410,44,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Drug interaction,,2022,Q4,3,F,20211101.0,20221005.0,20211220,20221013,EXP,CH-SM-2021-29093,CH-JNJFOC-20211239184,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20221014,,MD,CH,CH,2022,Q4,Adult
202094103,20209410,44,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Respiratory failure,,2022,Q4,3,F,20211101.0,20221005.0,20211220,20221013,EXP,CH-SM-2021-29093,CH-JNJFOC-20211239184,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20221014,,MD,CH,CH,2022,Q4,Adult
202094103,20209410,44,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Somnolence,,2022,Q4,3,F,20211101.0,20221005.0,20211220,20221013,EXP,CH-SM-2021-29093,CH-JNJFOC-20211239184,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20221014,,MD,CH,CH,2022,Q4,Adult
202094103,20209410,44,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Depressed level of consciousness,,2022,Q4,3,F,20211101.0,20221005.0,20211220,20221013,EXP,CH-SM-2021-29093,CH-JNJFOC-20211239184,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20221014,,MD,CH,CH,2022,Q4,Adult
202094103,20209410,44,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Trismus,,2022,Q4,3,F,20211101.0,20221005.0,20211220,20221013,EXP,CH-SM-2021-29093,CH-JNJFOC-20211239184,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20221014,,MD,CH,CH,2022,Q4,Adult
202094103,20209410,44,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Agitation,,2022,Q4,3,F,20211101.0,20221005.0,20211220,20221013,EXP,CH-SM-2021-29093,CH-JNJFOC-20211239184,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20221014,,MD,CH,CH,2022,Q4,Adult
202094103,20209410,44,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Disorientation,,2022,Q4,3,F,20211101.0,20221005.0,20211220,20221013,EXP,CH-SM-2021-29093,CH-JNJFOC-20211239184,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20221014,,MD,CH,CH,2022,Q4,Adult
202442102,20244210,42,C,Empagliflozin; Metformin,,2,,,,,D,,,,,,,,,2022,Q4,Confusional state,,2022,Q4,2,F,20211101.0,20221005.0,20211229,20221012,EXP,,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145671",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20221012,,HP,CH,CH,2022,Q4,Adult
202442102,20244210,42,C,Empagliflozin; Metformin,,2,,,,,D,,,,,,,,,2022,Q4,Depressed level of consciousness,,2022,Q4,2,F,20211101.0,20221005.0,20211229,20221012,EXP,,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145671",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20221012,,HP,CH,CH,2022,Q4,Adult
202442102,20244210,42,C,Empagliflozin; Metformin,,2,,,,,D,,,,,,,,,2022,Q4,Drug interaction,,2022,Q4,2,F,20211101.0,20221005.0,20211229,20221012,EXP,,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145671",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20221012,,HP,CH,CH,2022,Q4,Adult
202442102,20244210,42,C,Empagliflozin; Metformin,,2,,,,,D,,,,,,,,,2022,Q4,Respiratory failure,,2022,Q4,2,F,20211101.0,20221005.0,20211229,20221012,EXP,,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145671",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20221012,,HP,CH,CH,2022,Q4,Adult
202442102,20244210,42,C,Empagliflozin; Metformin,,2,,,,,D,,,,,,,,,2022,Q4,Trismus,,2022,Q4,2,F,20211101.0,20221005.0,20211229,20221012,EXP,,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145671",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20221012,,HP,CH,CH,2022,Q4,Adult
202923883,20292388,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 0-2-0-0, Tabletten",,,,,,,,,,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,3,F,,20221031.0,20220104,20221104,EXP,,DE-MYLANLABS-2021M1098083,MYLAN,,68.0,YR,,F,Y,103.3,KG,20221104,,PH,DE,DE,2022,Q4,Elderly
202923883,20292388,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 0-2-0-0, Tabletten",,,,,,,,,,Tablet,,2022,Q4,Product prescribing error,,2022,Q4,3,F,,20221031.0,20220104,20221104,EXP,,DE-MYLANLABS-2021M1098083,MYLAN,,68.0,YR,,F,Y,103.3,KG,20221104,,PH,DE,DE,2022,Q4,Elderly
202923883,20292388,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 0-2-0-0, Tabletten",,,,,,,,,,Tablet,,2022,Q4,Syncope,,2022,Q4,3,F,,20221031.0,20220104,20221104,EXP,,DE-MYLANLABS-2021M1098083,MYLAN,,68.0,YR,,F,Y,103.3,KG,20221104,,PH,DE,DE,2022,Q4,Elderly
202923883,20292388,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 0-2-0-0, Tabletten",,,,,,,,,,Tablet,,2022,Q4,Respiratory failure,,2022,Q4,3,F,,20221031.0,20220104,20221104,EXP,,DE-MYLANLABS-2021M1098083,MYLAN,,68.0,YR,,F,Y,103.3,KG,20221104,,PH,DE,DE,2022,Q4,Elderly
2033327526,20333275,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2022,Q4,Anaemia,,2022,Q4,26,F,20220105.0,20220928.0,20220113,20221005,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20221005,,MD,BR,,2022,Q4,Adult
2033327526,20333275,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2022,Q4,Adrenal insufficiency,,2022,Q4,26,F,20220105.0,20220928.0,20220113,20221005,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20221005,,MD,BR,,2022,Q4,Adult
2033327526,20333275,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2022,Q4,Aspartate aminotransferase increased,Aspartate aminotransferase increased,2022,Q4,26,F,20220105.0,20220928.0,20220113,20221005,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20221005,,MD,BR,,2022,Q4,Adult
2033327526,20333275,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2022,Q4,Alanine aminotransferase increased,,2022,Q4,26,F,20220105.0,20220928.0,20220113,20221005,PER,,BR-Eisai Medical Research-EC-2022-106612,EISAI,,64.0,YR,A,F,Y,63.7,KG,20221005,,MD,BR,,2022,Q4,Adult
203514707,20351470,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Atypical fibroxanthoma,,2022,Q4,7,F,20120101.0,20221129.0,20220119,20221206,EXP,,"BG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-108100",BOEHRINGER INGELHEIM,"Kandathil L, Dimchova N, Terziev I, Patterson J, Tchernev G, Oliveira N. Telmisartan (and/or nitrosamine) induced prostate carcinoma and atypical fibroxanthoma: first report in world literature. Medical Review. 2022;58 (1)65-67.",68.0,YR,E,M,Y,,,20221206,,HP,BG,BG,2022,Q4,Elderly
203514707,20351470,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Atypical fibroxanthoma,,2022,Q4,7,F,20120101.0,20221129.0,20220119,20221206,EXP,,"BG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-108100",BOEHRINGER INGELHEIM,"Kandathil L, Dimchova N, Terziev I, Patterson J, Tchernev G, Oliveira N. Telmisartan (and/or nitrosamine) induced prostate carcinoma and atypical fibroxanthoma: first report in world literature. Medical Review. 2022;58 (1)65-67.",68.0,YR,E,M,Y,,,20221206,,HP,BG,BG,2022,Q4,Elderly
203514707,20351470,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Prostate cancer,,2022,Q4,7,F,20120101.0,20221129.0,20220119,20221206,EXP,,"BG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-108100",BOEHRINGER INGELHEIM,"Kandathil L, Dimchova N, Terziev I, Patterson J, Tchernev G, Oliveira N. Telmisartan (and/or nitrosamine) induced prostate carcinoma and atypical fibroxanthoma: first report in world literature. Medical Review. 2022;58 (1)65-67.",68.0,YR,E,M,Y,,,20221206,,HP,BG,BG,2022,Q4,Elderly
203514707,20351470,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Prostate cancer,,2022,Q4,7,F,20120101.0,20221129.0,20220119,20221206,EXP,,"BG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-108100",BOEHRINGER INGELHEIM,"Kandathil L, Dimchova N, Terziev I, Patterson J, Tchernev G, Oliveira N. Telmisartan (and/or nitrosamine) induced prostate carcinoma and atypical fibroxanthoma: first report in world literature. Medical Review. 2022;58 (1)65-67.",68.0,YR,E,M,Y,,,20221206,,HP,BG,BG,2022,Q4,Elderly
203737965,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Tablet,,2022,Q4,Adrenal insufficiency,,2022,Q4,5,F,,20221022.0,20220125,20221031,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20221031,,MD,CA,CA,2022,Q4,Elderly
203737965,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Tablet,,2022,Q4,Hyperthyroidism,,2022,Q4,5,F,,20221022.0,20220125,20221031,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20221031,,MD,CA,CA,2022,Q4,Elderly
203737965,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Tablet,,2022,Q4,Hypotension,,2022,Q4,5,F,,20221022.0,20220125,20221031,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20221031,,MD,CA,CA,2022,Q4,Elderly
203737965,20373796,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Tablet,,2022,Q4,Troponin increased,,2022,Q4,5,F,,20221022.0,20220125,20221031,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20221031,,MD,CA,CA,2022,Q4,Elderly
203737965,20373796,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Film-coated tablet,,2022,Q4,Adrenal insufficiency,,2022,Q4,5,F,,20221022.0,20220125,20221031,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20221031,,MD,CA,CA,2022,Q4,Elderly
203737965,20373796,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Film-coated tablet,,2022,Q4,Hyperthyroidism,,2022,Q4,5,F,,20221022.0,20220125,20221031,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20221031,,MD,CA,CA,2022,Q4,Elderly
203737965,20373796,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Film-coated tablet,,2022,Q4,Hypotension,,2022,Q4,5,F,,20221022.0,20220125,20221031,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20221031,,MD,CA,CA,2022,Q4,Elderly
203737965,20373796,26,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,20.0,MG,Film-coated tablet,,2022,Q4,Troponin increased,,2022,Q4,5,F,,20221022.0,20220125,20221031,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20221031,,MD,CA,CA,2022,Q4,Elderly
203737965,20373796,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,200.0,MG,,,2022,Q4,Adrenal insufficiency,,2022,Q4,5,F,,20221022.0,20220125,20221031,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20221031,,MD,CA,CA,2022,Q4,Elderly
203737965,20373796,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,200.0,MG,,,2022,Q4,Hyperthyroidism,,2022,Q4,5,F,,20221022.0,20220125,20221031,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20221031,,MD,CA,CA,2022,Q4,Elderly
203737965,20373796,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,200.0,MG,,,2022,Q4,Hypotension,,2022,Q4,5,F,,20221022.0,20220125,20221031,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20221031,,MD,CA,CA,2022,Q4,Elderly
203737965,20373796,27,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 Days,,,U,,,,,200.0,MG,,,2022,Q4,Troponin increased,,2022,Q4,5,F,,20221022.0,20220125,20221031,EXP,CA-MHPD-E2B_03639641,CA-Accord-251078,ACCORD,,75.0,YR,E,M,Y,,,20221031,,MD,CA,CA,2022,Q4,Elderly
2037504414,20375044,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q4,Weight decreased,Weight decreased,2022,Q4,14,F,20220117.0,20221222.0,20220125,20221227,PER,,CH-Eisai Medical Research-EC-2022-107259,EISAI,,80.0,YR,E,M,Y,67.6,KG,20221227,,MD,CH,,2022,Q4,Elderly
203941365,20394136,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1.5 dosage form, (strength: 12.5/1000 unspecified units) (1 tab 1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q4,Blood creatinine increased,,2022,Q4,5,F,20220110.0,20221201.0,20220129,20221208,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,92.1,KG,20221208,,HP,TH,TH,2022,Q4,Adult
203941365,20394136,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1.5 dosage form, (strength: 12.5/1000 unspecified units) (1 tab 1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q4,Hyperlipidaemia,,2022,Q4,5,F,20220110.0,20221201.0,20220129,20221208,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,92.1,KG,20221208,,HP,TH,TH,2022,Q4,Adult
203941365,20394136,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1.5 dosage form, (strength: 12.5/1000 unspecified units) (1 tab 1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q4,Glomerular filtration rate decreased,,2022,Q4,5,F,20220110.0,20221201.0,20220129,20221208,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,92.1,KG,20221208,,HP,TH,TH,2022,Q4,Adult
203941365,20394136,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1.5 dosage form, (strength: 12.5/1000 unspecified units) (1 tab 1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q4,Prothrombin time abnormal,,2022,Q4,5,F,20220110.0,20221201.0,20220129,20221208,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,92.1,KG,20221208,,HP,TH,TH,2022,Q4,Adult
203941365,20394136,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1.5 dosage form, (strength: 12.5/1000 unspecified units) (1 tab 1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q4,Atrial fibrillation,,2022,Q4,5,F,20220110.0,20221201.0,20220129,20221208,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,92.1,KG,20221208,,HP,TH,TH,2022,Q4,Adult
203941365,20394136,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1.5 dosage form, (strength: 12.5/1000 unspecified units) (1 tab 1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q4,Weight increased,,2022,Q4,5,F,20220110.0,20221201.0,20220129,20221208,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,92.1,KG,20221208,,HP,TH,TH,2022,Q4,Adult
203941365,20394136,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1.5 dosage form, (strength: 12.5/1000 unspecified units) (1 tab 1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q4,Atrial flutter,,2022,Q4,5,F,20220110.0,20221201.0,20220129,20221208,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,92.1,KG,20221208,,HP,TH,TH,2022,Q4,Adult
203941365,20394136,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1.5 dosage form, (strength: 12.5/1000 unspecified units) (1 tab 1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q4,Heart rate increased,,2022,Q4,5,F,20220110.0,20221201.0,20220129,20221208,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,92.1,KG,20221208,,HP,TH,TH,2022,Q4,Adult
203941365,20394136,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1.5 dosage form, (strength: 12.5/1000 unspecified units) (1 tab 1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q4,Blood glucose increased,,2022,Q4,5,F,20220110.0,20221201.0,20220129,20221208,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,92.1,KG,20221208,,HP,TH,TH,2022,Q4,Adult
203941365,20394136,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1.5 dosage form, (strength: 12.5/1000 unspecified units) (1 tab 1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,5,F,20220110.0,20221201.0,20220129,20221208,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,92.1,KG,20221208,,HP,TH,TH,2022,Q4,Adult
203941365,20394136,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1.5 dosage form, (strength: 12.5/1000 unspecified units) (1 tab 1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q4,International normalised ratio decreased,,2022,Q4,5,F,20220110.0,20221201.0,20220129,20221208,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,92.1,KG,20221208,,HP,TH,TH,2022,Q4,Adult
203941365,20394136,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1.5 dosage form, (strength: 12.5/1000 unspecified units) (1 tab 1PC, 0.5 tab at evening)",,,U,,,,,,,,,2022,Q4,Arteriosclerosis,,2022,Q4,5,F,20220110.0,20221201.0,20220129,20221208,EXP,,NVSC2022TH014790,NOVARTIS,,54.0,YR,,M,Y,92.1,KG,20221208,,HP,TH,TH,2022,Q4,Adult
205912992,20591299,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q4,Product prescribing error,,2022,Q4,2,F,20220214.0,20221206.0,20220314,20221206,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-159075",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,75.0,KG,20221206,,MD,DE,DE,2022,Q4,Elderly
205912992,20591299,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,2,F,20220214.0,20221206.0,20220314,20221206,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-159075",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,75.0,KG,20221206,,MD,DE,DE,2022,Q4,Elderly
205912992,20591299,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,25.0,MG,,QD,2022,Q4,Failure to suspend medication,,2022,Q4,2,F,20220214.0,20221206.0,20220314,20221206,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-159075",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,75.0,KG,20221206,,MD,DE,DE,2022,Q4,Elderly
206469482,20646948,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,2,F,,20221103.0,20220329,20221110,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161622",BOEHRINGER INGELHEIM,"Leung M, Roitman D. PIK3CA Inhibitor, Alpelisib, and Diabetic Ketoacidosis: A Lesson on Choosing Wisely. Canadian Journal of Diabetes. 2021; 4529-",58.0,YR,A,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Adult
206469482,20646948,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Rash,,2022,Q4,2,F,,20221103.0,20220329,20221110,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161622",BOEHRINGER INGELHEIM,"Leung M, Roitman D. PIK3CA Inhibitor, Alpelisib, and Diabetic Ketoacidosis: A Lesson on Choosing Wisely. Canadian Journal of Diabetes. 2021; 4529-",58.0,YR,A,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Adult
206469482,20646948,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Pneumonia,,2022,Q4,2,F,,20221103.0,20220329,20221110,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161622",BOEHRINGER INGELHEIM,"Leung M, Roitman D. PIK3CA Inhibitor, Alpelisib, and Diabetic Ketoacidosis: A Lesson on Choosing Wisely. Canadian Journal of Diabetes. 2021; 4529-",58.0,YR,A,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Adult
206469482,20646948,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221103.0,20220329,20221110,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161622",BOEHRINGER INGELHEIM,"Leung M, Roitman D. PIK3CA Inhibitor, Alpelisib, and Diabetic Ketoacidosis: A Lesson on Choosing Wisely. Canadian Journal of Diabetes. 2021; 4529-",58.0,YR,A,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Adult
206469482,20646948,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,2,F,,20221103.0,20220329,20221110,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-161622",BOEHRINGER INGELHEIM,"Leung M, Roitman D. PIK3CA Inhibitor, Alpelisib, and Diabetic Ketoacidosis: A Lesson on Choosing Wisely. Canadian Journal of Diabetes. 2021; 4529-",58.0,YR,A,F,Y,,,20221110,,HP,CA,CA,2022,Q4,Adult
206920782,20692078,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q4,Gouty arthritis,,2022,Q4,2,F,,20221124.0,20220409,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20221202,,HP,CA,CA,2022,Q4,Adult
206920782,20692078,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q4,Rectal haemorrhage,,2022,Q4,2,F,,20221124.0,20220409,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20221202,,HP,CA,CA,2022,Q4,Adult
206920782,20692078,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q4,COVID-19,,2022,Q4,2,F,,20221124.0,20220409,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20221202,,HP,CA,CA,2022,Q4,Adult
206920782,20692078,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221124.0,20220409,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20221202,,HP,CA,CA,2022,Q4,Adult
206920782,20692078,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q4,Mobility decreased,,2022,Q4,2,F,,20221124.0,20220409,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20221202,,HP,CA,CA,2022,Q4,Adult
206920782,20692078,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q4,Nasal congestion,,2022,Q4,2,F,,20221124.0,20220409,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20221202,,HP,CA,CA,2022,Q4,Adult
206920782,20692078,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q4,Arthralgia,,2022,Q4,2,F,,20221124.0,20220409,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20221202,,HP,CA,CA,2022,Q4,Adult
206920782,20692078,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2022,Q4,Cough,,2022,Q4,2,F,,20221124.0,20220409,20221201,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-08060,SAMSUNG BIOEPIS,,49.0,YR,A,M,Y,118.0,KG,20221202,,HP,CA,CA,2022,Q4,Adult
207140953,20714095,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Central venous pressure decreased,,2022,Q4,3,F,20220101.0,20221025.0,20220415,20221025,EXP,,CA-PFIZER INC-2021522782,PFIZER,,75.0,YR,,M,Y,70.31,KG,20221025,,MD,CA,CA,2022,Q4,Elderly
207140953,20714095,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Iron deficiency anaemia,,2022,Q4,3,F,20220101.0,20221025.0,20220415,20221025,EXP,,CA-PFIZER INC-2021522782,PFIZER,,75.0,YR,,M,Y,70.31,KG,20221025,,MD,CA,CA,2022,Q4,Elderly
207140953,20714095,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Weight decreased,,2022,Q4,3,F,20220101.0,20221025.0,20220415,20221025,EXP,,CA-PFIZER INC-2021522782,PFIZER,,75.0,YR,,M,Y,70.31,KG,20221025,,MD,CA,CA,2022,Q4,Elderly
207140953,20714095,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Movement disorder,,2022,Q4,3,F,20220101.0,20221025.0,20220415,20221025,EXP,,CA-PFIZER INC-2021522782,PFIZER,,75.0,YR,,M,Y,70.31,KG,20221025,,MD,CA,CA,2022,Q4,Elderly
207140953,20714095,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Pruritus,,2022,Q4,3,F,20220101.0,20221025.0,20220415,20221025,EXP,,CA-PFIZER INC-2021522782,PFIZER,,75.0,YR,,M,Y,70.31,KG,20221025,,MD,CA,CA,2022,Q4,Elderly
207140953,20714095,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Feeling drunk,,2022,Q4,3,F,20220101.0,20221025.0,20220415,20221025,EXP,,CA-PFIZER INC-2021522782,PFIZER,,75.0,YR,,M,Y,70.31,KG,20221025,,MD,CA,CA,2022,Q4,Elderly
207140953,20714095,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Dyspnoea exertional,,2022,Q4,3,F,20220101.0,20221025.0,20220415,20221025,EXP,,CA-PFIZER INC-2021522782,PFIZER,,75.0,YR,,M,Y,70.31,KG,20221025,,MD,CA,CA,2022,Q4,Elderly
207140953,20714095,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Presyncope,,2022,Q4,3,F,20220101.0,20221025.0,20220415,20221025,EXP,,CA-PFIZER INC-2021522782,PFIZER,,75.0,YR,,M,Y,70.31,KG,20221025,,MD,CA,CA,2022,Q4,Elderly
207140953,20714095,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Cardiac failure chronic,,2022,Q4,3,F,20220101.0,20221025.0,20220415,20221025,EXP,,CA-PFIZER INC-2021522782,PFIZER,,75.0,YR,,M,Y,70.31,KG,20221025,,MD,CA,CA,2022,Q4,Elderly
207140953,20714095,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Angina pectoris,,2022,Q4,3,F,20220101.0,20221025.0,20220415,20221025,EXP,,CA-PFIZER INC-2021522782,PFIZER,,75.0,YR,,M,Y,70.31,KG,20221025,,MD,CA,CA,2022,Q4,Elderly
207140953,20714095,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Constipation,,2022,Q4,3,F,20220101.0,20221025.0,20220415,20221025,EXP,,CA-PFIZER INC-2021522782,PFIZER,,75.0,YR,,M,Y,70.31,KG,20221025,,MD,CA,CA,2022,Q4,Elderly
207140953,20714095,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Chest discomfort,,2022,Q4,3,F,20220101.0,20221025.0,20220415,20221025,EXP,,CA-PFIZER INC-2021522782,PFIZER,,75.0,YR,,M,Y,70.31,KG,20221025,,MD,CA,CA,2022,Q4,Elderly
207140953,20714095,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Oedema peripheral,,2022,Q4,3,F,20220101.0,20221025.0,20220415,20221025,EXP,,CA-PFIZER INC-2021522782,PFIZER,,75.0,YR,,M,Y,70.31,KG,20221025,,MD,CA,CA,2022,Q4,Elderly
207719529,20771952,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2022,Q4,Vitreous haemorrhage,,2022,Q4,9,F,20220418.0,20221219.0,20220501,20221223,EXP,,NVSC2022CN095120,NOVARTIS,,22.0,YR,,F,Y,,,20221223,,MD,CN,CN,2022,Q4,Youth
208454493,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Wrong technique in product usage process,,2022,Q4,3,F,20211008.0,20221124.0,20220518,20221201,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20221201,,CN,AR,AR,2022,Q4,Elderly
208454493,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Arrhythmia,,2022,Q4,3,F,20211008.0,20221124.0,20220518,20221201,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20221201,,CN,AR,AR,2022,Q4,Elderly
208454493,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Amnesia,,2022,Q4,3,F,20211008.0,20221124.0,20220518,20221201,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20221201,,CN,AR,AR,2022,Q4,Elderly
208454493,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Product quality issue,,2022,Q4,3,F,20211008.0,20221124.0,20220518,20221201,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20221201,,CN,AR,AR,2022,Q4,Elderly
208454493,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Renal disorder,,2022,Q4,3,F,20211008.0,20221124.0,20220518,20221201,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20221201,,CN,AR,AR,2022,Q4,Elderly
208454493,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Ejection fraction decreased,,2022,Q4,3,F,20211008.0,20221124.0,20220518,20221201,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20221201,,CN,AR,AR,2022,Q4,Elderly
208454493,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Varicose vein,,2022,Q4,3,F,20211008.0,20221124.0,20220518,20221201,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20221201,,CN,AR,AR,2022,Q4,Elderly
208454493,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Atrial fibrillation,,2022,Q4,3,F,20211008.0,20221124.0,20220518,20221201,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20221201,,CN,AR,AR,2022,Q4,Elderly
208454493,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Hypokinesia,,2022,Q4,3,F,20211008.0,20221124.0,20220518,20221201,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20221201,,CN,AR,AR,2022,Q4,Elderly
208454493,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Mobility decreased,,2022,Q4,3,F,20211008.0,20221124.0,20220518,20221201,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20221201,,CN,AR,AR,2022,Q4,Elderly
208454493,20845449,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Hypotension,,2022,Q4,3,F,20211008.0,20221124.0,20220518,20221201,EXP,,NVSC2021AR145891,NOVARTIS,,78.0,YR,,M,Y,,,20221201,,CN,AR,AR,2022,Q4,Elderly
208530973,20853097,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Labelled drug-drug interaction issue,,2022,Q4,3,F,,20221012.0,20220520,20221017,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8.,72.0,YR,E,F,Y,,,20221017,,HP,AT,AT,2022,Q4,Elderly
208530973,20853097,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Intestinal haemorrhage,,2022,Q4,3,F,,20221012.0,20220520,20221017,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8.,72.0,YR,E,F,Y,,,20221017,,HP,AT,AT,2022,Q4,Elderly
208530973,20853097,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Internal haemorrhage,,2022,Q4,3,F,,20221012.0,20220520,20221017,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8.,72.0,YR,E,F,Y,,,20221017,,HP,AT,AT,2022,Q4,Elderly
208530973,20853097,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Loss of consciousness,,2022,Q4,3,F,,20221012.0,20220520,20221017,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8.,72.0,YR,E,F,Y,,,20221017,,HP,AT,AT,2022,Q4,Elderly
208530973,20853097,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Labelled drug-drug interaction issue,,2022,Q4,3,F,,20221012.0,20220520,20221017,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8.,72.0,YR,E,F,Y,,,20221017,,HP,AT,AT,2022,Q4,Elderly
208530973,20853097,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Intestinal haemorrhage,,2022,Q4,3,F,,20221012.0,20220520,20221017,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8.,72.0,YR,E,F,Y,,,20221017,,HP,AT,AT,2022,Q4,Elderly
208530973,20853097,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Internal haemorrhage,,2022,Q4,3,F,,20221012.0,20220520,20221017,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8.,72.0,YR,E,F,Y,,,20221017,,HP,AT,AT,2022,Q4,Elderly
208530973,20853097,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Loss of consciousness,,2022,Q4,3,F,,20221012.0,20220520,20221017,EXP,,AT-SA-2022SA180454,SANOFI AVENTIS,Koudelka M.. Herausforderung Polypharmazie Vor allem bei ?lteren Menschen: Ein Medikament kommt selten allein.. Hausarzt: in.. 2022;9:45-8.,72.0,YR,E,F,Y,,,20221017,,HP,AT,AT,2022,Q4,Elderly
209183743,20918374,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Unknown,,,,,,,,,,,,2022,Q4,Weight decreased,,2022,Q4,3,F,,20221012.0,20220606,20221020,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-13280,SAMSUNG BIOEPIS,,40.0,YR,A,F,Y,,,20221020,,CN,CA,CA,2022,Q4,Adult
209183743,20918374,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Unknown,,,,,,,,,,,,2022,Q4,Drug ineffective,,2022,Q4,3,F,,20221012.0,20220606,20221020,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-13280,SAMSUNG BIOEPIS,,40.0,YR,A,F,Y,,,20221020,,CN,CA,CA,2022,Q4,Adult
209183743,20918374,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Unknown,,,,,,,,,,,,2022,Q4,Condition aggravated,,2022,Q4,3,F,,20221012.0,20220606,20221020,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-13280,SAMSUNG BIOEPIS,,40.0,YR,A,F,Y,,,20221020,,CN,CA,CA,2022,Q4,Adult
209183743,20918374,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Unknown,,,,,,,,,,,,2022,Q4,Hepatotoxicity,,2022,Q4,3,F,,20221012.0,20220606,20221020,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-13280,SAMSUNG BIOEPIS,,40.0,YR,A,F,Y,,,20221020,,CN,CA,CA,2022,Q4,Adult
209183743,20918374,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Unknown,,,,,,,,,,,,2022,Q4,Off label use,,2022,Q4,3,F,,20221012.0,20220606,20221020,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-13280,SAMSUNG BIOEPIS,,40.0,YR,A,F,Y,,,20221020,,CN,CA,CA,2022,Q4,Adult
209183743,20918374,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Unknown,,,,,,,,,,,,2022,Q4,C-reactive protein increased,,2022,Q4,3,F,,20221012.0,20220606,20221020,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-13280,SAMSUNG BIOEPIS,,40.0,YR,A,F,Y,,,20221020,,CN,CA,CA,2022,Q4,Adult
209183743,20918374,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Unknown,,,,,,,,,,,,2022,Q4,Psoriasis,,2022,Q4,3,F,,20221012.0,20220606,20221020,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-13280,SAMSUNG BIOEPIS,,40.0,YR,A,F,Y,,,20221020,,CN,CA,CA,2022,Q4,Adult
209948544,20994854,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Amp im,,2022,Q4,Off label use,,2022,Q4,4,F,20220529.0,20221019.0,20220622,20221023,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2022-062562,BRISTOL MYERS SQUIBB,,75.0,YR,E,M,Y,75.0,KG,20221024,,MD,ES,ES,2022,Q4,Elderly
209948544,20994854,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Amp im,,2022,Q4,Febrile neutropenia,,2022,Q4,4,F,20220529.0,20221019.0,20220622,20221023,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2022-062562,BRISTOL MYERS SQUIBB,,75.0,YR,E,M,Y,75.0,KG,20221024,,MD,ES,ES,2022,Q4,Elderly
209948544,20994854,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Amp im,,2022,Q4,Off label use,,2022,Q4,4,F,20220529.0,20221019.0,20220622,20221023,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2022-062562,BRISTOL MYERS SQUIBB,,75.0,YR,E,M,Y,75.0,KG,20221024,,MD,ES,ES,2022,Q4,Elderly
209948544,20994854,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Amp im,,2022,Q4,Febrile neutropenia,,2022,Q4,4,F,20220529.0,20221019.0,20220622,20221023,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2022-062562,BRISTOL MYERS SQUIBB,,75.0,YR,E,M,Y,75.0,KG,20221024,,MD,ES,ES,2022,Q4,Elderly
209948544,20994854,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q4,Off label use,,2022,Q4,4,F,20220529.0,20221019.0,20220622,20221023,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2022-062562,BRISTOL MYERS SQUIBB,,75.0,YR,E,M,Y,75.0,KG,20221024,,MD,ES,ES,2022,Q4,Elderly
209948544,20994854,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q4,Febrile neutropenia,,2022,Q4,4,F,20220529.0,20221019.0,20220622,20221023,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-2022-062562,BRISTOL MYERS SQUIBB,,75.0,YR,E,M,Y,75.0,KG,20221024,,MD,ES,ES,2022,Q4,Elderly
209975603,20997560,24,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2022,Q4,COVID-19 pneumonia,,2022,Q4,3,F,20220421.0,20221102.0,20220623,20221104,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-2022-050653,BRISTOL MYERS SQUIBB,,76.0,YR,E,M,Y,,,20221104,,HP,AU,AU,2022,Q4,Elderly
210216692,21021669,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,Unknown,,2022,Q4,Neurotoxicity,,2022,Q4,2,F,20211225.0,20220217.0,20220629,20221130,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-AUT-20211208544,BRISTOL MYERS SQUIBB,,71.0,YR,E,M,Y,88.0,KG,20221130,,MD,AT,AT,2022,Q4,Elderly
210823402,21082340,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Unknown,,2022,Q4,Colitis,,2022,Q4,2,F,20220622.0,20221007.0,20220714,20221014,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-068673,BRISTOL MYERS SQUIBB,,45.0,YR,A,M,Y,,,20221014,,HP,US,US,2022,Q4,Adult
210862932,21086293,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,,,,,,,,,,2022,Q4,Papillary thyroid cancer,,2022,Q4,2,F,,20220705.0,20220715,20221024,EXP,,BR-NOVOPROD-936769,NOVO NORDISK,,64.0,YR,,M,Y,92.0,KG,20221024,,MD,BR,BR,2022,Q4,Adult
210931133,21093113,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 in 1 D,,,U,,,,,10.0,MG,Unknown,QD,2022,Q4,Palmar-plantar erythrodysaesthesia syndrome,,2022,Q4,3,F,20220620.0,20220929.0,20220718,20221002,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-2022-074163,BRISTOL MYERS SQUIBB,,65.0,YR,E,M,Y,105.65,KG,20221003,,HP,GB,GB,2022,Q4,Elderly
210931133,21093113,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,Unknown,QD,2022,Q4,Palmar-plantar erythrodysaesthesia syndrome,,2022,Q4,3,F,20220620.0,20220929.0,20220718,20221002,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-2022-074163,BRISTOL MYERS SQUIBB,,65.0,YR,E,M,Y,105.65,KG,20221003,,HP,GB,GB,2022,Q4,Elderly
210974254,21097425,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,once a day in the morning,,,,,,,,10.0,MG,,QD,2022,Q4,Acute coronary syndrome,,2022,Q4,4,F,20220531.0,20221025.0,20220719,20221026,EXP,,US-ROCHE-3127711,ROCHE,,71.0,YR,,F,Y,87.3,KG,20221026,,MD,US,,2022,Q4,Elderly
210974254,21097425,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,once a day in the morning,,,,,,,,10.0,MG,,QD,2022,Q4,Ischaemic cardiomyopathy,,2022,Q4,4,F,20220531.0,20221025.0,20220719,20221026,EXP,,US-ROCHE-3127711,ROCHE,,71.0,YR,,F,Y,87.3,KG,20221026,,MD,US,,2022,Q4,Elderly
210974254,21097425,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,once a day in the morning,,,,,,,,10.0,MG,,QD,2022,Q4,Coronary artery disease,,2022,Q4,4,F,20220531.0,20221025.0,20220719,20221026,EXP,,US-ROCHE-3127711,ROCHE,,71.0,YR,,F,Y,87.3,KG,20221026,,MD,US,,2022,Q4,Elderly
211165704,21116570,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Toxic encephalopathy,,2022,Q4,4,F,20201020.0,20221209.0,20220722,20221216,EXP,,JP-TAKEDA-2022TUS049042,TAKEDA,Umaba K. A case of vidarabine-induced encephalopathy which developed during therapy with febuxostat (in Japanese). Clinical Neurology (Web). 2021;61(11): 790(41),75.0,YR,,M,Y,57.0,KG,20221216,,MD,JP,JP,2022,Q4,Elderly
211165704,21116570,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Drug interaction,,2022,Q4,4,F,20201020.0,20221209.0,20220722,20221216,EXP,,JP-TAKEDA-2022TUS049042,TAKEDA,Umaba K. A case of vidarabine-induced encephalopathy which developed during therapy with febuxostat (in Japanese). Clinical Neurology (Web). 2021;61(11): 790(41),75.0,YR,,M,Y,57.0,KG,20221216,,MD,JP,JP,2022,Q4,Elderly
212365954,21236595,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Spontaneous bacterial peritonitis,,2022,Q4,4,F,20220806.0,20221215.0,20220822,20221221,EXP,,ES-ROCHE-3157075,ROCHE,,70.0,YR,,M,Y,,,20221221,,MD,ES,,2022,Q4,Elderly
212365954,21236595,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Ascites,,2022,Q4,4,F,20220806.0,20221215.0,20220822,20221221,EXP,,ES-ROCHE-3157075,ROCHE,,70.0,YR,,M,Y,,,20221221,,MD,ES,,2022,Q4,Elderly
212365954,21236595,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Diarrhoea,,2022,Q4,4,F,20220806.0,20221215.0,20220822,20221221,EXP,,ES-ROCHE-3157075,ROCHE,,70.0,YR,,M,Y,,,20221221,,MD,ES,,2022,Q4,Elderly
212365954,21236595,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,COVID-19,,2022,Q4,4,F,20220806.0,20221215.0,20220822,20221221,EXP,,ES-ROCHE-3157075,ROCHE,,70.0,YR,,M,Y,,,20221221,,MD,ES,,2022,Q4,Elderly
212365954,21236595,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Spontaneous bacterial peritonitis,,2022,Q4,4,F,20220806.0,20221215.0,20220822,20221221,EXP,,ES-ROCHE-3157075,ROCHE,,70.0,YR,,M,Y,,,20221221,,MD,ES,,2022,Q4,Elderly
212365954,21236595,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Ascites,,2022,Q4,4,F,20220806.0,20221215.0,20220822,20221221,EXP,,ES-ROCHE-3157075,ROCHE,,70.0,YR,,M,Y,,,20221221,,MD,ES,,2022,Q4,Elderly
212365954,21236595,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Diarrhoea,,2022,Q4,4,F,20220806.0,20221215.0,20220822,20221221,EXP,,ES-ROCHE-3157075,ROCHE,,70.0,YR,,M,Y,,,20221221,,MD,ES,,2022,Q4,Elderly
212365954,21236595,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,COVID-19,,2022,Q4,4,F,20220806.0,20221215.0,20220822,20221221,EXP,,ES-ROCHE-3157075,ROCHE,,70.0,YR,,M,Y,,,20221221,,MD,ES,,2022,Q4,Elderly
212426582,21242658,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Epistaxis,,2022,Q4,2,F,,20221031.0,20220823,20221114,EXP,CA-MHPD-E2B_04938746,CA-Accord-274495,ACCORD,,37.0,YR,A,F,Y,,,20221114,,HP,CA,CA,2022,Q4,Adult
212426582,21242658,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Abdominal discomfort,,2022,Q4,2,F,,20221031.0,20220823,20221114,EXP,CA-MHPD-E2B_04938746,CA-Accord-274495,ACCORD,,37.0,YR,A,F,Y,,,20221114,,HP,CA,CA,2022,Q4,Adult
212426582,21242658,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Drug ineffective,,2022,Q4,2,F,,20221031.0,20220823,20221114,EXP,CA-MHPD-E2B_04938746,CA-Accord-274495,ACCORD,,37.0,YR,A,F,Y,,,20221114,,HP,CA,CA,2022,Q4,Adult
212426582,21242658,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Mouth haemorrhage,,2022,Q4,2,F,,20221031.0,20220823,20221114,EXP,CA-MHPD-E2B_04938746,CA-Accord-274495,ACCORD,,37.0,YR,A,F,Y,,,20221114,,HP,CA,CA,2022,Q4,Adult
212426582,21242658,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Thrombosis,,2022,Q4,2,F,,20221031.0,20220823,20221114,EXP,CA-MHPD-E2B_04938746,CA-Accord-274495,ACCORD,,37.0,YR,A,F,Y,,,20221114,,HP,CA,CA,2022,Q4,Adult
212426582,21242658,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Tablet,,2022,Q4,Alopecia,,2022,Q4,2,F,,20221031.0,20220823,20221114,EXP,CA-MHPD-E2B_04938746,CA-Accord-274495,ACCORD,,37.0,YR,A,F,Y,,,20221114,,HP,CA,CA,2022,Q4,Adult
212437273,21243727,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Vomiting,,2022,Q4,3,F,20220201.0,20221022.0,20220823,20221028,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202208008713,ELI LILLY AND CO,,52.0,YR,,F,Y,,,20221028,,CN,CO,CO,2022,Q4,Adult
212437273,21243727,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,General physical health deterioration,,2022,Q4,3,F,20220201.0,20221022.0,20220823,20221028,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202208008713,ELI LILLY AND CO,,52.0,YR,,F,Y,,,20221028,,CN,CO,CO,2022,Q4,Adult
212437273,21243727,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Decreased appetite,,2022,Q4,3,F,20220201.0,20221022.0,20220823,20221028,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202208008713,ELI LILLY AND CO,,52.0,YR,,F,Y,,,20221028,,CN,CO,CO,2022,Q4,Adult
212437273,21243727,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Nausea,,2022,Q4,3,F,20220201.0,20221022.0,20220823,20221028,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202208008713,ELI LILLY AND CO,,52.0,YR,,F,Y,,,20221028,,CN,CO,CO,2022,Q4,Adult
212437273,21243727,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Dehydration,,2022,Q4,3,F,20220201.0,20221022.0,20220823,20221028,EXP,,CO-ELI_LILLY_AND_COMPANY-CO202208008713,ELI LILLY AND CO,,52.0,YR,,F,Y,,,20221028,,CN,CO,CO,2022,Q4,Adult
212495092,21249509,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,COVID-19,,2022,Q4,2,F,,20221004.0,20220824,20221011,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187902",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20221011,,MD,DE,DE,2022,Q4,Elderly
212495092,21249509,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Cardiac failure,,2022,Q4,2,F,,20221004.0,20220824,20221011,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187902",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20221011,,MD,DE,DE,2022,Q4,Elderly
212495092,21249509,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Dyspnoea exertional,,2022,Q4,2,F,,20221004.0,20220824,20221011,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187902",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20221011,,MD,DE,DE,2022,Q4,Elderly
212495092,21249509,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Pneumonia,,2022,Q4,2,F,,20221004.0,20220824,20221011,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187902",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20221011,,MD,DE,DE,2022,Q4,Elderly
212495092,21249509,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1-0-0,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Renal impairment,,2022,Q4,2,F,,20221004.0,20220824,20221011,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187902",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20221011,,MD,DE,DE,2022,Q4,Elderly
212495092,21249509,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2022,Q4,COVID-19,,2022,Q4,2,F,,20221004.0,20220824,20221011,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187902",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20221011,,MD,DE,DE,2022,Q4,Elderly
212495092,21249509,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2022,Q4,Cardiac failure,,2022,Q4,2,F,,20221004.0,20220824,20221011,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187902",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20221011,,MD,DE,DE,2022,Q4,Elderly
212495092,21249509,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2022,Q4,Dyspnoea exertional,,2022,Q4,2,F,,20221004.0,20220824,20221011,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187902",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20221011,,MD,DE,DE,2022,Q4,Elderly
212495092,21249509,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2022,Q4,Pneumonia,,2022,Q4,2,F,,20221004.0,20220824,20221011,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187902",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20221011,,MD,DE,DE,2022,Q4,Elderly
212495092,21249509,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,204629.0,,,,,2022,Q4,Renal impairment,,2022,Q4,2,F,,20221004.0,20220824,20221011,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-187902",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,,,20221011,,MD,DE,DE,2022,Q4,Elderly
212536517,21253651,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,Tablets,,2022,Q4,Infection,,2022,Q4,7,F,20220816.0,20221013.0,20220825,20221020,EXP,,BR-Eisai Medical Research-EC-2022-121814,EISAI,,65.0,YR,E,F,Y,54.6,KG,20221020,,MD,BR,,2022,Q4,Elderly
212628022,21262802,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,in the morning,,,Y,,,,,10.0,MG,Tablet,,2022,Q4,Hepatic cytolysis,,2022,Q4,2,F,20190301.0,20221003.0,20220828,20221012,EXP,,RU-Accord-275355,ACCORD,"Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report. Russian Journal of Cardiology. 2021;26(11) 4471:102-8.",60.0,YR,A,F,Y,71.0,KG,20221012,,HP,RU,RU,2022,Q4,Adult
212628022,21262802,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,in the morning,,,Y,,,,,10.0,MG,Tablet,,2022,Q4,Electrocardiogram QT prolonged,,2022,Q4,2,F,20190301.0,20221003.0,20220828,20221012,EXP,,RU-Accord-275355,ACCORD,"Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report. Russian Journal of Cardiology. 2021;26(11) 4471:102-8.",60.0,YR,A,F,Y,71.0,KG,20221012,,HP,RU,RU,2022,Q4,Adult
212628022,21262802,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,in the morning,,,Y,,,,,10.0,MG,Tablet,,2022,Q4,Hypokalaemia,,2022,Q4,2,F,20190301.0,20221003.0,20220828,20221012,EXP,,RU-Accord-275355,ACCORD,"Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report. Russian Journal of Cardiology. 2021;26(11) 4471:102-8.",60.0,YR,A,F,Y,71.0,KG,20221012,,HP,RU,RU,2022,Q4,Adult
212628022,21262802,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,in the morning,,,Y,,,,,10.0,MG,Tablet,,2022,Q4,Rhabdomyolysis,,2022,Q4,2,F,20190301.0,20221003.0,20220828,20221012,EXP,,RU-Accord-275355,ACCORD,"Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report. Russian Journal of Cardiology. 2021;26(11) 4471:102-8.",60.0,YR,A,F,Y,71.0,KG,20221012,,HP,RU,RU,2022,Q4,Adult
212628022,21262802,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,in the morning,,,Y,,,,,10.0,MG,Tablet,,2022,Q4,Metabolic alkalosis,,2022,Q4,2,F,20190301.0,20221003.0,20220828,20221012,EXP,,RU-Accord-275355,ACCORD,"Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report. Russian Journal of Cardiology. 2021;26(11) 4471:102-8.",60.0,YR,A,F,Y,71.0,KG,20221012,,HP,RU,RU,2022,Q4,Adult
212678615,21267861,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg; 1x/day in the morning,,,Y,,,,,10.0,MG,,QD,2022,Q4,Rhabdomyolysis,,2022,Q4,5,F,20190301.0,20221003.0,20220829,20221010,EXP,,RU-PFIZER INC-202201085838,PFIZER,"Evdokimova, N.. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report.. Russian Journal of Cardiology.. 2021;26(11):102-8",60.0,YR,,F,Y,71.0,KG,20221010,,HP,RU,RU,2022,Q4,Adult
212678615,21267861,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg; 1x/day in the morning,,,Y,,,,,10.0,MG,,QD,2022,Q4,Electrocardiogram QT prolonged,,2022,Q4,5,F,20190301.0,20221003.0,20220829,20221010,EXP,,RU-PFIZER INC-202201085838,PFIZER,"Evdokimova, N.. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report.. Russian Journal of Cardiology.. 2021;26(11):102-8",60.0,YR,,F,Y,71.0,KG,20221010,,HP,RU,RU,2022,Q4,Adult
212678615,21267861,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg; 1x/day in the morning,,,Y,,,,,10.0,MG,,QD,2022,Q4,Hepatic cytolysis,,2022,Q4,5,F,20190301.0,20221003.0,20220829,20221010,EXP,,RU-PFIZER INC-202201085838,PFIZER,"Evdokimova, N.. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report.. Russian Journal of Cardiology.. 2021;26(11):102-8",60.0,YR,,F,Y,71.0,KG,20221010,,HP,RU,RU,2022,Q4,Adult
212678615,21267861,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg; 1x/day in the morning,,,Y,,,,,10.0,MG,,QD,2022,Q4,Metabolic alkalosis,,2022,Q4,5,F,20190301.0,20221003.0,20220829,20221010,EXP,,RU-PFIZER INC-202201085838,PFIZER,"Evdokimova, N.. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report.. Russian Journal of Cardiology.. 2021;26(11):102-8",60.0,YR,,F,Y,71.0,KG,20221010,,HP,RU,RU,2022,Q4,Adult
212678615,21267861,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg; 1x/day in the morning,,,Y,,,,,10.0,MG,,QD,2022,Q4,Hypokalaemia,,2022,Q4,5,F,20190301.0,20221003.0,20220829,20221010,EXP,,RU-PFIZER INC-202201085838,PFIZER,"Evdokimova, N.. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report.. Russian Journal of Cardiology.. 2021;26(11):102-8",60.0,YR,,F,Y,71.0,KG,20221010,,HP,RU,RU,2022,Q4,Adult
2129843010,21298430,9,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,1000.25,MG,Tablets,,2022,Q4,Gastrointestinal haemorrhage,,2022,Q4,10,F,20220829.0,20221030.0,20220906,20221107,PER,,IL-Eisai Medical Research-EC-2022-122677,EISAI,,72.0,YR,E,M,Y,105.0,KG,20221107,,MD,IL,,2022,Q4,Elderly
213055883,21305588,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, in the morning",,,,,,,,10.0,MG,Tablet,,2022,Q4,Rhabdomyolysis,,2022,Q4,3,F,,20220926.0,20220908,20221216,EXP,,RU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-353632,RANBAXY,"Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report. Russ J Cardiol. 2021;26(11):4471 (102-103)",60.0,YR,,F,Y,,,20221216,,HP,RU,RU,2022,Q4,Adult
213055883,21305588,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, in the morning",,,,,,,,10.0,MG,Tablet,,2022,Q4,Paresis,,2022,Q4,3,F,,20220926.0,20220908,20221216,EXP,,RU-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-353632,RANBAXY,"Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report. Russ J Cardiol. 2021;26(11):4471 (102-103)",60.0,YR,,F,Y,,,20221216,,HP,RU,RU,2022,Q4,Adult
2132871611,21328716,12,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,Tablets,,2022,Q4,Pancreatitis,,2022,Q4,11,F,20220825.0,20221201.0,20220913,20221207,PER,,IL-Eisai Medical Research-EC-2022-122399,EISAI,,63.0,YR,A,F,Y,77.3,KG,20221207,,MD,IL,,2022,Q4,Adult
213431833,21343183,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Unknown,,2022,Q4,Swelling,,2022,Q4,3,F,20220401.0,20221025.0,20220916,20221031,EXP,,CO-BRISTOL-MYERS SQUIBB COMPANY-2022-107047,BRISTOL MYERS SQUIBB,,80.0,YR,E,F,Y,,,20221031,,CN,CO,CO,2022,Q4,Elderly
213431833,21343183,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Unknown,,2022,Q4,Off label use,,2022,Q4,3,F,20220401.0,20221025.0,20220916,20221031,EXP,,CO-BRISTOL-MYERS SQUIBB COMPANY-2022-107047,BRISTOL MYERS SQUIBB,,80.0,YR,E,F,Y,,,20221031,,CN,CO,CO,2022,Q4,Elderly
213431833,21343183,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Unknown,,2022,Q4,Pneumonia,,2022,Q4,3,F,20220401.0,20221025.0,20220916,20221031,EXP,,CO-BRISTOL-MYERS SQUIBB COMPANY-2022-107047,BRISTOL MYERS SQUIBB,,80.0,YR,E,F,Y,,,20221031,,CN,CO,CO,2022,Q4,Elderly
213431833,21343183,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,Unknown,,2022,Q4,Pleural effusion,,2022,Q4,3,F,20220401.0,20221025.0,20220916,20221031,EXP,,CO-BRISTOL-MYERS SQUIBB COMPANY-2022-107047,BRISTOL MYERS SQUIBB,,80.0,YR,E,F,Y,,,20221031,,CN,CO,CO,2022,Q4,Elderly
213494642,21349464,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Cholelithiasis,,2022,Q4,2,F,,20221124.0,20220919,20221201,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,"Chwia?kowska A, Uruska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960",64.0,YR,,M,Y,163.0,KG,20221201,,HP,PL,PL,2022,Q4,Adult
213494642,21349464,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Treatment noncompliance,,2022,Q4,2,F,,20221124.0,20220919,20221201,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,"Chwia?kowska A, Uruska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960",64.0,YR,,M,Y,163.0,KG,20221201,,HP,PL,PL,2022,Q4,Adult
213494642,21349464,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Cardiac failure,,2022,Q4,2,F,,20221124.0,20220919,20221201,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,"Chwia?kowska A, Uruska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960",64.0,YR,,M,Y,163.0,KG,20221201,,HP,PL,PL,2022,Q4,Adult
213494642,21349464,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Diabetic neuropathy,,2022,Q4,2,F,,20221124.0,20220919,20221201,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,"Chwia?kowska A, Uruska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960",64.0,YR,,M,Y,163.0,KG,20221201,,HP,PL,PL,2022,Q4,Adult
213494642,21349464,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Lipohypertrophy,,2022,Q4,2,F,,20221124.0,20220919,20221201,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,"Chwia?kowska A, Uruska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960",64.0,YR,,M,Y,163.0,KG,20221201,,HP,PL,PL,2022,Q4,Adult
213494642,21349464,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Insulin resistance,,2022,Q4,2,F,,20221124.0,20220919,20221201,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,"Chwia?kowska A, Uruska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960",64.0,YR,,M,Y,163.0,KG,20221201,,HP,PL,PL,2022,Q4,Adult
213494642,21349464,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Blood glucose increased,,2022,Q4,2,F,,20221124.0,20220919,20221201,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,"Chwia?kowska A, Uruska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960",64.0,YR,,M,Y,163.0,KG,20221201,,HP,PL,PL,2022,Q4,Adult
213494642,21349464,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Hepatic steatosis,,2022,Q4,2,F,,20221124.0,20220919,20221201,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,"Chwia?kowska A, Uruska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960",64.0,YR,,M,Y,163.0,KG,20221201,,HP,PL,PL,2022,Q4,Adult
213494642,21349464,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q4,Injection site hypertrophy,,2022,Q4,2,F,,20221124.0,20220919,20221201,EXP,,PL-MYLANLABS-2022M1092778,MYLAN,"Chwia?kowska A, Uruska A. Insulin resistance: a case study. POSTGRADUATE DIABETOLOGY. 2022;3:37960",64.0,YR,,M,Y,163.0,KG,20221201,,HP,PL,PL,2022,Q4,Adult
213550682,21355068,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,Unknown,,206111.0,,,,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,2,F,20211113.0,20221016.0,20220920,20221021,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191832",BOEHRINGER INGELHEIM,,77.0,YR,E,M,Y,,,20221021,,PH,AU,AU,2022,Q4,Elderly
213550682,21355068,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,Unknown,,206111.0,,,,,2022,Q4,Pancreatitis,,2022,Q4,2,F,20211113.0,20221016.0,20220920,20221021,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191832",BOEHRINGER INGELHEIM,,77.0,YR,E,M,Y,,,20221021,,PH,AU,AU,2022,Q4,Elderly
213550682,21355068,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,Unknown,,206111.0,,,,,2022,Q4,Acute kidney injury,,2022,Q4,2,F,20211113.0,20221016.0,20220920,20221021,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-191832",BOEHRINGER INGELHEIM,,77.0,YR,E,M,Y,,,20221021,,PH,AU,AU,2022,Q4,Elderly
213555352,21355535,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Cardiac failure,,2022,Q4,2,F,,20221208.0,20220920,20221219,EXP,,PL-BAUSCH-BL-2022-022164,BAUSCH AND LOMB,"Chwialkowska A, Uruska A. Insulinooporno-opis przypadku. Diabetologia po Dyplomie. 2022 SEP;19(3):18-20.",64.0,YR,,M,Y,163.0,KG,20221219,,MD,PL,PL,2022,Q4,Adult
213555352,21355535,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Hepatic steatosis,,2022,Q4,2,F,,20221208.0,20220920,20221219,EXP,,PL-BAUSCH-BL-2022-022164,BAUSCH AND LOMB,"Chwialkowska A, Uruska A. Insulinooporno-opis przypadku. Diabetologia po Dyplomie. 2022 SEP;19(3):18-20.",64.0,YR,,M,Y,163.0,KG,20221219,,MD,PL,PL,2022,Q4,Adult
213555352,21355535,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Blood glucose increased,,2022,Q4,2,F,,20221208.0,20220920,20221219,EXP,,PL-BAUSCH-BL-2022-022164,BAUSCH AND LOMB,"Chwialkowska A, Uruska A. Insulinooporno-opis przypadku. Diabetologia po Dyplomie. 2022 SEP;19(3):18-20.",64.0,YR,,M,Y,163.0,KG,20221219,,MD,PL,PL,2022,Q4,Adult
213555352,21355535,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Lipohypertrophy,,2022,Q4,2,F,,20221208.0,20220920,20221219,EXP,,PL-BAUSCH-BL-2022-022164,BAUSCH AND LOMB,"Chwialkowska A, Uruska A. Insulinooporno-opis przypadku. Diabetologia po Dyplomie. 2022 SEP;19(3):18-20.",64.0,YR,,M,Y,163.0,KG,20221219,,MD,PL,PL,2022,Q4,Adult
213555352,21355535,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Diabetic neuropathy,,2022,Q4,2,F,,20221208.0,20220920,20221219,EXP,,PL-BAUSCH-BL-2022-022164,BAUSCH AND LOMB,"Chwialkowska A, Uruska A. Insulinooporno-opis przypadku. Diabetologia po Dyplomie. 2022 SEP;19(3):18-20.",64.0,YR,,M,Y,163.0,KG,20221219,,MD,PL,PL,2022,Q4,Adult
213555352,21355535,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Cholelithiasis,,2022,Q4,2,F,,20221208.0,20220920,20221219,EXP,,PL-BAUSCH-BL-2022-022164,BAUSCH AND LOMB,"Chwialkowska A, Uruska A. Insulinooporno-opis przypadku. Diabetologia po Dyplomie. 2022 SEP;19(3):18-20.",64.0,YR,,M,Y,163.0,KG,20221219,,MD,PL,PL,2022,Q4,Adult
213555352,21355535,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2022,Q4,Insulin resistance,,2022,Q4,2,F,,20221208.0,20220920,20221219,EXP,,PL-BAUSCH-BL-2022-022164,BAUSCH AND LOMB,"Chwialkowska A, Uruska A. Insulinooporno-opis przypadku. Diabetologia po Dyplomie. 2022 SEP;19(3):18-20.",64.0,YR,,M,Y,163.0,KG,20221219,,MD,PL,PL,2022,Q4,Adult
213599412,21359941,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Oedema peripheral,,2022,Q4,2,F,,20220928.0,20220921,20221003,EXP,,CA-PFIZER INC-PV202200067155,PFIZER,,66.0,YR,,M,Y,,,20221003,,MD,CA,CA,2022,Q4,Elderly
213599412,21359941,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Fluid retention,,2022,Q4,2,F,,20220928.0,20220921,20221003,EXP,,CA-PFIZER INC-PV202200067155,PFIZER,,66.0,YR,,M,Y,,,20221003,,MD,CA,CA,2022,Q4,Elderly
213599412,21359941,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Cardiac failure congestive,,2022,Q4,2,F,,20220928.0,20220921,20221003,EXP,,CA-PFIZER INC-PV202200067155,PFIZER,,66.0,YR,,M,Y,,,20221003,,MD,CA,CA,2022,Q4,Elderly
213599412,21359941,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Cognitive disorder,,2022,Q4,2,F,,20220928.0,20220921,20221003,EXP,,CA-PFIZER INC-PV202200067155,PFIZER,,66.0,YR,,M,Y,,,20221003,,MD,CA,CA,2022,Q4,Elderly
213599412,21359941,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Pleural effusion,,2022,Q4,2,F,,20220928.0,20220921,20221003,EXP,,CA-PFIZER INC-PV202200067155,PFIZER,,66.0,YR,,M,Y,,,20221003,,MD,CA,CA,2022,Q4,Elderly
213599412,21359941,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20220928.0,20220921,20221003,EXP,,CA-PFIZER INC-PV202200067155,PFIZER,,66.0,YR,,M,Y,,,20221003,,MD,CA,CA,2022,Q4,Elderly
213739302,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Blood pressure systolic decreased,,2022,Q4,2,F,,20221109.0,20220926,20221111,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20221111,,MD,JP,JP,2022,Q4,Elderly
213739302,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Cardiac failure,,2022,Q4,2,F,,20221109.0,20220926,20221111,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20221111,,MD,JP,JP,2022,Q4,Elderly
213739302,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Mitral valve incompetence,,2022,Q4,2,F,,20221109.0,20220926,20221111,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20221111,,MD,JP,JP,2022,Q4,Elderly
213739302,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Ejection fraction decreased,,2022,Q4,2,F,,20221109.0,20220926,20221111,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20221111,,MD,JP,JP,2022,Q4,Elderly
213739302,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Cardiac murmur,,2022,Q4,2,F,,20221109.0,20220926,20221111,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20221111,,MD,JP,JP,2022,Q4,Elderly
213739302,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221109.0,20220926,20221111,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20221111,,MD,JP,JP,2022,Q4,Elderly
213739302,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Pleural effusion,,2022,Q4,2,F,,20221109.0,20220926,20221111,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20221111,,MD,JP,JP,2022,Q4,Elderly
213739302,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Electrocardiogram T wave inversion,,2022,Q4,2,F,,20221109.0,20220926,20221111,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20221111,,MD,JP,JP,2022,Q4,Elderly
213739302,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Hypertension,,2022,Q4,2,F,,20221109.0,20220926,20221111,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20221111,,MD,JP,JP,2022,Q4,Elderly
213739302,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Crepitations,,2022,Q4,2,F,,20221109.0,20220926,20221111,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20221111,,MD,JP,JP,2022,Q4,Elderly
213739302,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Pulmonary congestion,,2022,Q4,2,F,,20221109.0,20220926,20221111,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20221111,,MD,JP,JP,2022,Q4,Elderly
213739302,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Left ventricular dysfunction,,2022,Q4,2,F,,20221109.0,20220926,20221111,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20221111,,MD,JP,JP,2022,Q4,Elderly
213739302,21373930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Left ventricular hypertrophy,,2022,Q4,2,F,,20221109.0,20220926,20221111,EXP,,NVSJ2022JP098016,NOVARTIS,,77.0,YR,,M,Y,,,20221111,,MD,JP,JP,2022,Q4,Elderly
213750933,21375093,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Renal failure,,2022,Q4,3,F,20220824.0,20221006.0,20220926,20221006,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193061",BOEHRINGER INGELHEIM,,63.0,YR,A,F,Y,,,20221006,,MD,PL,PL,2022,Q4,Adult
213752792,21375279,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Pollakiuria,,2022,Q4,2,F,20210907.0,20221006.0,20220926,20221013,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193289",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
213752792,21375279,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Acute kidney injury,,2022,Q4,2,F,20210907.0,20221006.0,20220926,20221013,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193289",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
213752792,21375279,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Cystitis,,2022,Q4,2,F,20210907.0,20221006.0,20220926,20221013,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193289",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
213752792,21375279,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Product monitoring error,,2022,Q4,2,F,20210907.0,20221006.0,20220926,20221013,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193289",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
213752792,21375279,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Urinary hesitation,,2022,Q4,2,F,20210907.0,20221006.0,20220926,20221013,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193289",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
213752792,21375279,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Labelled drug-drug interaction medication error,,2022,Q4,2,F,20210907.0,20221006.0,20220926,20221013,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193289",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
213752792,21375279,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q4,2,F,20210907.0,20221006.0,20220926,20221013,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193289",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
213752792,21375279,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Product administration error,,2022,Q4,2,F,20210907.0,20221006.0,20220926,20221013,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193289",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
213806822,21380682,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, unknown",,,,,,,,10.0,MG,,,2022,Q4,Renal cell carcinoma,,2022,Q4,2,F,,20220930.0,20220927,20221011,EXP,,SI-ELI_LILLY_AND_COMPANY-SI202209008198,ELI LILLY AND CO,,73.0,YR,,M,Y,82.0,KG,20221011,,MD,SI,SI,2022,Q4,Elderly
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Dyspnoea,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,"Hallucination, auditory",,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Body temperature increased,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Electrocardiogram ST segment elevation,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Blood triglycerides increased,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Ejection fraction decreased,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Blood glucose increased,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Mean cell volume decreased,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Dizziness,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Anion gap increased,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Electrocardiogram ST-T segment abnormal,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Blood pressure systolic decreased,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,QRS axis abnormal,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Ventricular internal diameter abnormal,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Mean cell haemoglobin decreased,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Diabetes mellitus inadequate control,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Drug hypersensitivity,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Sinus tachycardia,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Glomerular filtration rate decreased,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Blood lactic acid increased,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Electrocardiogram T wave inversion,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Cardiomyopathy,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Hyperhidrosis,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Myocardial infarction,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Blood sodium decreased,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Haematocrit decreased,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Electrocardiogram QRS complex prolonged,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Electrocardiogram QT prolonged,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Haemoglobin decreased,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Left atrial dilatation,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Left ventricular dysfunction,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Hypotension,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213876303,21387630,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, mane, daily",,,,,,,,10.0,MG,Tablet,,2022,Q4,Left ventricular hypertrophy,,2022,Q4,3,F,20010101.0,20220916.0,20220928,20221014,EXP,,AU-PFIZER INC-PV202200065774,PFIZER,,27.0,YR,,M,Y,90.0,KG,20221014,,MD,AU,AU,2022,Q4,Young Adult
213926392,21392639,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221004.0,20220929,20221014,EXP,,US-TEVA-2022-US-2076287,TEVA,,44.0,YR,A,F,Y,,,20221014,,MD,US,US,2022,Q4,Adult
213926392,21392639,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,2,F,,20221004.0,20220929,20221014,EXP,,US-TEVA-2022-US-2076287,TEVA,,44.0,YR,A,F,Y,,,20221014,,MD,US,US,2022,Q4,Adult
213926392,21392639,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Nausea,,2022,Q4,2,F,,20221004.0,20220929,20221014,EXP,,US-TEVA-2022-US-2076287,TEVA,,44.0,YR,A,F,Y,,,20221014,,MD,US,US,2022,Q4,Adult
213926392,21392639,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Vomiting,,2022,Q4,2,F,,20221004.0,20220929,20221014,EXP,,US-TEVA-2022-US-2076287,TEVA,,44.0,YR,A,F,Y,,,20221014,,MD,US,US,2022,Q4,Adult
213926392,21392639,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Drug ineffective,,2022,Q4,2,F,,20221004.0,20220929,20221014,EXP,,US-TEVA-2022-US-2076287,TEVA,,44.0,YR,A,F,Y,,,20221014,,MD,US,US,2022,Q4,Adult
213950563,21395056,34,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q4,Sepsis,,2022,Q4,3,F,20220908.0,20221005.0,20220930,20221017,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-108296,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,103.6,KG,20221017,,HP,US,US,2022,Q4,Adult
213950563,21395056,34,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q4,Klebsiella bacteraemia,,2022,Q4,3,F,20220908.0,20221005.0,20220930,20221017,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-108296,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,103.6,KG,20221017,,HP,US,US,2022,Q4,Adult
213950563,21395056,34,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q4,Urinary tract infection bacterial,,2022,Q4,3,F,20220908.0,20221005.0,20220930,20221017,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-108296,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,103.6,KG,20221017,,HP,US,US,2022,Q4,Adult
213993291,21399329,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Death,,2022,Q4,1,I,20220901.0,20220928.0,20221001,20221001,EXP,,"SK-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-194517",BOEHRINGER INGELHEIM,,72.0,YR,E,M,Y,,,20221001,,MD,SK,SK,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Skin turgor decreased,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Urine ketone body present,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Protein urine present,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,QRS axis abnormal,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Blood lactic acid increased,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Diabetic ketoacidosis,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Renal failure,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Pain,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Diarrhoea,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Glucose urine present,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Anion gap increased,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Abdominal pain,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Hypocapnia,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Acidosis,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Mucosal dryness,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Chest pain,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Electrocardiogram QT prolonged,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
213999372,21399937,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,unknown,,204629.0,10.0,MG,,QD,2022,Q4,Respiratory rate increased,,2022,Q4,2,F,,20221003.0,20221002,20221010,EXP,,"AT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193940",BOEHRINGER INGELHEIM,"Stollberger C, Wilfing R. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin. 2022 Sep; 22-24.",75.0,YR,E,F,Y,,,20221010,,MD,AT,AT,2022,Q4,Elderly
214000071,21400007,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Acute respiratory failure,,2022,Q4,1,I,,20220922.0,20221002,20221002,EXP,,DE-TEVA-2022-DE-2077750,TEVA,,78.0,YR,E,M,Y,,,20221002,,PH,DE,DE,2022,Q4,Elderly
214000071,21400007,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Renal impairment,,2022,Q4,1,I,,20220922.0,20221002,20221002,EXP,,DE-TEVA-2022-DE-2077750,TEVA,,78.0,YR,E,M,Y,,,20221002,,PH,DE,DE,2022,Q4,Elderly
214000071,21400007,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Tachycardia,,2022,Q4,1,I,,20220922.0,20221002,20221002,EXP,,DE-TEVA-2022-DE-2077750,TEVA,,78.0,YR,E,M,Y,,,20221002,,PH,DE,DE,2022,Q4,Elderly
214000071,21400007,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Arrhythmia,,2022,Q4,1,I,,20220922.0,20221002,20221002,EXP,,DE-TEVA-2022-DE-2077750,TEVA,,78.0,YR,E,M,Y,,,20221002,,PH,DE,DE,2022,Q4,Elderly
214000071,21400007,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Atrial fibrillation,,2022,Q4,1,I,,20220922.0,20221002,20221002,EXP,,DE-TEVA-2022-DE-2077750,TEVA,,78.0,YR,E,M,Y,,,20221002,,PH,DE,DE,2022,Q4,Elderly
214000071,21400007,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Electrocardiogram abnormal,,2022,Q4,1,I,,20220922.0,20221002,20221002,EXP,,DE-TEVA-2022-DE-2077750,TEVA,,78.0,YR,E,M,Y,,,20221002,,PH,DE,DE,2022,Q4,Elderly
214000071,21400007,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20220922.0,20221002,20221002,EXP,,DE-TEVA-2022-DE-2077750,TEVA,,78.0,YR,E,M,Y,,,20221002,,PH,DE,DE,2022,Q4,Elderly
214000071,21400007,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Systemic infection,,2022,Q4,1,I,,20220922.0,20221002,20221002,EXP,,DE-TEVA-2022-DE-2077750,TEVA,,78.0,YR,E,M,Y,,,20221002,,PH,DE,DE,2022,Q4,Elderly
214000071,21400007,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Acute myocardial infarction,,2022,Q4,1,I,,20220922.0,20221002,20221002,EXP,,DE-TEVA-2022-DE-2077750,TEVA,,78.0,YR,E,M,Y,,,20221002,,PH,DE,DE,2022,Q4,Elderly
214000071,21400007,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20220922.0,20221002,20221002,EXP,,DE-TEVA-2022-DE-2077750,TEVA,,78.0,YR,E,M,Y,,,20221002,,PH,DE,DE,2022,Q4,Elderly
214000071,21400007,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20220922.0,20221002,20221002,EXP,,DE-TEVA-2022-DE-2077750,TEVA,,78.0,YR,E,M,Y,,,20221002,,PH,DE,DE,2022,Q4,Elderly
214018371,21401837,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q4,Tachycardia,,2022,Q4,1,I,,20220926.0,20221003,20221003,EXP,,NVSC2022DE217116,NOVARTIS,,62.0,YR,,M,Y,,,20221003,,MD,DE,DE,2022,Q4,Adult
214018371,21401837,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q4,Liver function test abnormal,,2022,Q4,1,I,,20220926.0,20221003,20221003,EXP,,NVSC2022DE217116,NOVARTIS,,62.0,YR,,M,Y,,,20221003,,MD,DE,DE,2022,Q4,Adult
214018371,21401837,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q4,Arrhythmia,,2022,Q4,1,I,,20220926.0,20221003,20221003,EXP,,NVSC2022DE217116,NOVARTIS,,62.0,YR,,M,Y,,,20221003,,MD,DE,DE,2022,Q4,Adult
214018371,21401837,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q4,Ejection fraction decreased,,2022,Q4,1,I,,20220926.0,20221003,20221003,EXP,,NVSC2022DE217116,NOVARTIS,,62.0,YR,,M,Y,,,20221003,,MD,DE,DE,2022,Q4,Adult
214018371,21401837,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,,QD,2022,Q4,Ischaemic cardiomyopathy,,2022,Q4,1,I,,20220926.0,20221003,20221003,EXP,,NVSC2022DE217116,NOVARTIS,,62.0,YR,,M,Y,,,20221003,,MD,DE,DE,2022,Q4,Adult
214022072,21402207,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1 tablet after breakfast",,,D,,,,,25.0,MG,Tablet,,2022,Q4,Hypotension,,2022,Q4,2,F,,20220923.0,20221003,20221013,EXP,,JP-SA-2022SA192762,SANOFI AVENTIS,"Tsuji H, Mantani T, Yamamoto Y.. A Case of Severe Obesity Patient with Bipolar Affective Disorder Complicated with Acute Lithium Poisoning during Hospitalization for Low Calorie Diet Therapy.. Obesity Study. 2021;27(2):99-102",56.0,YR,A,M,Y,119.2,KG,20221013,,HP,JP,JP,2022,Q4,Adult
214022072,21402207,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1 tablet after breakfast",,,D,,,,,25.0,MG,Tablet,,2022,Q4,Drug ineffective,,2022,Q4,2,F,,20220923.0,20221003,20221013,EXP,,JP-SA-2022SA192762,SANOFI AVENTIS,"Tsuji H, Mantani T, Yamamoto Y.. A Case of Severe Obesity Patient with Bipolar Affective Disorder Complicated with Acute Lithium Poisoning during Hospitalization for Low Calorie Diet Therapy.. Obesity Study. 2021;27(2):99-102",56.0,YR,A,M,Y,119.2,KG,20221013,,HP,JP,JP,2022,Q4,Adult
214022072,21402207,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1 tablet after breakfast",,,D,,,,,25.0,MG,Tablet,,2022,Q4,Toxicity to various agents,,2022,Q4,2,F,,20220923.0,20221003,20221013,EXP,,JP-SA-2022SA192762,SANOFI AVENTIS,"Tsuji H, Mantani T, Yamamoto Y.. A Case of Severe Obesity Patient with Bipolar Affective Disorder Complicated with Acute Lithium Poisoning during Hospitalization for Low Calorie Diet Therapy.. Obesity Study. 2021;27(2):99-102",56.0,YR,A,M,Y,119.2,KG,20221013,,HP,JP,JP,2022,Q4,Adult
214022072,21402207,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1 tablet after breakfast",,,D,,,,,25.0,MG,Tablet,,2022,Q4,Bradycardia,,2022,Q4,2,F,,20220923.0,20221003,20221013,EXP,,JP-SA-2022SA192762,SANOFI AVENTIS,"Tsuji H, Mantani T, Yamamoto Y.. A Case of Severe Obesity Patient with Bipolar Affective Disorder Complicated with Acute Lithium Poisoning during Hospitalization for Low Calorie Diet Therapy.. Obesity Study. 2021;27(2):99-102",56.0,YR,A,M,Y,119.2,KG,20221013,,HP,JP,JP,2022,Q4,Adult
214025541,21402554,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,,,,QD,2022,Q4,Tachycardia,,2022,Q4,1,I,,20220923.0,20221003,20221003,EXP,,DE-EMD Serono-E2B_90089214,EMD SERONO INC,,66.0,YR,E,M,Y,87.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214025541,21402554,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,,,,QD,2022,Q4,Atrial fibrillation,,2022,Q4,1,I,,20220923.0,20221003,20221003,EXP,,DE-EMD Serono-E2B_90089214,EMD SERONO INC,,66.0,YR,E,M,Y,87.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214025541,21402554,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,,,,QD,2022,Q4,Anion gap increased,,2022,Q4,1,I,,20220923.0,20221003,20221003,EXP,,DE-EMD Serono-E2B_90089214,EMD SERONO INC,,66.0,YR,E,M,Y,87.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214025541,21402554,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,,,,QD,2022,Q4,Palpitations,,2022,Q4,1,I,,20220923.0,20221003,20221003,EXP,,DE-EMD Serono-E2B_90089214,EMD SERONO INC,,66.0,YR,E,M,Y,87.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214025541,21402554,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,,,,QD,2022,Q4,Lactic acidosis,,2022,Q4,1,I,,20220923.0,20221003,20221003,EXP,,DE-EMD Serono-E2B_90089214,EMD SERONO INC,,66.0,YR,E,M,Y,87.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214025541,21402554,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,,,,QD,2022,Q4,Hypoaesthesia,,2022,Q4,1,I,,20220923.0,20221003,20221003,EXP,,DE-EMD Serono-E2B_90089214,EMD SERONO INC,,66.0,YR,E,M,Y,87.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214025541,21402554,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,,,,QD,2022,Q4,Chest discomfort,,2022,Q4,1,I,,20220923.0,20221003,20221003,EXP,,DE-EMD Serono-E2B_90089214,EMD SERONO INC,,66.0,YR,E,M,Y,87.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214025541,21402554,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, 1-0-0-0",,,,,,,,,,,QD,2022,Q4,Hypoaesthesia,,2022,Q4,1,I,,20220923.0,20221003,20221003,EXP,,DE-EMD Serono-E2B_90089214,EMD SERONO INC,,66.0,YR,E,M,Y,87.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214049621,21404962,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,20220829.0,,20221003,20221003,DIR,FDA-CDER-CTU-2022-78341,,FDA-CTU,,50.0,YR,,F,N,,,20220926,N,PH,US,,2022,Q4,Adult
214051581,21405158,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20220922.0,20221004,20221004,EXP,DE-ADRED-08478-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10391,ALKEM,,54.0,YR,,M,Y,98.0,KG,20221004,,PH,DE,DE,2022,Q4,Adult
214051581,21405158,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20220922.0,20221004,20221004,EXP,DE-ADRED-08478-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10391,ALKEM,,54.0,YR,,M,Y,98.0,KG,20221004,,PH,DE,DE,2022,Q4,Adult
214051581,21405158,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q4,Condition aggravated,,2022,Q4,1,I,,20220922.0,20221004,20221004,EXP,DE-ADRED-08478-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10391,ALKEM,,54.0,YR,,M,Y,98.0,KG,20221004,,PH,DE,DE,2022,Q4,Adult
214051581,21405158,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q4,Labelled drug-drug interaction medication error,,2022,Q4,1,I,,20220922.0,20221004,20221004,EXP,DE-ADRED-08478-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10391,ALKEM,,54.0,YR,,M,Y,98.0,KG,20221004,,PH,DE,DE,2022,Q4,Adult
214051581,21405158,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q4,Polyneuropathy,,2022,Q4,1,I,,20220922.0,20221004,20221004,EXP,DE-ADRED-08478-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10391,ALKEM,,54.0,YR,,M,Y,98.0,KG,20221004,,PH,DE,DE,2022,Q4,Adult
214051581,21405158,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q4,Chest pain,,2022,Q4,1,I,,20220922.0,20221004,20221004,EXP,DE-ADRED-08478-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10391,ALKEM,,54.0,YR,,M,Y,98.0,KG,20221004,,PH,DE,DE,2022,Q4,Adult
214051581,21405158,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q4,Systemic infection,,2022,Q4,1,I,,20220922.0,20221004,20221004,EXP,DE-ADRED-08478-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10391,ALKEM,,54.0,YR,,M,Y,98.0,KG,20221004,,PH,DE,DE,2022,Q4,Adult
214051581,21405158,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2022,Q4,Electrocardiogram abnormal,,2022,Q4,1,I,,20220922.0,20221004,20221004,EXP,DE-ADRED-08478-01,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10391,ALKEM,,54.0,YR,,M,Y,98.0,KG,20221004,,PH,DE,DE,2022,Q4,Adult
214071721,21407172,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q4,Muscle spasms,,2022,Q4,1,I,20220926.0,20220930.0,20221004,20221004,EXP,GB-MHRA-TPP53062035C8007043YC1664186984804,GB-009507513-2210GBR000033,MERCK,,84.0,YR,,F,Y,69.0,KG,20221004,,MD,GB,GB,2022,Q4,Elderly
214078981,21407898,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0, Tablet",,,,,,,,,,,,2022,Q4,Microcytic anaemia,,2022,Q4,1,I,,20220927.0,20221004,20221004,EXP,,DE-AstraZeneca-2022A330216,ASTRAZENECA,,59.0,YR,,M,Y,93.0,KG,20221004,,MD,DE,,2022,Q4,Adult
214078981,21407898,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0, Tablet",,,,,,,,,,,,2022,Q4,Muscular weakness,,2022,Q4,1,I,,20220927.0,20221004,20221004,EXP,,DE-AstraZeneca-2022A330216,ASTRAZENECA,,59.0,YR,,M,Y,93.0,KG,20221004,,MD,DE,,2022,Q4,Adult
214078981,21407898,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0, Tablet",,,,,,,,,,,,2022,Q4,Dizziness,,2022,Q4,1,I,,20220927.0,20221004,20221004,EXP,,DE-AstraZeneca-2022A330216,ASTRAZENECA,,59.0,YR,,M,Y,93.0,KG,20221004,,MD,DE,,2022,Q4,Adult
214078981,21407898,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0, Tablet",,,,,,,,,,,,2022,Q4,Abdominal pain upper,,2022,Q4,1,I,,20220927.0,20221004,20221004,EXP,,DE-AstraZeneca-2022A330216,ASTRAZENECA,,59.0,YR,,M,Y,93.0,KG,20221004,,MD,DE,,2022,Q4,Adult
214078981,21407898,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0, Tablet",,,,,,,,,,,,2022,Q4,Dyspnoea exertional,,2022,Q4,1,I,,20220927.0,20221004,20221004,EXP,,DE-AstraZeneca-2022A330216,ASTRAZENECA,,59.0,YR,,M,Y,93.0,KG,20221004,,MD,DE,,2022,Q4,Adult
214078981,21407898,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0, Tablet",,,,,,,,,,,,2022,Q4,Faeces discoloured,,2022,Q4,1,I,,20220927.0,20221004,20221004,EXP,,DE-AstraZeneca-2022A330216,ASTRAZENECA,,59.0,YR,,M,Y,93.0,KG,20221004,,MD,DE,,2022,Q4,Adult
214078981,21407898,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0, Tablet",,,,,,,,,,,,2022,Q4,Fatigue,,2022,Q4,1,I,,20220927.0,20221004,20221004,EXP,,DE-AstraZeneca-2022A330216,ASTRAZENECA,,59.0,YR,,M,Y,93.0,KG,20221004,,MD,DE,,2022,Q4,Adult
214078981,21407898,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0, Tablet",,,,,,,,,,,,2022,Q4,Hyperhidrosis,,2022,Q4,1,I,,20220927.0,20221004,20221004,EXP,,DE-AstraZeneca-2022A330216,ASTRAZENECA,,59.0,YR,,M,Y,93.0,KG,20221004,,MD,DE,,2022,Q4,Adult
214078981,21407898,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0, Tablet",,,,,,,,,,,,2022,Q4,Abdominal pain,,2022,Q4,1,I,,20220927.0,20221004,20221004,EXP,,DE-AstraZeneca-2022A330216,ASTRAZENECA,,59.0,YR,,M,Y,93.0,KG,20221004,,MD,DE,,2022,Q4,Adult
214107101,21410710,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,37.5 MG AM PO,,,,,,,,37.5,MG,,999,2022,Q4,Dry mouth,,2022,Q4,1,I,20220829.0,,20221004,20221004,DIR,FDA-CDER-CTU-2022-78852,,FDA-CTU,,56.0,YR,,M,N,124.74,KG,20220930,N,HP,US,,2022,Q4,Adult
214115751,21411575,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 Dosage forms Daily; 25 mg, 1-0-0-0, Unit dose : 1 DF , frequency : OD, medication errors",,,U,,UNKNOWN,,,,,Tablet,QD,2022,Q4,Product monitoring error,,2022,Q4,1,I,,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078314,TEVA,,70.0,YR,E,M,Y,100.0,KG,20221005,,PH,DE,DE,2022,Q4,Elderly
214115751,21411575,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 Dosage forms Daily; 25 mg, 1-0-0-0, Unit dose : 1 DF , frequency : OD, medication errors",,,U,,UNKNOWN,,,,,Tablet,QD,2022,Q4,Inflammation,,2022,Q4,1,I,,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078314,TEVA,,70.0,YR,E,M,Y,100.0,KG,20221005,,PH,DE,DE,2022,Q4,Elderly
214115751,21411575,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 Dosage forms Daily; 25 mg, 1-0-0-0, Unit dose : 1 DF , frequency : OD, medication errors",,,U,,UNKNOWN,,,,,Tablet,QD,2022,Q4,Ulcer,,2022,Q4,1,I,,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078314,TEVA,,70.0,YR,E,M,Y,100.0,KG,20221005,,PH,DE,DE,2022,Q4,Elderly
214116051,21411605,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Haematochezia,,2022,Q4,1,I,20211001.0,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078202,TEVA,,73.0,YR,E,M,Y,,,20221005,,MD,DE,DE,2022,Q4,Elderly
214116051,21411605,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Asthenia,,2022,Q4,1,I,20211001.0,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078202,TEVA,,73.0,YR,E,M,Y,,,20221005,,MD,DE,DE,2022,Q4,Elderly
214116051,21411605,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Haemoglobin decreased,,2022,Q4,1,I,20211001.0,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078202,TEVA,,73.0,YR,E,M,Y,,,20221005,,MD,DE,DE,2022,Q4,Elderly
214116051,21411605,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Melaena,,2022,Q4,1,I,20211001.0,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078202,TEVA,,73.0,YR,E,M,Y,,,20221005,,MD,DE,DE,2022,Q4,Elderly
214116051,21411605,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Extra dose administered,,2022,Q4,1,I,20211001.0,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078202,TEVA,,73.0,YR,E,M,Y,,,20221005,,MD,DE,DE,2022,Q4,Elderly
214116051,21411605,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Upper gastrointestinal haemorrhage,,2022,Q4,1,I,20211001.0,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078202,TEVA,,73.0,YR,E,M,Y,,,20221005,,MD,DE,DE,2022,Q4,Elderly
214116051,21411605,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Product administration error,,2022,Q4,1,I,20211001.0,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078202,TEVA,,73.0,YR,E,M,Y,,,20221005,,MD,DE,DE,2022,Q4,Elderly
214119741,21411974,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q4,Limb injury,,2022,Q4,1,I,,20221005.0,20221005,20221005,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-195676",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,125.0,KG,20221005,,PH,DE,DE,2022,Q4,Adult
214119741,21411974,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q4,Wound secretion,,2022,Q4,1,I,,20221005.0,20221005,20221005,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-195676",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,125.0,KG,20221005,,PH,DE,DE,2022,Q4,Adult
214119741,21411974,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q4,Foot amputation,,2022,Q4,1,I,,20221005.0,20221005,20221005,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-195676",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,125.0,KG,20221005,,PH,DE,DE,2022,Q4,Adult
214119741,21411974,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q4,Impaired healing,,2022,Q4,1,I,,20221005.0,20221005,20221005,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-195676",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,125.0,KG,20221005,,PH,DE,DE,2022,Q4,Adult
214119741,21411974,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q4,Erythema,,2022,Q4,1,I,,20221005.0,20221005,20221005,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-195676",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,125.0,KG,20221005,,PH,DE,DE,2022,Q4,Adult
214119741,21411974,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q4,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q4,1,I,,20221005.0,20221005,20221005,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-195676",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,125.0,KG,20221005,,PH,DE,DE,2022,Q4,Adult
214129011,21412901,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q4,Ketoacidosis,,2022,Q4,1,I,,20221004.0,20221005,20221005,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-195781",BOEHRINGER INGELHEIM,,70.0,YR,E,F,Y,,,20221005,,MD,CO,CO,2022,Q4,Elderly
214129011,21412901,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q4,Chest pain,,2022,Q4,1,I,,20221004.0,20221005,20221005,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-195781",BOEHRINGER INGELHEIM,,70.0,YR,E,F,Y,,,20221005,,MD,CO,CO,2022,Q4,Elderly
214131411,21413141,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,,2022,Q4,Cardiomegaly,,2022,Q4,1,I,20220101.0,20221002.0,20221005,20221005,EXP,,HR-BAUSCH-BL-2022-022994,BAUSCH AND LOMB,,53.0,YR,,M,Y,,,20221006,,MD,HR,HR,2022,Q4,Adult
214131411,21413141,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,,2022,Q4,Oedema peripheral,,2022,Q4,1,I,20220101.0,20221002.0,20221005,20221005,EXP,,HR-BAUSCH-BL-2022-022994,BAUSCH AND LOMB,,53.0,YR,,M,Y,,,20221006,,MD,HR,HR,2022,Q4,Adult
214131411,21413141,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,,2022,Q4,Blood pressure systolic increased,,2022,Q4,1,I,20220101.0,20221002.0,20221005,20221005,EXP,,HR-BAUSCH-BL-2022-022994,BAUSCH AND LOMB,,53.0,YR,,M,Y,,,20221006,,MD,HR,HR,2022,Q4,Adult
214131411,21413141,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,,2022,Q4,Nocturnal dyspnoea,,2022,Q4,1,I,20220101.0,20221002.0,20221005,20221005,EXP,,HR-BAUSCH-BL-2022-022994,BAUSCH AND LOMB,,53.0,YR,,M,Y,,,20221006,,MD,HR,HR,2022,Q4,Adult
214131411,21413141,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,,2022,Q4,Bundle branch block left,,2022,Q4,1,I,20220101.0,20221002.0,20221005,20221005,EXP,,HR-BAUSCH-BL-2022-022994,BAUSCH AND LOMB,,53.0,YR,,M,Y,,,20221006,,MD,HR,HR,2022,Q4,Adult
214131411,21413141,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,,2022,Q4,N-terminal prohormone brain natriuretic peptide increased,,2022,Q4,1,I,20220101.0,20221002.0,20221005,20221005,EXP,,HR-BAUSCH-BL-2022-022994,BAUSCH AND LOMB,,53.0,YR,,M,Y,,,20221006,,MD,HR,HR,2022,Q4,Adult
214131411,21413141,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,,2022,Q4,Blood pressure decreased,,2022,Q4,1,I,20220101.0,20221002.0,20221005,20221005,EXP,,HR-BAUSCH-BL-2022-022994,BAUSCH AND LOMB,,53.0,YR,,M,Y,,,20221006,,MD,HR,HR,2022,Q4,Adult
214131411,21413141,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,,2022,Q4,Ejection fraction decreased,,2022,Q4,1,I,20220101.0,20221002.0,20221005,20221005,EXP,,HR-BAUSCH-BL-2022-022994,BAUSCH AND LOMB,,53.0,YR,,M,Y,,,20221006,,MD,HR,HR,2022,Q4,Adult
214131411,21413141,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,,2022,Q4,Dyspnoea exertional,,2022,Q4,1,I,20220101.0,20221002.0,20221005,20221005,EXP,,HR-BAUSCH-BL-2022-022994,BAUSCH AND LOMB,,53.0,YR,,M,Y,,,20221006,,MD,HR,HR,2022,Q4,Adult
214131411,21413141,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,,2022,Q4,Dizziness postural,,2022,Q4,1,I,20220101.0,20221002.0,20221005,20221005,EXP,,HR-BAUSCH-BL-2022-022994,BAUSCH AND LOMB,,53.0,YR,,M,Y,,,20221006,,MD,HR,HR,2022,Q4,Adult
214131411,21413141,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, QD (12.5/1000 mg in the morning)",,,U,,,,,,,,,2022,Q4,Effusion,,2022,Q4,1,I,20220101.0,20221002.0,20221005,20221005,EXP,,HR-BAUSCH-BL-2022-022994,BAUSCH AND LOMB,,53.0,YR,,M,Y,,,20221006,,MD,HR,HR,2022,Q4,Adult
214144811,21414481,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Pruritus,,2022,Q4,1,I,20220923.0,20221005.0,20221006,20221006,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-195829",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20221006,,HP,SG,SG,2022,Q4,Elderly
214149411,21414941,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (1-0-0-0),,,U,,,,,10.0,MG,,,2022,Q4,Systemic infection,,2022,Q4,1,I,,20220922.0,20221006,20221006,EXP,,DE-AUROBINDO-AUR-APL-2022-039942,AUROBINDO,,54.0,YR,,M,Y,98.0,KG,20221006,,PH,DE,DE,2022,Q4,Adult
214149411,21414941,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (1-0-0-0),,,U,,,,,10.0,MG,,,2022,Q4,Electrocardiogram abnormal,,2022,Q4,1,I,,20220922.0,20221006,20221006,EXP,,DE-AUROBINDO-AUR-APL-2022-039942,AUROBINDO,,54.0,YR,,M,Y,98.0,KG,20221006,,PH,DE,DE,2022,Q4,Adult
214149411,21414941,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (1-0-0-0),,,U,,,,,10.0,MG,,,2022,Q4,Polyneuropathy,,2022,Q4,1,I,,20220922.0,20221006,20221006,EXP,,DE-AUROBINDO-AUR-APL-2022-039942,AUROBINDO,,54.0,YR,,M,Y,98.0,KG,20221006,,PH,DE,DE,2022,Q4,Adult
214149411,21414941,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (1-0-0-0),,,U,,,,,10.0,MG,,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20220922.0,20221006,20221006,EXP,,DE-AUROBINDO-AUR-APL-2022-039942,AUROBINDO,,54.0,YR,,M,Y,98.0,KG,20221006,,PH,DE,DE,2022,Q4,Adult
214149411,21414941,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (1-0-0-0),,,U,,,,,10.0,MG,,,2022,Q4,Labelled drug-drug interaction medication error,,2022,Q4,1,I,,20220922.0,20221006,20221006,EXP,,DE-AUROBINDO-AUR-APL-2022-039942,AUROBINDO,,54.0,YR,,M,Y,98.0,KG,20221006,,PH,DE,DE,2022,Q4,Adult
214149411,21414941,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (1-0-0-0),,,U,,,,,10.0,MG,,,2022,Q4,Condition aggravated,,2022,Q4,1,I,,20220922.0,20221006,20221006,EXP,,DE-AUROBINDO-AUR-APL-2022-039942,AUROBINDO,,54.0,YR,,M,Y,98.0,KG,20221006,,PH,DE,DE,2022,Q4,Adult
214149411,21414941,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (1-0-0-0),,,U,,,,,10.0,MG,,,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20220922.0,20221006,20221006,EXP,,DE-AUROBINDO-AUR-APL-2022-039942,AUROBINDO,,54.0,YR,,M,Y,98.0,KG,20221006,,PH,DE,DE,2022,Q4,Adult
214149411,21414941,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram (1-0-0-0),,,U,,,,,10.0,MG,,,2022,Q4,Chest pain,,2022,Q4,1,I,,20220922.0,20221006,20221006,EXP,,DE-AUROBINDO-AUR-APL-2022-039942,AUROBINDO,,54.0,YR,,M,Y,98.0,KG,20221006,,PH,DE,DE,2022,Q4,Adult
214183301,21418330,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0,",,,,,Unknown,,,10.0,MG,Tablet,QD,2022,Q4,Hyperkalaemia,,2022,Q4,1,I,20210801.0,20220926.0,20221006,20221006,EXP,,DE-TEVA-2022-DE-2079031,TEVA,,64.0,YR,A,M,Y,85.0,KG,20221006,,PH,DE,DE,2022,Q4,Adult
214183301,21418330,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0,",,,,,Unknown,,,10.0,MG,Tablet,QD,2022,Q4,Haematuria,,2022,Q4,1,I,20210801.0,20220926.0,20221006,20221006,EXP,,DE-TEVA-2022-DE-2079031,TEVA,,64.0,YR,A,M,Y,85.0,KG,20221006,,PH,DE,DE,2022,Q4,Adult
214184941,21418494,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,U,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Labelled drug-drug interaction medication error,,2022,Q4,1,I,20210907.0,20220926.0,20221006,20221006,EXP,,DE-TEVA-2022-DE-2079001,TEVA,,73.0,YR,E,M,Y,,,20221006,,PH,DE,DE,2022,Q4,Elderly
214184941,21418494,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,U,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Product administration error,,2022,Q4,1,I,20210907.0,20220926.0,20221006,20221006,EXP,,DE-TEVA-2022-DE-2079001,TEVA,,73.0,YR,E,M,Y,,,20221006,,PH,DE,DE,2022,Q4,Elderly
214184941,21418494,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,U,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20210907.0,20220926.0,20221006,20221006,EXP,,DE-TEVA-2022-DE-2079001,TEVA,,73.0,YR,E,M,Y,,,20221006,,PH,DE,DE,2022,Q4,Elderly
214184941,21418494,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,U,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q4,1,I,20210907.0,20220926.0,20221006,20221006,EXP,,DE-TEVA-2022-DE-2079001,TEVA,,73.0,YR,E,M,Y,,,20221006,,PH,DE,DE,2022,Q4,Elderly
214184941,21418494,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,U,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Cystitis,,2022,Q4,1,I,20210907.0,20220926.0,20221006,20221006,EXP,,DE-TEVA-2022-DE-2079001,TEVA,,73.0,YR,E,M,Y,,,20221006,,PH,DE,DE,2022,Q4,Elderly
214184941,21418494,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,U,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Product monitoring error,,2022,Q4,1,I,20210907.0,20220926.0,20221006,20221006,EXP,,DE-TEVA-2022-DE-2079001,TEVA,,73.0,YR,E,M,Y,,,20221006,,PH,DE,DE,2022,Q4,Elderly
214184941,21418494,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,U,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Urinary hesitation,,2022,Q4,1,I,20210907.0,20220926.0,20221006,20221006,EXP,,DE-TEVA-2022-DE-2079001,TEVA,,73.0,YR,E,M,Y,,,20221006,,PH,DE,DE,2022,Q4,Elderly
214184941,21418494,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,U,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Pollakiuria,,2022,Q4,1,I,20210907.0,20220926.0,20221006,20221006,EXP,,DE-TEVA-2022-DE-2079001,TEVA,,73.0,YR,E,M,Y,,,20221006,,PH,DE,DE,2022,Q4,Elderly
214185801,21418580,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Epistaxis,,2022,Q4,1,I,20220713.0,20220929.0,20221006,20221006,EXP,,NVSC2022AU161958,NOVARTIS,,75.0,YR,,F,Y,58.1,KG,20221006,,MD,AU,AU,2022,Q4,Elderly
214185801,21418580,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,20220713.0,20220929.0,20221006,20221006,EXP,,NVSC2022AU161958,NOVARTIS,,75.0,YR,,F,Y,58.1,KG,20221006,,MD,AU,AU,2022,Q4,Elderly
214185801,21418580,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Fall,,2022,Q4,1,I,20220713.0,20220929.0,20221006,20221006,EXP,,NVSC2022AU161958,NOVARTIS,,75.0,YR,,F,Y,58.1,KG,20221006,,MD,AU,AU,2022,Q4,Elderly
214210181,21421018,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2022,Q4,Haematuria,,2022,Q4,1,I,20210801.0,20220922.0,20221007,20221007,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-357514,RANBAXY,,64.0,YR,,M,Y,85.0,KG,20221007,,PH,DE,DE,2022,Q4,Adult
214210181,21421018,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2022,Q4,Hyperkalaemia,,2022,Q4,1,I,20210801.0,20220922.0,20221007,20221007,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-357514,RANBAXY,,64.0,YR,,M,Y,85.0,KG,20221007,,PH,DE,DE,2022,Q4,Adult
214236561,21423656,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 Milligram Daily; 25 mg, 1-0-0-0",,,,,,,,25.0,MG,,QD,2022,Q4,Lactic acidosis,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079392,TEVA,,66.0,YR,E,M,Y,86.6,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236561,21423656,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 Milligram Daily; 25 mg, 1-0-0-0",,,,,,,,25.0,MG,,QD,2022,Q4,Hypoaesthesia,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079392,TEVA,,66.0,YR,E,M,Y,86.6,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236561,21423656,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 Milligram Daily; 25 mg, 1-0-0-0",,,,,,,,25.0,MG,,QD,2022,Q4,Hypoaesthesia,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079392,TEVA,,66.0,YR,E,M,Y,86.6,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236561,21423656,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 Milligram Daily; 25 mg, 1-0-0-0",,,,,,,,25.0,MG,,QD,2022,Q4,Tachycardia,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079392,TEVA,,66.0,YR,E,M,Y,86.6,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236561,21423656,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 Milligram Daily; 25 mg, 1-0-0-0",,,,,,,,25.0,MG,,QD,2022,Q4,Palpitations,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079392,TEVA,,66.0,YR,E,M,Y,86.6,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236561,21423656,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 Milligram Daily; 25 mg, 1-0-0-0",,,,,,,,25.0,MG,,QD,2022,Q4,Anion gap increased,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079392,TEVA,,66.0,YR,E,M,Y,86.6,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236561,21423656,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 Milligram Daily; 25 mg, 1-0-0-0",,,,,,,,25.0,MG,,QD,2022,Q4,Atrial fibrillation,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079392,TEVA,,66.0,YR,E,M,Y,86.6,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236561,21423656,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 Milligram Daily; 25 mg, 1-0-0-0",,,,,,,,25.0,MG,,QD,2022,Q4,Chest discomfort,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079392,TEVA,,66.0,YR,E,M,Y,86.6,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214259681,21425968,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg/d,,,Y,,,,,,,,,2022,Q4,Condition aggravated,,2022,Q4,1,I,20220411.0,20220930.0,20221008,20221008,EXP,FR-AFSSAPS-TO20222798,FR-Accord-280570,ACCORD,,97.0,YR,E,M,Y,,,20221008,,PH,FR,FR,2022,Q4,Elderly
214259681,21425968,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg/d,,,Y,,,,,,,,,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20220411.0,20220930.0,20221008,20221008,EXP,FR-AFSSAPS-TO20222798,FR-Accord-280570,ACCORD,,97.0,YR,E,M,Y,,,20221008,,PH,FR,FR,2022,Q4,Elderly
214293261,21429326,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Systemic infection,,2022,Q4,1,I,,20220929.0,20221009,20221009,EXP,,DE-TEVA-2022-DE-2080952,TEVA,,54.0,YR,A,M,Y,98.0,KG,20221009,,PH,DE,DE,2022,Q4,Adult
214293261,21429326,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Polyneuropathy,,2022,Q4,1,I,,20220929.0,20221009,20221009,EXP,,DE-TEVA-2022-DE-2080952,TEVA,,54.0,YR,A,M,Y,98.0,KG,20221009,,PH,DE,DE,2022,Q4,Adult
214293261,21429326,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Condition aggravated,,2022,Q4,1,I,,20220929.0,20221009,20221009,EXP,,DE-TEVA-2022-DE-2080952,TEVA,,54.0,YR,A,M,Y,98.0,KG,20221009,,PH,DE,DE,2022,Q4,Adult
214293261,21429326,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Labelled drug-drug interaction medication error,,2022,Q4,1,I,,20220929.0,20221009,20221009,EXP,,DE-TEVA-2022-DE-2080952,TEVA,,54.0,YR,A,M,Y,98.0,KG,20221009,,PH,DE,DE,2022,Q4,Adult
214293261,21429326,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20220929.0,20221009,20221009,EXP,,DE-TEVA-2022-DE-2080952,TEVA,,54.0,YR,A,M,Y,98.0,KG,20221009,,PH,DE,DE,2022,Q4,Adult
214293261,21429326,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Chest pain,,2022,Q4,1,I,,20220929.0,20221009,20221009,EXP,,DE-TEVA-2022-DE-2080952,TEVA,,54.0,YR,A,M,Y,98.0,KG,20221009,,PH,DE,DE,2022,Q4,Adult
214293261,21429326,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Electrocardiogram abnormal,,2022,Q4,1,I,,20220929.0,20221009,20221009,EXP,,DE-TEVA-2022-DE-2080952,TEVA,,54.0,YR,A,M,Y,98.0,KG,20221009,,PH,DE,DE,2022,Q4,Adult
214293261,21429326,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20220929.0,20221009,20221009,EXP,,DE-TEVA-2022-DE-2080952,TEVA,,54.0,YR,A,M,Y,98.0,KG,20221009,,PH,DE,DE,2022,Q4,Adult
214293261,21429326,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,QD,2022,Q4,Drug interaction,,2022,Q4,1,I,,20220929.0,20221009,20221009,EXP,,DE-TEVA-2022-DE-2080952,TEVA,,54.0,YR,A,M,Y,98.0,KG,20221009,,PH,DE,DE,2022,Q4,Adult
214319801,21431980,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 Dosage forms Daily; 10 mg, 1-0-0-0, Unit dose : 1 DF , frequency : OD",,,,,,,,,,,QD,2022,Q4,Ischaemic cardiomyopathy,,2022,Q4,1,I,,20220929.0,20221009,20221009,EXP,,DE-TEVA-2022-DE-2080969,TEVA,,62.0,YR,A,M,Y,,,20221009,,MD,DE,DE,2022,Q4,Adult
214319801,21431980,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 Dosage forms Daily; 10 mg, 1-0-0-0, Unit dose : 1 DF , frequency : OD",,,,,,,,,,,QD,2022,Q4,Ejection fraction decreased,,2022,Q4,1,I,,20220929.0,20221009,20221009,EXP,,DE-TEVA-2022-DE-2080969,TEVA,,62.0,YR,A,M,Y,,,20221009,,MD,DE,DE,2022,Q4,Adult
214319801,21431980,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 Dosage forms Daily; 10 mg, 1-0-0-0, Unit dose : 1 DF , frequency : OD",,,,,,,,,,,QD,2022,Q4,Liver function test abnormal,,2022,Q4,1,I,,20220929.0,20221009,20221009,EXP,,DE-TEVA-2022-DE-2080969,TEVA,,62.0,YR,A,M,Y,,,20221009,,MD,DE,DE,2022,Q4,Adult
214319801,21431980,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 Dosage forms Daily; 10 mg, 1-0-0-0, Unit dose : 1 DF , frequency : OD",,,,,,,,,,,QD,2022,Q4,Arrhythmia,,2022,Q4,1,I,,20220929.0,20221009,20221009,EXP,,DE-TEVA-2022-DE-2080969,TEVA,,62.0,YR,A,M,Y,,,20221009,,MD,DE,DE,2022,Q4,Adult
214319801,21431980,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 Dosage forms Daily; 10 mg, 1-0-0-0, Unit dose : 1 DF , frequency : OD",,,,,,,,,,,QD,2022,Q4,Tachycardia,,2022,Q4,1,I,,20220929.0,20221009,20221009,EXP,,DE-TEVA-2022-DE-2080969,TEVA,,62.0,YR,A,M,Y,,,20221009,,MD,DE,DE,2022,Q4,Adult
214319801,21431980,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 Dosage forms Daily; 10 mg, 1-0-0-0, Unit dose : 1 DF , frequency : OD",,,,,,,,,,,QD,2022,Q4,Cardioversion,,2022,Q4,1,I,,20220929.0,20221009,20221009,EXP,,DE-TEVA-2022-DE-2080969,TEVA,,62.0,YR,A,M,Y,,,20221009,,MD,DE,DE,2022,Q4,Adult
214339101,21433910,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2022,Q4,Diabetic metabolic decompensation,,2022,Q4,1,I,,20220928.0,20221010,20221010,EXP,,BR-NOVOPROD-964410,NOVO NORDISK,,26.0,YR,,F,Y,160.8,KG,20221010,,MD,BR,BR,2022,Q4,Young Adult
214339101,21433910,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2022,Q4,Erysipelas,,2022,Q4,1,I,,20220928.0,20221010,20221010,EXP,,BR-NOVOPROD-964410,NOVO NORDISK,,26.0,YR,,F,Y,160.8,KG,20221010,,MD,BR,BR,2022,Q4,Young Adult
214339101,21433910,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2022,Q4,Off label use,,2022,Q4,1,I,,20220928.0,20221010,20221010,EXP,,BR-NOVOPROD-964410,NOVO NORDISK,,26.0,YR,,F,Y,160.8,KG,20221010,,MD,BR,BR,2022,Q4,Young Adult
214356741,21435674,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg (1-0-0-0, Tabletten)",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Erythema,,2022,Q4,1,I,,20221006.0,20221010,20221010,EXP,DE-ADRED-07864-01,NVSC2022DE226247,NOVARTIS,,59.0,YR,,M,Y,125.0,KG,20221010,,PH,DE,DE,2022,Q4,Adult
214356741,21435674,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg (1-0-0-0, Tabletten)",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Wound secretion,,2022,Q4,1,I,,20221006.0,20221010,20221010,EXP,DE-ADRED-07864-01,NVSC2022DE226247,NOVARTIS,,59.0,YR,,M,Y,125.0,KG,20221010,,PH,DE,DE,2022,Q4,Adult
214356741,21435674,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg (1-0-0-0, Tabletten)",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Limb injury,,2022,Q4,1,I,,20221006.0,20221010,20221010,EXP,DE-ADRED-07864-01,NVSC2022DE226247,NOVARTIS,,59.0,YR,,M,Y,125.0,KG,20221010,,PH,DE,DE,2022,Q4,Adult
214356741,21435674,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg (1-0-0-0, Tabletten)",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Impaired healing,,2022,Q4,1,I,,20221006.0,20221010,20221010,EXP,DE-ADRED-07864-01,NVSC2022DE226247,NOVARTIS,,59.0,YR,,M,Y,125.0,KG,20221010,,PH,DE,DE,2022,Q4,Adult
214356741,21435674,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg (1-0-0-0, Tabletten)",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q4,1,I,,20221006.0,20221010,20221010,EXP,DE-ADRED-07864-01,NVSC2022DE226247,NOVARTIS,,59.0,YR,,M,Y,125.0,KG,20221010,,PH,DE,DE,2022,Q4,Adult
214390372,21439037,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK qd (12.5/ 1000 milligram, qd)",,,U,U,,,,,,,QD,2022,Q4,N-terminal prohormone brain natriuretic peptide increased,,2022,Q4,2,F,20220101.0,20221006.0,20221011,20221021,EXP,,HR-MYLANLABS-2022M1112684,MYLAN,,53.0,YR,,M,Y,,,20221021,,MD,HR,HR,2022,Q4,Adult
214390372,21439037,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK qd (12.5/ 1000 milligram, qd)",,,U,U,,,,,,,QD,2022,Q4,Ejection fraction decreased,,2022,Q4,2,F,20220101.0,20221006.0,20221011,20221021,EXP,,HR-MYLANLABS-2022M1112684,MYLAN,,53.0,YR,,M,Y,,,20221021,,MD,HR,HR,2022,Q4,Adult
214390372,21439037,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK qd (12.5/ 1000 milligram, qd)",,,U,U,,,,,,,QD,2022,Q4,Nocturnal dyspnoea,,2022,Q4,2,F,20220101.0,20221006.0,20221011,20221021,EXP,,HR-MYLANLABS-2022M1112684,MYLAN,,53.0,YR,,M,Y,,,20221021,,MD,HR,HR,2022,Q4,Adult
214390372,21439037,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK qd (12.5/ 1000 milligram, qd)",,,U,U,,,,,,,QD,2022,Q4,Bundle branch block left,,2022,Q4,2,F,20220101.0,20221006.0,20221011,20221021,EXP,,HR-MYLANLABS-2022M1112684,MYLAN,,53.0,YR,,M,Y,,,20221021,,MD,HR,HR,2022,Q4,Adult
214390372,21439037,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK qd (12.5/ 1000 milligram, qd)",,,U,U,,,,,,,QD,2022,Q4,Oedema peripheral,,2022,Q4,2,F,20220101.0,20221006.0,20221011,20221021,EXP,,HR-MYLANLABS-2022M1112684,MYLAN,,53.0,YR,,M,Y,,,20221021,,MD,HR,HR,2022,Q4,Adult
214390372,21439037,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK qd (12.5/ 1000 milligram, qd)",,,U,U,,,,,,,QD,2022,Q4,Blood pressure systolic increased,,2022,Q4,2,F,20220101.0,20221006.0,20221011,20221021,EXP,,HR-MYLANLABS-2022M1112684,MYLAN,,53.0,YR,,M,Y,,,20221021,,MD,HR,HR,2022,Q4,Adult
214390372,21439037,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK qd (12.5/ 1000 milligram, qd)",,,U,U,,,,,,,QD,2022,Q4,Dyspnoea exertional,,2022,Q4,2,F,20220101.0,20221006.0,20221011,20221021,EXP,,HR-MYLANLABS-2022M1112684,MYLAN,,53.0,YR,,M,Y,,,20221021,,MD,HR,HR,2022,Q4,Adult
214390372,21439037,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK qd (12.5/ 1000 milligram, qd)",,,U,U,,,,,,,QD,2022,Q4,Cardiomegaly,,2022,Q4,2,F,20220101.0,20221006.0,20221011,20221021,EXP,,HR-MYLANLABS-2022M1112684,MYLAN,,53.0,YR,,M,Y,,,20221021,,MD,HR,HR,2022,Q4,Adult
214390372,21439037,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK qd (12.5/ 1000 milligram, qd)",,,U,U,,,,,,,QD,2022,Q4,Effusion,,2022,Q4,2,F,20220101.0,20221006.0,20221011,20221021,EXP,,HR-MYLANLABS-2022M1112684,MYLAN,,53.0,YR,,M,Y,,,20221021,,MD,HR,HR,2022,Q4,Adult
214390372,21439037,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK qd (12.5/ 1000 milligram, qd)",,,U,U,,,,,,,QD,2022,Q4,Blood pressure decreased,,2022,Q4,2,F,20220101.0,20221006.0,20221011,20221021,EXP,,HR-MYLANLABS-2022M1112684,MYLAN,,53.0,YR,,M,Y,,,20221021,,MD,HR,HR,2022,Q4,Adult
214390372,21439037,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK qd (12.5/ 1000 milligram, qd)",,,U,U,,,,,,,QD,2022,Q4,Dizziness postural,,2022,Q4,2,F,20220101.0,20221006.0,20221011,20221021,EXP,,HR-MYLANLABS-2022M1112684,MYLAN,,53.0,YR,,M,Y,,,20221021,,MD,HR,HR,2022,Q4,Adult
214400221,21440022,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Acute respiratory failure,,2022,Q4,1,I,,20220928.0,20221011,20221011,EXP,,DE-drreddys-SPO/GER/22/0155377,DR REDDYS,,78.0,YR,E,M,Y,,,20221011,,PH,DE,DE,2022,Q4,Elderly
214400221,21440022,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Acute myocardial infarction,,2022,Q4,1,I,,20220928.0,20221011,20221011,EXP,,DE-drreddys-SPO/GER/22/0155377,DR REDDYS,,78.0,YR,E,M,Y,,,20221011,,PH,DE,DE,2022,Q4,Elderly
214400221,21440022,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20220928.0,20221011,20221011,EXP,,DE-drreddys-SPO/GER/22/0155377,DR REDDYS,,78.0,YR,E,M,Y,,,20221011,,PH,DE,DE,2022,Q4,Elderly
214400221,21440022,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Atrial fibrillation,,2022,Q4,1,I,,20220928.0,20221011,20221011,EXP,,DE-drreddys-SPO/GER/22/0155377,DR REDDYS,,78.0,YR,E,M,Y,,,20221011,,PH,DE,DE,2022,Q4,Elderly
214400221,21440022,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Systemic infection,,2022,Q4,1,I,,20220928.0,20221011,20221011,EXP,,DE-drreddys-SPO/GER/22/0155377,DR REDDYS,,78.0,YR,E,M,Y,,,20221011,,PH,DE,DE,2022,Q4,Elderly
214400221,21440022,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Electrocardiogram abnormal,,2022,Q4,1,I,,20220928.0,20221011,20221011,EXP,,DE-drreddys-SPO/GER/22/0155377,DR REDDYS,,78.0,YR,E,M,Y,,,20221011,,PH,DE,DE,2022,Q4,Elderly
214400221,21440022,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Arrhythmia,,2022,Q4,1,I,,20220928.0,20221011,20221011,EXP,,DE-drreddys-SPO/GER/22/0155377,DR REDDYS,,78.0,YR,E,M,Y,,,20221011,,PH,DE,DE,2022,Q4,Elderly
214400221,21440022,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20220928.0,20221011,20221011,EXP,,DE-drreddys-SPO/GER/22/0155377,DR REDDYS,,78.0,YR,E,M,Y,,,20221011,,PH,DE,DE,2022,Q4,Elderly
214400221,21440022,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20220928.0,20221011,20221011,EXP,,DE-drreddys-SPO/GER/22/0155377,DR REDDYS,,78.0,YR,E,M,Y,,,20221011,,PH,DE,DE,2022,Q4,Elderly
214400221,21440022,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Tachycardia,,2022,Q4,1,I,,20220928.0,20221011,20221011,EXP,,DE-drreddys-SPO/GER/22/0155377,DR REDDYS,,78.0,YR,E,M,Y,,,20221011,,PH,DE,DE,2022,Q4,Elderly
214400221,21440022,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Renal impairment,,2022,Q4,1,I,,20220928.0,20221011,20221011,EXP,,DE-drreddys-SPO/GER/22/0155377,DR REDDYS,,78.0,YR,E,M,Y,,,20221011,,PH,DE,DE,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Protein urine present,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Respiratory rate increased,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,QRS axis abnormal,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Skin turgor decreased,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Acidosis,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Glucose urine present,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Diarrhoea,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Hypocapnia,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Chest pain,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Anion gap increased,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Urine ketone body present,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Mucosal dryness,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Abdominal pain,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Electrocardiogram QT prolonged,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Diabetic ketoacidosis,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Blood lactic acid increased,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Pain,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214413765,21441376,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,,,,,,10.0,MG,,QD,2022,Q4,Renal failure,,2022,Q4,5,F,,20221114.0,20221011,20221117,EXP,,NVSC2022AT226932,NOVARTIS,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor-Therapie [Ketoacidosis under SGLT2-inhibitor therapy]. UNIVERSUM INNERE MEDIZIN. 2022;7:22-4",75.0,YR,,F,Y,,,20221117,,HP,AT,AT,2022,Q4,Elderly
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Weight increased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Arrhythmia supraventricular,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Heart rate increased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Troponin T increased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Fatigue,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Electrocardiogram T wave amplitude decreased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Mean cell haemoglobin increased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Ventricular tachycardia,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Vitamin B12 deficiency,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Atrial flutter,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Hyperlipidaemia,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Atrial fibrillation,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Supraventricular extrasystoles,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Blood thyroid stimulating hormone increased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Dyspnoea,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Atrial enlargement,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Heart rate irregular,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Electrocardiogram ST segment abnormal,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Hydrocholecystis,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Transferrin saturation decreased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Ventricular extrasystoles,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Ventricular tachycardia,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Chest pain,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Congestive cardiomyopathy,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Ventricular fibrillation,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Ejection fraction decreased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Exercise tolerance decreased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Atrial flutter,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Sciatica,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,International normalised ratio fluctuation,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Red cell distribution width increased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Condition aggravated,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Electrocardiogram abnormal,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Inflammatory marker increased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Drug effect less than expected,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Atrial fibrillation,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Sinus arrest,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Bundle branch block left,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Arrhythmia,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Platelet count decreased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Anaemia,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Glomerular filtration rate increased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Haemoglobin decreased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Pancreatitis,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Cholelithiasis,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Mean cell volume increased,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Extrasystoles,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Asthenia,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419171,21441917,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Cardiac failure congestive,,2022,Q4,1,I,20140101.0,20221002.0,20221011,20221011,EXP,,HU-BAUSCH-BL-2022-023008,BAUSCH AND LOMB,,53.0,YR,,M,Y,118.0,KG,20221011,,MD,HU,HU,2022,Q4,Adult
214419211,21441921,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tabletten",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Erythema,,2022,Q4,1,I,,20221005.0,20221011,20221011,EXP,,DE-BAUSCH-BL-2022-023204,BAUSCH AND LOMB,,59.0,YR,,M,Y,125.0,KG,20221011,,PH,DE,DE,2022,Q4,Adult
214419211,21441921,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tabletten",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Impaired healing,,2022,Q4,1,I,,20221005.0,20221011,20221011,EXP,,DE-BAUSCH-BL-2022-023204,BAUSCH AND LOMB,,59.0,YR,,M,Y,125.0,KG,20221011,,PH,DE,DE,2022,Q4,Adult
214419211,21441921,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tabletten",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Limb injury,,2022,Q4,1,I,,20221005.0,20221011,20221011,EXP,,DE-BAUSCH-BL-2022-023204,BAUSCH AND LOMB,,59.0,YR,,M,Y,125.0,KG,20221011,,PH,DE,DE,2022,Q4,Adult
214419211,21441921,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tabletten",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Wound secretion,,2022,Q4,1,I,,20221005.0,20221011,20221011,EXP,,DE-BAUSCH-BL-2022-023204,BAUSCH AND LOMB,,59.0,YR,,M,Y,125.0,KG,20221011,,PH,DE,DE,2022,Q4,Adult
214419211,21441921,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tabletten",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Foot amputation,,2022,Q4,1,I,,20221005.0,20221011,20221011,EXP,,DE-BAUSCH-BL-2022-023204,BAUSCH AND LOMB,,59.0,YR,,M,Y,125.0,KG,20221011,,PH,DE,DE,2022,Q4,Adult
214419211,21441921,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tabletten",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q4,1,I,,20221005.0,20221011,20221011,EXP,,DE-BAUSCH-BL-2022-023204,BAUSCH AND LOMB,,59.0,YR,,M,Y,125.0,KG,20221011,,PH,DE,DE,2022,Q4,Adult
214431081,21443108,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,U,,,,,10.0,MG,Tablet,,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20210907.0,20221006.0,20221012,20221012,EXP,,NVSC2022DE226186,NOVARTIS,,73.0,YR,,M,Y,,,20221012,,PH,DE,DE,2022,Q4,Elderly
214431081,21443108,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,U,,,,,10.0,MG,Tablet,,2022,Q4,Pollakiuria,,2022,Q4,1,I,20210907.0,20221006.0,20221012,20221012,EXP,,NVSC2022DE226186,NOVARTIS,,73.0,YR,,M,Y,,,20221012,,PH,DE,DE,2022,Q4,Elderly
214431081,21443108,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,U,,,,,10.0,MG,Tablet,,2022,Q4,Urinary hesitation,,2022,Q4,1,I,20210907.0,20221006.0,20221012,20221012,EXP,,NVSC2022DE226186,NOVARTIS,,73.0,YR,,M,Y,,,20221012,,PH,DE,DE,2022,Q4,Elderly
214431081,21443108,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,U,,,,,10.0,MG,Tablet,,2022,Q4,Cystitis,,2022,Q4,1,I,20210907.0,20221006.0,20221012,20221012,EXP,,NVSC2022DE226186,NOVARTIS,,73.0,YR,,M,Y,,,20221012,,PH,DE,DE,2022,Q4,Elderly
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Atrial flutter,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,International normalised ratio fluctuation,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Asthenia,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Platelet count decreased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Chest pain,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Heart rate increased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Cardiac failure congestive,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Arrhythmia,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Fatigue,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Atrial flutter,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Bundle branch block left,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Congestive cardiomyopathy,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Condition aggravated,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Exercise tolerance decreased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Mean cell volume increased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Hydrocholecystis,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Ventricular tachycardia,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Anaemia,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Ventricular tachycardia,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Blood thyroid stimulating hormone increased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Red cell distribution width increased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Ventricular extrasystoles,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Weight increased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Extrasystoles,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Ejection fraction decreased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Pancreatitis,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Atrial fibrillation,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Cholelithiasis,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Inflammatory marker increased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Sciatica,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Electrocardiogram T wave amplitude decreased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Vitamin B12 deficiency,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Sinus arrest,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Electrocardiogram abnormal,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Electrocardiogram ST segment abnormal,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Drug effect less than expected,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Atrial enlargement,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Atrial fibrillation,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Heart rate irregular,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Dyspnoea,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Glomerular filtration rate increased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Hyperlipidaemia,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Haemoglobin decreased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Supraventricular extrasystoles,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Arrhythmia supraventricular,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Mean cell haemoglobin increased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Transferrin saturation decreased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214453572,21445357,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,D,,,,,,,,,2022,Q4,Troponin T increased,,2022,Q4,2,F,20140101.0,20221006.0,20221012,20221028,EXP,HU-002147023-NVSC2022HU216711,HU-STRIDES ARCOLAB LIMITED-2022SP012859,STRIDES,,53.0,YR,,M,Y,118.0,KG,20221029,,MD,HU,HU,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Platelet count decreased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Bundle branch block left,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Sciatica,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Arrhythmia,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Cholelithiasis,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Heart rate irregular,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Atrial fibrillation,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Mean cell volume increased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,International normalised ratio fluctuation,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Glomerular filtration rate increased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Inflammatory marker increased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Atrial flutter,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Weight increased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Ventricular extrasystoles,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Exercise tolerance decreased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Vitamin B12 deficiency,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Heart rate increased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Electrocardiogram abnormal,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Asthenia,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Chest pain,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Cardiac failure congestive,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Electrocardiogram T wave amplitude decreased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Atrial enlargement,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Troponin T increased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Red cell distribution width increased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Condition aggravated,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Hyperlipidaemia,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Sinus arrest,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Supraventricular extrasystoles,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Electrocardiogram ST segment abnormal,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Ejection fraction decreased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Anaemia,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Mean cell haemoglobin increased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Ventricular fibrillation,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Haemoglobin decreased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Blood thyroid stimulating hormone increased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Ventricular tachycardia,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Arrhythmia supraventricular,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Extrasystoles,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Fatigue,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Congestive cardiomyopathy,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Pancreatitis,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Transferrin saturation decreased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Drug effect less than expected,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Dyspnoea,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214455491,21445549,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,,,,,,,,,QD,2022,Q4,Hydrocholecystis,,2022,Q4,1,I,20140101.0,20221004.0,20221012,20221012,EXP,,HU-AstraZeneca-2022A336305,ASTRAZENECA,,53.0,YR,,M,Y,118.0,KG,20221012,,MD,HU,,2022,Q4,Adult
214467881,21446788,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q4,Respiratory failure,,2022,Q4,1,I,20211213.0,,20221011,20221011,DIR,FDA-CDER-CTU-2022-81267,,FDA-CTU,,72.0,YR,,M,N,,,20220302,N,PH,US,,2022,Q4,Elderly
214467881,21446788,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q4,COVID-19,,2022,Q4,1,I,20211213.0,,20221011,20221011,DIR,FDA-CDER-CTU-2022-81267,,FDA-CTU,,72.0,YR,,M,N,,,20220302,N,PH,US,,2022,Q4,Elderly
214467881,21446788,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q4,Anion gap,,2022,Q4,1,I,20211213.0,,20221011,20221011,DIR,FDA-CDER-CTU-2022-81267,,FDA-CTU,,72.0,YR,,M,N,,,20220302,N,PH,US,,2022,Q4,Elderly
214467881,21446788,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q4,Malaise,,2022,Q4,1,I,20211213.0,,20221011,20221011,DIR,FDA-CDER-CTU-2022-81267,,FDA-CTU,,72.0,YR,,M,N,,,20220302,N,PH,US,,2022,Q4,Elderly
214467881,21446788,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,20211213.0,,20221011,20221011,DIR,FDA-CDER-CTU-2022-81267,,FDA-CTU,,72.0,YR,,M,N,,,20220302,N,PH,US,,2022,Q4,Elderly
214468141,21446814,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Dizziness,,2022,Q4,1,I,,20221002.0,20221012,20221012,EXP,,DE-TEVA-2022-DE-2081977,TEVA,,59.0,YR,A,M,Y,93.0,KG,20221012,,PH,DE,DE,2022,Q4,Adult
214468141,21446814,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Fatigue,,2022,Q4,1,I,,20221002.0,20221012,20221012,EXP,,DE-TEVA-2022-DE-2081977,TEVA,,59.0,YR,A,M,Y,93.0,KG,20221012,,PH,DE,DE,2022,Q4,Adult
214468141,21446814,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Muscular weakness,,2022,Q4,1,I,,20221002.0,20221012,20221012,EXP,,DE-TEVA-2022-DE-2081977,TEVA,,59.0,YR,A,M,Y,93.0,KG,20221012,,PH,DE,DE,2022,Q4,Adult
214468141,21446814,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Hyperhidrosis,,2022,Q4,1,I,,20221002.0,20221012,20221012,EXP,,DE-TEVA-2022-DE-2081977,TEVA,,59.0,YR,A,M,Y,93.0,KG,20221012,,PH,DE,DE,2022,Q4,Adult
214468141,21446814,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Microcytic anaemia,,2022,Q4,1,I,,20221002.0,20221012,20221012,EXP,,DE-TEVA-2022-DE-2081977,TEVA,,59.0,YR,A,M,Y,93.0,KG,20221012,,PH,DE,DE,2022,Q4,Adult
214468141,21446814,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Abdominal pain,,2022,Q4,1,I,,20221002.0,20221012,20221012,EXP,,DE-TEVA-2022-DE-2081977,TEVA,,59.0,YR,A,M,Y,93.0,KG,20221012,,PH,DE,DE,2022,Q4,Adult
214468141,21446814,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Dyspnoea exertional,,2022,Q4,1,I,,20221002.0,20221012,20221012,EXP,,DE-TEVA-2022-DE-2081977,TEVA,,59.0,YR,A,M,Y,93.0,KG,20221012,,PH,DE,DE,2022,Q4,Adult
214468141,21446814,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Faeces discoloured,,2022,Q4,1,I,,20221002.0,20221012,20221012,EXP,,DE-TEVA-2022-DE-2081977,TEVA,,59.0,YR,A,M,Y,93.0,KG,20221012,,PH,DE,DE,2022,Q4,Adult
214468141,21446814,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 Milligram Daily; 10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Abdominal pain upper,,2022,Q4,1,I,,20221002.0,20221012,20221012,EXP,,DE-TEVA-2022-DE-2081977,TEVA,,59.0,YR,A,M,Y,93.0,KG,20221012,,PH,DE,DE,2022,Q4,Adult
214481471,21448147,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,Tablet,,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20210907.0,20221006.0,20221012,20221012,EXP,,DE-BAUSCH-BL-2022-023221,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
214481471,21448147,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,Tablet,,2022,Q4,Cystitis,,2022,Q4,1,I,20210907.0,20221006.0,20221012,20221012,EXP,,DE-BAUSCH-BL-2022-023221,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
214481471,21448147,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,Tablet,,2022,Q4,Pollakiuria,,2022,Q4,1,I,20210907.0,20221006.0,20221012,20221012,EXP,,DE-BAUSCH-BL-2022-023221,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
214481471,21448147,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,Tablet,,2022,Q4,Urinary hesitation,,2022,Q4,1,I,20210907.0,20221006.0,20221012,20221012,EXP,,DE-BAUSCH-BL-2022-023221,BAUSCH AND LOMB,,73.0,YR,,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
214483931,21448393,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Pemphigus,,2022,Q4,1,I,20140822.0,20221005.0,20221013,20221013,EXP,,GB-AstraZeneca-2022A339039,ASTRAZENECA,,67.0,YR,,M,Y,84.0,KG,20221013,,MD,GB,,2022,Q4,Elderly
214530052,21453005,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,,,UNKNOWN,,,,,,,2022,Q4,Tumour lysis syndrome,,2022,Q4,2,F,20220911.0,20221128.0,20221013,20221202,EXP,,JP-ROCHE-3198618,ROCHE,,70.0,YR,,M,Y,70.5,KG,20221202,,MD,JP,JP,2022,Q4,Elderly
214530052,21453005,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,,,UNKNOWN,,,,,,,2022,Q4,Pyrexia,,2022,Q4,2,F,20220911.0,20221128.0,20221013,20221202,EXP,,JP-ROCHE-3198618,ROCHE,,70.0,YR,,M,Y,70.5,KG,20221202,,MD,JP,JP,2022,Q4,Elderly
214530052,21453005,4,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,,,UNKNOWN,,,,,,,2022,Q4,Rash,,2022,Q4,2,F,20220911.0,20221128.0,20221013,20221202,EXP,,JP-ROCHE-3198618,ROCHE,,70.0,YR,,M,Y,70.5,KG,20221202,,MD,JP,JP,2022,Q4,Elderly
214534565,21453456,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, 1x/day (12.5/ 1000 milligram, qd)",,,,,,,,,,,QD,2022,Q4,Blood pressure systolic increased,,2022,Q4,5,F,20220101.0,20221109.0,20221013,20221115,EXP,,HR-PFIZER INC-202201198306,PFIZER,,53.0,YR,,M,Y,,,20221115,,MD,HR,HR,2022,Q4,Adult
214534565,21453456,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, 1x/day (12.5/ 1000 milligram, qd)",,,,,,,,,,,QD,2022,Q4,Dyspnoea exertional,,2022,Q4,5,F,20220101.0,20221109.0,20221013,20221115,EXP,,HR-PFIZER INC-202201198306,PFIZER,,53.0,YR,,M,Y,,,20221115,,MD,HR,HR,2022,Q4,Adult
214534565,21453456,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, 1x/day (12.5/ 1000 milligram, qd)",,,,,,,,,,,QD,2022,Q4,N-terminal prohormone brain natriuretic peptide increased,,2022,Q4,5,F,20220101.0,20221109.0,20221013,20221115,EXP,,HR-PFIZER INC-202201198306,PFIZER,,53.0,YR,,M,Y,,,20221115,,MD,HR,HR,2022,Q4,Adult
214534565,21453456,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, 1x/day (12.5/ 1000 milligram, qd)",,,,,,,,,,,QD,2022,Q4,Bundle branch block left,,2022,Q4,5,F,20220101.0,20221109.0,20221013,20221115,EXP,,HR-PFIZER INC-202201198306,PFIZER,,53.0,YR,,M,Y,,,20221115,,MD,HR,HR,2022,Q4,Adult
214534565,21453456,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, 1x/day (12.5/ 1000 milligram, qd)",,,,,,,,,,,QD,2022,Q4,Blood pressure decreased,,2022,Q4,5,F,20220101.0,20221109.0,20221013,20221115,EXP,,HR-PFIZER INC-202201198306,PFIZER,,53.0,YR,,M,Y,,,20221115,,MD,HR,HR,2022,Q4,Adult
214534565,21453456,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, 1x/day (12.5/ 1000 milligram, qd)",,,,,,,,,,,QD,2022,Q4,Nocturnal dyspnoea,,2022,Q4,5,F,20220101.0,20221109.0,20221013,20221115,EXP,,HR-PFIZER INC-202201198306,PFIZER,,53.0,YR,,M,Y,,,20221115,,MD,HR,HR,2022,Q4,Adult
214534565,21453456,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, 1x/day (12.5/ 1000 milligram, qd)",,,,,,,,,,,QD,2022,Q4,Effusion,,2022,Q4,5,F,20220101.0,20221109.0,20221013,20221115,EXP,,HR-PFIZER INC-202201198306,PFIZER,,53.0,YR,,M,Y,,,20221115,,MD,HR,HR,2022,Q4,Adult
214534565,21453456,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, 1x/day (12.5/ 1000 milligram, qd)",,,,,,,,,,,QD,2022,Q4,Cardiomegaly,,2022,Q4,5,F,20220101.0,20221109.0,20221013,20221115,EXP,,HR-PFIZER INC-202201198306,PFIZER,,53.0,YR,,M,Y,,,20221115,,MD,HR,HR,2022,Q4,Adult
214534565,21453456,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, 1x/day (12.5/ 1000 milligram, qd)",,,,,,,,,,,QD,2022,Q4,Dizziness postural,,2022,Q4,5,F,20220101.0,20221109.0,20221013,20221115,EXP,,HR-PFIZER INC-202201198306,PFIZER,,53.0,YR,,M,Y,,,20221115,,MD,HR,HR,2022,Q4,Adult
214534565,21453456,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, 1x/day (12.5/ 1000 milligram, qd)",,,,,,,,,,,QD,2022,Q4,Oedema peripheral,,2022,Q4,5,F,20220101.0,20221109.0,20221013,20221115,EXP,,HR-PFIZER INC-202201198306,PFIZER,,53.0,YR,,M,Y,,,20221115,,MD,HR,HR,2022,Q4,Adult
214534565,21453456,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, 1x/day (12.5/ 1000 milligram, qd)",,,,,,,,,,,QD,2022,Q4,Ejection fraction decreased,,2022,Q4,5,F,20220101.0,20221109.0,20221013,20221115,EXP,,HR-PFIZER INC-202201198306,PFIZER,,53.0,YR,,M,Y,,,20221115,,MD,HR,HR,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Condition aggravated,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Supraventricular extrasystoles,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Pancreatitis,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Atrial fibrillation,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Weight increased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Heart rate irregular,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Hyperlipidaemia,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Asthenia,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Sinus arrest,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Atrial enlargement,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Atrial flutter,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Haemoglobin decreased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Cholelithiasis,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Ejection fraction decreased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Congestive cardiomyopathy,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Heart rate increased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Cardiac failure congestive,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Exercise tolerance decreased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,International normalised ratio fluctuation,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Electrocardiogram ST segment abnormal,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Mean cell volume increased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Arrhythmia,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Vitamin B12 deficiency,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Arrhythmia supraventricular,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Transferrin saturation decreased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Blood thyroid stimulating hormone increased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Red cell distribution width increased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Chest pain,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Platelet count decreased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Anaemia,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Drug effect less than expected,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Troponin T increased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Inflammatory marker increased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Dyspnoea,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Ventricular tachycardia,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Extrasystoles,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Electrocardiogram T wave amplitude decreased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Mean cell haemoglobin increased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Electrocardiogram abnormal,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Glomerular filtration rate increased,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Ventricular extrasystoles,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Hydrocholecystis,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Ventricular fibrillation,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Sciatica,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Fatigue,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214534654,21453465,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, qd",,,,,,,,,,,QD,2022,Q4,Bundle branch block left,,2022,Q4,4,F,20140101.0,20221027.0,20221013,20221102,EXP,,HU-PFIZER INC-202201199112,PFIZER,,53.0,YR,,M,Y,118.0,KG,20221102,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Glomerular filtration rate increased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Drug effect less than expected,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Atrial enlargement,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Congestive cardiomyopathy,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Supraventricular extrasystoles,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Condition aggravated,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Ventricular extrasystoles,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Atrial flutter,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Electrocardiogram T wave amplitude decreased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Ventricular tachycardia,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Arrhythmia,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Heart rate increased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Red cell distribution width increased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Ejection fraction decreased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Mean cell volume increased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Arrhythmia supraventricular,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Cardiac failure congestive,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Bundle branch block left,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Atrial fibrillation,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Exercise tolerance decreased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Fatigue,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Dyspnoea,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Platelet count decreased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Blood thyroid stimulating hormone increased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,International normalised ratio fluctuation,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Asthenia,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Hydrocholecystis,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Sciatica,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Transferrin saturation decreased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Vitamin B12 deficiency,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Inflammatory marker increased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Anaemia,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Extrasystoles,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Sinus arrest,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Haemoglobin decreased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Electrocardiogram ST segment abnormal,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Pancreatitis,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Troponin T increased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Electrocardiogram abnormal,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Cholelithiasis,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Mean cell haemoglobin increased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Hyperlipidaemia,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Ventricular fibrillation,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Heart rate irregular,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Chest pain,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214537902,21453790,14,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"2 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Weight increased,,2022,Q4,2,F,20140101.0,20221006.0,20221013,20221021,EXP,,HU-MYLANLABS-2022M1112807,MYLAN,,53.0,YR,,M,Y,118.0,KG,20221021,,MD,HU,HU,2022,Q4,Adult
214542041,21454204,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,Tablet,,2022,Q4,Urinary hesitation,,2022,Q4,1,I,20210907.0,20221011.0,20221013,20221013,EXP,,DE-009507513-2210DEU004104,MERCK,,73.0,YR,,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
214542041,21454204,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,Tablet,,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20210907.0,20221011.0,20221013,20221013,EXP,,DE-009507513-2210DEU004104,MERCK,,73.0,YR,,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
214542041,21454204,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,Tablet,,2022,Q4,Cystitis,,2022,Q4,1,I,20210907.0,20221011.0,20221013,20221013,EXP,,DE-009507513-2210DEU004104,MERCK,,73.0,YR,,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
214542041,21454204,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,U,,,,,10.0,MG,Tablet,,2022,Q4,Pollakiuria,,2022,Q4,1,I,20210907.0,20221011.0,20221013,20221013,EXP,,DE-009507513-2210DEU004104,MERCK,,73.0,YR,,M,Y,,,20221013,,PH,DE,DE,2022,Q4,Elderly
214563471,21456347,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd, 1-0-0-0",,,U,,,,,25.0,MG,,QD,2022,Q4,Foot amputation,,2022,Q4,1,I,,20221003.0,20221014,20221014,EXP,DE-BFARM-22007824,DE-NOVOPROD-965826,NOVO NORDISK,,59.0,YR,,M,Y,125.0,KG,20221014,,PH,DE,DE,2022,Q4,Adult
214563471,21456347,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd, 1-0-0-0",,,U,,,,,25.0,MG,,QD,2022,Q4,Wound secretion,,2022,Q4,1,I,,20221003.0,20221014,20221014,EXP,DE-BFARM-22007824,DE-NOVOPROD-965826,NOVO NORDISK,,59.0,YR,,M,Y,125.0,KG,20221014,,PH,DE,DE,2022,Q4,Adult
214563471,21456347,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd, 1-0-0-0",,,U,,,,,25.0,MG,,QD,2022,Q4,Erythema,,2022,Q4,1,I,,20221003.0,20221014,20221014,EXP,DE-BFARM-22007824,DE-NOVOPROD-965826,NOVO NORDISK,,59.0,YR,,M,Y,125.0,KG,20221014,,PH,DE,DE,2022,Q4,Adult
214563471,21456347,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd, 1-0-0-0",,,U,,,,,25.0,MG,,QD,2022,Q4,Limb injury,,2022,Q4,1,I,,20221003.0,20221014,20221014,EXP,DE-BFARM-22007824,DE-NOVOPROD-965826,NOVO NORDISK,,59.0,YR,,M,Y,125.0,KG,20221014,,PH,DE,DE,2022,Q4,Adult
214563471,21456347,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd, 1-0-0-0",,,U,,,,,25.0,MG,,QD,2022,Q4,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q4,1,I,,20221003.0,20221014,20221014,EXP,DE-BFARM-22007824,DE-NOVOPROD-965826,NOVO NORDISK,,59.0,YR,,M,Y,125.0,KG,20221014,,PH,DE,DE,2022,Q4,Adult
214563471,21456347,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd, 1-0-0-0",,,U,,,,,25.0,MG,,QD,2022,Q4,Impaired healing,,2022,Q4,1,I,,20221003.0,20221014,20221014,EXP,DE-BFARM-22007824,DE-NOVOPROD-965826,NOVO NORDISK,,59.0,YR,,M,Y,125.0,KG,20221014,,PH,DE,DE,2022,Q4,Adult
214597811,21459781,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 milligram, qd",,,U,U,,,,5.0,MG,,QD,2022,Q4,Drug ineffective,,2022,Q4,1,I,,20221006.0,20221014,20221014,EXP,,CN-MYLANLABS-2022M1114227,MYLAN,"Han J, Xie S, Jiao H. Sodium-glucose cotransporter-2 inhibitor-induced euglycemic diabetic ketoacidosis: A case report. J-Clin-Pharm-Ther 2022;47(9):1482-1485.",74.0,YR,,M,Y,,,20221014,,MD,CN,CN,2022,Q4,Elderly
214605811,21460581,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Cystitis,,2022,Q4,1,I,20210907.0,20221004.0,20221015,20221015,EXP,,DE-AUROBINDO-AUR-APL-2022-038736,AUROBINDO,,73.0,YR,,M,Y,,,20221015,,PH,DE,DE,2022,Q4,Elderly
214605811,21460581,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Urinary hesitation,,2022,Q4,1,I,20210907.0,20221004.0,20221015,20221015,EXP,,DE-AUROBINDO-AUR-APL-2022-038736,AUROBINDO,,73.0,YR,,M,Y,,,20221015,,PH,DE,DE,2022,Q4,Elderly
214605811,21460581,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Product administration error,,2022,Q4,1,I,20210907.0,20221004.0,20221015,20221015,EXP,,DE-AUROBINDO-AUR-APL-2022-038736,AUROBINDO,,73.0,YR,,M,Y,,,20221015,,PH,DE,DE,2022,Q4,Elderly
214605811,21460581,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q4,1,I,20210907.0,20221004.0,20221015,20221015,EXP,,DE-AUROBINDO-AUR-APL-2022-038736,AUROBINDO,,73.0,YR,,M,Y,,,20221015,,PH,DE,DE,2022,Q4,Elderly
214605811,21460581,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Labelled drug-drug interaction medication error,,2022,Q4,1,I,20210907.0,20221004.0,20221015,20221015,EXP,,DE-AUROBINDO-AUR-APL-2022-038736,AUROBINDO,,73.0,YR,,M,Y,,,20221015,,PH,DE,DE,2022,Q4,Elderly
214605811,21460581,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Pollakiuria,,2022,Q4,1,I,20210907.0,20221004.0,20221015,20221015,EXP,,DE-AUROBINDO-AUR-APL-2022-038736,AUROBINDO,,73.0,YR,,M,Y,,,20221015,,PH,DE,DE,2022,Q4,Elderly
214605811,21460581,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20210907.0,20221004.0,20221015,20221015,EXP,,DE-AUROBINDO-AUR-APL-2022-038736,AUROBINDO,,73.0,YR,,M,Y,,,20221015,,PH,DE,DE,2022,Q4,Elderly
214605811,21460581,6,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Product monitoring error,,2022,Q4,1,I,20210907.0,20221004.0,20221015,20221015,EXP,,DE-AUROBINDO-AUR-APL-2022-038736,AUROBINDO,,73.0,YR,,M,Y,,,20221015,,PH,DE,DE,2022,Q4,Elderly
214608881,21460888,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Limb injury,,2022,Q4,1,I,,20221003.0,20221015,20221015,EXP,,DE-AUROBINDO-AUR-APL-2022-041932,AUROBINDO,,59.0,YR,,M,Y,125.0,KG,20221015,,PH,DE,DE,2022,Q4,Adult
214608881,21460888,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Impaired healing,,2022,Q4,1,I,,20221003.0,20221015,20221015,EXP,,DE-AUROBINDO-AUR-APL-2022-041932,AUROBINDO,,59.0,YR,,M,Y,125.0,KG,20221015,,PH,DE,DE,2022,Q4,Adult
214608881,21460888,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Erythema,,2022,Q4,1,I,,20221003.0,20221015,20221015,EXP,,DE-AUROBINDO-AUR-APL-2022-041932,AUROBINDO,,59.0,YR,,M,Y,125.0,KG,20221015,,PH,DE,DE,2022,Q4,Adult
214608881,21460888,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Wound secretion,,2022,Q4,1,I,,20221003.0,20221015,20221015,EXP,,DE-AUROBINDO-AUR-APL-2022-041932,AUROBINDO,,59.0,YR,,M,Y,125.0,KG,20221015,,PH,DE,DE,2022,Q4,Adult
214608881,21460888,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Foot amputation,,2022,Q4,1,I,,20221003.0,20221015,20221015,EXP,,DE-AUROBINDO-AUR-APL-2022-041932,AUROBINDO,,59.0,YR,,M,Y,125.0,KG,20221015,,PH,DE,DE,2022,Q4,Adult
214608881,21460888,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q4,1,I,,20221003.0,20221015,20221015,EXP,,DE-AUROBINDO-AUR-APL-2022-041932,AUROBINDO,,59.0,YR,,M,Y,125.0,KG,20221015,,PH,DE,DE,2022,Q4,Adult
214624271,21462427,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2022,Q4,Urinary tract infection,,2022,Q4,1,I,20220908.0,,20221014,20221014,DIR,FDA-CDER-CTU-2022-82256,,FDA-CTU,,76.0,YR,,M,N,93.0,KG,20221007,N,PH,US,,2022,Q4,Elderly
214651241,21465124,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,,,unknown,,,,,,,2022,Q4,Disturbance in attention,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,,GB-NOVOPROD-948926,NOVO NORDISK,,50.0,YR,,M,Y,76.0,KG,20221017,,HP,GB,GB,2022,Q4,Adult
214651241,21465124,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,,,unknown,,,,,,,2022,Q4,Nausea,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,,GB-NOVOPROD-948926,NOVO NORDISK,,50.0,YR,,M,Y,76.0,KG,20221017,,HP,GB,GB,2022,Q4,Adult
214651241,21465124,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,,,unknown,,,,,,,2022,Q4,Fatigue,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,,GB-NOVOPROD-948926,NOVO NORDISK,,50.0,YR,,M,Y,76.0,KG,20221017,,HP,GB,GB,2022,Q4,Adult
214651511,21465151,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q4,Chest pain,,2022,Q4,1,I,20220310.0,,20221014,20221014,DIR,FDA-CDER-CTU-2022-82582,,FDA-CTU,,69.0,YR,,F,N,65.0,KG,20220818,N,PH,US,,2022,Q4,Elderly
214651511,21465151,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,20220310.0,,20221014,20221014,DIR,FDA-CDER-CTU-2022-82582,,FDA-CTU,,69.0,YR,,F,N,65.0,KG,20220818,N,PH,US,,2022,Q4,Elderly
214655341,21465534,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Diabetes mellitus inadequate control,,2022,Q4,1,I,20211102.0,,20221014,20221014,DIR,FDA-CDER-CTU-2022-82607,,FDA-CTU,,53.0,YR,,M,N,164.0,KG,20220118,N,PH,US,,2022,Q4,Adult
214655341,21465534,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,20211102.0,,20221014,20221014,DIR,FDA-CDER-CTU-2022-82607,,FDA-CTU,,53.0,YR,,M,N,164.0,KG,20220118,N,PH,US,,2022,Q4,Adult
214664371,21466437,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Tracheobronchitis,,2022,Q4,1,I,,20221010.0,20221017,20221017,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-196567",BOEHRINGER INGELHEIM,"Antunes A, Antunes A, Faria C, Falc?o C, Miragaia A. P No. 1827 The bitterness of diabetic ketoacidosis. Medicina Interna. 2022 Oct; 969-",61.0,YR,A,M,Y,,,20221017,,HP,PT,PT,2022,Q4,Adult
214664371,21466437,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Diabetic metabolic decompensation,,2022,Q4,1,I,,20221010.0,20221017,20221017,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-196567",BOEHRINGER INGELHEIM,"Antunes A, Antunes A, Faria C, Falc?o C, Miragaia A. P No. 1827 The bitterness of diabetic ketoacidosis. Medicina Interna. 2022 Oct; 969-",61.0,YR,A,M,Y,,,20221017,,HP,PT,PT,2022,Q4,Adult
214664371,21466437,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221010.0,20221017,20221017,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-196567",BOEHRINGER INGELHEIM,"Antunes A, Antunes A, Faria C, Falc?o C, Miragaia A. P No. 1827 The bitterness of diabetic ketoacidosis. Medicina Interna. 2022 Oct; 969-",61.0,YR,A,M,Y,,,20221017,,HP,PT,PT,2022,Q4,Adult
214679851,21467985,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Pancreatitis,,2022,Q4,1,I,20220916.0,20221005.0,20221017,20221017,PER,,US-ELI_LILLY_AND_COMPANY-US202210002203,ELI LILLY AND CO,,49.0,YR,,F,Y,98.0,KG,20221017,,HP,US,US,2022,Q4,Adult
214679851,21467985,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Off label use,,2022,Q4,1,I,20220916.0,20221005.0,20221017,20221017,PER,,US-ELI_LILLY_AND_COMPANY-US202210002203,ELI LILLY AND CO,,49.0,YR,,F,Y,98.0,KG,20221017,,HP,US,US,2022,Q4,Adult
214692333,21469233,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2022,Q4,Pyrexia,,2022,Q4,3,F,20220929.0,20221114.0,20221018,20221122,EXP,,JP-UCBSA-2022060320,UCB,,68.0,YR,,F,Y,54.5,KG,20221122,,PH,JP,JP,2022,Q4,Elderly
214692333,21469233,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2022,Q4,Drug eruption,,2022,Q4,3,F,20220929.0,20221114.0,20221018,20221122,EXP,,JP-UCBSA-2022060320,UCB,,68.0,YR,,F,Y,54.5,KG,20221122,,PH,JP,JP,2022,Q4,Elderly
214692333,21469233,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2022,Q4,Off label use,,2022,Q4,3,F,20220929.0,20221114.0,20221018,20221122,EXP,,JP-UCBSA-2022060320,UCB,,68.0,YR,,F,Y,54.5,KG,20221122,,PH,JP,JP,2022,Q4,Elderly
214692333,21469233,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2022,Q4,Malaise,,2022,Q4,3,F,20220929.0,20221114.0,20221018,20221122,EXP,,JP-UCBSA-2022060320,UCB,,68.0,YR,,F,Y,54.5,KG,20221122,,PH,JP,JP,2022,Q4,Elderly
214692333,21469233,5,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2022,Q4,Ocular hyperaemia,,2022,Q4,3,F,20220929.0,20221114.0,20221018,20221122,EXP,,JP-UCBSA-2022060320,UCB,,68.0,YR,,F,Y,54.5,KG,20221122,,PH,JP,JP,2022,Q4,Elderly
214698551,21469855,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2022,Q4,Glycosuria,,2022,Q4,1,I,,20221018.0,20221018,20221018,EXP,DE-BFARM-22008460,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-197818",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,76.0,KG,20221018,,MD,DE,DE,2022,Q4,Adult
214698551,21469855,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,Unknown,,204629.0,25.0,MG,Film-coated tablet,QD,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221018.0,20221018,20221018,EXP,DE-BFARM-22008460,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-197818",BOEHRINGER INGELHEIM,,51.0,YR,A,M,Y,76.0,KG,20221018,,MD,DE,DE,2022,Q4,Adult
214770141,21477014,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,OTHER QUANTITY : Dose: 12.5 MG;?Frequency : Daily;?,,,,,,,,,,,QD,2022,Q4,Urinary tract infection,,2022,Q4,1,I,20220408.0,,20221018,20221018,DIR,FDA-CDER-CTU-2022-83114,,FDA-CTU,,74.0,YR,,M,N,,,20220615,N,PH,US,,2022,Q4,Elderly
214785181,21478518,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,U,U,,,,,,,,2022,Q4,Urinary tract infection,,2022,Q4,1,I,20181217.0,20221010.0,20221019,20221019,EXP,,ES-MYLANLABS-2022M1115307,MYLAN,"Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144 (6):304-309",53.0,YR,,F,Y,,,20221019,,HP,ES,ES,2022,Q4,Adult
214785181,21478518,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,U,U,,,,,,,,2022,Q4,Perinephric abscess,,2022,Q4,1,I,20181217.0,20221010.0,20221019,20221019,EXP,,ES-MYLANLABS-2022M1115307,MYLAN,"Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144 (6):304-309",53.0,YR,,F,Y,,,20221019,,HP,ES,ES,2022,Q4,Adult
214785181,21478518,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,U,U,,,,,,,,2022,Q4,Drug ineffective,,2022,Q4,1,I,20181217.0,20221010.0,20221019,20221019,EXP,,ES-MYLANLABS-2022M1115307,MYLAN,"Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144 (6):304-309",53.0,YR,,F,Y,,,20221019,,HP,ES,ES,2022,Q4,Adult
214785181,21478518,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,U,U,,,,,,,,2022,Q4,Urinary tract infection enterococcal,,2022,Q4,1,I,20181217.0,20221010.0,20221019,20221019,EXP,,ES-MYLANLABS-2022M1115307,MYLAN,"Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144 (6):304-309",53.0,YR,,F,Y,,,20221019,,HP,ES,ES,2022,Q4,Adult
214785181,21478518,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,U,U,,,,,,,,2022,Q4,Urinary tract candidiasis,,2022,Q4,1,I,20181217.0,20221010.0,20221019,20221019,EXP,,ES-MYLANLABS-2022M1115307,MYLAN,"Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144 (6):304-309",53.0,YR,,F,Y,,,20221019,,HP,ES,ES,2022,Q4,Adult
214785181,21478518,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,U,U,,,,,,,,2022,Q4,Emphysematous pyelonephritis,,2022,Q4,1,I,20181217.0,20221010.0,20221019,20221019,EXP,,ES-MYLANLABS-2022M1115307,MYLAN,"Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144 (6):304-309",53.0,YR,,F,Y,,,20221019,,HP,ES,ES,2022,Q4,Adult
214785181,21478518,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,U,U,,,,,,,,2022,Q4,Septic shock,,2022,Q4,1,I,20181217.0,20221010.0,20221019,20221019,EXP,,ES-MYLANLABS-2022M1115307,MYLAN,"Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144 (6):304-309",53.0,YR,,F,Y,,,20221019,,HP,ES,ES,2022,Q4,Adult
214785181,21478518,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,U,U,,,,,,,,2022,Q4,Candida sepsis,,2022,Q4,1,I,20181217.0,20221010.0,20221019,20221019,EXP,,ES-MYLANLABS-2022M1115307,MYLAN,"Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144 (6):304-309",53.0,YR,,F,Y,,,20221019,,HP,ES,ES,2022,Q4,Adult
214785181,21478518,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown freq.",,,U,U,,,,,,,,2022,Q4,Candida infection,,2022,Q4,1,I,20181217.0,20221010.0,20221019,20221019,EXP,,ES-MYLANLABS-2022M1115307,MYLAN,"Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al.. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft.. Nephron. 2020;144 (6):304-309",53.0,YR,,F,Y,,,20221019,,HP,ES,ES,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Drug intolerance,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Inspiratory capacity decreased,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Sinusitis,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Tremor,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Asthma,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Wheezing,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Hospitalisation,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Chest discomfort,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Cough,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Bronchial hyperreactivity,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Dyspnoea,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Obstructive airways disorder,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Forced expiratory volume decreased,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Weight decreased,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214804941,21480494,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Total lung capacity decreased,,2022,Q4,1,I,20180401.0,20221013.0,20221019,20221019,EXP,,CA-AstraZeneca-2020SF02165,ASTRAZENECA,,50.0,YR,,M,Y,85.0,KG,20221019,,MD,CA,,2022,Q4,Adult
214858281,21485828,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,20220902.0,,20221020,20221020,DIR,635343,,FDA-CTU,,66.0,YR,,M,N,99.0,KG,20221020,N,PH,US,,2022,Q4,Elderly
214858281,21485828,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20220902.0,,20221020,20221020,DIR,635343,,FDA-CTU,,66.0,YR,,M,N,99.0,KG,20221020,N,PH,US,,2022,Q4,Elderly
214858281,21485828,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hypovolaemia,,2022,Q4,1,I,20220902.0,,20221020,20221020,DIR,635343,,FDA-CTU,,66.0,YR,,M,N,99.0,KG,20221020,N,PH,US,,2022,Q4,Elderly
214858281,21485828,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hyperkalaemia,,2022,Q4,1,I,20220902.0,,20221020,20221020,DIR,635343,,FDA-CTU,,66.0,YR,,M,N,99.0,KG,20221020,N,PH,US,,2022,Q4,Elderly
214869931,21486993,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD (1-0-0-0)",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,Melaena,,2022,Q4,1,I,,20221014.0,20221020,20221020,EXP,,NVSC2022DE232066,NOVARTIS,,67.0,YR,,M,Y,95.0,KG,20221020,,PH,DE,DE,2022,Q4,Elderly
214869931,21486993,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD (1-0-0-0)",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,Anaemia,,2022,Q4,1,I,,20221014.0,20221020,20221020,EXP,,NVSC2022DE232066,NOVARTIS,,67.0,YR,,M,Y,95.0,KG,20221020,,PH,DE,DE,2022,Q4,Elderly
214869931,21486993,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD (1-0-0-0)",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20221014.0,20221020,20221020,EXP,,NVSC2022DE232066,NOVARTIS,,67.0,YR,,M,Y,95.0,KG,20221020,,PH,DE,DE,2022,Q4,Elderly
214869931,21486993,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD (1-0-0-0)",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,Haematochezia,,2022,Q4,1,I,,20221014.0,20221020,20221020,EXP,,NVSC2022DE232066,NOVARTIS,,67.0,YR,,M,Y,95.0,KG,20221020,,PH,DE,DE,2022,Q4,Elderly
214869931,21486993,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD (1-0-0-0)",,,U,,,,,25.0,MG,Tablet,QD,2022,Q4,Diarrhoea,,2022,Q4,1,I,,20221014.0,20221020,20221020,EXP,,NVSC2022DE232066,NOVARTIS,,67.0,YR,,M,Y,95.0,KG,20221020,,PH,DE,DE,2022,Q4,Elderly
214870941,21487094,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Dizziness,,2022,Q4,1,I,20220922.0,20221016.0,20221020,20221020,PER,,SA-AMGEN-SAUSL2022179836,AMGEN,,54.0,YR,A,M,Y,,,20221020,,CN,SA,SA,2022,Q4,Adult
214870941,21487094,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Hypotension,,2022,Q4,1,I,20220922.0,20221016.0,20221020,20221020,PER,,SA-AMGEN-SAUSL2022179836,AMGEN,,54.0,YR,A,M,Y,,,20221020,,CN,SA,SA,2022,Q4,Adult
214870941,21487094,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Fatigue,,2022,Q4,1,I,20220922.0,20221016.0,20221020,20221020,PER,,SA-AMGEN-SAUSL2022179836,AMGEN,,54.0,YR,A,M,Y,,,20221020,,CN,SA,SA,2022,Q4,Adult
214894611,21489461,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Atrial fibrillation,,2022,Q4,1,I,,20221011.0,20221021,20221021,EXP,,PL-JNJFOC-20220641544,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221021,,HP,PL,PL,2022,Q4,Elderly
214894611,21489461,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Vessel puncture site haematoma,,2022,Q4,1,I,,20221011.0,20221021,20221021,EXP,,PL-JNJFOC-20220641544,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221021,,HP,PL,PL,2022,Q4,Elderly
214894611,21489461,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Oedema peripheral,,2022,Q4,1,I,,20221011.0,20221021,20221021,EXP,,PL-JNJFOC-20220641544,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221021,,HP,PL,PL,2022,Q4,Elderly
214894611,21489461,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Bradycardia,,2022,Q4,1,I,,20221011.0,20221021,20221021,EXP,,PL-JNJFOC-20220641544,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221021,,HP,PL,PL,2022,Q4,Elderly
214894611,21489461,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Rales,,2022,Q4,1,I,,20221011.0,20221021,20221021,EXP,,PL-JNJFOC-20220641544,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221021,,HP,PL,PL,2022,Q4,Elderly
214894611,21489461,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Vascular stenosis,,2022,Q4,1,I,,20221011.0,20221021,20221021,EXP,,PL-JNJFOC-20220641544,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221021,,HP,PL,PL,2022,Q4,Elderly
214894611,21489461,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Coronary artery occlusion,,2022,Q4,1,I,,20221011.0,20221021,20221021,EXP,,PL-JNJFOC-20220641544,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221021,,HP,PL,PL,2022,Q4,Elderly
214894611,21489461,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Erythema,,2022,Q4,1,I,,20221011.0,20221021,20221021,EXP,,PL-JNJFOC-20220641544,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221021,,HP,PL,PL,2022,Q4,Elderly
214894611,21489461,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Pruritus,,2022,Q4,1,I,,20221011.0,20221021,20221021,EXP,,PL-JNJFOC-20220641544,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221021,,HP,PL,PL,2022,Q4,Elderly
214894611,21489461,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Ejection fraction decreased,,2022,Q4,1,I,,20221011.0,20221021,20221021,EXP,,PL-JNJFOC-20220641544,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221021,,HP,PL,PL,2022,Q4,Elderly
214894611,21489461,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Crepitations,,2022,Q4,1,I,,20221011.0,20221021,20221021,EXP,,PL-JNJFOC-20220641544,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221021,,HP,PL,PL,2022,Q4,Elderly
214894611,21489461,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Varicose vein,,2022,Q4,1,I,,20221011.0,20221021,20221021,EXP,,PL-JNJFOC-20220641544,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221021,,HP,PL,PL,2022,Q4,Elderly
214894611,21489461,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Heart rate irregular,,2022,Q4,1,I,,20221011.0,20221021,20221021,EXP,,PL-JNJFOC-20220641544,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221021,,HP,PL,PL,2022,Q4,Elderly
214894611,21489461,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Diabetic foot,,2022,Q4,1,I,,20221011.0,20221021,20221021,EXP,,PL-JNJFOC-20220641544,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20221021,,HP,PL,PL,2022,Q4,Elderly
214905491,21490549,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Melaena,,2022,Q4,1,I,,20221012.0,20221021,20221021,EXP,,DE-AUROBINDO-AUR-APL-2022-043408,AUROBINDO,,67.0,YR,,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
214905491,21490549,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Diarrhoea,,2022,Q4,1,I,,20221012.0,20221021,20221021,EXP,,DE-AUROBINDO-AUR-APL-2022-043408,AUROBINDO,,67.0,YR,,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
214905491,21490549,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Anaemia,,2022,Q4,1,I,,20221012.0,20221021,20221021,EXP,,DE-AUROBINDO-AUR-APL-2022-043408,AUROBINDO,,67.0,YR,,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
214905491,21490549,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0",,,U,,,,,25.0,MG,Tablet,,2022,Q4,Haematochezia,,2022,Q4,1,I,,20221012.0,20221021,20221021,EXP,,DE-AUROBINDO-AUR-APL-2022-043408,AUROBINDO,,67.0,YR,,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
214905491,21490549,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, 1-0-0-0",,,U,,,,,25.0,MG,Tablet,,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20221012.0,20221021,20221021,EXP,,DE-AUROBINDO-AUR-APL-2022-043408,AUROBINDO,,67.0,YR,,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
214907761,21490776,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221018.0,20221021,20221021,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-197860",BOEHRINGER INGELHEIM,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Journal of Toxicology. Clinical Toxicology. 2022; 60(2)47-",33.0,YR,A,F,Y,,,20221021,,HP,US,US,2022,Q4,Young Adult
214907761,21490776,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221018.0,20221021,20221021,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-197860",BOEHRINGER INGELHEIM,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Journal of Toxicology. Clinical Toxicology. 2022; 60(2)47-",33.0,YR,A,F,Y,,,20221021,,HP,US,US,2022,Q4,Young Adult
214907761,21490776,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,1,I,,20221018.0,20221021,20221021,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-197860",BOEHRINGER INGELHEIM,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Journal of Toxicology. Clinical Toxicology. 2022; 60(2)47-",33.0,YR,A,F,Y,,,20221021,,HP,US,US,2022,Q4,Young Adult
214907761,21490776,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Muscle necrosis,,2022,Q4,1,I,,20221018.0,20221021,20221021,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-197860",BOEHRINGER INGELHEIM,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Journal of Toxicology. Clinical Toxicology. 2022; 60(2)47-",33.0,YR,A,F,Y,,,20221021,,HP,US,US,2022,Q4,Young Adult
214907761,21490776,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221018.0,20221021,20221021,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-197860",BOEHRINGER INGELHEIM,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Journal of Toxicology. Clinical Toxicology. 2022; 60(2)47-",33.0,YR,A,F,Y,,,20221021,,HP,US,US,2022,Q4,Young Adult
214907761,21490776,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221018.0,20221021,20221021,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-197860",BOEHRINGER INGELHEIM,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Journal of Toxicology. Clinical Toxicology. 2022; 60(2)47-",33.0,YR,A,F,Y,,,20221021,,HP,US,US,2022,Q4,Young Adult
214907761,21490776,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Embolic stroke,,2022,Q4,1,I,,20221018.0,20221021,20221021,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-197860",BOEHRINGER INGELHEIM,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Journal of Toxicology. Clinical Toxicology. 2022; 60(2)47-",33.0,YR,A,F,Y,,,20221021,,HP,US,US,2022,Q4,Young Adult
214907761,21490776,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221018.0,20221021,20221021,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-197860",BOEHRINGER INGELHEIM,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Journal of Toxicology. Clinical Toxicology. 2022; 60(2)47-",33.0,YR,A,F,Y,,,20221021,,HP,US,US,2022,Q4,Young Adult
214907761,21490776,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221018.0,20221021,20221021,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-197860",BOEHRINGER INGELHEIM,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Journal of Toxicology. Clinical Toxicology. 2022; 60(2)47-",33.0,YR,A,F,Y,,,20221021,,HP,US,US,2022,Q4,Young Adult
214907871,21490787,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablets",,,,,,,,25.0,MG,Tablet,QD,2022,Q4,Melaena,,2022,Q4,1,I,,20221017.0,20221021,20221021,EXP,,DE-MICRO LABS LIMITED-ML2022-05203,MICRO LABS,,67.0,YR,E,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
214907871,21490787,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablets",,,,,,,,25.0,MG,Tablet,QD,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20221017.0,20221021,20221021,EXP,,DE-MICRO LABS LIMITED-ML2022-05203,MICRO LABS,,67.0,YR,E,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
214907871,21490787,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablets",,,,,,,,25.0,MG,Tablet,QD,2022,Q4,Anaemia,,2022,Q4,1,I,,20221017.0,20221021,20221021,EXP,,DE-MICRO LABS LIMITED-ML2022-05203,MICRO LABS,,67.0,YR,E,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
214907871,21490787,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablets",,,,,,,,25.0,MG,Tablet,QD,2022,Q4,Haematochezia,,2022,Q4,1,I,,20221017.0,20221021,20221021,EXP,,DE-MICRO LABS LIMITED-ML2022-05203,MICRO LABS,,67.0,YR,E,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
214907871,21490787,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablets",,,,,,,,25.0,MG,Tablet,QD,2022,Q4,Diarrhoea,,2022,Q4,1,I,,20221017.0,20221021,20221021,EXP,,DE-MICRO LABS LIMITED-ML2022-05203,MICRO LABS,,67.0,YR,E,M,Y,95.0,KG,20221021,,PH,DE,DE,2022,Q4,Elderly
214927991,21492799,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Haematochezia,,2022,Q4,1,I,20201001.0,20221017.0,20221021,20221021,EXP,,NVSC2022DE233104,NOVARTIS,,79.0,YR,,F,Y,,,20221021,,MD,DE,DE,2022,Q4,Elderly
214927991,21492799,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2022,Q4,Rectal ulcer,,2022,Q4,1,I,20201001.0,20221017.0,20221021,20221021,EXP,,NVSC2022DE233104,NOVARTIS,,79.0,YR,,F,Y,,,20221021,,MD,DE,DE,2022,Q4,Elderly
214936102,21493610,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 milligram,,,,,,,,25.0,MG,,,2022,Q4,Bile duct stone,,2022,Q4,2,F,,20221212.0,20221021,20221220,EXP,,CA-TAKEDA-2022TUS075299,TAKEDA,,67.0,YR,,F,Y,,,20221220,,MD,CA,CA,2022,Q4,Elderly
214940971,21494097,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablet",,,U,,unknown,,,,,Tablet,,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20221017.0,20221021,20221021,EXP,,DE-FreseniusKabi-FK202214119,FRESENIUS KABI,,60.0,YR,A,M,Y,97.0,KG,20221021,,PH,DE,DE,2022,Q4,Adult
214940971,21494097,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablet",,,U,,unknown,,,,,Tablet,,2022,Q4,Product monitoring error,,2022,Q4,1,I,,20221017.0,20221021,20221021,EXP,,DE-FreseniusKabi-FK202214119,FRESENIUS KABI,,60.0,YR,A,M,Y,97.0,KG,20221021,,PH,DE,DE,2022,Q4,Adult
214940971,21494097,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablet",,,U,,unknown,,,,,Tablet,,2022,Q4,Condition aggravated,,2022,Q4,1,I,,20221017.0,20221021,20221021,EXP,,DE-FreseniusKabi-FK202214119,FRESENIUS KABI,,60.0,YR,A,M,Y,97.0,KG,20221021,,PH,DE,DE,2022,Q4,Adult
214940971,21494097,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0, Tablet",,,U,,unknown,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,1,I,,20221017.0,20221021,20221021,EXP,,DE-FreseniusKabi-FK202214119,FRESENIUS KABI,,60.0,YR,A,M,Y,97.0,KG,20221021,,PH,DE,DE,2022,Q4,Adult
214941791,21494179,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, daily",,,,,,,,25.0,MG,,QD,2022,Q4,Blood glucose increased,,2022,Q4,1,I,20211201.0,20221012.0,20221021,20221021,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202210005306,ELI LILLY AND CO,,57.0,YR,,M,Y,,,20221021,,CN,DE,DE,2022,Q4,Adult
214941791,21494179,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, daily",,,,,,,,25.0,MG,,QD,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,1,I,20211201.0,20221012.0,20221021,20221021,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202210005306,ELI LILLY AND CO,,57.0,YR,,M,Y,,,20221021,,CN,DE,DE,2022,Q4,Adult
214941791,21494179,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, daily",,,,,,,,25.0,MG,,QD,2022,Q4,Iliac artery stenosis,,2022,Q4,1,I,20211201.0,20221012.0,20221021,20221021,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202210005306,ELI LILLY AND CO,,57.0,YR,,M,Y,,,20221021,,CN,DE,DE,2022,Q4,Adult
214941791,21494179,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, daily",,,,,,,,25.0,MG,,QD,2022,Q4,Peripheral artery occlusion,,2022,Q4,1,I,20211201.0,20221012.0,20221021,20221021,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202210005306,ELI LILLY AND CO,,57.0,YR,,M,Y,,,20221021,,CN,DE,DE,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Hospitalisation,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Wheezing,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Forced expiratory volume decreased,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Chest discomfort,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Total lung capacity decreased,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Asthma,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Weight decreased,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Obstructive airways disorder,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Inspiratory capacity decreased,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Full blood count abnormal,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Bronchial hyperreactivity,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Drug intolerance,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Tremor,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Cough,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Therapeutic product effect incomplete,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Sinusitis,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214943461,21494346,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,UNKNOWN,,,,,,,2022,Q4,Dyspnoea,,2022,Q4,1,I,20180401.0,20221013.0,20221021,20221021,EXP,,CA-Covis Pharma GmbH-2021COV20091,COVIS PHARMA,,50.0,YR,A,M,Y,85.0,KG,20221021,,CN,CA,CA,2022,Q4,Adult
214967691,21496769,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 Milligram Daily; 25 mg, 1-0-0-0",,,U,,UNKNOWN,,,25.0,MG,Tablet,QD,2022,Q4,Wound secretion,,2022,Q4,1,I,,20221013.0,20221022,20221022,EXP,,DE-TEVA-2022-DE-2817883,TEVA,,59.0,YR,A,M,Y,125.0,KG,20221022,,PH,DE,DE,2022,Q4,Adult
214967691,21496769,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 Milligram Daily; 25 mg, 1-0-0-0",,,U,,UNKNOWN,,,25.0,MG,Tablet,QD,2022,Q4,Limb injury,,2022,Q4,1,I,,20221013.0,20221022,20221022,EXP,,DE-TEVA-2022-DE-2817883,TEVA,,59.0,YR,A,M,Y,125.0,KG,20221022,,PH,DE,DE,2022,Q4,Adult
214967691,21496769,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 Milligram Daily; 25 mg, 1-0-0-0",,,U,,UNKNOWN,,,25.0,MG,Tablet,QD,2022,Q4,Foot amputation,,2022,Q4,1,I,,20221013.0,20221022,20221022,EXP,,DE-TEVA-2022-DE-2817883,TEVA,,59.0,YR,A,M,Y,125.0,KG,20221022,,PH,DE,DE,2022,Q4,Adult
214967691,21496769,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 Milligram Daily; 25 mg, 1-0-0-0",,,U,,UNKNOWN,,,25.0,MG,Tablet,QD,2022,Q4,Erythema,,2022,Q4,1,I,,20221013.0,20221022,20221022,EXP,,DE-TEVA-2022-DE-2817883,TEVA,,59.0,YR,A,M,Y,125.0,KG,20221022,,PH,DE,DE,2022,Q4,Adult
214967691,21496769,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 Milligram Daily; 25 mg, 1-0-0-0",,,U,,UNKNOWN,,,25.0,MG,Tablet,QD,2022,Q4,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q4,1,I,,20221013.0,20221022,20221022,EXP,,DE-TEVA-2022-DE-2817883,TEVA,,59.0,YR,A,M,Y,125.0,KG,20221022,,PH,DE,DE,2022,Q4,Adult
214967691,21496769,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 Milligram Daily; 25 mg, 1-0-0-0",,,U,,UNKNOWN,,,25.0,MG,Tablet,QD,2022,Q4,Impaired healing,,2022,Q4,1,I,,20221013.0,20221022,20221022,EXP,,DE-TEVA-2022-DE-2817883,TEVA,,59.0,YR,A,M,Y,125.0,KG,20221022,,PH,DE,DE,2022,Q4,Adult
214980411,21498041,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221019.0,20221024,20221024,EXP,,US-009507513-2210USA007432,MERCK,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2:47-8",33.0,YR,,F,Y,,,20221024,,HP,US,US,2022,Q4,Young Adult
214980411,21498041,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221019.0,20221024,20221024,EXP,,US-009507513-2210USA007432,MERCK,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2:47-8",33.0,YR,,F,Y,,,20221024,,HP,US,US,2022,Q4,Young Adult
214985001,21498500,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q4,Abdominal pain upper,,2022,Q4,1,I,,20221021.0,20221024,20221024,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-126058,BRISTOL MYERS SQUIBB,,77.0,YR,E,M,Y,,,20221024,,PH,US,US,2022,Q4,Elderly
214991472,21499147,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Completed suicide,,2022,Q4,2,F,20200101.0,20221010.0,20221024,20221221,EXP,,"US-AZURITY PHARMACEUTICALS, INC.-US-2022ARB002593",AZURITY PHARMACEUTICALS,"Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Brinstein AC, Rivers LJ, et al.. 2020 Annual Report of the American Association of Poison Control Centers^ National Poison Data System (NPDS): 38th Annual Report. Clinical Toxicology. 2021;59(12):1282-1501",15.0,YR,,M,Y,,,20221221,,MD,US,US,2022,Q4,Youth
214991472,21499147,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Toxicity to various agents,,2022,Q4,2,F,20200101.0,20221010.0,20221024,20221221,EXP,,"US-AZURITY PHARMACEUTICALS, INC.-US-2022ARB002593",AZURITY PHARMACEUTICALS,"Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Brinstein AC, Rivers LJ, et al.. 2020 Annual Report of the American Association of Poison Control Centers^ National Poison Data System (NPDS): 38th Annual Report. Clinical Toxicology. 2021;59(12):1282-1501",15.0,YR,,M,Y,,,20221221,,MD,US,US,2022,Q4,Youth
215001182,21500118,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Urogenital infection bacterial,,2022,Q4,2,F,20220901.0,20221107.0,20221024,20221107,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198826",BOEHRINGER INGELHEIM,,45.0,YR,A,F,Y,,,20221107,,MD,DE,DE,2022,Q4,Adult
215001182,21500118,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Genital herpes zoster,,2022,Q4,2,F,20220901.0,20221107.0,20221024,20221107,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198826",BOEHRINGER INGELHEIM,,45.0,YR,A,F,Y,,,20221107,,MD,DE,DE,2022,Q4,Adult
215014461,21501446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221013.0,20221025,20221025,EXP,,BR-NOVOPROD-969878,NOVO NORDISK,,74.0,YR,,F,Y,,,20221025,,MD,BR,BR,2022,Q4,Elderly
215014461,21501446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Acute kidney injury,,2022,Q4,1,I,,20221013.0,20221025,20221025,EXP,,BR-NOVOPROD-969878,NOVO NORDISK,,74.0,YR,,F,Y,,,20221025,,MD,BR,BR,2022,Q4,Elderly
215014461,21501446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Weight decreased,,2022,Q4,1,I,,20221013.0,20221025,20221025,EXP,,BR-NOVOPROD-969878,NOVO NORDISK,,74.0,YR,,F,Y,,,20221025,,MD,BR,BR,2022,Q4,Elderly
215014461,21501446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Hepatitis acute,,2022,Q4,1,I,,20221013.0,20221025,20221025,EXP,,BR-NOVOPROD-969878,NOVO NORDISK,,74.0,YR,,F,Y,,,20221025,,MD,BR,BR,2022,Q4,Elderly
215014461,21501446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Syncope,,2022,Q4,1,I,,20221013.0,20221025,20221025,EXP,,BR-NOVOPROD-969878,NOVO NORDISK,,74.0,YR,,F,Y,,,20221025,,MD,BR,BR,2022,Q4,Elderly
215014461,21501446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Cholestasis,,2022,Q4,1,I,,20221013.0,20221025,20221025,EXP,,BR-NOVOPROD-969878,NOVO NORDISK,,74.0,YR,,F,Y,,,20221025,,MD,BR,BR,2022,Q4,Elderly
215014461,21501446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Intentional product misuse,,2022,Q4,1,I,,20221013.0,20221025,20221025,EXP,,BR-NOVOPROD-969878,NOVO NORDISK,,74.0,YR,,F,Y,,,20221025,,MD,BR,BR,2022,Q4,Elderly
215014603,21501460,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,Y,,,,,10.0,MG,Tablet,QD,2022,Q4,Dehydration,,2022,Q4,3,F,20220901.0,20221121.0,20221025,20221129,EXP,,JP-NOVOPROD-970464,NOVO NORDISK,,51.0,YR,,F,Y,80.9,KG,20221130,,MD,JP,JP,2022,Q4,Adult
215014603,21501460,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,Y,,,,,10.0,MG,Tablet,QD,2022,Q4,Acute kidney injury,,2022,Q4,3,F,20220901.0,20221121.0,20221025,20221129,EXP,,JP-NOVOPROD-970464,NOVO NORDISK,,51.0,YR,,F,Y,80.9,KG,20221130,,MD,JP,JP,2022,Q4,Adult
215014603,21501460,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,Y,,,,,10.0,MG,Tablet,QD,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,3,F,20220901.0,20221121.0,20221025,20221129,EXP,,JP-NOVOPROD-970464,NOVO NORDISK,,51.0,YR,,F,Y,80.9,KG,20221130,,MD,JP,JP,2022,Q4,Adult
215014603,21501460,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd",,,Y,,,,,10.0,MG,Tablet,QD,2022,Q4,Diarrhoea,,2022,Q4,3,F,20220901.0,20221121.0,20221025,20221129,EXP,,JP-NOVOPROD-970464,NOVO NORDISK,,51.0,YR,,F,Y,80.9,KG,20221130,,MD,JP,JP,2022,Q4,Adult
215041043,21504104,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Amp im,,2022,Q4,Pneumonia,,2022,Q4,3,F,20220927.0,20221206.0,20221025,20221212,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-2022-116055,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,95.0,KG,20221212,,MD,AU,AU,2022,Q4,Elderly
215041043,21504104,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Amp im,,2022,Q4,Vertebral column mass,,2022,Q4,3,F,20220927.0,20221206.0,20221025,20221212,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-2022-116055,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,95.0,KG,20221212,,MD,AU,AU,2022,Q4,Elderly
215041043,21504104,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Amp im,,2022,Q4,Renal cyst,,2022,Q4,3,F,20220927.0,20221206.0,20221025,20221212,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-2022-116055,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,95.0,KG,20221212,,MD,AU,AU,2022,Q4,Elderly
215041043,21504104,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Amp im,,2022,Q4,Metastatic neoplasm,,2022,Q4,3,F,20220927.0,20221206.0,20221025,20221212,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-2022-116055,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,95.0,KG,20221212,,MD,AU,AU,2022,Q4,Elderly
215041043,21504104,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Amp im,,2022,Q4,Second primary malignancy,,2022,Q4,3,F,20220927.0,20221206.0,20221025,20221212,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-2022-116055,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,95.0,KG,20221212,,MD,AU,AU,2022,Q4,Elderly
215041043,21504104,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Unknown,,2022,Q4,Pneumonia,,2022,Q4,3,F,20220927.0,20221206.0,20221025,20221212,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-2022-116055,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,95.0,KG,20221212,,MD,AU,AU,2022,Q4,Elderly
215041043,21504104,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Unknown,,2022,Q4,Vertebral column mass,,2022,Q4,3,F,20220927.0,20221206.0,20221025,20221212,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-2022-116055,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,95.0,KG,20221212,,MD,AU,AU,2022,Q4,Elderly
215041043,21504104,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Unknown,,2022,Q4,Renal cyst,,2022,Q4,3,F,20220927.0,20221206.0,20221025,20221212,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-2022-116055,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,95.0,KG,20221212,,MD,AU,AU,2022,Q4,Elderly
215041043,21504104,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Unknown,,2022,Q4,Metastatic neoplasm,,2022,Q4,3,F,20220927.0,20221206.0,20221025,20221212,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-2022-116055,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,95.0,KG,20221212,,MD,AU,AU,2022,Q4,Elderly
215041043,21504104,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Unknown,,2022,Q4,Second primary malignancy,,2022,Q4,3,F,20220927.0,20221206.0,20221025,20221212,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-2022-116055,BRISTOL MYERS SQUIBB,,75.0,YR,E,F,Y,95.0,KG,20221212,,MD,AU,AU,2022,Q4,Elderly
215052381,21505238,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Product use in unapproved indication,,2022,Q4,1,I,,20221021.0,20221026,20221026,EXP,,CA-ROCHE-3205352,ROCHE,,70.0,YR,,M,Y,,,20221026,,HP,CA,,2022,Q4,Elderly
215052381,21505238,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Proctalgia,,2022,Q4,1,I,,20221021.0,20221026,20221026,EXP,,CA-ROCHE-3205352,ROCHE,,70.0,YR,,M,Y,,,20221026,,HP,CA,,2022,Q4,Elderly
215052381,21505238,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Discomfort,,2022,Q4,1,I,,20221021.0,20221026,20221026,EXP,,CA-ROCHE-3205352,ROCHE,,70.0,YR,,M,Y,,,20221026,,HP,CA,,2022,Q4,Elderly
215052381,21505238,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Injection site pain,,2022,Q4,1,I,,20221021.0,20221026,20221026,EXP,,CA-ROCHE-3205352,ROCHE,,70.0,YR,,M,Y,,,20221026,,HP,CA,,2022,Q4,Elderly
215052381,21505238,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Constipation,,2022,Q4,1,I,,20221021.0,20221026,20221026,EXP,,CA-ROCHE-3205352,ROCHE,,70.0,YR,,M,Y,,,20221026,,HP,CA,,2022,Q4,Elderly
215052381,21505238,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Blood pressure increased,,2022,Q4,1,I,,20221021.0,20221026,20221026,EXP,,CA-ROCHE-3205352,ROCHE,,70.0,YR,,M,Y,,,20221026,,HP,CA,,2022,Q4,Elderly
215052381,21505238,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Haemoglobin increased,,2022,Q4,1,I,,20221021.0,20221026,20221026,EXP,,CA-ROCHE-3205352,ROCHE,,70.0,YR,,M,Y,,,20221026,,HP,CA,,2022,Q4,Elderly
215052893,21505289,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q4,Hypoglycaemia,,2022,Q4,3,F,,20221216.0,20221026,20221229,EXP,,PT-AUROBINDO-AUR-APL-2022-044348,AUROBINDO,"Silva A, Baptista M, Lima R, Lopes Ca?ola R.. PA n.? 0950 Diabetes Mellitus ? quando a hipoglicemia ? a personagem principal (Diabetes Mellitus - when hypoglycemia is the main character). Medicina Interna /28th National Congress of Internal Medicine. 2022;1485-1485",67.0,YR,,F,Y,,,20221229,,MD,PT,PT,2022,Q4,Elderly
215055152,21505515,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Capsule,QD,2022,Q4,Blood creatinine increased,,2022,Q4,2,F,20221010.0,20221123.0,20221026,20221208,EXP,,"CO-AKCEA THERAPEUTICS, INC.-2022IS004199",AKCEA THERAPEUTICS,,76.0,YR,,M,Y,64.136,KG,20221208,,HP,CO,CO,2022,Q4,Elderly
215087621,21508762,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,12.5,MG,,QD,2022,Q4,Fanconi syndrome,,2022,Q4,1,I,,20221019.0,20221026,20221026,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198749",BOEHRINGER INGELHEIM,"Fernandez N, Guez G, Escasinas E. Empagliflozin induced Fanconi syndrome in a patient with Covid-19. -.",61.0,YR,A,F,Y,,,20221026,,HP,US,US,2022,Q4,Adult
215087621,21508762,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Unknown,,204629.0,12.5,MG,,QD,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221019.0,20221026,20221026,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198749",BOEHRINGER INGELHEIM,"Fernandez N, Guez G, Escasinas E. Empagliflozin induced Fanconi syndrome in a patient with Covid-19. -.",61.0,YR,A,F,Y,,,20221026,,HP,US,US,2022,Q4,Adult
215091411,21509141,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,U,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Urinary hesitation,,2022,Q4,1,I,20210907.0,20221013.0,20221026,20221026,EXP,,DE-drreddys-SPO/GER/22/0155978,DR REDDYS,,73.0,YR,E,M,Y,,,20221026,,PH,DE,DE,2022,Q4,Elderly
215091411,21509141,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,U,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20210907.0,20221013.0,20221026,20221026,EXP,,DE-drreddys-SPO/GER/22/0155978,DR REDDYS,,73.0,YR,E,M,Y,,,20221026,,PH,DE,DE,2022,Q4,Elderly
215091411,21509141,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,U,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Cystitis,,2022,Q4,1,I,20210907.0,20221013.0,20221026,20221026,EXP,,DE-drreddys-SPO/GER/22/0155978,DR REDDYS,,73.0,YR,E,M,Y,,,20221026,,PH,DE,DE,2022,Q4,Elderly
215091411,21509141,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,U,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Product monitoring error,,2022,Q4,1,I,20210907.0,20221013.0,20221026,20221026,EXP,,DE-drreddys-SPO/GER/22/0155978,DR REDDYS,,73.0,YR,E,M,Y,,,20221026,,PH,DE,DE,2022,Q4,Elderly
215091411,21509141,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,U,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q4,1,I,20210907.0,20221013.0,20221026,20221026,EXP,,DE-drreddys-SPO/GER/22/0155978,DR REDDYS,,73.0,YR,E,M,Y,,,20221026,,PH,DE,DE,2022,Q4,Elderly
215091411,21509141,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,U,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Pollakiuria,,2022,Q4,1,I,20210907.0,20221013.0,20221026,20221026,EXP,,DE-drreddys-SPO/GER/22/0155978,DR REDDYS,,73.0,YR,E,M,Y,,,20221026,,PH,DE,DE,2022,Q4,Elderly
215091411,21509141,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,U,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Labelled drug-drug interaction medication error,,2022,Q4,1,I,20210907.0,20221013.0,20221026,20221026,EXP,,DE-drreddys-SPO/GER/22/0155978,DR REDDYS,,73.0,YR,E,M,Y,,,20221026,,PH,DE,DE,2022,Q4,Elderly
215091411,21509141,8,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,U,UNKNOWN,,,10.0,MG,Tablet,QD,2022,Q4,Product administration error,,2022,Q4,1,I,20210907.0,20221013.0,20221026,20221026,EXP,,DE-drreddys-SPO/GER/22/0155978,DR REDDYS,,73.0,YR,E,M,Y,,,20221026,,PH,DE,DE,2022,Q4,Elderly
215096511,21509651,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Hypernatraemia,,2022,Q4,1,I,,20221019.0,20221026,20221026,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198699",BOEHRINGER INGELHEIM,"Ahmed M, Truong T, Block C. Empagliflozin Associated Severe Hypernatremia in the Setting of subclinical Diabetes Insipidus: A Case Report.",67.0,YR,E,M,Y,,,20221026,,HP,US,US,2022,Q4,Elderly
215096511,21509651,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,,,204629.0,,,,,2022,Q4,Hypernatraemia,,2022,Q4,1,I,,20221019.0,20221026,20221026,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198699",BOEHRINGER INGELHEIM,"Ahmed M, Truong T, Block C. Empagliflozin Associated Severe Hypernatremia in the Setting of subclinical Diabetes Insipidus: A Case Report.",67.0,YR,E,M,Y,,,20221026,,HP,US,US,2022,Q4,Elderly
215111481,21511148,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Hydronephrosis,,2022,Q4,1,I,,20221019.0,20221027,20221027,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198759",BOEHRINGER INGELHEIM,"Haseeb A, Abu-Rmaileh M, Penfield J, Liu H, Van Buren P, Lederer E. A novel case of renal  Mucormycosis Associated With Empagliflozin Use.",63.0,YR,A,M,Y,,,20221027,,HP,US,US,2022,Q4,Adult
215111481,21511148,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Hydronephrosis,,2022,Q4,1,I,,20221019.0,20221027,20221027,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198759",BOEHRINGER INGELHEIM,"Haseeb A, Abu-Rmaileh M, Penfield J, Liu H, Van Buren P, Lederer E. A novel case of renal  Mucormycosis Associated With Empagliflozin Use.",63.0,YR,A,M,Y,,,20221027,,HP,US,US,2022,Q4,Adult
215111481,21511148,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Nephrolithiasis,,2022,Q4,1,I,,20221019.0,20221027,20221027,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198759",BOEHRINGER INGELHEIM,"Haseeb A, Abu-Rmaileh M, Penfield J, Liu H, Van Buren P, Lederer E. A novel case of renal  Mucormycosis Associated With Empagliflozin Use.",63.0,YR,A,M,Y,,,20221027,,HP,US,US,2022,Q4,Adult
215111481,21511148,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Pyelitis,,2022,Q4,1,I,,20221019.0,20221027,20221027,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198759",BOEHRINGER INGELHEIM,"Haseeb A, Abu-Rmaileh M, Penfield J, Liu H, Van Buren P, Lederer E. A novel case of renal  Mucormycosis Associated With Empagliflozin Use.",63.0,YR,A,M,Y,,,20221027,,HP,US,US,2022,Q4,Adult
215111481,21511148,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Emphysematous cystitis,,2022,Q4,1,I,,20221019.0,20221027,20221027,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198759",BOEHRINGER INGELHEIM,"Haseeb A, Abu-Rmaileh M, Penfield J, Liu H, Van Buren P, Lederer E. A novel case of renal  Mucormycosis Associated With Empagliflozin Use.",63.0,YR,A,M,Y,,,20221027,,HP,US,US,2022,Q4,Adult
215111481,21511148,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Ureteric injury,,2022,Q4,1,I,,20221019.0,20221027,20221027,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198759",BOEHRINGER INGELHEIM,"Haseeb A, Abu-Rmaileh M, Penfield J, Liu H, Van Buren P, Lederer E. A novel case of renal  Mucormycosis Associated With Empagliflozin Use.",63.0,YR,A,M,Y,,,20221027,,HP,US,US,2022,Q4,Adult
215111481,21511148,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Acute kidney injury,,2022,Q4,1,I,,20221019.0,20221027,20221027,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198759",BOEHRINGER INGELHEIM,"Haseeb A, Abu-Rmaileh M, Penfield J, Liu H, Van Buren P, Lederer E. A novel case of renal  Mucormycosis Associated With Empagliflozin Use.",63.0,YR,A,M,Y,,,20221027,,HP,US,US,2022,Q4,Adult
215111481,21511148,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Mucormycosis,,2022,Q4,1,I,,20221019.0,20221027,20221027,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198759",BOEHRINGER INGELHEIM,"Haseeb A, Abu-Rmaileh M, Penfield J, Liu H, Van Buren P, Lederer E. A novel case of renal  Mucormycosis Associated With Empagliflozin Use.",63.0,YR,A,M,Y,,,20221027,,HP,US,US,2022,Q4,Adult
215111481,21511148,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Necrosis,,2022,Q4,1,I,,20221019.0,20221027,20221027,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198759",BOEHRINGER INGELHEIM,"Haseeb A, Abu-Rmaileh M, Penfield J, Liu H, Van Buren P, Lederer E. A novel case of renal  Mucormycosis Associated With Empagliflozin Use.",63.0,YR,A,M,Y,,,20221027,,HP,US,US,2022,Q4,Adult
215147841,21514784,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221018.0,20221027,20221027,EXP,,US-EMD Serono-9359458,EMD SERONO INC,"Malley C, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A, Gramm E. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022 JAN 01;60(SUPPLEMENT 2):47-48.",33.0,YR,A,F,Y,,,20221027,,MD,US,,2022,Q4,Young Adult
215147841,21514784,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Embolic stroke,,2022,Q4,1,I,,20221018.0,20221027,20221027,EXP,,US-EMD Serono-9359458,EMD SERONO INC,"Malley C, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A, Gramm E. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022 JAN 01;60(SUPPLEMENT 2):47-48.",33.0,YR,A,F,Y,,,20221027,,MD,US,,2022,Q4,Young Adult
215147841,21514784,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221018.0,20221027,20221027,EXP,,US-EMD Serono-9359458,EMD SERONO INC,"Malley C, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A, Gramm E. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022 JAN 01;60(SUPPLEMENT 2):47-48.",33.0,YR,A,F,Y,,,20221027,,MD,US,,2022,Q4,Young Adult
215147841,21514784,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221018.0,20221027,20221027,EXP,,US-EMD Serono-9359458,EMD SERONO INC,"Malley C, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A, Gramm E. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022 JAN 01;60(SUPPLEMENT 2):47-48.",33.0,YR,A,F,Y,,,20221027,,MD,US,,2022,Q4,Young Adult
215147841,21514784,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221018.0,20221027,20221027,EXP,,US-EMD Serono-9359458,EMD SERONO INC,"Malley C, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A, Gramm E. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022 JAN 01;60(SUPPLEMENT 2):47-48.",33.0,YR,A,F,Y,,,20221027,,MD,US,,2022,Q4,Young Adult
215147841,21514784,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221018.0,20221027,20221027,EXP,,US-EMD Serono-9359458,EMD SERONO INC,"Malley C, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A, Gramm E. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022 JAN 01;60(SUPPLEMENT 2):47-48.",33.0,YR,A,F,Y,,,20221027,,MD,US,,2022,Q4,Young Adult
215147841,21514784,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Ventricular tachycardia,,2022,Q4,1,I,,20221018.0,20221027,20221027,EXP,,US-EMD Serono-9359458,EMD SERONO INC,"Malley C, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A, Gramm E. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022 JAN 01;60(SUPPLEMENT 2):47-48.",33.0,YR,A,F,Y,,,20221027,,MD,US,,2022,Q4,Young Adult
215147841,21514784,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221018.0,20221027,20221027,EXP,,US-EMD Serono-9359458,EMD SERONO INC,"Malley C, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A, Gramm E. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022 JAN 01;60(SUPPLEMENT 2):47-48.",33.0,YR,A,F,Y,,,20221027,,MD,US,,2022,Q4,Young Adult
215147841,21514784,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221018.0,20221027,20221027,EXP,,US-EMD Serono-9359458,EMD SERONO INC,"Malley C, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A, Gramm E. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022 JAN 01;60(SUPPLEMENT 2):47-48.",33.0,YR,A,F,Y,,,20221027,,MD,US,,2022,Q4,Young Adult
215165551,21516555,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00387,PRINSTON PHARMACEUTICAL,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215165551,21516555,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00387,PRINSTON PHARMACEUTICAL,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215165551,21516555,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00387,PRINSTON PHARMACEUTICAL,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215165551,21516555,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00387,PRINSTON PHARMACEUTICAL,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215165551,21516555,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00387,PRINSTON PHARMACEUTICAL,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215165551,21516555,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00387,PRINSTON PHARMACEUTICAL,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215165551,21516555,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Infarction,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00387,PRINSTON PHARMACEUTICAL,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215165551,21516555,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00387,PRINSTON PHARMACEUTICAL,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215165551,21516555,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00387,PRINSTON PHARMACEUTICAL,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215165551,21516555,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00387,PRINSTON PHARMACEUTICAL,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215165551,21516555,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00387,PRINSTON PHARMACEUTICAL,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215165551,21516555,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00387,PRINSTON PHARMACEUTICAL,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215165551,21516555,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00387,PRINSTON PHARMACEUTICAL,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215165551,21516555,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Infarction,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,US-PRINSTON PHARMACEUTICAL INC.-2022PRN00387,PRINSTON PHARMACEUTICAL,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215165911,21516591,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,"US-VistaPharm, Inc.-VER202210-000895",VISTAPHARM,,33.0,YR,A,F,Y,,,20221028,,HP,US,,2022,Q4,Young Adult
215165911,21516591,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,"US-VistaPharm, Inc.-VER202210-000895",VISTAPHARM,,33.0,YR,A,F,Y,,,20221028,,HP,US,,2022,Q4,Young Adult
215165911,21516591,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221017.0,20221027,20221027,EXP,,"US-VistaPharm, Inc.-VER202210-000895",VISTAPHARM,,33.0,YR,A,F,Y,,,20221028,,HP,US,,2022,Q4,Young Adult
215170231,21517023,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Fournier's gangrene,,2022,Q4,1,I,,20221025.0,20221028,20221028,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199240",BOEHRINGER INGELHEIM,"Jahir T, Hossain S, Bagum M, Saidi A, Risal R, Schmidt M. A Rare but Life-Threatening Case of Fournier^s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin. Cureus. 2022 Sep 17; 14:929264-",58.0,YR,A,F,Y,,,20221028,,MD,US,US,2022,Q4,Adult
215178321,21517832,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,Tablets,,2022,Q4,Condition aggravated,,2022,Q4,1,I,,20221018.0,20221028,20221028,EXP,,DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-22-59272,HIKMA,,60.0,YR,,M,Y,97.0,KG,20221028,,PH,DE,DE,2022,Q4,Adult
215178321,21517832,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,Tablets,,2022,Q4,Product monitoring error,,2022,Q4,1,I,,20221018.0,20221028,20221028,EXP,,DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-22-59272,HIKMA,,60.0,YR,,M,Y,97.0,KG,20221028,,PH,DE,DE,2022,Q4,Adult
215178321,21517832,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,Tablets,,2022,Q4,Cough,,2022,Q4,1,I,,20221018.0,20221028,20221028,EXP,,DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-22-59272,HIKMA,,60.0,YR,,M,Y,97.0,KG,20221028,,PH,DE,DE,2022,Q4,Adult
215178321,21517832,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,Tablets,,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20221018.0,20221028,20221028,EXP,,DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-22-59272,HIKMA,,60.0,YR,,M,Y,97.0,KG,20221028,,PH,DE,DE,2022,Q4,Adult
215198041,21519804,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2022,Q4,Angioedema,,2022,Q4,1,I,20220812.0,,20221027,20221027,DIR,FDA-CDER-CTU-2022-86109,,FDA-CTU,,58.0,YR,,M,N,,,20221021,N,PH,US,,2022,Q4,Adult
215204401,21520440,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Loss of consciousness,,2022,Q4,1,I,20220228.0,20221028.0,20221028,20221028,EXP,GB-MHRA-TPP2420136C32623YC1666109725027,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199972",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,113.0,KG,20221028,,PH,GB,GB,2022,Q4,Adult
215204401,21520440,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Nausea,,2022,Q4,1,I,20220228.0,20221028.0,20221028,20221028,EXP,GB-MHRA-TPP2420136C32623YC1666109725027,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199972",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,113.0,KG,20221028,,PH,GB,GB,2022,Q4,Adult
215204401,21520440,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Cold sweat,,2022,Q4,1,I,20220228.0,20221028.0,20221028,20221028,EXP,GB-MHRA-TPP2420136C32623YC1666109725027,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199972",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,113.0,KG,20221028,,PH,GB,GB,2022,Q4,Adult
215204401,21520440,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Vomiting,,2022,Q4,1,I,20220228.0,20221028.0,20221028,20221028,EXP,GB-MHRA-TPP2420136C32623YC1666109725027,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199972",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,113.0,KG,20221028,,PH,GB,GB,2022,Q4,Adult
215204401,21520440,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Hypoaesthesia,,2022,Q4,1,I,20220228.0,20221028.0,20221028,20221028,EXP,GB-MHRA-TPP2420136C32623YC1666109725027,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199972",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,113.0,KG,20221028,,PH,GB,GB,2022,Q4,Adult
215204401,21520440,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Diarrhoea,,2022,Q4,1,I,20220228.0,20221028.0,20221028,20221028,EXP,GB-MHRA-TPP2420136C32623YC1666109725027,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199972",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,113.0,KG,20221028,,PH,GB,GB,2022,Q4,Adult
215204401,21520440,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Arthralgia,,2022,Q4,1,I,20220228.0,20221028.0,20221028,20221028,EXP,GB-MHRA-TPP2420136C32623YC1666109725027,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199972",BOEHRINGER INGELHEIM,,57.0,YR,A,F,Y,113.0,KG,20221028,,PH,GB,GB,2022,Q4,Adult
215220401,21522040,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,,,,,,12.5,MG,,QD,2022,Q4,Rash,,2022,Q4,1,I,20220909.0,,20221027,20221027,DIR,FDA-CDER-CTU-2022-86150,,FDA-CTU,,71.0,YR,,M,N,,,20221013,N,HP,US,,2022,Q4,Elderly
215220861,21522086,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MBQ,,QD,2022,Q4,Dehydration,,2022,Q4,1,I,20220802.0,,20221027,20221027,DIR,FDA-CDER-CTU-2022-86193,,FDA-CTU,,58.0,YR,,M,N,128.0,KG,20220925,N,PH,US,,2022,Q4,Adult
215220861,21522086,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MBQ,,QD,2022,Q4,Urinary incontinence,,2022,Q4,1,I,20220802.0,,20221027,20221027,DIR,FDA-CDER-CTU-2022-86193,,FDA-CTU,,58.0,YR,,M,N,128.0,KG,20220925,N,PH,US,,2022,Q4,Adult
215220861,21522086,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MBQ,,QD,2022,Q4,Dry mouth,,2022,Q4,1,I,20220802.0,,20221027,20221027,DIR,FDA-CDER-CTU-2022-86193,,FDA-CTU,,58.0,YR,,M,N,128.0,KG,20220925,N,PH,US,,2022,Q4,Adult
215220881,21522088,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,,,,QD,2022,Q4,Urinary tract infection,,2022,Q4,1,I,,,20221027,20221027,DIR,FDA-CDER-CTU-2022-86196,,FDA-CTU,,67.0,YR,,M,N,,,20220924,N,PH,US,,2022,Q4,Elderly
215220941,21522094,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG AM PO?,,,Y,,,,,12.5,MG,,QD,2022,Q4,Pneumonia,,2022,Q4,1,I,20220707.0,,20221027,20221027,DIR,FDA-CDER-CTU-2022-86204,,FDA-CTU,,75.0,YR,,M,N,215.0,KG,20220918,N,HP,US,,2022,Q4,Elderly
215220941,21522094,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG AM PO?,,,Y,,,,,12.5,MG,,QD,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,20220707.0,,20221027,20221027,DIR,FDA-CDER-CTU-2022-86204,,FDA-CTU,,75.0,YR,,M,N,215.0,KG,20220918,N,HP,US,,2022,Q4,Elderly
215220941,21522094,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG AM PO?,,,Y,,,,,12.5,MG,,QD,2022,Q4,Sepsis,,2022,Q4,1,I,20220707.0,,20221027,20221027,DIR,FDA-CDER-CTU-2022-86204,,FDA-CTU,,75.0,YR,,M,N,215.0,KG,20220918,N,HP,US,,2022,Q4,Elderly
215221071,21522107,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,HALF TAB EVERY DAY PO? ,,,,,,,,,,,QD,2022,Q4,Flushing,,2022,Q4,1,I,20220610.0,,20221027,20221027,DIR,FDA-CDER-CTU-2022-86218,,FDA-CTU,,77.0,YR,,M,N,,,20220831,N,HP,US,,2022,Q4,Elderly
215234381,21523438,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 Milligram Daily; 1-0-0-0,,,,,,,,25.0,MG,Tablet,QD,2022,Q4,Melaena,,2022,Q4,1,I,,20221019.0,20221029,20221029,EXP,,DE-TEVA-2021-DE-1893979,TEVA,,67.0,YR,E,M,Y,95.0,KG,20221029,,PH,DE,DE,2022,Q4,Elderly
215234381,21523438,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 Milligram Daily; 1-0-0-0,,,,,,,,25.0,MG,Tablet,QD,2022,Q4,Haematochezia,,2022,Q4,1,I,,20221019.0,20221029,20221029,EXP,,DE-TEVA-2021-DE-1893979,TEVA,,67.0,YR,E,M,Y,95.0,KG,20221029,,PH,DE,DE,2022,Q4,Elderly
215234381,21523438,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 Milligram Daily; 1-0-0-0,,,,,,,,25.0,MG,Tablet,QD,2022,Q4,Diarrhoea,,2022,Q4,1,I,,20221019.0,20221029,20221029,EXP,,DE-TEVA-2021-DE-1893979,TEVA,,67.0,YR,E,M,Y,95.0,KG,20221029,,PH,DE,DE,2022,Q4,Elderly
215234381,21523438,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 Milligram Daily; 1-0-0-0,,,,,,,,25.0,MG,Tablet,QD,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20221019.0,20221029,20221029,EXP,,DE-TEVA-2021-DE-1893979,TEVA,,67.0,YR,E,M,Y,95.0,KG,20221029,,PH,DE,DE,2022,Q4,Elderly
215234381,21523438,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 Milligram Daily; 1-0-0-0,,,,,,,,25.0,MG,Tablet,QD,2022,Q4,Anaemia,,2022,Q4,1,I,,20221019.0,20221029,20221029,EXP,,DE-TEVA-2021-DE-1893979,TEVA,,67.0,YR,E,M,Y,95.0,KG,20221029,,PH,DE,DE,2022,Q4,Elderly
215236131,21523613,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Arthralgia,,2022,Q4,1,I,,20221022.0,20221029,20221029,EXP,CA-MHPD-E2B_05382188,CA-Accord-283824,ACCORD,,69.0,YR,E,,Y,,,20221029,,HP,CA,CA,2022,Q4,Elderly
215236131,21523613,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2022,Q4,Myocardial infarction,,2022,Q4,1,I,,20221022.0,20221029,20221029,EXP,CA-MHPD-E2B_05382188,CA-Accord-283824,ACCORD,,69.0,YR,E,,Y,,,20221029,,HP,CA,CA,2022,Q4,Elderly
215249941,21524994,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;  1-0-0-0,,,,,"UNKNOWN,Unknown",,,10.0,MG,Tablet,QD,2022,Q4,Rectal ulcer,,2022,Q4,1,I,20201001.0,20221020.0,20221030,20221030,EXP,,DE-TEVA-2020-DE-1860792,TEVA,,79.0,YR,E,F,Y,,,20221030,,MD,DE,DE,2022,Q4,Elderly
215249941,21524994,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;  1-0-0-0,,,,,"UNKNOWN,Unknown",,,10.0,MG,Tablet,QD,2022,Q4,Haematochezia,,2022,Q4,1,I,20201001.0,20221020.0,20221030,20221030,EXP,,DE-TEVA-2020-DE-1860792,TEVA,,79.0,YR,E,F,Y,,,20221030,,MD,DE,DE,2022,Q4,Elderly
215271501,21527150,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Ventricular tachycardia,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Embolic cerebellar infarction,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, unknown amount",,,D,,,,,,,,,2022,Q4,Ventricular tachycardia,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, unknown amount",,,D,,,,,,,,,2022,Q4,Embolic cerebellar infarction,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, unknown amount",,,D,,,,,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, unknown amount",,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, unknown amount",,,D,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, unknown amount",,,D,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, unknown amount",,,D,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, unknown amount",,,D,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215271501,21527150,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, unknown amount",,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221024.0,20221031,20221031,EXP,,US-CIPLA LTD.-2022US06327,CIPLA,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47 to 48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215283071,21528307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-GLENMARK PHARMACEUTICALS-2022GMK076092,GLENMARK,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47-48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215283071,21528307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-GLENMARK PHARMACEUTICALS-2022GMK076092,GLENMARK,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47-48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215283071,21528307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Embolic cerebellar infarction,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-GLENMARK PHARMACEUTICALS-2022GMK076092,GLENMARK,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47-48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215283071,21528307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-GLENMARK PHARMACEUTICALS-2022GMK076092,GLENMARK,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47-48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215283071,21528307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-GLENMARK PHARMACEUTICALS-2022GMK076092,GLENMARK,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47-48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215283071,21528307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Drug level increased,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-GLENMARK PHARMACEUTICALS-2022GMK076092,GLENMARK,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47-48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215283071,21528307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-GLENMARK PHARMACEUTICALS-2022GMK076092,GLENMARK,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47-48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215283071,21528307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-GLENMARK PHARMACEUTICALS-2022GMK076092,GLENMARK,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47-48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215283071,21528307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Ventricular tachycardia,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-GLENMARK PHARMACEUTICALS-2022GMK076092,GLENMARK,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47-48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215283071,21528307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-GLENMARK PHARMACEUTICALS-2022GMK076092,GLENMARK,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47-48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215283071,21528307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-GLENMARK PHARMACEUTICALS-2022GMK076092,GLENMARK,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60 (suppl 2):47-48",33.0,YR,,F,Y,,,20221031,,MD,US,US,2022,Q4,Young Adult
215301851,21530185,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-BEXIMCO-2022BEX00063,BEXIMCO PHARMACEUTICALS,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215301851,21530185,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-BEXIMCO-2022BEX00063,BEXIMCO PHARMACEUTICALS,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215301851,21530185,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-BEXIMCO-2022BEX00063,BEXIMCO PHARMACEUTICALS,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215301851,21530185,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-BEXIMCO-2022BEX00063,BEXIMCO PHARMACEUTICALS,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215301851,21530185,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-BEXIMCO-2022BEX00063,BEXIMCO PHARMACEUTICALS,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215301851,21530185,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Infarction,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-BEXIMCO-2022BEX00063,BEXIMCO PHARMACEUTICALS,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215301851,21530185,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-BEXIMCO-2022BEX00063,BEXIMCO PHARMACEUTICALS,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215301851,21530185,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-BEXIMCO-2022BEX00063,BEXIMCO PHARMACEUTICALS,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215301851,21530185,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-BEXIMCO-2022BEX00063,BEXIMCO PHARMACEUTICALS,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215301851,21530185,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-BEXIMCO-2022BEX00063,BEXIMCO PHARMACEUTICALS,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215301851,21530185,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-BEXIMCO-2022BEX00063,BEXIMCO PHARMACEUTICALS,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215301851,21530185,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-BEXIMCO-2022BEX00063,BEXIMCO PHARMACEUTICALS,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215301851,21530185,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Infarction,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-BEXIMCO-2022BEX00063,BEXIMCO PHARMACEUTICALS,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215301851,21530185,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221017.0,20221031,20221031,EXP,,US-BEXIMCO-2022BEX00063,BEXIMCO PHARMACEUTICALS,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60:47-48",33.0,YR,,F,Y,,,20221027,,HP,US,US,2022,Q4,Young Adult
215308241,21530824,1,PS,EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,D,,,,,,,,2022,Q4,Dizziness,,2022,Q4,1,I,20220401.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86610,,FDA-CTU,,69.0,YR,,M,N,,,20221027,N,PH,US,,2022,Q4,Elderly
215308241,21530824,1,PS,EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,D,,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,20220401.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86610,,FDA-CTU,,69.0,YR,,M,N,,,20221027,N,PH,US,,2022,Q4,Elderly
215308241,21530824,1,PS,EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,D,,,,,,,,2022,Q4,Blood urea increased,,2022,Q4,1,I,20220401.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86610,,FDA-CTU,,69.0,YR,,M,N,,,20221027,N,PH,US,,2022,Q4,Elderly
215308241,21530824,1,PS,EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,D,,,,,,,,2022,Q4,Blood creatinine increased,,2022,Q4,1,I,20220401.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86610,,FDA-CTU,,69.0,YR,,M,N,,,20221027,N,PH,US,,2022,Q4,Elderly
215308241,21530824,1,PS,EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,D,,,,,,,,2022,Q4,Asthenia,,2022,Q4,1,I,20220401.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86610,,FDA-CTU,,69.0,YR,,M,N,,,20221027,N,PH,US,,2022,Q4,Elderly
215308241,21530824,1,PS,EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,D,,,,,,,,2022,Q4,Renal disorder,,2022,Q4,1,I,20220401.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86610,,FDA-CTU,,69.0,YR,,M,N,,,20221027,N,PH,US,,2022,Q4,Elderly
215308241,21530824,1,PS,EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,D,,,,,,,,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,1,I,20220401.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86610,,FDA-CTU,,69.0,YR,,M,N,,,20221027,N,PH,US,,2022,Q4,Elderly
215312301,21531230,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER FREQUENCY : AM;?,,,,,,,,12.5,MG,,999,2022,Q4,Sepsis,,2022,Q4,1,I,20220917.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86628,,FDA-CTU,,48.0,YR,,M,N,85.0,KG,20221026,N,PH,US,,2022,Q4,Adult
215312301,21531230,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER FREQUENCY : AM;?,,,,,,,,12.5,MG,,999,2022,Q4,Urinary tract infection,,2022,Q4,1,I,20220917.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86628,,FDA-CTU,,48.0,YR,,M,N,85.0,KG,20221026,N,PH,US,,2022,Q4,Adult
215312301,21531230,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,OTHER FREQUENCY : AM;?,,,,,,,,12.5,MG,,999,2022,Q4,Haematuria,,2022,Q4,1,I,20220917.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86628,,FDA-CTU,,48.0,YR,,M,N,85.0,KG,20221026,N,PH,US,,2022,Q4,Adult
215312391,21531239,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Hypotension,,2022,Q4,1,I,20220811.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86635,,FDA-CTU,,64.0,YR,,M,N,,,20221021,N,HP,US,,2022,Q4,Adult
215312391,21531239,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Renal disorder,,2022,Q4,1,I,20220811.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86635,,FDA-CTU,,64.0,YR,,M,N,,,20221021,N,HP,US,,2022,Q4,Adult
215312391,21531239,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Orthostatic hypotension,,2022,Q4,1,I,20220811.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86635,,FDA-CTU,,64.0,YR,,M,N,,,20221021,N,HP,US,,2022,Q4,Adult
215312391,21531239,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20220811.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86635,,FDA-CTU,,64.0,YR,,M,N,,,20221021,N,HP,US,,2022,Q4,Adult
215312521,21531252,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2022,Q4,Hypoglycaemia,,2022,Q4,1,I,20220304.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86668,,FDA-CTU,,73.0,YR,,M,N,125.19,KG,20220819,N,PH,US,,2022,Q4,Elderly
215312521,21531252,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2022,Q4,Hypotension,,2022,Q4,1,I,20220304.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86668,,FDA-CTU,,73.0,YR,,M,N,125.19,KG,20220819,N,PH,US,,2022,Q4,Elderly
215313361,21531336,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2022,Q4,Blood urine present,,2022,Q4,1,I,20220721.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86675,,FDA-CTU,,69.0,YR,,M,N,82.0,KG,20220818,N,PH,US,,2022,Q4,Elderly
215313361,21531336,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2022,Q4,Dehydration,,2022,Q4,1,I,20220721.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86675,,FDA-CTU,,69.0,YR,,M,N,82.0,KG,20220818,N,PH,US,,2022,Q4,Elderly
215313551,21531355,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,,,Tablet,QD,2022,Q4,Perineal abscess,,2022,Q4,1,I,20220511.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86705,,FDA-CTU,,72.0,YR,,M,N,151.0,KG,20220630,N,PH,US,,2022,Q4,Elderly
215313591,21531359,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,,,,,12.5,MG,,QD,2022,Q4,Sepsis,,2022,Q4,1,I,20220504.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86713,,FDA-CTU,,60.0,YR,,M,N,154.0,KG,20220622,N,PH,US,,2022,Q4,Adult
215313591,21531359,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,,,,,12.5,MG,,QD,2022,Q4,Cellulitis,,2022,Q4,1,I,20220504.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86713,,FDA-CTU,,60.0,YR,,M,N,154.0,KG,20220622,N,PH,US,,2022,Q4,Adult
215313591,21531359,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,,,,,12.5,MG,,QD,2022,Q4,Urinary tract infection,,2022,Q4,1,I,20220504.0,,20221028,20221028,DIR,FDA-CDER-CTU-2022-86713,,FDA-CTU,,60.0,YR,,M,N,154.0,KG,20220622,N,PH,US,,2022,Q4,Adult
215319371,21531937,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,UNKNOWN,,,,,Unknown,,2022,Q4,Embolic cerebral infarction,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202210-001127,UNICHEM,,33.0,YR,A,F,Y,,,20221031,,HP,US,,2022,Q4,Young Adult
215319371,21531937,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,UNKNOWN,,,,,Unknown,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202210-001127,UNICHEM,,33.0,YR,A,F,Y,,,20221031,,HP,US,,2022,Q4,Young Adult
215319371,21531937,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,UNKNOWN,,,,,Unknown,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202210-001127,UNICHEM,,33.0,YR,A,F,Y,,,20221031,,HP,US,,2022,Q4,Young Adult
215319371,21531937,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,UNKNOWN,,,,,Unknown,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202210-001127,UNICHEM,,33.0,YR,A,F,Y,,,20221031,,HP,US,,2022,Q4,Young Adult
215319371,21531937,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,UNKNOWN,,,,,Unknown,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202210-001127,UNICHEM,,33.0,YR,A,F,Y,,,20221031,,HP,US,,2022,Q4,Young Adult
215319371,21531937,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,UNKNOWN,,,,,Unknown,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202210-001127,UNICHEM,,33.0,YR,A,F,Y,,,20221031,,HP,US,,2022,Q4,Young Adult
215319371,21531937,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,UNKNOWN,,,,,Unknown,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202210-001127,UNICHEM,,33.0,YR,A,F,Y,,,20221031,,HP,US,,2022,Q4,Young Adult
215319371,21531937,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,UNKNOWN,,,,,Unknown,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202210-001127,UNICHEM,,33.0,YR,A,F,Y,,,20221031,,HP,US,,2022,Q4,Young Adult
215319371,21531937,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,Unknown,,,,,UNKNOWN,,,,,Unknown,,2022,Q4,Blood lactic acid increased,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Unichem Pharmaceuticals (USA) Inc-UCM202210-001127,UNICHEM,,33.0,YR,A,F,Y,,,20221031,,HP,US,,2022,Q4,Young Adult
215327211,21532721,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Ajanta Pharma USA Inc.-2134339,AJANTA PHARMA,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology 2022;60: 47-48. DOI: 10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221101,,HP,US,US,2022,Q4,Young Adult
215327211,21532721,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Ajanta Pharma USA Inc.-2134339,AJANTA PHARMA,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology 2022;60: 47-48. DOI: 10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221101,,HP,US,US,2022,Q4,Young Adult
215327211,21532721,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Ajanta Pharma USA Inc.-2134339,AJANTA PHARMA,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology 2022;60: 47-48. DOI: 10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221101,,HP,US,US,2022,Q4,Young Adult
215327211,21532721,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Ajanta Pharma USA Inc.-2134339,AJANTA PHARMA,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology 2022;60: 47-48. DOI: 10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221101,,HP,US,US,2022,Q4,Young Adult
215327211,21532721,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Ajanta Pharma USA Inc.-2134339,AJANTA PHARMA,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology 2022;60: 47-48. DOI: 10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221101,,HP,US,US,2022,Q4,Young Adult
215327211,21532721,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Ajanta Pharma USA Inc.-2134339,AJANTA PHARMA,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology 2022;60: 47-48. DOI: 10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221101,,HP,US,US,2022,Q4,Young Adult
215327211,21532721,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Infarction,,2022,Q4,1,I,,20221017.0,20221101,20221101,EXP,,US-Ajanta Pharma USA Inc.-2134339,AJANTA PHARMA,"Malley C. Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology 2022;60: 47-48. DOI: 10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221101,,HP,US,US,2022,Q4,Young Adult
215349701,21534970,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Atrioventricular block,,2022,Q4,1,I,20220914.0,20221027.0,20221101,20221101,EXP,,NVSC2022GB242426,NOVARTIS,,63.0,YR,,F,Y,,,20221101,,HP,GB,GB,2022,Q4,Adult
215366621,21536662,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Haemoglobin increased,,2022,Q4,1,I,,20221026.0,20221101,20221101,EXP,,CA-PFIZER INC-202201260875,PFIZER,,70.0,YR,,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Elderly
215366621,21536662,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Injection site pain,,2022,Q4,1,I,,20221026.0,20221101,20221101,EXP,,CA-PFIZER INC-202201260875,PFIZER,,70.0,YR,,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Elderly
215366621,21536662,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Proctalgia,,2022,Q4,1,I,,20221026.0,20221101,20221101,EXP,,CA-PFIZER INC-202201260875,PFIZER,,70.0,YR,,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Elderly
215366621,21536662,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Discomfort,,2022,Q4,1,I,,20221026.0,20221101,20221101,EXP,,CA-PFIZER INC-202201260875,PFIZER,,70.0,YR,,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Elderly
215366621,21536662,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Constipation,,2022,Q4,1,I,,20221026.0,20221101,20221101,EXP,,CA-PFIZER INC-202201260875,PFIZER,,70.0,YR,,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Elderly
215366621,21536662,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Blood pressure increased,,2022,Q4,1,I,,20221026.0,20221101,20221101,EXP,,CA-PFIZER INC-202201260875,PFIZER,,70.0,YR,,M,Y,,,20221101,,HP,CA,CA,2022,Q4,Elderly
215397031,21539703,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Myocardial infarction,,2022,Q4,1,I,20221005.0,20221025.0,20221102,20221102,PER,,SA-AMGEN-SAUSP2022183964,AMGEN,,52.0,YR,A,M,Y,,,20221102,,CN,SA,SA,2022,Q4,Adult
215408451,21540845,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,UNKNOWN,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221024.0,20221102,20221102,EXP,,US-drreddys-SPO/USA/22/0156581,DR REDDYS,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60(2):47-8. doi:10.1080/15563650.2022.2107776",33.0,YR,A,F,Y,,,20221102,,MD,US,US,2022,Q4,Young Adult
215408451,21540845,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,UNKNOWN,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221024.0,20221102,20221102,EXP,,US-drreddys-SPO/USA/22/0156581,DR REDDYS,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60(2):47-8. doi:10.1080/15563650.2022.2107776",33.0,YR,A,F,Y,,,20221102,,MD,US,US,2022,Q4,Young Adult
215408451,21540845,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,UNKNOWN,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221024.0,20221102,20221102,EXP,,US-drreddys-SPO/USA/22/0156581,DR REDDYS,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60(2):47-8. doi:10.1080/15563650.2022.2107776",33.0,YR,A,F,Y,,,20221102,,MD,US,US,2022,Q4,Young Adult
215408451,21540845,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,UNKNOWN,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221024.0,20221102,20221102,EXP,,US-drreddys-SPO/USA/22/0156581,DR REDDYS,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60(2):47-8. doi:10.1080/15563650.2022.2107776",33.0,YR,A,F,Y,,,20221102,,MD,US,US,2022,Q4,Young Adult
215408451,21540845,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,UNKNOWN,,,,,,,2022,Q4,Ventricular tachycardia,,2022,Q4,1,I,,20221024.0,20221102,20221102,EXP,,US-drreddys-SPO/USA/22/0156581,DR REDDYS,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60(2):47-8. doi:10.1080/15563650.2022.2107776",33.0,YR,A,F,Y,,,20221102,,MD,US,US,2022,Q4,Young Adult
215408451,21540845,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,UNKNOWN,,,,,,,2022,Q4,Embolic cerebellar infarction,,2022,Q4,1,I,,20221024.0,20221102,20221102,EXP,,US-drreddys-SPO/USA/22/0156581,DR REDDYS,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60(2):47-8. doi:10.1080/15563650.2022.2107776",33.0,YR,A,F,Y,,,20221102,,MD,US,US,2022,Q4,Young Adult
215408451,21540845,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,UNKNOWN,,,,,,,2022,Q4,Drug level increased,,2022,Q4,1,I,,20221024.0,20221102,20221102,EXP,,US-drreddys-SPO/USA/22/0156581,DR REDDYS,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60(2):47-8. doi:10.1080/15563650.2022.2107776",33.0,YR,A,F,Y,,,20221102,,MD,US,US,2022,Q4,Young Adult
215408451,21540845,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,UNKNOWN,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221024.0,20221102,20221102,EXP,,US-drreddys-SPO/USA/22/0156581,DR REDDYS,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60(2):47-8. doi:10.1080/15563650.2022.2107776",33.0,YR,A,F,Y,,,20221102,,MD,US,US,2022,Q4,Young Adult
215408451,21540845,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,UNKNOWN,,,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,1,I,,20221024.0,20221102,20221102,EXP,,US-drreddys-SPO/USA/22/0156581,DR REDDYS,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60(2):47-8. doi:10.1080/15563650.2022.2107776",33.0,YR,A,F,Y,,,20221102,,MD,US,US,2022,Q4,Young Adult
215408451,21540845,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,UNKNOWN,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221024.0,20221102,20221102,EXP,,US-drreddys-SPO/USA/22/0156581,DR REDDYS,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60(2):47-8. doi:10.1080/15563650.2022.2107776",33.0,YR,A,F,Y,,,20221102,,MD,US,US,2022,Q4,Young Adult
215408451,21540845,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,UNKNOWN,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221024.0,20221102,20221102,EXP,,US-drreddys-SPO/USA/22/0156581,DR REDDYS,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol. 2022;60(2):47-8. doi:10.1080/15563650.2022.2107776",33.0,YR,A,F,Y,,,20221102,,MD,US,US,2022,Q4,Young Adult
215413022,21541302,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5/500mg,,,Y,,Unknown,,206111.0,,,Tablet,QD,2022,Q4,Vulvovaginal pruritus,,2022,Q4,2,F,20221001.0,20221031.0,20221102,20221107,EXP,,"KR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199638",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,61.5,KG,20221107,,CN,KR,KR,2022,Q4,Adult
215413022,21541302,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5/500mg,,,Y,,Unknown,,206111.0,,,Tablet,QD,2022,Q4,Vulvovaginal pain,,2022,Q4,2,F,20221001.0,20221031.0,20221102,20221107,EXP,,"KR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199638",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,61.5,KG,20221107,,CN,KR,KR,2022,Q4,Adult
215413022,21541302,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5/500mg,,,Y,,Unknown,,206111.0,,,Tablet,QD,2022,Q4,Vulval disorder,,2022,Q4,2,F,20221001.0,20221031.0,20221102,20221107,EXP,,"KR-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199638",BOEHRINGER INGELHEIM,,64.0,YR,A,F,Y,61.5,KG,20221107,,CN,KR,KR,2022,Q4,Adult
215424741,21542474,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Pain,,2022,Q4,1,I,,20221026.0,20221102,20221102,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199709",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,,,20221102,,CN,CA,CA,2022,Q4,Adult
215424741,21542474,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Discomfort,,2022,Q4,1,I,,20221026.0,20221102,20221102,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199709",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,,,20221102,,CN,CA,CA,2022,Q4,Adult
215424741,21542474,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Ankylosing spondylitis,,2022,Q4,1,I,,20221026.0,20221102,20221102,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199709",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,,,20221102,,CN,CA,CA,2022,Q4,Adult
215427012,21542701,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,25.0,MG,Unknown,QD,2022,Q4,Psoas abscess,,2022,Q4,2,F,20221010.0,20221124.0,20221102,20221129,EXP,,NO-BRISTOL-MYERS SQUIBB COMPANY-2022-129877,BRISTOL MYERS SQUIBB,,70.0,YR,E,F,Y,66.0,KG,20221129,,HP,NO,NO,2022,Q4,Elderly
215427012,21542701,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,25.0,MG,Unknown,QD,2022,Q4,Concussion,,2022,Q4,2,F,20221010.0,20221124.0,20221102,20221129,EXP,,NO-BRISTOL-MYERS SQUIBB COMPANY-2022-129877,BRISTOL MYERS SQUIBB,,70.0,YR,E,F,Y,66.0,KG,20221129,,HP,NO,NO,2022,Q4,Elderly
215452152,21545215,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,2,F,,20221114.0,20221103,20221128,EXP,,US-AUROBINDO-AUR-APL-2022-045770,AUROBINDO,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(suppl. 2):47-48",33.0,YR,,F,Y,,,20221128,,MD,US,US,2022,Q4,Young Adult
215452152,21545215,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,2,F,,20221114.0,20221103,20221128,EXP,,US-AUROBINDO-AUR-APL-2022-045770,AUROBINDO,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(suppl. 2):47-48",33.0,YR,,F,Y,,,20221128,,MD,US,US,2022,Q4,Young Adult
215452152,21545215,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Ventricular tachycardia,,2022,Q4,2,F,,20221114.0,20221103,20221128,EXP,,US-AUROBINDO-AUR-APL-2022-045770,AUROBINDO,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(suppl. 2):47-48",33.0,YR,,F,Y,,,20221128,,MD,US,US,2022,Q4,Young Adult
215452152,21545215,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,2,F,,20221114.0,20221103,20221128,EXP,,US-AUROBINDO-AUR-APL-2022-045770,AUROBINDO,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(suppl. 2):47-48",33.0,YR,,F,Y,,,20221128,,MD,US,US,2022,Q4,Young Adult
215452152,21545215,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,2,F,,20221114.0,20221103,20221128,EXP,,US-AUROBINDO-AUR-APL-2022-045770,AUROBINDO,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(suppl. 2):47-48",33.0,YR,,F,Y,,,20221128,,MD,US,US,2022,Q4,Young Adult
215452152,21545215,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,2,F,,20221114.0,20221103,20221128,EXP,,US-AUROBINDO-AUR-APL-2022-045770,AUROBINDO,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(suppl. 2):47-48",33.0,YR,,F,Y,,,20221128,,MD,US,US,2022,Q4,Young Adult
215452152,21545215,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Drug level increased,,2022,Q4,2,F,,20221114.0,20221103,20221128,EXP,,US-AUROBINDO-AUR-APL-2022-045770,AUROBINDO,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(suppl. 2):47-48",33.0,YR,,F,Y,,,20221128,,MD,US,US,2022,Q4,Young Adult
215452152,21545215,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,2,F,,20221114.0,20221103,20221128,EXP,,US-AUROBINDO-AUR-APL-2022-045770,AUROBINDO,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(suppl. 2):47-48",33.0,YR,,F,Y,,,20221128,,MD,US,US,2022,Q4,Young Adult
215452152,21545215,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,2,F,,20221114.0,20221103,20221128,EXP,,US-AUROBINDO-AUR-APL-2022-045770,AUROBINDO,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(suppl. 2):47-48",33.0,YR,,F,Y,,,20221128,,MD,US,US,2022,Q4,Young Adult
215452152,21545215,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Embolic cerebellar infarction,,2022,Q4,2,F,,20221114.0,20221103,20221128,EXP,,US-AUROBINDO-AUR-APL-2022-045770,AUROBINDO,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(suppl. 2):47-48",33.0,YR,,F,Y,,,20221128,,MD,US,US,2022,Q4,Young Adult
215452152,21545215,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,2,F,,20221114.0,20221103,20221128,EXP,,US-AUROBINDO-AUR-APL-2022-045770,AUROBINDO,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(suppl. 2):47-48",33.0,YR,,F,Y,,,20221128,,MD,US,US,2022,Q4,Young Adult
215468361,21546836,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221024.0,20221103,20221103,EXP,,US-BAUSCH-BL-2022-024248,BAUSCH AND LOMB,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(SUPPLEMENT 2):47-48. doi:10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221103,,HP,US,US,2022,Q4,Young Adult
215468361,21546836,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221024.0,20221103,20221103,EXP,,US-BAUSCH-BL-2022-024248,BAUSCH AND LOMB,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(SUPPLEMENT 2):47-48. doi:10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221103,,HP,US,US,2022,Q4,Young Adult
215468361,21546836,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221024.0,20221103,20221103,EXP,,US-BAUSCH-BL-2022-024248,BAUSCH AND LOMB,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(SUPPLEMENT 2):47-48. doi:10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221103,,HP,US,US,2022,Q4,Young Adult
215468361,21546836,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,1,I,,20221024.0,20221103,20221103,EXP,,US-BAUSCH-BL-2022-024248,BAUSCH AND LOMB,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(SUPPLEMENT 2):47-48. doi:10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221103,,HP,US,US,2022,Q4,Young Adult
215468361,21546836,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Embolic cerebral infarction,,2022,Q4,1,I,,20221024.0,20221103,20221103,EXP,,US-BAUSCH-BL-2022-024248,BAUSCH AND LOMB,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(SUPPLEMENT 2):47-48. doi:10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221103,,HP,US,US,2022,Q4,Young Adult
215468361,21546836,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221024.0,20221103,20221103,EXP,,US-BAUSCH-BL-2022-024248,BAUSCH AND LOMB,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(SUPPLEMENT 2):47-48. doi:10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221103,,HP,US,US,2022,Q4,Young Adult
215468361,21546836,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221024.0,20221103,20221103,EXP,,US-BAUSCH-BL-2022-024248,BAUSCH AND LOMB,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(SUPPLEMENT 2):47-48. doi:10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221103,,HP,US,US,2022,Q4,Young Adult
215468361,21546836,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221024.0,20221103,20221103,EXP,,US-BAUSCH-BL-2022-024248,BAUSCH AND LOMB,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(SUPPLEMENT 2):47-48. doi:10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221103,,HP,US,US,2022,Q4,Young Adult
215484321,21548432,8,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,25.0,MG,,,2022,Q4,Hepatic lesion,,2022,Q4,1,I,20221028.0,20221028.0,20221103,20221103,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-129885,BRISTOL MYERS SQUIBB,,70.0,YR,E,M,Y,67.13,KG,20221103,,PH,US,US,2022,Q4,Elderly
215510181,21551018,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Pathological fracture,,2022,Q4,1,I,,20221025.0,20221103,20221103,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199523",BOEHRINGER INGELHEIM,"Nadeau A, Bullis E, Macarthur K. Osteomyelitis pubis after initiation of an SGLT2 inhibitor. Annals of internal medicine clinical cases. 2022 Oct 18;",63.0,YR,A,F,Y,,,20221103,,MD,US,US,2022,Q4,Adult
215510181,21551018,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Arthritis bacterial,,2022,Q4,1,I,,20221025.0,20221103,20221103,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199523",BOEHRINGER INGELHEIM,"Nadeau A, Bullis E, Macarthur K. Osteomyelitis pubis after initiation of an SGLT2 inhibitor. Annals of internal medicine clinical cases. 2022 Oct 18;",63.0,YR,A,F,Y,,,20221103,,MD,US,US,2022,Q4,Adult
215510181,21551018,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Oedema,,2022,Q4,1,I,,20221025.0,20221103,20221103,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199523",BOEHRINGER INGELHEIM,"Nadeau A, Bullis E, Macarthur K. Osteomyelitis pubis after initiation of an SGLT2 inhibitor. Annals of internal medicine clinical cases. 2022 Oct 18;",63.0,YR,A,F,Y,,,20221103,,MD,US,US,2022,Q4,Adult
215510181,21551018,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Osteomyelitis,,2022,Q4,1,I,,20221025.0,20221103,20221103,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-199523",BOEHRINGER INGELHEIM,"Nadeau A, Bullis E, Macarthur K. Osteomyelitis pubis after initiation of an SGLT2 inhibitor. Annals of internal medicine clinical cases. 2022 Oct 18;",63.0,YR,A,F,Y,,,20221103,,MD,US,US,2022,Q4,Adult
215517871,21551787,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Acute myeloid leukaemia,,2022,Q4,1,I,20220705.0,20221101.0,20221104,20221104,EXP,,IL-ABBVIE-4186828,ABBVIE,,78.0,YR,,M,Y,98.0,KG,20221104,,MD,IL,IL,2022,Q4,Elderly
215517871,21551787,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Acute myeloid leukaemia recurrent,,2022,Q4,1,I,20220705.0,20221101.0,20221104,20221104,EXP,,IL-ABBVIE-4186828,ABBVIE,,78.0,YR,,M,Y,98.0,KG,20221104,,MD,IL,IL,2022,Q4,Elderly
215523171,21552317,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Atrioventricular block,,2022,Q4,1,I,20220914.0,20221027.0,20221104,20221104,EXP,,GB-AUROBINDO-AUR-APL-2022-046363,AUROBINDO,,63.0,YR,,F,Y,,,20221104,,HP,GB,GB,2022,Q4,Adult
215539331,21553933,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Somnolence,,2022,Q4,1,I,20220404.0,20220603.0,20221104,20221104,PER,,US-Accord-265889,ACCORD,,58.0,YR,,M,Y,115.67,KG,20221104,,CN,US,US,2022,Q4,Adult
215539331,21553933,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Constipation,,2022,Q4,1,I,20220404.0,20220603.0,20221104,20221104,PER,,US-Accord-265889,ACCORD,,58.0,YR,,M,Y,115.67,KG,20221104,,CN,US,US,2022,Q4,Adult
215539331,21553933,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Weight increased,,2022,Q4,1,I,20220404.0,20220603.0,20221104,20221104,PER,,US-Accord-265889,ACCORD,,58.0,YR,,M,Y,115.67,KG,20221104,,CN,US,US,2022,Q4,Adult
215539331,21553933,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Feeling jittery,,2022,Q4,1,I,20220404.0,20220603.0,20221104,20221104,PER,,US-Accord-265889,ACCORD,,58.0,YR,,M,Y,115.67,KG,20221104,,CN,US,US,2022,Q4,Adult
215539331,21553933,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Headache,,2022,Q4,1,I,20220404.0,20220603.0,20221104,20221104,PER,,US-Accord-265889,ACCORD,,58.0,YR,,M,Y,115.67,KG,20221104,,CN,US,US,2022,Q4,Adult
215539331,21553933,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Nausea,,2022,Q4,1,I,20220404.0,20220603.0,20221104,20221104,PER,,US-Accord-265889,ACCORD,,58.0,YR,,M,Y,115.67,KG,20221104,,CN,US,US,2022,Q4,Adult
215539331,21553933,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Dizziness,,2022,Q4,1,I,20220404.0,20220603.0,20221104,20221104,PER,,US-Accord-265889,ACCORD,,58.0,YR,,M,Y,115.67,KG,20221104,,CN,US,US,2022,Q4,Adult
215539331,21553933,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Peripheral swelling,,2022,Q4,1,I,20220404.0,20220603.0,20221104,20221104,PER,,US-Accord-265889,ACCORD,,58.0,YR,,M,Y,115.67,KG,20221104,,CN,US,US,2022,Q4,Adult
215539401,21553940,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Peripheral swelling,,2022,Q4,1,I,20220404.0,20220621.0,20221104,20221104,PER,,US-Accord-267604,ACCORD,,58.0,YR,,M,Y,115.6,KG,20221104,,CN,US,US,2022,Q4,Adult
215539401,21553940,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Somnolence,,2022,Q4,1,I,20220404.0,20220621.0,20221104,20221104,PER,,US-Accord-267604,ACCORD,,58.0,YR,,M,Y,115.6,KG,20221104,,CN,US,US,2022,Q4,Adult
215539401,21553940,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Insomnia,,2022,Q4,1,I,20220404.0,20220621.0,20221104,20221104,PER,,US-Accord-267604,ACCORD,,58.0,YR,,M,Y,115.6,KG,20221104,,CN,US,US,2022,Q4,Adult
215539401,21553940,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Weight increased,,2022,Q4,1,I,20220404.0,20220621.0,20221104,20221104,PER,,US-Accord-267604,ACCORD,,58.0,YR,,M,Y,115.6,KG,20221104,,CN,US,US,2022,Q4,Adult
215539401,21553940,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Constipation,,2022,Q4,1,I,20220404.0,20220621.0,20221104,20221104,PER,,US-Accord-267604,ACCORD,,58.0,YR,,M,Y,115.6,KG,20221104,,CN,US,US,2022,Q4,Adult
215539401,21553940,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Dizziness,,2022,Q4,1,I,20220404.0,20220621.0,20221104,20221104,PER,,US-Accord-267604,ACCORD,,58.0,YR,,M,Y,115.6,KG,20221104,,CN,US,US,2022,Q4,Adult
215539401,21553940,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Headache,,2022,Q4,1,I,20220404.0,20220621.0,20221104,20221104,PER,,US-Accord-267604,ACCORD,,58.0,YR,,M,Y,115.6,KG,20221104,,CN,US,US,2022,Q4,Adult
215539401,21553940,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Nausea,,2022,Q4,1,I,20220404.0,20220621.0,20221104,20221104,PER,,US-Accord-267604,ACCORD,,58.0,YR,,M,Y,115.6,KG,20221104,,CN,US,US,2022,Q4,Adult
215539401,21553940,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Blood pressure increased,,2022,Q4,1,I,20220404.0,20220621.0,20221104,20221104,PER,,US-Accord-267604,ACCORD,,58.0,YR,,M,Y,115.6,KG,20221104,,CN,US,US,2022,Q4,Adult
215539401,21553940,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Drug interaction,,2022,Q4,1,I,20220404.0,20220621.0,20221104,20221104,PER,,US-Accord-267604,ACCORD,,58.0,YR,,M,Y,115.6,KG,20221104,,CN,US,US,2022,Q4,Adult
215539401,21553940,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Feeling jittery,,2022,Q4,1,I,20220404.0,20220621.0,20221104,20221104,PER,,US-Accord-267604,ACCORD,,58.0,YR,,M,Y,115.6,KG,20221104,,CN,US,US,2022,Q4,Adult
215539401,21553940,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Palpitations,,2022,Q4,1,I,20220404.0,20220621.0,20221104,20221104,PER,,US-Accord-267604,ACCORD,,58.0,YR,,M,Y,115.6,KG,20221104,,CN,US,US,2022,Q4,Adult
215539401,21553940,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Muscle spasms,,2022,Q4,1,I,20220404.0,20220621.0,20221104,20221104,PER,,US-Accord-267604,ACCORD,,58.0,YR,,M,Y,115.6,KG,20221104,,CN,US,US,2022,Q4,Adult
215543771,21554377,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Death,,2022,Q4,1,I,,20221103.0,20221104,20221104,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-200913",BOEHRINGER INGELHEIM,,9.0,DEC,E,M,Y,,,20221104,,HP,GB,GB,2022,Q4,Child
215543771,21554377,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Ketoacidosis,,2022,Q4,1,I,,20221103.0,20221104,20221104,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-200913",BOEHRINGER INGELHEIM,,9.0,DEC,E,M,Y,,,20221104,,HP,GB,GB,2022,Q4,Child
215548161,21554816,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Drug level increased,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Embolic cerebellar infarction,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Ventricular tachycardia,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Drug level increased,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Embolic cerebellar infarction,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Ventricular tachycardia,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215548161,21554816,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,unknown amount,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221024.0,20221104,20221104,EXP,,US-Accord-284370,ACCORD,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(supplement 2):47-8",33.0,YR,A,F,Y,,,20221104,,MD,US,US,2022,Q4,Young Adult
215549631,21554963,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Polycythaemia vera,,2022,Q4,1,I,20221019.0,20221101.0,20221104,20221104,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-200593",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20221104,,HP,SG,SG,2022,Q4,Elderly
215576671,21557667,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Drug intolerance,,2022,Q4,1,I,,20221014.0,20221106,20221106,PER,,US-ORGANON-O2210USA001182,ORGANON,"Shekar P, Dipollina C, Roeuth DD. NEW-ONSET ACUTE DECOMPENSATED HEART FAILURE IN A PATIENT WITH ADVANCED PULMONARY SARCOIDOSIS, INACTIVE CARDIAC SARCOIDOSIS, AND INHERITED TTN GENE MUTATION. Chest. 2022;162(4):214A",61.0,YR,,F,Y,,,20221106,,HP,US,US,2022,Q4,Adult
215618081,21561808,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,U,,,,,10.0,MG,,,2022,Q4,Pain,,2022,Q4,1,I,,20221031.0,20221107,20221107,EXP,,CA-APOTEX-2022AP014959,APOTEX,,58.0,YR,,M,Y,,,20221107,,HP,CA,CA,2022,Q4,Adult
215618081,21561808,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,U,,,,,10.0,MG,,,2022,Q4,Discomfort,,2022,Q4,1,I,,20221031.0,20221107,20221107,EXP,,CA-APOTEX-2022AP014959,APOTEX,,58.0,YR,,M,Y,,,20221107,,HP,CA,CA,2022,Q4,Adult
215618081,21561808,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd",,,U,,,,,10.0,MG,,,2022,Q4,Ankylosing spondylitis,,2022,Q4,1,I,,20221031.0,20221107,20221107,EXP,,CA-APOTEX-2022AP014959,APOTEX,,58.0,YR,,M,Y,,,20221107,,HP,CA,CA,2022,Q4,Adult
215648151,21564815,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20221029.0,20221108,20221108,EXP,,DE-drreddys-SPO/GER/22/0156724,DR REDDYS,,54.0,YR,A,M,Y,98.0,KG,20221108,,PH,DE,DE,2022,Q4,Adult
215648151,21564815,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Condition aggravated,,2022,Q4,1,I,,20221029.0,20221108,20221108,EXP,,DE-drreddys-SPO/GER/22/0156724,DR REDDYS,,54.0,YR,A,M,Y,98.0,KG,20221108,,PH,DE,DE,2022,Q4,Adult
215648151,21564815,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Systemic infection,,2022,Q4,1,I,,20221029.0,20221108,20221108,EXP,,DE-drreddys-SPO/GER/22/0156724,DR REDDYS,,54.0,YR,A,M,Y,98.0,KG,20221108,,PH,DE,DE,2022,Q4,Adult
215648151,21564815,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Labelled drug-drug interaction medication error,,2022,Q4,1,I,,20221029.0,20221108,20221108,EXP,,DE-drreddys-SPO/GER/22/0156724,DR REDDYS,,54.0,YR,A,M,Y,98.0,KG,20221108,,PH,DE,DE,2022,Q4,Adult
215648151,21564815,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20221029.0,20221108,20221108,EXP,,DE-drreddys-SPO/GER/22/0156724,DR REDDYS,,54.0,YR,A,M,Y,98.0,KG,20221108,,PH,DE,DE,2022,Q4,Adult
215648151,21564815,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Polyneuropathy,,2022,Q4,1,I,,20221029.0,20221108,20221108,EXP,,DE-drreddys-SPO/GER/22/0156724,DR REDDYS,,54.0,YR,A,M,Y,98.0,KG,20221108,,PH,DE,DE,2022,Q4,Adult
215648151,21564815,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Electrocardiogram abnormal,,2022,Q4,1,I,,20221029.0,20221108,20221108,EXP,,DE-drreddys-SPO/GER/22/0156724,DR REDDYS,,54.0,YR,A,M,Y,98.0,KG,20221108,,PH,DE,DE,2022,Q4,Adult
215648151,21564815,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Chest pain,,2022,Q4,1,I,,20221029.0,20221108,20221108,EXP,,DE-drreddys-SPO/GER/22/0156724,DR REDDYS,,54.0,YR,A,M,Y,98.0,KG,20221108,,PH,DE,DE,2022,Q4,Adult
215648331,21564833,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Tachycardia,,2022,Q4,1,I,,20221029.0,20221108,20221108,EXP,,DE-drreddys-SPO/GER/22/0156738,DR REDDYS,,62.0,YR,A,M,Y,,,20221108,,MD,DE,DE,2022,Q4,Adult
215648331,21564833,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Ischaemic cardiomyopathy,,2022,Q4,1,I,,20221029.0,20221108,20221108,EXP,,DE-drreddys-SPO/GER/22/0156738,DR REDDYS,,62.0,YR,A,M,Y,,,20221108,,MD,DE,DE,2022,Q4,Adult
215648331,21564833,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Cardioversion,,2022,Q4,1,I,,20221029.0,20221108,20221108,EXP,,DE-drreddys-SPO/GER/22/0156738,DR REDDYS,,62.0,YR,A,M,Y,,,20221108,,MD,DE,DE,2022,Q4,Adult
215648331,21564833,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Liver function test abnormal,,2022,Q4,1,I,,20221029.0,20221108,20221108,EXP,,DE-drreddys-SPO/GER/22/0156738,DR REDDYS,,62.0,YR,A,M,Y,,,20221108,,MD,DE,DE,2022,Q4,Adult
215648331,21564833,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Ejection fraction decreased,,2022,Q4,1,I,,20221029.0,20221108,20221108,EXP,,DE-drreddys-SPO/GER/22/0156738,DR REDDYS,,62.0,YR,A,M,Y,,,20221108,,MD,DE,DE,2022,Q4,Adult
215648331,21564833,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Arrhythmia,,2022,Q4,1,I,,20221029.0,20221108,20221108,EXP,,DE-drreddys-SPO/GER/22/0156738,DR REDDYS,,62.0,YR,A,M,Y,,,20221108,,MD,DE,DE,2022,Q4,Adult
215667031,21566703,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500 mg,,,,,,,,,,,,2022,Q4,Abdominal pain,,2022,Q4,1,I,20201101.0,20221028.0,20221108,20221108,PER,,AU-Eisai Medical Research-EC-2022-127541,EISAI,,58.0,YR,A,F,Y,,,20221108,,MD,AU,,2022,Q4,Adult
215667031,21566703,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500 mg,,,,,,,,,,,,2022,Q4,Proteinuria,,2022,Q4,1,I,20201101.0,20221028.0,20221108,20221108,PER,,AU-Eisai Medical Research-EC-2022-127541,EISAI,,58.0,YR,A,F,Y,,,20221108,,MD,AU,,2022,Q4,Adult
215667031,21566703,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500 mg,,,,,,,,,,,,2022,Q4,Diarrhoea,,2022,Q4,1,I,20201101.0,20221028.0,20221108,20221108,PER,,AU-Eisai Medical Research-EC-2022-127541,EISAI,,58.0,YR,A,F,Y,,,20221108,,MD,AU,,2022,Q4,Adult
215667031,21566703,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500 mg,,,,,,,,,,,,2022,Q4,Nausea,,2022,Q4,1,I,20201101.0,20221028.0,20221108,20221108,PER,,AU-Eisai Medical Research-EC-2022-127541,EISAI,,58.0,YR,A,F,Y,,,20221108,,MD,AU,,2022,Q4,Adult
215667031,21566703,3,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500 mg,,,,,,,,,,,,2022,Q4,Vomiting,,2022,Q4,1,I,20201101.0,20221028.0,20221108,20221108,PER,,AU-Eisai Medical Research-EC-2022-127541,EISAI,,58.0,YR,A,F,Y,,,20221108,,MD,AU,,2022,Q4,Adult
215680431,21568043,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2022,Q4,Dizziness,,2022,Q4,1,I,20210801.0,20221104.0,20221108,20221108,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-201283",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,74.9,KG,20221108,,MD,JP,JP,2022,Q4,Elderly
215680431,21568043,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2022,Q4,Dizziness,,2022,Q4,1,I,20210801.0,20221104.0,20221108,20221108,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-201283",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,74.9,KG,20221108,,MD,JP,JP,2022,Q4,Elderly
215680431,21568043,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2022,Q4,Hypoaesthesia,,2022,Q4,1,I,20210801.0,20221104.0,20221108,20221108,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-201283",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,74.9,KG,20221108,,MD,JP,JP,2022,Q4,Elderly
215680431,21568043,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2022,Q4,Amyotrophic lateral sclerosis,,2022,Q4,1,I,20210801.0,20221104.0,20221108,20221108,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-201283",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,74.9,KG,20221108,,MD,JP,JP,2022,Q4,Elderly
215683281,21568328,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20220927.0,,20221107,20221107,DIR,FDA-CDER-CTU-2022-89127,,FDA-CTU,,71.0,YR,,M,N,62.0,KG,20221024,N,PH,US,,2022,Q4,Elderly
215683281,21568328,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q4,Fournier's gangrene,,2022,Q4,1,I,20220927.0,,20221107,20221107,DIR,FDA-CDER-CTU-2022-89127,,FDA-CTU,,71.0,YR,,M,N,62.0,KG,20221024,N,PH,US,,2022,Q4,Elderly
215683281,21568328,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q4,Tachycardia,,2022,Q4,1,I,20220927.0,,20221107,20221107,DIR,FDA-CDER-CTU-2022-89127,,FDA-CTU,,71.0,YR,,M,N,62.0,KG,20221024,N,PH,US,,2022,Q4,Elderly
215683281,21568328,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q4,Pyrexia,,2022,Q4,1,I,20220927.0,,20221107,20221107,DIR,FDA-CDER-CTU-2022-89127,,FDA-CTU,,71.0,YR,,M,N,62.0,KG,20221024,N,PH,US,,2022,Q4,Elderly
215683291,21568329,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Therapy cessation,,2022,Q4,1,I,20220801.0,,20221107,20221107,DIR,FDA-CDER-CTU-2022-89140,,FDA-CTU,,71.0,YR,,M,N,112.49,KG,20221021,N,PH,US,,2022,Q4,Elderly
215683291,21568329,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Fatigue,,2022,Q4,1,I,20220801.0,,20221107,20221107,DIR,FDA-CDER-CTU-2022-89140,,FDA-CTU,,71.0,YR,,M,N,112.49,KG,20221021,N,PH,US,,2022,Q4,Elderly
215683291,21568329,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Somnolence,,2022,Q4,1,I,20220801.0,,20221107,20221107,DIR,FDA-CDER-CTU-2022-89140,,FDA-CTU,,71.0,YR,,M,N,112.49,KG,20221021,N,PH,US,,2022,Q4,Elderly
215683321,21568332,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q4,Urinary tract infection,,2022,Q4,1,I,20210816.0,,20221107,20221107,DIR,FDA-CDER-CTU-2022-89157,,FDA-CTU,,73.0,YR,,M,N,,,20221105,N,PH,US,,2022,Q4,Elderly
215683321,21568332,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q4,Urosepsis,,2022,Q4,1,I,20210816.0,,20221107,20221107,DIR,FDA-CDER-CTU-2022-89157,,FDA-CTU,,73.0,YR,,M,N,,,20221105,N,PH,US,,2022,Q4,Elderly
215683331,21568333,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO?,,,D,D,,,,,,Tablet,QD,2022,Q4,Prostatic abscess,,2022,Q4,1,I,20210802.0,,20221107,20221107,DIR,FDA-CDER-CTU-2022-89160,,FDA-CTU,,74.0,YR,,M,N,64.41,KG,20221003,N,HP,US,,2022,Q4,Elderly
215683331,21568333,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO?,,,D,D,,,,,,Tablet,QD,2022,Q4,Prostatitis,,2022,Q4,1,I,20210802.0,,20221107,20221107,DIR,FDA-CDER-CTU-2022-89160,,FDA-CTU,,74.0,YR,,M,N,64.41,KG,20221003,N,HP,US,,2022,Q4,Elderly
215683331,21568333,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO?,,,D,D,,,,,,Tablet,QD,2022,Q4,Urinary tract infection staphylococcal,,2022,Q4,1,I,20210802.0,,20221107,20221107,DIR,FDA-CDER-CTU-2022-89160,,FDA-CTU,,74.0,YR,,M,N,64.41,KG,20221003,N,HP,US,,2022,Q4,Elderly
215708611,21570861,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Pruritus,,2022,Q4,1,I,20221022.0,20221108.0,20221109,20221109,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-201794",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20221109,,HP,SG,SG,2022,Q4,Elderly
215708611,21570861,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Rash,,2022,Q4,1,I,20221022.0,20221108.0,20221109,20221109,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-201794",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20221109,,HP,SG,SG,2022,Q4,Elderly
215708611,21570861,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Wheezing,,2022,Q4,1,I,20221022.0,20221108.0,20221109,20221109,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-201794",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20221109,,HP,SG,SG,2022,Q4,Elderly
215708611,21570861,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Dyspnoea,,2022,Q4,1,I,20221022.0,20221108.0,20221109,20221109,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-201794",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20221109,,HP,SG,SG,2022,Q4,Elderly
215733921,21573392,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Diabetic foot,,2022,Q4,1,I,20221102.0,,20221109,20221109,DIR,637738,,FDA-CTU,,79.0,YR,,M,N,83.25,KG,20221109,Y,PH,US,,2022,Q4,Elderly
215733921,21573392,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Speech disorder,,2022,Q4,1,I,20221102.0,,20221109,20221109,DIR,637738,,FDA-CTU,,79.0,YR,,M,N,83.25,KG,20221109,Y,PH,US,,2022,Q4,Elderly
215733921,21573392,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Delirium,,2022,Q4,1,I,20221102.0,,20221109,20221109,DIR,637738,,FDA-CTU,,79.0,YR,,M,N,83.25,KG,20221109,Y,PH,US,,2022,Q4,Elderly
215733921,21573392,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Mental disorder,,2022,Q4,1,I,20221102.0,,20221109,20221109,DIR,637738,,FDA-CTU,,79.0,YR,,M,N,83.25,KG,20221109,Y,PH,US,,2022,Q4,Elderly
215733921,21573392,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Confusional state,,2022,Q4,1,I,20221102.0,,20221109,20221109,DIR,637738,,FDA-CTU,,79.0,YR,,M,N,83.25,KG,20221109,Y,PH,US,,2022,Q4,Elderly
215733921,21573392,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Hallucination,,2022,Q4,1,I,20221102.0,,20221109,20221109,DIR,637738,,FDA-CTU,,79.0,YR,,M,N,83.25,KG,20221109,Y,PH,US,,2022,Q4,Elderly
215734232,21573423,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Pleural effusion,,2022,Q4,2,F,,20221209.0,20221109,20221216,EXP,,SI-009507513-2211SVN002372,MERCK,,79.0,YR,,F,Y,,,20221216,,MD,SI,SI,2022,Q4,Elderly
215773511,21577351,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Film-coated tablet,QD,2022,Q4,Pruritus,,2022,Q4,1,I,,20221109.0,20221110,20221110,EXP,,"LT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-202097",BOEHRINGER INGELHEIM,,86.0,YR,E,F,Y,,,20221110,,MD,LT,LT,2022,Q4,Elderly
215785431,21578543,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,patient reports non-compliance,,,,,,,,10.0,MG,,QD,2022,Q4,Cerebral disorder,,2022,Q4,1,I,20220713.0,20221102.0,20221110,20221110,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-200923",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20221110,,HP,PT,PT,2022,Q4,Elderly
215785431,21578543,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,patient reports non-compliance,,,,,,,,10.0,MG,,QD,2022,Q4,Encephalitis,,2022,Q4,1,I,20220713.0,20221102.0,20221110,20221110,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-200923",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20221110,,HP,PT,PT,2022,Q4,Elderly
215785431,21578543,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Cerebral disorder,,2022,Q4,1,I,20220713.0,20221102.0,20221110,20221110,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-200923",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20221110,,HP,PT,PT,2022,Q4,Elderly
215785431,21578543,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Encephalitis,,2022,Q4,1,I,20220713.0,20221102.0,20221110,20221110,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-200923",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20221110,,HP,PT,PT,2022,Q4,Elderly
215816561,21581656,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q4,Pain,,2022,Q4,1,I,,20221027.0,20221111,20221111,EXP,,CA-AUROBINDO-AUR-APL-2022-047611,AUROBINDO,,58.0,YR,,M,Y,,,20221111,,HP,CA,CA,2022,Q4,Adult
215816561,21581656,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q4,Discomfort,,2022,Q4,1,I,,20221027.0,20221111,20221111,EXP,,CA-AUROBINDO-AUR-APL-2022-047611,AUROBINDO,,58.0,YR,,M,Y,,,20221111,,HP,CA,CA,2022,Q4,Adult
215816561,21581656,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2022,Q4,Ankylosing spondylitis,,2022,Q4,1,I,,20221027.0,20221111,20221111,EXP,,CA-AUROBINDO-AUR-APL-2022-047611,AUROBINDO,,58.0,YR,,M,Y,,,20221111,,HP,CA,CA,2022,Q4,Adult
215824111,21582411,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q4,Ketoacidosis,,2022,Q4,1,I,20221001.0,20221111.0,20221111,20221111,EXP,DE-CADRBFARM-2022310086,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-202313",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,80.0,KG,20221111,,MD,DE,DE,2022,Q4,Elderly
215824111,21582411,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q4,General physical health deterioration,,2022,Q4,1,I,20221001.0,20221111.0,20221111,20221111,EXP,DE-CADRBFARM-2022310086,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-202313",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,80.0,KG,20221111,,MD,DE,DE,2022,Q4,Elderly
215824111,21582411,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q4,Dyspnoea,,2022,Q4,1,I,20221001.0,20221111.0,20221111,20221111,EXP,DE-CADRBFARM-2022310086,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-202313",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,80.0,KG,20221111,,MD,DE,DE,2022,Q4,Elderly
215847981,21584798,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Thirst,,2022,Q4,1,I,20221102.0,20221111.0,20221111,20221111,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-202411",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,0.0,KG,20221111,,PH,GB,GB,2022,Q4,Adult
215847981,21584798,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Urine output increased,,2022,Q4,1,I,20221102.0,20221111.0,20221111,20221111,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-202411",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,0.0,KG,20221111,,PH,GB,GB,2022,Q4,Adult
215847981,21584798,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Dysgeusia,,2022,Q4,1,I,20221102.0,20221111.0,20221111,20221111,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-202411",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,0.0,KG,20221111,,PH,GB,GB,2022,Q4,Adult
215848891,21584889,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221109.0,20221111,20221111,EXP,,NVSC2022US253476,NOVARTIS,"Malley C, Grammb E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. CLINICAL TOXICOLOGY. 2022;60:47-8",33.0,YR,,F,Y,,,20221111,,HP,US,US,2022,Q4,Young Adult
215848891,21584889,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221109.0,20221111,20221111,EXP,,NVSC2022US253476,NOVARTIS,"Malley C, Grammb E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. CLINICAL TOXICOLOGY. 2022;60:47-8",33.0,YR,,F,Y,,,20221111,,HP,US,US,2022,Q4,Young Adult
215848891,21584889,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221109.0,20221111,20221111,EXP,,NVSC2022US253476,NOVARTIS,"Malley C, Grammb E, Adkins A, Trautman W, Scanlon M, Abesamis M et al.. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. CLINICAL TOXICOLOGY. 2022;60:47-8",33.0,YR,,F,Y,,,20221111,,HP,US,US,2022,Q4,Young Adult
215859251,21585925,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,10.0,MG,,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,,20221109.0,20221111,20221111,EXP,,AT-BAUSCH-BL-2022-023932,BAUSCH AND LOMB,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor- Therapie. Universum Innere Medizin. 2022 JUL;7:22-24.",75.0,YR,,F,Y,,,20221111,,MD,AT,AT,2022,Q4,Elderly
215859251,21585925,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,10.0,MG,,,2022,Q4,Blood lactic acid increased,,2022,Q4,1,I,,20221109.0,20221111,20221111,EXP,,AT-BAUSCH-BL-2022-023932,BAUSCH AND LOMB,"Wilfing R, Stollberger C. Ketoazidose unter SGLT2-Inhibitor- Therapie. Universum Innere Medizin. 2022 JUL;7:22-24.",75.0,YR,,F,Y,,,20221111,,MD,AT,AT,2022,Q4,Elderly
215887491,21588749,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, mane",,,U,,,,,10.0,MG,,,2022,Q4,Mental disorder,,2022,Q4,1,I,,20221030.0,20221114,20221114,EXP,,AU-HETERO-HET2022AU02711,HETERO,,48.0,YR,,M,Y,90.0,KG,20221114,,MD,AU,AU,2022,Q4,Adult
215887491,21588749,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, mane",,,U,,,,,10.0,MG,,,2022,Q4,Schizophrenia,,2022,Q4,1,I,,20221030.0,20221114,20221114,EXP,,AU-HETERO-HET2022AU02711,HETERO,,48.0,YR,,M,Y,90.0,KG,20221114,,MD,AU,AU,2022,Q4,Adult
215887491,21588749,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, mane",,,U,,,,,10.0,MG,,,2022,Q4,Blood pressure decreased,,2022,Q4,1,I,,20221030.0,20221114,20221114,EXP,,AU-HETERO-HET2022AU02711,HETERO,,48.0,YR,,M,Y,90.0,KG,20221114,,MD,AU,AU,2022,Q4,Adult
215887491,21588749,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, mane",,,U,,,,,10.0,MG,,,2022,Q4,Dizziness,,2022,Q4,1,I,,20221030.0,20221114,20221114,EXP,,AU-HETERO-HET2022AU02711,HETERO,,48.0,YR,,M,Y,90.0,KG,20221114,,MD,AU,AU,2022,Q4,Adult
215887491,21588749,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, mane",,,U,,,,,10.0,MG,,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20221030.0,20221114,20221114,EXP,,AU-HETERO-HET2022AU02711,HETERO,,48.0,YR,,M,Y,90.0,KG,20221114,,MD,AU,AU,2022,Q4,Adult
215888693,21588869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2022,Q4,Left ventricular diastolic collapse,,2022,Q4,3,F,20221031.0,20221227.0,20221114,20221229,EXP,,NVSC2022ES254025,NOVARTIS,,75.0,YR,,M,Y,86.0,KG,20221229,,MD,ES,ES,2022,Q4,Elderly
215888693,21588869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2022,Q4,Oedema,,2022,Q4,3,F,20221031.0,20221227.0,20221114,20221229,EXP,,NVSC2022ES254025,NOVARTIS,,75.0,YR,,M,Y,86.0,KG,20221229,,MD,ES,ES,2022,Q4,Elderly
215888693,21588869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2022,Q4,Cardiac failure acute,,2022,Q4,3,F,20221031.0,20221227.0,20221114,20221229,EXP,,NVSC2022ES254025,NOVARTIS,,75.0,YR,,M,Y,86.0,KG,20221229,,MD,ES,ES,2022,Q4,Elderly
215888693,21588869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2022,Q4,Pericardial effusion,,2022,Q4,3,F,20221031.0,20221227.0,20221114,20221229,EXP,,NVSC2022ES254025,NOVARTIS,,75.0,YR,,M,Y,86.0,KG,20221229,,MD,ES,ES,2022,Q4,Elderly
215888693,21588869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2022,Q4,Shock,,2022,Q4,3,F,20221031.0,20221227.0,20221114,20221229,EXP,,NVSC2022ES254025,NOVARTIS,,75.0,YR,,M,Y,86.0,KG,20221229,,MD,ES,ES,2022,Q4,Elderly
215888693,21588869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2022,Q4,Right ventricular dysfunction,,2022,Q4,3,F,20221031.0,20221227.0,20221114,20221229,EXP,,NVSC2022ES254025,NOVARTIS,,75.0,YR,,M,Y,86.0,KG,20221229,,MD,ES,ES,2022,Q4,Elderly
215888693,21588869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2022,Q4,Blood creatinine increased,,2022,Q4,3,F,20221031.0,20221227.0,20221114,20221229,EXP,,NVSC2022ES254025,NOVARTIS,,75.0,YR,,M,Y,86.0,KG,20221229,,MD,ES,ES,2022,Q4,Elderly
215888693,21588869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2022,Q4,Mouth haemorrhage,,2022,Q4,3,F,20221031.0,20221227.0,20221114,20221229,EXP,,NVSC2022ES254025,NOVARTIS,,75.0,YR,,M,Y,86.0,KG,20221229,,MD,ES,ES,2022,Q4,Elderly
215888693,21588869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2022,Q4,Coagulopathy,,2022,Q4,3,F,20221031.0,20221227.0,20221114,20221229,EXP,,NVSC2022ES254025,NOVARTIS,,75.0,YR,,M,Y,86.0,KG,20221229,,MD,ES,ES,2022,Q4,Elderly
215888693,21588869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2022,Q4,Unresponsive to stimuli,,2022,Q4,3,F,20221031.0,20221227.0,20221114,20221229,EXP,,NVSC2022ES254025,NOVARTIS,,75.0,YR,,M,Y,86.0,KG,20221229,,MD,ES,ES,2022,Q4,Elderly
215888693,21588869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2022,Q4,Renal failure,,2022,Q4,3,F,20221031.0,20221227.0,20221114,20221229,EXP,,NVSC2022ES254025,NOVARTIS,,75.0,YR,,M,Y,86.0,KG,20221229,,MD,ES,ES,2022,Q4,Elderly
215888693,21588869,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,D,,,,,10.0,MG,,QD,2022,Q4,Dyspnoea,,2022,Q4,3,F,20221031.0,20221227.0,20221114,20221229,EXP,,NVSC2022ES254025,NOVARTIS,,75.0,YR,,M,Y,86.0,KG,20221229,,MD,ES,ES,2022,Q4,Elderly
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Nausea,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Blood glucose increased,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Haemoglobin decreased,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Thirst,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Appetite disorder,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Dry mouth,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Musculoskeletal stiffness,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Blood glucose increased,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,White blood cell count increased,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Chills,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Pain in extremity,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Dizziness,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Pollakiuria,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Mobility decreased,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Vomiting,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Dysgeusia,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Cyst,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Product dose omission issue,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Product dose omission issue,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215907852,21590785,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2022,Q4,Abdominal distension,,2022,Q4,2,F,20220930.0,20221110.0,20221114,20221123,EXP,,ID-ELI_LILLY_AND_COMPANY-ID202210005173,ELI LILLY AND CO,,43.0,YR,,F,Y,66.0,KG,20221123,,CN,ID,ID,2022,Q4,Adult
215908101,21590810,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Acute myocardial infarction,,2022,Q4,1,I,,20221107.0,20221114,20221114,EXP,,DE-MYLANLABS-2022M1124304,MYLAN,,78.0,YR,,M,Y,,,20221114,,PH,DE,DE,2022,Q4,Elderly
215908101,21590810,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Atrial fibrillation,,2022,Q4,1,I,,20221107.0,20221114,20221114,EXP,,DE-MYLANLABS-2022M1124304,MYLAN,,78.0,YR,,M,Y,,,20221114,,PH,DE,DE,2022,Q4,Elderly
215908101,21590810,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Arrhythmia,,2022,Q4,1,I,,20221107.0,20221114,20221114,EXP,,DE-MYLANLABS-2022M1124304,MYLAN,,78.0,YR,,M,Y,,,20221114,,PH,DE,DE,2022,Q4,Elderly
215908101,21590810,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Acute respiratory failure,,2022,Q4,1,I,,20221107.0,20221114,20221114,EXP,,DE-MYLANLABS-2022M1124304,MYLAN,,78.0,YR,,M,Y,,,20221114,,PH,DE,DE,2022,Q4,Elderly
215908101,21590810,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Renal impairment,,2022,Q4,1,I,,20221107.0,20221114,20221114,EXP,,DE-MYLANLABS-2022M1124304,MYLAN,,78.0,YR,,M,Y,,,20221114,,PH,DE,DE,2022,Q4,Elderly
215908101,21590810,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Electrocardiogram abnormal,,2022,Q4,1,I,,20221107.0,20221114,20221114,EXP,,DE-MYLANLABS-2022M1124304,MYLAN,,78.0,YR,,M,Y,,,20221114,,PH,DE,DE,2022,Q4,Elderly
215908101,21590810,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Systemic infection,,2022,Q4,1,I,,20221107.0,20221114,20221114,EXP,,DE-MYLANLABS-2022M1124304,MYLAN,,78.0,YR,,M,Y,,,20221114,,PH,DE,DE,2022,Q4,Elderly
215908101,21590810,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Tachycardia,,2022,Q4,1,I,,20221107.0,20221114,20221114,EXP,,DE-MYLANLABS-2022M1124304,MYLAN,,78.0,YR,,M,Y,,,20221114,,PH,DE,DE,2022,Q4,Elderly
215908101,21590810,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20221107.0,20221114,20221114,EXP,,DE-MYLANLABS-2022M1124304,MYLAN,,78.0,YR,,M,Y,,,20221114,,PH,DE,DE,2022,Q4,Elderly
215908101,21590810,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20221107.0,20221114,20221114,EXP,,DE-MYLANLABS-2022M1124304,MYLAN,,78.0,YR,,M,Y,,,20221114,,PH,DE,DE,2022,Q4,Elderly
215908101,21590810,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221107.0,20221114,20221114,EXP,,DE-MYLANLABS-2022M1124304,MYLAN,,78.0,YR,,M,Y,,,20221114,,PH,DE,DE,2022,Q4,Elderly
215918131,21591813,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Gastrointestinal disorder,,2022,Q4,1,I,20221027.0,20221107.0,20221114,20221114,PER,,SA-AMGEN-SAUSP2022192849,AMGEN,,65.0,YR,E,F,Y,,,20221114,,CN,SA,SA,2022,Q4,Elderly
215918131,21591813,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Nausea,,2022,Q4,1,I,20221027.0,20221107.0,20221114,20221114,PER,,SA-AMGEN-SAUSP2022192849,AMGEN,,65.0,YR,E,F,Y,,,20221114,,CN,SA,SA,2022,Q4,Elderly
215918131,21591813,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2022,Q4,Dyspnoea,,2022,Q4,1,I,20221027.0,20221107.0,20221114,20221114,PER,,SA-AMGEN-SAUSP2022192849,AMGEN,,65.0,YR,E,F,Y,,,20221114,,CN,SA,SA,2022,Q4,Elderly
215960391,21596039,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,U,,,,,10.0,MG,,,2022,Q4,Discomfort,,2022,Q4,1,I,,20221101.0,20221115,20221115,EXP,CA-MHPD-E2B_05613121,CA-Accord-285328,ACCORD,,58.0,YR,A,M,Y,,,20221115,,HP,CA,CA,2022,Q4,Adult
215960391,21596039,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,U,,,,,10.0,MG,,,2022,Q4,Ankylosing spondylitis,,2022,Q4,1,I,,20221101.0,20221115,20221115,EXP,CA-MHPD-E2B_05613121,CA-Accord-285328,ACCORD,,58.0,YR,A,M,Y,,,20221115,,HP,CA,CA,2022,Q4,Adult
215960391,21596039,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 every 1 days,,,U,,,,,10.0,MG,,,2022,Q4,Pain,,2022,Q4,1,I,,20221101.0,20221115,20221115,EXP,CA-MHPD-E2B_05613121,CA-Accord-285328,ACCORD,,58.0,YR,A,M,Y,,,20221115,,HP,CA,CA,2022,Q4,Adult
215961001,21596100,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2022,Q4,Gastric haemorrhage,,2022,Q4,1,I,20221105.0,20221110.0,20221115,20221115,EXP,,"RO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-202142",BOEHRINGER INGELHEIM,,65.0,YR,E,F,Y,,,20221115,,MD,RO,RO,2022,Q4,Elderly
215961001,21596100,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2022,Q4,Headache,,2022,Q4,1,I,20221105.0,20221110.0,20221115,20221115,EXP,,"RO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-202142",BOEHRINGER INGELHEIM,,65.0,YR,E,F,Y,,,20221115,,MD,RO,RO,2022,Q4,Elderly
215967211,21596721,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,U,U,,,,,,Tablet,,2022,Q4,Product monitoring error,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,DE-MYLANLABS-2022M1124747,MYLAN,,55.0,YR,,M,Y,84.0,KG,20221115,,PH,DE,DE,2022,Q4,Adult
215967211,21596721,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,U,U,,,,,,Tablet,,2022,Q4,Therapeutic drug monitoring analysis not performed,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,DE-MYLANLABS-2022M1124747,MYLAN,,55.0,YR,,M,Y,84.0,KG,20221115,,PH,DE,DE,2022,Q4,Adult
215967211,21596721,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tablet",,,U,U,,,,,,Tablet,,2022,Q4,Wound,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,DE-MYLANLABS-2022M1124747,MYLAN,,55.0,YR,,M,Y,84.0,KG,20221115,,PH,DE,DE,2022,Q4,Adult
215970301,21597030,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,US-MYLANLABS-2022M1126855,MYLAN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin-Toxicol-(Phila) 2022;60 (Suppl. 2):47-48.",33.0,YR,,F,Y,,,20221115,,HP,US,US,2022,Q4,Young Adult
215970301,21597030,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Cerebral infarction,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,US-MYLANLABS-2022M1126855,MYLAN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin-Toxicol-(Phila) 2022;60 (Suppl. 2):47-48.",33.0,YR,,F,Y,,,20221115,,HP,US,US,2022,Q4,Young Adult
215970301,21597030,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,US-MYLANLABS-2022M1126855,MYLAN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin-Toxicol-(Phila) 2022;60 (Suppl. 2):47-48.",33.0,YR,,F,Y,,,20221115,,HP,US,US,2022,Q4,Young Adult
215970301,21597030,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,US-MYLANLABS-2022M1126855,MYLAN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin-Toxicol-(Phila) 2022;60 (Suppl. 2):47-48.",33.0,YR,,F,Y,,,20221115,,HP,US,US,2022,Q4,Young Adult
215970301,21597030,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,US-MYLANLABS-2022M1126855,MYLAN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin-Toxicol-(Phila) 2022;60 (Suppl. 2):47-48.",33.0,YR,,F,Y,,,20221115,,HP,US,US,2022,Q4,Young Adult
215970301,21597030,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,US-MYLANLABS-2022M1126855,MYLAN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin-Toxicol-(Phila) 2022;60 (Suppl. 2):47-48.",33.0,YR,,F,Y,,,20221115,,HP,US,US,2022,Q4,Young Adult
215970301,21597030,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,US-MYLANLABS-2022M1126855,MYLAN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin-Toxicol-(Phila) 2022;60 (Suppl. 2):47-48.",33.0,YR,,F,Y,,,20221115,,HP,US,US,2022,Q4,Young Adult
215970301,21597030,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,US-MYLANLABS-2022M1126855,MYLAN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin-Toxicol-(Phila) 2022;60 (Suppl. 2):47-48.",33.0,YR,,F,Y,,,20221115,,HP,US,US,2022,Q4,Young Adult
215984582,21598458,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg every morning,,,D,N,,,,,,,,2022,Q4,Acute kidney injury,,2022,Q4,2,F,20221021.0,20221128.0,20221115,20221209,EXP,,CA-HLS-202201955,HLS THERAPEUTICS,,61.0,YR,A,M,Y,100.0,KG,20221209,,PH,CA,CA,2022,Q4,Adult
215984582,21598458,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg every morning,,,D,N,,,,,,,,2022,Q4,Off label use,,2022,Q4,2,F,20221021.0,20221128.0,20221115,20221209,EXP,,CA-HLS-202201955,HLS THERAPEUTICS,,61.0,YR,A,M,Y,100.0,KG,20221209,,PH,CA,CA,2022,Q4,Adult
215984582,21598458,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg every morning,,,D,N,,,,,,,,2022,Q4,Shigella infection,,2022,Q4,2,F,20221021.0,20221128.0,20221115,20221209,EXP,,CA-HLS-202201955,HLS THERAPEUTICS,,61.0,YR,A,M,Y,100.0,KG,20221209,,PH,CA,CA,2022,Q4,Adult
215984582,21598458,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 mg every morning,,,D,N,,,,,,,,2022,Q4,Normocytic anaemia,,2022,Q4,2,F,20221021.0,20221128.0,20221115,20221209,EXP,,CA-HLS-202201955,HLS THERAPEUTICS,,61.0,YR,A,M,Y,100.0,KG,20221209,,PH,CA,CA,2022,Q4,Adult
215985411,21598541,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0",,,U,U,,,,25.0,MG,Tablet,QD,2022,Q4,Product monitoring error,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,DE-MYLANLABS-2022M1124631,MYLAN,,70.0,YR,,M,Y,100.0,KG,20221115,,PH,DE,DE,2022,Q4,Elderly
215985411,21598541,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0",,,U,U,,,,25.0,MG,Tablet,QD,2022,Q4,Inflammation,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,DE-MYLANLABS-2022M1124631,MYLAN,,70.0,YR,,M,Y,100.0,KG,20221115,,PH,DE,DE,2022,Q4,Elderly
215985411,21598541,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1-0-0-0",,,U,U,,,,25.0,MG,Tablet,QD,2022,Q4,Ulcer,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,DE-MYLANLABS-2022M1124631,MYLAN,,70.0,YR,,M,Y,100.0,KG,20221115,,PH,DE,DE,2022,Q4,Elderly
215987451,21598745,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,20221109.0,,20221115,20221115,DIR,638398,,FDA-CTU,,75.0,YR,,M,N,60.3,KG,20221115,Y,PH,US,,2022,Q4,Elderly
216017631,21601763,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q4,Lip swelling,,2022,Q4,1,I,20221102.0,20221108.0,20221116,20221116,EXP,GB-MHRA-TPP1267601C6782292YC1667385006229,GB-MICRO LABS LIMITED-ML2022-05644,MICRO LABS,,57.0,YR,A,M,Y,86.0,KG,20221116,,HP,GB,GB,2022,Q4,Adult
216052232,21605223,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2022,Q4,Pulmonary embolism,,2022,Q4,2,F,20211117.0,20221207.0,20221116,20221208,EXP,,RU-JNJFOC-20211156015,JOHNSON AND JOHNSON,,69.0,YR,E,F,Y,88.0,KG,20221208,,MD,RU,RU,2022,Q4,Elderly
216052232,21605223,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,2,F,20211117.0,20221207.0,20221116,20221208,EXP,,RU-JNJFOC-20211156015,JOHNSON AND JOHNSON,,69.0,YR,E,F,Y,88.0,KG,20221208,,MD,RU,RU,2022,Q4,Elderly
216057891,21605789,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"160 dosage form, Once a Day",,,U,,,,,,,,QD,2022,Q4,Lip swelling,,2022,Q4,1,I,20221102.0,20221108.0,20221116,20221116,EXP,,GB-AUROBINDO-AUR-APL-2022-048363,AUROBINDO,,57.0,YR,,M,Y,86.0,KG,20221117,,HP,GB,GB,2022,Q4,Adult
216074791,21607479,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221108.0,20221117,20221117,EXP,,US-APOTEX-2022AP015499,APOTEX,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology (Phila). 2022;60(S2):47-48",33.0,YR,,F,Y,,,20221117,,HP,US,US,2022,Q4,Young Adult
216074791,21607479,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221108.0,20221117,20221117,EXP,,US-APOTEX-2022AP015499,APOTEX,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology (Phila). 2022;60(S2):47-48",33.0,YR,,F,Y,,,20221117,,HP,US,US,2022,Q4,Young Adult
216074791,21607479,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221108.0,20221117,20221117,EXP,,US-APOTEX-2022AP015499,APOTEX,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology (Phila). 2022;60(S2):47-48",33.0,YR,,F,Y,,,20221117,,HP,US,US,2022,Q4,Young Adult
216074791,21607479,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221108.0,20221117,20221117,EXP,,US-APOTEX-2022AP015499,APOTEX,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology (Phila). 2022;60(S2):47-48",33.0,YR,,F,Y,,,20221117,,HP,US,US,2022,Q4,Young Adult
216074791,21607479,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221108.0,20221117,20221117,EXP,,US-APOTEX-2022AP015499,APOTEX,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology (Phila). 2022;60(S2):47-48",33.0,YR,,F,Y,,,20221117,,HP,US,US,2022,Q4,Young Adult
216074791,21607479,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,1,I,,20221108.0,20221117,20221117,EXP,,US-APOTEX-2022AP015499,APOTEX,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology (Phila). 2022;60(S2):47-48",33.0,YR,,F,Y,,,20221117,,HP,US,US,2022,Q4,Young Adult
216074791,21607479,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Ventricular tachycardia,,2022,Q4,1,I,,20221108.0,20221117,20221117,EXP,,US-APOTEX-2022AP015499,APOTEX,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology (Phila). 2022;60(S2):47-48",33.0,YR,,F,Y,,,20221117,,HP,US,US,2022,Q4,Young Adult
216074791,21607479,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Blood lactic acid increased,,2022,Q4,1,I,,20221108.0,20221117,20221117,EXP,,US-APOTEX-2022AP015499,APOTEX,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology (Phila). 2022;60(S2):47-48",33.0,YR,,F,Y,,,20221117,,HP,US,US,2022,Q4,Young Adult
216074791,21607479,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221108.0,20221117,20221117,EXP,,US-APOTEX-2022AP015499,APOTEX,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology (Phila). 2022;60(S2):47-48",33.0,YR,,F,Y,,,20221117,,HP,US,US,2022,Q4,Young Adult
216074791,21607479,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221108.0,20221117,20221117,EXP,,US-APOTEX-2022AP015499,APOTEX,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology (Phila). 2022;60(S2):47-48",33.0,YR,,F,Y,,,20221117,,HP,US,US,2022,Q4,Young Adult
216074791,21607479,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Embolic cerebral infarction,,2022,Q4,1,I,,20221108.0,20221117,20221117,EXP,,US-APOTEX-2022AP015499,APOTEX,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, Pizon A. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology (Phila). 2022;60(S2):47-48",33.0,YR,,F,Y,,,20221117,,HP,US,US,2022,Q4,Young Adult
216092841,21609284,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, 1-0-0-0, Tablets",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q4,Cystitis,,2022,Q4,1,I,20210907.0,20221110.0,20221117,20221117,EXP,,DE-MYLANLABS-2022M1125455,MYLAN,,73.0,YR,,M,Y,,,20221117,,PH,DE,DE,2022,Q4,Elderly
216092841,21609284,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, 1-0-0-0, Tablets",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20210907.0,20221110.0,20221117,20221117,EXP,,DE-MYLANLABS-2022M1125455,MYLAN,,73.0,YR,,M,Y,,,20221117,,PH,DE,DE,2022,Q4,Elderly
216092841,21609284,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, 1-0-0-0, Tablets",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q4,Product monitoring error,,2022,Q4,1,I,20210907.0,20221110.0,20221117,20221117,EXP,,DE-MYLANLABS-2022M1125455,MYLAN,,73.0,YR,,M,Y,,,20221117,,PH,DE,DE,2022,Q4,Elderly
216092841,21609284,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, 1-0-0-0, Tablets",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q4,Urinary hesitation,,2022,Q4,1,I,20210907.0,20221110.0,20221117,20221117,EXP,,DE-MYLANLABS-2022M1125455,MYLAN,,73.0,YR,,M,Y,,,20221117,,PH,DE,DE,2022,Q4,Elderly
216092841,21609284,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, 1-0-0-0, Tablets",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q4,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q4,1,I,20210907.0,20221110.0,20221117,20221117,EXP,,DE-MYLANLABS-2022M1125455,MYLAN,,73.0,YR,,M,Y,,,20221117,,PH,DE,DE,2022,Q4,Elderly
216092841,21609284,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, 1-0-0-0, Tablets",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q4,Labelled drug-drug interaction medication error,,2022,Q4,1,I,20210907.0,20221110.0,20221117,20221117,EXP,,DE-MYLANLABS-2022M1125455,MYLAN,,73.0,YR,,M,Y,,,20221117,,PH,DE,DE,2022,Q4,Elderly
216092841,21609284,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, 1-0-0-0, Tablets",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q4,Product administration error,,2022,Q4,1,I,20210907.0,20221110.0,20221117,20221117,EXP,,DE-MYLANLABS-2022M1125455,MYLAN,,73.0,YR,,M,Y,,,20221117,,PH,DE,DE,2022,Q4,Elderly
216092841,21609284,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, 1-0-0-0, Tablets",,,U,U,,,,10.0,MG,Tablet,QD,2022,Q4,Pollakiuria,,2022,Q4,1,I,20210907.0,20221110.0,20221117,20221117,EXP,,DE-MYLANLABS-2022M1125455,MYLAN,,73.0,YR,,M,Y,,,20221117,,PH,DE,DE,2022,Q4,Elderly
216098082,21609808,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Parkinsonism,,2022,Q4,2,F,20221103.0,20221220.0,20221117,20221228,EXP,,GB-JNJFOC-20221130705,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,,,20221228,,CN,GB,GB,2022,Q4,Elderly
216098921,21609892,4,C,EMPAGLIFLOZIN,,1,,,,,,,,,,,,,,2022,Q4,Therapy interrupted,,2022,Q4,1,I,20221115.0,,20221117,20221117,DIR,638681,,FDA-CTU,,82.0,YR,,M,N,103.5,KG,20221117,Y,,US,,2022,Q4,Elderly
216098921,21609892,4,C,EMPAGLIFLOZIN,,1,,,,,,,,,,,,,,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20221115.0,,20221117,20221117,DIR,638681,,FDA-CTU,,82.0,YR,,M,N,103.5,KG,20221117,Y,,US,,2022,Q4,Elderly
216104861,21610486,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,With breakfast,10.0,MG,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Diarrhoea,,2022,Q4,1,I,20221025.0,20221117.0,20221117,20221117,EXP,GB-MHRA-TPP26674666C7252582YC1667907422038,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203413",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,127.0,KG,20221117,,MD,GB,GB,2022,Q4,Adult
216120391,21612039,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,in the MORNING,,,N,U,not known,,204629.0,25.0,MG,Tablet,QD,2022,Q4,Fournier's gangrene,,2022,Q4,1,I,20221114.0,20221116.0,20221118,20221118,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203366",BOEHRINGER INGELHEIM,,76.0,YR,E,M,Y,93.0,KG,20221118,,HP,GB,GB,2022,Q4,Elderly
216133481,21613348,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Daily",,,Y,,,,,25.0,MG,,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221103.0,20221118,20221118,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-364332,RANBAXY,"Yehya A, Sadhu A. Sodium-glucose cotransporter 2 inhibitor-associated prolonged euglycemic diabetic ketoacidosis in type 2 diabetes: A case report and literature review. Clin Diabet. 2020;38(1):112-116",57.0,YR,,F,Y,,,20221118,,HP,US,US,2022,Q4,Adult
216133811,21613381,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,eGFR above 60). I...,,,Y,U,Unknown,,204629.0,,,,QD,2022,Q4,Pruritus,,2022,Q4,1,I,20221115.0,20221116.0,20221118,20221118,EXP,GB-MHRA-TPP30842895C1752567YC1668509440996,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203364",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,89.0,KG,20221118,,HP,GB,GB,2022,Q4,Adult
216133811,21613381,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,eGFR above 60). I...,,,Y,U,Unknown,,204629.0,,,,QD,2022,Q4,Pollakiuria,,2022,Q4,1,I,20221115.0,20221116.0,20221118,20221118,EXP,GB-MHRA-TPP30842895C1752567YC1668509440996,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203364",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,89.0,KG,20221118,,HP,GB,GB,2022,Q4,Adult
216133811,21613381,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,eGFR above 60). I...,,,Y,U,Unknown,,204629.0,,,,QD,2022,Q4,Diarrhoea,,2022,Q4,1,I,20221115.0,20221116.0,20221118,20221118,EXP,GB-MHRA-TPP30842895C1752567YC1668509440996,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203364",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,89.0,KG,20221118,,HP,GB,GB,2022,Q4,Adult
216133811,21613381,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Pruritus,,2022,Q4,1,I,20221115.0,20221116.0,20221118,20221118,EXP,GB-MHRA-TPP30842895C1752567YC1668509440996,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203364",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,89.0,KG,20221118,,HP,GB,GB,2022,Q4,Adult
216133811,21613381,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Pollakiuria,,2022,Q4,1,I,20221115.0,20221116.0,20221118,20221118,EXP,GB-MHRA-TPP30842895C1752567YC1668509440996,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203364",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,89.0,KG,20221118,,HP,GB,GB,2022,Q4,Adult
216133811,21613381,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Diarrhoea,,2022,Q4,1,I,20221115.0,20221116.0,20221118,20221118,EXP,GB-MHRA-TPP30842895C1752567YC1668509440996,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203364",BOEHRINGER INGELHEIM,,52.0,YR,A,M,Y,89.0,KG,20221118,,HP,GB,GB,2022,Q4,Adult
216151721,21615172,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd(25 mg, 1-0-0-0)",,,,,,,,25.0,MG,,QD,2022,Q4,Hypoaesthesia,,2022,Q4,1,I,,20221111.0,20221118,20221118,EXP,,DE-MYLANLABS-2022M1126697,MYLAN,,66.0,YR,,M,Y,86.6,KG,20221118,,PH,DE,DE,2022,Q4,Elderly
216151721,21615172,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd(25 mg, 1-0-0-0)",,,,,,,,25.0,MG,,QD,2022,Q4,Lactic acidosis,,2022,Q4,1,I,,20221111.0,20221118,20221118,EXP,,DE-MYLANLABS-2022M1126697,MYLAN,,66.0,YR,,M,Y,86.6,KG,20221118,,PH,DE,DE,2022,Q4,Elderly
216151721,21615172,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd(25 mg, 1-0-0-0)",,,,,,,,25.0,MG,,QD,2022,Q4,Tachycardia,,2022,Q4,1,I,,20221111.0,20221118,20221118,EXP,,DE-MYLANLABS-2022M1126697,MYLAN,,66.0,YR,,M,Y,86.6,KG,20221118,,PH,DE,DE,2022,Q4,Elderly
216151721,21615172,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd(25 mg, 1-0-0-0)",,,,,,,,25.0,MG,,QD,2022,Q4,Anion gap increased,,2022,Q4,1,I,,20221111.0,20221118,20221118,EXP,,DE-MYLANLABS-2022M1126697,MYLAN,,66.0,YR,,M,Y,86.6,KG,20221118,,PH,DE,DE,2022,Q4,Elderly
216151721,21615172,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd(25 mg, 1-0-0-0)",,,,,,,,25.0,MG,,QD,2022,Q4,Atrial fibrillation,,2022,Q4,1,I,,20221111.0,20221118,20221118,EXP,,DE-MYLANLABS-2022M1126697,MYLAN,,66.0,YR,,M,Y,86.6,KG,20221118,,PH,DE,DE,2022,Q4,Elderly
216151721,21615172,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd(25 mg, 1-0-0-0)",,,,,,,,25.0,MG,,QD,2022,Q4,Palpitations,,2022,Q4,1,I,,20221111.0,20221118,20221118,EXP,,DE-MYLANLABS-2022M1126697,MYLAN,,66.0,YR,,M,Y,86.6,KG,20221118,,PH,DE,DE,2022,Q4,Elderly
216151721,21615172,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd(25 mg, 1-0-0-0)",,,,,,,,25.0,MG,,QD,2022,Q4,Chest discomfort,,2022,Q4,1,I,,20221111.0,20221118,20221118,EXP,,DE-MYLANLABS-2022M1126697,MYLAN,,66.0,YR,,M,Y,86.6,KG,20221118,,PH,DE,DE,2022,Q4,Elderly
216156431,21615643,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,20221109.0,20221115.0,20221118,20221118,EXP,,US-AstraZeneca-2022A379680,ASTRAZENECA,,27502.0,DY,,M,Y,60.8,KG,20221118,,PH,US,,2022,Q4,Elderly
216181781,21618178,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,Unknown,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221108.0,20221119,20221119,EXP,,US-35507-2022-13577,LUPIN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(2):47-48",33.0,YR,,F,Y,,,20221119,,HP,US,US,2022,Q4,Young Adult
216181781,21618178,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,Unknown,,,,,,,2022,Q4,Cerebral infarction,,2022,Q4,1,I,,20221108.0,20221119,20221119,EXP,,US-35507-2022-13577,LUPIN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(2):47-48",33.0,YR,,F,Y,,,20221119,,HP,US,US,2022,Q4,Young Adult
216181781,21618178,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,Unknown,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221108.0,20221119,20221119,EXP,,US-35507-2022-13577,LUPIN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(2):47-48",33.0,YR,,F,Y,,,20221119,,HP,US,US,2022,Q4,Young Adult
216181781,21618178,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,Unknown,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221108.0,20221119,20221119,EXP,,US-35507-2022-13577,LUPIN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(2):47-48",33.0,YR,,F,Y,,,20221119,,HP,US,US,2022,Q4,Young Adult
216181781,21618178,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,Unknown,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221108.0,20221119,20221119,EXP,,US-35507-2022-13577,LUPIN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(2):47-48",33.0,YR,,F,Y,,,20221119,,HP,US,US,2022,Q4,Young Adult
216181781,21618178,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,Unknown,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221108.0,20221119,20221119,EXP,,US-35507-2022-13577,LUPIN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(2):47-48",33.0,YR,,F,Y,,,20221119,,HP,US,US,2022,Q4,Young Adult
216181781,21618178,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,Unknown,,,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,1,I,,20221108.0,20221119,20221119,EXP,,US-35507-2022-13577,LUPIN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(2):47-48",33.0,YR,,F,Y,,,20221119,,HP,US,US,2022,Q4,Young Adult
216181781,21618178,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,Unknown,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221108.0,20221119,20221119,EXP,,US-35507-2022-13577,LUPIN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(2):47-48",33.0,YR,,F,Y,,,20221119,,HP,US,US,2022,Q4,Young Adult
216181781,21618178,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,Unknown,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221108.0,20221119,20221119,EXP,,US-35507-2022-13577,LUPIN,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology. 2022;60(2):47-48",33.0,YR,,F,Y,,,20221119,,HP,US,US,2022,Q4,Young Adult
216209461,21620946,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,25.0,MG,,,2022,Q4,Blood creatinine increased,,2022,Q4,1,I,,20221110.0,20221121,20221121,EXP,CA-MHPD-000992534,CA-Accord-287076,ACCORD,,62.0,YR,A,F,Y,,,20221121,,HP,CA,CA,2022,Q4,Adult
216209461,21620946,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,25.0,MG,,,2022,Q4,Blood pressure diastolic decreased,,2022,Q4,1,I,,20221110.0,20221121,20221121,EXP,CA-MHPD-000992534,CA-Accord-287076,ACCORD,,62.0,YR,A,F,Y,,,20221121,,HP,CA,CA,2022,Q4,Adult
216209461,21620946,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,25.0,MG,,,2022,Q4,Blood pressure systolic decreased,,2022,Q4,1,I,,20221110.0,20221121,20221121,EXP,CA-MHPD-000992534,CA-Accord-287076,ACCORD,,62.0,YR,A,F,Y,,,20221121,,HP,CA,CA,2022,Q4,Adult
216209461,21620946,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,25.0,MG,,,2022,Q4,COVID-19,,2022,Q4,1,I,,20221110.0,20221121,20221121,EXP,CA-MHPD-000992534,CA-Accord-287076,ACCORD,,62.0,YR,A,F,Y,,,20221121,,HP,CA,CA,2022,Q4,Adult
216209461,21620946,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,25.0,MG,,,2022,Q4,Urosepsis,,2022,Q4,1,I,,20221110.0,20221121,20221121,EXP,CA-MHPD-000992534,CA-Accord-287076,ACCORD,,62.0,YR,A,F,Y,,,20221121,,HP,CA,CA,2022,Q4,Adult
216215651,21621565,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,,2022,Q4,Infection,,2022,Q4,1,I,20221103.0,20221117.0,20221121,20221121,EXP,,DE-Eisai Medical Research-EC-2022-128366,EISAI,,73.0,YR,E,M,Y,125.3,KG,20221121,,MD,DE,,2022,Q4,Elderly
216215651,21621565,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,,2022,Q4,Malignant neoplasm progression,,2022,Q4,1,I,20221103.0,20221117.0,20221121,20221121,EXP,,DE-Eisai Medical Research-EC-2022-128366,EISAI,,73.0,YR,E,M,Y,125.3,KG,20221121,,MD,DE,,2022,Q4,Elderly
216232561,21623256,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Systemic infection,,2022,Q4,1,I,,20221115.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1129184,MYLAN,,54.0,YR,,M,Y,98.0,KG,20221121,,PH,DE,DE,2022,Q4,Adult
216232561,21623256,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Chest pain,,2022,Q4,1,I,,20221115.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1129184,MYLAN,,54.0,YR,,M,Y,98.0,KG,20221121,,PH,DE,DE,2022,Q4,Adult
216232561,21623256,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20221115.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1129184,MYLAN,,54.0,YR,,M,Y,98.0,KG,20221121,,PH,DE,DE,2022,Q4,Adult
216232561,21623256,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20221115.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1129184,MYLAN,,54.0,YR,,M,Y,98.0,KG,20221121,,PH,DE,DE,2022,Q4,Adult
216232561,21623256,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Electrocardiogram abnormal,,2022,Q4,1,I,,20221115.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1129184,MYLAN,,54.0,YR,,M,Y,98.0,KG,20221121,,PH,DE,DE,2022,Q4,Adult
216232561,21623256,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Labelled drug-drug interaction medication error,,2022,Q4,1,I,,20221115.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1129184,MYLAN,,54.0,YR,,M,Y,98.0,KG,20221121,,PH,DE,DE,2022,Q4,Adult
216232561,21623256,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Condition aggravated,,2022,Q4,1,I,,20221115.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1129184,MYLAN,,54.0,YR,,M,Y,98.0,KG,20221121,,PH,DE,DE,2022,Q4,Adult
216232561,21623256,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, 10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2022,Q4,Polyneuropathy,,2022,Q4,1,I,,20221115.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1129184,MYLAN,,54.0,YR,,M,Y,98.0,KG,20221121,,PH,DE,DE,2022,Q4,Adult
216233931,21623393,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Glomerular filtration rate decreased,,2022,Q4,1,I,20220101.0,20221117.0,20221121,20221121,EXP,,NVSC2022NZ259657,NOVARTIS,,53.0,YR,,M,Y,,,20221121,,MD,NZ,NZ,2022,Q4,Adult
216233931,21623393,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Left ventricular dilatation,,2022,Q4,1,I,20220101.0,20221117.0,20221121,20221121,EXP,,NVSC2022NZ259657,NOVARTIS,,53.0,YR,,M,Y,,,20221121,,MD,NZ,NZ,2022,Q4,Adult
216233931,21623393,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Infection,,2022,Q4,1,I,20220101.0,20221117.0,20221121,20221121,EXP,,NVSC2022NZ259657,NOVARTIS,,53.0,YR,,M,Y,,,20221121,,MD,NZ,NZ,2022,Q4,Adult
216233931,21623393,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Mitral valve incompetence,,2022,Q4,1,I,20220101.0,20221117.0,20221121,20221121,EXP,,NVSC2022NZ259657,NOVARTIS,,53.0,YR,,M,Y,,,20221121,,MD,NZ,NZ,2022,Q4,Adult
216233931,21623393,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Tricuspid valve incompetence,,2022,Q4,1,I,20220101.0,20221117.0,20221121,20221121,EXP,,NVSC2022NZ259657,NOVARTIS,,53.0,YR,,M,Y,,,20221121,,MD,NZ,NZ,2022,Q4,Adult
216233931,21623393,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Cardiac failure acute,,2022,Q4,1,I,20220101.0,20221117.0,20221121,20221121,EXP,,NVSC2022NZ259657,NOVARTIS,,53.0,YR,,M,Y,,,20221121,,MD,NZ,NZ,2022,Q4,Adult
216233931,21623393,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2022,Q4,Blood creatinine increased,,2022,Q4,1,I,20220101.0,20221117.0,20221121,20221121,EXP,,NVSC2022NZ259657,NOVARTIS,,53.0,YR,,M,Y,,,20221121,,MD,NZ,NZ,2022,Q4,Adult
216270461,21627046,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,25.0,MG,Tablet,,2022,Q4,Urosepsis,,2022,Q4,1,I,,20221110.0,20221122,20221122,EXP,CA-MHPD-000993078,CA-Accord-287074,ACCORD,,62.0,YR,A,F,Y,,,20221122,,HP,CA,CA,2022,Q4,Adult
216270461,21627046,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,25.0,MG,Tablet,,2022,Q4,Failure to suspend medication,,2022,Q4,1,I,,20221110.0,20221122,20221122,EXP,CA-MHPD-000993078,CA-Accord-287074,ACCORD,,62.0,YR,A,F,Y,,,20221122,,HP,CA,CA,2022,Q4,Adult
216297271,21629727,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram 1-0-0-0,,,,,,,,10.0,MG,,,2022,Q4,Tachycardia,,2022,Q4,1,I,,20221115.0,20221122,20221122,EXP,,DE-MYLANLABS-2022M1129319,MYLAN,,62.0,YR,,M,Y,,,20221122,,MD,DE,DE,2022,Q4,Adult
216297271,21629727,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram 1-0-0-0,,,,,,,,10.0,MG,,,2022,Q4,Liver function test abnormal,,2022,Q4,1,I,,20221115.0,20221122,20221122,EXP,,DE-MYLANLABS-2022M1129319,MYLAN,,62.0,YR,,M,Y,,,20221122,,MD,DE,DE,2022,Q4,Adult
216297271,21629727,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram 1-0-0-0,,,,,,,,10.0,MG,,,2022,Q4,Cardioversion,,2022,Q4,1,I,,20221115.0,20221122,20221122,EXP,,DE-MYLANLABS-2022M1129319,MYLAN,,62.0,YR,,M,Y,,,20221122,,MD,DE,DE,2022,Q4,Adult
216297271,21629727,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram 1-0-0-0,,,,,,,,10.0,MG,,,2022,Q4,Ejection fraction decreased,,2022,Q4,1,I,,20221115.0,20221122,20221122,EXP,,DE-MYLANLABS-2022M1129319,MYLAN,,62.0,YR,,M,Y,,,20221122,,MD,DE,DE,2022,Q4,Adult
216297271,21629727,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram 1-0-0-0,,,,,,,,10.0,MG,,,2022,Q4,Ischaemic cardiomyopathy,,2022,Q4,1,I,,20221115.0,20221122,20221122,EXP,,DE-MYLANLABS-2022M1129319,MYLAN,,62.0,YR,,M,Y,,,20221122,,MD,DE,DE,2022,Q4,Adult
216297271,21629727,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram 1-0-0-0,,,,,,,,10.0,MG,,,2022,Q4,Arrhythmia,,2022,Q4,1,I,,20221115.0,20221122,20221122,EXP,,DE-MYLANLABS-2022M1129319,MYLAN,,62.0,YR,,M,Y,,,20221122,,MD,DE,DE,2022,Q4,Adult
216303981,21630398,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221108.0,20221122,20221122,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-364695,RANBAXY,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol (Phila). 2022;60 (Suppl. 2):abstract 94; 47-48",33.0,YR,,F,Y,,,20221123,,HP,US,US,2022,Q4,Young Adult
216303981,21630398,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,,20221108.0,20221122,20221122,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-364695,RANBAXY,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol (Phila). 2022;60 (Suppl. 2):abstract 94; 47-48",33.0,YR,,F,Y,,,20221123,,HP,US,US,2022,Q4,Young Adult
216303981,21630398,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221108.0,20221122,20221122,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-364695,RANBAXY,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol (Phila). 2022;60 (Suppl. 2):abstract 94; 47-48",33.0,YR,,F,Y,,,20221123,,HP,US,US,2022,Q4,Young Adult
216303981,21630398,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,1,I,,20221108.0,20221122,20221122,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-364695,RANBAXY,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol (Phila). 2022;60 (Suppl. 2):abstract 94; 47-48",33.0,YR,,F,Y,,,20221123,,HP,US,US,2022,Q4,Young Adult
216303981,21630398,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221108.0,20221122,20221122,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-364695,RANBAXY,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol (Phila). 2022;60 (Suppl. 2):abstract 94; 47-48",33.0,YR,,F,Y,,,20221123,,HP,US,US,2022,Q4,Young Adult
216303981,21630398,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221108.0,20221122,20221122,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-364695,RANBAXY,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol (Phila). 2022;60 (Suppl. 2):abstract 94; 47-48",33.0,YR,,F,Y,,,20221123,,HP,US,US,2022,Q4,Young Adult
216303981,21630398,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,1,I,,20221108.0,20221122,20221122,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-364695,RANBAXY,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clin Toxicol (Phila). 2022;60 (Suppl. 2):abstract 94; 47-48",33.0,YR,,F,Y,,,20221123,,HP,US,US,2022,Q4,Young Adult
216342062,21634206,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1 tablet",,,,,,,,10.0,MG,,,2022,Q4,Acute kidney injury,,2022,Q4,2,F,,20221118.0,20221123,20221130,EXP,,JP-AstraZeneca-2022A382519,ASTRAZENECA,,71.0,YR,,M,Y,,,20221130,,MD,JP,,2022,Q4,Elderly
216342062,21634206,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1 tablet",,,,,,,,10.0,MG,,,2022,Q4,Cardiac failure,,2022,Q4,2,F,,20221118.0,20221123,20221130,EXP,,JP-AstraZeneca-2022A382519,ASTRAZENECA,,71.0,YR,,M,Y,,,20221130,,MD,JP,,2022,Q4,Elderly
216343761,21634376,4,C,Empagliflozin (Jardiance) 25 mg,,2,,,,,,,,,,,,,,2022,Q4,Immune-mediated nephritis,,2022,Q4,1,I,20221115.0,,20221123,20221123,DIR,639251,,FDA-CTU,,82.0,YR,,M,N,103.5,KG,20221123,Y,,US,,2022,Q4,Elderly
216343761,21634376,4,C,Empagliflozin (Jardiance) 25 mg,,2,,,,,,,,,,,,,,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20221115.0,,20221123,20221123,DIR,639251,,FDA-CTU,,82.0,YR,,M,N,103.5,KG,20221123,Y,,US,,2022,Q4,Elderly
216343761,21634376,4,C,Empagliflozin (Jardiance) 25 mg,,2,,,,,,,,,,,,,,2022,Q4,Deep vein thrombosis,,2022,Q4,1,I,20221115.0,,20221123,20221123,DIR,639251,,FDA-CTU,,82.0,YR,,M,N,103.5,KG,20221123,Y,,US,,2022,Q4,Elderly
216348891,21634889,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,UNK,,,,,,,2022,Q4,Oedema peripheral,,2022,Q4,1,I,,20221114.0,20221123,20221123,EXP,NZ-ALVOGEN-2022088660,NZ-ALVOGEN-2022088660,ALVOGEN,,66.0,YR,,M,Y,,,20221123,,CN,NZ,NZ,2022,Q4,Elderly
216348891,21634889,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,UNK,,,,,,,2022,Q4,Acute kidney injury,,2022,Q4,1,I,,20221114.0,20221123,20221123,EXP,NZ-ALVOGEN-2022088660,NZ-ALVOGEN-2022088660,ALVOGEN,,66.0,YR,,M,Y,,,20221123,,CN,NZ,NZ,2022,Q4,Elderly
216348891,21634889,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,UNK,,,,,,,2022,Q4,Vomiting,,2022,Q4,1,I,,20221114.0,20221123,20221123,EXP,NZ-ALVOGEN-2022088660,NZ-ALVOGEN-2022088660,ALVOGEN,,66.0,YR,,M,Y,,,20221123,,CN,NZ,NZ,2022,Q4,Elderly
216348891,21634889,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,UNK,,,,,,,2022,Q4,Purpura,,2022,Q4,1,I,,20221114.0,20221123,20221123,EXP,NZ-ALVOGEN-2022088660,NZ-ALVOGEN-2022088660,ALVOGEN,,66.0,YR,,M,Y,,,20221123,,CN,NZ,NZ,2022,Q4,Elderly
216348891,21634889,5,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,UNK,,,,,,,2022,Q4,Arthralgia,,2022,Q4,1,I,,20221114.0,20221123,20221123,EXP,NZ-ALVOGEN-2022088660,NZ-ALVOGEN-2022088660,ALVOGEN,,66.0,YR,,M,Y,,,20221123,,CN,NZ,NZ,2022,Q4,Elderly
216361761,21636176,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2022,Q4,Off label use,,2022,Q4,1,I,,20220824.0,20221124,20221124,PER,,US-STRIDES ARCOLAB LIMITED-2022SP010961,STRIDES,"Corpuz E, Dean J-HL, Cahill M.. Pass The Salt? Acute Asymptomatic Hyponatremia Following Inpatient Initiation Of Angiotensin Reeeptor-Neprilysin Inhibitor.. J-Gen-Intern-Med;. 2022;37 (Suppl. 2):S497",71.0,YR,,F,Y,,,20221124,,HP,US,US,2022,Q4,Elderly
216361761,21636176,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, reinitiated",,,D,,,,,,,,,2022,Q4,Off label use,,2022,Q4,1,I,,20220824.0,20221124,20221124,PER,,US-STRIDES ARCOLAB LIMITED-2022SP010961,STRIDES,"Corpuz E, Dean J-HL, Cahill M.. Pass The Salt? Acute Asymptomatic Hyponatremia Following Inpatient Initiation Of Angiotensin Reeeptor-Neprilysin Inhibitor.. J-Gen-Intern-Med;. 2022;37 (Suppl. 2):S497",71.0,YR,,F,Y,,,20221124,,HP,US,US,2022,Q4,Elderly
216367531,21636753,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,U,U,Unknown,,,25.0,MG,,,2022,Q4,Decreased appetite,,2022,Q4,1,I,,20220916.0,20221124,20221124,EXP,,TR-ALKEM LABORATORIES LIMITED-TR-ALKEM-2022-10729,ALKEM,"Bahat G, Catikkas NM, Karan MA, Petrovic M.. Management of type 2 diabetes mellitus in older adults: eight case studies with focus SGLT-2 inhibitors and metformin.. ACTA CLINICA BELGICA. 2022;77(4):727-734",75.0,YR,,M,Y,,,20221124,,HP,TR,TR,2022,Q4,Elderly
216367741,21636774,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd (every 1 day)",,,U,U,Unknown,,,,,,QD,2022,Q4,Blood potassium increased,,2022,Q4,1,I,20221005.0,20221018.0,20221124,20221124,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-11400,ALKEM,,60.0,YR,,M,Y,,,20221124,,MD,DE,DE,2022,Q4,Adult
216367741,21636774,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, qd (every 1 day)",,,U,U,Unknown,,,,,,QD,2022,Q4,Blood potassium increased,,2022,Q4,1,I,20221005.0,20221018.0,20221124,20221124,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-11400,ALKEM,,60.0,YR,,M,Y,,,20221124,,MD,DE,DE,2022,Q4,Adult
216367781,21636778,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,,,Unknown,,,25.0,MG,,,2022,Q4,Decreased appetite,,2022,Q4,1,I,,20220916.0,20221124,20221124,EXP,,TR-ALKEM LABORATORIES LIMITED-TR-ALKEM-2022-08763,ALKEM,"Bahat G, Catikkas NM, Karan MA, Petrovic M. Management of type 2 diabetes mellitus in older adults: eight case studies with focus SGLT-2 inhibitors and metformin. Acta Clin Belg. 2022;77(4):727-734",81.0,YR,,F,Y,,,20221124,,HP,TR,TR,2022,Q4,Elderly
216367781,21636778,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,,,Unknown,,,25.0,MG,,,2022,Q4,Asthenia,,2022,Q4,1,I,,20220916.0,20221124,20221124,EXP,,TR-ALKEM LABORATORIES LIMITED-TR-ALKEM-2022-08763,ALKEM,"Bahat G, Catikkas NM, Karan MA, Petrovic M. Management of type 2 diabetes mellitus in older adults: eight case studies with focus SGLT-2 inhibitors and metformin. Acta Clin Belg. 2022;77(4):727-734",81.0,YR,,F,Y,,,20221124,,HP,TR,TR,2022,Q4,Elderly
216367781,21636778,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 milligram,,,,,Unknown,,,25.0,MG,,,2022,Q4,Weight decreased,,2022,Q4,1,I,,20220916.0,20221124,20221124,EXP,,TR-ALKEM LABORATORIES LIMITED-TR-ALKEM-2022-08763,ALKEM,"Bahat G, Catikkas NM, Karan MA, Petrovic M. Management of type 2 diabetes mellitus in older adults: eight case studies with focus SGLT-2 inhibitors and metformin. Acta Clin Belg. 2022;77(4):727-734",81.0,YR,,F,Y,,,20221124,,HP,TR,TR,2022,Q4,Elderly
216369843,21636984,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Sepsis,,2022,Q4,3,F,20221117.0,20221219.0,20221124,20221221,EXP,,NZ-ROCHE-3222704,ROCHE,,49.0,YR,,F,Y,95.3,KG,20221221,,MD,NZ,,2022,Q4,Adult
216384711,21638471,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q4,Renal cyst,,2022,Q4,1,I,,20221115.0,20221124,20221124,EXP,,AU-drreddys-SPO/AUS/22/0157395,DR REDDYS,,75.0,YR,E,F,Y,,,20221124,,CN,AU,AU,2022,Q4,Elderly
216384711,21638471,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q4,Vertebral lesion,,2022,Q4,1,I,,20221115.0,20221124,20221124,EXP,,AU-drreddys-SPO/AUS/22/0157395,DR REDDYS,,75.0,YR,E,F,Y,,,20221124,,CN,AU,AU,2022,Q4,Elderly
216384711,21638471,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q4,Pneumonia,,2022,Q4,1,I,,20221115.0,20221124,20221124,EXP,,AU-drreddys-SPO/AUS/22/0157395,DR REDDYS,,75.0,YR,E,F,Y,,,20221124,,CN,AU,AU,2022,Q4,Elderly
216384711,21638471,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q4,Second primary malignancy,,2022,Q4,1,I,,20221115.0,20221124,20221124,EXP,,AU-drreddys-SPO/AUS/22/0157395,DR REDDYS,,75.0,YR,E,F,Y,,,20221124,,CN,AU,AU,2022,Q4,Elderly
216384711,21638471,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,UNKNOWN,,,,,,,2022,Q4,Vertebral column mass,,2022,Q4,1,I,,20221115.0,20221124,20221124,EXP,,AU-drreddys-SPO/AUS/22/0157395,DR REDDYS,,75.0,YR,E,F,Y,,,20221124,,CN,AU,AU,2022,Q4,Elderly
216416511,21641651,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500 mg od,,,U,,Unknown,,208658.0,,,,QD,2022,Q4,Cardiac ablation,,2022,Q4,1,I,20220201.0,20221118.0,20221125,20221125,EXP,,"ID-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203654",BOEHRINGER INGELHEIM,,55.0,YR,A,F,Y,93.0,KG,20221125,,MD,ID,ID,2022,Q4,Adult
216416511,21641651,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500 mg od,,,U,,Unknown,,208658.0,,,,QD,2022,Q4,Intentional product use issue,,2022,Q4,1,I,20220201.0,20221118.0,20221125,20221125,EXP,,"ID-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203654",BOEHRINGER INGELHEIM,,55.0,YR,A,F,Y,93.0,KG,20221125,,MD,ID,ID,2022,Q4,Adult
216416511,21641651,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500 mg od,,,U,,Unknown,,208658.0,,,,QD,2022,Q4,Hypotension,,2022,Q4,1,I,20220201.0,20221118.0,20221125,20221125,EXP,,"ID-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203654",BOEHRINGER INGELHEIM,,55.0,YR,A,F,Y,93.0,KG,20221125,,MD,ID,ID,2022,Q4,Adult
216416511,21641651,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500 mg od,,,U,,Unknown,,208658.0,,,,QD,2022,Q4,Dizziness,,2022,Q4,1,I,20220201.0,20221118.0,20221125,20221125,EXP,,"ID-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203654",BOEHRINGER INGELHEIM,,55.0,YR,A,F,Y,93.0,KG,20221125,,MD,ID,ID,2022,Q4,Adult
216416511,21641651,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500 mg od,,,U,,Unknown,,208658.0,,,,QD,2022,Q4,Cardiac ablation,,2022,Q4,1,I,20220201.0,20221118.0,20221125,20221125,EXP,,"ID-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203654",BOEHRINGER INGELHEIM,,55.0,YR,A,F,Y,93.0,KG,20221125,,MD,ID,ID,2022,Q4,Adult
216416511,21641651,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500 mg od,,,U,,Unknown,,208658.0,,,,QD,2022,Q4,Intentional product use issue,,2022,Q4,1,I,20220201.0,20221118.0,20221125,20221125,EXP,,"ID-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203654",BOEHRINGER INGELHEIM,,55.0,YR,A,F,Y,93.0,KG,20221125,,MD,ID,ID,2022,Q4,Adult
216416511,21641651,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500 mg od,,,U,,Unknown,,208658.0,,,,QD,2022,Q4,Hypotension,,2022,Q4,1,I,20220201.0,20221118.0,20221125,20221125,EXP,,"ID-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203654",BOEHRINGER INGELHEIM,,55.0,YR,A,F,Y,93.0,KG,20221125,,MD,ID,ID,2022,Q4,Adult
216416511,21641651,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5/500 mg od,,,U,,Unknown,,208658.0,,,,QD,2022,Q4,Dizziness,,2022,Q4,1,I,20220201.0,20221118.0,20221125,20221125,EXP,,"ID-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203654",BOEHRINGER INGELHEIM,,55.0,YR,A,F,Y,93.0,KG,20221125,,MD,ID,ID,2022,Q4,Adult
216444741,21644474,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Headache,,2022,Q4,1,I,20220901.0,20221118.0,20221125,20221125,EXP,GB-MHRA-TPP5530364C1446924YC1668076919727,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203727",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,86.0,KG,20221125,,MD,GB,GB,2022,Q4,Elderly
216444741,21644474,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Hyperhidrosis,,2022,Q4,1,I,20220901.0,20221118.0,20221125,20221125,EXP,GB-MHRA-TPP5530364C1446924YC1668076919727,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203727",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,86.0,KG,20221125,,MD,GB,GB,2022,Q4,Elderly
216444741,21644474,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Decreased appetite,,2022,Q4,1,I,20220901.0,20221118.0,20221125,20221125,EXP,GB-MHRA-TPP5530364C1446924YC1668076919727,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203727",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,86.0,KG,20221125,,MD,GB,GB,2022,Q4,Elderly
216444741,21644474,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Decreased appetite,,2022,Q4,1,I,20220901.0,20221118.0,20221125,20221125,EXP,GB-MHRA-TPP5530364C1446924YC1668076919727,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203727",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,86.0,KG,20221125,,MD,GB,GB,2022,Q4,Elderly
216444741,21644474,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Weight decreased,,2022,Q4,1,I,20220901.0,20221118.0,20221125,20221125,EXP,GB-MHRA-TPP5530364C1446924YC1668076919727,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203727",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,86.0,KG,20221125,,MD,GB,GB,2022,Q4,Elderly
216444741,21644474,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q4,Headache,,2022,Q4,1,I,20220901.0,20221118.0,20221125,20221125,EXP,GB-MHRA-TPP5530364C1446924YC1668076919727,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203727",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,86.0,KG,20221125,,MD,GB,GB,2022,Q4,Elderly
216444741,21644474,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q4,Hyperhidrosis,,2022,Q4,1,I,20220901.0,20221118.0,20221125,20221125,EXP,GB-MHRA-TPP5530364C1446924YC1668076919727,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203727",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,86.0,KG,20221125,,MD,GB,GB,2022,Q4,Elderly
216444741,21644474,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q4,Decreased appetite,,2022,Q4,1,I,20220901.0,20221118.0,20221125,20221125,EXP,GB-MHRA-TPP5530364C1446924YC1668076919727,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203727",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,86.0,KG,20221125,,MD,GB,GB,2022,Q4,Elderly
216444741,21644474,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q4,Decreased appetite,,2022,Q4,1,I,20220901.0,20221118.0,20221125,20221125,EXP,GB-MHRA-TPP5530364C1446924YC1668076919727,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203727",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,86.0,KG,20221125,,MD,GB,GB,2022,Q4,Elderly
216444741,21644474,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q4,Weight decreased,,2022,Q4,1,I,20220901.0,20221118.0,20221125,20221125,EXP,GB-MHRA-TPP5530364C1446924YC1668076919727,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-203727",BOEHRINGER INGELHEIM,,84.0,YR,E,M,Y,86.0,KG,20221125,,MD,GB,GB,2022,Q4,Elderly
216468442,21646844,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Telangiectasia,,2022,Q4,2,F,20220706.0,20221207.0,20221127,20221216,EXP,PT-INFARMED-V202211-339,PT-TEVA-2022-PT-2829251,TEVA,,66.0,YR,E,F,Y,,,20221216,,PH,PT,PT,2022,Q4,Elderly
216468442,21646844,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Alopecia,,2022,Q4,2,F,20220706.0,20221207.0,20221127,20221216,EXP,PT-INFARMED-V202211-339,PT-TEVA-2022-PT-2829251,TEVA,,66.0,YR,E,F,Y,,,20221216,,PH,PT,PT,2022,Q4,Elderly
216469272,21646927,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Additional info: Overdose,,,D,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,2,F,,20221201.0,20221127,20221209,EXP,,US-TEVA-2022-US-2827913,TEVA,,33.0,YR,A,F,Y,,,20221209,,HP,US,US,2022,Q4,Young Adult
216469272,21646927,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Additional info: Overdose,,,D,,,,,,,,,2022,Q4,Cerebral infarction,,2022,Q4,2,F,,20221201.0,20221127,20221209,EXP,,US-TEVA-2022-US-2827913,TEVA,,33.0,YR,A,F,Y,,,20221209,,HP,US,US,2022,Q4,Young Adult
216469272,21646927,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Additional info: Overdose,,,D,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,2,F,,20221201.0,20221127,20221209,EXP,,US-TEVA-2022-US-2827913,TEVA,,33.0,YR,A,F,Y,,,20221209,,HP,US,US,2022,Q4,Young Adult
216469272,21646927,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Additional info: Overdose,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,2,F,,20221201.0,20221127,20221209,EXP,,US-TEVA-2022-US-2827913,TEVA,,33.0,YR,A,F,Y,,,20221209,,HP,US,US,2022,Q4,Young Adult
216469272,21646927,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Additional info: Overdose,,,D,,,,,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,2,F,,20221201.0,20221127,20221209,EXP,,US-TEVA-2022-US-2827913,TEVA,,33.0,YR,A,F,Y,,,20221209,,HP,US,US,2022,Q4,Young Adult
216469272,21646927,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Additional info: Overdose,,,D,,,,,,,,,2022,Q4,Respiratory arrest,,2022,Q4,2,F,,20221201.0,20221127,20221209,EXP,,US-TEVA-2022-US-2827913,TEVA,,33.0,YR,A,F,Y,,,20221209,,HP,US,US,2022,Q4,Young Adult
216469272,21646927,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Additional info: Overdose,,,D,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,2,F,,20221201.0,20221127,20221209,EXP,,US-TEVA-2022-US-2827913,TEVA,,33.0,YR,A,F,Y,,,20221209,,HP,US,US,2022,Q4,Young Adult
216469272,21646927,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Additional info: Overdose,,,D,,,,,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,2,F,,20221201.0,20221127,20221209,EXP,,US-TEVA-2022-US-2827913,TEVA,,33.0,YR,A,F,Y,,,20221209,,HP,US,US,2022,Q4,Young Adult
216485851,21648585,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Form strength: 12.5/1000 mg. Dosage was not reported.,,,Y,U,Unknown,,206111.0,,,,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,20210101.0,20221123.0,20221128,20221128,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-204370",BOEHRINGER INGELHEIM,,4.0,DEC,A,M,Y,,,20221128,,MD,AU,AU,2022,Q4,Child
216485851,21648585,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Form strength: 12.5/1000 mg. Dosage was not reported.,,,Y,U,Unknown,,206111.0,,,,,2022,Q4,Diabetes mellitus inadequate control,,2022,Q4,1,I,20210101.0,20221123.0,20221128,20221128,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-204370",BOEHRINGER INGELHEIM,,4.0,DEC,A,M,Y,,,20221128,,MD,AU,AU,2022,Q4,Child
216485851,21648585,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Form strength: 12.5/1000 mg. Dosage was not reported.,,,Y,U,Unknown,,206111.0,,,,,2022,Q4,Blood glucose increased,,2022,Q4,1,I,20210101.0,20221123.0,20221128,20221128,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-204370",BOEHRINGER INGELHEIM,,4.0,DEC,A,M,Y,,,20221128,,MD,AU,AU,2022,Q4,Child
216493121,21649312,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Off label use,,2022,Q4,1,I,20220901.0,20221123.0,20221128,20221128,EXP,,NVSC2022MX275242,NOVARTIS,,70.0,YR,,F,Y,57.0,KG,20221128,,CN,MX,MX,2022,Q4,Elderly
216493121,21649312,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, QD",,,,,,,,,,,QD,2022,Q4,Pulmonary oedema,,2022,Q4,1,I,20220901.0,20221123.0,20221128,20221128,EXP,,NVSC2022MX275242,NOVARTIS,,70.0,YR,,F,Y,57.0,KG,20221128,,CN,MX,MX,2022,Q4,Elderly
216500701,21650070,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Rash erythematous,,2022,Q4,1,I,20221001.0,,20221123,20221123,DIR,639335,,FDA-CTU,,65.0,YR,,M,N,115.2,KG,20221123,N,CN,US,,2022,Q4,Elderly
216500701,21650070,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Skin exfoliation,,2022,Q4,1,I,20221001.0,,20221123,20221123,DIR,639335,,FDA-CTU,,65.0,YR,,M,N,115.2,KG,20221123,N,CN,US,,2022,Q4,Elderly
216558341,21655834,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"strength: 10mg, 1-0-0-0",,,U,,,,,10.0,MG,,,2022,Q4,Cardiogenic shock,,2022,Q4,1,I,20210501.0,20221116.0,20221129,20221129,EXP,DE-BFARM-22007015,DE-Accord-288138,ACCORD,,78.0,YR,E,M,Y,83.0,KG,20221129,,PH,DE,DE,2022,Q4,Elderly
216558341,21655834,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"strength: 10mg, 1-0-0-0",,,U,,,,,10.0,MG,,,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20210501.0,20221116.0,20221129,20221129,EXP,DE-BFARM-22007015,DE-Accord-288138,ACCORD,,78.0,YR,E,M,Y,83.0,KG,20221129,,PH,DE,DE,2022,Q4,Elderly
216558341,21655834,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"strength: 10mg, 1-0-0-0",,,U,,,,,10.0,MG,,,2022,Q4,Weight increased,,2022,Q4,1,I,20210501.0,20221116.0,20221129,20221129,EXP,DE-BFARM-22007015,DE-Accord-288138,ACCORD,,78.0,YR,E,M,Y,83.0,KG,20221129,,PH,DE,DE,2022,Q4,Elderly
216558341,21655834,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"strength: 10mg, 1-0-0-0",,,U,,,,,10.0,MG,,,2022,Q4,Medication error,,2022,Q4,1,I,20210501.0,20221116.0,20221129,20221129,EXP,DE-BFARM-22007015,DE-Accord-288138,ACCORD,,78.0,YR,E,M,Y,83.0,KG,20221129,,PH,DE,DE,2022,Q4,Elderly
216563051,21656305,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,,,,,,Tablet,,2022,Q4,Haematuria,,2022,Q4,1,I,20210801.0,20221116.0,20221129,20221129,EXP,DE-BFARM-22007344,DE-Accord-287923,ACCORD,,64.0,YR,A,M,Y,85.0,KG,20221129,,PH,DE,DE,2022,Q4,Adult
216563051,21656305,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,,,,,,Tablet,,2022,Q4,Hyperkalaemia,,2022,Q4,1,I,20210801.0,20221116.0,20221129,20221129,EXP,DE-BFARM-22007344,DE-Accord-287923,ACCORD,,64.0,YR,A,M,Y,85.0,KG,20221129,,PH,DE,DE,2022,Q4,Adult
216631051,21663105,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221124.0,20221130,20221130,EXP,,US-SCIEGENP-2022SCLIT00725,SCIEGEN,"Malley C, et al. .Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis.Clinical Toxicology.jan-2022;60 (2):47-48",33.0,YR,A,F,Y,,,20221130,,HP,US,US,2022,Q4,Young Adult
216631051,21663105,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221124.0,20221130,20221130,EXP,,US-SCIEGENP-2022SCLIT00725,SCIEGEN,"Malley C, et al. .Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis.Clinical Toxicology.jan-2022;60 (2):47-48",33.0,YR,A,F,Y,,,20221130,,HP,US,US,2022,Q4,Young Adult
216631051,21663105,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221124.0,20221130,20221130,EXP,,US-SCIEGENP-2022SCLIT00725,SCIEGEN,"Malley C, et al. .Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis.Clinical Toxicology.jan-2022;60 (2):47-48",33.0,YR,A,F,Y,,,20221130,,HP,US,US,2022,Q4,Young Adult
216634226,21663422,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,,,,Unknown,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,6,F,20221116.0,20221215.0,20221130,20221216,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2022-145071,BRISTOL MYERS SQUIBB,,71.0,YR,E,F,Y,,,20221216,,HP,DE,DE,2022,Q4,Elderly
216637082,21663708,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Vomiting,,2022,Q4,2,F,20211214.0,20221208.0,20221130,20221215,EXP,,AU-TAKEDA-2021TUS081693,TAKEDA,,76.0,YR,,M,Y,,,20221215,,MD,AU,AU,2022,Q4,Elderly
216637082,21663708,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Plasma cell myeloma,,2022,Q4,2,F,20211214.0,20221208.0,20221130,20221215,EXP,,AU-TAKEDA-2021TUS081693,TAKEDA,,76.0,YR,,M,Y,,,20221215,,MD,AU,AU,2022,Q4,Elderly
216637082,21663708,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Nausea,,2022,Q4,2,F,20211214.0,20221208.0,20221130,20221215,EXP,,AU-TAKEDA-2021TUS081693,TAKEDA,,76.0,YR,,M,Y,,,20221215,,MD,AU,AU,2022,Q4,Elderly
216637082,21663708,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Anxiety,,2022,Q4,2,F,20211214.0,20221208.0,20221130,20221215,EXP,,AU-TAKEDA-2021TUS081693,TAKEDA,,76.0,YR,,M,Y,,,20221215,,MD,AU,AU,2022,Q4,Elderly
216643391,21664339,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram (25 mg, 1-0-0-0, Tablet)",,,U,U,,,,25.0,MG,Tablet,,2022,Q4,Therapeutic drug monitoring analysis incorrectly performed,,2022,Q4,1,I,,20221128.0,20221130,20221130,EXP,,DE-MYLANLABS-2022M1134110,MYLAN,,59.0,YR,,M,Y,125.0,KG,20221130,,PH,DE,DE,2022,Q4,Adult
216643391,21664339,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram (25 mg, 1-0-0-0, Tablet)",,,U,U,,,,25.0,MG,Tablet,,2022,Q4,Erythema,,2022,Q4,1,I,,20221128.0,20221130,20221130,EXP,,DE-MYLANLABS-2022M1134110,MYLAN,,59.0,YR,,M,Y,125.0,KG,20221130,,PH,DE,DE,2022,Q4,Adult
216643391,21664339,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram (25 mg, 1-0-0-0, Tablet)",,,U,U,,,,25.0,MG,Tablet,,2022,Q4,Wound secretion,,2022,Q4,1,I,,20221128.0,20221130,20221130,EXP,,DE-MYLANLABS-2022M1134110,MYLAN,,59.0,YR,,M,Y,125.0,KG,20221130,,PH,DE,DE,2022,Q4,Adult
216643391,21664339,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram (25 mg, 1-0-0-0, Tablet)",,,U,U,,,,25.0,MG,Tablet,,2022,Q4,Limb injury,,2022,Q4,1,I,,20221128.0,20221130,20221130,EXP,,DE-MYLANLABS-2022M1134110,MYLAN,,59.0,YR,,M,Y,125.0,KG,20221130,,PH,DE,DE,2022,Q4,Adult
216643391,21664339,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram (25 mg, 1-0-0-0, Tablet)",,,U,U,,,,25.0,MG,Tablet,,2022,Q4,Impaired healing,,2022,Q4,1,I,,20221128.0,20221130,20221130,EXP,,DE-MYLANLABS-2022M1134110,MYLAN,,59.0,YR,,M,Y,125.0,KG,20221130,,PH,DE,DE,2022,Q4,Adult
216643391,21664339,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram (25 mg, 1-0-0-0, Tablet)",,,U,U,,,,25.0,MG,Tablet,,2022,Q4,Foot amputation,,2022,Q4,1,I,,20221128.0,20221130,20221130,EXP,,DE-MYLANLABS-2022M1134110,MYLAN,,59.0,YR,,M,Y,125.0,KG,20221130,,PH,DE,DE,2022,Q4,Adult
216647461,21664746,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221124.0,20221130,20221130,EXP,,US-MYLANLABS-2022M1134296,MYLAN,"Hendrickson AL, Ye XQ, Kalra SS, Franck AJ, Urbine D. Euglycemic diabetic ketoacidosis in a patient prescribed empagliflozin and a ketogenic diet: A case of misdiagnosed type 1 diabetes. Clin-Diabet 2021;39(1):121-123.",70.0,YR,,F,Y,,,20221130,,HP,US,US,2022,Q4,Elderly
216664642,21666464,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Diarrhoea,,2022,Q4,2,F,20220101.0,20221206.0,20221201,20221208,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20221208,,MD,CH,CH,2022,Q4,Elderly
216664642,21666464,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Muscle spasms,,2022,Q4,2,F,20220101.0,20221206.0,20221201,20221208,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20221208,,MD,CH,CH,2022,Q4,Elderly
216664642,21666464,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,COVID-19,,2022,Q4,2,F,20220101.0,20221206.0,20221201,20221208,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20221208,,MD,CH,CH,2022,Q4,Elderly
216664642,21666464,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Tenosynovitis stenosans,,2022,Q4,2,F,20220101.0,20221206.0,20221201,20221208,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20221208,,MD,CH,CH,2022,Q4,Elderly
216664642,21666464,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,COVID-19,,2022,Q4,2,F,20220101.0,20221206.0,20221201,20221208,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20221208,,MD,CH,CH,2022,Q4,Elderly
216664642,21666464,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Diarrhoea,,2022,Q4,2,F,20220101.0,20221206.0,20221201,20221208,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20221208,,MD,CH,CH,2022,Q4,Elderly
216664642,21666464,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,COVID-19,,2022,Q4,2,F,20220101.0,20221206.0,20221201,20221208,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20221208,,MD,CH,CH,2022,Q4,Elderly
216664642,21666464,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Neutropenia,,2022,Q4,2,F,20220101.0,20221206.0,20221201,20221208,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20221208,,MD,CH,CH,2022,Q4,Elderly
216664642,21666464,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,10.0,MG,,QD,2022,Q4,Thrombocytopenia,,2022,Q4,2,F,20220101.0,20221206.0,20221201,20221208,EXP,,CH-ABBVIE-22K-151-4499914-00,ABBVIE,,88.0,YR,,M,Y,70.0,KG,20221208,,MD,CH,CH,2022,Q4,Elderly
216667511,21666751,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,Unknown,,206111.0,,,,,2022,Q4,Hyperlactacidaemia,,2022,Q4,1,I,20221104.0,20221124.0,20221201,20221201,EXP,CH-SM-2022-21573,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-204707",BOEHRINGER INGELHEIM,,76.0,YR,E,F,Y,84.6,KG,20221201,,PH,CH,CH,2022,Q4,Elderly
216667511,21666751,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,Y,U,Unknown,,206111.0,,,,,2022,Q4,Diarrhoea,,2022,Q4,1,I,20221104.0,20221124.0,20221201,20221201,EXP,CH-SM-2022-21573,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-204707",BOEHRINGER INGELHEIM,,76.0,YR,E,F,Y,84.6,KG,20221201,,PH,CH,CH,2022,Q4,Elderly
216689631,21668963,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Pancytopenia,,2022,Q4,1,I,20221107.0,,20221201,20221201,DIR,639919,,FDA-CTU,,78.0,YR,,F,N,59.4,KG,20221201,N,PH,US,,2022,Q4,Elderly
216689631,21668963,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Chills,,2022,Q4,1,I,20221107.0,,20221201,20221201,DIR,639919,,FDA-CTU,,78.0,YR,,F,N,59.4,KG,20221201,N,PH,US,,2022,Q4,Elderly
216689631,21668963,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Cardiac arrest,,2022,Q4,1,I,20221107.0,,20221201,20221201,DIR,639919,,FDA-CTU,,78.0,YR,,F,N,59.4,KG,20221201,N,PH,US,,2022,Q4,Elderly
216703231,21670323,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2022,Q4,Delirium,,2022,Q4,1,I,,20221122.0,20221201,20221201,EXP,,JP-JNJFOC-20221200218,JOHNSON AND JOHNSON,,81.0,YR,E,M,Y,,,20221202,,MD,JP,JP,2022,Q4,Elderly
216703231,21670323,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2022,Q4,Pulmonary oedema,,2022,Q4,1,I,,20221122.0,20221201,20221201,EXP,,JP-JNJFOC-20221200218,JOHNSON AND JOHNSON,,81.0,YR,E,M,Y,,,20221202,,MD,JP,JP,2022,Q4,Elderly
216721061,21672106,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, 1-0-0-0, Tablet",,,,,,,,,,Tablet,,2022,Q4,Cough,,2022,Q4,1,I,,20221119.0,20221202,20221202,EXP,DE-BFARM-20010225,DE-Accord-288808,ACCORD,,60.0,YR,A,M,Y,97.0,KG,20221202,,PH,DE,DE,2022,Q4,Adult
216721061,21672106,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, 1-0-0-0, Tablet",,,,,,,,,,Tablet,,2022,Q4,Condition aggravated,,2022,Q4,1,I,,20221119.0,20221202,20221202,EXP,DE-BFARM-20010225,DE-Accord-288808,ACCORD,,60.0,YR,A,M,Y,97.0,KG,20221202,,PH,DE,DE,2022,Q4,Adult
216721061,21672106,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, 1-0-0-0, Tablet",,,,,,,,,,Tablet,,2022,Q4,Product monitoring error,,2022,Q4,1,I,,20221119.0,20221202,20221202,EXP,DE-BFARM-20010225,DE-Accord-288808,ACCORD,,60.0,YR,A,M,Y,97.0,KG,20221202,,PH,DE,DE,2022,Q4,Adult
216721061,21672106,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, 1-0-0-0, Tablet",,,,,,,,,,Tablet,,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20221119.0,20221202,20221202,EXP,DE-BFARM-20010225,DE-Accord-288808,ACCORD,,60.0,YR,A,M,Y,97.0,KG,20221202,,PH,DE,DE,2022,Q4,Adult
216747061,21674706,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Feeling abnormal,,2022,Q4,1,I,,20221129.0,20221202,20221202,PER,,US-SA-2022SA490140,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20221202,,CN,US,US,2022,Q4,Elderly
216747061,21674706,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Nausea,,2022,Q4,1,I,,20221129.0,20221202,20221202,PER,,US-SA-2022SA490140,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20221202,,CN,US,US,2022,Q4,Elderly
216747061,21674706,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Weight decreased,,2022,Q4,1,I,,20221129.0,20221202,20221202,PER,,US-SA-2022SA490140,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20221202,,CN,US,US,2022,Q4,Elderly
216747061,21674706,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Tremor,,2022,Q4,1,I,,20221129.0,20221202,20221202,PER,,US-SA-2022SA490140,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20221202,,CN,US,US,2022,Q4,Elderly
216747061,21674706,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Blood glucose decreased,,2022,Q4,1,I,,20221129.0,20221202,20221202,PER,,US-SA-2022SA490140,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20221202,,CN,US,US,2022,Q4,Elderly
216747061,21674706,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Illness,,2022,Q4,1,I,,20221129.0,20221202,20221202,PER,,US-SA-2022SA490140,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20221202,,CN,US,US,2022,Q4,Elderly
216747061,21674706,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Injection site pain,,2022,Q4,1,I,,20221129.0,20221202,20221202,PER,,US-SA-2022SA490140,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20221202,,CN,US,US,2022,Q4,Elderly
216747061,21674706,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2022,Q4,Malaise,,2022,Q4,1,I,,20221129.0,20221202,20221202,PER,,US-SA-2022SA490140,SANOFI AVENTIS,,76.0,YR,E,F,Y,,,20221202,,CN,US,US,2022,Q4,Elderly
216753031,21675303,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,20221201.0,,20221202,20221202,DIR,640102,,FDA-CTU,,79.0,YR,,M,N,81.0,KG,20221202,N,PH,US,,2022,Q4,Elderly
216753031,21675303,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,20221201.0,,20221202,20221202,DIR,640102,,FDA-CTU,,79.0,YR,,M,N,81.0,KG,20221202,N,PH,US,,2022,Q4,Elderly
216785771,21678577,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Chronic kidney disease,,2022,Q4,1,I,,20221121.0,20221203,20221203,EXP,,JP-NOVOPROD-986001,NOVO NORDISK,"Hidekatsu Yanai et al.,. Chronic Kidney Disease Stage G4 in a Diabetic Patient Improved by Multi-Disciplinary Treatments Based Upon Literature Search for Therapeutic Evidence. cardiology research. 2022;13:309-314",72.0,YR,,M,Y,,,20221203,,HP,JP,JP,2022,Q4,Elderly
216802431,21680243,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,,,,UNK,,2022,Q4,Overdose,,2022,Q4,1,I,,20221123.0,20221205,20221205,EXP,,US-GRANULES-US-2022GRALIT00299,GRANULES INDIA,,33.0,YR,A,F,Y,,,20221205,,HP,US,US,2022,Q4,Young Adult
216802431,21680243,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,,,,UNK,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221123.0,20221205,20221205,EXP,,US-GRANULES-US-2022GRALIT00299,GRANULES INDIA,,33.0,YR,A,F,Y,,,20221205,,HP,US,US,2022,Q4,Young Adult
216802641,21680264,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,,,,UNK,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221123.0,20221205,20221205,EXP,,US-GRANULES-US-2022GRALIT00300,GRANULES INDIA,,33.0,YR,A,F,Y,,,20221205,,HP,US,US,2022,Q4,Young Adult
216802641,21680264,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,,,,UNK,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221123.0,20221205,20221205,EXP,,US-GRANULES-US-2022GRALIT00300,GRANULES INDIA,,33.0,YR,A,F,Y,,,20221205,,HP,US,US,2022,Q4,Young Adult
216802641,21680264,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,,,,UNK,,2022,Q4,Overdose,,2022,Q4,1,I,,20221123.0,20221205,20221205,EXP,,US-GRANULES-US-2022GRALIT00300,GRANULES INDIA,,33.0,YR,A,F,Y,,,20221205,,HP,US,US,2022,Q4,Young Adult
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Respiratory rate increased,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Skin turgor decreased,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Mucosal dryness,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Blood lactic acid increased,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Diabetic ketoacidosis,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Pain,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,QRS axis abnormal,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Protein urine present,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Renal failure,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Chest pain,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Ketoacidosis,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Electrocardiogram QT prolonged,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Urine ketone body present,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Abdominal pain,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Anion gap increased,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Glucose urine present,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Hypocapnia,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Diarrhoea,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216810963,21681096,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,Y,U,,,,10.0,MG,,QD,2022,Q4,Acidosis,,2022,Q4,3,F,20190501.0,20221221.0,20221205,20221228,EXP,,AT-MYLANLABS-2022M1134192,MYLAN,"Wilfing R, Stollberger C.. Ketoacidosis under SGLT2-inhibitor therapy. Universum Innere Medizin.. 2022;07:22-24",75.0,YR,,F,Y,,,20221228,,HP,AT,AT,2022,Q4,Elderly
216867931,21686793,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,,,2022,Q4,Contraindicated product administered,,2022,Q4,1,I,,20221124.0,20221206,20221206,EXP,,US-APOTEX-2022AP016263,APOTEX,"Hendrickson AL, Ye XQ, Kalra SS, Franck AJ, Urbine D. Euglycemic Diabetic Ketoacidosis in a Patient Prescribed Empagliflozin and a Ketogenic Diet: A Case of Misdiagnosed Type 1 Diabetes. Clinical Diabetes Journal. 2021;39(1):121-123",70.0,YR,,F,Y,,,20221206,,HP,US,US,2022,Q4,Elderly
216867931,21686793,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221124.0,20221206,20221206,EXP,,US-APOTEX-2022AP016263,APOTEX,"Hendrickson AL, Ye XQ, Kalra SS, Franck AJ, Urbine D. Euglycemic Diabetic Ketoacidosis in a Patient Prescribed Empagliflozin and a Ketogenic Diet: A Case of Misdiagnosed Type 1 Diabetes. Clinical Diabetes Journal. 2021;39(1):121-123",70.0,YR,,F,Y,,,20221206,,HP,US,US,2022,Q4,Elderly
216871351,21687135,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Electrolyte imbalance,,2022,Q4,1,I,20220905.0,20221123.0,20221206,20221206,EXP,CZ-CZSUKL-22005190,CZ-Accord-289708,ACCORD,,46.0,YR,A,M,Y,,,20221206,,MD,CZ,CZ,2022,Q4,Adult
216871351,21687135,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Dehydration,,2022,Q4,1,I,20220905.0,20221123.0,20221206,20221206,EXP,CZ-CZSUKL-22005190,CZ-Accord-289708,ACCORD,,46.0,YR,A,M,Y,,,20221206,,MD,CZ,CZ,2022,Q4,Adult
216871351,21687135,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Acute respiratory failure,,2022,Q4,1,I,20220905.0,20221123.0,20221206,20221206,EXP,CZ-CZSUKL-22005190,CZ-Accord-289708,ACCORD,,46.0,YR,A,M,Y,,,20221206,,MD,CZ,CZ,2022,Q4,Adult
216871351,21687135,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Immunodeficiency,,2022,Q4,1,I,20220905.0,20221123.0,20221206,20221206,EXP,CZ-CZSUKL-22005190,CZ-Accord-289708,ACCORD,,46.0,YR,A,M,Y,,,20221206,,MD,CZ,CZ,2022,Q4,Adult
216871351,21687135,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Sepsis,,2022,Q4,1,I,20220905.0,20221123.0,20221206,20221206,EXP,CZ-CZSUKL-22005190,CZ-Accord-289708,ACCORD,,46.0,YR,A,M,Y,,,20221206,,MD,CZ,CZ,2022,Q4,Adult
216871351,21687135,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Pneumonia legionella,,2022,Q4,1,I,20220905.0,20221123.0,20221206,20221206,EXP,CZ-CZSUKL-22005190,CZ-Accord-289708,ACCORD,,46.0,YR,A,M,Y,,,20221206,,MD,CZ,CZ,2022,Q4,Adult
216876381,21687638,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,Unknown,,,,,,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221124.0,20221206,20221206,EXP,,US-LUPIN PHARMACEUTICALS INC.-2022-14054,LUPIN,"Hendrickson AL, Ye XQ, Kalra SS, Franck AJ, Urbine D. Euglycemic diabetic ketoacidosis in a patient prescribed empagliflozin and a ketogenic diet: A case of misdiagnosed type 1 diabetes. Clinical Diabetes. 2021;39(1):121-123",70.0,YR,,F,Y,,,20221206,,HP,US,US,2022,Q4,Elderly
216883651,21688365,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Fournier's gangrene,,2022,Q4,1,I,20221126.0,,20221205,20221205,DIR,640462,,FDA-CTU,,59.0,YR,,M,N,103.9,KG,20221205,N,PH,US,,2022,Q4,Adult
216887061,21688706,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Atrioventricular block,,2022,Q4,1,I,20220601.0,20221129.0,20221206,20221206,EXP,,"PL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-205327",BOEHRINGER INGELHEIM,,75.0,YR,E,M,Y,,,20221206,,MD,PL,PL,2022,Q4,Elderly
216912231,21691223,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U,,,,,,,,2022,Q4,Overdose,,2022,Q4,1,I,,20221125.0,20221207,20221207,EXP,,US-ACI HealthCare Limited-2135625,ACI HEALTHCARE,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology 60 (Suppl. 2): 47-48, Jan 2022. URL: http://doi.org/10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221207,,HP,US,US,2022,Q4,Young Adult
216912231,21691223,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U,,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221125.0,20221207,20221207,EXP,,US-ACI HealthCare Limited-2135625,ACI HEALTHCARE,"Malley C, Gramm E, Adkins A, Trautman W, Scanlon M, Abesamis M, et al. Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis. Clinical Toxicology 60 (Suppl. 2): 47-48, Jan 2022. URL: http://doi.org/10.1080/15563650.2022.2107776",33.0,YR,,F,Y,,,20221207,,HP,US,US,2022,Q4,Young Adult
216944331,21694433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,20220908.0,,20221206,20221206,DIR,640576,,FDA-CTU,,35.0,YR,,F,N,,,20221206,N,,US,,2022,Q4,Adult
216960271,21696027,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q4,Medication error,,2022,Q4,1,I,20221206.0,20221207.0,20221207,20221207,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-206815",BOEHRINGER INGELHEIM,,83.0,YR,E,M,Y,68.0,KG,20221207,,HP,GB,GB,2022,Q4,Elderly
216960271,21696027,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,25.0,MG,Tablet,QD,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,20221206.0,20221207.0,20221207,20221207,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-206815",BOEHRINGER INGELHEIM,,83.0,YR,E,M,Y,68.0,KG,20221207,,HP,GB,GB,2022,Q4,Elderly
216962011,21696201,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,Y,,,,12.5,MG,,QD,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20221024.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97140,,FDA-CTU,,73.0,YR,,M,N,243.0,KG,20221201,N,PH,US,,2022,Q4,Elderly
216962101,21696210,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,25.0,MG,,QD,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,20221004.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97148,,FDA-CTU,,49.0,YR,,M,N,115.0,KG,20221201,N,PH,US,,2022,Q4,Adult
216965991,21696599,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Poor quality sleep,,2022,Q4,1,I,,20221129.0,20221207,20221207,EXP,,SI-JNJFOC-20221208822,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,,,20221208,,HP,SI,SI,2022,Q4,Elderly
216965991,21696599,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20221129.0,20221207,20221207,EXP,,SI-JNJFOC-20221208822,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,,,20221208,,HP,SI,SI,2022,Q4,Elderly
216965991,21696599,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Fatigue,,2022,Q4,1,I,,20221129.0,20221207,20221207,EXP,,SI-JNJFOC-20221208822,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,,,20221208,,HP,SI,SI,2022,Q4,Elderly
216965991,21696599,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Cardiac failure,,2022,Q4,1,I,,20221129.0,20221207,20221207,EXP,,SI-JNJFOC-20221208822,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,,,20221208,,HP,SI,SI,2022,Q4,Elderly
216965991,21696599,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Loss of personal independence in daily activities,,2022,Q4,1,I,,20221129.0,20221207,20221207,EXP,,SI-JNJFOC-20221208822,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,,,20221208,,HP,SI,SI,2022,Q4,Elderly
217001231,21700123,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Urinary tract infection,,2022,Q4,1,I,20220923.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97227,,FDA-CTU,,89.0,YR,,M,N,,,20221127,N,PH,US,,2022,Q4,Elderly
217001231,21700123,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Genital infection,,2022,Q4,1,I,20220923.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97227,,FDA-CTU,,89.0,YR,,M,N,,,20221127,N,PH,US,,2022,Q4,Elderly
217001231,21700123,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Dehydration,,2022,Q4,1,I,20220923.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97227,,FDA-CTU,,89.0,YR,,M,N,,,20221127,N,PH,US,,2022,Q4,Elderly
217006301,21700630,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Hypertension,,2022,Q4,1,I,20220923.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97276,,FDA-CTU,,76.0,YR,,M,N,88.0,KG,20221119,N,PH,US,,2022,Q4,Elderly
217006301,21700630,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Atrial fibrillation,,2022,Q4,1,I,20220923.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97276,,FDA-CTU,,76.0,YR,,M,N,88.0,KG,20221119,N,PH,US,,2022,Q4,Elderly
217006301,21700630,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Palpitations,,2022,Q4,1,I,20220923.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97276,,FDA-CTU,,76.0,YR,,M,N,88.0,KG,20221119,N,PH,US,,2022,Q4,Elderly
217006301,21700630,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,20220923.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97276,,FDA-CTU,,76.0,YR,,M,N,88.0,KG,20221119,N,PH,US,,2022,Q4,Elderly
217010501,21701050,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Nausea,,2022,Q4,1,I,20221112.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97330,,FDA-CTU,,78.0,YR,,M,N,86.0,KG,20221116,N,HP,US,,2022,Q4,Elderly
217010501,21701050,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,20221112.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97330,,FDA-CTU,,78.0,YR,,M,N,86.0,KG,20221116,N,HP,US,,2022,Q4,Elderly
217010501,21701050,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Dehydration,,2022,Q4,1,I,20221112.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97330,,FDA-CTU,,78.0,YR,,M,N,86.0,KG,20221116,N,HP,US,,2022,Q4,Elderly
217010501,21701050,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Gastroenteritis,,2022,Q4,1,I,20221112.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97330,,FDA-CTU,,78.0,YR,,M,N,86.0,KG,20221116,N,HP,US,,2022,Q4,Elderly
217010501,21701050,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Vomiting,,2022,Q4,1,I,20221112.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97330,,FDA-CTU,,78.0,YR,,M,N,86.0,KG,20221116,N,HP,US,,2022,Q4,Elderly
217010501,21701050,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Lactic acidosis,,2022,Q4,1,I,20221112.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97330,,FDA-CTU,,78.0,YR,,M,N,86.0,KG,20221116,N,HP,US,,2022,Q4,Elderly
217010501,21701050,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Mental status changes,,2022,Q4,1,I,20221112.0,,20221207,20221207,DIR,FDA-CDER-CTU-2022-97330,,FDA-CTU,,78.0,YR,,M,N,86.0,KG,20221116,N,HP,US,,2022,Q4,Elderly
217023151,21702315,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,,Unknown,,206073.0,,,Tablet,,2022,Q4,Pneumonia aspiration,,2022,Q4,1,I,20221031.0,20221208.0,20221208,20221208,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207157",BOEHRINGER INGELHEIM,,65.0,YR,E,M,Y,74.6,KG,20221209,,PH,JP,JP,2022,Q4,Elderly
217023151,21702315,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,,Unknown,,206073.0,,,Tablet,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,20221031.0,20221208.0,20221208,20221208,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207157",BOEHRINGER INGELHEIM,,65.0,YR,E,M,Y,74.6,KG,20221209,,PH,JP,JP,2022,Q4,Elderly
217023151,21702315,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,,Unknown,,206073.0,,,Tablet,,2022,Q4,Myasthenia gravis,,2022,Q4,1,I,20221031.0,20221208.0,20221208,20221208,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207157",BOEHRINGER INGELHEIM,,65.0,YR,E,M,Y,74.6,KG,20221209,,PH,JP,JP,2022,Q4,Elderly
217023151,21702315,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,,Unknown,,206073.0,,,Tablet,,2022,Q4,SARS-CoV-2 test positive,,2022,Q4,1,I,20221031.0,20221208.0,20221208,20221208,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207157",BOEHRINGER INGELHEIM,,65.0,YR,E,M,Y,74.6,KG,20221209,,PH,JP,JP,2022,Q4,Elderly
217038391,21703839,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q4,Nephroureterectomy,,2022,Q4,1,I,,20221129.0,20221209,20221209,EXP,,US-SPECGX-T202202401,SPECGX,"Haseeb A, Abu-Rmaileh M, Penfield JG, Liu H, Van Buren PN, Lederer ED et al. A novel case of renal mucormycosis associated with empagliflozin use. Journal of the American Society of Nephrology. 2022;33:355",63.0,YR,,M,Y,,,20221209,,HP,US,US,2022,Q4,Adult
217038391,21703839,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q4,Partial cystectomy,,2022,Q4,1,I,,20221129.0,20221209,20221209,EXP,,US-SPECGX-T202202401,SPECGX,"Haseeb A, Abu-Rmaileh M, Penfield JG, Liu H, Van Buren PN, Lederer ED et al. A novel case of renal mucormycosis associated with empagliflozin use. Journal of the American Society of Nephrology. 2022;33:355",63.0,YR,,M,Y,,,20221209,,HP,US,US,2022,Q4,Adult
217038391,21703839,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q4,Nephrostomy,,2022,Q4,1,I,,20221129.0,20221209,20221209,EXP,,US-SPECGX-T202202401,SPECGX,"Haseeb A, Abu-Rmaileh M, Penfield JG, Liu H, Van Buren PN, Lederer ED et al. A novel case of renal mucormycosis associated with empagliflozin use. Journal of the American Society of Nephrology. 2022;33:355",63.0,YR,,M,Y,,,20221209,,HP,US,US,2022,Q4,Adult
217038391,21703839,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q4,Ureteral stent insertion,,2022,Q4,1,I,,20221129.0,20221209,20221209,EXP,,US-SPECGX-T202202401,SPECGX,"Haseeb A, Abu-Rmaileh M, Penfield JG, Liu H, Van Buren PN, Lederer ED et al. A novel case of renal mucormycosis associated with empagliflozin use. Journal of the American Society of Nephrology. 2022;33:355",63.0,YR,,M,Y,,,20221209,,HP,US,US,2022,Q4,Adult
217038391,21703839,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2022,Q4,Hydronephrosis,,2022,Q4,1,I,,20221129.0,20221209,20221209,EXP,,US-SPECGX-T202202401,SPECGX,"Haseeb A, Abu-Rmaileh M, Penfield JG, Liu H, Van Buren PN, Lederer ED et al. A novel case of renal mucormycosis associated with empagliflozin use. Journal of the American Society of Nephrology. 2022;33:355",63.0,YR,,M,Y,,,20221209,,HP,US,US,2022,Q4,Adult
217060592,21706059,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 mg,,,,,,,,10.0,MG,,,2022,Q4,Chest pain,,2022,Q4,2,F,20220504.0,20221215.0,20221209,20221221,EXP,,SI-009507513-2212SVN003118,MERCK,,54.0,YR,,M,Y,76.0,KG,20221221,,MD,SI,SI,2022,Q4,Adult
217074092,21707409,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25,MG,DAILY",,,,,,,,,,,,2022,Q4,Transformation to acute myeloid leukaemia,,2022,Q4,2,F,20221130.0,20221222.0,20221209,20221227,EXP,,AU-GILEAD-2022-0608325,GILEAD,,64.0,YR,A,M,Y,74.0,KG,20221227,,MD,AU,AU,2022,Q4,Adult
217091301,21709130,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK (take one daily),,,U,,,,,,,,,2022,Q4,Adverse drug reaction,,2022,Q4,1,I,20221207.0,20221208.0,20221210,20221210,EXP,GB-MHRA-TPP14349120C7959779YC1670404809149,NVSC2022GB285570,NOVARTIS,,46.0,YR,,F,Y,87.0,KG,20221210,,MD,GB,GB,2022,Q4,Adult
217115291,21711529,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,,,,,,2022,Q4,Eosinophilic myocarditis,,2022,Q4,1,I,,20221128.0,20221212,20221212,EXP,,US-EPICPHARMA-US-2022EPCLIT01764,EPIC PHARM,Carin Malley.Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis.Clinical Toxicology.JAN-2022;60 (Suppl. 2):47-48,33.0,YR,A,F,Y,,,20221212,,HP,US,US,2022,Q4,Young Adult
217115291,21711529,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221128.0,20221212,20221212,EXP,,US-EPICPHARMA-US-2022EPCLIT01764,EPIC PHARM,Carin Malley.Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis.Clinical Toxicology.JAN-2022;60 (Suppl. 2):47-48,33.0,YR,A,F,Y,,,20221212,,HP,US,US,2022,Q4,Young Adult
217115291,21711529,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,,,,,,2022,Q4,Overdose,,2022,Q4,1,I,,20221128.0,20221212,20221212,EXP,,US-EPICPHARMA-US-2022EPCLIT01764,EPIC PHARM,Carin Malley.Acute necrotizing eosinophilic myocarditis and sudden death in a patient with metformin associated metabolic acidosis.Clinical Toxicology.JAN-2022;60 (Suppl. 2):47-48,33.0,YR,A,F,Y,,,20221212,,HP,US,US,2022,Q4,Young Adult
217128751,21712875,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10mg; ;,,,Y,U,Unknown,,204629.0,,,Tablet,,2022,Q4,Arterial thrombosis,,2022,Q4,1,I,20221028.0,20221211.0,20221212,20221212,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207508",BOEHRINGER INGELHEIM,,55.0,YR,A,F,Y,105.0,KG,20221212,,MD,GB,GB,2022,Q4,Adult
217134601,21713460,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO? ?,,,,,,,,12.5,MG,,QD,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,20220827.0,,20221208,20221208,DIR,FDA-CDER-CTU-2022-97943,,FDA-CTU,,46.0,YR,,M,N,,,20221021,N,HP,US,,2022,Q4,Adult
217138151,21713815,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG EVERY DAY PO,,,Y,,D62119,20240531.0,,25.0,MG,,QD,2022,Q4,Abscess,,2022,Q4,1,I,20220826.0,,20221208,20221208,DIR,FDA-CDER-CTU-2022-97970,,FDA-CTU,,60.0,YR,,M,N,90.0,KG,20221021,N,HP,US,,2022,Q4,Adult
217138481,21713848,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG EVERY DAY PO,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Pancreatitis acute,,2022,Q4,1,I,20221010.0,,20221208,20221208,DIR,FDA-CDER-CTU-2022-97964,,FDA-CTU,,86.0,YR,,M,N,85.0,KG,20221021,N,HP,US,,2022,Q4,Elderly
217140211,21714021,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,20210804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98105,,FDA-CTU,,64.0,YR,,M,N,,,20221209,N,PH,US,,2022,Q4,Adult
217145261,21714526,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q4,Fournier's gangrene,,2022,Q4,1,I,20220804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98212,,FDA-CTU,,76.0,YR,,M,N,107.5,KG,20221021,N,PH,US,,2022,Q4,Elderly
217145261,21714526,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q4,Systemic inflammatory response syndrome,,2022,Q4,1,I,20220804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98212,,FDA-CTU,,76.0,YR,,M,N,107.5,KG,20221021,N,PH,US,,2022,Q4,Elderly
217145261,21714526,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q4,Sepsis,,2022,Q4,1,I,20220804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98212,,FDA-CTU,,76.0,YR,,M,N,107.5,KG,20221021,N,PH,US,,2022,Q4,Elderly
217145261,21714526,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q4,Culture wound positive,,2022,Q4,1,I,20220804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98212,,FDA-CTU,,76.0,YR,,M,N,107.5,KG,20221021,N,PH,US,,2022,Q4,Elderly
217145261,21714526,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q4,Decreased appetite,,2022,Q4,1,I,20220804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98212,,FDA-CTU,,76.0,YR,,M,N,107.5,KG,20221021,N,PH,US,,2022,Q4,Elderly
217145261,21714526,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q4,COVID-19,,2022,Q4,1,I,20220804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98212,,FDA-CTU,,76.0,YR,,M,N,107.5,KG,20221021,N,PH,US,,2022,Q4,Elderly
217145261,21714526,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q4,Cough,,2022,Q4,1,I,20220804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98212,,FDA-CTU,,76.0,YR,,M,N,107.5,KG,20221021,N,PH,US,,2022,Q4,Elderly
217145261,21714526,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q4,Tremor,,2022,Q4,1,I,20220804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98212,,FDA-CTU,,76.0,YR,,M,N,107.5,KG,20221021,N,PH,US,,2022,Q4,Elderly
217145261,21714526,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q4,Perirectal abscess,,2022,Q4,1,I,20220804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98212,,FDA-CTU,,76.0,YR,,M,N,107.5,KG,20221021,N,PH,US,,2022,Q4,Elderly
217145261,21714526,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q4,Nasal congestion,,2022,Q4,1,I,20220804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98212,,FDA-CTU,,76.0,YR,,M,N,107.5,KG,20221021,N,PH,US,,2022,Q4,Elderly
217145261,21714526,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q4,Staphylococcal infection,,2022,Q4,1,I,20220804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98212,,FDA-CTU,,76.0,YR,,M,N,107.5,KG,20221021,N,PH,US,,2022,Q4,Elderly
217145261,21714526,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q4,Dyspnoea,,2022,Q4,1,I,20220804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98212,,FDA-CTU,,76.0,YR,,M,N,107.5,KG,20221021,N,PH,US,,2022,Q4,Elderly
217145261,21714526,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q4,Bacteroides infection,,2022,Q4,1,I,20220804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98212,,FDA-CTU,,76.0,YR,,M,N,107.5,KG,20221021,N,PH,US,,2022,Q4,Elderly
217145261,21714526,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q4,Acute kidney injury,,2022,Q4,1,I,20220804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98212,,FDA-CTU,,76.0,YR,,M,N,107.5,KG,20221021,N,PH,US,,2022,Q4,Elderly
217145261,21714526,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,N,D,,,,12.5,MG,,QD,2022,Q4,Diarrhoea,,2022,Q4,1,I,20220804.0,,20221209,20221209,DIR,FDA-CDER-CTU-2022-98212,,FDA-CTU,,76.0,YR,,M,N,107.5,KG,20221021,N,PH,US,,2022,Q4,Elderly
217147631,21714763,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2022,Q4,Thrombosis,,2022,Q4,1,I,20221129.0,20221201.0,20221212,20221212,EXP,,CO-DSJP-DSE-2022-144016,DAIICHI,,69.0,YR,,M,Y,,,20221212,,CN,CO,CO,2022,Q4,Elderly
217175071,21717507,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q4,Nausea,,2022,Q4,1,I,20220925.0,,20221212,20221212,DIR,FDA-CDER-CTU-2022-98560,,FDA-CTU,,64.0,YR,,M,N,89.0,KG,20221119,N,PH,US,,2022,Q4,Adult
217175071,21717507,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q4,Vomiting,,2022,Q4,1,I,20220925.0,,20221212,20221212,DIR,FDA-CDER-CTU-2022-98560,,FDA-CTU,,64.0,YR,,M,N,89.0,KG,20221119,N,PH,US,,2022,Q4,Adult
217175071,21717507,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,20220925.0,,20221212,20221212,DIR,FDA-CDER-CTU-2022-98560,,FDA-CTU,,64.0,YR,,M,N,89.0,KG,20221119,N,PH,US,,2022,Q4,Adult
217193181,21719318,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Pruritus,,2022,Q4,1,I,20221130.0,20221212.0,20221213,20221213,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207480",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20221213,,HP,SG,SG,2022,Q4,Elderly
217193531,21719353,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Decreased appetite,,2022,Q4,1,I,20221018.0,20221205.0,20221213,20221213,PER,,SA-AMGEN-SAUSP2022211503,AMGEN,,47.0,YR,A,M,Y,,,20221213,,CN,SA,SA,2022,Q4,Adult
217210601,21721060,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2022,Q4,Catheter placement,,2022,Q4,1,I,20221129.0,20221205.0,20221213,20221213,PER,,SA-AMGEN-SAUSP2022211486,AMGEN,,60.0,YR,A,M,Y,,,20221213,,CN,SA,SA,2022,Q4,Adult
217228661,21722866,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2022,Q4,Hypercatabolism,,2022,Q4,1,I,,20221129.0,20221213,20221213,EXP,,JP-PRAXGEN-2022PPLIT00025,PRAXGEN PHARMACEUTICALS,"Nawata T, et al..Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.Rheumatol Adv Pract.07-JUL-2021;5 (3):1-3",71.0,YR,E,F,Y,61.3,KG,20221213,,HP,JP,JP,2022,Q4,Elderly
217228661,21722866,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2022,Q4,Product use in unapproved indication,,2022,Q4,1,I,,20221129.0,20221213,20221213,EXP,,JP-PRAXGEN-2022PPLIT00025,PRAXGEN PHARMACEUTICALS,"Nawata T, et al..Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.Rheumatol Adv Pract.07-JUL-2021;5 (3):1-3",71.0,YR,E,F,Y,61.3,KG,20221213,,HP,JP,JP,2022,Q4,Elderly
217228661,21722866,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2022,Q4,Drug interaction,,2022,Q4,1,I,,20221129.0,20221213,20221213,EXP,,JP-PRAXGEN-2022PPLIT00025,PRAXGEN PHARMACEUTICALS,"Nawata T, et al..Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.Rheumatol Adv Pract.07-JUL-2021;5 (3):1-3",71.0,YR,E,F,Y,61.3,KG,20221213,,HP,JP,JP,2022,Q4,Elderly
217228661,21722866,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221129.0,20221213,20221213,EXP,,JP-PRAXGEN-2022PPLIT00025,PRAXGEN PHARMACEUTICALS,"Nawata T, et al..Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.Rheumatol Adv Pract.07-JUL-2021;5 (3):1-3",71.0,YR,E,F,Y,61.3,KG,20221213,,HP,JP,JP,2022,Q4,Elderly
217228661,21722866,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2022,Q4,Polyuria,,2022,Q4,1,I,,20221129.0,20221213,20221213,EXP,,JP-PRAXGEN-2022PPLIT00025,PRAXGEN PHARMACEUTICALS,"Nawata T, et al..Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.Rheumatol Adv Pract.07-JUL-2021;5 (3):1-3",71.0,YR,E,F,Y,61.3,KG,20221213,,HP,JP,JP,2022,Q4,Elderly
217228661,21722866,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,QD,2022,Q4,Weight decreased,,2022,Q4,1,I,,20221129.0,20221213,20221213,EXP,,JP-PRAXGEN-2022PPLIT00025,PRAXGEN PHARMACEUTICALS,"Nawata T, et al..Rapid weight loss in a patient with anti-synthetase syndrome treated with sodium-glucose cotransporter 2 inhibitors and corticosteroids.Rheumatol Adv Pract.07-JUL-2021;5 (3):1-3",71.0,YR,E,F,Y,61.3,KG,20221213,,HP,JP,JP,2022,Q4,Elderly
217235851,21723585,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,,2022,Q4,Hypersensitivity,,2022,Q4,1,I,20221108.0,20221204.0,20221213,20221213,EXP,,DE-PFIZER INC-202201337373,PFIZER,,66.0,YR,,M,Y,105.0,KG,20221213,,HP,DE,DE,2022,Q4,Elderly
217235851,21723585,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,,2022,Q4,Hypersensitivity,,2022,Q4,1,I,20221108.0,20221204.0,20221213,20221213,EXP,,DE-PFIZER INC-202201337373,PFIZER,,66.0,YR,,M,Y,105.0,KG,20221213,,HP,DE,DE,2022,Q4,Elderly
217236092,21723609,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,daily,,,U,,,,,10.0,MG,,QD,2022,Q4,Neutropenia,,2022,Q4,2,F,20221121.0,20221222.0,20221213,20221226,EXP,,NVSC2022DE285738,NOVARTIS,,90.0,YR,,M,Y,87.0,KG,20221226,,MD,DE,DE,2022,Q4,Elderly
217238051,21723805,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q4,Fall,,2022,Q4,1,I,,20221207.0,20221213,20221213,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-206997",BOEHRINGER INGELHEIM,"McConnell M, Shieh A. Polypharmacy in Osteoporosis Treatment. Clinics in geritric medicine. 2022;38;4715-726.doi:10.1016/j.cger.2022.05.011.",85.0,YR,E,F,Y,,,20221213,,MD,US,US,2022,Q4,Elderly
217238051,21723805,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q4,Spinal compression fracture,,2022,Q4,1,I,,20221207.0,20221213,20221213,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-206997",BOEHRINGER INGELHEIM,"McConnell M, Shieh A. Polypharmacy in Osteoporosis Treatment. Clinics in geritric medicine. 2022;38;4715-726.doi:10.1016/j.cger.2022.05.011.",85.0,YR,E,F,Y,,,20221213,,MD,US,US,2022,Q4,Elderly
217238051,21723805,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q4,Glycosylated haemoglobin abnormal,,2022,Q4,1,I,,20221207.0,20221213,20221213,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-206997",BOEHRINGER INGELHEIM,"McConnell M, Shieh A. Polypharmacy in Osteoporosis Treatment. Clinics in geritric medicine. 2022;38;4715-726.doi:10.1016/j.cger.2022.05.011.",85.0,YR,E,F,Y,,,20221213,,MD,US,US,2022,Q4,Elderly
217238051,21723805,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,25.0,MG,,QD,2022,Q4,Glomerular filtration rate abnormal,,2022,Q4,1,I,,20221207.0,20221213,20221213,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-206997",BOEHRINGER INGELHEIM,"McConnell M, Shieh A. Polypharmacy in Osteoporosis Treatment. Clinics in geritric medicine. 2022;38;4715-726.doi:10.1016/j.cger.2022.05.011.",85.0,YR,E,F,Y,,,20221213,,MD,US,US,2022,Q4,Elderly
217298171,21729817,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Vulval ulceration,,2022,Q4,1,I,20221028.0,20221211.0,20221214,20221214,EXP,GB-MHRA-TPP22432934C9250843YC1666963017777,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207509",BOEHRINGER INGELHEIM,,59.0,YR,A,F,Y,101.0,KG,20221214,,MD,GB,GB,2022,Q4,Adult
217299792,21729979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Ventricular tachycardia,,2022,Q4,2,F,20220501.0,20221222.0,20221214,20221229,EXP,,SI-009507513-2212SVN004836,MERCK,,65.0,YR,,M,Y,,,20221229,,MD,SI,SI,2022,Q4,Elderly
217299792,21729979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Ventricular tachycardia,,2022,Q4,2,F,20220501.0,20221222.0,20221214,20221229,EXP,,SI-009507513-2212SVN004836,MERCK,,65.0,YR,,M,Y,,,20221229,,MD,SI,SI,2022,Q4,Elderly
217299792,21729979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Syncope,,2022,Q4,2,F,20220501.0,20221222.0,20221214,20221229,EXP,,SI-009507513-2212SVN004836,MERCK,,65.0,YR,,M,Y,,,20221229,,MD,SI,SI,2022,Q4,Elderly
217299792,21729979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Presyncope,,2022,Q4,2,F,20220501.0,20221222.0,20221214,20221229,EXP,,SI-009507513-2212SVN004836,MERCK,,65.0,YR,,M,Y,,,20221229,,MD,SI,SI,2022,Q4,Elderly
217299792,21729979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Heart transplant,,2022,Q4,2,F,20220501.0,20221222.0,20221214,20221229,EXP,,SI-009507513-2212SVN004836,MERCK,,65.0,YR,,M,Y,,,20221229,,MD,SI,SI,2022,Q4,Elderly
217299792,21729979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,2,F,20220501.0,20221222.0,20221214,20221229,EXP,,SI-009507513-2212SVN004836,MERCK,,65.0,YR,,M,Y,,,20221229,,MD,SI,SI,2022,Q4,Elderly
217299792,21729979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Arrhythmic storm,,2022,Q4,2,F,20220501.0,20221222.0,20221214,20221229,EXP,,SI-009507513-2212SVN004836,MERCK,,65.0,YR,,M,Y,,,20221229,,MD,SI,SI,2022,Q4,Elderly
217299792,21729979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Dizziness postural,,2022,Q4,2,F,20220501.0,20221222.0,20221214,20221229,EXP,,SI-009507513-2212SVN004836,MERCK,,65.0,YR,,M,Y,,,20221229,,MD,SI,SI,2022,Q4,Elderly
217299792,21729979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Presyncope,,2022,Q4,2,F,20220501.0,20221222.0,20221214,20221229,EXP,,SI-009507513-2212SVN004836,MERCK,,65.0,YR,,M,Y,,,20221229,,MD,SI,SI,2022,Q4,Elderly
217299792,21729979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Ventricular fibrillation,,2022,Q4,2,F,20220501.0,20221222.0,20221214,20221229,EXP,,SI-009507513-2212SVN004836,MERCK,,65.0,YR,,M,Y,,,20221229,,MD,SI,SI,2022,Q4,Elderly
217299792,21729979,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2022,Q4,Dizziness,,2022,Q4,2,F,20220501.0,20221222.0,20221214,20221229,EXP,,SI-009507513-2212SVN004836,MERCK,,65.0,YR,,M,Y,,,20221229,,MD,SI,SI,2022,Q4,Elderly
217315811,21731581,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,Unknown,,206073.0,,,Tablet,,2022,Q4,Alcoholic liver disease,,2022,Q4,1,I,20221111.0,20221213.0,20221215,20221215,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208160",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20221215,,PH,JP,JP,2022,Q4,Adult
217331621,21733162,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2022,Q4,Multiple drug therapy,,2022,Q4,1,I,,20221207.0,20221215,20221215,EXP,,US-SA-2022SA501932,SANOFI AVENTIS,"McConnell M, Shieh A.. Polypharmacy in Osteoporosis Treatment. Clin Geriatr Med.. 2022;38(4):715-26",85.0,YR,E,F,Y,,,20221215,,MD,US,US,2022,Q4,Elderly
217331621,21733162,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2022,Q4,Spinal compression fracture,,2022,Q4,1,I,,20221207.0,20221215,20221215,EXP,,US-SA-2022SA501932,SANOFI AVENTIS,"McConnell M, Shieh A.. Polypharmacy in Osteoporosis Treatment. Clin Geriatr Med.. 2022;38(4):715-26",85.0,YR,E,F,Y,,,20221215,,MD,US,US,2022,Q4,Elderly
217331621,21733162,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, QD",,,U,,,,,25.0,MG,,QD,2022,Q4,Fall,,2022,Q4,1,I,,20221207.0,20221215,20221215,EXP,,US-SA-2022SA501932,SANOFI AVENTIS,"McConnell M, Shieh A.. Polypharmacy in Osteoporosis Treatment. Clin Geriatr Med.. 2022;38(4):715-26",85.0,YR,E,F,Y,,,20221215,,MD,US,US,2022,Q4,Elderly
217358991,21735899,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,212614.0,,,,,2022,Q4,Drug ineffective,,2022,Q4,1,I,20221205.0,20221215.0,20221215,20221215,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208277",BOEHRINGER INGELHEIM,,65.0,YR,E,M,Y,,,20221215,,CN,US,US,2022,Q4,Elderly
217373521,21737352,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,unknown,,,,,,,2022,Q4,Prostate cancer,,2022,Q4,1,I,20220301.0,20221207.0,20221216,20221216,EXP,,JP-NOVOPROD-1000110,NOVO NORDISK,,8.0,DEC,,M,Y,79.0,KG,20221216,,MD,JP,JP,2022,Q4,Child
217373521,21737352,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,unknown,,,,,,,2022,Q4,Colon cancer,,2022,Q4,1,I,20220301.0,20221207.0,20221216,20221216,EXP,,JP-NOVOPROD-1000110,NOVO NORDISK,,8.0,DEC,,M,Y,79.0,KG,20221216,,MD,JP,JP,2022,Q4,Child
217401901,21740190,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO?,,,D,D,,,,,,,QD,2022,Q4,Myalgia,,2022,Q4,1,I,20220815.0,,20221215,20221215,DIR,FDA-CDER-CTU-2022-99800,,FDA-CTU,,94.0,YR,,M,N,83.46,KG,20221021,N,HP,US,,2022,Q4,Elderly
217401901,21740190,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO?,,,D,D,,,,,,,QD,2022,Q4,Asthenia,,2022,Q4,1,I,20220815.0,,20221215,20221215,DIR,FDA-CDER-CTU-2022-99800,,FDA-CTU,,94.0,YR,,M,N,83.46,KG,20221021,N,HP,US,,2022,Q4,Elderly
217401901,21740190,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO?,,,D,D,,,,,,,QD,2022,Q4,Arthralgia,,2022,Q4,1,I,20220815.0,,20221215,20221215,DIR,FDA-CDER-CTU-2022-99800,,FDA-CTU,,94.0,YR,,M,N,83.46,KG,20221021,N,HP,US,,2022,Q4,Elderly
217401901,21740190,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 TAB EVERY DAY PO?,,,D,D,,,,,,,QD,2022,Q4,Fall,,2022,Q4,1,I,20220815.0,,20221215,20221215,DIR,FDA-CDER-CTU-2022-99800,,FDA-CTU,,94.0,YR,,M,N,83.46,KG,20221021,N,HP,US,,2022,Q4,Elderly
217402851,21740285,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Ketonuria,,2022,Q4,1,I,,20221212.0,20221216,20221216,EXP,,"RS-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207538",BOEHRINGER INGELHEIM,"Heart and blood vessels, vol 41, edition 4",69.0,YR,E,F,Y,,,20221216,,MD,RS,RS,2022,Q4,Elderly
217402851,21740285,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Infection,,2022,Q4,1,I,,20221212.0,20221216,20221216,EXP,,"RS-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207538",BOEHRINGER INGELHEIM,"Heart and blood vessels, vol 41, edition 4",69.0,YR,E,F,Y,,,20221216,,MD,RS,RS,2022,Q4,Elderly
217402851,21740285,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Lethargy,,2022,Q4,1,I,,20221212.0,20221216,20221216,EXP,,"RS-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207538",BOEHRINGER INGELHEIM,"Heart and blood vessels, vol 41, edition 4",69.0,YR,E,F,Y,,,20221216,,MD,RS,RS,2022,Q4,Elderly
217402851,21740285,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Fatigue,,2022,Q4,1,I,,20221212.0,20221216,20221216,EXP,,"RS-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207538",BOEHRINGER INGELHEIM,"Heart and blood vessels, vol 41, edition 4",69.0,YR,E,F,Y,,,20221216,,MD,RS,RS,2022,Q4,Elderly
217402851,21740285,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Pyrexia,,2022,Q4,1,I,,20221212.0,20221216,20221216,EXP,,"RS-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207538",BOEHRINGER INGELHEIM,"Heart and blood vessels, vol 41, edition 4",69.0,YR,E,F,Y,,,20221216,,MD,RS,RS,2022,Q4,Elderly
217402851,21740285,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Glycosuria,,2022,Q4,1,I,,20221212.0,20221216,20221216,EXP,,"RS-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207538",BOEHRINGER INGELHEIM,"Heart and blood vessels, vol 41, edition 4",69.0,YR,E,F,Y,,,20221216,,MD,RS,RS,2022,Q4,Elderly
217402851,21740285,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Ketoacidosis,,2022,Q4,1,I,,20221212.0,20221216,20221216,EXP,,"RS-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207538",BOEHRINGER INGELHEIM,"Heart and blood vessels, vol 41, edition 4",69.0,YR,E,F,Y,,,20221216,,MD,RS,RS,2022,Q4,Elderly
217402851,21740285,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Pulmonary embolism,,2022,Q4,1,I,,20221212.0,20221216,20221216,EXP,,"RS-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207538",BOEHRINGER INGELHEIM,"Heart and blood vessels, vol 41, edition 4",69.0,YR,E,F,Y,,,20221216,,MD,RS,RS,2022,Q4,Elderly
217402851,21740285,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Pleural effusion,,2022,Q4,1,I,,20221212.0,20221216,20221216,EXP,,"RS-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207538",BOEHRINGER INGELHEIM,"Heart and blood vessels, vol 41, edition 4",69.0,YR,E,F,Y,,,20221216,,MD,RS,RS,2022,Q4,Elderly
217402851,21740285,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20221212.0,20221216,20221216,EXP,,"RS-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207538",BOEHRINGER INGELHEIM,"Heart and blood vessels, vol 41, edition 4",69.0,YR,E,F,Y,,,20221216,,MD,RS,RS,2022,Q4,Elderly
217406331,21740633,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,0.5 MG EVERY DAY PO?,,,Y,,,,,,,,QD,2022,Q4,Urinary tract infection,,2022,Q4,1,I,20221123.0,,20221215,20221215,DIR,FDA-CDER-CTU-2022-99748,,FDA-CTU,,72.0,YR,,M,N,85.73,KG,20221213,N,HP,US,,2022,Q4,Elderly
217408521,21740852,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q4,Anal abscess,,2022,Q4,1,I,20220801.0,,20221215,20221215,DIR,FDA-CDER-CTU-2022-99804,,FDA-CTU,,70.0,YR,,M,N,105.0,KG,20221021,N,HP,US,,2022,Q4,Elderly
217408521,21740852,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q4,Prostatic abscess,,2022,Q4,1,I,20220801.0,,20221215,20221215,DIR,FDA-CDER-CTU-2022-99804,,FDA-CTU,,70.0,YR,,M,N,105.0,KG,20221021,N,HP,US,,2022,Q4,Elderly
217408521,21740852,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q4,Prostatitis,,2022,Q4,1,I,20220801.0,,20221215,20221215,DIR,FDA-CDER-CTU-2022-99804,,FDA-CTU,,70.0,YR,,M,N,105.0,KG,20221021,N,HP,US,,2022,Q4,Elderly
217408521,21740852,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2022,Q4,Kidney infection,,2022,Q4,1,I,20220801.0,,20221215,20221215,DIR,FDA-CDER-CTU-2022-99804,,FDA-CTU,,70.0,YR,,M,N,105.0,KG,20221021,N,HP,US,,2022,Q4,Elderly
217430361,21743036,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,Unknown,,,,,,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221207.0,20221217,20221217,EXP,,US-GRANULES-US-2022GRALIT00310,GRANULES INDIA,Andrew J. Franck.Euglycemic diabetic ketoacidosis in a patient prescribed empagliflozin and a ketogenic diet: A case of misdiagnosed type 1 diabetes.Clinical Diabetes.JAN-2021;39 (No. 1):121-123,70.0,YR,E,F,Y,,,20221217,,HP,US,US,2022,Q4,Elderly
217438851,21743885,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2022,Q4,Product use issue,,2022,Q4,1,I,,20221129.0,20221217,20221217,PER,,US-009507513-2212USA001135,MERCK,"Haseeb A, Abu-Rmaileh M, Penfield JG, Liu H, Van Buren PN, Lederer ED, et al.. A Novel Case of Renal Mucormycosis Associated With Empagliflozin Use. Journal of the American Society of Nephrology. 2022;33:335",63.0,YR,,M,Y,,,20221217,,HP,US,US,2022,Q4,Adult
217450991,21745099,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,UNK,,,,,,,,,,,,2022,Q4,Diarrhoea,,2022,Q4,1,I,20220810.0,20221208.0,20221219,20221219,PER,,"AU-TOLMAR, INC.-22AU037785",TOLMAR,,83.0,YR,,M,Y,,,20221219,,MD,AU,AU,2022,Q4,Elderly
217472581,21747258,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221205.0,20221219,20221219,EXP,,US-AUROBINDO-AUR-APL-2022-053380,AUROBINDO,"Hendrickson AL, Ye XQ, Kalra SS, Franck AJ, Urbine D.. Euglycemic diabetic ketoacidosis in a patient prescribed empagliflozin and a ketogenic diet: A case of misdiagnosed type 1 diabetes. Clin- Diabet. 2021;39(1):121-123",70.0,YR,,F,Y,,,20221219,,HP,US,US,2022,Q4,Elderly
217472581,21747258,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221205.0,20221219,20221219,EXP,,US-AUROBINDO-AUR-APL-2022-053380,AUROBINDO,"Hendrickson AL, Ye XQ, Kalra SS, Franck AJ, Urbine D.. Euglycemic diabetic ketoacidosis in a patient prescribed empagliflozin and a ketogenic diet: A case of misdiagnosed type 1 diabetes. Clin- Diabet. 2021;39(1):121-123",70.0,YR,,F,Y,,,20221219,,HP,US,US,2022,Q4,Elderly
217532451,21753245,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,,,,,,,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,20221025.0,,20221219,20221219,DIR,FDA-CDER-CTU-2022-100604,,FDA-CTU,,62.0,YR,,M,N,,,20221215,N,PH,US,,2022,Q4,Adult
217532451,21753245,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,,,,,,,,2022,Q4,Dizziness,,2022,Q4,1,I,20221025.0,,20221219,20221219,DIR,FDA-CDER-CTU-2022-100604,,FDA-CTU,,62.0,YR,,M,N,,,20221215,N,PH,US,,2022,Q4,Adult
217536581,21753658,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2022,Q4,Candida infection,,2022,Q4,1,I,20221216.0,20221218.0,20221220,20221220,EXP,GB-MHRA-TPP6928760C5469370YC1671204381395,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208731",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,97.0,KG,20221220,,HP,GB,GB,2022,Q4,Adult
217536581,21753658,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U,Unknown,,204629.0,,,,,2022,Q4,Eye infection fungal,,2022,Q4,1,I,20221216.0,20221218.0,20221220,20221220,EXP,GB-MHRA-TPP6928760C5469370YC1671204381395,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208731",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,97.0,KG,20221220,,HP,GB,GB,2022,Q4,Adult
217536581,21753658,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q4,Candida infection,,2022,Q4,1,I,20221216.0,20221218.0,20221220,20221220,EXP,GB-MHRA-TPP6928760C5469370YC1671204381395,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208731",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,97.0,KG,20221220,,HP,GB,GB,2022,Q4,Adult
217536581,21753658,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,QD,2022,Q4,Eye infection fungal,,2022,Q4,1,I,20221216.0,20221218.0,20221220,20221220,EXP,GB-MHRA-TPP6928760C5469370YC1671204381395,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208731",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,97.0,KG,20221220,,HP,GB,GB,2022,Q4,Adult
217554091,21755409,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,,,,,2022,Q4,Pemphigoid,,2022,Q4,1,I,,20221213.0,20221220,20221220,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-207744",BOEHRINGER INGELHEIM,"Dyson S, Patel P, Igali L, Millington G. Bullous pemphigoid in a patient with a neuropsychological disorder and a possible novel drug trigger: A case report and review of the literature. Skin Health and Disease. 2022;2:4176-doi:10.1002/ski2.176.",59.0,YR,A,F,Y,,,20221220,,HP,GB,GB,2022,Q4,Adult
217558611,21755861,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2022,Q4,Hypoglycaemia,,2022,Q4,1,I,,20221219.0,20221220,20221220,EXP,,NVSC2022PT258889,NOVARTIS,"Silva AS, Baptista M, Lima R, Lopes Cacola R. Diabetes Mellitus - when hypoglycemia is the main character. 28TH NATIONAL CONGRESS OF INTERNAL MEDICINE. 2022;1485",67.0,YR,,F,Y,,,20221220,,HP,PT,PT,2022,Q4,Elderly
217573011,21757301,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Dizziness,,2022,Q4,1,I,20221118.0,20221220.0,20221220,20221220,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208999",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20221221,,HP,SG,SG,2022,Q4,Elderly
217573011,21757301,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Pollakiuria,,2022,Q4,1,I,20221118.0,20221220.0,20221220,20221220,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208999",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20221221,,HP,SG,SG,2022,Q4,Elderly
217573541,21757354,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Abdominal pain lower,,2022,Q4,1,I,20221115.0,20221220.0,20221220,20221220,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208997",BOEHRINGER INGELHEIM,,53.0,YR,A,M,Y,,,20221221,,HP,SG,SG,2022,Q4,Adult
217599741,21759974,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,Unknown,,,,,,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221212.0,20221221,20221221,EXP,,US-EPICPHARMA-US-2022EPCLIT01817,EPIC PHARM,Franck AJ.Euglycemic diabetic ketoacidosis in a patient prescribed empagliflozin and a ketogenic diet: A case of misdiagnosed type 1 diabetes.Clinical Diabetes.JAN-2021;39:121-123,70.0,YR,E,F,Y,,,20221221,,HP,US,US,2022,Q4,Elderly
217603941,21760394,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,20221214.0,,20221220,20221220,DIR,642139,,FDA-CTU,,70.0,YR,,M,N,75.1,KG,20221220,Y,PH,US,,2022,Q4,Elderly
217628731,21762873,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG AM PO?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Genital infection,,2022,Q4,1,I,20221014.0,,20221220,20221220,DIR,FDA-CDER-CTU-2022-101178,,FDA-CTU,,75.0,YR,,M,N,,,20221216,N,PH,US,,2022,Q4,Elderly
217628731,21762873,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG AM PO?,,,Y,D,,,,12.5,MG,,QD,2022,Q4,Acidosis,,2022,Q4,1,I,20221014.0,,20221220,20221220,DIR,FDA-CDER-CTU-2022-101178,,FDA-CTU,,75.0,YR,,M,N,,,20221216,N,PH,US,,2022,Q4,Elderly
217628821,21762882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,Tablet,,2022,Q4,Anion gap increased,,2022,Q4,1,I,20220301.0,,20221220,20221220,DIR,FDA-CDER-CTU-2022-101187,,FDA-CTU,,76.0,YR,,M,N,77.0,KG,20220519,N,PH,US,,2022,Q4,Elderly
217628821,21762882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,Tablet,,2022,Q4,Blood urea increased,,2022,Q4,1,I,20220301.0,,20221220,20221220,DIR,FDA-CDER-CTU-2022-101187,,FDA-CTU,,76.0,YR,,M,N,77.0,KG,20220519,N,PH,US,,2022,Q4,Elderly
217628821,21762882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,Tablet,,2022,Q4,Blood creatinine increased,,2022,Q4,1,I,20220301.0,,20221220,20221220,DIR,FDA-CDER-CTU-2022-101187,,FDA-CTU,,76.0,YR,,M,N,77.0,KG,20220519,N,PH,US,,2022,Q4,Elderly
217628821,21762882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,Tablet,,2022,Q4,Blood glucose increased,,2022,Q4,1,I,20220301.0,,20221220,20221220,DIR,FDA-CDER-CTU-2022-101187,,FDA-CTU,,76.0,YR,,M,N,77.0,KG,20220519,N,PH,US,,2022,Q4,Elderly
217628821,21762882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,Tablet,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,20220301.0,,20221220,20221220,DIR,FDA-CDER-CTU-2022-101187,,FDA-CTU,,76.0,YR,,M,N,77.0,KG,20220519,N,PH,US,,2022,Q4,Elderly
217628821,21762882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,Tablet,,2022,Q4,Acidosis,,2022,Q4,1,I,20220301.0,,20221220,20221220,DIR,FDA-CDER-CTU-2022-101187,,FDA-CTU,,76.0,YR,,M,N,77.0,KG,20220519,N,PH,US,,2022,Q4,Elderly
217628821,21762882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,Tablet,,2022,Q4,Blood chloride decreased,,2022,Q4,1,I,20220301.0,,20221220,20221220,DIR,FDA-CDER-CTU-2022-101187,,FDA-CTU,,76.0,YR,,M,N,77.0,KG,20220519,N,PH,US,,2022,Q4,Elderly
217628821,21762882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,Tablet,,2022,Q4,Polydipsia,,2022,Q4,1,I,20220301.0,,20221220,20221220,DIR,FDA-CDER-CTU-2022-101187,,FDA-CTU,,76.0,YR,,M,N,77.0,KG,20220519,N,PH,US,,2022,Q4,Elderly
217628821,21762882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,Tablet,,2022,Q4,Carbon dioxide decreased,,2022,Q4,1,I,20220301.0,,20221220,20221220,DIR,FDA-CDER-CTU-2022-101187,,FDA-CTU,,76.0,YR,,M,N,77.0,KG,20220519,N,PH,US,,2022,Q4,Elderly
217628821,21762882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,Tablet,,2022,Q4,Polyuria,,2022,Q4,1,I,20220301.0,,20221220,20221220,DIR,FDA-CDER-CTU-2022-101187,,FDA-CTU,,76.0,YR,,M,N,77.0,KG,20220519,N,PH,US,,2022,Q4,Elderly
217642891,21764289,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2022,Q4,Drug eruption,,2022,Q4,1,I,,20221216.0,20221222,20221222,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208592",BOEHRINGER INGELHEIM,"Auguste B, Yau K, Poon S. Drug eruption associated with empagliflozin. Canadian Medical Association Journal. 2022;194:481651-1652.doi:10.1503/cmaj.220934.",61.0,YR,A,M,Y,,,20221222,,HP,CA,CA,2022,Q4,Adult
217642891,21764289,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2022,Q4,Superficial inflammatory dermatosis,,2022,Q4,1,I,,20221216.0,20221222,20221222,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208592",BOEHRINGER INGELHEIM,"Auguste B, Yau K, Poon S. Drug eruption associated with empagliflozin. Canadian Medical Association Journal. 2022;194:481651-1652.doi:10.1503/cmaj.220934.",61.0,YR,A,M,Y,,,20221222,,HP,CA,CA,2022,Q4,Adult
217642891,21764289,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,5.0,MG,,QD,2022,Q4,Skin abrasion,,2022,Q4,1,I,,20221216.0,20221222,20221222,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208592",BOEHRINGER INGELHEIM,"Auguste B, Yau K, Poon S. Drug eruption associated with empagliflozin. Canadian Medical Association Journal. 2022;194:481651-1652.doi:10.1503/cmaj.220934.",61.0,YR,A,M,Y,,,20221222,,HP,CA,CA,2022,Q4,Adult
217642891,21764289,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Drug eruption,,2022,Q4,1,I,,20221216.0,20221222,20221222,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208592",BOEHRINGER INGELHEIM,"Auguste B, Yau K, Poon S. Drug eruption associated with empagliflozin. Canadian Medical Association Journal. 2022;194:481651-1652.doi:10.1503/cmaj.220934.",61.0,YR,A,M,Y,,,20221222,,HP,CA,CA,2022,Q4,Adult
217642891,21764289,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Superficial inflammatory dermatosis,,2022,Q4,1,I,,20221216.0,20221222,20221222,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208592",BOEHRINGER INGELHEIM,"Auguste B, Yau K, Poon S. Drug eruption associated with empagliflozin. Canadian Medical Association Journal. 2022;194:481651-1652.doi:10.1503/cmaj.220934.",61.0,YR,A,M,Y,,,20221222,,HP,CA,CA,2022,Q4,Adult
217642891,21764289,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Skin abrasion,,2022,Q4,1,I,,20221216.0,20221222,20221222,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208592",BOEHRINGER INGELHEIM,"Auguste B, Yau K, Poon S. Drug eruption associated with empagliflozin. Canadian Medical Association Journal. 2022;194:481651-1652.doi:10.1503/cmaj.220934.",61.0,YR,A,M,Y,,,20221222,,HP,CA,CA,2022,Q4,Adult
217652301,21765230,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,0.5,MG/KG,,QD,2022,Q4,Pancreatitis acute,,2022,Q4,1,I,,20221216.0,20221222,20221222,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208692",BOEHRINGER INGELHEIM,"Spiegel R, Hexner-Erlichman Z, Veiga-da-Cunha M, Zehavi Y, Vadasz Z, Sabag A. Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients. Frontiers in Pediatrics. 2022 Nov 23;101071464-doi:10.3389/fped.2022.1071464.",16.0,YR,T,F,Y,,,20221222,,HP,IL,IL,2022,Q4,Youth
217652301,21765230,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,0.5,MG/KG,,QD,2022,Q4,Off label use,,2022,Q4,1,I,,20221216.0,20221222,20221222,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208692",BOEHRINGER INGELHEIM,"Spiegel R, Hexner-Erlichman Z, Veiga-da-Cunha M, Zehavi Y, Vadasz Z, Sabag A. Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients. Frontiers in Pediatrics. 2022 Nov 23;101071464-doi:10.3389/fped.2022.1071464.",16.0,YR,T,F,Y,,,20221222,,HP,IL,IL,2022,Q4,Youth
217652301,21765230,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,0.65,MG/KG,,QD,2022,Q4,Pancreatitis acute,,2022,Q4,1,I,,20221216.0,20221222,20221222,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208692",BOEHRINGER INGELHEIM,"Spiegel R, Hexner-Erlichman Z, Veiga-da-Cunha M, Zehavi Y, Vadasz Z, Sabag A. Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients. Frontiers in Pediatrics. 2022 Nov 23;101071464-doi:10.3389/fped.2022.1071464.",16.0,YR,T,F,Y,,,20221222,,HP,IL,IL,2022,Q4,Youth
217652301,21765230,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,0.65,MG/KG,,QD,2022,Q4,Off label use,,2022,Q4,1,I,,20221216.0,20221222,20221222,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208692",BOEHRINGER INGELHEIM,"Spiegel R, Hexner-Erlichman Z, Veiga-da-Cunha M, Zehavi Y, Vadasz Z, Sabag A. Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients. Frontiers in Pediatrics. 2022 Nov 23;101071464-doi:10.3389/fped.2022.1071464.",16.0,YR,T,F,Y,,,20221222,,HP,IL,IL,2022,Q4,Youth
217652301,21765230,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,204629.0,,,,,2022,Q4,Pancreatitis acute,,2022,Q4,1,I,,20221216.0,20221222,20221222,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208692",BOEHRINGER INGELHEIM,"Spiegel R, Hexner-Erlichman Z, Veiga-da-Cunha M, Zehavi Y, Vadasz Z, Sabag A. Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients. Frontiers in Pediatrics. 2022 Nov 23;101071464-doi:10.3389/fped.2022.1071464.",16.0,YR,T,F,Y,,,20221222,,HP,IL,IL,2022,Q4,Youth
217652301,21765230,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,204629.0,,,,,2022,Q4,Off label use,,2022,Q4,1,I,,20221216.0,20221222,20221222,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-208692",BOEHRINGER INGELHEIM,"Spiegel R, Hexner-Erlichman Z, Veiga-da-Cunha M, Zehavi Y, Vadasz Z, Sabag A. Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients. Frontiers in Pediatrics. 2022 Nov 23;101071464-doi:10.3389/fped.2022.1071464.",16.0,YR,T,F,Y,,,20221222,,HP,IL,IL,2022,Q4,Youth
217684471,21768447,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,,,,,2022,Q4,Pancreatitis,,2022,Q4,1,I,20221111.0,20221220.0,20221222,20221222,EXP,,"SG-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209004",BOEHRINGER INGELHEIM,,59.0,YR,A,M,Y,,,20221222,,HP,SG,SG,2022,Q4,Adult
217697421,21769742,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2022,Q4,Surgery,,2022,Q4,1,I,20221208.0,20221221.0,20221223,20221223,EXP,,"RO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209251",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20221223,,CN,RO,RO,2022,Q4,Adult
217714301,21771430,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,,,,,,25.0,MG,,,2022,Q4,Weight decreased,,2022,Q4,1,I,20220101.0,20221212.0,20221223,20221223,EXP,DE-EMA-20221209-AUTODUP-1670624371984,DE-Accord-292923,ACCORD,,61.0,YR,A,F,Y,,,20221223,,CN,DE,DE,2022,Q4,Adult
217714301,21771430,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,,,,,,25.0,MG,,,2022,Q4,Eye pruritus,,2022,Q4,1,I,20220101.0,20221212.0,20221223,20221223,EXP,DE-EMA-20221209-AUTODUP-1670624371984,DE-Accord-292923,ACCORD,,61.0,YR,A,F,Y,,,20221223,,CN,DE,DE,2022,Q4,Adult
217714301,21771430,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,,,,,,25.0,MG,,,2022,Q4,Liver function test increased,,2022,Q4,1,I,20220101.0,20221212.0,20221223,20221223,EXP,DE-EMA-20221209-AUTODUP-1670624371984,DE-Accord-292923,ACCORD,,61.0,YR,A,F,Y,,,20221223,,CN,DE,DE,2022,Q4,Adult
217714301,21771430,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,,,,,,25.0,MG,,,2022,Q4,Injection site erythema,,2022,Q4,1,I,20220101.0,20221212.0,20221223,20221223,EXP,DE-EMA-20221209-AUTODUP-1670624371984,DE-Accord-292923,ACCORD,,61.0,YR,A,F,Y,,,20221223,,CN,DE,DE,2022,Q4,Adult
217714301,21771430,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,,,,,,25.0,MG,,,2022,Q4,Liver disorder,,2022,Q4,1,I,20220101.0,20221212.0,20221223,20221223,EXP,DE-EMA-20221209-AUTODUP-1670624371984,DE-Accord-292923,ACCORD,,61.0,YR,A,F,Y,,,20221223,,CN,DE,DE,2022,Q4,Adult
217714301,21771430,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 milligram,,,,,,,,25.0,MG,,,2022,Q4,Aortic disorder,,2022,Q4,1,I,20220101.0,20221212.0,20221223,20221223,EXP,DE-EMA-20221209-AUTODUP-1670624371984,DE-Accord-292923,ACCORD,,61.0,YR,A,F,Y,,,20221223,,CN,DE,DE,2022,Q4,Adult
217740141,21774014,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2022,Q4,Sepsis,,2022,Q4,1,I,,20221223.0,20221223,20221223,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209684",BOEHRINGER INGELHEIM,"Sharma A, Sharma A, Kornberg R. From Insult to Injury: A Rare Consequence of Sodium Glucose Cotransporter 2 Inhibitors. Circulation. 2022 Oct 30;146doi:10.1161/circ.1 46.suppl_1.15183.",74.0,YR,E,M,Y,,,20221223,,HP,US,US,2022,Q4,Elderly
217740141,21774014,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2022,Q4,Cystitis,,2022,Q4,1,I,,20221223.0,20221223,20221223,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209684",BOEHRINGER INGELHEIM,"Sharma A, Sharma A, Kornberg R. From Insult to Injury: A Rare Consequence of Sodium Glucose Cotransporter 2 Inhibitors. Circulation. 2022 Oct 30;146doi:10.1161/circ.1 46.suppl_1.15183.",74.0,YR,E,M,Y,,,20221223,,HP,US,US,2022,Q4,Elderly
217740141,21774014,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,,,,,2022,Q4,Emphysematous pyelonephritis,,2022,Q4,1,I,,20221223.0,20221223,20221223,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209684",BOEHRINGER INGELHEIM,"Sharma A, Sharma A, Kornberg R. From Insult to Injury: A Rare Consequence of Sodium Glucose Cotransporter 2 Inhibitors. Circulation. 2022 Oct 30;146doi:10.1161/circ.1 46.suppl_1.15183.",74.0,YR,E,M,Y,,,20221223,,HP,US,US,2022,Q4,Elderly
217740141,21774014,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,204629.0,,,,,2022,Q4,Sepsis,,2022,Q4,1,I,,20221223.0,20221223,20221223,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209684",BOEHRINGER INGELHEIM,"Sharma A, Sharma A, Kornberg R. From Insult to Injury: A Rare Consequence of Sodium Glucose Cotransporter 2 Inhibitors. Circulation. 2022 Oct 30;146doi:10.1161/circ.1 46.suppl_1.15183.",74.0,YR,E,M,Y,,,20221223,,HP,US,US,2022,Q4,Elderly
217740141,21774014,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,204629.0,,,,,2022,Q4,Cystitis,,2022,Q4,1,I,,20221223.0,20221223,20221223,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209684",BOEHRINGER INGELHEIM,"Sharma A, Sharma A, Kornberg R. From Insult to Injury: A Rare Consequence of Sodium Glucose Cotransporter 2 Inhibitors. Circulation. 2022 Oct 30;146doi:10.1161/circ.1 46.suppl_1.15183.",74.0,YR,E,M,Y,,,20221223,,HP,US,US,2022,Q4,Elderly
217740141,21774014,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,204629.0,,,,,2022,Q4,Emphysematous pyelonephritis,,2022,Q4,1,I,,20221223.0,20221223,20221223,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209684",BOEHRINGER INGELHEIM,"Sharma A, Sharma A, Kornberg R. From Insult to Injury: A Rare Consequence of Sodium Glucose Cotransporter 2 Inhibitors. Circulation. 2022 Oct 30;146doi:10.1161/circ.1 46.suppl_1.15183.",74.0,YR,E,M,Y,,,20221223,,HP,US,US,2022,Q4,Elderly
217773721,21777372,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Atrial fibrillation,,2022,Q4,1,I,,20221223.0,20221226,20221226,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209676",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20221226,,MD,ES,ES,2022,Q4,Elderly
217773721,21777372,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Renal impairment,,2022,Q4,1,I,,20221223.0,20221226,20221226,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209676",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20221226,,MD,ES,ES,2022,Q4,Elderly
217773721,21777372,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Hyperkalaemia,,2022,Q4,1,I,,20221223.0,20221226,20221226,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209676",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20221226,,MD,ES,ES,2022,Q4,Elderly
217773721,21777372,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Hypotension,,2022,Q4,1,I,,20221223.0,20221226,20221226,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209676",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20221226,,MD,ES,ES,2022,Q4,Elderly
217773721,21777372,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Atrial fibrillation,,2022,Q4,1,I,,20221223.0,20221226,20221226,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209676",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20221226,,MD,ES,ES,2022,Q4,Elderly
217773721,21777372,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Renal impairment,,2022,Q4,1,I,,20221223.0,20221226,20221226,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209676",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20221226,,MD,ES,ES,2022,Q4,Elderly
217773721,21777372,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Hyperkalaemia,,2022,Q4,1,I,,20221223.0,20221226,20221226,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209676",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20221226,,MD,ES,ES,2022,Q4,Elderly
217773721,21777372,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Hypotension,,2022,Q4,1,I,,20221223.0,20221226,20221226,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209676",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20221226,,MD,ES,ES,2022,Q4,Elderly
217816171,21781617,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Acidosis,,2022,Q4,1,I,20221110.0,20221227.0,20221227,20221227,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209878",BOEHRINGER INGELHEIM,,94.0,YR,E,M,Y,55.0,KG,20221227,,MD,DE,DE,2022,Q4,Elderly
217816171,21781617,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Sepsis,,2022,Q4,1,I,20221110.0,20221227.0,20221227,20221227,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209878",BOEHRINGER INGELHEIM,,94.0,YR,E,M,Y,55.0,KG,20221227,,MD,DE,DE,2022,Q4,Elderly
217816171,21781617,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,10.0,MG,,QD,2022,Q4,Urosepsis,,2022,Q4,1,I,20221110.0,20221227.0,20221227,20221227,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209878",BOEHRINGER INGELHEIM,,94.0,YR,E,M,Y,55.0,KG,20221227,,MD,DE,DE,2022,Q4,Elderly
217818171,21781817,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,12.5,MG,,Q12H,2022,Q4,Hepatocellular injury,,2022,Q4,1,I,20220709.0,20221227.0,20221227,20221227,EXP,ES-AEMPS-1311091,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209889",BOEHRINGER INGELHEIM,,75.0,YR,E,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Elderly
217818171,21781817,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,12.5,MG,,Q12H,2022,Q4,Hepatic encephalopathy,,2022,Q4,1,I,20220709.0,20221227.0,20221227,20221227,EXP,ES-AEMPS-1311091,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209889",BOEHRINGER INGELHEIM,,75.0,YR,E,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Elderly
217823001,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Blood pressure diastolic decreased,,2022,Q4,1,I,,20221224.0,20221227,20221227,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20221227,,HP,CA,,2022,Q4,Elderly
217823001,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Type 2 diabetes mellitus,,2022,Q4,1,I,,20221224.0,20221227,20221227,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20221227,,HP,CA,,2022,Q4,Elderly
217823001,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Blood pressure diastolic abnormal,,2022,Q4,1,I,,20221224.0,20221227,20221227,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20221227,,HP,CA,,2022,Q4,Elderly
217823001,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Blood pressure systolic increased,,2022,Q4,1,I,,20221224.0,20221227,20221227,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20221227,,HP,CA,,2022,Q4,Elderly
217823001,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Weight decreased,,2022,Q4,1,I,,20221224.0,20221227,20221227,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20221227,,HP,CA,,2022,Q4,Elderly
217823001,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Blood glucose increased,,2022,Q4,1,I,,20221224.0,20221227,20221227,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20221227,,HP,CA,,2022,Q4,Elderly
217823001,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Blood pressure fluctuation,,2022,Q4,1,I,,20221224.0,20221227,20221227,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20221227,,HP,CA,,2022,Q4,Elderly
217823001,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Weight increased,,2022,Q4,1,I,,20221224.0,20221227,20221227,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20221227,,HP,CA,,2022,Q4,Elderly
217823001,21782300,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,UNKNOWN,,,10.0,MG,,QD,2022,Q4,Blood pressure increased,,2022,Q4,1,I,,20221224.0,20221227,20221227,EXP,,CA-ROCHE-3250633,ROCHE,,66.0,YR,,F,Y,89.0,KG,20221227,,HP,CA,,2022,Q4,Elderly
217844251,21784425,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Sleep terror,,2022,Q4,1,I,20221115.0,20221227.0,20221227,20221227,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209925",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,102.0,KG,20221227,,CN,GB,GB,2022,Q4,Adult
217903041,21790304,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Scrotal pain,,2022,Q4,1,I,20220721.0,20221225.0,20221228,20221228,EXP,GB-MHRA-EMIS-9964-a1da77af-6980-4930-9d96-784b6d62d26a,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209837",BOEHRINGER INGELHEIM,,75.0,YR,E,M,Y,73.0,KG,20221228,,MD,GB,GB,2022,Q4,Elderly
217903041,21790304,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Rash,,2022,Q4,1,I,20220721.0,20221225.0,20221228,20221228,EXP,GB-MHRA-EMIS-9964-a1da77af-6980-4930-9d96-784b6d62d26a,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209837",BOEHRINGER INGELHEIM,,75.0,YR,E,M,Y,73.0,KG,20221228,,MD,GB,GB,2022,Q4,Elderly
217926231,21792623,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2022,Q4,Waist circumference increased,,2022,Q4,1,I,20221101.0,20221222.0,20221229,20221229,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209650",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20221229,,MD,ES,ES,2022,Q4,Elderly
217926231,21792623,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2022,Q4,Weight increased,,2022,Q4,1,I,20221101.0,20221222.0,20221229,20221229,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209650",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20221229,,MD,ES,ES,2022,Q4,Elderly
217926231,21792623,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,Unknown,,204629.0,10.0,MG,,,2022,Q4,Generalised oedema,,2022,Q4,1,I,20221101.0,20221222.0,20221229,20221229,EXP,,"ES-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-209650",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,,,20221229,,MD,ES,ES,2022,Q4,Elderly
217926671,21792667,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",586.047,MG,,,,,,25.0,MG,Film-coated tablet,QD,2022,Q4,Pyelonephritis,,2022,Q4,1,I,20221118.0,20221226.0,20221229,20221229,EXP,DK-DKMA-WBS-1002819,DK-SA-2022SA520383,SANOFI AVENTIS,,62.0,YR,A,M,Y,117.0,KG,20221229,,MD,DK,DK,2022,Q4,Adult
217936161,21793616,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Acute kidney injury,,2022,Q4,1,I,,20221219.0,20221229,20221229,EXP,CA-MHPD-001011319,CA-Accord-293420,ACCORD,,72.0,YR,E,M,Y,96.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
217936161,21793616,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2022,Q4,Hepatic failure,,2022,Q4,1,I,,20221219.0,20221229,20221229,EXP,CA-MHPD-001011319,CA-Accord-293420,ACCORD,,72.0,YR,E,M,Y,96.0,KG,20221229,,MD,CA,CA,2022,Q4,Elderly
217989451,21798945,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5 - 2.5 1000 MG twice daily,,,U,,Unknown,,212614.0,,,Tablet,Q12H,2022,Q4,Deafness,,2022,Q4,1,I,20190601.0,20221229.0,20221230,20221230,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-210378",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,,,20221230,,CN,US,US,2022,Q4,Adult
217994301,21799430,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2022,Q4,Cough,,2022,Q4,1,I,,20221229.0,20221230,20221230,EXP,GB-MHRA-TPP16373293C8701962YC1671466834982,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-210440",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,75.0,KG,20221230,,PH,GB,GB,2022,Q4,Elderly
218015421,21801542,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,Y,,,,,25.0,MG,,,2022,Q4,Decreased appetite,,2022,Q4,1,I,,20221219.0,20221230,20221230,EXP,,PT-TEVA-2022-PT-2839945,TEVA,,82.0,YR,E,F,Y,,,20221230,,MD,PT,PT,2022,Q4,Elderly
218015421,21801542,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,Y,,,,,25.0,MG,,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221219.0,20221230,20221230,EXP,,PT-TEVA-2022-PT-2839945,TEVA,,82.0,YR,E,F,Y,,,20221230,,MD,PT,PT,2022,Q4,Elderly
218027021,21802702,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Fall,,2022,Q4,1,I,,20221218.0,20221231,20221231,EXP,,GB-AUROBINDO-AUR-APL-2022-056116,AUROBINDO,,91.0,YR,,,Y,,,20221231,,PH,GB,GB,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Inappropriate schedule of product administration,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Influenza,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Rales,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Blood pressure increased,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Palpitations,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Pulmonary oedema,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Bronchitis,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Limb injury,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Heart rate decreased,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Fatigue,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Pneumonia,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Orthopnoea,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Heart rate increased,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Joint injury,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Blood pressure decreased,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Blood pressure systolic increased,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Malaise,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Blood pressure diastolic increased,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Cough,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Blood pressure fluctuation,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Dyspnoea,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Oedema peripheral,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Cardiac failure congestive,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Small intestinal obstruction,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Vital functions abnormal,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Atrial fibrillation,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Fall,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Pericardial effusion,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
902813622,9028136,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Dizziness,,2022,Q4,22,F,20121025.0,20221116.0,20130123,20221122,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20221122,,MD,CA,CA,2022,Q4,Elderly
